identification O
of O
a O
##p O
##c O
##2 O
, O
a O
ho O
##mo O
##logue O
of O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
t I-Disease
##umour I-Disease
suppress O
##or O
. O

the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( I-Disease
a I-Disease
##p I-Disease
##c I-Disease
) I-Disease
t I-Disease
##umour I-Disease
- O
suppress O
##or O
protein O
controls O
the O
w O
##nt O
signalling O
pathway O
by O
forming O
a O
complex O
with O
g O
##ly O
##co O
##gen O
s O
##ynth O
##ase O
kinase O
3 O
##bet O
##a O
( O
g O
##sk O
- O
3 O
##bet O
##a O
) O
, O
a O
##xin O
/ O
conduct O
##in O
and O
beta O
##cate O
##nin O
. O

complex O
formation O
induce O
##s O
the O
rapid O
degradation O
of O
beta O
##cate O
##nin O
. O

in O
co B-Disease
##lon I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cells O
, O
loss O
of O
a O
##p O
##c O
leads O
to O
the O
accumulation O
of O
beta O
##cate O
##nin O
in O
the O
nucleus O
, O
where O
it O
binds O
to O
and O
activate O
##s O
the O
t O
##c O
##f O
- O
4 O
transcription O
factor O
( O
reviewed O
in O
[ O
1 O
] O
[ O
2 O
] O
) O
. O

here O
, O
we O
report O
the O
identification O
and O
g O
##eno O
##mic O
structure O
of O
a O
##p O
##c O
ho O
##mo O
##logue O
##s O
. O

ma O
##mmal O
##ian O
a O
##p O
##c O
##2 O
, O
which O
closely O
resembles O
a O
##p O
##c O
in O
overall O
domain O
structure O
, O
was O
functional O
##ly O
analyzed O
and O
shown O
to O
contain O
two O
sa O
##mp O
domains O
, O
both O
of O
which O
are O
required O
for O
binding O
to O
conduct O
##in O
. O

like O
a O
##p O
##c O
, O
a O
##p O
##c O
##2 O
regulate O
##s O
the O
formation O
of O
active O
beta O
##cate O
##nin O
- O
t O
##c O
##f O
complexes O
, O
as O
demonstrated O
using O
trans O
##ient O
transcription O
##al O
activation O
ass O
##ays O
in O
a O
##p O
##c O
- O
/ O
- O
co B-Disease
##lon I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cells O
. O

human O
a O
##p O
##c O
##2 O
maps O
to O
chromosome O
19 O
##p O
##13 O
. O

3 O
. O

a O
##p O
##c O
and O
a O
##p O
##c O
##2 O
may O
therefore O
have O
comparable O
functions O
in O
development O
and O
cancer B-Disease
. O

a O
common O
m O
##sh O
##2 O
mutation O
in O
en O
##gli O
##sh O
and O
north O
am O
##eric O
##an O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
families O
: O
origin O
, O
p O
##hen O
##otypic O
expression O
, O
and O
sex O
specific O
differences O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

the O
frequency O
, O
origin O
, O
and O
p O
##hen O
##otypic O
expression O
of O
a O
g O
##er O
##m O
##line O
m O
##sh O
##2 O
gene O
mutation O
previously O
identified O
in O
seven O
kind O
##red O
##s O
with O
hereditary B-Disease
non I-Disease
- I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
cancer I-Disease
syndrome I-Disease
( O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
) O
was O
investigated O
. O

the O
mutation O
( O
a O
- O
- O
[UNK] O
t O
at O
n O
##t O
##9 O
##43 O
+ O
3 O
) O
disrupt O
##s O
the O
3 O
s O
##p O
##lice O
site O
of O
ex O
##on O
5 O
leading O
to O
the O
del O
##eti O
##on O
of O
this O
ex O
##on O
from O
m O
##sh O
##2 O
m O
##rna O
and O
represents O
the O
only O
frequent O
m O
##sh O
##2 O
mutation O
so O
far O
reported O
. O

although O
this O
mutation O
was O
initially O
detected O
in O
four O
of O
33 O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
families O
anal O
##ys O
##ed O
from O
eastern O
en O
##g O
##land O
, O
more O
extensive O
analysis O
has O
reduced O
the O
frequency O
to O
four O
of O
52 O
( O
8 O
% O
) O
en O
##gli O
##sh O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
kind O
##red O
##s O
anal O
##ys O
##ed O
. O

in O
contrast O
, O
the O
m O
##sh O
##2 O
mutation O
was O
identified O
in O
10 O
of O
20 O
( O
50 O
% O
) O
separately O
identified O
color B-Disease
##ec I-Disease
##tal I-Disease
families O
from O
new O
##found O
##land O
. O

to O
investigate O
the O
origin O
of O
this O
mutation O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
families O
from O
en O
##g O
##land O
( O
n O
= O
4 O
) O
, O
new O
##found O
##land O
( O
n O
= O
10 O
) O
, O
and O
the O
united O
states O
( O
n O
= O
3 O
) O
, O
ha O
##p O
##lot O
##ype O
analysis O
using O
micro O
##sat O
##elli O
##te O
markers O
linked O
to O
m O
##sh O
##2 O
was O
performed O
. O

within O
the O
en O
##gli O
##sh O
and O
us O
families O
there O
was O
little O
evidence O
for O
a O
recent O
common O
origin O
of O
the O
m O
##sh O
##2 O
s O
##p O
##lice O
site O
mutation O
in O
most O
families O
. O

in O
contrast O
, O
a O
common O
ha O
##p O
##lot O
##ype O
was O
identified O
at O
the O
two O
flank O
##ing O
markers O
( O
ca O
##5 O
and O
d O
##2 O
##s O
##28 O
##8 O
) O
in O
eight O
of O
the O
new O
##found O
##land O
families O
. O

these O
findings O
suggested O
a O
founder O
effect O
within O
new O
##found O
##land O
similar O
to O
that O
reported O
by O
others O
for O
two O
m O
##l O
##h O
##1 O
mutations O
in O
fin O
##nish O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
families O
. O

we O
calculated O
age O
related O
risks O
of O
all O
, O
color B-Disease
##ec I-Disease
##tal I-Disease
, I-Disease
end I-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
, I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
in O
n O
##t O
##9 O
##43 O
+ O
3 O
a O
- O
- O
[UNK] O
t O
m O
##sh O
##2 O
mutation O
carriers O
( O
n O
= O
76 O
) O
for O
all O
patients O
and O
for O
men O
and O
women O
separately O
. O

for O
both O
sexes O
combined O
, O
the O
pen O
##et O
##rance O
##s O
at O
age O
60 O
years O
for O
all O
cancer B-Disease
##s I-Disease
and O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
were O
0 O
. O

86 O
and O
0 O
. O

57 O
, O
respectively O
. O

the O
risk O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
was O
significantly O
higher O
( O
p O
[UNK] O
0 O
. O
01 O
) O
in O
males O
than O
females O
( O
0 O
. O
63 O
v O
0 O
. O
30 O
and O
0 O
. O
84 O
v O
0 O
. O
44 O
at O
ages O
50 O
and O
60 O
years O
, O
respectively O
) O
. O

for O
females O
there O
was O
a O
high O
risk O
of O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
cancer I-Disease
( O
0 O
. O
5 O
at O
age O
60 O
years O
) O
and O
pre B-Disease
##men I-Disease
##op I-Disease
##aus I-Disease
##al I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
( O
0 O
. O
2 O
at O
50 O
years O
) O
. O

these O
inter O
##sex O
differences O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
risks O
have O
implications O
for O
screening O
programmes O
and O
for O
attempts O
to O
identify O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
m O
##od O
##ifier O
##s O
. O

age O
of O
onset O
in O
hunting B-Disease
##ton I-Disease
disease I-Disease
: O
sex O
specific O
influence O
of O
a O
##poli O
##pop O
##rote O
##in O
e O
g O
##eno O
##type O
and O
normal O
ca O
##g O
repeat O
length O
. O

age O
of O
onset O
( O
a O
##o O
) O
of O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
is O
known O
to O
be O
correlated O
with O
the O
length O
of O
an O
expanded O
ca O
##g O
repeat O
in O
the O
h B-Disease
##d I-Disease
gene O
. O

a O
##poli O
##pop O
##rote O
##in O
e O
( O
a O
##po O
##e O
) O
g O
##eno O
##type O
, O
in O
turn O
, O
is O
known O
to O
influence O
a O
##o O
in O
al B-Disease
##z I-Disease
##heimer I-Disease
disease I-Disease
, O
rendering O
the O
a O
##po O
##e O
gene O
a O
likely O
candidate O
to O
affect O
a O
##o O
in O
other O
ne B-Disease
##uro I-Disease
##logical I-Disease
diseases I-Disease
too O
. O

we O
therefore O
determined O
a O
##po O
##e O
g O
##eno O
##type O
and O
normal O
ca O
##g O
repeat O
length O
in O
the O
h B-Disease
##d I-Disease
gene O
for O
138 O
h B-Disease
##d I-Disease
patients O
who O
were O
previously O
anal O
##ys O
##ed O
with O
respect O
to O
ca O
##g O
repeat O
length O
. O

g O
##eno O
##ty O
##ping O
for O
a O
##po O
##e O
was O
performed O
blind O
to O
clinical O
information O
. O

in O
addition O
to O
highlighting O
the O
effect O
of O
the O
normal O
repeat O
length O
upon O
a O
##o O
in O
maternal O
##ly O
inherited O
h B-Disease
##d I-Disease
and O
in O
male O
patients O
, O
we O
show O
that O
the O
a O
##po O
##e O
e O
##ps O
##ilon O
##2 O
##ep O
##si O
##lon O
##3 O
g O
##eno O
##type O
is O
associated O
with O
significantly O
earlier O
a O
##o O
in O
males O
than O
in O
females O
. O

such O
a O
sex O
difference O
in O
a O
##o O
was O
not O
apparent O
for O
any O
of O
the O
other O
a O
##po O
##e O
g O
##eno O
##type O
##s O
. O

our O
findings O
suggest O
that O
subtle O
differences O
in O
the O
course O
of O
the O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##ration I-Disease
in O
h B-Disease
##d I-Disease
may O
allow O
interacting O
genes O
to O
ex O
##ert O
gender O
specific O
effects O
upon O
a O
##o O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
deficiency I-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
associated O
with O
re O
##current O
b B-Disease
##act I-Disease
##ere I-Disease
##mic I-Disease
infections I-Disease
due I-Disease
to I-Disease
ne I-Disease
##isse I-Disease
##ria I-Disease
. O

the O
serum O
of O
a O
29 O
- O
year O
old O
woman O
with O
a O
recent O
episode O
of O
di B-Disease
##sse I-Disease
##minated I-Disease
go I-Disease
##no I-Disease
##co I-Disease
##cca I-Disease
##l I-Disease
infection I-Disease
and O
a O
history O
of O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
and O
art B-Disease
##hr I-Disease
##itis I-Disease
as O
a O
child O
was O
found O
to O
lack O
serum O
hem O
##oly O
##tic O
complement O
activity O
. O

the O
seventh O
component O
of O
complement O
( O
c O
##7 O
) O
was O
not O
detected O
by O
functional O
or O
im O
##mu O
##no O
##chemical O
ass O
##ays O
, O
whereas O
other O
components O
were O
normal O
by O
hem O
##oly O
##tic O
and O
im O
##mu O
##no O
##chemical O
assessment O
. O

her O
fresh O
serum O
lacked O
complement O
- O
mediated O
b O
##act O
##eric O
##idal O
activity O
against O
ne O
##isse O
##ria O
go O
##nor O
##r O
##hoe O
##ae O
, O
but O
the O
addition O
of O
fresh O
normal O
serum O
or O
pu O
##rified O
c O
##7 O
restored O
b O
##act O
##eric O
##idal O
activity O
as O
well O
as O
hem O
##oly O
##tic O
activity O
. O

the O
absence B-Disease
of I-Disease
functional I-Disease
c I-Disease
##7 I-Disease
activity O
could O
not O
be O
accounted O
for O
on O
the O
basis O
of O
an O
inhibitor O
. O

op O
##son O
##ization O
and O
generation O
of O
ch O
##em O
##ota O
##ctic O
activity O
functioned O
normally O
. O

complete B-Disease
absence I-Disease
of I-Disease
c I-Disease
##7 I-Disease
was O
also O
found O
in O
one O
sibling O
who O
had O
the O
clinical O
syndrome O
of O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
and O
art B-Disease
##hr I-Disease
##itis I-Disease
as O
a O
child O
and O
in O
this O
siblings O
clinical O
##ly O
well O
eight O
- O
year O
- O
old O
son O
. O

h O
##la O
his O
##to O
##com O
##pa O
##ti O
##bility O
typing O
of O
the O
family O
members O
did O
not O
demonstrate O
evidence O
for O
genetic O
link O
##age O
of O
c B-Disease
##7 I-Disease
deficiency I-Disease
with O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
lo O
##ci O
. O

this O
report O
represents O
the O
first O
cases O
of O
c B-Disease
##7 I-Disease
deficiency I-Disease
associated O
with O
infectious O
complications O
and O
suggests O
that O
b O
##act O
##eric O
##idal O
activity O
may O
be O
important O
in O
host O
defense O
against O
b B-Disease
##act I-Disease
##ere I-Disease
##mic I-Disease
ne I-Disease
##isse I-Disease
##ria I-Disease
infections I-Disease
. O

increased O
incidence O
of O
cancer B-Disease
in O
patients O
with O
cart B-Disease
##ila I-Disease
##ge I-Disease
- I-Disease
hair I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
. O

objective O
previous O
reports O
have O
suggested O
an O
increased O
risk O
of O
cancer B-Disease
among O
patients O
with O
cart B-Disease
##ila I-Disease
##ge I-Disease
- I-Disease
hair I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
( O
ch B-Disease
##h I-Disease
) O
. O

this O
study O
was O
carried O
out O
to O
further O
evaluate O
this O
risk O
among O
patients O
with O
ch B-Disease
##h I-Disease
and O
their O
first O
- O
degree O
relatives O
. O

study O
design O
one O
hundred O
twenty O
- O
two O
patients O
with O
ch B-Disease
##h I-Disease
were O
identified O
through O
2 O
country O
##wide O
e O
##pid O
##em O
##iol O
##og O
##ic O
surveys O
in O
1974 O
and O
in O
1986 O
. O

their O
parents O
and O
non O
##af O
##fected O
siblings O
were O
identified O
through O
the O
population O
register O
center O
. O

this O
co O
##hor O
##t O
underwent O
follow O
- O
up O
for O
cancer B-Disease
incidence O
through O
the O
fin O
##nish O
cancer O
registry O
to O
the O
end O
of O
1995 O
. O

results O
a O
statistical O
##ly O
significant O
excess O
risk O
of O
cancer B-Disease
was O
seen O
among O
the O
patients O
with O
ch B-Disease
##h I-Disease
( O
standardized O
incidence O
ratio O
6 O
. O
9 O
, O
95 O
% O
confidence O
interval O
2 O
. O
3 O
to O
16 O
) O
, O
which O
was O
mainly O
at O
##tri O
##but O
##able O
to O
non B-Disease
- I-Disease
ho I-Disease
##d I-Disease
##g I-Disease
##kins I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
( O
standardized O
incidence O
ratio O
90 O
, O
95 O
% O
confidence O
interval O
18 O
to O
264 O
) O
. O

in O
addition O
, O
a O
significant O
excess O
risk O
of O
basal B-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
was O
seen O
( O
standardized O
incidence O
ratio O
35 O
, O
95 O
% O
confidence O
interval O
7 O
. O
2 O
to O
102 O
) O
. O

the O
cancer B-Disease
incidence O
among O
the O
siblings O
or O
the O
parents O
did O
not O
differ O
from O
the O
average O
cancer B-Disease
incidence O
in O
the O
fin O
##nish O
population O
. O

conclusions O
this O
study O
confirms O
an O
increased O
risk O
of O
cancer B-Disease
, O
especially O
non B-Disease
- I-Disease
ho I-Disease
##d I-Disease
##g I-Disease
##kins I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
, O
probably O
at O
##tri O
##but O
##able O
to O
defect O
##ive O
immunity O
, O
among O
patients O
with O
ch B-Disease
##h I-Disease
. O

g O
##eno O
##type O
and O
p O
##hen O
##otype O
in O
patients O
with O
di B-Disease
##hy I-Disease
##dr I-Disease
##opy I-Disease
##rim I-Disease
##id I-Disease
##ine I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
. O

di B-Disease
##hy I-Disease
##dr I-Disease
##opy I-Disease
##rim I-Disease
##id I-Disease
##ine I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
d I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
characterised O
by O
thy O
##mine O
- O
u O
##rac O
##il O
##uria O
in O
ho O
##mo O
##zy O
##go O
##us O
def O
##icient O
patients O
and O
has O
been O
associated O
with O
a O
variable O
clinical O
p O
##hen O
##otype O
. O

in O
order O
to O
understand O
the O
genetic O
and O
p O
##hen O
##otypic O
basis O
for O
d B-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
we O
have O
reviewed O
17 O
families O
presenting O
22 O
patients O
with O
complete O
deficiency B-Disease
of I-Disease
d I-Disease
##p I-Disease
##d I-Disease
. O

in O
this O
group O
of O
patients O
, O
7 O
different O
mutations O
have O
been O
identified O
, O
including O
2 O
del O
##eti O
##ons O
[ O
295 O
- O
29 O
##8 O
##del O
##t O
##cat O
, O
1897 O
##del O
##c O
] O
, O
1 O
s O
##p O
##lice O
- O
site O
mutation O
[ O
i O
##v O
##s O
##14 O
+ O
1 O
##g O
[UNK] O
a O
) O
] O
and O
4 O
miss O
##ense O
mutations O
( O
85 O
##t O
[UNK] O
c O
, O
70 O
##3 O
##c O
[UNK] O
t O
, O
265 O
##8 O
##g O
[UNK] O
a O
, O
29 O
##8 O
##3 O
##g O
[UNK] O
t O
) O
. O

analysis O
of O
the O
prevalence O
of O
the O
various O
mutations O
among O
d B-Disease
##p I-Disease
##d I-Disease
patients O
has O
shown O
that O
the O
g O
- O
- O
[UNK] O
a O
point O
mutation O
in O
the O
invariant O
s O
##p O
##lice O
donor O
site O
is O
by O
far O
the O
most O
common O
( O
52 O
% O
) O
, O
whereas O
the O
other O
six O
mutations O
are O
less O
frequently O
observed O
. O

a O
large O
p O
##hen O
##otypic O
var O
##iability O
has O
been O
observed O
, O
with O
con B-Disease
##vu I-Disease
##lsive I-Disease
disorders I-Disease
, O
motor B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
being O
the O
most O
abundant O
manifest O
##ations O
. O

a O
clear O
correlation O
between O
the O
g O
##eno O
##type O
and O
p O
##hen O
##otype O
has O
not O
been O
established O
. O

an O
altered O
beta O
- O
al O
##ani O
##ne O
, O
u O
##rac O
##il O
and O
thy O
##mine O
home O
##ost O
##asis O
might O
under O
##lie O
the O
various O
clinical B-Disease
abnormal I-Disease
##ities I-Disease
encountered O
in O
patients O
with O
d B-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

fi O
##bro O
##blast O
growth O
factor O
ho O
##mo O
##log O
##ous O
factor O
2 O
( O
f O
##h O
##f O
##2 O
) O
: O
gene O
structure O
, O
expression O
and O
mapping O
to O
the O
b B-Disease
##or I-Disease
##je I-Disease
##son I-Disease
- I-Disease
for I-Disease
##ss I-Disease
##man I-Disease
- I-Disease
le I-Disease
##hmann I-Disease
syndrome I-Disease
region O
in O
x O
##q O
##26 O
del O
##ine O
##ated O
by O
a O
du O
##plication O
break O
##point O
in O
a O
b B-Disease
##f I-Disease
##ls I-Disease
- O
like O
patient O
. O

b B-Disease
##or I-Disease
##je I-Disease
##son I-Disease
- I-Disease
for I-Disease
##ss I-Disease
##man I-Disease
- I-Disease
le I-Disease
##hmann I-Disease
syndrome I-Disease
( O
b B-Disease
##f I-Disease
##ls I-Disease
) O
is O
a O
s O
##yn O
##dr O
##oma O
##l O
x B-Disease
- I-Disease
linked I-Disease
mental I-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
which O
maps O
by O
link O
##age O
to O
the O
q O
##26 O
region O
of O
the O
human O
x O
chromosome O
. O

we O
have O
identified O
a O
male O
patient O
with O
b B-Disease
##f I-Disease
##ls I-Disease
- O
like O
features O
and O
a O
du O
##plication O
, O
46 O
, O
y O
, O
du O
##p O
( O
x O
) O
( O
q O
##26 O
##q O
##28 O
) O
, O
inherited O
from O
his O
p O
##hen O
##otypic O
##ally O
normal O
mother O
. O

flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##isation O
using O
yeast O
artificial O
chromosome O
clone O
##s O
from O
x O
##q O
##26 O
local O
##ised O
the O
du O
##plication O
break O
##point O
to O
an O
approximately O
400 O
- O
k O
##b O
interval O
in O
the O
x O
##q O
##26 O
. O

3 O
region O
between O
d O
##x O
##s O
##15 O
##5 O
and O
d O
##x O
##s O
##29 O
##4 O
/ O
d O
##x O
##s O
##7 O
##30 O
. O

database O
searches O
and O
analysis O
of O
available O
g O
##eno O
##mic O
d O
##na O
sequence O
from O
the O
region O
revealed O
the O
presence O
of O
the O
fi O
##bro O
##blast O
growth O
factor O
ho O
##mo O
##log O
##ous O
factor O
gene O
, O
f O
##h O
##f O
##2 O
, O
within O
the O
du O
##plication O
break O
##point O
interval O
. O

the O
gene O
structure O
of O
f O
##h O
##f O
##2 O
was O
determined O
and O
two O
new O
ex O
##ons O
were O
identified O
, O
including O
a O
new O
5 O
end O
ex O
##on O
, O
1 O
##b O
. O

f O
##h O
##f O
##2 O
is O
a O
large O
gene O
extending O
over O
approximately O
200 O
k O
##b O
in O
x O
##q O
##26 O
. O

3 O
and O
is O
composed O
of O
at O
least O
seven O
ex O
##ons O
. O

it O
shows O
tissue O
- O
specific O
alternative O
s O
##p O
##licing O
and O
alternative O
transcription O
starts O
. O

northern O
b O
##lot O
hybrid O
##isation O
showed O
highest O
expression O
in O
brain O
and O
skeletal O
muscle O
. O

the O
f O
##h O
##f O
##2 O
gene O
local O
##isation O
and O
tissue O
- O
specific O
expression O
pattern O
suggest O
it O
to O
be O
a O
candidate O
gene O
for O
f O
##ami O
##lial O
cases O
of O
the O
b B-Disease
##f I-Disease
##ls I-Disease
syndrome I-Disease
and O
other O
s O
##yn O
##dr O
##oma O
##l O
and O
non O
- O
specific O
forms O
of O
x B-Disease
- I-Disease
linked I-Disease
mental I-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
mapping O
to O
the O
region O
. O

g O
##er O
##m O
##line O
e O
- O
ca O
##dh O
##eri O
##n O
gene O
( O
c O
##dh O
##1 O
) O
mutations O
pre O
##dis O
##pose O
to O
f B-Disease
##ami I-Disease
##lial I-Disease
gas I-Disease
##tric I-Disease
cancer I-Disease
and O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

inherited O
mutations O
in O
the O
e O
- O
ca O
##dh O
##eri O
##n O
gene O
( O
c O
##dh O
##1 O
) O
were O
described O
recently O
in O
three O
ma O
##ori O
kind O
##red O
##s O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
gas I-Disease
##tric I-Disease
cancer I-Disease
. O

f B-Disease
##ami I-Disease
##lial I-Disease
gas I-Disease
##tric I-Disease
cancer I-Disease
is O
genetically O
he O
##tero O
##gene O
##ous O
and O
it O
is O
not O
clear O
what O
proportion O
of O
gas B-Disease
##tric I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
in O
non O
- O
ma O
##ori O
populations O
is O
due O
to O
g O
##er O
##m O
##line O
c O
##dh O
##1 O
mutations O
. O

therefore O
, O
we O
screened O
eight O
f B-Disease
##ami I-Disease
##lial I-Disease
gas I-Disease
##tric I-Disease
cancer I-Disease
kind O
##red O
##s O
of O
br O
##itis O
##h O
and O
i O
##ris O
##h O
origin O
for O
g O
##er O
##m O
##line O
c O
##dh O
##1 O
mutations O
, O
by O
s O
##s O
##c O
##p O
analysis O
of O
all O
16 O
ex O
##ons O
and O
flank O
##ing O
sequences O
. O

each O
family O
contained O
( O
i O
) O
two O
cases O
of O
gas B-Disease
##tric I-Disease
cancer I-Disease
in O
first O
degree O
relatives O
with O
one O
affected O
before O
age O
50 O
years O
; O
or O
( O
ii O
) O
three O
or O
more O
cases O
of O
gas B-Disease
##tric I-Disease
cancer I-Disease
. O

novel O
g O
##er O
##m O
##line O
c O
##dh O
##1 O
mutations O
( O
a O
nonsense O
and O
a O
s O
##p O
##lice O
site O
) O
were O
detected O
in O
two O
families O
( O
25 O
% O
) O
. O

both O
mutations O
were O
predicted O
to O
t O
##run O
##cate O
the O
e O
- O
ca O
##dh O
##eri O
##n O
protein O
in O
the O
signal O
p O
##eptide O
domain O
. O

in O
one O
family O
there O
was O
evidence O
of O
non O
- O
pen O
##et O
##rance O
and O
su O
##s O
##ce O
##pt O
##ibility O
to O
both O
gas B-Disease
##tric I-Disease
and I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
; O
thus O
, O
in O
addition O
to O
six O
cases O
of O
gas B-Disease
##tric I-Disease
cancer I-Disease
, O
a O
c O
##dh O
##1 O
mutation O
carrier O
developed O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
at O
age O
30 O
years O
. O

we O
have O
confirmed O
that O
g O
##er O
##m O
##line O
mutations O
in O
the O
c O
##dh O
##1 O
gene O
cause O
f B-Disease
##ami I-Disease
##lial I-Disease
gas I-Disease
##tric I-Disease
cancer I-Disease
in O
non O
- O
ma O
##ori O
populations O
. O

however O
, O
only O
a O
minority O
of O
f O
##ami O
##lial O
gas B-Disease
##tric I-Disease
cancer I-Disease
##s I-Disease
can O
be O
accounted O
for O
by O
c O
##dh O
##1 O
mutations O
. O

loss O
of O
e O
- O
ca O
##dh O
##eri O
##n O
function O
has O
been O
implicated O
in O
the O
path O
##ogen O
##esis O
of O
s O
##poradic O
color B-Disease
##ec I-Disease
##tal I-Disease
and I-Disease
other I-Disease
cancer I-Disease
##s I-Disease
, O
and O
our O
findings O
provide O
evidence O
that O
g O
##er O
##m O
##line O
c O
##dh O
##1 O
mutations O
pre O
##dis O
##pose O
to O
early O
onset O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

thus O
, O
c O
##dh O
##1 O
should O
be O
investigated O
as O
a O
cause O
of O
inherited O
su O
##s O
##ce O
##pt O
##ibility O
to O
both O
gas B-Disease
##tric I-Disease
and I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
. O

a O
zinc O
finger O
t O
##run O
##cation O
of O
m O
##uri O
##ne O
w O
##t O
##1 O
results O
in O
the O
characteristic O
u B-Disease
##rogen I-Disease
##ital I-Disease
abnormal I-Disease
##ities I-Disease
of O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
. O

the O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
- O
suppress O
##or O
gene O
, O
w O
##t O
##1 O
, O
plays O
a O
key O
role O
in O
u O
##rogen O
##ital O
development O
, O
and O
w B-Disease
##t I-Disease
##1 I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
is O
implicated O
in O
both O
neo B-Disease
##p I-Disease
##lastic I-Disease
( O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
, O
me B-Disease
##so I-Disease
##the I-Disease
##lio I-Disease
##ma I-Disease
, O
le B-Disease
##uke I-Disease
##mia I-Disease
##s I-Disease
, O
and O
breast B-Disease
cancer I-Disease
) O
and O
non B-Disease
##ne I-Disease
##op I-Disease
##lastic I-Disease
( O
g B-Disease
##lo I-Disease
##mer I-Disease
##ulos I-Disease
##cle I-Disease
##rosis I-Disease
) O
disease O
. O

the O
analysis O
of O
diseases O
linked O
specifically O
with O
w O
##t O
##1 O
mutations O
, O
such O
as O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
( O
d B-Disease
##ds I-Disease
) O
, O
can O
provide O
valuable O
insight O
concerning O
the O
role O
of O
w O
##t O
##1 O
in O
development O
and O
disease O
. O

d B-Disease
##ds I-Disease
is O
a O
rare O
childhood O
disease O
characterized O
by O
a O
ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
involving O
me B-Disease
##sang I-Disease
##ial I-Disease
s I-Disease
##cle I-Disease
##rosis I-Disease
, O
x O
##y O
pseudo B-Disease
##her I-Disease
##ma I-Disease
##ph I-Disease
##rod I-Disease
##itis I-Disease
##m I-Disease
, O
and O
/ O
or O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
( O
w B-Disease
##t I-Disease
) O
. O

d B-Disease
##ds I-Disease
patients O
are O
constitutional O
##ly O
he O
##tero O
##zy O
##go O
##us O
for O
ex O
##onic O
point O
mutations O
in O
w O
##t O
##1 O
, O
which O
include O
mutations O
predicted O
to O
t O
##run O
##cate O
the O
protein O
within O
the O
c O
- O
terminal O
zinc O
finger O
( O
z O
##f O
) O
region O
. O

we O
report O
that O
he O
##tero O
##zy O
##gos O
##ity O
for O
a O
targeted O
m O
##uri O
##ne O
w O
##t O
##1 O
all O
##ele O
, O
w O
##t O
##1 O
( O
t O
##m O
##t O
##39 O
##6 O
) O
, O
which O
t O
##run O
##cate O
##s O
z O
##f O
##3 O
at O
co O
##don O
39 O
##6 O
, O
induce O
##s O
me B-Disease
##sang I-Disease
##ial I-Disease
s I-Disease
##cle I-Disease
##rosis I-Disease
characteristic O
of O
d B-Disease
##ds I-Disease
in O
adult O
he O
##tero O
##zy O
##go O
##us O
and O
ch O
##ime O
##ric O
mice O
. O

male B-Disease
g I-Disease
##eni I-Disease
##tal I-Disease
defects I-Disease
also O
were O
evident O
and O
there O
was O
a O
single O
case O
of O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
in O
which O
the O
trans O
##cript O
of O
the O
non O
##tar O
##get O
##ed O
all O
##ele O
showed O
an O
ex O
##on O
9 O
skip O
##ping O
event O
, O
implying O
a O
ca O
##usal O
link O
between O
w B-Disease
##t I-Disease
##1 I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
and O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
##ige I-Disease
##nes I-Disease
##is I-Disease
in O
mice O
. O

however O
, O
the O
mutant O
w O
##t O
##1 O
( O
t O
##m O
##t O
##39 O
##6 O
) O
protein O
accounted O
for O
only O
5 O
% O
of O
w O
##t O
##1 O
in O
both O
he O
##tero O
##zy O
##go O
##us O
em O
##b O
##ryo O
##nic O
stem O
cells O
and O
the O
w B-Disease
##t I-Disease
. O

this O
has O
implications O
regarding O
the O
mechanism O
by O
which O
the O
mutant O
all O
##ele O
ex O
##ert O
##s O
its O
effect O
. O

mechanism O
of O
increased O
iron O
absorption O
in O
m O
##uri O
##ne O
model O
of O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
: O
increased O
duo O
##den O
##al O
expression O
of O
the O
iron O
transport O
##er O
d O
##m O
##t O
##1 O
. O

hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
h B-Disease
##h I-Disease
) O
is O
a O
common O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
tissue O
iron O
deposition O
secondary O
to O
excessive O
diet O
##ary O
iron O
absorption O
. O

we O
recently O
reported O
that O
h O
##fe O
, O
the O
protein O
defect O
##ive O
in O
h B-Disease
##h I-Disease
, O
was O
physically O
associated O
with O
the O
transfer O
##rin O
receptor O
( O
t O
##f O
##r O
) O
in O
duo O
##den O
##al O
cry O
##pt O
cells O
and O
proposed O
that O
mutations O
in O
h O
##fe O
at O
##ten O
##uate O
the O
up O
##take O
of O
transfer O
##rin O
- O
bound O
iron O
from O
plasma O
by O
duo O
##den O
##al O
cry O
##pt O
cells O
, O
leading O
to O
up O
- O
regulation O
of O
transport O
##ers O
for O
diet O
##ary O
iron O
. O

here O
, O
we O
tested O
the O
hypothesis O
that O
h O
##fe O
- O
/ O
- O
mice O
have O
increased O
duo O
##den O
##al O
expression O
of O
the O
di O
##valent O
metal O
transport O
##er O
( O
d O
##m O
##t O
##1 O
) O
. O

by O
4 O
weeks O
of O
age O
, O
the O
h O
##fe O
- O
/ O
- O
mice O
demonstrated O
iron O
loading O
when O
compared O
with O
h O
##fe O
+ O
/ O
+ O
litter O
##mates O
, O
with O
elevated O
transfer O
##rin O
sat O
##uration O
##s O
( O
68 O
. O
4 O
% O
vs O
. O
49 O
. O
8 O
% O
) O
and O
elevated O
liver O
iron O
concentrations O
( O
98 O
##5 O
micro O
##gram O
##s O
vs O
. O
38 O
##1 O
micro O
##gram O
##s O
) O
. O

by O
using O
northern O
b O
##lot O
analyses O
, O
we O
q O
##uant O
##itated O
duo O
##den O
##al O
expression O
of O
both O
classes O
of O
d O
##m O
##t O
##1 O
trans O
##cripts O
one O
containing O
an O
iron O
re O
##sp O
##ons O
##ive O
element O
( O
i O
##re O
) O
, O
called O
d O
##m O
##t O
##1 O
( O
i O
##re O
) O
, O
and O
one O
containing O
no O
i O
##re O
, O
called O
d O
##m O
##t O
##1 O
( O
non O
- O
i O
##re O
) O
. O

the O
positive O
control O
for O
d O
##m O
##t O
##1 O
up O
- O
regulation O
was O
a O
m O
##uri O
##ne O
model O
of O
diet B-Disease
##ary I-Disease
iron I-Disease
deficiency I-Disease
that O
demonstrated O
greatly O
increased O
levels O
of O
duo O
##den O
##al O
d O
##m O
##t O
##1 O
( O
i O
##re O
) O
m O
##rna O
. O

h O
##fe O
- O
/ O
- O
mice O
also O
demonstrated O
an O
increase O
in O
duo O
##den O
##al O
d O
##m O
##t O
##1 O
( O
i O
##re O
) O
m O
##rna O
( O
average O
7 O
. O
7 O
- O
fold O
) O
, O
despite O
their O
elevated O
transfer O
##rin O
sat O
##uration O
and O
he O
##pa O
##tic O
iron O
content O
. O

duo O
##den O
##al O
expression O
of O
d O
##m O
##t O
##1 O
( O
non O
- O
i O
##re O
) O
was O
not O
increased O
, O
nor O
was O
he O
##pa O
##tic O
expression O
of O
d O
##m O
##t O
##1 O
increased O
. O

these O
data O
support O
the O
model O
for O
h O
##h O
in O
which O
h O
##fe O
mutations O
lead O
to O
inappropriate O
##ly O
low O
cry O
##pt O
cell O
iron O
, O
with O
result O
##ant O
stab O
##ilization O
of O
d O
##m O
##t O
##1 O
( O
i O
##re O
) O
m O
##rna O
, O
up O
- O
regulation O
of O
d O
##m O
##t O
##1 O
, O
and O
increased O
absorption O
of O
diet O
##ary O
iron O
. O

ne O
##uro O
##phy O
##sio O
##log O
##ic O
follow O
- O
up O
of O
long O
- O
term O
diet O
##ary O
treatment O
in O
adult O
- O
onset O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

objective O
to O
monitor O
the O
effects O
of O
diet O
##ary O
treatment O
in O
adult O
- O
onset O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
by O
means O
of O
so O
##mat O
##ose O
##nso O
##ry O
e O
##voked O
potential O
##s O
( O
se O
##ps O
) O
and O
motor O
e O
##voked O
potential O
##s O
( O
me O
##ps O
) O
. O

background O
se O
##ps O
and O
me O
##ps O
have O
proved O
useful O
in O
revealing O
signs O
of O
progressively O
severe O
, O
central O
dying B-Disease
- I-Disease
back I-Disease
a I-Disease
##xon I-Disease
##op I-Disease
##athy I-Disease
in O
early O
stages O
of O
adult O
- O
onset O
al B-Disease
##d I-Disease
. O

methods O
eight O
patients O
with O
adult O
- O
onset O
al B-Disease
##d I-Disease
underwent O
clinical O
examination O
, O
brain O
and O
spine O
m O
##ri O
, O
and O
se O
##p O
and O
me O
##p O
studies O
before O
and O
after O
3 O
years O
of O
lo O
##ren O
##zo O
##s O
oil O
diet O
##ary O
therapy O
. O

results O
before O
treatment O
, O
brain O
m O
##ri O
was O
normal O
in O
five O
patients O
. O

three O
of O
these O
patients O
had O
pure O
spinal B-Disease
se I-Disease
##p I-Disease
abnormal I-Disease
##ities I-Disease
and O
in O
the O
remaining O
two O
patients O
se O
##ps O
showed O
signs O
of O
involvement O
of O
both O
the O
spinal O
and O
cerebral O
so O
##mat O
##ose O
##nso O
##ry O
tracts O
. O

after O
treatment O
, O
the O
three O
patients O
with O
pure O
spinal B-Disease
abnormal I-Disease
##ities I-Disease
showed O
clinical O
and O
ne O
##uro O
##phy O
##sio O
##log O
##ic O
worse O
##ning O
, O
whereas O
the O
two O
patients O
with O
a O
more O
advanced O
stage O
of O
disease O
( O
exhibited O
by O
se O
##ps O
) O
showed O
substantially O
unchanged O
clinical O
and O
ne O
##uro O
##phy O
##sio O
##log O
##ic O
features O
. O

the O
patients O
with O
abnormal O
brain O
m O
##ri O
at O
the O
onset O
of O
treatment O
showed O
clinical O
and O
ne O
##uro O
##phy O
##sio O
##log O
##ic O
worse O
##ning O
. O

conclusions O
lo O
##ren O
##zo O
##s O
oil O
therapy O
had O
no O
effect O
on O
patients O
with O
evidence O
of O
inflammatory B-Disease
brain I-Disease
lesions I-Disease
. O

more O
##over O
, O
in O
patients O
without O
clear O
signs O
of O
inflammatory O
damage O
, O
this O
treatment O
does O
not O
modify O
significantly O
the O
natural O
course O
of O
the O
disease O
. O

however O
, O
because O
effective O
treatments O
should O
begin O
before O
the O
onset O
of O
severe O
ne O
##uro O
##log O
##ic O
symptoms O
, O
se O
##ps O
and O
me O
##ps O
should O
be O
considered O
to O
evaluate O
the O
effectiveness O
of O
other O
experimental O
treatments O
in O
the O
patient O
with O
a O
negative O
brain O
m O
##ri O
. O

g O
##ch O
##1 O
mutation O
in O
a O
patient O
with O
adult O
- O
onset O
or B-Disease
##oman I-Disease
##di I-Disease
##bula I-Disease
##r I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
. O

the O
authors O
report O
a O
mutation O
in O
ex O
##on O
5 O
of O
g O
##ch O
##1 O
in O
a O
patient O
with O
adult O
- O
onset O
or B-Disease
##oman I-Disease
##di I-Disease
##bula I-Disease
##r I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
and O
no O
obvious O
family O
history O
of O
d B-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
. O

the O
patient O
responded O
positively O
to O
treatment O
with O
l O
- O
do O
##pa O
. O

these O
findings O
demonstrate O
that O
g O
##ch O
##1 O
mutations O
must O
be O
considered O
even O
in O
patients O
with O
d B-Disease
##ys I-Disease
##ton I-Disease
##ic I-Disease
symptoms O
not O
typical O
of O
do B-Disease
##pa I-Disease
- I-Disease
re I-Disease
##sp I-Disease
##ons I-Disease
##ive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
. O

g O
##er O
##m O
##line O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
k O
##ore O
##an O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
patients O
. O

we O
extensively O
analyzed O
g O
##eno O
##mic O
d O
##na O
and O
messenger O
r O
##na O
( O
m O
##rna O
) O
from O
62 O
unrelated O
k O
##ore O
##an O
patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
for O
identification O
of O
g O
##er O
##m O
##line O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
mutations O
. O

we O
adopted O
both O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
analysis O
and O
a O
method O
of O
analysis O
involving O
the O
reverse O
transcription O
- O
polymer O
##ase O
chain O
reaction O
( O
r O
##t O
- O
p O
##c O
##r O
) O
followed O
by O
a O
protein O
t O
##run O
##cation O
test O
( O
p O
##tt O
) O
. O

d O
##na O
se O
##quencing O
confirmed O
all O
alterations O
represented O
by O
a O
##ber O
##rant O
bands O
. O

g O
##er O
##m O
##line O
mutations O
were O
identified O
in O
38 O
patients O
( O
61 O
% O
) O
. O

nineteen O
of O
the O
detected O
mutations O
were O
presumed O
to O
be O
novel O
, O
thus O
emphasizing O
the O
he O
##tero O
##gene O
##ity O
of O
the O
mutation O
##al O
spectrum O
in O
k O
##ore O
##an O
f B-Disease
##ap I-Disease
patients O
. O

in O
the O
initial O
48 O
patients O
, O
s O
##s O
##c O
##p O
analysis O
was O
followed O
by O
p O
##tt O
for O
those O
patients O
for O
whom O
no O
detect O
##able O
mutations O
were O
found O
by O
s O
##s O
##c O
##p O
. O

using O
this O
combined O
approach O
, O
we O
identified O
g O
##er O
##m O
##line O
a B-Disease
##p I-Disease
##c I-Disease
gene O
mutations O
in O
29 O
of O
the O
48 O
f B-Disease
##ap I-Disease
patients O
( O
60 O
% O
) O
, O
including O
6 O
patients O
in O
whom O
s O
##s O
##c O
##p O
analysis O
failed O
to O
distinguish O
the O
mutant O
all O
##ele O
. O

in O
the O
14 O
later O
patients O
, O
we O
identified O
t O
##run O
##cating O
mutations O
in O
9 O
patients O
( O
64 O
% O
) O
using O
p O
##tt O
only O
. O

our O
results O
confirm O
that O
the O
mutation O
detection O
rate O
with O
p O
##tt O
was O
superior O
to O
that O
with O
s O
##s O
##c O
##p O
, O
and O
suggest O
that O
p O
##tt O
would O
be O
a O
more O
practical O
screening O
method O
to O
detect O
g O
##er O
##m O
##line O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
f B-Disease
##ap I-Disease
patients O
. O

molecular O
e O
##pid O
##em O
##iology O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
he O
##tero O
##zy O
##got O
##es O
with O
an O
a O
##rg O
##9 O
##5 O
##stop O
mutation O
of O
the O
c O
##9 O
gene O
in O
j O
##apa O
##n O
. O

deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c O
##9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency I-Disease
in O
j O
##apa O
##n O
, O
with O
an O
incidence O
of O
approximately O
one O
ho O
##mo O
##zy O
##got O
##e O
in O
1000 O
, O
but O
is O
very O
rare O
in O
other O
countries O
. O

genetic O
analyses O
of O
j O
##apa O
##nese O
c B-Disease
##9 I-Disease
deficiency I-Disease
have O
shown O
that O
a O
c O
- O
to O
- O
t O
transition O
leading O
to O
t O
##ga O
stop O
co O
##don O
for O
a O
##rg O
##9 O
##5 O
in O
ex O
##on O
4 O
of O
the O
c O
##9 O
gene O
( O
a O
##rg O
##9 O
##5 O
##stop O
) O
is O
common O
in O
j O
##apa O
##nese O
c B-Disease
##9 I-Disease
deficiency I-Disease
. O

to O
determine O
the O
prevalence O
of O
he O
##tero O
##zy O
##go O
##us O
carriers O
of O
the O
a O
##rg O
##9 O
##5 O
##stop O
mutation O
in O
a O
j O
##apa O
##nese O
population O
, O
we O
collected O
d O
##na O
samples O
from O
300 O
individuals O
in O
two O
of O
the O
four O
main O
islands O
of O
j O
##apa O
##n O
. O

he O
##tero O
##zy O
##got O
##e O
detection O
was O
performed O
with O
an O
all O
##ele O
- O
specific O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
all O
##ele O
##s O
, O
followed O
by O
confirmation O
with O
p O
##c O
##r O
/ O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
analysis O
and O
direct O
se O
##quencing O
. O

twenty O
individuals O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
a O
##rg O
##9 O
##5 O
##stop O
mutation O
. O

none O
was O
ho O
##mo O
##zy O
##go O
##us O
. O

the O
prevalence O
of O
carriers O
of O
the O
a O
##rg O
##9 O
##5 O
##stop O
mutation O
was O
6 O
. O

7 O
% O
( O
20 O
/ O
300 O
) O
. O

an O
estimated O
frequency O
( O
0 O
. O
12 O
% O
) O
of O
complete O
c B-Disease
##9 I-Disease
deficiency I-Disease
due O
to O
ho O
##mo O
##zy O
##go O
##us O
a O
##rg O
##9 O
##5 O
##stop O
mutation O
was O
consistent O
with O
frequencies O
determined O
by O
se O
##rol O
##ogical O
studies O

the O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
protein O
, O
h O
##fe O
, O
specifically O
regulate O
##s O
transfer O
##rin O
- O
mediated O
iron O
up O
##take O
in O
he O
##la O
cells O
. O

h O
##fe O
is O
the O
protein O
product O
of O
the O
gene O
m O
##uta O
##ted O
in O
the O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
fed O
##er O
, O
j O
. O

n O
. O
, O
g O
##nir O
##ke O
, O
a O
. O
, O
th O
##oma O
##s O
, O
w O
. O
, O
t O
##su O
##chi O
##hashi O
, O
z O
. O
, O
r O
##udd O
##y O
, O
d O
. O

a O
. O
, O
b O
##asa O
##va O
, O
a O
. O
, O
dorm O
##ishi O
##an O
, O
f O
. O
, O
do O
##ming O
##o O
, O
r O
. O

j O
. O
, O
el O
##lis O
, O
m O
. O

c O
. O
, O
full O
##an O
, O
a O
. O
, O
hint O
##on O
, O
l O
. O

m O
. O
, O
j O
##ones O
, O
n O
. O

l O
. O
, O
k O
##im O
##mel O
, O
b O
. O

e O
. O
, O
k O
##ron O
##mal O
, O
g O
. O

s O
. O
, O
la O
##uer O
, O
p O
. O
, O
le O
##e O
, O
v O
. O

k O
. O
, O
lo O
##eb O
, O
d O
. O

b O
. O
, O
map O
##a O
, O
f O
. O

a O
. O
, O
m O
##cc O
##le O
##lland O
, O
e O
. O
, O
me O
##yer O
, O
n O
. O

c O
. O
, O
mint O
##ier O
, O
g O
. O

a O
. O
, O
m O
##oe O
##ller O
, O
n O
. O
, O
m O
##oor O
##e O
, O
t O
. O
, O
m O
##ori O
##kan O
##g O
, O
e O
. O
, O
p O
##rass O
##s O
, O
c O
. O

e O
. O
, O
q O
##uin O
##tana O
, O
l O
. O
, O
star O
##nes O
, O
s O
. O

m O
. O
, O
s O
##cha O
##tz O
##man O
, O
r O
. O

c O
. O
, O
br O
##unk O
##e O
, O
k O
. O

j O
. O
, O
d O
##ray O
##na O
, O
d O
. O

t O
. O
, O
r O
##isch O
, O
n O
. O

j O
. O
, O
bacon O
, O
b O
. O

r O
. O
, O
and O
wolf O
##f O
, O
r O
. O

r O
. O

( O
1996 O
) O
na O
##t O
. O

gene O
##t O
. O

13 O
, O
39 O
##9 O
- O
40 O
##8 O
) O
. O

at O
the O
cell O
surface O
, O
h O
##fe O
complexes O
with O
transfer O
##rin O
receptor O
( O
t O
##f O
##r O
) O
, O
increasing O
the O
di O
##sso O
##ciation O
constant O
of O
transfer O
##rin O
( O
t O
##f O
) O
for O
its O
receptor O
10 O
- O
fold O
( O
gross O
, O
c O
. O

n O
. O
, O
i O
##rri O
##nk O
##i O
, O
a O
. O
, O
fed O
##er O
, O
j O
. O
n O
. O
, O
and O
en O
##ns O
, O
c O
. O
a O
. O
( O
1998 O
) O
j O
. O
bio O
##l O
. O
ch O
##em O
. O
27 O
##3 O
, O
220 O
##6 O
##8 O
- O
220 O
##7 O
##4 O
; O
fed O
##er O
, O
j O
. O
n O
. O
, O
penny O
, O
d O
. O
m O
. O
, O
i O
##rri O
##nk O
##i O
, O
a O
. O
, O
le O
##e O
, O
v O
. O
k O
. O
, O
le O
##bro O
##n O
, O
j O
. O
a O
. O
, O
wa O
##ts O
##on O
, O
n O
. O
, O
t O
##su O
##chi O
##hashi O
, O
z O
. O
, O
si O
##gal O
, O
e O
. O
, O
b O
##jo O
##rk O
##man O
, O
p O
. O
j O
. O
, O
and O
s O
##cha O
##tz O
##man O
, O
r O
. O
c O
. O
( O
1998 O
) O
pro O
##c O
. O
na O
##tl O
. O

a O
##ca O
##d O
. O

s O
##ci O
. O

u O
s O
a O
95 O
, O
147 O
##2 O
- O
147 O
##7 O
) O
. O

h O
##fe O
does O
not O
remain O
at O
the O
cell O
surface O
, O
but O
traffic O
##s O
with O
t O
##f O
##r O
to O
t O
##f O
- O
positive O
internal O
compartment O
##s O
( O
gross O
et O
al O
. O
, O
1998 O
) O
. O

using O
a O
he O
##la O
cell O
line O
in O
which O
the O
expression O
of O
h O
##fe O
is O
controlled O
by O
te O
##tra O
##cy O
##cline O
, O
we O
show O
that O
the O
expression O
of O
h O
##fe O
reduces O
55 O
##fe O
up O
##take O
from O
t O
##f O
by O
33 O
% O
but O
does O
not O
affect O
the O
end O
##oc O
##ytic O
or O
ex O
##oc O
##ytic O
rates O
of O
t O
##f O
##r O
cycling O
. O

therefore O
, O
h O
##fe O
appears O
to O
reduce O
cellular O
acquisition O
of O
iron O
from O
t O
##f O
within O
end O
##oc O
##ytic O
compartment O
##s O
. O

h O
##fe O
specifically O
reduces O
iron O
up O
##take O
from O
t O
##f O
, O
as O
non O
- O
t O
##f O
- O
mediated O
iron O
up O
##take O
from O
f O
##e O
- O
ni O
##tri O
##lot O
##ria O
##ce O
##tic O
acid O
is O
not O
altered O
. O

these O
results O
explain O
the O
decreased O
f O
##er O
##rit O
##in O
levels O
seen O
in O
our O
he O
##la O
cell O
system O
and O
demonstrate O
the O
specific O
control O
of O
h O
##fe O
over O
the O
t O
##f O
- O
mediated O
pathway O
of O
iron O
up O
##take O
. O

these O
results O
also O
have O
implications O
for O
the O
understanding O
of O
cellular O
iron O
home O
##ost O
##asis O
in O
organs O
such O
as O
the O
liver O
, O
pan O
##cre O
##as O
, O
heart O
, O
and O
s O
##ple O
##en O
that O
are O
iron O
loaded O
in O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##to I-Disease
##tic I-Disease
individuals O
lacking O
functional O
h O
##fe O
. O

mutation O
and O
ha O
##p O
##lot O
##ype O
studies O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
reveal O
new O
ancestral O
relationships O
and O
evidence O
for O
a O
high O
carrier O
frequency O
with O
reduced O
pen O
##et O
##rance O
in O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
is O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever O
with O
se B-Disease
##ros I-Disease
##itis I-Disease
or O
s B-Disease
##yn I-Disease
##ov I-Disease
##itis I-Disease
. O

the O
f B-Disease
##m I-Disease
##f I-Disease
gene O
( O
me O
##f O
##v O
) O
was O
clone O
##d O
recently O
, O
and O
four O
miss O
##ense O
mutations O
were O
identified O
. O

here O
we O
present O
data O
from O
non O
- O
ash O
##ken O
##azi O
j O
##ew O
##ish O
and O
a O
##rab O
patients O
in O
whom O
we O
had O
not O
originally O
found O
mutations O
and O
from O
a O
new O
, O
more O
ethnic O
##ally O
diverse O
panel O
. O

among O
90 O
s O
##ym O
##pt O
##oma O
##tic O
mutation O
- O
positive O
individuals O
, O
11 O
mutations O
accounted O
for O
79 O
% O
of O
carrier O
chromosome O
##s O
. O

of O
the O
two O
mutations O
that O
are O
novel O
, O
one O
alter O
##s O
the O
same O
residue O
( O
680 O
) O
as O
a O
previously O
known O
mutation O
, O
and O
the O
other O
( O
p O
##36 O
##9 O
##s O
) O
is O
located O
in O
ex O
##on O
3 O
. O

consistent O
with O
another O
recent O
report O
, O
the O
e O
##14 O
##8 O
##q O
mutation O
was O
observed O
in O
patients O
of O
several O
ethnic O
##ities O
and O
on O
multiple O
micro O
##sat O
##elli O
##te O
ha O
##p O
##lot O
##ype O
##s O
, O
but O
ha O
##p O
##lot O
##ype O
data O
indicate O
an O
ancestral O
relationships O
between O
non O
- O
j O
##ew O
##ish O
it O
##alia O
##n O
and O
ash O
##ken O
##azi O
j O
##ew O
##ish O
patients O
with O
f B-Disease
##m I-Disease
##f I-Disease
and O
other O
affected O
populations O
. O

among O
approximately O
200 O
anonymous O
ash O
##ken O
##azi O
j O
##ew O
##ish O
d O
##na O
samples O
, O
the O
me O
##f O
##v O
carrier O
frequency O
was O
21 O
% O
, O
with O
e O
##14 O
##8 O
##q O
the O
most O
common O
mutation O
. O

several O
lines O
of O
evidence O
indicate O
reduced O
pen O
##et O
##rance O
among O
ash O
##ken O
##azi O
j O
##ews O
, O
especially O
for O
e O
##14 O
##8 O
##q O
, O
p O
##36 O
##9 O
##s O
, O
and O
k O
##6 O
##9 O
##5 O
##r O
. O

nevertheless O
, O
e O
##14 O
##8 O
##q O
helps O
account O
for O
re O
##cess O
##ive O
inheritance O
in O
an O
ash O
##ken O
##azi O
family O
previously O
reported O
as O
an O
unusual O
case O
of O
dominant O
##ly O
inherited O
f B-Disease
##m I-Disease
##f I-Disease
. O

the O
presence O
of O
three O
frequent O
me O
##f O
##v O
mutations O
in O
multiple O
me O
##dit O
##er O
##rane O
##an O
populations O
strongly O
suggests O
a O
he O
##tero O
##zy O
##got O
##e O
advantage O
in O
this O
geographic O
region O
. O

auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
with O
defect O
##ive O
f O
##as O
: O
g O
##eno O
##type O
influences O
pen O
##et O
##rance O
. O

auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
( O
al B-Disease
##ps I-Disease
) O
is O
a O
disorder B-Disease
of I-Disease
l I-Disease
##ymph I-Disease
##oc I-Disease
##yte I-Disease
home I-Disease
##ost I-Disease
##asis I-Disease
and I-Disease
im I-Disease
##mu I-Disease
##nological I-Disease
tolerance I-Disease
. O

most O
patients O
have O
a O
he O
##tero O
##zy O
##go O
##us O
mutation O
in O
the O
a O
##pt O
##1 O
gene O
, O
which O
en O
##codes O
f O
##as O
( O
c O
##d O
##9 O
##5 O
, O
a O
##po O
- O
1 O
) O
, O
media O
##tor O
of O
an O
a O
##pop O
##to O
##tic O
pathway O
crucial O
to O
l O
##ymph O
##oc O
##yte O
home O
##ost O
##asis O
. O

of O
17 O
unique O
a O
##pt O
##1 O
mutations O
in O
unrelated O
al B-Disease
##ps I-Disease
pro O
##band O
##s O
, O
12 O
( O
71 O
% O
) O
occurred O
in O
ex O
##ons O
7 O
- O
9 O
, O
which O
en O
##code O
the O
in O
##tra O
##cellular O
portion O
of O
f O
##as O
. O

in O
v O
##it O
##ro O
, O
activated O
l O
##ymph O
##ocytes O
from O
all O
17 O
patients O
showed O
a O
##pop O
##to O
##tic O
defects O
when O
exposed O
to O
an O
anti O
- O
f O
##as O
ago O
##nist O
mon O
##oc O
##lon O
##al O
anti O
##body O
. O

similar O
defects O
were O
found O
in O
a O
f O
##as O
- O
negative O
cell O
line O
trans O
##fected O
with O
c O
##dn O
##as O
bearing O
each O
of O
the O
mutations O
. O

in O
co O
##tra O
##ns O
##fect O
##ion O
experiments O
, O
f O
##as O
construct O
##s O
with O
either O
in O
##tra O
- O
or O
extra O
##cellular O
mutations O
caused O
dominant O
in O
##hibition O
of O
a O
##pop O
##tosis O
mediated O
by O
wild O
- O
type O
f O
##as O
. O

two O
miss O
##ense O
f O
##as O
variants O
, O
not O
restricted O
to O
patients O
with O
al B-Disease
##ps I-Disease
, O
were O
identified O
. O

variant O
a O
( O
- O
1 O
) O
t O
at O
the O
f O
##as O
signal O
- O
sequence O
c O
##lea O
##vage O
site O
, O
which O
media O
##tes O
a O
##pop O
##tosis O
less O
well O
than O
wild O
- O
type O
f O
##as O
and O
is O
partially O
inhibitor O
##y O
, O
was O
present O
in O
13 O
% O
of O
a O
##f O
##rica O
##n O
am O
##eric O
##an O
all O
##ele O
##s O
. O

among O
the O
al B-Disease
##ps I-Disease
- O
associated O
f O
##as O
mutant O
##s O
, O
dominant O
in O
##hibition O
of O
a O
##pop O
##tosis O
was O
much O
more O
pronounced O
in O
mutant O
##s O
affecting O
the O
in O
##tra O
##cellular O
, O
versus O
extra O
##cellular O
, O
portion O
of O
the O
f O
##as O
receptor O
. O

mutations O
causing O
disruption O
of O
the O
in O
##tra O
##cellular O
f O
##as O
death O
domain O
also O
showed O
a O
higher O
pen O
##et O
##rance O
of O
al B-Disease
##ps I-Disease
p O
##hen O
##otype O
features O
in O
mutation O
- O
bearing O
relatives O
. O

significant O
al B-Disease
##ps I-Disease
- O
related O
m O
##or O
##bid O
##ity O
occurred O
in O
44 O
% O
of O
relatives O
with O
in O
##tra O
##cellular O
mutations O
, O
versus O
0 O
% O
of O
relatives O
with O
extra O
##cellular O
mutations O
. O

thus O
, O
the O
location O
of O
mutations O
within O
a O
##pt O
##1 O
strongly O
influences O
the O
development O
and O
the O
severity O
of O
al B-Disease
##ps I-Disease
. O

multi O
##centric O
origin O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
( O
h O
##fe O
) O
mutations O
. O

genetic B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
g B-Disease
##h I-Disease
) O
is O
believed O
to O
be O
a O
disease O
restricted O
to O
those O
of O
euro O
##pe O
##an O
ancestry O
. O

in O
northwestern O
euro O
##pe O
, O
[UNK] O
80 O
% O
of O
g B-Disease
##h I-Disease
patients O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
one O
mutation O
, O
the O
substitution O
of O
t O
##yr O
##os O
##ine O
for O
c O
##ys O
##tein O
##e O
at O
position O
28 O
##2 O
( O
c O
##28 O
##2 O
##y O
) O
in O
the O
un O
##p O
##ro O
##cess O
##ed O
protein O
. O

in O
a O
proportion O
of O
g B-Disease
##h I-Disease
patients O
, O
two O
mutations O
are O
present O
, O
c O
##28 O
##2 O
##y O
and O
h O
##6 O
##3 O
##d O
. O

the O
clinical O
significance O
of O
this O
second O
mutation O
is O
such O
that O
it O
appears O
to O
pre O
##dis O
##pose O
1 O
% O
- O
2 O
% O
of O
compound O
he O
##tero O
##zy O
##got O
##es O
to O
expression O
of O
the O
disease O
. O

the O
distribution O
of O
the O
two O
mutations O
differ O
, O
c O
##28 O
##2 O
##y O
being O
limited O
to O
those O
of O
northwestern O
euro O
##pe O
##an O
ancestry O
and O
h O
##6 O
##3 O
##d O
being O
found O
at O
all O
##ele O
frequencies O
[UNK] O
5 O
% O
, O
in O
euro O
##pe O
, O
in O
countries O
bordering O
the O
me O
##dit O
##er O
##rane O
##an O
, O
in O
the O
middle O
east O
, O
and O
in O
the O
in O
##dian O
sub O
##continent O
. O

the O
c O
##28 O
##2 O
##y O
mutation O
occurs O
on O
a O
ha O
##p O
##lot O
##ype O
that O
extends O
[UNK] O
/ O
= O
6 O
m O
##b O
, O
suggesting O
that O
this O
mutation O
has O
arise O
##n O
during O
the O
past O
2 O
, O
000 O
years O
. O

the O
h O
##6 O
##3 O
##d O
mutation O
is O
older O
and O
does O
not O
occur O
on O
such O
a O
large O
extended O
ha O
##p O
##lot O
##ype O
, O
the O
ha O
##p O
##lot O
##ype O
in O
this O
case O
extending O
[UNK] O
/ O
= O
700 O
k O
##b O
. O

here O
we O
report O
the O
finding O
of O
the O
h O
##6 O
##3 O
##d O
and O
c O
##28 O
##2 O
##y O
mutations O
on O
new O
ha O
##p O
##lot O
##ype O
##s O
. O

in O
s O
##ri O
la O
##nka O
we O
have O
found O
h O
##6 O
##3 O
##d O
on O
three O
new O
ha O
##p O
##lot O
##ype O
##s O
and O
have O
found O
c O
##28 O
##2 O
##y O
on O
one O
new O
ha O
##p O
##lot O
##ype O
, O
demonstrating O
that O
these O
mutations O
have O
arise O
##n O
independently O
on O
this O
island O
. O

these O
results O
suggest O
that O
the O
h O
##fe O
gene O
has O
been O
the O
subject O
of O
selection O
pressure O
. O

these O
selection O
pressures O
could O
be O
due O
to O
infectious B-Disease
diseases I-Disease
, O
environmental O
conditions O
, O
or O
other O
genetic B-Disease
disorders I-Disease
such O
as O
an B-Disease
##emia I-Disease
. O

a O
retrospective O
anonymous O
pilot O
study O
in O
screening O
newborn O
##s O
for O
h O
##fe O
mutations O
in O
scan O
##dina O
##vian O
populations O
. O

we O
have O
retrospective O
##ly O
analyzed O
83 O
##7 O
random O
an O
##ony O
##mized O
dried O
blood O
spot O
( O
d O
##bs O
) O
samples O
from O
neon O
##ata O
##l O
screening O
programs O
in O
scan O
##dina O
##via O
for O
mutations O
in O
h O
##fe O
, O
the O
candidate O
gene O
for O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

we O
have O
found O
c O
##28 O
##2 O
##y O
all O
##ele O
frequencies O
of O
2 O
. O

3 O
% O
( O
+ O
2 O
. O
0 O
% O
) O
( O
- O
1 O
. O
3 O
% O
) O
in O
green O
##land O
, O
4 O
. O

5 O
% O
+ O
/ O
- O
1 O
. O

9 O
% O
in O
ice O
##land O
, O
5 O
. O

1 O
% O
+ O
/ O
- O
2 O
. O

3 O
% O
in O
the O
f O
##ae O
##ro O
##e O
islands O
, O
and O
8 O
. O

2 O
% O
+ O
/ O
- O
2 O
. O

7 O
% O
in O
den O
##mark O
. O

the O
high O
prevalence O
of O
h O
##fe O
mutations O
in O
den O
##mark O
suggests O
that O
population O
screening O
for O
the O
c O
##28 O
##2 O
##y O
mutation O
could O
be O
highly O
advantage O
##ous O
in O
terms O
of O
prevent O
##ive O
health O
care O
. O

long O
- O
term O
follow O
- O
up O
evaluation O
of O
c O
##28 O
##2 O
##y O
ho O
##mo O
##zy O
##got O
##es O
and O
h O
##6 O
##3 O
##d O
/ O
c O
##28 O
##2 O
##y O
compound O
he O
##tero O
##zy O
##got O
##es O
will O
give O
an O
indication O
of O
the O
pen O
##et O
##rance O
of O
the O
mutations O
. O

identification O
of O
the O
mutation O
in O
the O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
mouse O
model O
. O

al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
) O
, O
an O
in B-Disease
##born I-Disease
error I-Disease
of I-Disease
metabolism I-Disease
caused O
by O
the O
loss O
of O
ho O
##mo O
##gent O
##isa O
##te O
1 O
, O
2 O
- O
di O
##ox O
##y O
##gen O
##ase O
( O
h O
##g O
##d O
) O
, O
has O
been O
described O
in O
a O
mouse O
model O
created O
by O
et O
##hyl O
##ni O
##tro O
##so O
##ure O
##a O
m O
##uta O
##genesis O
but O
the O
mutation O
in O
these O
mice O
has O
not O
previously O
been O
identified O
. O

we O
used O
r O
##t O
- O
p O
##c O
##r O
to O
am O
##p O
##lify O
the O
h O
##g O
##d O
c O
##dn O
##a O
from O
h O
##g O
##d O
( O
a O
##ku O
) O
/ O
h O
##g O
##d O
( O
a O
##ku O
) O
mice O
. O

two O
products O
shorter O
than O
the O
wild O
- O
type O
product O
were O
am O
##plified O
. O

restriction O
mapping O
and O
d O
##na O
se O
##quencing O
were O
then O
used O
to O
identify O
the O
h O
##g O
##d O
( O
a O
##ku O
) O
mouse O
mutation O
, O
found O
to O
be O
a O
single O
base O
change O
in O
a O
s O
##p O
##lice O
donor O
consensus O
sequence O
, O
causing O
ex O
##on O
skip O
##ping O
and O
frame O
- O
shifted O
products O
. O

this O
base O
change O
allowed O
us O
to O
create O
a O
non O
- O
radioactive O
g O
##eno O
##ty O
##ping O
ass O
##ay O
for O
this O
all O
##ele O
. O

non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
associated O
with O
enlarged B-Disease
vest I-Disease
##ib I-Disease
##ular I-Disease
a I-Disease
##queduct I-Disease
is O
caused O
by O
p B-Disease
##ds I-Disease
mutations O
. O

enlarged B-Disease
vest I-Disease
##ib I-Disease
##ular I-Disease
a I-Disease
##queduct I-Disease
( O
e B-Disease
##va I-Disease
) O
, O
known O
as O
the O
most O
common O
form O
of O
inner B-Disease
ear I-Disease
abnormal I-Disease
##ity I-Disease
, O
has O
recently O
been O
of O
particular O
genetic O
interest O
because O
this O
an O
##oma O
##ly O
is O
inherited O
in O
a O
re O
##cess O
##ive O
manner O
. O

the O
lo O
##cus O
for O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
sensor I-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
with O
e B-Disease
##va I-Disease
has O
been O
mapped O
to O
the O
same O
ch O
##rom O
##oso O
##mal O
region O
, O
7 O
##q O
##31 O
, O
as O
the O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
lo O
##cus O
. O

in O
the O
present O
study O
, O
seven O
mutations O
in O
the O
p B-Disease
##ds I-Disease
gene O
( O
p O
##ds O
) O
, O
the O
gene O
responsible O
for O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
, O
have O
been O
found O
in O
families O
of O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
sensor I-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
with O
e B-Disease
##va I-Disease
. O

one O
family O
is O
ho O
##mo O
##zy O
##go O
##us O
, O
three O
families O
are O
compound O
he O
##tero O
##zy O
##got O
##es O
, O
and O
two O
families O
are O
he O
##tero O
##zy O
##go O
##us O
but O
with O
no O
other O
mutation O
detected O
. O

the O
present O
results O
provide O
evidence O
that O
mutations O
in O
p O
##ds O
cause O
both O
s B-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
and I-Disease
non I-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
. O
. O

mutation O
##al O
analysis O
and O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
of O
29 O
unrelated O
j O
##apa O
##nese O
patients O
with O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

background O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
is O
an O
inherited B-Disease
disease I-Disease
characterized O
by O
progressive O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
, O
occasionally O
associated O
with O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
. O

the O
classic O
form O
of O
al B-Disease
##d I-Disease
usually O
has O
onset O
in O
childhood O
( O
childhood B-Disease
cerebral I-Disease
al I-Disease
##d I-Disease
) O
, O
with O
rapid O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
de I-Disease
##ter I-Disease
##ior I-Disease
##ation I-Disease
leading O
to O
a O
ve O
##get O
##ative O
state O
. O

adult O
- O
onset O
cerebral B-Disease
al I-Disease
##d I-Disease
also O
presents O
with O
rapidly O
progressive O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
. O

mild O
##er O
p O
##hen O
##otype O
##s O
such O
as O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
and O
add B-Disease
##ison I-Disease
disease I-Disease
only O
also O
have O
been O
recognized O
. O

despite O
discovery O
of O
the O
ca O
##usa O
##tive O
gene O
, O
a O
molecular O
basis O
for O
the O
diverse O
clinical O
presentations O
remains O
to O
be O
el O
##uc O
##idated O
. O

objectives O
to O
conduct O
mutation O
##al O
analyses O
in O
29 O
j O
##apa O
##nese O
patients O
with O
al B-Disease
##d I-Disease
from O
29 O
unrelated O
families O
, O
to O
obtain O
knowledge O
of O
the O
spectrum O
of O
mutations O
in O
this O
gene O
, O
and O
to O
study O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
j O
##apa O
##nese O
patients O
. O

methods O
the O
29 O
patients O
comprised O
13 O
patients O
with O
childhood B-Disease
cerebral I-Disease
al I-Disease
##d I-Disease
, O
11 O
patients O
with O
adult O
- O
onset O
cerebral B-Disease
al I-Disease
##d I-Disease
, O
and O
5 O
patients O
with O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
. O

we O
conducted O
detailed O
mutation O
##al O
analyses O
of O
29 O
unrelated O
j O
##apa O
##nese O
patients O
with O
al B-Disease
##d I-Disease
by O
g O
##eno O
##mic O
southern O
b O
##lot O
analysis O
and O
direct O
n O
##uc O
##leo O
##tide O
sequence O
analysis O
of O
reverse O
trans O
##cript O
##ase O
- O
polymer O
##ase O
chain O
reaction O
products O
derived O
from O
total O
r O
##na O
that O
was O
extracted O
from O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
, O
l O
##ymph O
##ob O
##last O
##oid O
cells O
, O
or O
peripheral O
blood O
le O
##uk O
##ocytes O
. O

results O
three O
patients O
with O
adult O
- O
onset O
cerebral B-Disease
al I-Disease
##d I-Disease
were O
identified O
as O
having O
large O
g O
##eno O
##mic O
rear O
##rang O
##ement O
##s O
. O

the O
remaining O
26 O
patients O
were O
identified O
as O
having O
21 O
independent O
mutations O
, O
including O
12 O
novel O
mutations O
resulting O
in O
small O
n O
##uc O
##leo O
##tide O
alterations O
in O
the O
al B-Disease
##d I-Disease
gene O
. O

eighteen O
( O
69 O
% O
) O
of O
26 O
mutations O
were O
miss O
##ense O
mutations O
. O

most O
miss O
##ense O
mutations O
involved O
amino O
acids O
conserved O
in O
ho O
##mo O
##log O
##ous O
gene O
products O
, O
including O
pm O
##p O
##70 O
, O
ma O
##ld O
##rp O
, O
and O
p O
##xa O
##1 O
##p O
. O

the O
a O
##g O
din O
##uc O
##leo O
##tide O
del O
##eti O
##on O
at O
position O
108 O
##1 O
- O
108 O
##2 O
, O
which O
has O
been O
reported O
previously O
to O
be O
the O
most O
common O
mutation O
in O
white O
patients O
( O
12 O
% O
- O
17 O
% O
) O
, O
was O
also O
identified O
as O
the O
most O
common O
mutation O
in O
j O
##apa O
##nese O
patients O
( O
12 O
% O
) O
. O

all O
p O
##hen O
##otype O
##s O
were O
associated O
with O
mutations O
resulting O
in O
protein O
t O
##run O
##cation O
or O
subtle O
amino O
acid O
changes O
. O

there O
were O
no O
differences O
in O
p O
##hen O
##otypic O
expressions O
between O
miss O
##ense O
mutations O
involving O
conserved O
amino O
acids O
and O
those O
involving O
non O
##con O
##serve O
##d O
amino O
acids O
. O

conclusions O
there O
are O
no O
obvious O
correlation O
##s O
between O
the O
p O
##hen O
##otype O
##s O
of O
patients O
with O
al B-Disease
##d I-Disease
and O
their O
g O
##eno O
##type O
##s O
, O
suggesting O
that O
other O
genetic O
or O
environmental O
factors O
modify O
the O
p O
##hen O
##otypic O
expressions O
of O
al B-Disease
##d I-Disease
. O
. O

a O
common O
human O
skin B-Disease
t I-Disease
##umour I-Disease
is O
caused O
by O
act O
##ivating O
mutations O
in O
beta O
- O
cat O
##eni O
##n O
. O

w O
##nt O
signalling O
orchestra O
##tes O
a O
number O
of O
developmental O
programs O
. O

in O
response O
to O
this O
stimulus O
, O
c O
##yt O
##op O
##las O
##mic O
beta O
- O
cat O
##eni O
##n O
( O
encoded O
by O
c O
##t O
##nn O
##b O
##1 O
) O
is O
stab O
##ilized O
, O
enabling O
downstream O
transcription O
##al O
activation O
by O
members O
of O
the O
le O
##f O
/ O
t O
##c O
##f O
family O
. O

one O
of O
the O
target O
genes O
for O
beta O
- O
cat O
##eni O
##n O
/ O
t O
##c O
##f O
en O
##codes O
c O
- O
my O
##c O
, O
explaining O
why O
con O
##st O
##it O
##utive O
activation O
of O
the O
w O
##nt O
pathway O
can O
lead O
to O
cancer B-Disease
, O
particularly O
in O
the O
co O
##lon O
. O

most O
co B-Disease
##lon I-Disease
cancer I-Disease
##s I-Disease
arise O
from O
mutations O
in O
the O
gene O
encoding O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
, O
a O
protein O
required O
for O
u O
##bi O
##qui O
##tin O
- O
mediated O
degradation O
of O
beta O
- O
cat O
##eni O
##n O
, O
but O
a O
small O
percentage O
of O
co B-Disease
##lon I-Disease
and I-Disease
some I-Disease
other I-Disease
cancer I-Disease
##s I-Disease
harbour O
beta O
- O
cat O
##eni O
##n O
- O
stab O
##ili O
##zing O
mutations O
. O

recently O
, O
we O
discovered O
that O
trans O
##genic O
mice O
expressing O
an O
activated O
beta O
- O
cat O
##eni O
##n O
are O
pre O
##dis O
##posed O
to O
developing O
skin B-Disease
t I-Disease
##umour I-Disease
##s I-Disease
resembling O
p B-Disease
##ilo I-Disease
##mat I-Disease
##ric I-Disease
##oma I-Disease
##s I-Disease
. O

given O
that O
the O
skin O
of O
these O
adult O
mice O
also O
exhibits O
signs O
of O
de O
no O
##vo O
hair O
- O
f O
##oll O
##icle O
m O
##or O
##ph O
##ogen O
##esis O
, O
we O
wondered O
whether O
human O
p B-Disease
##ilo I-Disease
##mat I-Disease
##ric I-Disease
##oma I-Disease
##s I-Disease
might O
originate O
from O
hair O
matrix O
cells O
and O
whether O
they O
might O
possess O
beta O
- O
cat O
##eni O
##n O
- O
stab O
##ili O
##zing O
mutations O
. O

here O
, O
we O
explore O
the O
cell O
origin O
and O
a O
##eti O
##ology O
of O
this O
common O
human O
skin B-Disease
t I-Disease
##umour I-Disease
. O

we O
found O
nuclear O
le O
##f O
- O
1 O
in O
the O
dividing O
t B-Disease
##umour I-Disease
cells O
, O
providing O
bio O
##chemical O
evidence O
that O
p B-Disease
##ilo I-Disease
##mat I-Disease
##ric I-Disease
##oma I-Disease
##s I-Disease
are O
derived O
from O
hair O
matrix O
cells O
. O

at O
least O
75 O
% O
of O
these O
t B-Disease
##umour I-Disease
##s I-Disease
possess O
mutations O
affecting O
the O
amino O
- O
terminal O
segment O
, O
normally O
involved O
in O
p O
##hos O
##ph O
##ory O
##lation O
- O
dependent O
, O
u O
##bi O
##qui O
##tin O
- O
mediated O
degradation O
of O
the O
protein O
. O

this O
percentage O
of O
c O
##t O
##nn O
##b O
##1 O
mutations O
is O
greater O
than O
in O
all O
other O
human O
t B-Disease
##umour I-Disease
##s I-Disease
examined O
thus O
far O
, O
and O
directly O
imp O
##lica O
##tes O
beta O
- O
cat O
##eni O
##n O
/ O
le O
##f O
mi O
##s O
##re O
##gu O
##lation O
as O
the O
major O
cause O
of O
hair O
matrix O
cell O
tumor O
##ige O
##nes O
##is O
in O
humans O
. O
. O

the O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
gene O
en O
##codes O
a O
chloride O
- O
i O
##od O
##ide O
transport O
protein O
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
is O
the O
most O
common O
form O
of O
s B-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
deaf I-Disease
##ness I-Disease
and O
characterized O
by O
con O
##gen O
##ital O
sensor B-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
and O
go B-Disease
##it I-Disease
##re I-Disease
. O

this O
disorder O
was O
mapped O
to O
chromosome O
7 O
and O
the O
gene O
causing O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
( O
p B-Disease
##ds I-Disease
) O
was O
subsequently O
identified O
by O
position O
##al O
c O
##lon O
##ing O
. O

p O
##ds O
en O
##codes O
a O
put O
##ative O
trans O
##me O
##mb O
##rane O
protein O
designated O
pen O
##dr O
##in O
. O

pen O
##dr O
##in O
is O
closely O
related O
to O
a O
family O
of O
su O
##lf O
##ate O
transport O
proteins O
that O
includes O
the O
rat O
su O
##lf O
##ate O
- O
an O
##ion O
transport O
##er O
( O
encoded O
by O
sat O
- O
1 O
; O
29 O
% O
amino O
acid O
sequence O
identity O
) O
, O
the O
human O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
su O
##lf O
##ate O
transport O
##er O
( O
encoded O
by O
d O
##t O
##d O
; O
32 O
% O
) O
and O
the O
human O
su O
##lf O
##ate O
transport O
##er O
down O
##re O
##gu O
##lated O
in O
ad B-Disease
##eno I-Disease
##ma I-Disease
( O
encoded O
by O
d O
##ra O
; O
45 O
% O
) O
. O

on O
the O
basis O
of O
this O
ho O
##mology O
and O
the O
presence O
of O
a O
slightly O
modified O
su O
##lf O
##ate O
- O
transport O
##er O
signature O
sequence O
comprising O
its O
put O
##ative O
second O
trans O
##me O
##mb O
##rane O
domain O
, O
pen O
##dr O
##in O
has O
been O
proposed O
to O
function O
as O
a O
su O
##lf O
##ate O
transport O
##er O
. O

we O
were O
unable O
to O
detect O
evidence O
of O
su O
##lf O
##ate O
transport O
following O
the O
expression O
of O
pen O
##dr O
##in O
in O
x O
##eno O
##pus O
la O
##ev O
##is O
o O
##ocytes O
by O
micro O
##in O
##jection O
of O
p O
##ds O
c O
##rna O
or O
in O
s O
##f O
##9 O
cells O
following O
infection O
with O
p O
##ds O
- O
re O
##comb O
##ina O
##nt O
b O
##ac O
##ulo O
##virus O
. O

the O
rates O
of O
transport O
for O
i O
##od O
##ide O
and O
chloride O
were O
significantly O
increased O
following O
the O
expression O
of O
pen O
##dr O
##in O
in O
both O
cell O
systems O
. O

our O
results O
demonstrate O
that O
pen O
##dr O
##in O
functions O
as O
a O
transport O
##er O
of O
chloride O
and O
i O
##od O
##ide O
, O
but O
not O
su O
##lf O
##ate O
, O
and O
may O
provide O
insight O
into O
thy O
##roid O
physiology O
and O
the O
path O
##op O
##hy O
##sio O
##logy O
of O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
. O
. O

h O
##fe O
mutations O
analysis O
in O
71 O
##1 O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
pro O
##band O
##s O
: O
evidence O
for O
s O
##65 O
##c O
imp O
##lication O
in O
mild O
form O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
h B-Disease
##h I-Disease
) O
is O
a O
common O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
genetic I-Disease
disorder I-Disease
of O
iron O
metabolism O
. O

the O
h O
##fe O
candidate O
gene O
encoding O
an O
h O
##la O
class O
i O
- O
like O
protein O
involved O
in O
h B-Disease
##h I-Disease
was O
identified O
in O
1996 O
. O

two O
miss O
##ense O
mutations O
have O
been O
described O
c O
##28 O
##2 O
##y O
, O
accounting O
for O
80 O
% O
to O
90 O
% O
of O
h B-Disease
##h I-Disease
chromosome O
##s O
, O
and O
h O
##6 O
##3 O
##d O
, O
which O
is O
associated O
with O
a O
mild O
##er O
form O
of O
the O
disease O
representing O
40 O
% O
to O
70 O
% O
of O
non O
- O
c O
##28 O
##2 O
##y O
h B-Disease
##h I-Disease
chromosome O
##s O
. O

we O
report O
here O
on O
the O
analysis O
of O
c O
##28 O
##2 O
##y O
, O
h O
##6 O
##3 O
##d O
, O
and O
the O
193 O
##a O
- O
- O
[UNK] O
t O
substitution O
leading O
to O
the O
s O
##65 O
##c O
miss O
##ense O
substitution O
in O
a O
large O
series O
of O
pro O
##band O
##s O
and O
controls O
. O

the O
results O
confirm O
that O
the O
c O
##28 O
##2 O
##y O
substitution O
was O
the O
main O
mutation O
involved O
in O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
accounting O
for O
85 O
% O
of O
carrier O
chromosome O
##s O
, O
whereas O
the O
h O
##6 O
##3 O
##d O
substitution O
represented O
39 O
% O
of O
the O
h B-Disease
##h I-Disease
chromosome O
##s O
that O
did O
not O
carry O
the O
c O
##28 O
##2 O
##y O
mutation O
. O

in O
addition O
, O
our O
screening O
showed O
that O
the O
s O
##65 O
##c O
substitution O
was O
significantly O
en O
##rich O
##ed O
in O
pro O
##band O
##s O
with O
at O
least O
one O
chromosome O
without O
an O
assigned O
mutation O
. O

this O
substitution O
accounted O
for O
7 O
. O

8 O
% O
of O
h B-Disease
##h I-Disease
chromosome O
##s O
that O
were O
neither O
c O
##28 O
##2 O
##y O
nor O
h O
##6 O
##3 O
##d O
. O

this O
en O
##rich O
##ment O
of O
s O
##65 O
##c O
among O
h B-Disease
##h I-Disease
chromosome O
##s O
suggests O
that O
the O
s O
##65 O
##c O
substitution O
is O
associated O
with O
the O
mild O
form O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

g O
##er O
##m O
##line O
br O
##ca O
##1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
. O

the O
objective O
of O
this O
study O
was O
to O
provide O
more O
accurate O
frequency O
estimates O
of O
breast B-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
1 O
( O
br O
##ca O
##1 O
) O
g O
##er O
##m O
##line O
alterations O
in O
the O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
population O
. O

to O
achieve O
this O
, O
we O
determined O
the O
prevalence O
of O
br O
##ca O
##1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
consecutive O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
. O

this O
is O
the O
first O
population O
- O
based O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
study O
reporting O
br O
##ca O
##1 O
alterations O
derived O
from O
a O
comprehensive O
screen O
of O
the O
entire O
coding O
region O
. O

one O
hundred O
and O
seven O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
were O
analyzed O
for O
br O
##ca O
##1 O
alterations O
using O
the O
r O
##nas O
##e O
mi O
##sma O
##tch O
c O
##lea O
##vage O
ass O
##ay O
followed O
by O
direct O
se O
##quencing O
. O

two O
t O
##run O
##cating O
mutations O
, O
96 O
##2 O
##del O
##4 O
and O
360 O
##0 O
##del O
##11 O
, O
were O
identified O
. O

both O
patients O
had O
a O
family O
history O
of O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

several O
novel O
as O
well O
as O
previously O
reported O
un O
##cha O
##rac O
##ter O
##ized O
variants O
were O
also O
identified O
, O
some O
of O
which O
were O
associated O
with O
a O
family O
history O
of O
cancer B-Disease
. O

the O
frequency O
distribution O
of O
common O
p O
##oly O
##mor O
##phism O
##s O
was O
determined O
in O
the O
91 O
ca O
##uca O
##sian O
cancer B-Disease
cases O
in O
this O
series O
and O
24 O
sister O
controls O
using O
all O
##ele O
- O
specific O
am O
##p O
##lification O
. O

the O
rare O
form O
of O
the O
q O
##35 O
##6 O
##r O
p O
##oly O
##mor O
##phism O
was O
significantly O
( O
p O
= O
0 O
. O
03 O
) O
associated O
with O
a O
family O
history O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
suggesting O
that O
this O
p O
##oly O
##mor O
##phism O
may O
influence O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risk O
. O

in O
summary O
, O
our O
data O
suggest O
a O
role O
for O
some O
un O
##cha O
##rac O
##ter O
##ized O
variants O
and O
rare O
forms O
of O
p O
##oly O
##mor O
##phism O
##s O
in O
determining O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risk O
, O
and O
highlight O
the O
necessity O
to O
screen O
for O
miss O
##ense O
alterations O
as O
well O
as O
t O
##run O
##cating O
mutations O
in O
this O
population O
. O

ad O
##ren O
##ole O
##uk O
##ody O
##stro O
##phy O
- O
related O
protein O
can O
compensate O
functional O
##ly O
for O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
protein I-Disease
deficiency I-Disease
( O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
) O
: O
implications O
for O
therapy O
. O

inherited B-Disease
defects I-Disease
in O
the O
per O
##ox O
##is O
##oma O
##l O
at O
##p O
- O
binding O
cassette O
( O
a O
##b O
##c O
) O
transport O
##er O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
protein O
( O
al O
##d O
##p O
) O
lead O
to O
the O
lethal O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorder I-Disease
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
) O
, O
for O
which O
no O
efficient O
treatment O
has O
been O
established O
so O
far O
. O

three O
other O
per O
##ox O
##is O
##oma O
##l O
a O
##b O
##c O
transport O
##ers O
currently O
are O
known O
ad O
##ren O
##ole O
##uk O
##ody O
##stro O
##phy O
- O
related O
protein O
( O
al O
##dr O
##p O
) O
, O
70 O
k O
##da O
per O
##ox O
##is O
##oma O
##l O
membrane O
protein O
( O
pm O
##p O
##70 O
) O
and O
pm O
##p O
##70 O
- O
related O
protein O
. O

by O
using O
trans O
##ient O
and O
stable O
over O
##ex O
##press O
##ion O
of O
human O
c O
##dn O
##as O
encoding O
al O
##d O
##p O
and O
its O
closest O
relative O
al O
##dr O
##p O
, O
we O
could O
restore O
the O
impaired O
per O
##ox O
##is O
##oma O
##l O
beta O
- O
oxidation O
in O
fi O
##bro O
##blast O
##s O
of O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
patients O
. O

the O
path O
##og O
##no O
##mon O
##ic O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
could O
also O
be O
prevented O
by O
over O
##ex O
##press O
##ion O
of O
al O
##dr O
##p O
in O
immortal O
##ized O
x O
- O
al O
##d O
cells O
. O

im O
##mu O
##no O
##f O
##lu O
##ores O
##cence O
analysis O
demonstrated O
that O
the O
functional O
replacement O
of O
al O
##d O
##p O
by O
al O
##dr O
##p O
was O
not O
due O
to O
stab O
##ilization O
of O
the O
m O
##uta O
##ted O
al O
##d O
##p O
itself O
. O

more O
##over O
, O
we O
were O
able O
to O
restore O
the O
per O
##ox O
##is O
##oma O
##l O
beta O
- O
oxidation O
defect O
in O
the O
liver O
of O
al O
##d O
##p O
- O
def O
##icient O
mice O
by O
stimulation O
of O
al O
##dr O
##p O
and O
pm O
##p O
##70 O
gene O
expression O
through O
a O
diet O
##ary O
treatment O
with O
the O
per O
##ox O
##is O
##ome O
pro O
##life O
##rator O
f O
##eno O
##fi O
##bra O
##te O
. O

these O
results O
suggest O
that O
a O
correction O
of O
the O
bio O
##chemical O
defect O
in O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
could O
be O
possible O
by O
drug O
- O
induced O
over O
##ex O
##press O
##ion O
or O
e O
##ct O
##op O
##ic O
expression O
of O
al O
##dr O
##p O
. O
. O

cent O
##ros O
##ome O
am O
##p O
##lification O
and O
a O
defect O
##ive O
g O
##2 O
- O
m O
cell O
cycle O
check O
##point O
induce O
genetic O
instability O
in O
br O
##ca O
##1 O
ex O
##on O
11 O
is O
##of O
##orm O
- O
def O
##icient O
cells O
. O

g O
##er O
##m O
##line O
mutations O
of O
the O
br O
##ca O
##1 O
tumor B-Disease
suppress O
##or O
gene O
pre O
##dis O
##pose O
women O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

to O
study O
mechanisms O
underlying O
br O
##ca O
##1 O
- O
related O
tumor O
##ige O
##nes O
##is O
, O
we O
derived O
mouse O
em O
##b O
##ryo O
##nic O
fi O
##bro O
##blast O
cells O
carrying O
a O
targeted O
del O
##eti O
##on O
of O
ex O
##on O
11 O
of O
the O
br O
##ca O
##1 O
gene O
. O

we O
show O
that O
the O
mutant O
cells O
maintain O
an O
intact O
g O
##1 O
- O
s O
cell O
cycle O
check O
##point O
and O
pro O
##life O
##rate O
poorly O
. O

however O
, O
a O
defect O
##ive O
g O
##2 O
- O
m O
check O
##point O
in O
these O
cells O
is O
accompanied O
by O
extensive O
ch B-Disease
##rom I-Disease
##oso I-Disease
##mal I-Disease
abnormal I-Disease
##ities I-Disease
. O

mutant O
fi O
##bro O
##blast O
##s O
contain O
multiple O
, O
functional O
cent O
##ros O
##ome O
##s O
, O
which O
lead O
to O
une O
##qua O
##l O
chromosome O
segregation O
, O
abnormal O
nuclear O
division O
, O
and O
an B-Disease
##eu I-Disease
##p I-Disease
##lo I-Disease
##idy I-Disease
. O

these O
data O
un O
##cover O
an O
essential O
role O
of O
br O
##ca O
##1 O
in O
maintaining O
genetic O
stability O
through O
the O
regulation O
of O
cent O
##ros O
##ome O
du O
##plication O
and O
the O
g O
##2 O
- O
m O
check O
##point O
and O
provide O
a O
molecular O
basis O
for O
the O
role O
of O
br O
##ca O
##1 O
in O
tumor O
##ige O
##nes O
##is O
. O
. O

defect O
##ive O
c O
##d O
##9 O
##5 O
/ O
a O
##po O
- O
1 O
/ O
f O
##as O
signal O
complex O
formation O
in O
the O
human O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
, I-Disease
type I-Disease
i I-Disease
##a I-Disease
. O

he O
##tero O
##zy O
##go O
##us O
mutations O
in O
the O
c O
##d O
##9 O
##5 O
( O
a O
##po O
- O
1 O
/ O
f O
##as O
) O
receptor O
occur O
in O
most O
individuals O
with O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
( O
al B-Disease
##ps I-Disease
) O
and O
dominant O
##ly O
interfere O
with O
a O
##pop O
##tosis O
by O
an O
unknown O
mechanism O
. O

we O
show O
that O
local O
or O
global O
alterations O
in O
the O
structure O
of O
the O
c O
##yt O
##op O
##las O
##mic O
death O
domain O
from O
nine O
independent O
al B-Disease
##ps I-Disease
c O
##d O
##9 O
##5 O
death O
- O
domain O
mutations O
result O
in O
a O
failure O
to O
bind O
the O
f O
##ad O
##d O
/ O
m O
##ort O
##1 O
signaling O
protein O
. O

despite O
he O
##tero O
##zy O
##gos O
##ity O
for O
the O
abnormal O
all O
##ele O
, O
l O
##ymph O
##ocytes O
from O
al B-Disease
##ps I-Disease
patients O
showed O
marked O
##ly O
decreased O
f O
##ad O
##d O
association O
and O
a O
loss O
of O
ca O
##sp O
##ase O
recruitment O
and O
activation O
after O
c O
##d O
##9 O
##5 O
cross O
##link O
##ing O
. O

these O
data O
suggest O
that O
in O
##tra O
##cy O
##top O
##las O
##mic O
c O
##d O
##9 O
##5 O
mutations O
in O
al B-Disease
##ps I-Disease
imp O
##air O
a O
##pop O
##tosis O
chiefly O
by O
disrupt O
##ing O
death O
- O
domain O
interactions O
with O
the O
signaling O
protein O
f O
##ad O
##d O
/ O
m O
##ort O
##1 O
. O
. O

analysis O
of O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
) O
mutations O
and O
p O
##oly O
##mor O
##phism O
##s O
reveals O
that O
the O
cc O
##c O
sequence O
motif O
is O
a O
mutation O
##al O
hot O
spot O
in O
the O
ho O
##mo O
##gent O
##isa O
##te O
1 O
, O
2 O
di O
##ox O
##y O
##gen O
##ase O
gene O
( O
h O
##go O
) O
. O

we O
recently O
showed O
that O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
) O
is O
caused O
by O
loss O
- O
of O
- O
function O
mutations O
in O
the O
ho O
##mo O
##gent O
##isa O
##te O
1 O
, O
2 O
di O
##ox O
##y O
##gen O
##ase O
gene O
( O
h O
##go O
) O
. O

here O
##in O
we O
describe O
ha O
##p O
##lot O
##ype O
and O
mutation O
##al O
analyses O
of O
h O
##go O
in O
seven O
new O
a B-Disease
##ku I-Disease
p O
##ed O
##ig O
##ree O
##s O
. O

these O
analyses O
identified O
two O
novel O
single O
- O
n O
##uc O
##leo O
##tide O
p O
##oly O
##mor O
##phism O
##s O
( O
in O
##v O
##4 O
+ O
31 O
##a O
- O
- O
[UNK] O
g O
and O
in O
##v O
##11 O
+ O
18 O
##a O
- O
- O
[UNK] O
g O
) O
and O
six O
novel O
a B-Disease
##ku I-Disease
mutations O
( O
in O
##v O
##1 O
- O
1 O
##g O
- O
- O
[UNK] O
a O
, O
w O
##60 O
##g O
, O
y O
##6 O
##2 O
##c O
, O
a O
##12 O
##2 O
##d O
, O
p O
##23 O
##0 O
##t O
, O
and O
d O
##29 O
##1 O
##e O
) O
, O
which O
further O
illustrate O
##s O
the O
remarkable O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
found O
in O
a B-Disease
##ku I-Disease
. O

re O
##ex O
##ami O
##nation O
of O
all O
29 O
mutations O
and O
p O
##oly O
##mor O
##phism O
##s O
thus O
far O
described O
in O
h O
##go O
shows O
that O
these O
n O
##uc O
##leo O
##tide O
changes O
are O
not O
randomly O
distributed O
; O
the O
cc O
##c O
sequence O
motif O
and O
its O
inverted O
complement O
, O
g O
##gg O
, O
are O
prefer O
##ential O
##ly O
m O
##uta O
##ted O
. O

these O
analyses O
also O
demonstrated O
that O
the O
n O
##uc O
##leo O
##tide O
substitution O
##s O
in O
h O
##go O
do O
not O
involve O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
##s O
, O
which O
illustrate O
##s O
important O
differences O
between O
h O
##go O
and O
other O
genes O
for O
the O
occurrence O
of O
mutation O
at O
specific O
short O
- O
sequence O
motifs O
. O

because O
the O
cc O
##c O
sequence O
motifs O
comprise O
a O
significant O
proportion O
( O
34 O
. O
5 O
% O
) O
of O
all O
m O
##uta O
##ted O
bases O
that O
have O
been O
observed O
in O
h O
##go O
, O
we O
conclude O
that O
the O
cc O
##c O
triple O
##t O
is O
a O
mutation O
##al O
hot O
spot O
in O
h O
##go O
. O

f B-Disease
##ab I-Disease
##ry I-Disease
disease I-Disease
: O
identification O
of O
novel O
alpha O
- O
gal O
##act O
##os O
##idas O
##e O
a O
mutations O
and O
molecular O
carrier O
detection O
by O
use O
of O
fluorescent O
chemical O
c O
##lea O
##vage O
of O
mi O
##sma O
##tches O
. O

f B-Disease
##ab I-Disease
##ry I-Disease
disease I-Disease
( O
f B-Disease
##d I-Disease
) O
( O
an B-Disease
##gio I-Disease
##ker I-Disease
##ato I-Disease
##ma I-Disease
co I-Disease
##rp I-Disease
##oris I-Disease
di I-Disease
##ff I-Disease
##us I-Disease
##um I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
in I-Disease
##born I-Disease
error I-Disease
of I-Disease
g I-Disease
##ly I-Disease
##cos I-Disease
##phi I-Disease
##ngo I-Disease
##lip I-Disease
##id I-Disease
metabolism I-Disease
caused O
by O
defects O
in O
the O
l O
##ys O
##oso O
##mal O
alpha O
- O
gal O
##act O
##os O
##idas O
##e O
a O
gene O
( O
g O
##la O
) O
. O

the O
en O
##zy O
##matic O
defect O
leads O
to O
the O
systemic O
accumulation O
of O
neutral O
g O
##ly O
##cos O
##phi O
##ngo O
##lip O
##ids O
with O
terminal O
alpha O
- O
gal O
##act O
##osy O
##l O
m O
##oi O
##eti O
##es O
. O

clinical O
##ly O
, O
affected O
hem O
##iz O
##y O
##go O
##us O
males O
have O
an B-Disease
##gio I-Disease
##ker I-Disease
##ato I-Disease
##ma I-Disease
, O
severe B-Disease
a I-Disease
##c I-Disease
##rop I-Disease
##ares I-Disease
##the I-Disease
##sia I-Disease
, O
re B-Disease
##nal I-Disease
failure I-Disease
, O
and O
v B-Disease
##as I-Disease
##cu I-Disease
##lop I-Disease
##athy I-Disease
of I-Disease
the I-Disease
heart I-Disease
and I-Disease
brain I-Disease
. O

while O
demonstration O
of O
alpha B-Disease
- I-Disease
gal I-Disease
##act I-Disease
##os I-Disease
##idas I-Disease
##e I-Disease
deficiency I-Disease
in O
le O
##uk O
##ocytes O
is O
diagnostic O
in O
affected O
males O
, O
en O
##zy O
##matic O
detection O
of O
female O
carriers O
is O
often O
in O
##con O
##clusive O
, O
due O
to O
random O
x O
- O
ch O
##rom O
##oso O
##mal O
in O
##act O
##ivation O
, O
under O
##lining O
the O
need O
of O
molecular O
investigations O
for O
accurate O
genetic O
counseling O
. O

by O
use O
of O
chemical O
c O
##lea O
##vage O
of O
mi O
##sma O
##tches O
adapted O
to O
flu O
##ores O
##cence O
- O
based O
detection O
systems O
, O
we O
have O
characterized O
the O
mutations O
underlying O
alpha B-Disease
- I-Disease
gal I-Disease
a I-Disease
deficiency I-Disease
in O
16 O
individuals O
from O
six O
unrelated O
families O
with O
f B-Disease
##d I-Disease
. O

the O
mutation O
##al O
spectrum O
included O
five O
miss O
##ense O
mutations O
( O
c O
##20 O
##2 O
##w O
, O
c O
##22 O
##3 O
##g O
, O
n O
##22 O
##4 O
##d O
, O
r O
##30 O
##1 O
##q O
, O
and O
q O
##32 O
##7 O
##k O
) O
and O
one O
s O
##p O
##lice O
- O
site O
mutation O
[ O
i O
##v O
##s O
##3 O
g O
( O
- O
1 O
) O
- O
- O
[UNK] O
c O
] O
. O

studies O
at O
the O
m O
##rna O
level O
showed O
that O
the O
latter O
led O
to O
altered O
pre O
- O
m O
##rna O
s O
##p O
##licing O
with O
con O
##se O
##quent O
alter O
##ation O
of O
the O
m O
##rna O
translation O
##al O
reading O
frame O
and O
generation O
of O
a O
premature O
termination O
co O
##don O
of O
translation O
. O

by O
use O
of O
this O
strategy O
, O
carrier O
status O
was O
accurately O
assessed O
in O
all O
seven O
at O
- O
risk O
females O
tested O
, O
whereas O
en O
##zy O
##matic O
dos O
##ages O
failed O
to O
di O
##ag O
##nose O
or O
exclude O
he O
##tero O
##zy O
##gos O
##ity O
. O
. O

pre O
##nat O
##al O
diagnosis O
by O
fish O
in O
a O
family O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
caused O
by O
du O
##plication O
of O
p O
##l O
##p O
gene O
. O

a O
diagnosis O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
mi O
##m O
312 O
##0 O
##80 O
) O
was O
made O
in O
a O
young O
boy O
. O

no O
mutation O
in O
the O
coding O
region O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
had O
been O
found O
. O

the O
boys O
maternal O
aunt O
came O
for O
pre O
##nat O
##al O
diagnosis O
when O
16 O
+ O
weeks O
pregnant O
and O
carrying O
a O
male O
f O
##etus O
. O

samples O
were O
tested O
for O
du O
##plication O
of O
the O
p O
##l O
##p O
gene O
, O
by O
inter O
##pha O
##se O
fish O
, O
in O
l O
##ymph O
##oc O
##yte O
preparations O
from O
the O
pro O
##band O
, O
his O
aunt O
and O
an O
am O
##nio O
##tic O
fluid O
cell O
preparation O
from O
the O
f O
##etus O
. O

the O
pro O
##band O
was O
found O
to O
carry O
the O
du O
##plication O
, O
thus O
confirming O
the O
diagnosis O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
, O
but O
neither O
the O
aunt O
nor O
the O
f O
##etus O
carried O
a O
du O
##plication O
. O
. O

dominant O
negative O
effect O
of O
the O
a O
##p O
##c O
##13 O
##0 O
##9 O
mutation O
: O
a O
possible O
explanation O
for O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
. O

in O
##act O
##ivation O
of O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
product O
initiate O
##s O
color O
##ec O
##tal O
tumor O
##ige O
##nes O
##is O
. O

patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
a I-Disease
##p I-Disease
##c I-Disease
( O
f B-Disease
##ap I-Disease
) O
carry O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
and O
develop O
multiple O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
and O
subsequent O
car B-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
early O
in O
life O
. O

the O
severity O
of O
the O
disease O
co O
##rrel O
##ates O
with O
the O
position O
of O
the O
inherited O
a B-Disease
##p I-Disease
##c I-Disease
mutation O
( O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
) O
. O

together O
with O
the O
fact O
that O
both O
g O
##er O
##m O
- O
line O
and O
s O
##poradic O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
cluster O
in O
the O
central O
region O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
this O
points O
to O
a O
dominant O
negative O
effect O
of O
certain O
a B-Disease
##p I-Disease
##c I-Disease
mutant O
##s O
. O

loss O
of O
a B-Disease
##p I-Disease
##c I-Disease
function O
was O
recently O
shown O
to O
result O
in O
enhanced O
beta O
- O
cat O
##eni O
##n O
- O
/ O
t O
##c O
##f O
- O
mediated O
transcription O
in O
co O
##lon O
e O
##pit O
##hel O
##ial O
cells O
. O

here O
, O
we O
provide O
experimental O
evidence O
for O
a O
dominant O
negative O
effect O
of O
a B-Disease
##p I-Disease
##c I-Disease
gene O
products O
associated O
with O
severe O
p B-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
. O

wild O
- O
type O
a B-Disease
##p I-Disease
##c I-Disease
activity O
in O
beta O
- O
cat O
##eni O
##n O
- O
/ O
t O
##c O
##f O
- O
mediated O
transcription O
was O
strongly O
in O
##hibit O
##ed O
by O
a O
mutant O
a B-Disease
##p I-Disease
##c I-Disease
that O
is O
t O
##runcated O
at O
co O
##don O
130 O
##9 O
. O

in O
contrast O
, O
mutant O
a B-Disease
##p I-Disease
##c I-Disease
gene O
products O
that O
are O
associated O
with O
at B-Disease
##ten I-Disease
##uated I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
co O
##don O
38 O
##6 O
or O
146 O
##5 O
) O
interfere O
##d O
only O
weakly O
with O
wild O
- O
type O
a B-Disease
##p I-Disease
##c I-Disease
activity O
. O

these O
results O
suggest O
a O
molecular O
explanation O
for O
the O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
in O
f B-Disease
##ap I-Disease
patients O
and O
support O
the O
idea O
that O
color B-Disease
##ec I-Disease
##tal I-Disease
tumor I-Disease
growth O
might O
be O
, O
in O
part O
, O
driven O
by O
selection O
for O
a O
mutation O
in O
the O
mutation O
cluster O
region O
. O
. O

br O
##ca O
##1 O
interact O
##s O
with O
components O
of O
the O
his O
##tone O
de O
##ace O
##ty O
##lase O
complex O
. O

g O
##er O
##m O
- O
line O
mutations O
in O
the O
br O
##ca O
##1 O
tumor O
- O
suppress O
##or O
gene O
are O
associated O
with O
an O
increased O
su O
##s O
##ce O
##pt O
##ibility O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

br O
##ca O
##1 O
contains O
a O
car O
##box O
##yl O
- O
terminal O
domain O
( O
br O
##ct O
) O
that O
is O
shared O
with O
several O
other O
proteins O
involved O
in O
maintaining O
genome O
integrity O
. O

in O
an O
effort O
to O
understand O
the O
function O
of O
br O
##ca O
##1 O
, O
we O
sought O
to O
is O
##olate O
proteins O
that O
interact O
with O
the O
br O
##ct O
domain O
. O

pu O
##rified O
br O
##ct O
p O
##oly O
##pe O
##pt O
##ide O
was O
used O
as O
a O
probe O
to O
screen O
a O
human O
place O
##nta O
c O
##dn O
##a O
expression O
library O
by O
far O
western O
analysis O
. O

here O
we O
report O
that O
br O
##ca O
##1 O
interact O
##s O
in O
v O
##ivo O
and O
in O
v O
##it O
##ro O
with O
the O
r O
##b O
- O
binding O
proteins O
, O
r O
##ba O
##p O
##46 O
and O
r O
##ba O
##p O
##48 O
, O
as O
well O
as O
with O
r O
##b O
. O

more O
##over O
, O
the O
br O
##ct O
domain O
associates O
with O
the O
his O
##tone O
de O
##ace O
##ty O
##lase O
##s O
h O
##da O
##c O
##1 O
and O
h O
##da O
##c O
##2 O
. O

these O
results O
demonstrate O
that O
br O
##ca O
##1 O
interact O
##s O
with O
components O
of O
the O
his O
##tone O
de O
##ace O
##ty O
##lase O
complex O
, O
and O
therefore O
may O
explain O
the O
involvement O
of O
br O
##ca O
##1 O
in O
multiple O
processes O
such O
as O
transcription O
, O
d O
##na O
repair O
, O
and O
re O
##comb O
##ination O
. O
. O

combined B-Disease
genetic I-Disease
deficiency I-Disease
of I-Disease
c I-Disease
##6 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
in O
man O
. O

by O
routine O
screening O
of O
se O
##ra O
, O
a O
subject O
was O
discovered O
who O
showed O
a O
sub B-Disease
- I-Disease
total I-Disease
deficiency I-Disease
of I-Disease
c I-Disease
##6 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
. O

no O
clinical O
disease O
was O
associated O
with O
this O
deficiency O
which O
was O
transmitted O
through O
the O
subjects O
family O
as O
a O
single O
genetic O
characteristic O
, O
the O
c B-Disease
##6 I-Disease
deficiency I-Disease
being O
associated O
with O
a O
silent O
all O
##ele O
at O
the O
structural O
lo O
##cus O
. O

the O
prop O
##os O
##it O
##us O
was O
found O
to O
have O
low O
quantities O
of O
an O
abnormal O
c O
##6 O
which O
was O
both O
anti O
##genic O
##ally O
def O
##icient O
and O
smaller O
in O
size O
than O
normal O
c O
##6 O
( O
110 O
, O
000 O
da O
##lton O
##s O
compared O
with O
140 O
, O
000 O
da O
##lton O
##s O
) O
and O
small O
quantities O
of O
apparently O
normal O
c O
##7 O
. O

it O
is O
concluded O
that O
the O
most O
likely O
explanation O
for O
this O
defect O
is O
that O
the O
subject O
has O
a O
structural O
mutation O
in O
his O
c O
##6 O
gene O
which O
produces O
h O
##yo O
##psy O
##nt O
##hesis O
not O
only O
of O
c O
##6 O
but O
also O
of O
the O
closely O
linked O
gene O
for O
c O
##7 O
. O

these O
findings O
suggest O
the O
possibility O
that O
c O
##6 O
and O
c O
##7 O
may O
function O
as O
a O
single O
genetic O
unit O
and O
that O
the O
primary O
trans O
##cript O
copied O
from O
the O
genome O
includes O
information O
for O
both O
proteins O
. O
. O

changes O
at O
p O
##18 O
##3 O
of O
em O
##eri O
##n O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
characterized O
by O
early O
contract B-Disease
##ures I-Disease
of I-Disease
the I-Disease
elbows I-Disease
, I-Disease
a I-Disease
##chi I-Disease
##lles I-Disease
tend I-Disease
##ons I-Disease
and I-Disease
spine I-Disease
, O
slowly O
progressive O
muscle B-Disease
wasting I-Disease
and O
weakness B-Disease
, O
and O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
associated O
with O
cardiac B-Disease
conduct I-Disease
##ion I-Disease
defects I-Disease
. O

the O
em O
##eri O
##n O
gene O
has O
been O
mapped O
to O
x O
##q O
##28 O
and O
en O
##codes O
a O
34 O
- O
k O
##da O
se O
##rine O
- O
rich O
protein O
, O
em O
##eri O
##n O
, O
which O
has O
been O
localized O
to O
the O
nuclear O
envelope O
in O
a O
wide O
variety O
of O
tissues O
, O
including O
skeletal O
and O
cardiac O
muscle O
. O

mutations O
spanning O
the O
em O
##eri O
##n O
gene O
have O
been O
identified O
in O
patients O
with O
ed B-Disease
##m I-Disease
##d I-Disease
. O

we O
present O
here O
the O
effect O
, O
on O
em O
##eri O
##n O
protein O
expression O
, O
of O
two O
miss O
##ense O
mutations O
identified O
in O
unrelated O
ed B-Disease
##m I-Disease
##d I-Disease
patients O
. O

these O
alterations O
predict O
the O
replacement O
of O
a O
pro O
##line O
residue O
at O
position O
183 O
with O
either O
a O
his O
##ti O
##dine O
or O
a O
th O
##re O
##oni O
##ne O
. O

bio O
##chemical O
analysis O
has O
demonstrated O
that O
the O
mobility O
and O
expression O
levels O
of O
the O
mutant O
forms O
of O
em O
##eri O
##n O
are O
in O
##dis O
##ting O
##ui O
##sha O
##ble O
from O
that O
of O
wild O
- O
type O
em O
##eri O
##n O
, O
but O
that O
they O
have O
weakened O
interactions O
with O
nuclear O
la O
##mina O
components O
. O

in O
comparison O
with O
the O
usual O
ed B-Disease
##m I-Disease
##d I-Disease
p O
##hen O
##otype O
, O
patients O
with O
p O
##18 O
##3 O
miss O
##ense O
mutations O
have O
a O
later O
age O
at O
onset O
of O
first O
symptoms O
, O
elbow B-Disease
contract I-Disease
##ures I-Disease
, O
ankle B-Disease
contract I-Disease
##ures I-Disease
, O
upper B-Disease
limb I-Disease
weakness I-Disease
and O
lower B-Disease
limb I-Disease
weakness I-Disease
, O
but O
there O
is O
no O
difference O
for O
the O
age O
at O
onset O
of O
cardiac B-Disease
involvement I-Disease
. O

this O
is O
the O
first O
report O
of O
protein O
studies O
on O
patients O
with O
miss O
##ense O
mutations O
resulting O
in O
the O
clinical O
features O
of O
ed B-Disease
##m I-Disease
##d I-Disease
. O

these O
studies O
demonstrate O
the O
importance O
of O
pro O
##line O
183 O
for O
the O
proper O
structure O
/ O
function O
of O
em O
##eri O
##n O
. O
. O

micro O
##del O
##eti O
##ons O
at O
chromosome O
bands O
1 O
##q O
##32 O
- O
q O
##41 O
as O
a O
cause O
of O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
. O

van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
( O
v B-Disease
##ws I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
comprising O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
and O
/ O
or O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
and O
lip B-Disease
pits I-Disease
. O

we O
reported O
previously O
a O
family O
whose O
underlying O
mutation O
is O
a O
500 O
- O
800 O
k O
##b O
del O
##eti O
##on O
localized O
to O
chromosome O
bands O
1 O
##q O
##32 O
- O
q O
##41 O
[ O
sand O
##er O
et O
al O
. O
, O
1994 O
hum O
m O
##ol O
gene O
##t O
3 O
57 O
##6 O
- O
57 O
##8 O
] O
. O

along O
with O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
/ I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
and O
lip B-Disease
pits I-Disease
, O
affected O
relatives O
exhibit O
developmental B-Disease
delays I-Disease
, O
suggesting O
that O
the O
function O
of O
a O
gene O
nearby O
may O
also O
be O
disrupted O
. O

to O
further O
local O
##ize O
the O
v B-Disease
##ws I-Disease
gene O
we O
searched O
for O
other O
del O
##eti O
##ons O
that O
cause O
v B-Disease
##ws I-Disease
. O

an O
all O
##ele O
loss O
ass O
##ay O
was O
performed O
using O
a O
novel O
highly O
p O
##oly O
##morphic O
marker O
, O
d O
##1 O
##s O
##37 O
##53 O
. O

from O
a O
panel O
of O
37 O
unrelated O
individuals O
, O
we O
detected O
an O
all O
##ele O
loss O
in O
one O
family O
, O
indicating O
the O
presence O
of O
a O
del O
##eti O
##on O
. O

in O
this O
family O
, O
the O
p O
##hen O
##otype O
in O
three O
generations O
of O
affected O
individuals O
was O
confined O
to O
the O
cardinal O
signs O
of O
v B-Disease
##ws I-Disease
. O

surprisingly O
, O
mapping O
of O
the O
new O
del O
##eti O
##on O
showed O
that O
it O
extended O
0 O
. O

2 O
- O
1 O
m O
##b O
beyond O
the O
pro O
##ximal O
break O
##point O
for O
the O
del O
##eti O
##on O
described O
previously O
. O

no O
del O
##eti O
##ons O
were O
detected O
in O
seven O
cases O
of O
pop B-Disease
##lite I-Disease
##al I-Disease
p I-Disease
##tery I-Disease
##gia I-Disease
syndrome I-Disease
, O
76 O
cases O
of O
mixed O
s B-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
forms I-Disease
of I-Disease
c I-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
and I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
, O
and O
178 O
cases O
of O
non B-Disease
##sy I-Disease
##nd I-Disease
##rom I-Disease
##ic I-Disease
c I-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
and I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
. O

s O
##p O
##licing O
defects O
in O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
, O
at O
##m O
: O
underlying O
mutations O
and O
consequences O
. O

mutations O
resulting O
in O
defect O
##ive O
s O
##p O
##licing O
constitute O
a O
significant O
proportion O
( O
30 O
/ O
62 O
[ O
48 O
% O
] O
) O
of O
a O
new O
series O
of O
mutations O
in O
the O
at O
##m O
gene O
in O
patients O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
at B-Disease
) O
that O
were O
detected O
by O
the O
protein O
- O
t O
##run O
##cation O
ass O
##ay O
followed O
by O
sequence O
analysis O
of O
g O
##eno O
##mic O
d O
##na O
. O

fewer O
than O
half O
of O
the O
s O
##p O
##licing O
mutations O
involved O
the O
canonical O
a O
##g O
s O
##p O
##lice O
- O
accept O
##or O
site O
or O
g O
##t O
s O
##p O
##lice O
- O
donor O
site O
. O

a O
higher O
percentage O
of O
mutations O
occurred O
at O
less O
string O
##ently O
conserved O
sites O
, O
including O
silent O
mutations O
of O
the O
last O
n O
##uc O
##leo O
##tide O
of O
ex O
##ons O
, O
mutations O
in O
n O
##uc O
##leo O
##tide O
##s O
other O
than O
the O
conserved O
a O
##g O
and O
g O
##t O
in O
the O
consensus O
s O
##p O
##lice O
sites O
, O
and O
creation O
of O
s O
##p O
##lice O
- O
accept O
##or O
or O
s O
##p O
##lice O
- O
donor O
sites O
in O
either O
intro O
##ns O
or O
ex O
##ons O
. O

these O
s O
##p O
##licing O
mutations O
led O
to O
a O
variety O
of O
consequences O
, O
including O
ex O
##on O
skip O
##ping O
and O
, O
to O
a O
lesser O
degree O
, O
intro O
##n O
retention O
, O
activation O
of O
cry O
##ptic O
s O
##p O
##lice O
sites O
, O
or O
creation O
of O
new O
s O
##p O
##lice O
sites O
. O

in O
addition O
, O
5 O
of O
12 O
nonsense O
mutations O
and O
1 O
miss O
##ense O
mutation O
were O
associated O
with O
del O
##eti O
##on O
in O
the O
c O
##dn O
##a O
of O
the O
ex O
##ons O
in O
which O
the O
mutations O
occurred O
. O

no O
at O
##m O
protein O
was O
detected O
by O
western O
b O
##lot O
##ting O
in O
any O
at B-Disease
cell O
line O
in O
which O
s O
##p O
##licing O
mutations O
were O
identified O
. O

several O
cases O
of O
ex O
##on O
skip O
##ping O
in O
both O
normal O
controls O
and O
patients O
for O
whom O
no O
underlying O
defect O
could O
be O
found O
in O
g O
##eno O
##mic O
d O
##na O
were O
also O
observed O
, O
suggesting O
caution O
in O
the O
interpretation O
of O
ex O
##on O
del O
##eti O
##ons O
observed O
in O
at O
##m O
c O
##dn O
##a O
when O
there O
is O
no O
accompanying O
identification O
of O
g O
##eno O
##mic O
mutations O
. O
. O

alpha O
- O
cardiac O
act O
##in O
is O
a O
novel O
disease O
gene O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
h I-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
. O

we O
identified O
the O
alpha O
- O
cardiac O
act O
##in O
gene O
( O
act O
##c O
) O
as O
a O
novel O
disease O
gene O
in O
a O
p O
##ed O
##ig O
##ree O
suffering O
from O
f B-Disease
##ami I-Disease
##lial I-Disease
h I-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
( O
f B-Disease
##h I-Disease
##c I-Disease
) O
. O

link O
##age O
analyses O
excluded O
all O
the O
previously O
reported O
f B-Disease
##h I-Disease
##c I-Disease
lo O
##ci O
as O
possible O
disease O
lo O
##ci O
in O
the O
family O
studied O
, O
with O
lo O
##d O
scores O
varying O
between O
- O
2 O
. O

5 O
and O
- O
6 O
. O

0 O
0 O
. O

further O
link O
##age O
analyses O
of O
plausible O
candidate O
genes O
highly O
expressed O
in O
the O
adult O
human O
heart O
identified O
act O
##c O
as O
the O
most O
likely O
disease O
gene O
, O
showing O
a O
ma O
##ximal O
lo O
##d O
score O
of O
3 O
. O

6 O
6 O
. O

mutation O
analysis O
of O
act O
##c O
revealed O
an O
al O
##a O
##29 O
##5 O
##ser O
mutation O
in O
ex O
##on O
5 O
close O
to O
2 O
miss O
##ense O
mutations O
recently O
described O
to O
cause O
the O
inherited O
form O
of O
id B-Disease
##io I-Disease
##pathic I-Disease
di I-Disease
##lated I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
( O
id B-Disease
##c I-Disease
) O
. O

over B-Disease
##gro I-Disease
##wth I-Disease
of I-Disease
oral I-Disease
m I-Disease
##uc I-Disease
##osa I-Disease
and I-Disease
facial I-Disease
skin I-Disease
, O
a O
novel O
feature O
of O
as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
. O

as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
( O
a B-Disease
##gu I-Disease
) O
is O
a O
l B-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
as I-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##ni I-Disease
##das I-Disease
##e I-Disease
( O
a O
##ga O
) O
. O

the O
main O
s O
##ym O
##pt O
##om O
is O
progressive O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
. O

a O
spectrum O
of O
different O
mutations O
has O
been O
reported O
in O
this O
disease O
, O
one O
miss O
##ense O
mutation O
( O
c O
##ys O
##16 O
##3 O
##ser O
) O
being O
responsible O
for O
the O
majority O
of O
fin O
##nish O
cases O
. O

we O
were O
able O
to O
examine O
66 O
fin O
##nish O
a B-Disease
##gu I-Disease
patients O
for O
changes O
in O
the O
oral O
m O
##uc O
##osa O
and O
44 O
of O
these O
for O
changes O
in O
facial O
skin O
. O

bio O
##psy O
specimens O
of O
16 O
oral O
lesions O
, O
12 O
of O
them O
associated O
with O
the O
teeth O
, O
plus O
two O
facial B-Disease
lesions I-Disease
were O
studied O
his O
##to O
##logical O
##ly O
. O

im O
##mu O
##no O
##his O
##to O
##chemical O
stain O
##ing O
for O
a O
##ga O
was O
performed O
on O
15 O
oral O
specimens O
. O

skin O
was O
se O
##bor O
##r O
##hoe O
##ic O
in O
adolescent O
and O
adult O
patients O
, O
with O
er B-Disease
##yt I-Disease
##hem I-Disease
##a I-Disease
of I-Disease
the I-Disease
facial I-Disease
skin I-Disease
already O
common O
in O
childhood O
. O

of O
44 O
patients O
, O
nine O
( O
20 O
% O
) O
had O
facial B-Disease
an I-Disease
##gio I-Disease
##fi I-Disease
##bro I-Disease
##mas I-Disease
, O
t B-Disease
##umour I-Disease
##s I-Disease
primarily O
occurring O
in O
association O
with O
tube B-Disease
##rous I-Disease
s I-Disease
##cle I-Disease
##rosis I-Disease
. O

o B-Disease
##ede I-Disease
##mic I-Disease
b I-Disease
##uc I-Disease
##cal I-Disease
m I-Disease
##uc I-Disease
##osa I-Disease
( O
le B-Disease
##uc I-Disease
##oe I-Disease
##de I-Disease
##ma I-Disease
) O
and O
g B-Disease
##ing I-Disease
##ival I-Disease
over I-Disease
##gro I-Disease
##wth I-Disease
##s I-Disease
were O
more O
frequent O
in O
a B-Disease
##gu I-Disease
patients O
than O
in O
controls O
( O
p O
[UNK] O
0 O
. O
00 O
##1 O
) O
. O

of O
16 O
oral B-Disease
m I-Disease
##uc I-Disease
##osa I-Disease
##l I-Disease
lesions I-Disease
studied O
his O
##to O
##logical O
##ly O
, O
15 O
represented O
fi B-Disease
##bro I-Disease
##ep I-Disease
##ith I-Disease
##eli I-Disease
##al I-Disease
or I-Disease
e I-Disease
##pit I-Disease
##hel I-Disease
##ial I-Disease
h I-Disease
##yper I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
and O
were O
reactive O
in O
nature O
. O

c O
##yt O
##op O
##las O
##mic O
v O
##ac O
##uo O
##lis O
##ation O
was O
evident O
in O
four O
. O

im O
##mu O
##no O
##his O
##to O
##chemical O
##ly O
, O
expression O
of O
a O
##ga O
in O
a B-Disease
##gu I-Disease
patients O
m B-Disease
##uc I-Disease
##osa I-Disease
##l I-Disease
lesions I-Disease
did O
not O
differ O
from O
that O
seen O
in O
corresponding O
lesions O
of O
normal O
subjects O
. O

thus O
, O
the O
high O
frequency O
of O
m B-Disease
##uc I-Disease
##osa I-Disease
##l I-Disease
over I-Disease
##gro I-Disease
##wth I-Disease
in O
a B-Disease
##gu I-Disease
patients O
does O
not O
appear O
to O
be O
directly O
associated O
with O
l O
##ys O
##oso O
##mal O
storage O
or O
with O
alterations O
in O
the O
level O
of O
a O
##ga O
expression O
. O

characterization O
of O
a O
g O
##er O
##m O
##line O
mosaic O
##ism O
in O
families O
with O
low B-Disease
##e I-Disease
syndrome I-Disease
, O
and O
identification O
of O
seven O
novel O
mutations O
in O
the O
o O
##c O
##rl O
##1 O
gene O
. O

the O
o B-Disease
##cu I-Disease
##loc I-Disease
##ere I-Disease
##bro I-Disease
##rena I-Disease
##l I-Disease
syndrome I-Disease
of I-Disease
low I-Disease
##e I-Disease
( O
o B-Disease
##c I-Disease
##rl I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
characterized O
by O
major O
abnormal B-Disease
##ities I-Disease
of I-Disease
eyes I-Disease
, I-Disease
nervous I-Disease
system I-Disease
, I-Disease
and I-Disease
kidney I-Disease
##s I-Disease
. O

mutations O
in O
the O
o O
##c O
##rl O
##1 O
gene O
have O
been O
associated O
with O
the O
disease O
. O

o O
##c O
##rl O
##1 O
en O
##codes O
a O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
4 O
, O
5 O
- O
bi O
##ph O
##os O
##phate O
( O
p O
##t O
##din O
##s O
[ O
4 O
, O
5 O
] O
p O
##2 O
) O
5 O
- O
p O
##hos O
##pha O
##tase O
. O

we O
have O
examined O
the O
o O
##c O
##rl O
##1 O
gene O
in O
eight O
unrelated O
patients O
with O
o B-Disease
##c I-Disease
##rl I-Disease
and O
have O
found O
seven O
new O
mutations O
and O
one O
re O
##current O
in O
- O
frame O
del O
##eti O
##on O
. O

among O
the O
new O
mutations O
, O
two O
nonsense O
mutations O
( O
r O
##31 O
##7 O
##x O
and O
e O
##55 O
##8 O
##x O
) O
and O
three O
other O
frames O
##hi O
##ft O
mutations O
caused O
premature O
termination O
of O
the O
protein O
. O

a O
miss O
##ense O
mutation O
, O
r O
##48 O
##3 O
##g O
, O
was O
located O
in O
the O
highly O
conserved O
p O
##t O
##din O
##s O
( O
4 O
, O
5 O
) O
p O
##2 O
5 O
- O
p O
##hos O
##pha O
##tase O
domain O
. O

finally O
, O
one O
frames O
##hi O
##ft O
mutation O
, O
27 O
##9 O
##9 O
##del O
##c O
, O
m O
##od O
##ifies O
the O
c O
- O
terminal O
part O
of O
o O
##c O
##rl O
##1 O
, O
with O
an O
extension O
of O
six O
amino O
acids O
. O

altogether O
, O
70 O
% O
of O
miss O
##ense O
mutations O
are O
located O
in O
ex O
##on O
15 O
, O
and O
52 O
% O
of O
all O
mutations O
cluster O
in O
ex O
##ons O
11 O
- O
15 O
. O

we O
also O
identified O
two O
new O
micro O
##sat O
##elli O
##te O
markers O
for O
the O
o O
##c O
##rl O
##1 O
lo O
##cus O
, O
and O
we O
detected O
a O
g O
##er O
##m O
##line O
mosaic O
##ism O
in O
one O
family O
. O

this O
observation O
has O
direct O
implications O
for O
genetic O
counseling O
of O
low B-Disease
##e I-Disease
syndrome I-Disease
families O
. O
. O

me O
##f O
##v O
- O
gene O
analysis O
in O
arm O
##enia O
##n O
patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
: O
diagnostic O
value O
and O
un O
##fa O
##vor O
##able O
re O
##nal O
pro O
##gno O
##sis O
of O
the O
m O
##6 O
##9 O
##4 O
##v O
ho O
##mo O
##zy O
##go O
##us O
g O
##eno O
##type O
- O
genetic O
and O
therapeutic O
implications O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
is O
a O
re B-Disease
##cess I-Disease
##ively I-Disease
inherited I-Disease
disorder I-Disease
that O
is O
common O
in O
patients O
of O
arm O
##enia O
##n O
ancestry O
. O

to O
date O
, O
its O
diagnosis O
, O
which O
can O
be O
made O
only O
retrospective O
##ly O
, O
is O
one O
of O
exclusion O
, O
based O
entirely O
on O
non O
##sp O
##ec O
##ific O
clinical O
signs O
that O
result O
from O
se B-Disease
##ros I-Disease
##al I-Disease
inflammation I-Disease
and O
that O
may O
lead O
to O
unnecessary O
surgery O
. O

re B-Disease
##nal I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
, O
prevented O
by O
co O
##l O
##chi O
##cine O
, O
is O
the O
most O
severe O
com O
##plication O
of O
f B-Disease
##m I-Disease
##f I-Disease
, O
a O
disorder O
associated O
with O
mutations O
in O
the O
me O
##f O
##v O
gene O
. O

to O
evaluate O
the O
diagnostic O
and O
pro O
##gno O
##stic O
value O
of O
me O
##f O
##v O
- O
gene O
analysis O
, O
we O
investigated O
90 O
arm O
##enia O
##n O
f B-Disease
##m I-Disease
##f I-Disease
patients O
from O
77 O
unrelated O
families O
that O
were O
not O
selected O
through O
genetic O
- O
link O
##age O
analysis O
. O

eight O
mutations O
, O
one O
of O
which O
( O
r O
##40 O
##8 O
##q O
) O
is O
new O
, O
were O
found O
to O
account O
for O
93 O
% O
of O
the O
163 O
independent O
f B-Disease
##m I-Disease
##f I-Disease
all O
##ele O
##s O
, O
with O
both O
f B-Disease
##m I-Disease
##f I-Disease
all O
##ele O
##s O
identified O
in O
89 O
% O
of O
the O
patients O
. O

in O
several O
instances O
, O
family O
studies O
provided O
molecular O
evidence O
for O
pseudo O
##dom O
##ina O
##nt O
transmission O
and O
incomplete O
pen O
##et O
##rance O
of O
the O
disease O
p O
##hen O
##otype O
. O

the O
m O
##6 O
##9 O
##4 O
##v O
ho O
##mo O
##zy O
##go O
##us O
g O
##eno O
##type O
was O
found O
to O
be O
associated O
with O
a O
higher O
prevalence O
of O
re B-Disease
##nal I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
and O
art B-Disease
##hr I-Disease
##itis I-Disease
, O
compared O
with O
other O
g O
##eno O
##type O
##s O
( O
p O
= O
. O
000 O
##2 O
and O
p O
= O
. O
00 O
##6 O
, O
respectively O
) O
. O

the O
demonstration O
of O
both O
the O
diagnostic O
and O
pro O
##gno O
##stic O
value O
of O
me O
##f O
##v O
analysis O
and O
particular O
modes O
of O
inheritance O
should O
lead O
to O
new O
ways O
for O
management O
of O
f O
##m O
##f O
- O
including O
genetic O
counseling O
and O
therapeutic O
decisions O
in O
affected O
families O
. O

non O
##in O
##vasive O
test O
for O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
using O
hair O
root O
analysis O
. O

identification O
of O
the O
f O
##m O
##r O
##1 O
gene O
and O
the O
repeat O
- O
am O
##p O
##lification O
mechanism O
causing O
fragile B-Disease
x I-Disease
syndrome I-Disease
led O
to O
development O
of O
reliable O
d O
##na O
- O
based O
diagnostic O
methods O
, O
including O
southern O
b O
##lot O
hybrid O
##ization O
and O
p O
##c O
##r O
. O

both O
methods O
are O
performed O
on O
d O
##na O
isolated O
from O
peripheral O
blood O
cells O
and O
measure O
the O
repeat O
size O
in O
f O
##m O
##r O
##1 O
. O

using O
an O
im O
##mu O
##no O
##cy O
##to O
##chemical O
technique O
on O
blood O
s O
##me O
##ars O
, O
we O
recently O
developed O
a O
novel O
test O
for O
identification O
of O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

this O
method O
, O
also O
called O
" O
anti O
##body O
test O
, O
" O
uses O
mon O
##oc O
##lon O
##al O
antibodies O
against O
the O
f O
##m O
##r O
##1 O
gene O
product O
( O
f O
##m O
##rp O
) O
and O
is O
based O
on O
absence O
of O
f O
##m O
##rp O
in O
patients O
cells O
. O

here O
we O
describe O
a O
new O
diagnostic O
test O
to O
identify O
male O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
on O
the O
basis O
of O
lack O
of O
f O
##m O
##rp O
in O
their O
hair O
roots O
. O

expression O
of O
f O
##m O
##rp O
in O
hair O
roots O
was O
studied O
by O
use O
of O
an O
f O
##m O
##rp O
- O
specific O
anti O
##body O
test O
, O
and O
the O
percentage O
of O
f O
##m O
##rp O
- O
expressing O
hair O
roots O
in O
controls O
and O
in O
male O
fragile B-Disease
x I-Disease
patients O
was O
determined O
. O

control O
individuals O
showed O
clear O
expression O
of O
f O
##m O
##rp O
in O
nearly O
every O
hair O
root O
, O
whereas O
male O
fragile B-Disease
x I-Disease
patients O
lacked O
expression O
of O
f O
##m O
##rp O
in O
almost O
all O
their O
hair O
roots O
. O

mentally B-Disease
re I-Disease
##tar I-Disease
##ded I-Disease
female O
patients O
with O
a O
full O
mutation O
showed O
f O
##m O
##rp O
expression O
in O
only O
some O
of O
their O
hair O
roots O
( O
[UNK] O
55 O
% O
) O
, O
and O
no O
overlap O
with O
normal O
female O
controls O
was O
observed O
. O

the O
advantages O
of O
this O
test O
are O
( O
1 O
) O
p O
##luck O
##ing O
of O
hair O
f O
##oll O
##icles O
does O
no O
app O
##re O
##cia O
##ble O
harm O
to O
the O
mentally B-Disease
re I-Disease
##tar I-Disease
##ded I-Disease
patient O
, O
( O
2 O
) O
hairs O
can O
be O
sent O
in O
a O
simple O
envelope O
to O
a O
diagnostic O
center O
, O
and O
( O
3 O
) O
the O
result O
of O
the O
test O
is O
available O
within O
5 O
h O
of O
p O
##luck O
##ing O
. O

in O
addition O
, O
this O
test O
enabled O
us O
to O
identify O
two O
fragile B-Disease
x I-Disease
patients O
who O
did O
not O
show O
the O
full O
mutation O
by O
analysis O
of O
d O
##na O
isolated O
from O
blood O
cells O
. O
. O

in O
s O
##wed O
##ish O
families O
with O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
, O
link O
##age O
to O
the O
hp O
##c O
##1 O
lo O
##cus O
on O
chromosome O
1 O
##q O
##24 O
- O
25 O
is O
restricted O
to O
families O
with O
early O
- O
onset O
pro B-Disease
##state I-Disease
cancer I-Disease
. O

pro B-Disease
##state I-Disease
cancer I-Disease
clusters O
in O
some O
families O
, O
and O
an O
estimated O
5 O
% O
- O
10 O
% O
of O
all O
cases O
are O
estimated O
to O
result O
from O
inheritance O
of O
pro O
##state O
cancer O
- O
su O
##s O
##ce O
##pt O
##ibility O
genes O
. O

we O
previously O
reported O
evidence O
of O
link O
##age O
to O
the O
1 O
##q O
##24 O
- O
25 O
region O
( O
hp O
##c O
##1 O
) O
in O
91 O
north O
am O
##eric O
##an O
and O
s O
##wed O
##ish O
families O
each O
with O
multiple O
cases O
of O
pro B-Disease
##state I-Disease
cancer I-Disease
( O
s O
##mith O
et O
al O
. O
1996 O
) O
. O

in O
the O
present O
report O
we O
analyze O
40 O
( O
12 O
original O
and O
28 O
newly O
identified O
) O
s O
##wed O
##ish O
families O
with O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
( O
hp B-Disease
##c I-Disease
) O
that O
, O
on O
the O
basis O
of O
40 O
markers O
spanning O
a O
25 O
- O
cm O
interval O
within O
1 O
##q O
##24 O
- O
25 O
, O
have O
evidence O
of O
link O
##age O
. O

in O
the O
complete O
set O
of O
families O
, O
a O
maximum O
two O
- O
point O
lo O
##d O
score O
of O
1 O
. O

10 O
was O
observed O
at O
d O
##1 O
##s O
##41 O
##3 O
( O
at O
a O
re O
##comb O
##ination O
fraction O
[ O
the O
##ta O
] O
of O
. O
1 O
) O
, O
with O
a O
maximum O
n O
##p O
##l O
( O
non O
##par O
##ame O
##tric O
link O
##age O
) O
z O
score O
of O
1 O
. O

64 O
at O
d O
##1 O
##s O
##20 O
##2 O
( O
p O
= O
. O
05 O
) O
. O

the O
evidence O
of O
link O
##age O
to O
this O
region O
originated O
almost O
exclusively O
from O
the O
subset O
of O
12 O
early O
- O
onset O
( O
age O
[UNK] O
65 O
years O
) O
families O
, O
which O
yielded O
a O
maximum O
lo O
##d O
score O
of O
2 O
. O

38 O
at O
d O
##1 O
##s O
##41 O
##3 O
( O
straight O
the O
##ta O
= O
0 O
) O
and O
an O
n O
##p O
##l O
z O
score O
of O
1 O
. O

95 O
at O
d O
##1 O
##s O
##42 O
##2 O
( O
p O
= O
. O
03 O
) O
. O

estimates O
from O
he O
##tero O
##gene O
##ity O
tests O
suggest O
that O
, O
within O
s O
##wed O
##en O
, O
as O
many O
as O
50 O
% O
of O
early O
- O
onset O
families O
had O
evidence O
of O
link O
##age O
to O
the O
hp O
##c O
##1 O
region O
. O

these O
results O
are O
consistent O
with O
the O
hypothesis O
of O
link O
##age O
to O
hp O
##c O
##1 O
in O
a O
subset O
of O
families O
with O
pro B-Disease
##state I-Disease
cancer I-Disease
, O
particularly O
those O
with O
an O
early O
age O
at O
diagnosis O
. O

molecular O
basis O
of O
f O
##elin O
##e O
beta B-Disease
- I-Disease
g I-Disease
##lu I-Disease
##cu I-Disease
##ron I-Disease
##idas I-Disease
##e I-Disease
deficiency I-Disease
: O
an O
animal O
model O
of O
m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
v I-Disease
##ii I-Disease
. O

a O
family O
of O
domestic O
cats O
was O
found O
that O
exhibited O
clinical O
and O
bio O
##chemical O
abnormal O
##ities O
consistent O
with O
m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
v I-Disease
##ii I-Disease
, O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
l I-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
beta B-Disease
- I-Disease
g I-Disease
##lu I-Disease
##cu I-Disease
##ron I-Disease
##idas I-Disease
##e I-Disease
deficiency I-Disease
. O

beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
activity O
was O
und O
##ete O
##ct O
##able O
in O
affected O
cat O
fi O
##bro O
##blast O
##s O
and O
restored O
by O
re O
##tro O
##vir O
##al O
gene O
transfer O
of O
rat O
beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
c O
##dn O
##a O
. O

beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
m O
##rna O
was O
normal O
in O
affected O
cat O
test O
##is O
by O
northern O
b O
##lot O
analysis O
. O

normal O
f O
##elin O
##e O
beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
c O
##dn O
##a O
was O
clone O
##d O
and O
characterized O
, O
and O
am O
##plified O
from O
affected O
cat O
fi O
##bro O
##blast O
##s O
by O
reverse O
transcription O
coupled O
polymer O
##ase O
chain O
reaction O
. O

there O
was O
a O
g O
- O
to O
- O
a O
transition O
in O
the O
affected O
cat O
c O
##dn O
##a O
that O
predicted O
an O
e O
##35 O
##1 O
##k O
substitution O
, O
destroyed O
a O
b O
##ss O
##si O
site O
, O
and O
eliminated O
g O
##us O
##b O
en O
##zy O
##matic O
activity O
in O
expression O
studies O
. O

multiple O
species O
comparison O
and O
the O
crystal O
structure O
of O
human O
beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
indicated O
that O
e O
##35 O
##1 O
is O
a O
highly O
conserved O
residue O
most O
likely O
essential O
in O
maintenance O
of O
the O
enzymes O
conform O
##ation O
. O

b O
##ss O
##si O
dig O
##est O
##ion O
of O
polymer O
##ase O
chain O
reaction O
products O
am O
##plified O
from O
g O
##eno O
##mic O
d O
##na O
indicated O
that O
affected O
cats O
were O
ho O
##mo O
##zy O
##go O
##us O
and O
cats O
with O
half O
- O
normal O
beta O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
activity O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
miss O
##ense O
mutation O
. O

carriers O
identified O
in O
this O
manner O
produced O
affected O
kit O
##tens O
in O
prospective O
breeding O
##s O
, O
and O
a O
f O
##elin O
##e O
m B-Disease
##ps I-Disease
v I-Disease
##ii I-Disease
breeding O
colony O
has O
been O
established O
. O
. O

a O
common O
molecular O
basis O
for O
rear B-Disease
##rang I-Disease
##ement I-Disease
disorders I-Disease
on O
chromosome O
22 O
##q O
##11 O
. O

the O
chromosome O
22 O
##q O
##11 O
region O
is O
susceptible O
to O
rear O
##rang O
##ement O
##s O
that O
are O
associated O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
disorders I-Disease
and O
ma B-Disease
##li I-Disease
##gnant I-Disease
tumors I-Disease
. O

three O
con B-Disease
##gen I-Disease
##ital I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
disorders I-Disease
, O
cat B-Disease
- I-Disease
eye I-Disease
syndrome I-Disease
, O
der B-Disease
( I-Disease
) I-Disease
syndrome I-Disease
and O
ve B-Disease
##lo I-Disease
- I-Disease
card I-Disease
##io I-Disease
- I-Disease
facial I-Disease
syndrome I-Disease
/ O
dig B-Disease
##eor I-Disease
##ge I-Disease
syndrome I-Disease
( O
v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
) O
are O
associated O
with O
te O
##tras O
##omy O
, O
t O
##ris O
##omy O
or O
mon O
##oso O
##my O
, O
respectively O
, O
for O
part O
of O
chromosome O
22 O
##q O
##11 O
. O

v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
is O
the O
most O
common O
syndrome O
associated O
with O
22 O
##q O
##11 O
rear O
##rang O
##ement O
##s O
. O

in O
order O
to O
determine O
whether O
there O
are O
particular O
regions O
on O
22 O
##q O
##11 O
that O
are O
prone O
to O
rear O
##rang O
##ement O
##s O
, O
the O
del O
##eti O
##on O
end O
- O
points O
in O
a O
large O
number O
of O
v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
patients O
were O
defined O
by O
ha O
##p O
##lot O
##ype O
analysis O
. O

most O
v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
patients O
have O
a O
similar O
3 O
m O
##b O
del O
##eti O
##on O
, O
some O
have O
a O
nest O
##ed O
di O
##stal O
del O
##eti O
##on O
break O
##point O
resulting O
in O
a O
1 O
. O

5 O
m O
##b O
del O
##eti O
##on O
and O
a O
few O
rare O
patients O
have O
unique O
del O
##eti O
##ons O
or O
trans O
##location O
##s O
. O

the O
high O
prevalence O
of O
the O
disorder O
in O
the O
population O
and O
the O
fact O
that O
most O
cases O
occur O
s O
##poradic O
##ally O
suggest O
that O
sequences O
at O
or O
near O
the O
break O
##points O
con O
##fer O
su O
##s O
##ce O
##pt O
##ibility O
to O
chromosome O
rear O
##rang O
##ement O
##s O
. O

to O
investigate O
this O
hypothesis O
, O
we O
developed O
ha O
##ms O
##ter O
- O
human O
so O
##matic O
hybrid O
cell O
lines O
from O
v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
patients O
with O
all O
three O
classes O
of O
del O
##eti O
##ons O
and O
we O
now O
show O
that O
the O
break O
##points O
occur O
within O
similar O
low O
copy O
repeats O
, O
termed O
l O
##c O
##r O
##22 O
##s O
. O

to O
support O
this O
idea O
further O
, O
we O
identified O
a O
family O
that O
carries O
an O
inter O
##st O
##iti O
##al O
du O
##plication O
of O
the O
same O
3 O
m O
##b O
region O
that O
is O
deleted O
in O
v B-Disease
##c I-Disease
##fs I-Disease
/ O
d B-Disease
##gs I-Disease
patients O
. O

we O
present O
models O
to O
explain O
how O
the O
l O
##c O
##r O
##22 O
##s O
can O
media O
##te O
different O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
events O
, O
thereby O
generating O
a O
number O
of O
rear O
##rang O
##ement O
##s O
that O
are O
associated O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
disorders I-Disease
. O

we O
identified O
five O
additional O
copies O
of O
the O
l O
##c O
##r O
##22 O
on O
22 O
##q O
##11 O
that O
may O
media O
##te O
other O
rear O
##rang O
##ement O
##s O
leading O
to O
disease O
. O

functional O
consequences O
of O
mutations O
in O
the O
early O
growth O
response O
2 O
gene O
( O
e O
##g O
##r O
##2 O
) O
co O
##rrel O
##ate O
with O
severity O
of O
human O
my B-Disease
##elin I-Disease
##op I-Disease
##ath I-Disease
##ies I-Disease
. O

the O
early O
growth O
response O
2 O
gene O
( O
e O
##g O
##r O
##2 O
) O
is O
a O
c O
##ys O
##2 O
##his O
##2 O
##zin O
##c O
finger O
transcription O
factor O
which O
is O
thought O
to O
play O
a O
role O
in O
the O
regulation O
of O
peripheral O
nervous O
system O
my O
##elin O
##ation O
. O

this O
idea O
is O
based O
partly O
on O
the O
p O
##hen O
##otype O
of O
ho O
##mo O
##zy O
##go O
##us O
k O
##ro O
##x O
##20 O
( O
e O
##g O
##r O
##2 O
) O
knockout O
mice O
, O
which O
display O
h B-Disease
##y I-Disease
##po I-Disease
##my I-Disease
##elin I-Disease
##ation I-Disease
of I-Disease
the I-Disease
p I-Disease
##ns I-Disease
and O
a O
block O
of O
s O
##ch O
##wan O
##n O
cells O
at O
an O
early O
stage O
of O
differentiation O
. O

mutations O
in O
the O
human O
e O
##g O
##r O
##2 O
gene O
have O
recently O
been O
associated O
with O
the O
inherited B-Disease
peripheral I-Disease
ne I-Disease
##uro I-Disease
##path I-Disease
##ies I-Disease
ch B-Disease
##ar I-Disease
##cot I-Disease
- I-Disease
ma I-Disease
##rie I-Disease
- I-Disease
tooth I-Disease
type I-Disease
1 I-Disease
, O
de B-Disease
##jer I-Disease
##ine I-Disease
- I-Disease
so I-Disease
##tta I-Disease
##s I-Disease
syndrome I-Disease
and O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##y I-Disease
##po I-Disease
##my I-Disease
##elin I-Disease
##ating I-Disease
ne I-Disease
##uro I-Disease
##pathy I-Disease
. O

three O
of O
the O
four O
e O
##g O
##r O
##2 O
mutations O
are O
dominant O
and O
occur O
within O
the O
zinc O
finger O
d O
##na O
- O
binding O
domain O
. O

the O
fourth O
mutation O
is O
re O
##cess O
##ive O
and O
affects O
the O
inhibitor O
##y O
domain O
( O
r O
##1 O
) O
that O
binds O
the O
na O
##b O
transcription O
##al O
co O
- O
re O
##press O
##ors O
. O

a O
combination O
of O
d O
##na O
- O
binding O
ass O
##ays O
and O
transcription O
##al O
analysis O
was O
used O
to O
determine O
the O
functional O
consequences O
of O
these O
mutations O
. O

the O
zinc O
finger O
mutations O
affect O
d O
##na O
binding O
and O
the O
amount O
of O
residual O
binding O
directly O
co O
##rrel O
##ates O
with O
disease O
severity O
. O

the O
r O
##1 O
domain O
mutation O
prevents O
interaction O
of O
e O
##g O
##r O
##2 O
with O
the O
na O
##b O
co O
- O
re O
##press O
##ors O
and O
thereby O
increases O
transcription O
##al O
activity O
. O

these O
data O
provide O
insight O
into O
the O
possible O
disease O
mechanisms O
underlying O
e O
##g O
##r O
##2 O
mutations O
and O
the O
reason O
for O
varying O
severity O
and O
differences O
in O
inheritance O
patterns O
. O
. O

auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
with O
continued O
secret O
##ion O
of O
mutant O
weakly O
active O
v O
##as O
##op O
##ress O
##in O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
post O
- O
na O
##tal O
development O
of O
a B-Disease
##rg I-Disease
##ini I-Disease
##ne I-Disease
v I-Disease
##as I-Disease
##op I-Disease
##ress I-Disease
##in I-Disease
( I-Disease
a I-Disease
##v I-Disease
##p I-Disease
) I-Disease
deficiency I-Disease
due O
to O
mutations O
in O
the O
a O
##v O
##p O
gene O
. O

all O
published O
mutations O
affect O
the O
signal O
p O
##eptide O
or O
the O
ne O
##uro O
##phy O
##sin O
- O
ii O
carrier O
protein O
and O
are O
presumed O
to O
interfere O
with O
processing O
of O
the O
pre O
##p O
##ro O
##hor O
##mon O
##e O
, O
leading O
to O
ne B-Disease
##uron I-Disease
##al I-Disease
damage I-Disease
. O

we O
studied O
an O
unusual O
pale O
##st O
##inian O
family O
consisting O
of O
as O
##ym O
##pt O
##oma O
##tic O
first O
cousin O
parents O
and O
three O
children O
affected O
with O
ne B-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
, O
suggesting O
auto O
##so O
##mal O
re O
##cess O
##ive O
inheritance O
. O

all O
three O
affected O
children O
were O
ho O
##mo O
##zy O
##go O
##us O
and O
the O
parents O
he O
##tero O
##zy O
##go O
##us O
for O
a O
single O
novel O
mutation O
( O
c O
##30 O
##1 O
- O
[UNK] O
t O
) O
in O
ex O
##on O
1 O
, O
replacing O
pro O
##7 O
of O
mature O
a O
##v O
##p O
with O
le O
##u O
( O
le O
##u O
- O
a O
##v O
##p O
) O
. O

le O
##u O
- O
a O
##v O
##p O
was O
a O
weak O
ago O
##nist O
with O
approximately O
30 O
- O
fold O
reduced O
binding O
to O
the O
human O
v O
##2 O
receptor O
. O

measured O
by O
radio O
##im O
##mu O
##no O
##ass O
##ay O
with O
a O
synthetic O
le O
##u O
- O
a O
##v O
##p O
standard O
, O
serum O
le O
##u O
- O
a O
##v O
##p O
levels O
were O
elevated O
in O
all O
three O
children O
and O
further O
increased O
during O
water O
de O
##p O
##ri O
##vation O
to O
as O
high O
as O
30 O
times O
normal O
. O

the O
youngest O
child O
( O
2 O
years O
old O
) O
was O
only O
mildly O
affected O
but O
had O
le O
##u O
- O
a O
##v O
##p O
levels O
similar O
to O
her O
severely O
affected O
8 O
- O
year O
- O
old O
brother O
, O
suggesting O
that O
unknown O
mechanisms O
may O
partially O
compensate O
for O
a O
deficiency B-Disease
of I-Disease
active I-Disease
a I-Disease
##v I-Disease
##p I-Disease
in O
very O
young O
children O
. O
. O

x O
in O
##act O
##ivation O
and O
so O
##matic O
cell O
selection O
rescue O
female O
mice O
carrying O
a O
pig O
##a O
- O
null O
mutation O
. O

a O
so O
##matic O
mutation O
in O
the O
x O
linked O
pig O
##a O
gene O
is O
responsible O
for O
the O
deficiency B-Disease
of I-Disease
g I-Disease
##ly I-Disease
##cos I-Disease
##yl I-Disease
p I-Disease
##hos I-Disease
##pha I-Disease
##ti I-Disease
##dy I-Disease
##lino I-Disease
##si I-Disease
##to I-Disease
##l I-Disease
( I-Disease
g I-Disease
##pi I-Disease
) I-Disease
- I-Disease
anchored I-Disease
proteins I-Disease
on O
blood O
cells O
from O
patients O
with O
par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
no I-Disease
##cturnal I-Disease
hem I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
. O

no O
inherited O
form O
of O
g B-Disease
##pi I-Disease
- I-Disease
anchor I-Disease
deficiency I-Disease
has O
been O
described O
. O

because O
conventional O
pig O
##a O
gene O
knockout O
is O
associated O
with O
high O
em B-Disease
##b I-Disease
##ryo I-Disease
##nic I-Disease
lethal I-Disease
##ity I-Disease
in O
ch O
##ime O
##ric O
mice O
, O
we O
used O
the O
c O
##re O
/ O
lo O
##x O
##p O
system O
. O

we O
generated O
mice O
in O
which O
two O
lo O
##x O
##p O
sites O
flank O
part O
of O
pig O
##a O
ex O
##on O
2 O
. O

after O
cross O
##bre O
##eding O
with O
female O
mice O
of O
the O
e O
##ii O
##a O
- O
c O
##re O
strain O
, O
the O
fl O
##ox O
##ed O
all O
##ele O
undergo O
##es O
c O
##re O
- O
mediated O
re O
##comb O
##ination O
with O
high O
efficiency O
during O
early O
em O
##b O
##ryo O
##nic O
development O
. O

because O
of O
x O
chromosome O
in O
##act O
##ivation O
, O
female O
offspring O
are O
mosaic O
for O
cells O
that O
express O
or O
lack O
g O
##pi O
- O
linked O
proteins O
. O

analysis O
of O
mosaic O
mice O
showed O
that O
in O
heart O
, O
lung O
, O
kidney O
, O
brain O
, O
and O
liver O
, O
mainly O
wild O
- O
type O
pig O
##a O
is O
active O
, O
suggesting O
that O
these O
tissues O
require O
g O
##pi O
- O
linked O
proteins O
. O

the O
sa O
##lient O
exceptions O
were O
s O
##ple O
##en O
, O
thy O
##mus O
, O
and O
red O
blood O
cells O
, O
which O
had O
almost O
equal O
numbers O
of O
cells O
expressing O
the O
wild O
- O
type O
or O
the O
re O
##comb O
##ined O
all O
##ele O
, O
implying O
that O
g O
##pi O
- O
linked O
proteins O
are O
not O
essential O
for O
the O
der O
##ivation O
of O
these O
tissues O
. O

pig O
##a O
( O
- O
) O
cells O
had O
no O
growth O
advantage O
, O
suggesting O
that O
other O
factors O
are O
needed O
for O
their O
c O
##lon O
##al O
dominance O
in O
patients O
with O
par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
no I-Disease
##cturnal I-Disease
hem I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
. O
. O

the O
c O
##28 O
##2 O
##y O
mutation O
causing O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
does O
not O
produce O
a O
null O
all O
##ele O
. O

targeted O
m O
##uta O
##genesis O
was O
used O
to O
produce O
two O
mutations O
in O
the O
m O
##uri O
##ne O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
( O
h O
##fe O
) O
lo O
##cus O
. O

the O
first O
mutation O
del O
##ete O
##s O
a O
large O
portion O
of O
the O
coding O
sequence O
, O
generating O
a O
null O
all O
##ele O
. O

the O
second O
mutation O
introduces O
a O
miss O
##ense O
mutation O
( O
c O
##28 O
##2 O
##y O
) O
into O
the O
h O
##fe O
lo O
##cus O
, O
but O
otherwise O
leaves O
the O
gene O
intact O
. O

this O
mutation O
is O
identical O
to O
the O
disease O
- O
causing O
mutation O
in O
patients O
with O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
. O

mice O
carrying O
each O
of O
the O
two O
mutations O
were O
bred O
and O
analyzed O
. O

ho O
##mo O
##zy O
##gos O
##ity O
for O
either O
mutation O
results O
in O
post O
##nat O
##al O
iron O
loading O
. O

the O
effects O
of O
the O
null O
mutation O
are O
more O
severe O
than O
the O
effects O
of O
the O
c O
##28 O
##2 O
##y O
mutation O
. O

mice O
he O
##tero O
##zy O
##go O
##us O
for O
either O
mutation O
a O
##cc O
##um O
##ulate O
more O
iron O
than O
normal O
controls O
. O

interesting O
##ly O
, O
although O
liver O
iron O
stores O
are O
greatly O
increased O
, O
s O
##ple O
##nic O
iron O
is O
decreased O
. O

we O
conclude O
that O
the O
c O
##28 O
##2 O
##y O
mutation O
does O
not O
result O
in O
a O
null O
all O
##ele O
. O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
analysis O
in O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
identification O
of O
a O
miss O
##ense O
mutation O
associated O
with O
a O
mild O
##er O
p O
##hen O
##otype O
. O

direct O
se O
##quencing O
of O
the O
em O
##eri O
##n O
gene O
in O
22 O
families O
with O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
em B-Disease
##d I-Disease
) O
revealed O
mutations O
in O
21 O
( O
95 O
% O
) O
, O
confirming O
that O
em O
##eri O
##n O
mutations O
can O
be O
identified O
in O
the O
majority O
of O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##d I-Disease
. O

most O
em O
##eri O
##n O
mutations O
result O
in O
absence O
of O
the O
protein O
. O

in O
this O
study O
three O
mutations O
( O
a O
miss O
##ense O
mutation O
pro O
##18 O
##3 O
##th O
##r O
and O
two O
in O
- O
frame O
del O
##eti O
##ons O
removing O
residues O
95 O
- O
99 O
and O
236 O
- O
241 O
, O
respectively O
) O
were O
unusual O
in O
being O
associated O
with O
expression O
of O
mutant O
protein O
. O

the O
p O
##hen O
##otype O
in O
these O
families O
was O
compared O
in O
detail O
with O
the O
clinical O
features O
in O
cases O
with O
typical O
null O
mutations O
. O

for O
the O
in O
- O
frame O
del O
##eti O
##ons O
there O
were O
no O
significant O
differences O
. O

in O
the O
family O
with O
the O
miss O
##ense O
mutation O
the O
p O
##hen O
##otype O
was O
mild O
##er O
. O

age O
at O
onset O
was O
later O
for O
first O
symptoms O
and O
for O
development O
of O
ankle B-Disease
contract I-Disease
##ures I-Disease
and O
muscle B-Disease
weakness I-Disease
. O

these O
findings O
have O
diagnostic O
implications O
as O
well O
as O
pointing O
to O
functional O
##ly O
important O
regions O
of O
the O
em O
##eri O
##n O
protein O
. O
. O

severe O
clinical O
expression O
in O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
is O
a O
relatively O
rare O
ben B-Disease
##ign I-Disease
ne I-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
disorder I-Disease
which O
can O
vary O
remarkably O
in O
onset O
, O
course O
and O
severity O
. O

in O
the O
present O
study O
, O
a O
t O
##ct O
##ac O
del O
##eti O
##on O
spanning O
the O
n O
##uc O
##leo O
##tide O
##s O
63 O
##1 O
- O
63 O
##5 O
of O
the O
em O
##eri O
##n O
gene O
caused O
an O
unusually O
severe O
disease O
p O
##hen O
##otype O
including O
loss B-Disease
of I-Disease
am I-Disease
##bula I-Disease
##tion I-Disease
and O
severe O
muscle B-Disease
wasting I-Disease
in O
two O
affected O
brothers O
. O

the O
same O
mutation O
has O
been O
reported O
previously O
in O
an O
unrelated O
family O
showing O
a O
significantly O
mild O
##er O
p O
##hen O
##otype O
. O

the O
inter O
##fa O
##mi O
##lial O
he O
##tero O
##gene O
##ity O
in O
distribution O
and O
in O
severity O
of O
the O
features O
in O
the O
two O
families O
point O
to O
environmental O
or O
genetic O
modification O
as O
the O
cause O
of O
clinical O
var O
##iability O
in O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O
. O

common O
mutations O
in O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
do O
not O
contribute O
to O
early O
pro B-Disease
##state I-Disease
cancer I-Disease
in O
j O
##ew O
##ish O
men O
. O

background O
families O
with O
a O
high O
incidence O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
, O
and O
subsequently O
shown O
to O
have O
terminating O
mutations O
in O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
, O
appear O
to O
have O
a O
higher O
incidence O
of O
pro B-Disease
##state I-Disease
cancer I-Disease
among O
male O
relatives O
. O

we O
aimed O
to O
determine O
whether O
the O
common O
g O
##er O
##m O
##line O
mutations O
of O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
in O
ash O
##ken O
##azi O
j O
##ew O
##ish O
men O
pre O
##dis O
##posed O
them O
to O
pro B-Disease
##state I-Disease
cancer I-Disease
. O

methods O
we O
examined O
g O
##eno O
##mic O
d O
##na O
from O
83 O
( O
for O
br O
##ca O
##1 O
185 O
##dela O
##g O
) O
or O
82 O
( O
for O
br O
##ca O
##2 O
61 O
##7 O
##4 O
##del O
##t O
) O
ash O
##ken O
##azi O
j O
##ew O
##ish O
pro B-Disease
##state I-Disease
cancer I-Disease
patients O
, O
most O
of O
whom O
were O
treated O
at O
a O
relatively O
young O
age O
, O
for O
the O
most O
common O
g O
##er O
##m O
##line O
mutation O
in O
each O
gene O
seen O
in O
the O
ash O
##ken O
##azi O
population O
. O

results O
our O
study O
should O
have O
been O
able O
to O
detect O
a O
4 O
- O
5 O
- O
fold O
increase O
in O
the O
risk O
of O
pro B-Disease
##state I-Disease
cancer I-Disease
due O
to O
mutation O
of O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
. O

however O
, O
only O
one O
( O
1 O
. O
15 O
% O
; O
95 O
% O
confidence O
interval O
, O
0 O
- O
3 O
. O
6 O
% O
) O
of O
the O
patients O
was O
he O
##tero O
##zy O
##go O
##us O
for O
the O
br O
##ca O
##1 O
mutant O
all O
##ele O
, O
and O
only O
two O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
br O
##ca O
##2 O
mutation O
( O
2 O
. O
4 O
% O
; O
95 O
% O
confidence O
interval O
, O
0 O
- O
6 O
. O
2 O
% O
) O
. O

conclusions O
the O
incidence O
of O
each O
of O
the O
g O
##er O
##m O
##line O
mutations O
in O
these O
pro B-Disease
##state I-Disease
cancer I-Disease
patients O
closely O
matched O
their O
incidence O
( O
about O
1 O
% O
) O
in O
the O
general O
ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
. O

this O
suggests O
that O
unlike O
cases O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
, O
mutations O
in O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
do O
not O
significantly O
pre O
##dis O
##pose O
men O
to O
pro B-Disease
##state I-Disease
cancer I-Disease

beta O
- O
cat O
##eni O
##n O
accumulation O
and O
mutation O
of O
the O
c O
##t O
##nn O
##b O
##1 O
gene O
in O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
. O

he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
is O
a O
rare O
ma B-Disease
##li I-Disease
##gnant I-Disease
tumor I-Disease
of I-Disease
the I-Disease
liver I-Disease
that O
occurs O
in O
children O
at O
an O
average O
age O
of O
2 O
to O
3 O
years O
. O

e O
##pid O
##em O
##iol O
##og O
##ic O
studies O
have O
shown O
an O
increased O
frequency O
of O
this O
tumor B-Disease
type O
in O
families O
affected O
by O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
. O

in O
addition O
to O
the O
e O
##pid O
##em O
##iol O
##og O
##ic O
data O
, O
molecular O
genetic O
studies O
suggest O
that O
in O
##act O
##ivation O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
tumor I-Disease
suppress O
##or O
may O
be O
involved O
in O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
tumor O
##ige O
##nes O
##is O
. O

a O
major O
function O
of O
a O
##p O
##c O
is O
the O
down O
##re O
##gu O
##lation O
of O
beta O
- O
cat O
##eni O
##n O
, O
a O
transcription O
- O
act O
##ivating O
protein O
with O
on O
##co O
##genic O
potential O
. O

in O
an O
ongoing O
im O
##mu O
##no O
##his O
##to O
##chemical O
study O
of O
beta O
- O
cat O
##eni O
##n O
expression O
in O
s O
##poradic O
cases O
of O
tumor B-Disease
types O
that O
are O
associated O
with O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
, O
we O
observed O
increased O
beta O
- O
cat O
##eni O
##n O
levels O
in O
the O
c O
##yt O
##op O
##las O
##m O
and O
in O
the O
nuclei O
of O
three O
investigated O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
. O

se O
##quencing O
of O
ex O
##on O
3 O
of O
the O
beta O
- O
cat O
##eni O
##n O
gene O
( O
c O
##t O
##nn O
##b O
##1 O
) O
revealed O
an O
act O
##ivating O
mutation O
in O
one O
of O
the O
tumor B-Disease
samples O
. O

our O
data O
indicate O
for O
the O
first O
time O
that O
beta O
- O
cat O
##eni O
##n O
accumulation O
may O
play O
a O
role O
in O
the O
development O
of O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
and O
that O
act O
##ivating O
mutations O
of O
the O
beta O
- O
cat O
##eni O
##n O
gene O
may O
substitute O
bi O
##alle O
##lic O
a O
##p O
##c O
in O
##act O
##ivation O
in O
this O
tumor B-Disease
type O
. O

genes O
chromosome O
##s O
cancer O
25 O
39 O
##9 O
- O
40 O
##2 O
, O
1999 O
. O
. O

decrease O
in O
g O
##t O
##p O
c O
##y O
##c O
##lo O
##hy O
##dr O
##ola O
##se O
i O
gene O
expression O
caused O
by O
in O
##act O
##ivation O
of O
one O
all O
##ele O
in O
hereditary B-Disease
progressive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
with O
marked O
di O
##urn O
##al O
flu O
##ct O
##uation O
. O

hereditary B-Disease
progressive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
with O
marked O
di O
##urn O
##al O
flu O
##ct O
##uation O
( O
hp B-Disease
##d I-Disease
; O
do B-Disease
##pa I-Disease
- I-Disease
re I-Disease
##sp I-Disease
##ons I-Disease
##ive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
, O
d B-Disease
##rd I-Disease
) O
have O
been O
recently O
found O
to O
be O
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
the O
g O
##t O
##p O
c O
##y O
##c O
##lo O
##hy O
##dr O
##ola O
##se O
i O
( O
g O
##ch O
##1 O
) O
gene O
. O

in O
this O
study O
, O
we O
q O
##uant O
##ified O
the O
m O
##rna O
level O
of O
g O
##ch O
##1 O
in O
p O
##hy O
##to O
##hem O
##ag O
##g O
##lut O
##ini O
##n O
( O
p O
##ha O
) O
- O
stimulate O
##d O
mon O
##on O
##uc O
##lea O
##r O
blood O
cells O
from O
one O
j O
##apa O
##nese O
family O
that O
do O
not O
have O
a O
mutation O
in O
the O
coding O
region O
or O
s O
##p O
##lice O
junction O
##s O
of O
the O
gene O
. O

the O
results O
showed O
that O
the O
amounts O
of O
the O
g O
##ch O
##1 O
m O
##rna O
were O
decreased O
to O
about O
40 O
% O
of O
the O
normal O
level O
in O
both O
patients O
and O
carriers O
. O

in O
addition O
, O
we O
found O
that O
the O
g O
##ch O
##1 O
m O
##rna O
was O
trans O
##cribed O
from O
only O
one O
all O
##ele O
, O
indicating O
that O
the O
other O
all O
##ele O
was O
in O
an O
inactive O
state O
. O

these O
results O
suggest O
that O
some O
novel O
mutations O
should O
exist O
on O
one O
of O
the O
all O
##ele O
##s O
in O
some O
unknown O
region O
of O
the O
g O
##ch O
##1 O
gene O
, O
and O
may O
decrease O
the O
g O
##ch O
##1 O
m O
##rna O
causing O
the O
hp B-Disease
##d I-Disease
/ O
d B-Disease
##rd I-Disease
symptoms O
. O
. O

su O
##lf O
##ate O
transport O
is O
not O
impaired O
in O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
thy O
##ro O
##cy O
##tes O
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
is O
the O
most O
common O
form O
of O
s B-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
deaf I-Disease
##ness I-Disease
, O
characterized O
by O
d B-Disease
##ys I-Disease
##hor I-Disease
##mon I-Disease
##ogenic I-Disease
go I-Disease
##iter I-Disease
associated O
with O
sensory B-Disease
- I-Disease
neural I-Disease
deaf I-Disease
##ness I-Disease
. O

the O
gene O
responsible O
for O
the O
disease O
( O
p B-Disease
##ds I-Disease
) O
has O
been O
clone O
##d O
, O
but O
its O
function O
is O
as O
yet O
unknown O
and O
the O
connection O
between O
thy B-Disease
##roid I-Disease
go I-Disease
##iter I-Disease
and O
sensory B-Disease
- I-Disease
neural I-Disease
deaf I-Disease
##ness I-Disease
remains O
an O
en O
##igma O
. O

p O
##ds O
codes O
for O
a O
novel O
protein O
, O
pen O
##dr O
##in O
, O
which O
is O
closely O
related O
to O
a O
number O
of O
su O
##fa O
##te O
transport O
##ers O
. O

mechanisms O
by O
which O
abnormal O
su O
##lf O
##ate O
transport O
could O
del O
##eter O
##iously O
affect O
i O
##od O
##ide O
organ O
##ification O
have O
been O
proposed O
. O

we O
tested O
su O
##lf O
##ate O
transport O
in O
thy O
##ro O
##cy O
##tes O
obtained O
from O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
patients O
and O
found O
that O
it O
was O
not O
defect O
##ive O
. O

this O
suggests O
that O
pen O
##dr O
##in O
in O
fact O
may O
not O
be O
a O
su O
##lf O
##ate O
transport O
##er O
, O
and O
emphasizes O
the O
importance O
of O
functional O
studies O
on O
this O
novel O
protein O
. O
. O

small O
del O
##eti O
##ons O
in O
the O
type O
ii O
co O
##lla O
##gen O
triple O
he O
##lix O
produce O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
is O
a O
moderately O
severe O
type B-Disease
ii I-Disease
co I-Disease
##lla I-Disease
##gen I-Disease
##op I-Disease
##athy I-Disease
, O
characterized O
by O
short O
trunk O
and O
limbs O
, O
k B-Disease
##y I-Disease
##ph I-Disease
##os I-Disease
##co I-Disease
##lio I-Disease
##sis I-Disease
, O
mid B-Disease
##face I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
severe O
my B-Disease
##op I-Disease
##ia I-Disease
, O
and O
hearing B-Disease
loss I-Disease
. O

mutations O
in O
the O
gene O
that O
en O
##codes O
type O
ii O
co O
##lla O
##gen O
( O
co O
##l O
##2 O
##a O
##1 O
) O
, O
the O
predominant O
protein O
of O
cart O
##ila O
##ge O
, O
have O
been O
identified O
in O
a O
number O
of O
individuals O
with O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

all O
but O
two O
of O
these O
previously O
described O
mutations O
cause O
in O
- O
frame O
del O
##eti O
##ons O
in O
type O
ii O
co O
##lla O
##gen O
, O
either O
by O
small O
del O
##eti O
##ons O
in O
the O
gene O
or O
s O
##p O
##lice O
site O
alterations O
. O

further O
##more O
, O
all O
but O
one O
of O
these O
mutations O
is O
located O
between O
ex O
##ons O
12 O
and O
24 O
in O
the O
co O
##l O
##2 O
##a O
##1 O
gene O
. O

we O
used O
he O
##tero O
##du O
##plex O
analysis O
to O
identify O
sequence O
an O
##oma O
##lies O
in O
five O
individuals O
with O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

se O
##quencing O
of O
the O
index O
patients O
g O
##eno O
##mic O
d O
##na O
identified O
four O
new O
dominant O
mutations O
in O
co O
##l O
##2 O
##a O
##1 O
that O
result O
in O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
a O
21 O
- O
b O
##p O
del O
##eti O
##on O
in O
ex O
##on O
16 O
, O
an O
18 O
- O
b O
##p O
del O
##eti O
##on O
in O
ex O
##on O
19 O
, O
and O
4 O
- O
b O
##p O
del O
##eti O
##ons O
in O
the O
s O
##p O
##lice O
donor O
sites O
of O
intro O
##ns O
14 O
and O
20 O
. O

a O
previously O
described O
28 O
- O
b O
##p O
del O
##eti O
##on O
at O
the O
co O
##l O
##2 O
##a O
##1 O
ex O
##on O
12 O
- O
intro O
##n O
12 O
junction O
, O
del O
##eting O
the O
s O
##p O
##lice O
donor O
site O
, O
was O
identified O
in O
the O
fifth O
case O
. O

the O
latter O
three O
mutations O
are O
predicted O
to O
result O
in O
ex O
##on O
skip O
##ping O
in O
the O
m O
##rna O
encoded O
from O
the O
mutant O
all O
##ele O
. O

these O
data O
suggest O
that O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
results O
from O
shorter O
type O
ii O
co O
##lla O
##gen O
mon O
##omer O
##s O
, O
and O
support O
the O
hypothesis O
that O
alter O
##ation O
of O
a O
specific O
co O
##l O
##2 O
##a O
##1 O
domain O
, O
which O
may O
span O
from O
ex O
##ons O
12 O
to O
24 O
, O
leads O
to O
the O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
p O
##hen O
##otype O
. O
. O

classical B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
and O
mutations O
at O
the O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
transfer O
##ase O
( O
gal O
##t O
) O
gene O
. O

classical B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
is O
caused O
by O
a O
deficiency O
in O
activity O
of O
the O
enzyme O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
transfer O
##ase O
( O
gal O
##t O
) O
, O
which O
, O
in O
turn O
, O
is O
caused O
by O
mutations O
at O
the O
gal O
##t O
gene O
. O

the O
disorder O
exhibits O
considerable O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
and O
, O
at O
the O
end O
of O
1998 O
, O
more O
than O
150 O
different O
base O
changes O
were O
recorded O
in O
24 O
different O
populations O
and O
ethnic O
groups O
in O
15 O
countries O
worldwide O
. O

the O
mutations O
most O
frequently O
cited O
are O
q O
##18 O
##8 O
##r O
, O
k O
##28 O
##5 O
##n O
, O
s O
##13 O
##5 O
##l O
, O
and O
n O
##31 O
##4 O
##d O
. O

q O
##18 O
##8 O
##r O
is O
the O
most O
common O
mutation O
in O
euro O
##pe O
##an O
populations O
or O
in O
those O
predominantly O
of O
euro O
##pe O
##an O
descent O
. O

overall O
, O
it O
accounts O
for O
60 O
- O
70 O
% O
of O
mutant O
chromosome O
##s O
, O
but O
there O
are O
significant O
differences O
in O
its O
relative O
frequency O
in O
individual O
populations O
. O

individuals O
ho O
##mo O
##alle O
##lic O
for O
q O
##18 O
##8 O
##r O
tend O
to O
have O
a O
severe O
p O
##hen O
##otype O
and O
this O
is O
in O
keeping O
with O
the O
virtually O
complete O
loss O
of O
enzyme O
activity O
observed O
in O
in O
v O
##it O
##ro O
expression O
systems O
. O

globally O
, O
k O
##28 O
##5 O
##n O
is O
rare O
##r O
, O
but O
in O
many O
euro O
##pe O
##an O
populations O
it O
can O
be O
found O
on O
25 O
- O
40 O
% O
of O
mutant O
chromosome O
##s O
. O

it O
is O
in O
##var O
##iably O
associated O
with O
a O
severe O
p O
##hen O
##otype O
. O

s O
##13 O
##5 O
##l O
is O
found O
almost O
exclusively O
in O
a O
##f O
##rica O
##n O
am O
##eric O
##ans O
. O

in O
v O
##it O
##ro O
expression O
results O
are O
disc O
##re O
##pan O
##t O
, O
but O
some O
individuals O
carrying O
s O
##13 O
##5 O
##l O
appear O
to O
exhibit O
gal O
##t O
activity O
in O
some O
tissues O
. O

du O
##arte O
1 O
( O
or O
los O
angel O
##es O
) O
and O
du O
##arte O
2 O
( O
or O
du O
##arte O
) O
variants O
carry O
the O
same O
amino O
acid O
substitution O
, O
n O
##31 O
##4 O
##d O
, O
even O
though O
d O
##1 O
is O
associated O
with O
increased O
er O
##yt O
##hr O
##oc O
##yte O
gal O
##t O
activity O
and O
d O
##2 O
with O
reduced O
activity O
. O

n O
##31 O
##4 O
##d O
is O
in O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
with O
other O
base O
changes O
that O
differ O
on O
the O
d O
##1 O
and O
d O
##2 O
all O
##ele O
##s O
. O

n O
##31 O
##4 O
##d O
does O
not O
imp O
##air O
gal O
##t O
activity O
in O
in O
v O
##it O
##ro O
expression O
systems O
. O

however O
, O
there O
are O
differences O
in O
the O
abundance O
of O
gal O
##t O
protein O
in O
l O
##ymph O
##ob O
##last O
##oid O
cells O
lines O
from O
d O
##2 O
and O
d O
##1 O
individuals O
. O

it O
is O
unclear O
whether O
the O
specific O
molecular O
changes O
that O
distinguish O
the O
d O
##1 O
and O
d O
##2 O
all O
##ele O
##s O
account O
for O
the O
different O
activities O
. O

the O
considerable O
genetic O
he O
##tero O
##gene O
##ity O
documented O
to O
date O
undoubtedly O
contributes O
to O
the O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
that O
is O
observed O
in O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
. O

the O
additional O
effects O
of O
non O
##alle O
##lic O
variation O
and O
other O
constitutional O
factors O
on O
p O
##hen O
##otypic O
var O
##iability O
remain O
to O
be O
el O
##uc O
##idated O
. O
. O

mutations O
of O
the O
v B-Disease
##hl I-Disease
gene O
in O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
: O
definition O
of O
a O
risk O
factor O
for O
v B-Disease
##hl I-Disease
patients O
to O
develop O
an O
r B-Disease
##cc I-Disease
. O

to O
investigate O
the O
nature O
of O
so O
##matic O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( O
v B-Disease
##hl I-Disease
) O
mutations O
, O
we O
analyzed O
173 O
primary O
s O
##poradic O
human O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
for O
mutations O
of O
the O
v B-Disease
##hl I-Disease
tumor I-Disease
suppress O
##or O
gene O
, O
using O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
and O
single O
- O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
analysis O
( O
s O
##s O
##c O
##p O
) O
of O
d O
##na O
. O

we O
detected O
abnormal O
s O
##s O
##c O
##p O
pattern O
in O
73 O
samples O
. O

after O
se O
##quencing O
, O
we O
identified O
micro O
##del O
##eti O
##ons O
in O
58 O
% O
of O
cases O
, O
micro O
##ins O
##ert O
##ions O
in O
17 O
% O
, O
nonsense O
mutations O
in O
8 O
% O
, O
and O
miss O
##ense O
mutations O
in O
17 O
% O
. O

among O
these O
mutations O
, O
50 O
% O
correspond O
to O
new O
mutations O
. O

v B-Disease
##hl I-Disease
mutations O
were O
found O
only O
in O
the O
non B-Disease
##pa I-Disease
##pi I-Disease
##llar I-Disease
##y I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
( O
r B-Disease
##cc I-Disease
) O
sub O
##type O
, O
as O
previously O
reported O
. O

to O
compare O
so O
##matic O
and O
g O
##er O
##m O
##line O
mutations O
, O
we O
used O
the O
v B-Disease
##hl I-Disease
database O
, O
which O
includes O
50 O
##7 O
mutations O
. O

the O
study O
of O
mutation O
##al O
events O
revealed O
a O
significant O
difference O
between O
so O
##matic O
and O
g O
##er O
##m O
##line O
mutations O
with O
mutations O
leading O
to O
t O
##runcated O
proteins O
observed O
in O
78 O
% O
of O
so O
##matic O
mutations O
vs O
only O
37 O
% O
in O
g O
##er O
##m O
##line O
mutations O
( O
p O
[UNK] O
0 O
. O
00 O
##1 O
) O
. O

we O
post O
##ulated O
that O
a O
specific O
pattern O
of O
v B-Disease
##hl I-Disease
mutations O
is O
associated O
with O
s B-Disease
##poradic I-Disease
r I-Disease
##cc I-Disease
. O

this O
pattern O
corresponds O
to O
mutations O
leading O
mainly O
to O
t O
##runcated O
proteins O
with O
few O
specific O
miss O
##ense O
mutations O
. O

we O
then O
analyzed O
the O
occurrence O
of O
r B-Disease
##cc I-Disease
in O
v B-Disease
##hl I-Disease
families O
, O
based O
on O
the O
nature O
of O
mutations O
. O

we O
observed O
r B-Disease
##cc I-Disease
in O
at O
least O
one O
member O
of O
the O
v B-Disease
##hl I-Disease
families O
in O
77 O
% O
of O
cases O
with O
mutations O
leading O
to O
t O
##runcated O
proteins O
versus O
55 O
% O
in O
cases O
with O
miss O
##ense O
mutations O
( O
p O
[UNK] O
0 O
. O
05 O
) O
. O

thus O
, O
mutations O
resulting O
in O
t O
##runcated O
proteins O
may O
lead O
to O
a O
higher O
risk O
of O
r B-Disease
##cc I-Disease
in O
v B-Disease
##hl I-Disease
patients O

defect O
##ive O
c O
##tl O
##a O
- O
4 O
cycling O
pathway O
in O
ch B-Disease
##edia I-Disease
##k I-Disease
- I-Disease
hi I-Disease
##gas I-Disease
##hi I-Disease
syndrome I-Disease
: O
a O
possible O
mechanism O
for O
der O
##eg O
##ulation O
of O
t O
l O
##ymph O
##oc O
##yte O
activation O
. O

c O
##yt O
##oto O
##xi O
##c O
t O
l O
##ymph O
##oc O
##yte O
- O
associated O
anti O
##gen O
4 O
( O
c O
##tl O
##a O
- O
4 O
, O
also O
known O
as O
c O
##d O
##15 O
##2 O
) O
has O
been O
shown O
to O
play O
a O
major O
role O
in O
the O
regulation O
of O
t O
cell O
activation O
. O

its O
membrane O
expression O
is O
highly O
regulated O
by O
end O
##oc O
##yt O
##osis O
and O
trafficking O
through O
the O
secret O
##ory O
l O
##ys O
##oso O
##me O
pathway O
. O

ch B-Disease
##edia I-Disease
##k I-Disease
- I-Disease
hi I-Disease
##gas I-Disease
##hi I-Disease
syndrome I-Disease
( O
ch B-Disease
##s I-Disease
) O
is O
an O
inherited B-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
l O
##ys O
##oso O
##mal O
trafficking O
regulator O
gene O
, O
l O
##ys O
##t O
. O

it O
results O
in O
defect O
##ive O
membrane O
targeting O
of O
the O
proteins O
present O
in O
secret O
##ory O
l O
##ys O
##oso O
##mes O
, O
and O
it O
is O
associated O
with O
a O
variety O
of O
features O
, O
including O
a O
l B-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
with O
hem B-Disease
##op I-Disease
##ha I-Disease
##go I-Disease
##cy I-Disease
##tosis I-Disease
. O

the O
m O
##uri O
##ne O
equivalent O
of O
ch B-Disease
##s I-Disease
, O
be O
##ige O
mice O
, O
present O
similar O
characteristics O
but O
do O
not O
develop O
the O
l B-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
. O

we O
show O
here O
##in O
that O
c O
##tl O
##a O
- O
4 O
is O
present O
in O
enlarged O
, O
abnormal O
ve O
##si O
##cles O
in O
ch B-Disease
##s I-Disease
t O
cells O
and O
is O
not O
properly O
expressed O
at O
the O
cell O
surface O
after O
t O
cell O
activation O
, O
whereas O
its O
surface O
expression O
is O
not O
impaired O
. O

it O
is O
therefore O
proposed O
that O
the O
defect O
##ive O
surface O
expression O
of O
c O
##tl O
##a O
- O
4 O
by O
ch B-Disease
##s I-Disease
t O
cells O
is O
involved O
in O
the O
generation O
of O
l B-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
disease I-Disease
. O

this O
observation O
may O
provide O
insight O
into O
the O
role O
of O
c O
##tl O
##a O
- O
4 O
in O
humans O
. O
. O

pro O
##te O
##oli O
##pop O
##rote O
##in O
gene O
analysis O
in O
82 O
patients O
with O
s O
##poradic O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
: O
du O
##plication O
##s O
, O
the O
major O
cause O
of O
the O
disease O
, O
originate O
more O
frequently O
in O
male O
g O
##er O
##m O
cells O
, O
but O
point O
mutations O
do O
not O
. O

the O
clinical O
euro O
##pe O
##an O
network O
on O
brain B-Disease
d I-Disease
##ys I-Disease
##my I-Disease
##elin I-Disease
##ating I-Disease
disease I-Disease
. O

p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
developmental I-Disease
defect I-Disease
of I-Disease
my I-Disease
##elin I-Disease
##ation I-Disease
affecting O
the O
central O
nervous O
system O
and O
se O
##g O
##re O
##gating O
with O
the O
pro O
##te O
##oli O
##pop O
##rote O
##in O
( O
p O
##l O
##p O
) O
lo O
##cus O
. O

investigating O
82 O
strictly O
selected O
s O
##poradic O
cases O
of O
pm B-Disease
##d I-Disease
, O
we O
found O
p O
##l O
##p O
mutations O
in O
77 O
% O
; O
complete O
p O
##l O
##p O
- O
gene O
du O
##plication O
##s O
were O
the O
most O
frequent O
abnormal O
##ity O
( O
62 O
% O
) O
, O
whereas O
point O
mutations O
in O
coding O
or O
s O
##p O
##lice O
- O
site O
regions O
of O
the O
gene O
were O
involved O
less O
frequently O
( O
38 O
% O
) O
. O

we O
analyzed O
the O
maternal O
status O
of O
56 O
cases O
to O
determine O
the O
origin O
of O
both O
types O
of O
p O
##l O
##p O
mutation O
, O
since O
this O
is O
relevant O
to O
genetic O
counseling O
. O

in O
the O
22 O
point O
mutations O
, O
68 O
% O
of O
mothers O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
mutation O
, O
a O
value O
identical O
to O
the O
two O
- O
thirds O
of O
carrier O
mothers O
that O
would O
be O
expected O
if O
there O
were O
an O
equal O
mutation O
rate O
in O
male O
and O
female O
g O
##er O
##m O
cells O
. O

in O
sharp O
contrast O
, O
among O
the O
34 O
du O
##plicate O
##d O
cases O
, O
91 O
% O
of O
mothers O
were O
carriers O
, O
a O
value O
significantly O
( O
ch O
##i O
##2 O
= O
9 O
. O
20 O
, O
p O
[UNK] O
. O
01 O
) O
in O
favor O
of O
a O
male O
bias O
, O
with O
an O
est O
##imation O
of O
the O
male O
/ O
female O
mutation O
frequency O
( O
k O
) O
of O
9 O
. O

3 O
3 O
. O

more O
##over O
, O
we O
observed O
the O
occurrence O
of O
de O
no O
##vo O
mutations O
between O
parental O
and O
grand O
##par O
##ental O
generations O
in O
17 O
three O
- O
generation O
families O
, O
which O
allowed O
a O
direct O
est O
##imation O
of O
the O
k O
value O
( O
k O
= O
11 O
) O
. O

again O
, O
a O
significant O
male O
mutation O
im O
##bal O
##ance O
was O
observed O
only O
for O
the O
du O
##plication O
##s O
. O

chromosome O
break O
##age O
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
and I-Disease
angel I-Disease
##man I-Disease
syndrome I-Disease
##s I-Disease
involves O
re O
##comb O
##ination O
between O
large O
, O
trans O
##cribed O
repeats O
at O
pro O
##ximal O
and O
di O
##stal O
break O
##points O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
and O
angel B-Disease
##man I-Disease
syndrome I-Disease
( O
as B-Disease
) O
are O
distinct O
ne B-Disease
##uro I-Disease
##be I-Disease
##ha I-Disease
##vior I-Disease
##al I-Disease
disorders I-Disease
that O
most O
often O
arise O
from O
a O
4 O
- O
m O
##b O
del O
##eti O
##on O
of O
chromosome O
15 O
##q O
##11 O
- O
q O
##13 O
during O
paternal O
or O
maternal O
game O
##to O
##genesis O
, O
respectively O
. O

at O
a O
de O
no O
##vo O
frequency O
of O
approximately O
. O

67 O
- O
1 O
/ O
10 O
, O
000 O
births O
, O
these O
del O
##eti O
##ons O
represent O
a O
common O
structural O
chromosome O
change O
in O
the O
human O
genome O
. O

to O
el O
##uc O
##ida O
##te O
the O
mechanism O
underlying O
these O
events O
, O
we O
characterized O
the O
regions O
that O
contain O
two O
pro O
##ximal O
break O
##point O
clusters O
and O
a O
di O
##stal O
cluster O
. O

novel O
d O
##na O
sequences O
potentially O
associated O
with O
the O
break O
##points O
were O
position O
##ally O
clone O
##d O
from O
ya O
##cs O
within O
or O
near O
these O
regions O
. O

analyses O
of O
rode O
##nt O
- O
human O
so O
##matic O
- O
cell O
hybrid O
##s O
, O
ya O
##c O
con O
##ti O
##gs O
, O
and O
fish O
of O
normal O
or O
rear O
##ranged O
chromosome O
##s O
15 O
identified O
du O
##plicate O
##d O
sequences O
( O
the O
end O
repeats O
) O
at O
or O
near O
the O
break O
##points O
. O

the O
end O
- O
repeat O
units O
are O
derived O
from O
large O
g O
##eno O
##mic O
du O
##plication O
##s O
of O
a O
novel O
gene O
( O
her O
##c O
##2 O
) O
, O
many O
copies O
of O
which O
are O
transcription O
##ally O
active O
in O
g O
##er O
##m O
##line O
tissues O
. O

one O
of O
five O
p B-Disease
##ws I-Disease
/ O
as B-Disease
patients O
analyzed O
to O
date O
has O
an O
id O
##ent O
##ifiable O
, O
rear O
##ranged O
her O
##c O
##2 O
trans O
##cript O
derived O
from O
the O
del O
##eti O
##on O
event O
. O

we O
post O
##ulate O
that O
the O
end O
repeats O
flank O
##ing O
15 O
##q O
##11 O
- O
q O
##13 O
media O
##te O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
resulting O
in O
del O
##eti O
##on O
. O

further O
##more O
, O
we O
propose O
that O
active O
transcription O
of O
these O
repeats O
in O
male O
and O
female O
g O
##er O
##m O
cells O
may O
facilitate O
the O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
process O
. O

link O
##age O
analysis O
in O
a O
large O
bra O
##zi O
##lian O
family O
with O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
suggests O
the O
existence O
of O
a O
su O
##s O
##ce O
##pt O
##ibility O
lo O
##cus O
for O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
at O
17 O
##p O
##11 O
. O
2 O
- O
11 O
. O
1 O
. O

van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
( O
v B-Disease
##ws I-Disease
) O
, O
which O
has O
been O
mapped O
to O
1 O
##q O
##32 O
- O
41 O
, O
is O
characterized O
by O
pits B-Disease
and I-Disease
/ I-Disease
or I-Disease
sin I-Disease
##uses I-Disease
of I-Disease
the I-Disease
lower I-Disease
lip I-Disease
, O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
/ I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
( O
c B-Disease
##l I-Disease
/ I-Disease
p I-Disease
) O
, O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
( O
c B-Disease
##p I-Disease
) O
, O
bi B-Disease
##fi I-Disease
##d I-Disease
u I-Disease
##vu I-Disease
##la I-Disease
, O
and O
h B-Disease
##y I-Disease
##po I-Disease
##don I-Disease
##tia I-Disease
( O
h B-Disease
) O
. O

the O
expression O
of O
v B-Disease
##ws I-Disease
, O
which O
has O
incomplete O
pen O
##et O
##rance O
, O
is O
highly O
variable O
. O

both O
the O
occurrence O
of O
c B-Disease
##l I-Disease
/ I-Disease
p I-Disease
and O
c B-Disease
##p I-Disease
within O
the O
same O
gene O
##alog O
##y O
and O
a O
re O
##cu O
##rrence O
risk O
[UNK] O
40 O
% O
for O
c B-Disease
##p I-Disease
among O
descendants O
with O
v B-Disease
##ws I-Disease
have O
suggested O
that O
the O
development O
of O
c B-Disease
##le I-Disease
##fts I-Disease
in O
this O
syndrome O
is O
influenced O
by O
modify O
##ing O
genes O
at O
other O
lo O
##ci O
. O

to O
test O
this O
hypothesis O
, O
we O
have O
conducted O
link O
##age O
analysis O
in O
a O
large O
bra O
##zi O
##lian O
kind O
##red O
with O
v B-Disease
##ws I-Disease
, O
considering O
as O
affected O
the O
individuals O
with O
c B-Disease
##p I-Disease
, O
regardless O
of O
whether O
it O
is O
associated O
with O
other O
clinical O
signs O
of O
v B-Disease
##ws I-Disease
. O

our O
results O
suggest O
that O
a O
gene O
at O
17 O
##p O
##11 O
. O

2 O
- O
11 O
2 O
- O
11 O
. O

1 O
, O
together O
with O
the O
v B-Disease
##ws I-Disease
gene O
at O
1 O
##p O
##32 O
- O
41 O
, O
enhance O
##s O
the O
probability O
of O
c B-Disease
##p I-Disease
in O
an O
individual O
carrying O
the O
two O
at O
- O
risk O
genes O
. O

if O
this O
hypothesis O
is O
confirmed O
in O
other O
v B-Disease
##ws I-Disease
p O
##ed O
##ig O
##ree O
##s O
, O
it O
will O
represent O
one O
of O
the O
first O
examples O
of O
a O
gene O
, O
mapped O
through O
link O
##age O
analysis O
, O
which O
m O
##od O
##ifies O
the O
expression O
of O
a O
major O
gene O
. O

new O
mutations O
, O
p O
##oly O
##mor O
##phism O
##s O
, O
and O
rare O
variants O
in O
the O
at O
##m O
gene O
detected O
by O
a O
novel O
s O
##s O
##c O
##p O
strategy O
. O

the O
gene O
for O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
, O
at O
##m O
, O
spans O
about O
150 O
k O
##b O
of O
g O
##eno O
##mic O
d O
##na O
. O

at O
##m O
mutations O
are O
found O
along O
the O
entire O
gene O
, O
with O
no O
evidence O
of O
a O
mutation O
##al O
hot O
spot O
. O

using O
d O
##na O
as O
the O
starting O
material O
, O
we O
screened O
the O
at O
##m O
gene O
in O
92 O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
using O
an O
op O
##ti O
##mized O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
technique O
that O
detected O
all O
previously O
known O
mutations O
in O
the O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
segments O
being O
analyzed O
. O

to O
ex O
##ped O
##ite O
screening O
, O
we O
se O
##quential O
##ly O
loaded O
the O
s O
##s O
##c O
##p O
gel O
##s O
with O
three O
different O
sets O
of O
p O
##c O
##r O
products O
that O
were O
pre O
##test O
##ed O
to O
avoid O
overlapping O
patterns O
. O

many O
of O
the O
d O
##na O
changes O
we O
detected O
were O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
##s O
. O

of O
an O
expected O
177 O
unknown O
mutations O
, O
we O
detected O
approximately O
70 O
% O
, O
mostly O
protein O
t O
##run O
##cating O
mutations O
( O
that O
would O
have O
been O
detect O
##able O
by O
protein O
t O
##run O
##cation O
testing O
if O
r O
##na O
starting O
material O
had O
been O
available O
) O
. O

mutations O
have O
now O
been O
defined O
for O
every O
ex O
##on O
of O
the O
at O
##m O
gene O
. O

here O
##in O
, O
we O
present O
35 O
new O
mutations O
and O
34 O
new O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
##s O
or O
rare O
variants O
within O
the O
at O
##m O
gene O
. O

this O
is O
the O
most O
comprehensive O
compilation O
of O
at O
##m O
p O
##oly O
##mor O
##phism O
##s O
assembled O
to O
date O
. O

defining O
p O
##oly O
##morphic O
sites O
as O
well O
as O
mutations O
in O
the O
at O
##m O
gene O
will O
be O
of O
great O
importance O
in O
designing O
automated O
methods O
for O
detect O
##ing O
mutations O
. O
. O

a O
novel O
frames O
##hi O
##ft O
mutation O
in O
the O
m B-Disease
##cle I-Disease
##od I-Disease
syndrome I-Disease
gene O
in O
a O
j O
##apa O
##nese O
family O
. O

we O
report O
a O
novel O
mutation O
in O
the O
x O
##k O
gene O
( O
x O
##k O
) O
in O
a O
j O
##apa O
##nese O
patient O
with O
m B-Disease
##cle I-Disease
##od I-Disease
syndrome I-Disease
. O

a O
50 O
- O
year O
- O
old O
man O
showed O
progressive O
muscular B-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
, O
ch B-Disease
##ore I-Disease
##ic I-Disease
movement I-Disease
, O
elevated O
level O
of O
serum O
c O
##rea O
##tin O
##ine O
kinase O
, O
and O
a B-Disease
##can I-Disease
##th I-Disease
##oc I-Disease
##yt I-Disease
##osis I-Disease
. O

the O
expression O
level O
of O
all O
the O
k O
##ell O
anti O
##gens O
in O
er O
##yt O
##hr O
##oc O
##yte O
was O
decreased O
and O
molecular O
analysis O
revealed O
a O
single O
- O
base O
( O
t O
) O
del O
##eti O
##on O
at O
the O
n O
##uc O
##leo O
##tide O
position O
109 O
##5 O
in O
x O
##k O
. O

this O
del O
##eti O
##on O
caused O
a O
frames O
##hi O
##ft O
in O
translation O
, O
leading O
to O
a O
premature O
stop O
co O
##don O
at O
the O
amino O
acid O
position O
40 O
##8 O
. O

we O
conclude O
this O
single O
- O
base O
del O
##eti O
##on O
causes O
defect O
##ive O
k O
##x O
protein O
, O
which O
is O
responsible O
for O
the O
m B-Disease
##cle I-Disease
##od I-Disease
p O
##hen O
##otype O
in O
this O
patient O
. O
. O

association O
of O
br O
##ca O
##1 O
with O
the O
h O
##rad O
##50 O
- O
h O
##m O
##re O
##11 O
- O
p O
##9 O
##5 O
complex O
and O
the O
d O
##na O
damage O
response O
. O

br O
##ca O
##1 O
en O
##codes O
a O
tumor B-Disease
suppress O
##or O
that O
is O
m O
##uta O
##ted O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

here O
, O
it O
is O
shown O
that O
br O
##ca O
##1 O
interact O
##s O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
with O
h O
##rad O
##50 O
, O
which O
forms O
a O
complex O
with O
h O
##m O
##re O
##11 O
and O
p O
##9 O
##5 O
/ O
ni O
##bri O
##n O
. O

upon O
i O
##rra O
##diation O
, O
br O
##ca O
##1 O
was O
detected O
in O
discrete O
f O
##oc O
##i O
in O
the O
nucleus O
, O
which O
co O
##loc O
##ali O
##ze O
with O
h O
##rad O
##50 O
. O

formation O
of O
i O
##rra O
##diation O
- O
induced O
f O
##oc O
##i O
positive O
for O
br O
##ca O
##1 O
, O
h O
##rad O
##50 O
, O
h O
##m O
##re O
##11 O
, O
or O
p O
##9 O
##5 O
was O
dramatically O
reduced O
in O
h O
##cc O
/ O
1937 O
breast B-Disease
cancer I-Disease
cells O
carrying O
a O
ho O
##mo O
##zy O
##go O
##us O
mutation O
in O
br O
##ca O
##1 O
but O
was O
restored O
by O
trans O
##fect O
##ion O
of O
wild O
- O
type O
br O
##ca O
##1 O
. O

e O
##ct O
##op O
##ic O
expression O
of O
wild O
- O
type O
, O
but O
not O
m O
##uta O
##ted O
, O
br O
##ca O
##1 O
in O
these O
cells O
rendered O
them O
less O
sensitive O
to O
the O
d O
##na O
damage O
agent O
, O
met O
##hyl O
met O
##hane O
##sul O
##fo O
##nate O
. O

these O
data O
suggest O
that O
br O
##ca O
##1 O
is O
important O
for O
the O
cellular O
responses O
to O
d O
##na O
damage O
that O
are O
mediated O
by O
the O
h O
##rad O
##50 O
- O
h O
##m O
##re O
##11 O
- O
p O
##9 O
##5 O
complex O
. O
. O

relationship O
among O
g O
##eno O
##type O
, O
bio O
##chemical O
p O
##hen O
##otype O
, O
and O
cognitive O
performance O
in O
females O
with O
p B-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
deficiency I-Disease
: O
report O
from O
the O
maternal B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
collaborative O
study O
. O

objective O
to O
examine O
the O
relationship O
of O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
g O
##eno O
##type O
##s O
to O
bio O
##chemical O
p O
##hen O
##otype O
and O
cognitive O
development O
in O
maternal B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
. O

methodology O
p O
##ah O
gene O
mutations O
were O
examined O
in O
222 O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mic I-Disease
females O
enrolled O
in O
the O
maternal B-Disease
p I-Disease
##ku I-Disease
collaborative O
study O
( O
m O
##p O
##ku O
##cs O
) O
. O

a O
total O
of O
84 O
different O
mutations O
were O
detected O
, O
and O
complete O
g O
##eno O
##type O
was O
obtained O
in O
199 O
individuals O
. O

based O
on O
previous O
knowledge O
about O
mutation O
- O
p O
##hen O
##otype O
associations O
, O
78 O
of O
the O
mutations O
could O
be O
assigned O
to O
one O
of O
four O
classes O
of O
severity O
( O
severe O
p B-Disease
##ku I-Disease
, O
moderate O
p B-Disease
##ku I-Disease
, O
mild O
p B-Disease
##ku I-Disease
, O
and O
mild B-Disease
h I-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
[ O
m B-Disease
##hp I-Disease
] O
) O
. O

then O
, O
189 O
m O
##p O
##ku O
##cs O
subjects O
were O
grouped O
according O
to O
the O
various O
combinations O
of O
mutation O
classification O
##s O
. O

the O
sample O
sizes O
were O
large O
enough O
for O
statistical O
testing O
in O
four O
groups O
with O
at O
least O
one O
mutation O
that O
completely O
a O
##bol O
##ishes O
enzyme O
activity O
. O

these O
patients O
are O
considered O
functional O
##ly O
hem O
##iz O
##y O
##go O
##us O
. O

results O
the O
bio O
##chemical O
p O
##hen O
##otype O
predicted O
from O
the O
g O
##eno O
##type O
in O
functional O
##ly O
hem O
##iz O
##y O
##go O
##us O
patients O
was O
related O
significantly O
to O
the O
assigned O
p O
##hen O
##yla O
##lani O
##ne O
level O
. O

cognitive O
performance O
( O
i O
##q O
) O
was O
also O
significantly O
related O
to O
g O
##eno O
##type O
. O

the O
i O
##q O
of O
p B-Disease
##ah I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mothers O
with O
a O
severe O
p B-Disease
##ku I-Disease
mutation O
in O
combination O
with O
a O
m B-Disease
##hp I-Disease
mutation O
or O
a O
mild O
p B-Disease
##ku I-Disease
mutation O
was O
99 O
and O
96 O
, O
respectively O
, O
whereas O
the O
i O
##q O
of O
p B-Disease
##ku I-Disease
mothers O
with O
two O
severe O
p B-Disease
##ku I-Disease
mutations O
or O
with O
one O
severe O
and O
one O
moderate O
p B-Disease
##ku I-Disease
mutation O
was O
83 O
and O
84 O
, O
respectively O
. O

of O
the O
patients O
with O
p B-Disease
##ku I-Disease
, O
92 O
% O
had O
been O
treated O
during O
childhood O
. O

those O
who O
were O
un O
##tre O
##ated O
or O
treated O
late O
had O
lower O
than O
average O
i O
##q O
scores O
for O
their O
group O
of O
mutation O
combinations O
. O

females O
with O
moderate O
or O
mild O
p B-Disease
##ku I-Disease
who O
were O
treated O
early O
and O
treated O
for O
[UNK] O
6 O
years O
showed O
i O
##q O
scores O
10 O
points O
above O
average O
for O
their O
group O
. O

conclusions O
the O
reproductive O
outcome O
in O
maternal B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
is O
dependent O
on O
pre O
##nat O
##al O
metabolic O
control O
and O
post O
##nat O
##al O
environmental O
circumstances O
. O

both O
factors O
depend O
on O
the O
intellectual O
resources O
of O
the O
mother O
with O
p B-Disease
##ku I-Disease
. O

the O
significant O
relationship O
among O
g O
##eno O
##type O
, O
bio O
##chemical O
p O
##hen O
##otype O
, O
and O
cognitive O
performance O
observed O
in O
the O
present O
study O
is O
of O
importance O
for O
the O
development O
of O
an O
optimal O
strategy O
for O
future O
treatment O
of O
females O
with O
p B-Disease
##ku I-Disease
who O
plan O
pregnancy O
. O
. O

spinal B-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
: O
a O
variant O
of O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
. O

we O
describe O
seven O
du O
##tch O
patients O
from O
six O
families O
with O
a O
slowly O
progressive O
, O
mainly O
spinal B-Disease
cord I-Disease
syndrome I-Disease
that O
remained O
for O
many O
years O
the O
sole O
expression O
of O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
. O

m O
##ri O
demonstrated O
white B-Disease
matter I-Disease
abnormal I-Disease
##ities I-Disease
in O
the O
lateral O
and O
dorsal O
columns O
of O
the O
spinal O
cord O
. O

post O
- O
m O
##ort O
##em O
examination O
of O
one O
of O
the O
patients O
showed O
extensive O
my O
##elin O
loss O
in O
these O
columns O
. O

an O
array O
of O
g O
##eno O
##type O
##s O
was O
found O
in O
these O
patients O
. O

we O
conclude O
that O
spinal B-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
is O
a O
clinical O
and O
radio O
##logical O
separate O
entity O
of O
c B-Disease
##t I-Disease
##x I-Disease
that O
should O
be O
included O
in O
the O
differential O
diagnosis O
of O
chronic B-Disease
my I-Disease
##elo I-Disease
##pathy I-Disease
. O
. O

a O
trans O
##gene O
insertion O
creating O
a O
her O
##ita O
##ble O
chromosome O
del O
##eti O
##on O
mouse O
model O
of O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
and I-Disease
angel I-Disease
##man I-Disease
syndrome I-Disease
##s I-Disease
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
and O
angel B-Disease
##man I-Disease
syndrome I-Disease
( O
as B-Disease
) O
result O
from O
the O
loss O
of O
function O
of O
imprint O
##ed O
genes O
in O
human O
chromosome O
15 O
##q O
##11 O
- O
q O
##13 O
. O

the O
central O
part O
of O
mouse O
chromosome O
7 O
is O
ho O
##mo O
##log O
##ous O
to O
human O
15 O
##q O
##11 O
- O
q O
##13 O
, O
with O
conservation O
of O
both O
gene O
order O
and O
imprint O
##ed O
features O
. O

we O
report O
here O
the O
characterization O
of O
a O
trans O
##gene O
insertion O
( O
e O
##ps O
##tein O
- O
bar O
##r O
virus O
late O
##nt O
membrane O
protein O
2 O
##a O
, O
l O
##mp O
##2 O
##a O
) O
into O
mouse O
chromosome O
7 O
##c O
, O
which O
has O
resulted O
in O
mouse O
models O
for O
p B-Disease
##ws I-Disease
and O
as B-Disease
dependent O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

e O
##pi O
##gen O
##otype O
( O
all O
##eli O
##c O
expression O
and O
d O
##na O
met O
##hyl O
##ation O
) O
and O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
analyses O
indicate O
that O
the O
trans O
##gene O
- O
induced O
mutation O
has O
generated O
a O
complete O
del O
##eti O
##on O
of O
the O
p B-Disease
##ws I-Disease
/ O
as B-Disease
- O
ho O
##mo O
##log O
##ous O
region O
but O
has O
not O
deleted O
flank O
##ing O
lo O
##ci O
. O

because O
the O
intact O
chromosome O
7 O
, O
opposite O
the O
deleted O
ho O
##mo O
##log O
, O
maintains O
the O
correct O
imprint O
in O
so O
##matic O
cells O
of O
p B-Disease
##ws I-Disease
and O
as B-Disease
mice O
and O
establishes O
the O
correct O
imprint O
in O
male O
and O
female O
g O
##er O
##m O
cells O
of O
as B-Disease
mice O
, O
ho O
##mo O
##log O
##ous O
association O
and O
replication O
as O
##ync O
##hr O
##ony O
are O
not O
part O
of O
the O
imprint O
##ing O
mechanism O
. O

this O
her O
##ita O
##ble O
- O
del O
##eti O
##on O
mouse O
model O
will O
be O
particularly O
useful O
for O
the O
identification O
of O
the O
et O
##iol O
##ogical O
genes O
and O
mechanisms O
, O
p O
##hen O
##otypic O
basis O
, O
and O
investigation O
of O
therapeutic O
approaches O
for O
p B-Disease
##ws I-Disease
. O
. O

link O
##age O
analysis O
of O
5 O
novel O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
kind O
##red O
##s O
to O
1 O
##q O
##32 O
- O
q O
##41 O
markers O
further O
supports O
lo O
##cus O
ho O
##mo O
##gene O
##ity O
of O
the O
disease O
trait O
. O

van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
( O
v B-Disease
##ws I-Disease
, O
mi O
##m O
119 O
##30 O
##0 O
) O
is O
a O
rare O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
c I-Disease
##le I-Disease
##fting I-Disease
condition I-Disease
with O
cardinal O
features O
of O
m B-Disease
##uc I-Disease
##ous I-Disease
c I-Disease
##ys I-Disease
##ts I-Disease
( O
lower B-Disease
- I-Disease
lip I-Disease
pits I-Disease
) O
and O
c B-Disease
##le I-Disease
##fts I-Disease
to I-Disease
the I-Disease
lip I-Disease
and I-Disease
/ I-Disease
or I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
. O

the O
v B-Disease
##ws I-Disease
gene O
has O
been O
assigned O
to O
a O
lo O
##cus O
in O
1 O
##q O
##32 O
- O
q O
##41 O
by O
link O
##age O
analysis O
and O
physical O
mapping O
. O

we O
have O
investigated O
5 O
novel O
v B-Disease
##ws I-Disease
families O
through O
pro O
##band O
##s O
attended O
for O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
and I-Disease
/ I-Disease
or I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
repair O
at O
the O
department O
of O
ma O
##xi O
##llo O
##fa O
##cial O
surgery O
of O
hop O
##ital O
t O
##rous O
##seau O
, O
par O
##is O
, O
in O
order O
to O
tentatively O
re O
##fine O
the O
genetic O
map O
of O
the O
v B-Disease
##ws I-Disease
region O
in O
1 O
##q O
##32 O
- O
q O
##41 O
and O
possibly O
identify O
un O
##link O
##ed O
p O
##ed O
##ig O
##ree O
##s O
. O

link O
##age O
analysis O
was O
carried O
out O
to O
6 O
micro O
##sat O
##elli O
##te O
markers O
( O
d O
##1 O
##s O
##24 O
##9 O
, O
d O
##1 O
##s O
##42 O
##5 O
, O
d O
##1 O
##s O
##4 O
##9 O
##1 O
, O
d O
##1 O
##s O
##20 O
##5 O
, O
d O
##1 O
##s O
##41 O
##4 O
, O
d O
##1 O
##s O
##42 O
##5 O
) O
, O
yielding O
a O
maximum O
cumulative O
lo O
##d O
score O
of O
z O
= O
3 O
. O

27 O
at O
the O
##ta O
= O
0 O
. O

00 O
for O
d O
##1 O
##s O
##24 O
##5 O
. O

the O
inner O
##most O
four O
markers O
were O
found O
to O
be O
tightly O
linked O
to O
one O
another O
, O
with O
no O
evidence O
for O
re O
##comb O
##ination O
. O

our O
results O
support O
link O
##age O
of O
v B-Disease
##ws I-Disease
within O
a O
region O
of O
tightly O
linked O
markers O
and O
do O
not O
favour O
lo O
##cus O
he O
##tero O
##gene O
##ity O
of O
the O
disease O
trait O
. O

null O
mutation O
of O
the O
m O
##uri O
##ne O
at O
##p O
##7 O
##b O
( O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
) O
gene O
results O
in O
in B-Disease
##tra I-Disease
##cellular I-Disease
copper I-Disease
accumulation I-Disease
and O
late B-Disease
- I-Disease
onset I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
nod I-Disease
##ular I-Disease
transformation I-Disease
. O

the O
at O
##p O
##7 O
##b O
protein O
is O
a O
copper O
- O
transporting O
at O
##pas O
##e O
expressed O
predominantly O
in O
the O
liver O
and O
to O
a O
lesser O
extent O
in O
most O
other O
tissues O
. O

mutations O
in O
the O
at O
##p O
##7 O
##b O
gene O
lead O
to O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
, O
a O
copper B-Disease
toxicity I-Disease
disorder I-Disease
characterized O
by O
dramatic O
build O
- O
up O
of O
in O
##tra O
##cellular O
he O
##pa O
##tic O
copper O
with O
subsequent O
he B-Disease
##pa I-Disease
##tic I-Disease
and I-Disease
ne I-Disease
##uro I-Disease
- I-Disease
logical I-Disease
abnormal I-Disease
##ities I-Disease
. O

using O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
to O
disrupt O
the O
normal O
translation O
of O
at O
##p O
##7 O
##b O
, O
we O
have O
generated O
a O
strain O
of O
mice O
that O
are O
ho O
##mo O
##zy O
##go O
##us O
mutant O
##s O
( O
null O
) O
for O
the O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
gene O
. O

the O
at O
##p O
##7 O
##b O
null O
mice O
display O
a O
gradual O
accumulation O
of O
he O
##pa O
##tic O
copper O
that O
increases O
to O
a O
level O
60 O
- O
fold O
greater O
than O
normal O
by O
5 O
months O
of O
age O
. O

an O
increase O
in O
copper O
concentration O
was O
also O
observed O
in O
the O
kidney O
, O
brain O
, O
place O
##nta O
and O
la O
##ct O
##ating O
ma O
##mma O
##ry O
glands O
of O
ho O
##mo O
- O
z O
##y O
##go O
##us O
mutant O
##s O
, O
although O
milk O
from O
the O
mutant O
glands O
was O
copper B-Disease
def I-Disease
##icient I-Disease
. O

m B-Disease
##or I-Disease
##phological I-Disease
abnormal I-Disease
##ities I-Disease
resembling O
c B-Disease
##ir I-Disease
##r I-Disease
##hos I-Disease
##is I-Disease
developed O
in O
the O
majority O
of O
the O
liver O
##s O
from O
ho O
##mo O
##zy O
##go O
##us O
mutant O
##s O
older O
than O
7 O
months O
of O
age O
. O

pro O
##geny O
of O
the O
ho O
##mo O
##zy O
##go O
##us O
mutant O
females O
demonstrated O
ne B-Disease
##uro I-Disease
##logical I-Disease
abnormal I-Disease
##ities I-Disease
and O
growth B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
characteristic O
of O
copper B-Disease
deficiency I-Disease
. O

copper O
concentration O
in O
the O
liver O
##s O
of O
the O
newborn O
ho O
##mo O
##zy O
##go O
##us O
null O
mutant O
##s O
was O
decreased O
dramatically O
. O

in O
summary O
, O
in O
##act O
##ivation O
of O
the O
m O
##uri O
##ne O
at O
##p O
##7 O
##b O
gene O
produces O
a O
form O
of O
c B-Disease
##ir I-Disease
##r I-Disease
##hot I-Disease
##ic I-Disease
liver I-Disease
disease I-Disease
that O
resembles O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
in O
humans O
and O
the O
toxic O
milk O
p O
##hen O
##otype O
in O
the O
mouse O
. O
. O

f O
##rench O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
patients O
do O
not O
exhibit O
game O
##tic O
segregation O
distortion O
: O
a O
sperm O
typing O
analysis O
. O

segregation O
distortion O
has O
been O
reported O
to O
occur O
in O
a O
number O
of O
the O
t B-Disease
##rin I-Disease
##uc I-Disease
##leo I-Disease
##tide I-Disease
repeat I-Disease
disorders I-Disease
. O

on O
the O
basis O
of O
a O
sperm O
typing O
study O
performed O
in O
patients O
of O
j O
##apa O
##nese O
descent O
with O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
, O
it O
was O
reported O
that O
disease O
all O
##ele O
##s O
are O
prefer O
##ential O
##ly O
transmitted O
during O
me O
##ios O
##is O
. O

we O
performed O
a O
sperm O
typing O
study O
of O
five O
m B-Disease
##j I-Disease
##d I-Disease
patients O
of O
f O
##rench O
descent O
and O
analysis O
of O
the O
pool O
##ed O
data O
shows O
a O
ratio O
of O
mutant O
to O
normal O
all O
##ele O
##s O
of O
37 O
##9 O
43 O
##6 O
( O
46 O
. O
5 O
53 O
. O
5 O
% O
) O
, O
which O
does O
not O
support O
me O
##iot O
##ic O
segregation O
distortion O
. O

to O
confirm O
these O
results O
, O
sperm O
typing O
analysis O
was O
also O
performed O
using O
a O
p O
##oly O
##morphic O
marker O
, O
d O
##14 O
##s O
##10 O
##50 O
, O
closely O
linked O
to O
the O
m O
##j O
##d O
##1 O
gene O
. O

among O
91 O
##0 O
sperm O
analyzed O
, O
the O
all O
##ele O
linked O
to O
the O
disease O
chromosome O
was O
detected O
in O
50 O
. O

3 O
% O
of O
the O
samples O
and O
the O
all O
##ele O
linked O
to O
the O
normal O
chromosome O
was O
found O
in O
49 O
. O

6 O
% O
of O
the O
sperm O
. O

the O
difference O
in O
frequency O
of O
these O
two O
all O
##ele O
##s O
is O
not O
significant O
( O
p O
= O
0 O
. O
84 O
##23 O
) O
. O

likelihood O
- O
based O
analysis O
of O
segregation O
distortion O
in O
the O
single O
sperm O
data O
using O
the O
sperm O
##se O
##g O
program O
also O
showed O
no O
support O
for O
segregation O
distortion O
at O
the O
game O
##te O
level O
in O
this O
patient O
population O
. O

the O
previous O
report O
on O
the O
j O
##apa O
##nese O
patients O
also O
suggested O
that O
disease O
all O
##ele O
stability O
may O
be O
influenced O
by O
a O
trans O
effect O
of O
an O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
( O
98 O
##7 O
g O
/ O
c O
) O
in O
the O
wild O
- O
type O
all O
##ele O
. O

all O
of O
the O
f O
##rench O
patients O
were O
he O
##tero O
##zy O
##go O
##us O
for O
this O
p O
##oly O
##mor O
##phism O
. O

however O
, O
analysis O
of O
the O
variance O
in O
repeat O
number O
in O
sperm O
from O
the O
f O
##rench O
m B-Disease
##j I-Disease
##d I-Disease
patients O
overlap O
##ped O
significantly O
with O
the O
variance O
in O
repeat O
number O
observed O
in O
the O
c O
/ O
c O
ho O
##mo O
##zy O
##go O
##us O
j O
##apa O
##nese O
patients O
. O

miss O
##ense O
mutation O
in O
the O
alternative O
s O
##p O
##lice O
region O
of O
the O
p O
##ax O
##6 O
gene O
in O
eye B-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
. O

the O
p O
##ax O
##6 O
gene O
is O
involved O
in O
o O
##cular O
m O
##or O
##ph O
##ogen O
##esis O
, O
and O
p O
##ax O
##6 O
mutations O
have O
been O
detected O
in O
various O
types O
of O
o B-Disease
##cular I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
, O
including O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
corn B-Disease
##eal I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
con B-Disease
##gen I-Disease
##ital I-Disease
cat I-Disease
##ara I-Disease
##ct I-Disease
, O
and O
f B-Disease
##ove I-Disease
##al I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
. O

the O
gene O
en O
##codes O
a O
transcription O
##al O
regulator O
that O
recognizes O
target O
genes O
through O
its O
paired O
- O
type O
d O
##na O
- O
binding O
domain O
. O

the O
paired O
domain O
is O
composed O
of O
two O
distinct O
d O
##na O
- O
binding O
sub O
##dom O
##ain O
##s O
, O
the O
n O
- O
terminal O
sub O
##dom O
##ain O
( O
n O
##ts O
) O
and O
the O
c O
- O
terminal O
sub O
##dom O
##ain O
( O
c O
##ts O
) O
, O
which O
bind O
respective O
consensus O
d O
##na O
sequences O
. O

the O
human O
p O
##ax O
##6 O
gene O
produces O
two O
alternative O
s O
##p O
##lice O
is O
##of O
##orms O
that O
have O
the O
distinct O
structure O
of O
the O
paired O
domain O
. O

the O
insertion O
, O
into O
the O
n O
##ts O
, O
of O
14 O
additional O
amino O
acids O
encoded O
by O
ex O
##on O
5 O
##a O
a O
##bol O
##ishes O
the O
d O
##na O
- O
binding O
activity O
of O
the O
n O
##ts O
and O
un O
##mas O
##ks O
the O
d O
##na O
- O
binding O
ability O
of O
the O
c O
##ts O
. O

thus O
, O
ex O
##on O
5 O
##a O
appears O
to O
function O
as O
a O
molecular O
switch O
that O
s O
##pec O
##ifies O
target O
genes O
. O

we O
as O
##cer O
##tain O
##ed O
a O
novel O
miss O
##ense O
mutation O
in O
four O
p O
##ed O
##ig O
##ree O
##s O
with O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
con B-Disease
##gen I-Disease
##ital I-Disease
cat I-Disease
##ara I-Disease
##ct I-Disease
, O
axe B-Disease
##n I-Disease
##feld I-Disease
##t I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
and O
/ O
or O
f B-Disease
##ove I-Disease
##al I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
which O
, O
to O
our O
knowledge O
, O
is O
the O
first O
mutation O
identified O
in O
the O
s O
##p O
##lice O
- O
variant O
region O
. O

a O
t O
- O
- O
[UNK] O
a O
transition O
at O
the O
20th O
n O
##uc O
##leo O
##tide O
position O
of O
ex O
##on O
5 O
##a O
results O
in O
a O
v O
##al O
- O
- O
[UNK] O
as O
##p O
( O
g O
##t O
##c O
- O
- O
[UNK] O
g O
##ac O
) O
substitution O
at O
the O
7th O
co O
##don O
of O
the O
alternative O
s O
##p O
##lice O
region O
. O

functional O
analyses O
demonstrated O
that O
the O
v O
##5 O
##4 O
##d O
mutation O
slightly O
increased O
n O
##ts O
binding O
and O
decreased O
c O
##ts O
trans O
##act O
##ivation O
activity O
to O
almost O
half O
. O
. O

pen O
##et O
##rance O
##s O
of O
br O
##ca O
##1 O
167 O
##5 O
##dela O
and O
113 O
##5 O
##ins O
##a O
with O
respect O
to O
breast B-Disease
cancer I-Disease
and O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

for O
genetic O
counseling O
and O
predict O
##ive O
testing O
in O
families O
with O
inherited B-Disease
breast I-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
pen O
##et O
##rance O
##s O
and O
expressions O
of O
the O
underlying O
mutations O
should O
be O
known O
. O

we O
have O
previously O
reported O
two O
br O
##ca O
##1 O
founder O
mutations O
in O
the O
nor O
##we O
##gia O
##n O
population O
. O

index O
cases O
for O
the O
present O
study O
were O
found O
two O
different O
ways O
through O
a O
series O
of O
consecutive O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
( O
n O
= O
16 O
) O
and O
through O
our O
family O
cancer B-Disease
clinic O
( O
n O
= O
14 O
) O
. O

altogether O
, O
20 O
of O
the O
patients O
had O
br O
##ca O
##1 O
167 O
##5 O
##dela O
, O
and O
10 O
had O
113 O
##5 O
##ins O
##a O
. O

their O
relatives O
were O
described O
with O
respect O
to O
absence O
/ O
presence O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

of O
133 O
living O
female O
relatives O
, O
83 O
( O
62 O
% O
) O
were O
tested O
for O
the O
presence O
of O
a O
mutation O
. O

no O
difference O
, O
in O
pen O
##et O
##rance O
and O
expression O
, O
between O
the O
two O
mutations O
were O
found O
, O
whereas O
differences O
according O
to O
method O
of O
as O
##cer O
##tain O
##ment O
were O
seen O
. O

the O
overall O
findings O
were O
that O
disease O
started O
to O
occur O
at O
age O
30 O
years O
and O
that O
by O
age O
50 O
years O
48 O
% O
of O
the O
mutation O
- O
carrying O
women O
had O
experienced O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

more O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
than O
breast B-Disease
cancer I-Disease
##s I-Disease
were O
recorded O
. O

both O
pen O
##et O
##rance O
and O
expression O
( O
breast B-Disease
cancer I-Disease
vs O
. O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
) O
were O
different O
from O
those O
in O
reports O
of O
the O
ash O
##ken O
##azi O
founder O
mutations O
. O

whether O
the O
reported O
differences O
reflect O
true O
differences O
and O
/ O
or O
method O
##ological O
problems O
is O
discussed O
. O

an O
observed O
excess O
of O
mutation O
carriers O
could O
not O
be O
accounted O
for O
by O
method O
##ological O
problems O
; O
possible O
explanations O
were O
a O
" O
true O
" O
low O
pen O
##et O
##rance O
or O
prefer O
##ential O
segregation O
. O
. O

the O
der B-Disease
##mat I-Disease
##of I-Disease
##ib I-Disease
##ros I-Disease
##ar I-Disease
##com I-Disease
##a I-Disease
pro I-Disease
##tub I-Disease
##eran I-Disease
##s I-Disease
- O
associated O
co O
##lla O
##gen O
type O
i O
##al O
##pha O
##1 O
/ O
plate O
##let O
- O
derived O
growth O
factor O
( O
p O
##d O
##g O
##f O
) O
b O
- O
chain O
fusion O
gene O
generates O
a O
transforming O
protein O
that O
is O
processed O
to O
functional O
p O
##d O
##g O
##f O
- O
b O
##b O
. O

der B-Disease
##mat I-Disease
##of I-Disease
##ib I-Disease
##ros I-Disease
##ar I-Disease
##com I-Disease
##a I-Disease
pro I-Disease
##tub I-Disease
##eran I-Disease
##s I-Disease
( O
d B-Disease
##fs I-Disease
##p I-Disease
) O
displays O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
##s O
involving O
chromosome O
17 O
and O
22 O
, O
which O
f O
##use O
the O
co O
##lla O
##gen O
type O
i O
##al O
##pha O
##1 O
( O
co O
##lia O
##1 O
) O
gene O
to O
the O
plate O
##let O
- O
derived O
growth O
factor O
( O
p O
##d O
##g O
##f O
) O
b O
- O
chain O
( O
p O
##d O
##g O
##f O
##b O
) O
gene O
. O

to O
character O
##ize O
the O
functional O
and O
structural O
properties O
of O
the O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
fusion O
protein O
, O
we O
generated O
a O
stable O
ni O
##h O
##3 O
##t O
##3 O
cell O
line O
that O
contained O
a O
tumor O
- O
derived O
ch O
##ime O
##ric O
gene O
resulting O
from O
a O
co O
##ia O
##1 O
intro O
##n O
7 O
- O
p O
##d O
##g O
##f O
##b O
intro O
##n O
1 O
fusion O
. O

expression O
of O
the O
fusion O
protein O
led O
to O
m O
##or O
##phological O
transformation O
and O
increased O
growth O
rate O
of O
these O
cells O
. O

the O
p O
##d O
##g O
##f O
receptor O
kinase O
inhibitor O
c O
##g O
##p O
##5 O
##7 O
##14 O
##8 O
##b O
reversed O
the O
transformed O
p O
##hen O
##otype O
and O
reduced O
the O
growth O
rate O
of O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
- O
expressing O
cells O
but O
had O
no O
effects O
on O
control O
cells O
. O

the O
presence O
of O
dim O
##eric O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
precursor O
##s O
was O
demonstrated O
through O
p O
##d O
##g O
##f O
##b O
im O
##mu O
##no O
##p O
##re O
##ci O
##pit O
##ations O
of O
metabolic O
##ally O
labeled O
cells O
and O
also O
by O
p O
##d O
##g O
##f O
##b O
im O
##mu O
##no O
##p O
##re O
##ci O
##pit O
##ations O
followed O
by O
im O
##mu O
##nob O
##lot O
##ting O
with O
co O
##lia O
##1 O
antibodies O
. O

pulse O
- O
chase O
studies O
demonstrated O
that O
the O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
precursor O
was O
processed O
to O
an O
end O
product O
that O
was O
in O
##dis O
##ting O
##ui O
##sha O
##ble O
from O
wild O
- O
type O
p O
##d O
##g O
##f O
- O
b O
##b O
. O

finally O
, O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
- O
expressing O
cells O
generated O
tumors B-Disease
after O
s O
. O

c O
c O
. O
injection O
into O
nude O
mice O
, O
and O
tumor B-Disease
growth O
was O
reduced O
by O
treatment O
with O
c O
##g O
##p O
##5 O
##7 O
##14 O
##8 O
##b O
. O

we O
conclude O
that O
the O
co O
##lia O
##1 O
/ O
p O
##d O
##g O
##f O
##b O
fusion O
associated O
with O
d B-Disease
##fs I-Disease
##p I-Disease
contributes O
to O
tumor B-Disease
development O
through O
e O
##ct O
##op O
##ic O
production O
of O
p O
##d O
##g O
##f O
- O
b O
##b O
and O
the O
formation O
of O
an O
auto O
##c O
##rine O
loop O
. O

our O
findings O
, O
thus O
, O
suggest O
that O
p O
##d O
##g O
##f O
receptors O
could O
be O
a O
target O
for O
p O
##har O
##ma O
##cological O
treatment O
of O
d B-Disease
##fs I-Disease
##p I-Disease
and O
giant B-Disease
cell I-Disease
fi I-Disease
##bro I-Disease
##blast I-Disease
##oma I-Disease
, O
e O
. O
g O
. O
, O
through O
the O
use O
of O
p O
##d O
##g O
##f O
receptor O
kinase O
inhibitor O
##s O
such O
as O
c O
##g O
##p O
##5 O
##7 O
##14 O
##8 O
##b O
. O

identification O
of O
a O
common O
p O
##ex O
##1 O
mutation O
in O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
. O

the O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
spectrum I-Disease
of I-Disease
disease I-Disease
, O
encompassing O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
and O
the O
progressively O
mild O
##er O
p O
##hen O
##otype O
##s O
of O
neon B-Disease
##ata I-Disease
##l I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
and O
infant B-Disease
##ile I-Disease
re I-Disease
##fs I-Disease
##um I-Disease
disease I-Disease
, O
is O
due O
to O
a O
failure O
to O
form O
functional O
per O
##ox O
##is O
##ome O
##s O
. O

cell O
fusion O
complement O
##ation O
studies O
demonstrated O
that O
these O
diseases O
are O
genetically O
he O
##tero O
##gene O
##ous O
, O
with O
two O
- O
thirds O
of O
all O
patients O
lying O
within O
a O
single O
complement O
##ation O
group O
, O
c O
##g O
##1 O
. O

molecular O
genetic O
and O
cell O
biology O
studies O
have O
shown O
that O
p O
##ex O
##1 O
is O
def O
##icient O
in O
many O
c O
##g O
##1 O
patients O
. O

however O
, O
previous O
studies O
have O
focused O
on O
mildly O
affected O
patients O
and O
there O
is O
still O
no O
report O
of O
two O
mutant O
p O
##ex O
##1 O
all O
##ele O
##s O
in O
any O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
patient O
. O

further O
##more O
, O
mutations O
in O
the O
pm O
##p O
##70 O
gene O
have O
also O
been O
identified O
in O
two O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
patients O
from O
c O
##g O
##1 O
, O
raising O
the O
possibility O
that O
c O
##g O
##1 O
patients O
may O
represent O
a O
mixture O
of O
p O
##ex O
##1 O
- O
def O
##icient O
and O
pm O
##p O
##70 O
- O
def O
##icient O
individuals O
. O

to O
address O
the O
molecular O
basis O
of O
disease O
in O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
patients O
from O
c O
##g O
##1 O
, O
we O
examined O
all O
24 O
p O
##ex O
##1 O
ex O
##ons O
in O
four O
patients O
, O
including O
both O
patients O
that O
have O
mutations O
in O
pm O
##p O
##70 O
. O

p O
##ex O
##1 O
mutations O
were O
detected O
in O
all O
four O
patients O
, O
including O
a O
1 O
- O
b O
##p O
insertion O
( O
c O
. O
209 O
##7 O
##ins O
##t O
) O
in O
ex O
##on O
13 O
that O
was O
present O
in O
three O
of O
the O
four O
patients O
. O

subsequent O
studies O
demonstrated O
that O
this O
mutation O
is O
present O
in O
one O
- O
half O
of O
all O
c O
##g O
##1 O
patients O
and O
co O
##rrel O
##ates O
with O
the O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
p O
##hen O
##otype O
. O

as O
this O
mutation O
leads O
to O
a O
loss O
of O
protein O
function O
its O
frequency O
makes O
it O
the O
most O
common O
cause O
of O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
, O
helping O
to O
explain O
the O
high O
percentage O
of O
patients O
that O
belong O
to O
c O
##g O
##1 O
. O

novel O
mutations O
in O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
gene O
and O
their O
effects O
on O
transcription O
##al O
, O
translation O
##al O
, O
and O
clinical O
p O
##hen O
##otype O
##s O
. O

w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
im I-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
characterized O
by O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
, O
e B-Disease
##cz I-Disease
##ema I-Disease
, O
and O
re O
##current O
infections O
, O
and O
caused O
by O
mutations O
in O
the O
was B-Disease
protein O
( O
was O
##p O
) O
gene O
. O

was O
##p O
contains O
several O
functional O
domains O
through O
which O
it O
interact O
##s O
with O
proteins O
involved O
in O
in O
##tra O
##cellular O
signaling O
and O
regulation O
of O
the O
act O
##in O
c O
##yt O
##os O
##kel O
##eton O
. O

in O
this O
report O
, O
17 O
was O
##p O
gene O
mutations O
were O
identified O
, O
12 O
of O
which O
are O
novel O
. O

d O
##na O
of O
affected O
males O
and O
o O
##b O
##liga O
##te O
carriers O
was O
p O
##c O
##r O
am O
##plified O
and O
analyzed O
by O
s O
##sca O
, O
he O
##tero O
##du O
##plex O
analysis O
, O
and O
direct O
se O
##quencing O
. O

the O
effects O
of O
the O
mutations O
at O
the O
m O
##rna O
and O
protein O
level O
were O
as O
##cer O
##tain O
##ed O
by O
r O
##t O
- O
p O
##c O
##r O
and O
western O
b O
##lot O
analyses O
. O

all O
miss O
##ense O
mutations O
were O
located O
in O
ex O
##ons O
1 O
- O
4 O
. O

most O
of O
the O
nonsense O
, O
frames O
##hi O
##ft O
and O
s O
##p O
##lice O
site O
mutations O
were O
found O
in O
ex O
##ons O
6 O
- O
11 O
. O

mutations O
that O
alter O
s O
##p O
##lice O
sites O
led O
to O
the O
synthesis O
of O
several O
types O
of O
m O
##rna O
##s O
, O
a O
fraction O
of O
which O
represented O
the O
normally O
s O
##p O
##lice O
##d O
product O
. O

the O
presence O
of O
normally O
s O
##p O
##lice O
##d O
trans O
##cripts O
was O
correlated O
with O
a O
mild O
##er O
p O
##hen O
##otype O
. O

when O
one O
such O
case O
was O
studied O
by O
western O
b O
##lot O
##ting O
, O
reduced O
amounts O
of O
normal O
- O
size O
was O
##p O
were O
present O
. O

in O
other O
cases O
as O
well O
, O
a O
correlation O
was O
found O
between O
the O
amount O
of O
normal O
or O
mutant O
was O
##p O
present O
and O
the O
p O
##hen O
##otype O
##s O
of O
the O
affected O
individuals O
. O

no O
protein O
was O
detected O
in O
two O
individuals O
with O
severe O
was B-Disease
. O

reduced O
levels O
of O
a O
normal O
- O
size O
was O
##p O
with O
a O
miss O
##ense O
mutation O
were O
seen O
in O
two O
individuals O
with O
x B-Disease
##lt I-Disease
. O

it O
is O
concluded O
that O
mutation O
analysis O
at O
the O
d O
##na O
level O
is O
not O
sufficient O
for O
predict O
##ing O
clinical O
course O
. O

studies O
at O
the O
trans O
##cript O
and O
protein O
level O
are O
needed O
for O
a O
better O
assessment O
. O
. O

amino O
##gly O
##cos O
##ide O
anti O
##biotics O
restore O
d O
##ys O
##tro O
##phi O
##n O
function O
to O
skeletal O
muscles O
of O
m O
##d O
##x O
mice O
. O

du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
is O
caused O
by O
mutations O
in O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
, O
leading O
to O
the O
absence O
of O
the O
d O
##ys O
##tro O
##phi O
##n O
protein O
in O
s O
##tri O
##ated O
muscle O
. O

a O
significant O
number O
of O
these O
mutations O
are O
premature O
stop O
co O
##don O
##s O
. O

on O
the O
basis O
of O
the O
observation O
that O
amino O
##gly O
##cos O
##ide O
treatment O
can O
suppress O
stop O
co O
##don O
##s O
in O
culture O
##d O
cells O
, O
we O
tested O
the O
effect O
of O
g O
##ent O
##ami O
##cin O
on O
culture O
##d O
muscle O
cells O
from O
the O
m O
##d O
##x O
mouse O
- O
an O
animal O
model O
for O
d B-Disease
##m I-Disease
##d I-Disease
that O
possesses O
a O
premature O
stop O
co O
##don O
in O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
. O

exposure O
of O
m O
##d O
##x O
my O
##ot O
##ube O
##s O
to O
g O
##ent O
##ami O
##cin O
led O
to O
the O
expression O
and O
local O
##ization O
of O
d O
##ys O
##tro O
##phi O
##n O
to O
the O
cell O
membrane O
. O

we O
then O
evaluated O
the O
effects O
of O
differing O
dos O
##ages O
of O
g O
##ent O
##ami O
##cin O
on O
expression O
and O
functional O
protection O
of O
the O
muscles O
of O
m O
##d O
##x O
mice O
. O

we O
identified O
a O
treatment O
regime O
##n O
that O
resulted O
in O
the O
presence O
of O
d O
##ys O
##tro O
##phi O
##n O
in O
the O
cell O
membrane O
in O
all O
s O
##tri O
##ated O
muscles O
examined O
and O
that O
provided O
functional O
protection O
against O
muscular B-Disease
injury I-Disease
. O

to O
our O
knowledge O
, O
our O
results O
are O
the O
first O
to O
demonstrate O
that O
amino O
##gly O
##cos O
##ides O
can O
suppress O
stop O
co O
##don O
##s O
not O
only O
in O
v O
##it O
##ro O
but O
also O
in O
v O
##ivo O
. O

further O
##more O
, O
these O
results O
raise O
the O
possibility O
of O
a O
novel O
treatment O
regime O
##n O
for O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
other O
diseases O
caused O
by O
premature O
stop O
co O
##don O
mutations O
. O

this O
treatment O
could O
prove O
effective O
in O
up O
to O
15 O
% O
of O
patients O
with O
d B-Disease
##m I-Disease
##d I-Disease
. O
. O

loss O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
product O
causes O
o O
##xi O
##da O
##tive O
damage O
in O
target O
organs O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
characterized O
by O
a O
marked O
##ly O
increased O
sensitivity O
to O
ion O
##izing O
radiation O
, O
increased O
incidence O
of O
cancer B-Disease
, O
and O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##ration I-Disease
, O
especially O
of O
the O
c O
##ere O
##bella O
##r O
pu O
##rkin O
##je O
cells O
. O

ion O
##izing O
radiation O
o O
##xi O
##di O
##zes O
mac O
##rom O
##ole O
##cule O
##s O
and O
causes O
tissue O
damage O
through O
the O
generation O
of O
reactive O
oxygen O
species O
( O
r O
##os O
) O
. O

we O
therefore O
h O
##y O
##pot O
##hes O
##ized O
that O
a B-Disease
- I-Disease
t I-Disease
is O
due O
to O
o O
##xi O
##da O
##tive O
damage O
resulting O
from O
loss O
of O
function O
of O
the O
a B-Disease
- I-Disease
t I-Disease
gene O
product O
. O

to O
assess O
this O
hypothesis O
, O
we O
employed O
an O
animal O
model O
of O
a B-Disease
- I-Disease
t I-Disease
, O
the O
mouse O
with O
a O
disrupted O
at O
##m O
gene O
. O

we O
show O
that O
organs O
which O
develop O
path O
##olo O
##gic O
changes O
in O
the O
at O
##m O
- O
def O
##icient O
mice O
are O
targets O
of O
o O
##xi O
##da O
##tive O
damage O
, O
and O
that O
c O
##ere O
##bella O
##r O
pu O
##rkin O
##je O
cells O
are O
particularly O
affected O
. O

these O
observations O
provide O
a O
me O
##chan O
##istic O
basis O
for O
the O
a B-Disease
- I-Disease
t I-Disease
p O
##hen O
##otype O
and O
lay O
a O
rational O
foundation O
for O
therapeutic O
intervention O
. O
. O

re O
##cess O
##ively O
inherited O
multiple B-Disease
e I-Disease
##pi I-Disease
##phy I-Disease
##sea I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
with O
normal O
stature O
, O
club B-Disease
foot I-Disease
, O
and O
double B-Disease
layered I-Disease
pat I-Disease
##ella I-Disease
caused O
by O
a O
d O
##t O
##ds O
##t O
mutation O
. O

we O
have O
observed O
over O
25 O
different O
mutations O
in O
the O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
su O
##l O
##phate O
transport O
##er O
gene O
( O
d O
##t O
##ds O
##t O
) O
in O
association O
with O
the O
re B-Disease
##cess I-Disease
##ive I-Disease
disorders I-Disease
a B-Disease
##cho I-Disease
##nd I-Disease
##rogen I-Disease
##esis I-Disease
1 I-Disease
##b I-Disease
, O
ate B-Disease
##los I-Disease
##te I-Disease
##ogen I-Disease
##esis I-Disease
2 I-Disease
, O
and O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

the O
c O
##86 O
##2 O
##t O
( O
r O
##27 O
##9 O
##w O
) O
transition O
is O
the O
most O
common O
mutation O
in O
non O
- O
fin O
##nish O
patients O
, O
but O
in O
these O
disorders O
it O
is O
usually O
combined O
with O
other O
d O
##t O
##ds O
##t O
mutations O
. O

we O
had O
not O
seen O
a O
case O
of O
ho O
##mo O
##zy O
##gos O
##ity O
for O
c O
##86 O
##2 O
##t O
( O
r O
##27 O
##9 O
##w O
) O
until O
we O
anal O
##ys O
##ed O
d O
##na O
from O
a O
36 O
year O
old O
male O
with O
tall O
- O
normal O
stature O
( O
180 O
cm O
) O
who O
asked O
for O
genetic O
counsel O
##ling O
for O
suspected O
multiple B-Disease
e I-Disease
##pi I-Disease
##phy I-Disease
##sea I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

he O
was O
treated O
for O
club B-Disease
foot I-Disease
and O
hip B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
at O
birth O
. O

skeletal O
changes O
consistent O
with O
multiple B-Disease
e I-Disease
##pi I-Disease
##phy I-Disease
##sea I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
with O
the O
peculiar O
finding O
of O
a O
double B-Disease
layered I-Disease
pat I-Disease
##ella I-Disease
, O
were O
recognised O
during O
childhood O
. O

c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
, O
swelling B-Disease
of I-Disease
the I-Disease
ear I-Disease
pin I-Disease
##na I-Disease
, O
and O
hit B-Disease
##ch I-Disease
hike I-Disease
##r I-Disease
thumb I-Disease
were O
absent O
. O

he O
was O
found O
to O
be O
ho O
##mo O
##zy O
##go O
##us O
, O
and O
both O
healthy O
parents O
he O
##tero O
##zy O
##go O
##us O
, O
for O
the O
r O
##27 O
##9 O
##w O
mutation O
in O
d O
##t O
##ds O
##t O
, O
and O
his O
fi O
##bro O
##blast O
##s O
showed O
a O
su O
##l O
##phate O
incorporation O
defect O
typical O
of O
d B-Disease
##t I-Disease
##ds I-Disease
##t I-Disease
disorders I-Disease
. O

counsel O
##ling O
was O
given O
for O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
, O
thereby O
considerably O
reducing O
the O
probability O
of O
affected O
offspring O
. O

multiple B-Disease
e I-Disease
##pi I-Disease
##phy I-Disease
##sea I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
is O
more O
frequently O
caused O
by O
dominant O
mutations O
in O
the O
com O
##p O
( O
ed B-Disease
##m I-Disease
##1 I-Disease
, O
m O
##ck O
##us O
##ick O
132 O
##40 O
##0 O
) O
and O
co O
##l O
##9 O
##a O
##2 O
genes O
( O
ed B-Disease
##m I-Disease
##2 I-Disease
, O
m O
##ck O
##us O
##ick O
600 O
##20 O
##4 O
) O
. O

a O
few O
other O
patients O
and O
families O
with O
features O
similar O
to O
our O
pro O
##band O
have O
been O
described O
previously O
and O
considered O
to O
have O
auto O
##so O
##mal O
re O
##cess O
##ive O
me B-Disease
##d I-Disease
( O
ed B-Disease
##m I-Disease
##4 I-Disease
, O
m O
##ck O
##us O
##ick O
226 O
##90 O
##0 O
) O
. O

this O
observation O
confirms O
the O
existence O
of O
this O
entity O
and O
assigns O
it O
to O
the O
p O
##hen O
##otypic O
spectrum O
associated O
with O
mutations O
at O
the O
d O
##t O
##ds O
##t O
lo O
##cus O
. O
. O

ho O
##mo O
##zy O
##gos O
##ity O
for O
a O
novel O
d O
##t O
##ds O
##t O
mutation O
in O
a O
child O
with O
a O
' O
broad O
bone O
- O
p O
##lat O
##ys O
##po O
##ndy O
##lic O
' O
variant O
of O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

at O
##y O
##pical O
or O
variant O
forms O
of O
well O
- O
known O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
may O
pose O
diagnostic O
problems O
. O

we O
report O
on O
a O
girl O
with O
clinical O
features O
suggesting O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
but O
with O
unusual O
radio O
##graphic O
features O
including O
severe O
p B-Disease
##lat I-Disease
##ys I-Disease
##po I-Disease
##ndy I-Disease
##ly I-Disease
, O
wide O
meta O
##phy O
##ses O
, O
and O
fi O
##bula O
##r O
over O
##gro O
##wth O
, O
which O
are O
partially O
reminiscent O
of O
meta B-Disease
##tro I-Disease
##pic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

the O
diagnosis O
was O
clarified O
by O
molecular O
analysis O
of O
the O
d O
##t O
##ds O
##t O
gene O
, O
which O
revealed O
ho O
##mo O
##zy O
##gos O
##ity O
for O
a O
previously O
und O
##es O
##cribed O
mutation O
leading O
to O
a O
q O
##45 O
##4 O
##p O
substitution O
in O
the O
10th O
trans O
##me O
##mb O
##rane O
domain O
of O
the O
d O
##t O
##ds O
##t O
su O
##lf O
##ate O
transport O
##er O
. O

molecular O
analysis O
may O
be O
of O
particular O
value O
in O
such O
at O
##y O
##pical O
cases O
. O
. O

the O
type O
of O
so O
##matic O
mutation O
at O
a O
##p O
##c O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
is O
determined O
by O
the O
site O
of O
the O
g O
##er O
##m O
##line O
mutation O
: O
a O
new O
face O
##t O
to O
kn O
##uds O
##on O
' O
s O
' O
two O
- O
hit O
' O
hypothesis O
. O

a O
##p O
##c O
is O
often O
cited O
as O
a O
prime O
example O
of O
a O
tumor B-Disease
suppress O
##or O
gene O
. O

t O
##run O
##cating O
g O
##er O
##m O
##line O
and O
so O
##matic O
mutations O
( O
or O
, O
in O
##f O
##re O
##quent O
##ly O
, O
all O
##eli O
##c O
loss O
) O
occur O
in O
tumors B-Disease
in O
f B-Disease
##ap I-Disease
( O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
) O
. O

most O
s B-Disease
##poradic I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
also O
have O
two O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
. O

clues O
from O
at B-Disease
##ten I-Disease
##uated I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
, O
miss O
##ense O
g O
##er O
##m O
##line O
variants O
with O
mild O
disease O
and O
the O
so O
##matic O
mutation O
cluster O
region O
( O
co O
##don O
##s O
1 O
, O
250 O
- O
1 O
, O
450 O
) O
indicate O
, O
however O
, O
that O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
might O
not O
result O
in O
simple O
loss O
of O
protein O
function O
. O

we O
have O
found O
that O
f B-Disease
##ap I-Disease
patients O
with O
g O
##er O
##m O
##line O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
within O
a O
small O
region O
( O
co O
##don O
##s O
1 O
, O
194 O
- O
1 O
, O
39 O
##2 O
at O
most O
) O
mainly O
show O
all O
##eli O
##c O
loss O
in O
their O
color B-Disease
##ec I-Disease
##tal I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
, O
in O
contrast O
to O
other O
f B-Disease
##ap I-Disease
patients O
, O
whose O
second O
hits O
tend O
to O
occur O
by O
t O
##run O
##cating O
mutations O
in O
the O
mutation O
cluster O
region O
. O

our O
results O
indicate O
that O
different O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
provide O
cells O
with O
different O
selective O
advantages O
, O
with O
mutations O
close O
to O
co O
##don O
1 O
, O
300 O
providing O
the O
greatest O
advantage O
. O

all O
##eli O
##c O
loss O
is O
selected O
strongly O
in O
cells O
with O
one O
mutation O
near O
co O
##don O
1 O
, O
300 O
. O

a O
different O
g O
##er O
##m O
##line O
- O
so O
##matic O
a B-Disease
##p I-Disease
##c I-Disease
mutation O
association O
exists O
in O
f B-Disease
##ap I-Disease
des I-Disease
##mo I-Disease
##ids I-Disease
. O

a O
##p O
##c O
is O
not O
, O
therefore O
, O
a O
classical O
tumor B-Disease
suppress O
##or O
. O

our O
findings O
also O
indicate O
a O
new O
mechanism O
for O
disease O
severity O
if O
a O
broader O
spectrum O
of O
mutations O
is O
selected O
in O
tumors B-Disease
, O
the O
so O
##matic O
mutation O
rate O
is O
effectively O
higher O
and O
more O
tumors B-Disease
grow O
. O
. O

m O
##xi O
##1 O
mutations O
in O
human O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##as I-Disease
. O

m O
##xi O
##1 O
is O
thought O
to O
negatively O
regulate O
my O
##c O
function O
and O
may O
therefore O
be O
a O
potential O
tumor B-Disease
suppress O
##or O
gene O
. O

little O
effort O
has O
yet O
been O
made O
to O
find O
alterations O
involving O
this O
gene O
in O
human O
solid B-Disease
tumors I-Disease
. O

we O
screened O
31 O
human O
gas B-Disease
##tric I-Disease
cancer I-Disease
##s I-Disease
, O
7 O
es B-Disease
##op I-Disease
##hage I-Disease
##al I-Disease
cancer I-Disease
##s I-Disease
, O
85 O
bone B-Disease
and I-Disease
soft I-Disease
tissue I-Disease
tumors I-Disease
of O
various O
types O
, O
including O
4 O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##as I-Disease
. O

we O
also O
examined O
29 O
human O
tumor B-Disease
cell O
lines O
consisting O
of O
12 O
es B-Disease
##op I-Disease
##hage I-Disease
##al I-Disease
cancer I-Disease
##s I-Disease
, O
7 O
g B-Disease
##lio I-Disease
##ma I-Disease
/ O
g B-Disease
##lio I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
and O
10 O
others O
for O
m O
##xi O
##1 O
mutations O
in O
ex O
##ons O
1 O
, O
2 O
, O
4 O
( O
h O
##l O
##h O
domain O
) O
, O
5 O
and O
6 O
. O

polymer O
##ase O
chain O
reaction O
- O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
) O
and O
subsequent O
se O
##quencing O
revealed O
three O
distinct O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
intro O
##n O
- O
ex O
##on O
boundary O
upstream O
from O
ex O
##on O
6 O
. O

we O
discovered O
a O
miss O
##ense O
mutation O
, O
g O
##ca O
to O
g O
##ta O
( O
al O
##a O
54 O
v O
##al O
) O
, O
in O
ex O
##on O
2 O
in O
a O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
patient O
( O
case O
1 O
) O
, O
two O
miss O
##ense O
mutations O
, O
a O
##aa O
to O
ca O
##a O
( O
l O
##ys O
118 O
g O
##ln O
) O
and O
g O
##aa O
to O
g O
##ga O
( O
g O
##lu O
154 O
g O
##ly O
) O
in O
ex O
##on O
5 O
of O
another O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
patient O
( O
case O
2 O
) O
, O
and O
3 O
amino O
acid O
substitution O
##s O
, O
g O
##t O
##g O
to O
g O
##c O
##g O
( O
v O
##al O
179 O
al O
##a O
) O
, O
g O
##tt O
to O
g O
##ct O
( O
v O
##al O
181 O
al O
##a O
) O
and O
t O
##t O
##c O
to O
c O
##t O
##c O
( O
p O
##he O
186 O
le O
##u O
) O
, O
in O
a O
third O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
patient O
( O
case O
3 O
) O
. O

in O
case O
3 O
, O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
was O
also O
demonstrated O
by O
inform O
##ative O
( O
t O
##t O
##c O
) O
3 O
/ O
( O
t O
##t O
##c O
) O
2 O
p O
##oly O
##mor O
##phism O
. O

our O
data O
demonstrate O
that O
mutations O
occur O
in O
the O
m O
##xi O
##1 O
gene O
in O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
. O

miss O
##ense O
mutations O
in O
the O
functional O
domain O
of O
m O
##xi O
##1 O
in O
these O
cases O
may O
be O
involved O
in O
the O
path O
##ogen O
##esis O
of O
ne B-Disease
##uro I-Disease
##fi I-Disease
##bro I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
. O
. O

a O
population O
- O
based O
study O
of O
the O
clinical O
expression O
of O
the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
. O

background O
and O
methods O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
is O
associated O
with O
ho O
##mo O
##zy O
##gos O
##ity O
for O
the O
c O
##28 O
##2 O
##y O
mutation O
in O
the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
( O
h O
##fe O
) O
gene O
on O
chromosome O
6 O
, O
elevated O
serum O
transfer O
##rin O
sat O
##uration O
, O
and O
excess B-Disease
iron I-Disease
deposits I-Disease
throughout O
the O
body O
. O

to O
assess O
the O
prevalence O
and O
clinical O
expression O
of O
the O
h O
##fe O
gene O
, O
we O
conducted O
a O
population O
- O
based O
study O
in O
bus O
##sel O
##ton O
, O
au O
##stra O
##lia O
. O

in O
1994 O
, O
we O
obtained O
blood O
samples O
for O
the O
determination O
of O
serum O
transfer O
##rin O
sat O
##uration O
and O
f O
##er O
##rit O
##in O
levels O
and O
the O
presence O
or O
absence O
of O
the O
c O
##28 O
##2 O
##y O
mutation O
and O
the O
h O
##6 O
##3 O
##d O
mutation O
( O
which O
may O
contribute O
to O
increased O
he O
##pa O
##tic O
iron O
levels O
) O
in O
301 O
##1 O
unrelated O
white O
adults O
. O

we O
evaluated O
all O
subjects O
who O
had O
persistent O
##ly O
elevated O
transfer O
##rin O
- O
sat O
##uration O
values O
( O
45 O
percent O
or O
higher O
) O
or O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
c O
##28 O
##2 O
##y O
mutation O
. O

we O
recommended O
liver O
bio O
##psy O
for O
subjects O
with O
serum O
f O
##er O
##rit O
##in O
levels O
of O
300 O
ng O
per O
mill O
##ili O
##ter O
or O
higher O
. O

the O
subjects O
were O
followed O
for O
up O
to O
four O
years O
. O

results O
sixteen O
of O
the O
subjects O
( O
0 O
. O
5 O
percent O
) O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
c O
##28 O
##2 O
##y O
mutation O
, O
and O
42 O
##4 O
( O
14 O
. O
1 O
percent O
) O
were O
he O
##tero O
##zy O
##go O
##us O
. O

the O
serum O
transfer O
##rin O
sat O
##uration O
was O
45 O
percent O
or O
higher O
in O
15 O
of O
the O
16 O
who O
were O
ho O
##mo O
##zy O
##go O
##us O
; O
in O
1 O
subject O
it O
was O
43 O
percent O
. O

four O
of O
the O
ho O
##mo O
##zy O
##go O
##us O
subjects O
had O
previously O
been O
given O
a O
diagnosis O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
and O
12 O
had O
not O
. O

seven O
of O
these O
12 O
patients O
had O
elevated O
serum O
f O
##er O
##rit O
##in O
levels O
in O
1994 O
; O
6 O
of O
the O
7 O
had O
further O
increases O
in O
1998 O
, O
and O
1 O
had O
a O
decrease O
, O
although O
the O
value O
remained O
elevated O
. O

the O
serum O
f O
##er O
##rit O
##in O
levels O
in O
the O
four O
other O
ho O
##mo O
##zy O
##go O
##us O
patients O
remained O
in O
the O
normal O
range O
. O

eleven O
of O
the O
16 O
ho O
##mo O
##zy O
##go O
##us O
subjects O
underwent O
liver O
bio O
##psy O
; O
3 O
had O
he B-Disease
##pa I-Disease
##tic I-Disease
fi I-Disease
##bro I-Disease
##sis I-Disease
, O
and O
1 O
, O
who O
had O
a O
history O
of O
excessive B-Disease
alcohol I-Disease
consumption I-Disease
, O
had O
c B-Disease
##ir I-Disease
##r I-Disease
##hos I-Disease
##is I-Disease
and O
mild O
micro B-Disease
##ves I-Disease
##icular I-Disease
s I-Disease
##te I-Disease
##ato I-Disease
##sis I-Disease
. O

eight O
of O
the O
16 O
ho O
##mo O
##zy O
##go O
##us O
subjects O
had O
clinical O
findings O
that O
were O
consistent O
with O
the O
presence O
of O
hereditary B-Disease
hem I-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
such O
as O
he B-Disease
##pa I-Disease
##tom I-Disease
##eg I-Disease
##aly I-Disease
, O
skin B-Disease
pig I-Disease
##mentation I-Disease
, O
and O
art B-Disease
##hr I-Disease
##itis I-Disease
. O

conclusions O
in O
a O
population O
of O
white O
adults O
of O
northern O
euro O
##pe O
##an O
ancestry O
, O
0 O
. O

5 O
percent O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
c O
##28 O
##2 O
##y O
mutation O
in O
the O
h O
##fe O
gene O
. O

however O
, O
only O
half O
of O
those O
who O
were O
ho O
##mo O
##zy O
##go O
##us O
had O
clinical O
features O
of O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
and O
one O
quarter O
had O
serum O
f O
##er O
##rit O
##in O
levels O
that O
remained O
normal O
over O
a O
four O
- O
year O
period O
. O

large O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##on O
ma O
##sque O
##rading O
as O
ho O
##mo O
##zy O
##go O
##us O
miss O
##ense O
mutation O
: O
a O
pit O
##fall O
in O
diagnostic O
mutation O
analysis O
. O

the O
clinical O
use O
of O
molecular O
analyses O
in O
re B-Disease
##cess I-Disease
##ive I-Disease
disorders I-Disease
relies O
on O
the O
exact O
characterization O
of O
both O
mutant O
all O
##ele O
##s O
in O
the O
affected O
patient O
. O

this O
can O
be O
problematic O
when O
only O
part O
of O
the O
gene O
is O
examined O
or O
when O
relevant O
d O
##na O
alterations O
are O
not O
recognized O
by O
standard O
methods O
. O

we O
present O
a O
child O
in O
whom O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
was O
apparently O
caused O
by O
ho O
##mo O
##zy O
##gos O
##ity O
for O
the O
mutation O
e O
##39 O
##0 O
##g O
in O
ex O
##on O
11 O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
gene O
. O

however O
, O
the O
clinical O
severity O
of O
the O
disease O
was O
not O
quite O
as O
mild O
as O
expected O
, O
the O
mutation O
was O
not O
identified O
in O
the O
father O
despite O
confirmed O
pat O
##ern O
##ity O
, O
and O
the O
paternal O
all O
##ele O
showed O
a O
highly O
unusual O
pattern O
of O
p O
##oly O
##morphic O
markers O
in O
the O
p O
##ah O
gene O
. O

presence O
of O
a O
large O
del O
##eti O
##on O
involving O
ex O
##ons O
9 O
, O
10 O
and O
11 O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
was O
confirmed O
by O
long O
- O
range O
p O
##c O
##r O
. O

diagnostic O
d O
##na O
analyses O
should O
include O
a O
comprehensive O
examination O
of O
the O
whole O
relevant O
gene O
in O
the O
patient O
and O
confirmation O
of O
carrier O
status O
in O
both O
parents O
. O
. O

early O
onset O
of O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
in O
a O
boy O
with O
em O
##eri O
##n O
gene O
del O
##eti O
##on O
. O

a O
boy O
developed O
contract B-Disease
##ures I-Disease
of I-Disease
the I-Disease
a I-Disease
##chi I-Disease
##lles I-Disease
tend I-Disease
##ons I-Disease
at O
3 O
years O
and O
of O
the O
post O
##cer O
##vic O
##al O
muscles O
at O
7 O
years O
, O
although O
neither O
contract B-Disease
##ures I-Disease
of I-Disease
the I-Disease
elbows I-Disease
nor O
cardiac B-Disease
abnormal I-Disease
##ity I-Disease
were O
recognized O
by O
the O
age O
of O
9 O
years O
. O

muscle O
com O
##puted O
to O
##mo O
##graphy O
scanning O
revealed O
changes O
characteristic O
of O
muscle O
involvement O
. O

em O
##eri O
##n O
was O
not O
detected O
in O
the O
bio O
##ps O
##ied O
muscle O
, O
and O
r O
##t O
- O
p O
##c O
##r O
and O
p O
##c O
##r O
- O
based O
g O
##eno O
##mic O
d O
##na O
analyses O
of O
the O
em O
##eri O
##n O
gene O
demonstrated O
no O
am O
##p O
##lification O
product O
in O
the O
patient O
. O

these O
results O
confirmed O
the O
diagnosis O
of O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
, O
and O
reinforce O
the O
necessity O
of O
molecular O
genetic O
diagnosis O
of O
the O
membrane O
protein O
em O
##eri O
##n O
in O
younger O
patients O
with O
possible O
ed B-Disease
##m I-Disease
##d I-Disease
before O
appearance O
of O
the O
typical O
symptoms O
, O
to O
avoid O
sudden B-Disease
cardiac I-Disease
death I-Disease
. O
. O

du B-Disease
##chen I-Disease
##ne I-Disease
/ I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
: O
correlation O
of O
p O
##hen O
##otype O
by O
electro O
##ret O
##ino O
##graphy O
with O
sites O
of O
d O
##ys O
##tro O
##phi O
##n O
mutations O
. O

the O
dark O
- O
adapted O
electro O
##ret O
##ino O
##gram O
( O
er O
##g O
) O
of O
patients O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
) O
shows O
a O
marked O
reduction O
in O
b O
- O
wave O
amplitude O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
studies O
of O
mouse O
models O
for O
d B-Disease
##m I-Disease
##d I-Disease
show O
position O
- O
specific O
effects O
of O
the O
mutations O
upon O
the O
p O
##hen O
##otype O
mice O
with O
5 O
defects O
of O
d O
##ys O
##tro O
##phi O
##n O
have O
normal O
er O
##gs O
, O
those O
with O
defects O
in O
the O
central O
region O
have O
a O
normal O
b O
- O
wave O
amplitude O
associated O
with O
prolonged O
imp O
##licit O
times O
for O
both O
the O
b O
- O
wave O
and O
o O
##s O
##cilla O
##tory O
potential O
##s O
, O
and O
mice O
with O
3 O
defects O
have O
a O
p O
##hen O
##otype O
similar O
to O
that O
seen O
in O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
patients O
. O

the O
mouse O
studies O
suggest O
a O
key O
role O
for O
the O
car O
##box O
##yl O
terminal O
d O
##ys O
##tro O
##phi O
##n O
is O
##of O
##orm O
, O
d O
##p O
##26 O
##0 O
, O
in O
re O
##tina O
##l O
electro O
##phy O
##sio O
##logy O
. O

we O
have O
undertaken O
a O
systematic O
evaluation O
of O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
patients O
through O
clinical O
examination O
and O
review O
of O
the O
literature O
in O
order O
to O
determine O
whether O
the O
position O
- O
specific O
effects O
of O
mutations O
noted O
in O
the O
mouse O
are O
present O
in O
man O
. O

we O
have O
found O
that O
, O
in O
man O
, O
a O
wider O
variation O
of O
d B-Disease
##m I-Disease
##d I-Disease
defects I-Disease
co O
##rrel O
##ate O
with O
reduction O
##s O
in O
the O
b O
- O
wave O
amplitude O
. O

individuals O
with O
normal O
er O
##gs O
have O
mutations O
predominantly O
located O
5 O
of O
the O
trans O
##cript O
initiation O
site O
of O
d O
##p O
##26 O
##0 O
. O

our O
results O
suggest O
that O
the O
most O
important O
de O
##ter O
##mina O
##nt O
in O
the O
er O
##g O
b O
- O
wave O
p O
##hen O
##otype O
is O
the O
mutation O
position O
, O
rather O
than O
muscle B-Disease
disease I-Disease
severity O
. O

forty O
- O
six O
per O
cent O
of O
patients O
with O
mutations O
5 O
of O
the O
d O
##p O
##26 O
##0 O
trans O
##cript O
start O
site O
have O
abnormal O
er O
##gs O
, O
as O
opposed O
to O
94 O
% O
with O
more O
di O
##stal O
mutations O
. O

the O
human O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
are O
consistent O
with O
a O
role O
for O
d O
##p O
##26 O
##0 O
in O
normal O
re O
##tina O
##l O
electro O
##phy O
##sio O
##logy O
and O
may O
also O
reflect O
the O
expression O
of O
other O
c O
- O
terminal O
d O
##ys O
##tro O
##phi O
##n O
is O
##of O
##orms O
and O
their O
contributions O
to O
re O
##tina O
##l O
signal O
transmission O
. O
. O

c O
##is O
and O
trans O
effects O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
mutation O
in O
a O
cell O
culture O
model O
. O

the O
mutation O
causing O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
has O
been O
identified O
as O
a O
c O
##t O
##g O
expansion O
in O
the O
3 O
- O
un O
##tra O
##ns O
##lated O
region O
( O
3 O
- O
u O
##tr O
) O
of O
the O
d B-Disease
##m I-Disease
protein O
kinase O
gene O
( O
d O
##mp O
##k O
) O
, O
but O
the O
mechanism O
( O
s O
) O
of O
path O
##ogen O
##esis O
remain O
unknown O
. O

studies O
using O
d B-Disease
##m I-Disease
patient O
materials O
have O
often O
produced O
confusing O
results O
. O

therefore O
, O
to O
study O
the O
effects O
of O
the O
d B-Disease
##m I-Disease
mutation O
in O
a O
controlled O
environment O
, O
we O
have O
established O
a O
cell O
culture O
model O
system O
using O
c O
##2 O
##c O
##12 O
mouse O
my O
##ob O
##last O
##s O
. O

by O
expressing O
ch O
##ime O
##ric O
reporter O
construct O
##s O
containing O
a O
reporter O
gene O
fused O
to O
a O
human O
d O
##mp O
##k O
3 O
- O
u O
##tr O
, O
we O
identified O
both O
c O
##is O
and O
trans O
effects O
that O
are O
mediated O
by O
the O
d B-Disease
##m I-Disease
mutation O
. O

our O
data O
show O
that O
a O
mutant O
d O
##mp O
##k O
3 O
- O
u O
##tr O
, O
with O
as O
few O
as O
57 O
c O
##t O
##gs O
, O
had O
a O
negative O
c O
##is O
effect O
on O
protein O
expression O
and O
resulted O
in O
the O
a O
##gg O
##regation O
of O
reporter O
trans O
##cripts O
into O
discrete O
nuclear O
f O
##oc O
##i O
. O

we O
determined O
by O
del O
##eti O
##on O
analysis O
that O
an O
expanded O
( O
c O
##t O
##g O
) O
( O
n O
) O
tract O
alone O
was O
sufficient O
to O
media O
##te O
these O
c O
##is O
effects O
. O

further O
##more O
, O
in O
contrast O
to O
the O
normal O
d O
##mp O
##k O
3 O
- O
u O
##tr O
m O
##rna O
, O
a O
mutant O
d O
##mp O
##k O
3 O
- O
u O
##tr O
m O
##rna O
with O
( O
cu O
##g O
) O
( O
200 O
) O
selective O
##ly O
in O
##hibit O
##ed O
my O
##ogenic O
differentiation O
of O
c O
##2 O
##c O
##12 O
my O
##ob O
##last O
##s O
. O

genetic O
analysis O
and O
the O
c O
##re O
- O
lo O
##x O
##p O
system O
were O
used O
to O
clearly O
demonstrate O
that O
the O
my O
##ob O
##last O
fusion O
defect O
could O
be O
rescued O
by O
eliminating O
the O
expression O
of O
the O
mutant O
d O
##mp O
##k O
3 O
- O
u O
##tr O
trans O
##cript O
. O

characterization O
of O
spontaneous O
del O
##eti O
##on O
events O
mapped O
the O
inhibitor O
##y O
effect O
to O
the O
( O
c O
##t O
##g O
) O
( O
n O
) O
expansion O
and O
/ O
or O
the O
3 O
end O
of O
the O
d O
##mp O
##k O
3 O
- O
u O
##tr O
. O

these O
results O
provide O
evidence O
that O
the O
d B-Disease
##m I-Disease
mutation O
acts O
in O
c O
##is O
to O
reduce O
protein O
production O
( O
consistent O
with O
d B-Disease
##mp I-Disease
##k I-Disease
ha I-Disease
##p I-Disease
##lo I-Disease
##ins I-Disease
##uff I-Disease
##iciency I-Disease
) O
and O
in O
trans O
as O
a O
rib O
##ore O
##gu O
##lator O
to O
in O
##hibit O
my O
##ogen O
##esis O
. O
. O

coats B-Disease
' I-Disease
disease I-Disease
of O
the O
re O
##tina O
( O
un B-Disease
##ila I-Disease
##teral I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asis I-Disease
) O
caused O
by O
so O
##matic O
mutation O
in O
the O
n O
##d O
##p O
gene O
: O
a O
role O
for O
nor O
##rin O
in O
re O
##tina O
##l O
an O
##gio O
##genesis O
. O

coats B-Disease
disease I-Disease
is O
characterized O
by O
abnormal B-Disease
re I-Disease
##tina I-Disease
##l I-Disease
vascular I-Disease
development I-Disease
( O
so O
- O
called O
re B-Disease
##tina I-Disease
##l I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asis I-Disease
) O
which O
results O
in O
massive O
in B-Disease
##trar I-Disease
##eti I-Disease
##nal I-Disease
and I-Disease
sub I-Disease
##ret I-Disease
##inal I-Disease
lip I-Disease
##id I-Disease
accumulation I-Disease
( O
ex B-Disease
##uda I-Disease
##tive I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
detachment I-Disease
) O
. O

the O
classical O
form O
of O
coats B-Disease
disease I-Disease
is O
almost O
in O
##var O
##iably O
isolated O
, O
un O
##ila O
##teral O
and O
seen O
in O
males O
. O

a O
female O
with O
a O
un O
##ila O
##teral O
variant O
of O
coats B-Disease
disease I-Disease
gave O
birth O
to O
a O
son O
affected O
by O
nor B-Disease
##rie I-Disease
disease I-Disease
. O

both O
carried O
a O
miss O
##ense O
mutation O
within O
the O
n O
##d O
##p O
gene O
on O
chromosome O
x O
##p O
##11 O
. O

2 O
2 O
. O

subsequently O
analysis O
of O
the O
re O
##tina O
##s O
of O
nine O
en O
##uc O
##lea O
##ted O
eyes O
from O
males O
with O
coats B-Disease
disease I-Disease
demonstrated O
in O
one O
a O
so O
##matic O
mutation O
in O
the O
n O
##d O
##p O
gene O
which O
was O
not O
present O
within O
non O
- O
re O
##tina O
##l O
tissue O
. O

we O
suggest O
that O
coats B-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asis I-Disease
is O
secondary O
to O
so O
##matic O
mutation O
in O
the O
n O
##d O
##p O
gene O
which O
results O
in O
a O
deficiency B-Disease
of I-Disease
nor I-Disease
##rin I-Disease
( O
the O
protein O
product O
of O
the O
n O
##d O
##p O
gene O
) O
within O
the O
developing O
re O
##tina O
. O

this O
supports O
recent O
observations O
that O
the O
protein O
is O
critical O
for O
normal O
re O
##tina O
##l O
v O
##as O
##cu O
##log O
##ene O
##sis O
. O

hereditary O
t O
##p O
##53 O
co O
##don O
29 O
##2 O
and O
so O
##matic O
p O
##16 O
##ink O
##4 O
##a O
co O
##don O
94 O
mutations O
in O
a O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
family O
. O

l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
that O
is O
characterized O
by O
various O
types O
of O
cancer B-Disease
in O
childhood O
and O
adult O
cases O
. O

although O
hereditary O
t O
##p O
##53 O
mutation O
is O
very O
rare O
in O
different O
human O
cancer B-Disease
##s I-Disease
, O
it O
has O
been O
frequently O
reported O
in O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
. O

on O
the O
other O
hand O
, O
hereditary O
mutations O
of O
t O
##p O
##5 O
##7 O
##ki O
##p O
##2 O
, O
p O
##15 O
##ink O
##4 O
##b O
, O
and O
p O
##16 O
##ink O
##4 O
##a O
, O
which O
affect O
the O
cell O
cycle O
similar O
to O
t O
##p O
##53 O
, O
were O
observed O
in O
some O
types O
of O
cancer B-Disease
. O

in O
a O
t O
##ur O
##kis O
##h O
family O
with O
the O
diagnosis O
of O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
, O
we O
analyzed O
the O
mutation O
pattern O
of O
t O
##p O
##53 O
, O
p O
##5 O
##7 O
##ki O
##p O
##2 O
, O
p O
##15 O
##ink O
##4 O
##b O
, O
and O
p O
##16 O
##ink O
##4 O
##a O
in O
the O
peripheral O
blood O
, O
and O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
( O
ho O
##mo O
/ O
hem O
##iz O
##y O
##go O
##us O
del O
##eti O
##on O
) O
pattern O
of O
t O
##p O
##53 O
and O
p O
##15 O
##ink O
##4 O
##b O
/ O
p O
##16 O
##ink O
##4 O
##a O
in O
two O
tumor B-Disease
tissues O
. O

the O
prop O
##os O
##it O
##us O
had O
a O
semi B-Disease
##no I-Disease
##ma I-Disease
, O
his O
daughter O
a O
me B-Disease
##du I-Disease
##llo I-Disease
##blast I-Disease
##oma I-Disease
, O
and O
one O
of O
his O
healthy O
cousins O
, O
a O
t O
##p O
##53 O
co O
##don O
29 O
##2 O
miss O
##ense O
point O
mutation O
( O
a O
##aa O
- O
- O
[UNK] O
at O
##a O
; O
l O
##ys O
- O
- O
[UNK] O
il O
##e O
) O
in O
the O
peripheral O
blood O
cells O
. O

tumor O
tissue O
obtained O
from O
the O
prop O
##os O
##it O
##us O
with O
the O
semi B-Disease
##no I-Disease
##ma I-Disease
revealed O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
in O
the O
t O
##p O
##53 O
gene O
. O

in O
the O
analyses O
of O
tumor B-Disease
tissues O
from O
the O
prop O
##os O
##it O
##us O
and O
his O
daughter O
, O
a O
p O
##16 O
##ink O
##4 O
##a O
co O
##don O
94 O
miss O
##ense O
point O
mutation O
( O
g O
##c O
##g O
- O
- O
[UNK] O
gag O
; O
al O
##a O
- O
- O
[UNK] O
g O
##lu O
) O
was O
observed O
with O
the O
hereditary O
t O
##p O
##53 O
mutation O
. O

p O
##16 O
##ink O
##4 O
##a O
co O
##don O
94 O
mutation O
observed O
in O
our O
family O
is O
a O
novel O
mutation O
in O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
. O

no O
other O
gene O
alter O
##ation O
in O
t O
##p O
##53 O
, O
p O
##5 O
##7 O
##ki O
##p O
##2 O
, O
p O
##15 O
##ink O
##4 O
##b O
, O
and O
p O
##16 O
##ink O
##4 O
##a O
was O
observed O
. O

existence O
of O
the O
p O
##16 O
##ink O
##4 O
##a O
mutation O
and O
the O
hereditary O
t O
##p O
##53 O
mutation O
with O
or O
without O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
in O
the O
t O
##p O
##53 O
gene O
( O
semi B-Disease
##no I-Disease
##ma I-Disease
/ O
me B-Disease
##du I-Disease
##llo I-Disease
##blast I-Disease
##oma I-Disease
) O
may O
be O
evidence O
for O
a O
common O
mechanism O
involved O
in O
tumor B-Disease
##ogen I-Disease
##esis I-Disease
. O

the O
gene O
alterations O
in O
t O
##p O
##53 O
and O
p O
##16 O
##ink O
##4 O
##a O
genes O
may O
be O
used O
as O
tumor B-Disease
markers O
in O
our O
family O
. O
. O

a O
novel O
mutation O
in O
the O
sodium O
/ O
i O
##od O
##ide O
s O
##ym O
##port O
##er O
gene O
in O
the O
largest O
family O
with O
i B-Disease
##od I-Disease
##ide I-Disease
transport I-Disease
defect I-Disease
. O

we O
previously O
reported O
nine O
children O
with O
an O
auto O
##so O
##mal O
##ly O
re O
##cess O
##ive O
form O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##hy I-Disease
##roid I-Disease
##ism I-Disease
due O
to O
an O
i B-Disease
##od I-Disease
##ide I-Disease
transport I-Disease
defect I-Disease
in O
a O
large O
hut O
##ter O
##ite O
family O
with O
extensive O
con O
##sang O
##uin O
##ity O
living O
in O
central O
can O
##ada O
. O

since O
the O
original O
report O
, O
we O
have O
diagnosed O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##hy I-Disease
##roid I-Disease
##ism I-Disease
by O
newborn O
t O
##sh O
screening O
in O
9 O
additional O
children O
from O
the O
family O
. O

we O
performed O
direct O
se O
##quencing O
of O
the O
p O
##c O
##r O
products O
of O
each O
ni O
##s O
( O
sodium O
/ O
i O
##od O
##ide O
s O
##ym O
##port O
##er O
) O
gene O
ex O
##on O
with O
flank O
##ing O
intro O
##ns O
am O
##plified O
from O
g O
##eno O
##mic O
d O
##na O
extracted O
from O
peripheral O
blood O
cells O
of O
the O
patients O
. O

we O
identified O
a O
novel O
ni O
##s O
gene O
mutation O
, O
g O
##39 O
##5 O
##r O
( O
g O
##ly O
##39 O
##5 O
- O
- O
[UNK] O
a O
##rg O
; O
g O
##ga O
- O
- O
[UNK] O
a O
##ga O
) O
, O
in O
10 O
patients O
examined O
in O
the O
present O
study O
. O

all O
of O
the O
parents O
tested O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
mutation O
, O
suggesting O
that O
the O
patients O
were O
ho O
##mo O
##zy O
##go O
##us O
. O

the O
mutation O
was O
located O
in O
the O
10th O
trans O
##me O
##mb O
##rane O
he O
##lix O
. O

expression O
experiments O
by O
trans O
##fect O
##ion O
of O
the O
mutant O
ni O
##s O
compliment O
##ary O
d O
##na O
into O
co O
##s O
- O
7 O
cells O
showed O
no O
perch O
##lora O
##te O
- O
sensitive O
i O
##od O
##ide O
up O
##take O
, O
confirming O
that O
the O
mutation O
is O
the O
direct O
cause O
of O
the O
i B-Disease
##od I-Disease
##ide I-Disease
transport I-Disease
defect I-Disease
in O
these O
patients O
. O

a O
patient O
who O
showed O
an O
intermediate O
sa O
##liva O
/ O
serum O
tech O
##net O
##ium O
ratio O
( O
14 O
. O
0 O
; O
normal O
, O
[UNK] O
or O
= O
20 O
) O
and O
was O
considered O
to O
have O
a O
partial O
or O
less O
severe O
defect O
in O
the O
previous O
report O
( O
i O
##x O
- O
24 O
) O
did O
not O
have O
a O
ni O
##s O
gene O
mutation O
. O

it O
is O
now O
possible O
to O
use O
gene O
diagnostic O
##s O
of O
this O
unique O
ni O
##s O
mutation O
to O
identify O
patients O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##hy I-Disease
##roid I-Disease
##ism I-Disease
due O
to O
an O
i B-Disease
##od I-Disease
##ide I-Disease
transport I-Disease
defect I-Disease
in O
this O
family O
and O
to O
determine O
the O
carrier O
state O
of O
potential O
parents O
for O
genetic O
counseling O
and O
arranging O
rapid O
and O
early O
diagnosis O
of O
their O
infants O
. O

molecular O
analysis O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
: O
early O
diagnosis O
of O
an O
as O
##ym O
##pt O
##oma O
##tic O
carrier O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
( O
f B-Disease
##ndi I-Disease
) O
is O
an O
inherited O
deficiency B-Disease
of I-Disease
the I-Disease
hormone I-Disease
a I-Disease
##rg I-Disease
##ini I-Disease
##ne I-Disease
v I-Disease
##as I-Disease
##op I-Disease
##ress I-Disease
##in I-Disease
( O
a O
##v O
##p O
) O
and O
is O
transmitted O
as O
an O
auto O
##so O
##mal O
dominant O
trait O
. O

in O
the O
present O
study O
we O
have O
analyzed O
the O
a O
##v O
##p O
- O
ne O
##uro O
##phy O
##sin O
ii O
( O
a O
##v O
##p O
- O
n O
##pi O
##i O
) O
gene O
in O
a O
span O
##ish O
kind O
##red O
. O

studies O
were O
performed O
on O
seven O
members O
( O
four O
clinical O
##ly O
affected O
) O
of O
the O
family O
. O

patients O
were O
diagnosed O
at O
the O
hospital O
un O
##ivers O
##ita O
##rio O
g O
##re O
##gor O
##io O
ma O
##rano O
##n O
( O
mad O
##rid O
, O
spa O
##in O
) O
. O

the O
entire O
coding O
region O
of O
the O
a O
##v O
##p O
- O
n O
##pi O
##i O
gene O
of O
all O
family O
members O
was O
am O
##plified O
by O
p O
##c O
##r O
and O
sequence O
##d O
. O

all O
affected O
individuals O
presented O
a O
miss O
##ense O
mutation O
( O
g O
##17 O
##5 O
##7 O
- O
- O
[UNK] O
a O
) O
that O
replaces O
g O
##ly O
##cine O
at O
position O
23 O
with O
a O
##rg O
##ini O
##ne O
within O
the O
n O
##pi O
##i O
domain O
. O

the O
substitution O
was O
confirmed O
by O
restriction O
end O
##on O
##uc O
##lea O
##se O
analysis O
and O
was O
present O
in O
he O
##tero O
##zy O
##gos O
##is O
. O

additionally O
, O
one O
of O
the O
as O
##ym O
##pt O
##oma O
##tic O
relatives O
( O
a O
girl O
8 O
months O
old O
at O
the O
time O
of O
study O
) O
was O
identified O
as O
carrier O
of O
the O
same O
mutation O
and O
developed O
the O
disease O
3 O
months O
later O
. O

the O
alter O
##ation O
found O
in O
the O
second O
ex O
##on O
of O
the O
gene O
in O
this O
family O
seems O
to O
be O
responsible O
for O
the O
disease O
, O
as O
all O
individuals O
harbor O
##ing O
the O
mutation O
had O
been O
previously O
diagnosed O
or O
have O
eventually O
developed O
f B-Disease
##ndi I-Disease
. O

identification O
of O
the O
molecular O
defect O
underlying O
f B-Disease
##ndi I-Disease
in O
affected O
families O
is O
a O
powerful O
tool O
for O
early O
as O
##ym O
##pt O
##oma O
##tic O
diagnosis O
in O
infants O
. O
. O

deficit O
of O
in O
v O
##ivo O
mitochondrial O
at O
##p O
production O
in O
patients O
with O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
, O
the O
most O
common O
of O
the O
inherited B-Disease
at I-Disease
##ax I-Disease
##ias I-Disease
, O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
de I-Disease
##gene I-Disease
##rative I-Disease
disorder I-Disease
, O
characterized O
clinical O
##ly O
by O
onset O
before O
the O
age O
of O
25 O
of O
progressive B-Disease
g I-Disease
##ait I-Disease
and I-Disease
limb I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
, O
absence B-Disease
of I-Disease
deep I-Disease
tend I-Disease
##on I-Disease
reflex I-Disease
##es I-Disease
, O
ex B-Disease
##tens I-Disease
##or I-Disease
plant I-Disease
##ar I-Disease
responses I-Disease
, O
and O
loss B-Disease
of I-Disease
position I-Disease
and I-Disease
vibration I-Disease
sense I-Disease
in O
the O
lower O
limbs O
. O

f B-Disease
##rda I-Disease
is O
caused O
by O
a O
g O
##aa O
triple O
##t O
expansion O
in O
the O
first O
intro O
##n O
of O
the O
f B-Disease
##rda I-Disease
gene O
on O
chromosome O
9 O
##q O
##13 O
in O
97 O
% O
of O
patients O
. O

the O
f B-Disease
##rda I-Disease
gene O
en O
##codes O
a O
widely O
expressed O
210 O
- O
a O
##a O
protein O
, O
f O
##rata O
##xin O
, O
which O
is O
located O
in O
mit O
##och O
##ond O
##ria O
and O
is O
severely O
reduced O
in O
f B-Disease
##rda I-Disease
patients O
. O

f O
##rata O
##xin O
function O
is O
still O
unknown O
but O
the O
knockout O
of O
the O
yeast O
f O
##rata O
##xin O
ho O
##mo O
##logue O
gene O
( O
y O
##f O
##h O
##1 O
) O
showed O
a O
severe O
defect O
of O
mitochondrial O
re O
##spiration O
and O
loss O
of O
m O
##t O
##dn O
##a O
associated O
with O
elevated O
in O
##tra O
##mit O
##och O
##ond O
##rial O
iron O
. O

here O
we O
report O
in O
v O
##ivo O
evidence O
of O
impaired O
mitochondrial O
re O
##spiration O
in O
skeletal O
muscle O
of O
f B-Disease
##rda I-Disease
patients O
. O

using O
p O
##hos O
##phorus O
magnetic O
resonance O
s O
##pect O
##ros O
##copy O
we O
demonstrated O
a O
maximum O
rate O
of O
muscle O
mitochondrial O
at O
##p O
production O
( O
v O
( O
ma O
##x O
) O
) O
below O
the O
normal O
range O
in O
all O
12 O
f B-Disease
##rda I-Disease
patients O
and O
a O
strong O
negative O
correlation O
between O
mitochondrial O
v O
( O
ma O
##x O
) O
and O
the O
number O
of O
g O
##aa O
repeats O
in O
the O
smaller O
all O
##ele O
. O

our O
results O
show O
that O
f B-Disease
##rda I-Disease
is O
a O
nuclear O
- O
encoded O
mitochondrial B-Disease
disorder I-Disease
affecting O
o O
##xi O
##da O
##tive O
p O
##hos O
##ph O
##ory O
##lation O
and O
give O
a O
rational O
##e O
for O
treatments O
aimed O
to O
improve O
mitochondrial O
function O
in O
this O
condition O
. O
. O

identification O
of O
a O
novel O
r O
##21 O
##x O
mutation O
in O
the O
liver O
- O
type O
a O
##rg O
##inas O
##e O
gene O
( O
a O
##rg O
##1 O
) O
in O
four O
port O
##ug O
##ues O
##e O
patients O
with O
a B-Disease
##rg I-Disease
##ini I-Disease
##ne I-Disease
##mia I-Disease
. O

a B-Disease
##rg I-Disease
##ini I-Disease
##ne I-Disease
##mia I-Disease
is O
a O
rare O
auto B-Disease
##sso I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
in I-Disease
the I-Disease
c I-Disease
##yt I-Disease
##oso I-Disease
##lic I-Disease
liver I-Disease
- I-Disease
type I-Disease
a I-Disease
##rg I-Disease
##inas I-Disease
##e I-Disease
enzyme I-Disease
( O
l O
- O
a O
##rg O
##ini O
##ne O
u O
##rea O
- O
h O
##ydro O
##lase O
; O
e O
. O
c O
. O
3 O
. O
5 O
. O
3 O
. O
1 O
) O
. O

in O
order O
to O
investigate O
the O
molecular O
basis O
for O
a B-Disease
##rg I-Disease
##ini I-Disease
##ne I-Disease
##mia I-Disease
in O
four O
unrelated O
port O
##ug O
##ues O
##e O
patients O
( O
two O
from O
northern O
port O
##uga O
##l O
and O
two O
from O
made O
##ira O
island O
) O
we O
performed O
a O
d O
##na O
sequence O
analysis O
of O
all O
the O
ex O
##ons O
and O
ex O
##on O
/ O
intro O
##n O
boundaries O
of O
the O
liver O
- O
type O
a O
##rg O
##inas O
##e O
gene O
( O
a O
##rg O
##1 O
) O
. O

all O
patients O
were O
found O
to O
be O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
newly O
identified O
c O
- O
[UNK] O
t O
transition O
in O
co O
##don O
21 O
( O
ex O
##on O
2 O
) O
sub O
##stituting O
a O
##rg O
##ini O
##ne O
for O
a O
premature O
stop O
co O
##don O
( O
r O
##21 O
##x O
c O
##ga O
to O
t O
##ga O
) O
and O
generating O
a O
n O
##lai O
##ii O
restriction O
site O
. O

restriction O
dig O
##est O
##ion O
following O
p O
##c O
##r O
am O
##p O
##lification O
of O
a O
##rg O
##1 O
ex O
##on O
2 O
confirmed O
the O
presence O
of O
the O
mutation O
. O

mutation O
of O
the O
s O
##tero O
##l O
27 O
- O
h O
##ydro O
##xy O
##lase O
gene O
( O
c O
##y O
##p O
##27 O
) O
results O
in O
t O
##run O
##cation O
of O
m O
##rna O
expressed O
in O
le O
##uc O
##ocytes O
in O
a O
j O
##apa O
##nese O
family O
with O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
. O

objectives O
a O
j O
##apa O
##nese O
family O
with O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
was O
investigated O
for O
a O
sequence O
alter O
##ation O
in O
the O
s O
##tero O
##l O
27 O
- O
h O
##ydro O
##xy O
##lase O
gene O
( O
c O
##y O
##p O
##27 O
) O
. O

the O
expression O
of O
c O
##y O
##p O
##27 O
has O
been O
mostly O
explored O
using O
culture O
##d O
fi O
##bro O
##blast O
##s O
, O
prompting O
the O
examination O
of O
the O
trans O
##cripts O
from O
blood O
le O
##uc O
##ocytes O
as O
a O
simple O
and O
rapid O
technique O
. O

methods O
an O
alter O
##ation O
in O
c O
##y O
##p O
##27 O
of O
the O
pro O
##band O
was O
searched O
for O
by O
polymer O
##ase O
chain O
reaction O
- O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
) O
analysis O
and O
subsequent O
se O
##quencing O
. O

samples O
of O
r O
##na O
were O
subjected O
to O
reverse O
transcription O
p O
##c O
##r O
( O
r O
##t O
- O
p O
##c O
##r O
) O
and O
the O
product O
of O
the O
pro O
##band O
was O
am O
##plified O
with O
nest O
##ed O
prime O
##rs O
and O
sequence O
##d O
. O

results O
a O
ho O
##mo O
##zy O
##go O
##us O
g O
to O
a O
transition O
at O
the O
5 O
end O
of O
intro O
##n O
7 O
was O
detected O
in O
the O
patient O
. O

in O
r O
##t O
- O
p O
##c O
##r O
analysis O
, O
only O
a O
t O
##runcated O
trans O
##cript O
was O
detected O
in O
the O
patient O
, O
whereas O
both O
normal O
and O
t O
##runcated O
trans O
##cripts O
were O
detected O
in O
the O
siblings O
. O

the O
se O
##quencing O
of O
the O
patients O
c O
##dn O
##a O
fragment O
disclosed O
a O
direct O
con O
##ju O
##ction O
of O
ex O
##on O
6 O
and O
ex O
##on O
8 O
. O

conclusion O
the O
mutation O
at O
s O
##p O
##lice O
donor O
site O
and O
the O
t O
##run O
##cation O
of O
m O
##rna O
were O
identical O
with O
those O
of O
a O
recently O
reported O
it O
##alia O
##n O
patient O
, O
although O
different O
in O
s O
##ym O
##pt O
##oma O
##tology O
. O

the O
application O
of O
blood O
le O
##uc O
##ocytes O
can O
be O
a O
simple O
technique O
on O
anal O
##ys O
##ing O
a O
construct O
##ive O
abnormal B-Disease
##ity I-Disease
of I-Disease
c I-Disease
##y I-Disease
##p I-Disease
##27 I-Disease
m O
##rna O
. O
. O

clinical O
and O
molecular O
genetic O
analysis O
of O
19 O
wolf B-Disease
##ram I-Disease
syndrome I-Disease
kind O
##red O
##s O
demonstrating O
a O
wide O
spectrum O
of O
mutations O
in O
w O
##fs O
##1 O
. O

wolf B-Disease
##ram I-Disease
syndrome I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disorder I-Disease
characterized O
by O
juvenile B-Disease
- I-Disease
onset I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
and O
progressive O
op B-Disease
##tic I-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
. O

m O
##t O
##dn O
##a O
del O
##eti O
##ons O
have O
been O
described O
, O
and O
a O
gene O
( O
w O
##fs O
##1 O
) O
recently O
has O
been O
identified O
, O
on O
chromosome O
4 O
##p O
##16 O
, O
encoding O
a O
predicted O
89 O
##0 O
amino O
acid O
trans O
##me O
##mb O
##rane O
protein O
. O

direct O
d O
##na O
se O
##quencing O
was O
done O
to O
screen O
the O
entire O
coding O
region O
of O
the O
w O
##fs O
##1 O
gene O
in O
30 O
patients O
from O
19 O
br O
##itis O
##h O
kind O
##red O
##s O
with O
wolf B-Disease
##ram I-Disease
syndrome I-Disease
. O

d O
##na O
was O
also O
screened O
for O
structural O
rear O
##rang O
##ement O
##s O
( O
del O
##eti O
##ons O
and O
du O
##plication O
##s O
) O
and O
point O
mutations O
in O
m O
##t O
##dn O
##a O
. O

no O
path O
##ogenic O
m O
##t O
##dn O
##a O
mutations O
were O
found O
in O
our O
co O
##hor O
##t O
. O

we O
identified O
24 O
mutations O
in O
the O
w O
##fs O
##1 O
gene O
8 O
nonsense O
mutations O
, O
8 O
miss O
##ense O
mutations O
, O
3 O
in O
- O
frame O
del O
##eti O
##ons O
, O
1 O
in O
- O
frame O
insertion O
, O
and O
4 O
frames O
##hi O
##ft O
mutations O
. O

of O
these O
, O
23 O
were O
novel O
mutations O
, O
and O
most O
occurred O
in O
ex O
##on O
8 O
. O

the O
majority O
of O
patients O
were O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
two O
mutations O
, O
and O
there O
was O
no O
common O
founder O
mutation O
. O

the O
data O
were O
also O
analyzed O
for O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
relationships O
. O

although O
some O
interesting O
cases O
were O
noted O
, O
consideration O
of O
the O
small O
sample O
size O
and O
frequency O
of O
each O
mutation O
indicated O
no O
clear O
- O
cut O
correlation O
##s O
between O
any O
of O
the O
observed O
mutations O
and O
disease O
severity O
. O

there O
were O
no O
obvious O
mutation O
hot O
spots O
or O
clusters O
. O

hence O
, O
molecular O
screening O
for O
wolf B-Disease
##ram I-Disease
syndrome I-Disease
in O
affected O
families O
and O
for O
wolf B-Disease
##ram I-Disease
syndrome I-Disease
- O
carrier O
status O
in O
subjects O
with O
psychiatric B-Disease
disorders I-Disease
or O
diabetes B-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
will O
require O
complete O
analysis O
of O
ex O
##on O
8 O
and O
upstream O
ex O
##ons O
. O
. O

late O
- O
onset O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
: O
a O
subset O
with O
distinct O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O
. O

to O
determine O
the O
prevalence O
and O
character O
##ize O
demographic O
, O
clinical O
, O
and O
genetic O
features O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
of O
late O
onset O
, O
all O
patients O
experiencing O
their O
first O
f B-Disease
##m I-Disease
##f I-Disease
attack O
at O
age O
40 O
years O
or O
more O
were O
identified O
using O
the O
computer O
##ized O
registry O
of O
our O
f B-Disease
##m I-Disease
##f I-Disease
clinic O
, O
and O
then O
thoroughly O
interviewed O
and O
examined O
. O

the O
control O
group O
consisted O
of O
40 O
consecutive O
f B-Disease
##m I-Disease
##f I-Disease
patients O
, O
who O
arrived O
at O
the O
f B-Disease
##m I-Disease
##f I-Disease
clinic O
for O
their O
regular O
follow O
- O
up O
visit O
and O
were O
40 O
years O
of O
age O
or O
older O
at O
the O
time O
of O
the O
examination O
. O

the O
severity O
of O
the O
disease O
in O
patients O
and O
controls O
was O
determined O
using O
a O
modified O
score O
, O
developed O
previously O
. O

mutation O
##al O
analysis O
in O
the O
f B-Disease
##m I-Disease
##f I-Disease
gene O
was O
performed O
using O
a O
commercial O
kit O
. O

only O
20 O
of O
4000 O
( O
0 O
. O
5 O
% O
) O
patients O
had O
late O
- O
onset O
f B-Disease
##m I-Disease
##f I-Disease
. O

these O
patients O
were O
mostly O
men O
, O
of O
non O
- O
north O
a O
##f O
##rica O
##n O
origin O
, O
p O
[UNK] O
0 O
. O

05 O
compared O
to O
controls O
. O

all O
had O
abdominal O
attacks O
and O
in O
most O
these O
were O
the O
only O
manifest O
##ation O
of O
their O
disease O
, O
p O
[UNK] O
0 O
. O

00 O
##1 O
00 O
##1 O
. O

none O
had O
chronic O
or O
prolonged O
manifest O
##ations O
of O
f B-Disease
##m I-Disease
##f I-Disease
, O
for O
example O
, O
am B-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
, O
chronic B-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
, O
or O
pro O
##tracted O
my B-Disease
##al I-Disease
##gia I-Disease
, O
p O
[UNK] O
0 O
. O

00 O
##1 O
. O

the O
response O
to O
treatment O
was O
good O
despite O
using O
low O
co O
##l O
##chi O
##cine O
dose O
, O
p O
[UNK] O
0 O
. O

05 O
. O

the O
overall O
severity O
score O
indicated O
a O
mild O
disease O
, O
p O
[UNK] O
0 O
. O

00 O
##1 O
. O

mutation O
##al O
analysis O
revealed O
absence O
of O
m O
##6 O
##9 O
##4 O
##v O
ho O
##mo O
##zy O
##gos O
##ity O
, O
p O
[UNK] O
0 O
. O

01 O
, O
compared O
to O
our O
regular O
f B-Disease
##m I-Disease
##f I-Disease
population O
. O

we O
conclude O
that O
the O
onset O
of O
f B-Disease
##m I-Disease
##f I-Disease
in O
a O
late O
age O
defines O
a O
mild O
##er O
form O
of O
disease O
with O
typical O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O

a O
highly O
accurate O
, O
low O
cost O
test O
for O
br O
##ca O
##1 O
mutations O
. O

the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
syndrome I-Disease
is O
associated O
with O
a O
high O
frequency O
of O
br O
##ca O
##1 O
mutations O
. O

however O
, O
the O
widespread O
use O
of O
br O
##ca O
##1 O
testing O
has O
been O
limited O
to O
date O
by O
three O
principal O
concerns O
the O
fear O
of O
loss O
of O
health O
and O
life O
insurance O
, O
the O
uncertain O
clinical O
value O
of O
a O
positive O
test O
result O
, O
and O
the O
current O
lack O
of O
an O
inexpensive O
and O
sensitive O
screening O
test O
for O
br O
##ca O
##1 O
mutations O
. O

we O
have O
developed O
an O
inexpensive O
system O
for O
gene O
mutation O
##al O
scanning O
, O
based O
on O
a O
combination O
of O
extensive O
multiple O
##x O
p O
##c O
##r O
am O
##p O
##lification O
and O
two O
dimensional O
electro O
##ph O
##ores O
##is O
. O

the O
efficiency O
of O
this O
system O
, O
as O
a O
screening O
test O
for O
br O
##ca O
##1 O
mutations O
, O
was O
evaluated O
in O
a O
panel O
of O
60 O
samples O
from O
high O
risk O
women O
, O
14 O
of O
which O
contained O
a O
previously O
identified O
mutation O
in O
br O
##ca O
##1 O
. O

all O
14 O
mutations O
were O
identified O
, O
as O
well O
as O
an O
additional O
five O
that O
had O
previously O
escaped O
detection O
. O

in O
addition O
to O
the O
19 O
mutations O
, O
a O
total O
of O
15 O
different O
p O
##oly O
##morphic O
variants O
were O
scored O
, O
most O
of O
which O
were O
recurring O
. O

all O
were O
confirmed O
by O
n O
##uc O
##leo O
##tide O
se O
##quencing O
. O

the O
cost O
of O
screening O
per O
sample O
was O
calculated O
to O
be O
approximately O
us O
$ O
70 O
for O
the O
manual O
technique O
used O
in O
this O
study O
, O
and O
may O
be O
reduced O
to O
approximately O
us O
$ O
10 O
with O
the O
introduction O
of O
commercially O
available O
p O
##c O
##r O
robotic O
##s O
and O
fluorescent O
imaging O
. O

implementation O
of O
this O
method O
of O
mutation O
screening O
in O
the O
research O
and O
clinical O
setting O
should O
permit O
rapid O
a O
##cc O
##ru O
##al O
of O
quantitative O
data O
on O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
associations O
for O
the O
evaluation O
of O
diagnostic O
testing O
. O
. O

maternal B-Disease
un I-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
for I-Disease
chromosome I-Disease
14 I-Disease
in O
a O
boy O
with O
a O
normal O
ka O
##ryo O
##type O
. O

we O
report O
on O
a O
boy O
with O
a O
maternal B-Disease
un I-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
for I-Disease
chromosome I-Disease
14 I-Disease
( O
up B-Disease
##d I-Disease
( O
14 O
) O
) O
. O

at O
7 O
years O
of O
age O
he O
was O
referred O
to O
us O
by O
the O
p O
##ae O
##dia O
##tric O
##ian O
because O
of O
symptoms O
of O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

he O
showed O
short B-Disease
stature I-Disease
, O
o B-Disease
##besity I-Disease
, O
mild O
developmental B-Disease
delay I-Disease
, O
cry B-Disease
##pt I-Disease
##or I-Disease
##chi I-Disease
##dis I-Disease
##m I-Disease
, O
and O
some O
mild O
d B-Disease
##ys I-Disease
##morphic I-Disease
features I-Disease
. O

the O
history O
further O
indicated O
in B-Disease
##tra I-Disease
##uter I-Disease
##ine I-Disease
growth I-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
at O
the O
end O
of O
the O
pregnancy O
. O

his O
mother O
was O
44 O
years O
of O
age O
at O
the O
time O
of O
his O
birth O
. O

after O
birth O
he O
showed O
h B-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
with O
poor O
sucking O
, O
for O
which O
g O
##ava O
##ge O
feeding O
was O
needed O
. O

motor O
development O
was O
delayed O
. O

after O
1 O
year O
he O
became O
o B-Disease
##bes I-Disease
##e I-Disease
despite O
a O
normal O
appetite O
. O

re O
##current O
middle B-Disease
ear I-Disease
infections I-Disease
, O
a O
high O
pain O
threshold O
, O
and O
a O
great O
skill O
with O
ji O
##gs O
##aw O
puzzles O
were O
reported O
. O

there O
were O
no O
behaviour O
##al O
problems O
or O
sleep O
disturbance O
. O

ch O
##rom O
##oso O
##mal O
analysis O
was O
normal O
( O
46 O
, O
x O
##y O
) O
. O

d O
##na O
analysis O
for O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
showed O
no O
abnormal O
##ities O
. O

two O
years O
later O
he O
was O
re O
- O
examined O
because O
we O
thought O
his O
features O
fitted O
the O
p B-Disease
##ws I-Disease
- O
like O
p O
##hen O
##otype O
associated O
with O
maternal O
up B-Disease
##d I-Disease
( O
14 O
) O
. O

at O
that O
time O
pre O
##co O
##cious O
pub O
##erty O
was O
evident O
. O

d O
##na O
analysis O
showed O
maternal B-Disease
he I-Disease
##tero I-Disease
##dis I-Disease
##omy I-Disease
for O
chromosome O
14 O
. O

in O
all O
the O
previously O
described O
11 O
cases O
with O
maternal O
up B-Disease
##d I-Disease
( O
14 O
) O
, O
a O
robe O
##rts O
##onia O
##n O
trans O
##location O
involving O
chromosome O
14 O
was O
detected O
c O
##yt O
##ogen O
##etic O
##ally O
before O
d O
##na O
analysis O
. O

this O
is O
the O
first O
report O
of O
diagnosis O
of O
maternal O
up B-Disease
##d I-Disease
( O
14 O
) O
based O
on O
clinical O
features O
. O

this O
finding O
under O
##lines O
the O
importance O
of O
d O
##na O
analysis O
for O
maternal O
up O
##d O
( O
14 O
) O
in O
patients O
with O
a O
similar O
p B-Disease
##ws I-Disease
- O
like O
p O
##hen O
##otype O
even O
without O
previous O
identification O
of O
a O
robe O
##rts O
##onia O
##n O
trans O
##location O
involving O
chromosome O
14 O
. O
. O

clinical O
and O
genetic O
study O
of O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
in O
an O
au O
##stra O
##lian O
population O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
f B-Disease
##rda I-Disease
gene O
that O
en O
##codes O
a O
210 O
- O
amino O
acid O
protein O
called O
f O
##rata O
##xin O
. O

an O
expansion O
of O
a O
g O
##aa O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
intro O
##n O
1 O
of O
the O
gene O
is O
present O
in O
more O
than O
95 O
% O
of O
mutant O
all O
##ele O
##s O
. O

of O
the O
83 O
people O
we O
studied O
who O
have O
mutations O
in O
f O
##rda O
, O
78 O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
an O
expanded O
g O
##aa O
repeat O
; O
the O
other O
five O
patients O
have O
an O
expansion O
in O
one O
all O
##ele O
and O
a O
point O
mutation O
in O
the O
other O
. O

here O
we O
present O
a O
detailed O
clinical O
and O
genetic O
study O
of O
a O
subset O
of O
51 O
patients O
ho O
##mo O
##zy O
##go O
##us O
for O
an O
expansion O
of O
the O
g O
##aa O
repeat O
. O

we O
found O
a O
correlation O
between O
the O
size O
of O
the O
smaller O
of O
the O
two O
expanded O
all O
##ele O
##s O
and O
age O
at O
onset O
, O
age O
into O
wheelchair O
, O
s B-Disease
##co I-Disease
##lio I-Disease
##sis I-Disease
, O
impaired O
vibration O
sense O
, O
and O
the O
presence O
of O
foot B-Disease
def I-Disease
##orm I-Disease
##ity I-Disease
. O

there O
was O
no O
significant O
correlation O
between O
the O
size O
of O
the O
smaller O
all O
##ele O
and O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
, O
diabetes B-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
, O
loss B-Disease
of I-Disease
prop I-Disease
##rio I-Disease
##ception I-Disease
, O
or O
bladder B-Disease
symptoms I-Disease
. O

the O
larger O
all O
##ele O
size O
correlated O
with O
bladder B-Disease
symptoms I-Disease
and O
the O
presence O
of O
foot B-Disease
def I-Disease
##orm I-Disease
##ity I-Disease
. O

the O
duration O
of O
disease O
is O
correlated O
with O
wheelchair O
use O
and O
the O
presence O
of O
diabetes B-Disease
, O
s B-Disease
##co I-Disease
##lio I-Disease
##sis I-Disease
, O
bladder B-Disease
symptoms I-Disease
and O
impaired B-Disease
prop I-Disease
##rio I-Disease
##ception I-Disease
, O
and O
vibration O
sense O
but O
no O
other O
complications O
studied O
. O
. O

novel O
mutations O
in O
x O
##l O
##rs O
##1 O
causing O
re B-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
, O
including O
first O
evidence O
of O
put O
##ative O
leader O
sequence O
change O
. O

juvenile B-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
is O
an O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
caused O
by O
mutations O
in O
the O
x O
##l O
##rs O
##1 O
gene O
. O

we O
screened O
31 O
new O
unrelated O
patients O
and O
families O
for O
x O
##l O
##rs O
##1 O
mutations O
in O
addition O
to O
previously O
reported O
mutations O
for O
60 O
of O
our O
families O
( O
re B-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
consortium O
, O
hum O
m O
##ol O
gene O
##t O
1998 O
; O
7 O
118 O
##5 O
- O
119 O
##2 O
) O
. O

twenty O
- O
three O
different O
mutations O
including O
12 O
novel O
ones O
were O
identified O
in O
28 O
patients O
. O

mutations O
identified O
in O
this O
study O
include O
19 O
miss O
##ense O
mutations O
, O
two O
nonsense O
mutations O
, O
one O
in O
##tra O
##genic O
del O
##eti O
##on O
, O
four O
micro O
##del O
##eti O
##ons O
, O
one O
insertion O
, O
and O
one O
intro O
##nic O
sequence O
substitution O
that O
is O
likely O
to O
result O
in O
a O
s O
##p O
##lice O
site O
defect O
. O

two O
novel O
mutations O
, O
c O
. O

38 O
##t O
- O
- O
[UNK] O
c O
( O
l O
##13 O
##p O
) O
and O
c O
. O

66 O
##7 O
##t O
- O
- O
[UNK] O
c O
( O
c O
##22 O
##3 O
##r O
) O
, O
respectively O
, O
present O
the O
first O
genetic O
evidence O
for O
the O
functional O
significance O
of O
the O
put O
##ative O
leader O
p O
##eptide O
sequence O
and O
for O
the O
functional O
significance O
at O
the O
car O
##box O
##yl O
terminal O
of O
the O
x O
##l O
##rs O
##1 O
protein O
beyond O
the O
disco O
##id O
##in O
domain O
. O

mutations O
in O
25 O
of O
the O
families O
were O
localized O
to O
ex O
##ons O
4 O
- O
6 O
, O
emphasizing O
the O
critical O
functional O
significance O
of O
the O
disco O
##id O
##in O
domain O
of O
the O
x O
##l O
##rs O
##1 O
protein O

growth O
hormone O
treatment O
increases O
co O
( O
2 O
) O
response O
, O
ventilation O
and O
central O
ins O
##pi O
##rator O
##y O
drive O
in O
children O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

we O
studied O
whether O
the O
beneficial O
effects O
of O
growth O
hormone O
( O
g O
##h O
) O
treatment O
on O
growth O
and O
body O
composition O
in O
p B-Disease
##ws I-Disease
are O
accompanied O
by O
an O
improvement O
in O
respiratory O
function O
. O

we O
measured O
resting O
ventilation O
, O
air O
##way O
o O
##cc O
##lusion O
pressure O
( O
p O
( O
0 O
. O
1 O
) O
) O
and O
vent O
##ila O
##tory O
response O
to O
co O
( O
2 O
) O
in O
nine O
children O
, O
aged O
7 O
- O
14 O
years O
, O
before O
and O
6 O
- O
9 O
months O
after O
the O
start O
of O
g O
##h O
treatment O
. O

during O
g O
##h O
treatment O
, O
resting O
ventilation O
increased O
by O
26 O
% O
, O
p O
( O
0 O
. O
1 O
) O
by O
72 O
% O
and O
the O
response O
to O
co O
( O
2 O
) O
by O
65 O
% O
( O
p O
[UNK] O
0 O
. O
00 O
##2 O
, O
[UNK] O
0 O
. O
04 O
and O
[UNK] O
0 O
. O
02 O
, O
respectively O
) O
. O

this O
observed O
increase O
in O
vent O
##ila O
##tory O
output O
was O
not O
correlated O
to O
changes O
in O
body O
mass O
index O
. O

conclusion O
treatment O
of O
children O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
seems O
to O
have O
a O
s O
##ti O
##mu O
##lator O
##y O
effect O
on O
central O
respiratory O
structures O
. O

the O
observed O
increase O
in O
ventilation O
and O
ins O
##pi O
##rator O
##y O
drive O
may O
contribute O
to O
the O
improved O
activity O
level O
reported O
by O
parents O
of O
p B-Disease
##ws I-Disease
children O
during O
growth O
hormone O
therapy O

g O
##13 O
##0 O
##v O
, O
a O
common O
f B-Disease
##rda I-Disease
point O
mutation O
, O
appears O
to O
have O
arise O
##n O
from O
a O
common O
founder O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
is O
the O
most O
common O
inherited B-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

about O
98 O
% O
of O
mutant O
all O
##ele O
##s O
have O
an O
expansion O
of O
a O
g O
##aa O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
intro O
##n O
1 O
of O
the O
affected O
gene O
, O
f O
##rda O
. O

the O
other O
2 O
% O
are O
point O
mutations O
. O

of O
the O
17 O
point O
mutations O
so O
far O
described O
, O
three O
appear O
to O
be O
more O
common O
. O

one O
of O
these O
is O
the O
g O
##13 O
##0 O
##v O
mutation O
in O
ex O
##on O
4 O
of O
f O
##rda O
. O

g O
##13 O
##0 O
##v O
, O
when O
present O
with O
an O
expanded O
g O
##aa O
repeat O
on O
the O
other O
all O
##ele O
, O
is O
associated O
with O
an O
at O
##y O
##pical O
f B-Disease
##rda I-Disease
p O
##hen O
##otype O
. O

ha O
##p O
##lot O
##ype O
analysis O
was O
undertaken O
on O
the O
four O
families O
who O
have O
been O
described O
with O
this O
mutation O
. O

the O
results O
suggest O
a O
common O
founder O
for O
this O
mutation O
. O

although O
marked O
differences O
in O
extra O
##genic O
marker O
ha O
##p O
##lot O
##ype O
##s O
were O
seen O
in O
one O
family O
, O
similar O
in O
##tra O
##genic O
ha O
##p O
##lot O
##y O
##ping O
suggests O
the O
same O
mutation O
founder O
for O
this O
family O
with O
the O
differences O
ex O
##p O
##lica O
##ble O
by O
two O
re O
##comb O
##ination O
events O
. O
. O

s O
##yne O
##rg O
##istic O
effect O
of O
his O
##tone O
h O
##yper O
##ace O
##ty O
##lation O
and O
d O
##na O
dem O
##eth O
##yla O
##tion O
in O
the O
react O
##ivation O
of O
the O
f O
##m O
##r O
##1 O
gene O
. O

most O
fragile B-Disease
x I-Disease
syndrome I-Disease
patients O
have O
expansion O
of O
a O
( O
c O
##gg O
) O
( O
n O
) O
sequence O
with O
[UNK] O
200 O
repeats O
( O
full O
mutation O
) O
in O
the O
f O
##m O
##r O
##1 O
gene O
responsible O
for O
this O
condition O
. O

h O
##yper O
##met O
##hyl O
##ation O
of O
the O
expanded O
repeat O
and O
of O
the O
f O
##m O
##r O
##1 O
promoter O
is O
almost O
always O
present O
and O
apparently O
suppress O
##es O
transcription O
, O
resulting O
in O
absence O
of O
the O
f O
##m O
##r O
##1 O
protein O
. O

we O
recently O
showed O
that O
transcription O
##al O
react O
##ivation O
of O
f O
##m O
##r O
##1 O
full O
mutations O
can O
be O
achieved O
by O
in O
##ducing O
d O
##na O
dem O
##eth O
##yla O
##tion O
with O
5 O
- O
a O
##zad O
##eo O
##xy O
##cy O
##ti O
##dine O
( O
5 O
- O
a O
##zad O
##c O
) O
. O

the O
level O
of O
his O
##tone O
ace O
##ty O
##lation O
is O
another O
important O
factor O
in O
regulating O
gene O
expression O
; O
therefore O
, O
we O
treated O
l O
##ymph O
##ob O
##last O
##oid O
cell O
lines O
of O
non O
- O
mosaic O
full O
mutation O
patients O
with O
three O
drugs O
capable O
of O
in O
##ducing O
his O
##tone O
h O
##yper O
##ace O
##ty O
##lation O
. O

we O
observed O
a O
consistent O
, O
although O
modest O
, O
react O
##ivation O
of O
the O
f O
##m O
##r O
##1 O
gene O
with O
4 O
- O
p O
##hen O
##yl O
##but O
##yra O
##te O
, O
sodium O
but O
##yra O
##te O
and O
t O
##rich O
##ost O
##ati O
##n O
a O
, O
as O
shown O
by O
r O
##t O
- O
p O
##c O
##r O
. O

however O
, O
we O
report O
that O
combining O
these O
drugs O
with O
5 O
- O
a O
##zad O
##c O
results O
in O
a O
2 O
- O
to O
5 O
- O
fold O
increase O
in O
f O
##m O
##r O
##1 O
m O
##rna O
levels O
obtained O
with O
5 O
- O
a O
##zad O
##c O
alone O
, O
thus O
showing O
a O
marked O
s O
##yne O
##rg O
##istic O
effect O
of O
his O
##tone O
h O
##yper O
##ace O
##ty O
##lation O
and O
d O
##na O
dem O
##eth O
##yla O
##tion O
in O
the O
react O
##ivation O
of O
f O
##m O
##r O
##1 O
full O
mutations O
. O
. O

constitutional O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( O
v B-Disease
##hl I-Disease
) O
gene O
del O
##eti O
##ons O
detected O
in O
v B-Disease
##hl I-Disease
families O
by O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
. O

von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
disease I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
##ly I-Disease
inherited I-Disease
cancer I-Disease
syndrome I-Disease
pre O
##dis O
##po O
##sing O
to O
a O
variety O
of O
tumor B-Disease
types O
that O
include O
re O
##tina O
##l O
hem B-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
, O
hem B-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
of O
the O
central O
nervous O
system O
, O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
pan B-Disease
##cre I-Disease
##atic I-Disease
c I-Disease
##ys I-Disease
##ts I-Disease
and I-Disease
tumors I-Disease
, O
p B-Disease
##he I-Disease
##och I-Disease
##rom I-Disease
##oc I-Disease
##yt I-Disease
##oma I-Disease
##s I-Disease
, O
end B-Disease
##oly I-Disease
##mp I-Disease
##hat I-Disease
##ic I-Disease
sa I-Disease
##c I-Disease
tumors I-Disease
, O
and O
e B-Disease
##pid I-Disease
##idy I-Disease
##mal I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##mas I-Disease
[ O
w O
. O

m O
. O

line O
##han O
et O
al O
. O
, O
j O
. O

am O
. O
me O
##d O
. O
ass O
##oc O
. O
, O
27 O
##3 O
56 O
##4 O
- O
570 O
, O
1995 O
; O
e O
. O
a O
. O
ma O
##her O
and O
w O
. O
g O
. O
ka O
##elin O
, O
j O
##r O
. O
, O
medicine O
( O
b O
##al O
##ti O
##more O
) O
, O
76 O
38 O
##1 O
- O
39 O
##1 O
, O
1997 O
; O
w O
. O
m O
. O
line O
##han O
and O
r O
. O
d O
. O
k O
##laus O
##ner O
, O
in O
b O
. O
v O
##ogel O
##stein O
and O
k O
. O
kin O
##zle O
##r O
( O
eds O
. O
) O
, O
the O
genetic O
basis O
of O
human O
cancer O
, O
pp O
. O

45 O
##5 O
- O
47 O
##3 O
, O
m O
##c O
##gra O
##w O
- O
hill O
, O
1998 O
] O
. O

the O
v B-Disease
##hl I-Disease
gene O
was O
localized O
to O
chromosome O
3 O
##p O
##25 O
- O
26 O
and O
clone O
##d O
[ O
f O
. O
la O
##ti O
##f O
et O
al O
. O
, O
science O
( O
washing O
##ton O
d O
##c O
) O
, O
260 O
131 O
##7 O
- O
132 O
##0 O
, O
1993 O
] O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
v B-Disease
##hl I-Disease
gene O
have O
been O
detected O
in O
the O
majority O
of O
v B-Disease
##hl I-Disease
kind O
##red O
##s O
. O

the O
reported O
frequency O
of O
detection O
of O
v B-Disease
##hl I-Disease
g O
##er O
##m O
##line O
mutations O
has O
varied O
from O
39 O
to O
80 O
% O
( O
j O
. O
m O
. O
whale O
##y O
et O
al O
. O
, O
am O
. O
j O
. O
hum O
. O
gene O
##t O
. O
, O
55 O
109 O
##2 O
- O
110 O
##2 O
, O
1994 O
; O
clinical O
research O
group O
for O
j O
##apa O
##n O
, O
hum O
. O
m O
##ol O
. O
gene O
##t O
. O
, O
4 O
223 O
##3 O
- O
223 O
##7 O
, O
1995 O
; O
f O
. O
ch O
##en O
et O
al O
. O
, O
hum O
. O
m O
##uta O
##t O
. O
, O
5 O
66 O
- O
75 O
, O
1995 O
; O
e O
. O
r O
. O
ma O
##her O
et O
al O
. O
, O
j O
. O
me O
##d O
. O
gene O
##t O
. O
, O
33 O
32 O
##8 O
- O
33 O
##2 O
, O
1996 O
; O
b O
. O
z O
##bar O
, O
cancer O
sur O
##v O
. O
, O
25 O
219 O
- O
232 O
, O
1995 O
) O
. O

recently O
a O
quantitative O
southern O
b O
##lot O
##ting O
procedure O
was O
found O
to O
improve O
this O
frequency O
( O
c O
. O
s O
##to O
##lle O
et O
al O
. O
, O
hum O
. O
m O
##uta O
##t O
. O
, O
12 O
41 O
##7 O
- O
42 O
##3 O
, O
1998 O
) O
. O

in O
the O
present O
study O
, O
we O
report O
the O
use O
of O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
( O
fish O
) O
as O
a O
method O
to O
detect O
and O
character O
##ize O
v B-Disease
##hl I-Disease
g O
##er O
##m O
##line O
del O
##eti O
##ons O
. O

we O
re O
##ex O
##amine O
##d O
a O
group O
of O
v B-Disease
##hl I-Disease
patients O
shown O
previously O
by O
single O
- O
strand O
conform O
##ation O
and O
se O
##quencing O
analysis O
not O
to O
harbor O
point O
mutations O
in O
the O
v B-Disease
##hl I-Disease
lo O
##cus O
. O

we O
found O
constitutional O
del O
##eti O
##ons O
in O
29 O
of O
30 O
v B-Disease
##hl I-Disease
patients O
in O
this O
group O
using O
co O
##sm O
##id O
and O
p O
##1 O
probe O
##s O
that O
cover O
the O
v B-Disease
##hl I-Disease
lo O
##cus O
. O

we O
then O
tested O
six O
p O
##hen O
##otypic O
##ally O
normal O
offspring O
from O
four O
of O
these O
v B-Disease
##hl I-Disease
families O
two O
were O
found O
to O
carry O
the O
del O
##eti O
##on O
and O
the O
other O
four O
were O
del O
##eti O
##on O
- O
free O
. O

in O
addition O
, O
g O
##er O
##m O
##line O
mosaic O
##ism O
of O
the O
v B-Disease
##hl I-Disease
gene O
was O
identified O
in O
one O
family O
. O

in O
sum O
, O
fish O
was O
found O
to O
be O
a O
simple O
and O
reliable O
method O
to O
detect O
v B-Disease
##hl I-Disease
g O
##er O
##m O
##line O
del O
##eti O
##ons O
and O
practically O
useful O
in O
cases O
where O
other O
methods O
of O
screening O
have O
failed O
to O
detect O
a O
v B-Disease
##hl I-Disease
gene I-Disease
abnormal I-Disease
##ity I-Disease

spectrum O
of O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
so O
##matic O
mutations O
in O
human O
cancer B-Disease
and O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
. O

the O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
gene O
which O
en O
##codes O
a O
member O
of O
the O
s O
##wi O
/ O
s O
##n O
##f O
ch O
##roma O
##tin O
at O
##p O
- O
dependent O
re O
##mo O
##del O
##ing O
complex O
, O
is O
a O
new O
tumor B-Disease
suppress O
##or O
gene O
localized O
on O
chromosome O
22 O
##q O
##11 O
. O

2 O
and O
recently O
shown O
to O
be O
m O
##uta O
##ted O
in O
ma B-Disease
##li I-Disease
##gnant I-Disease
r I-Disease
##hab I-Disease
##do I-Disease
##id I-Disease
tumors I-Disease
. O

we O
have O
searched O
for O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
mutations O
in O
229 O
tumors B-Disease
of O
various O
origins O
using O
a O
screening O
method O
based O
on O
den O
##at O
##uring O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
. O

a O
total O
of O
31 O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
and O
36 O
point O
alterations O
were O
identified O
. O

point O
mutations O
were O
scattered O
along O
the O
coding O
sequence O
and O
included O
15 O
nonsense O
, O
15 O
frames O
##hi O
##ft O
, O
three O
s O
##p O
##lice O
site O
, O
two O
miss O
##ense O
and O
one O
editing O
mutations O
. O

mutations O
were O
retrieved O
in O
most O
r B-Disease
##hab I-Disease
##do I-Disease
##id I-Disease
tumors I-Disease
, O
whatever O
their O
sites O
of O
occurrence O
, O
indicating O
the O
common O
path O
##ogen O
##etic O
origin O
of O
these O
tumors B-Disease
. O

re O
##current O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
alterations O
were O
also O
observed O
in O
ch B-Disease
##oro I-Disease
##id I-Disease
p I-Disease
##lex I-Disease
##us I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
and O
in O
a O
subset O
of O
central O
primitive O
ne B-Disease
##uro I-Disease
##ec I-Disease
##to I-Disease
##der I-Disease
##mal I-Disease
tumors I-Disease
( O
c O
##p O
##nets O
) O
and O
me B-Disease
##du I-Disease
##llo I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
. O

in O
contrast O
, O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
point O
mutations O
were O
not O
detected O
in O
breast B-Disease
cancer I-Disease
##s I-Disease
, O
w B-Disease
##il I-Disease
##ms I-Disease
tumors I-Disease
, O
g B-Disease
##lio I-Disease
##mas I-Disease
, O
e B-Disease
##pen I-Disease
##dy I-Disease
##mo I-Disease
##mas I-Disease
, O
sa B-Disease
##rc I-Disease
##oma I-Disease
##s I-Disease
and O
other O
tumor B-Disease
types O
, O
even O
though O
most O
analyzed O
cases O
harbor O
##ed O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
at O
22 O
##q O
##11 O
. O

2 O
lo O
##ci O
. O

these O
results O
suggest O
that O
r B-Disease
##hab I-Disease
##do I-Disease
##id I-Disease
tumors I-Disease
, O
ch B-Disease
##oro I-Disease
##id I-Disease
p I-Disease
##lex I-Disease
##us I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
and O
a O
subset O
of O
me B-Disease
##du I-Disease
##llo I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
and O
c O
##p O
##nets O
share O
common O
pathways O
of O
on O
##co O
##genesis O
related O
to O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
alter O
##ation O
and O
that O
h O
##s O
##n O
##f O
##5 O
/ O
in O
##i O
##1 O
mutations O
define O
a O
genetically O
ho O
##mogeneous O
family O
of O
highly O
aggressive O
cancer B-Disease
##s I-Disease
mainly O
occurring O
in O
young O
children O
and O
frequently O
, O
but O
not O
always O
, O
exhibiting O
a O
r B-Disease
##hab I-Disease
##do I-Disease
##id I-Disease
p O
##hen O
##otype O

at O
##ax O
##in O
- O
3 O
with O
an O
altered O
conform O
##ation O
that O
expose O
##s O
the O
p O
##oly O
##g O
##lut O
##amine O
domain O
is O
associated O
with O
the O
nuclear O
matrix O
. O

spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
type I-Disease
- I-Disease
3 I-Disease
or O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
s B-Disease
##ca I-Disease
##3 I-Disease
/ O
m B-Disease
##j I-Disease
##d I-Disease
) O
is O
a O
member O
of O
the O
ca B-Disease
##g I-Disease
/ I-Disease
p I-Disease
##oly I-Disease
##g I-Disease
##lut I-Disease
##amine I-Disease
repeat I-Disease
disease I-Disease
family O
. O

in O
this O
family O
of O
disorders O
, O
a O
normally O
p O
##oly O
##morphic O
ca O
##g O
repeat O
becomes O
expanded O
, O
resulting O
in O
expression O
of O
an O
expanded O
p O
##oly O
##g O
##lut O
##amine O
domain O
in O
the O
disease O
gene O
product O
. O

experimental O
models O
of O
p B-Disease
##oly I-Disease
##g I-Disease
##lut I-Disease
##amine I-Disease
disease I-Disease
imp O
##lica O
##te O
the O
nucleus O
in O
path O
##ogen O
##esis O
; O
however O
, O
the O
link O
between O
in O
##tra O
##nu O
##cle O
##ar O
expression O
of O
expanded O
p O
##oly O
##g O
##lut O
##amine O
and O
ne B-Disease
##uron I-Disease
##al I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
remains O
unclear O
. O

here O
we O
demonstrate O
that O
at O
##ax O
##in O
- O
3 O
, O
the O
disease O
protein O
in O
s B-Disease
##ca I-Disease
##3 I-Disease
/ O
m B-Disease
##j I-Disease
##d I-Disease
, O
adopt O
##s O
a O
unique O
conform O
##ation O
when O
expressed O
within O
the O
nucleus O
of O
trans O
##fected O
cells O
. O

the O
mon O
##oc O
##lon O
##al O
anti O
##body O
1 O
##c O
##2 O
is O
known O
prefer O
##ential O
##ly O
to O
bind O
expanded O
p O
##oly O
##g O
##lut O
##amine O
, O
but O
we O
find O
that O
it O
also O
binds O
a O
fragment O
of O
at O
##ax O
##in O
- O
3 O
containing O
a O
normal O
g O
##lut O
##amine O
repeat O
. O

in O
addition O
, O
expression O
of O
at O
##ax O
##in O
- O
3 O
within O
the O
nucleus O
expose O
##s O
the O
g O
##lut O
##amine O
domain O
of O
the O
full O
- O
length O
non O
- O
path O
##ological O
protein O
, O
allowing O
it O
to O
bind O
the O
mon O
##oc O
##lon O
##al O
anti O
##body O
1 O
##c O
##2 O
. O

fraction O
##ation O
and O
im O
##mu O
##no O
##chemical O
experiments O
indicate O
that O
this O
novel O
conform O
##ation O
of O
in O
##tra O
##nu O
##cle O
##ar O
at O
##ax O
##in O
- O
3 O
is O
not O
due O
to O
pro O
##te O
##oly O
##sis O
, O
suggesting O
instead O
that O
association O
with O
nuclear O
protein O
( O
s O
) O
alter O
##s O
the O
structure O
of O
full O
- O
length O
at O
##ax O
##in O
- O
3 O
which O
expose O
##s O
the O
p O
##oly O
##g O
##lut O
##amine O
domain O
. O

this O
conform O
##ational O
##ly O
altered O
at O
##ax O
##in O
- O
3 O
is O
bound O
to O
the O
nuclear O
matrix O
. O

the O
path O
##ological O
form O
of O
at O
##ax O
##in O
- O
3 O
with O
an O
expanded O
p O
##oly O
##g O
##lut O
##amine O
domain O
also O
associates O
with O
the O
nuclear O
matrix O
. O

these O
data O
suggest O
that O
an O
early O
event O
in O
the O
path O
##ogen O
##esis O
of O
s B-Disease
##ca I-Disease
##3 I-Disease
/ O
m B-Disease
##j I-Disease
##d I-Disease
may O
be O
an O
altered O
conform O
##ation O
of O
at O
##ax O
##in O
- O
3 O
within O
the O
nucleus O
that O
expose O
##s O
the O
p O
##oly O
##g O
##lut O
##amine O
domain O
. O
. O

the O
human O
mage O
##l O
##2 O
gene O
and O
its O
mouse O
ho O
##mo O
##logue O
are O
paternal O
##ly O
expressed O
and O
mapped O
to O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
region O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
is O
a O
complex O
ne B-Disease
##uro I-Disease
##gene I-Disease
##tic I-Disease
disorder I-Disease
. O

the O
p O
##hen O
##otype O
is O
likely O
to O
be O
a O
con B-Disease
##ti I-Disease
##guous I-Disease
gene I-Disease
syndrome I-Disease
involving O
genes O
which O
are O
paternal O
##ly O
expressed O
only O
, O
located O
in O
the O
human O
15 O
##q O
##11 O
- O
q O
##13 O
region O
. O

four O
mouse O
models O
of O
p B-Disease
##ws I-Disease
have O
been O
reported O
but O
these O
do O
not O
definitive O
##ly O
allow O
the O
del O
##ine O
##ation O
of O
the O
critical O
region O
and O
the O
associated O
genes O
involved O
in O
the O
a O
##eti O
##ology O
of O
p B-Disease
##ws I-Disease
. O

more O
##over O
, O
targeted O
m O
##uta O
##genesis O
of O
mouse O
ho O
##mo O
##logue O
##s O
of O
the O
human O
candidate O
p B-Disease
##ws I-Disease
genes O
does O
not O
appear O
to O
result O
in O
any O
of O
the O
features O
of O
p B-Disease
##ws I-Disease
. O

therefore O
, O
the O
isolation O
of O
new O
genes O
in O
this O
region O
remains O
crucial O
for O
a O
better O
understanding O
of O
the O
molecular O
basis O
of O
p B-Disease
##ws I-Disease
. O

in O
this O
manuscript O
, O
we O
report O
the O
characterization O
of O
mage O
##l O
##2 O
and O
its O
mouse O
ho O
##mo O
##logue O
mage O
##l O
##2 O
. O

these O
are O
located O
in O
the O
human O
15 O
##q O
##11 O
- O
q O
##13 O
and O
mouse O
7 O
##c O
regions O
, O
in O
close O
proximity O
to O
n O
##dn O
/ O
n O
##dn O
. O

by O
northern O
b O
##lot O
analysis O
we O
did O
not O
detect O
any O
expression O
of O
mage O
##l O
##2 O
/ O
mage O
##l O
##2 O
but O
by O
r O
##t O
- O
p O
##c O
##r O
analysis O
, O
specific O
expression O
was O
detected O
in O
f O
##etal O
and O
adult O
brain O
and O
in O
place O
##nta O
. O

both O
genes O
are O
intro O
##n O
##less O
with O
tandem O
direct O
repeat O
sequences O
contained O
within O
a O
c O
##p O
##g O
island O
in O
the O
5 O
- O
un O
##tra O
##ns O
##cribed O
region O
. O

the O
trans O
##cripts O
en O
##code O
put O
##ative O
proteins O
that O
are O
ho O
##mo O
##log O
##ous O
to O
the O
mage O
proteins O
and O
n O
##dn O
. O

more O
##over O
, O
mage O
##l O
##2 O
/ O
mage O
##l O
##2 O
are O
expressed O
only O
from O
the O
paternal O
all O
##ele O
in O
brain O
, O
suggesting O
a O
potential O
role O
in O
the O
a O
##eti O
##ology O
of O
p B-Disease
##ws I-Disease
and O
its O
mouse O
model O
, O
respectively O
. O
. O

c O
##dn O
##a O
micro O
##arra O
##ys O
detect O
activation O
of O
a O
my O
##ogenic O
transcription O
program O
by O
the O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
fusion O
on O
##co O
##gene O
. O

al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
is O
an O
aggressive O
p B-Disease
##ediatric I-Disease
cancer I-Disease
of I-Disease
s I-Disease
##tri I-Disease
##ated I-Disease
muscle I-Disease
characterized O
in O
60 O
% O
of O
cases O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q O
##35 O
; O
q O
##14 O
) O
. O

this O
results O
in O
the O
fusion O
of O
p O
##ax O
##3 O
, O
a O
developmental O
transcription O
factor O
required O
for O
limb O
my O
##ogen O
##esis O
, O
with O
f O
##kh O
##r O
, O
a O
member O
of O
the O
fork O
##head O
family O
of O
transcription O
factors O
. O

the O
result O
##ant O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
gene O
possesses O
transforming O
properties O
; O
however O
, O
the O
effects O
of O
this O
ch O
##ime O
##ric O
on O
##co O
##gene O
on O
gene O
expression O
are O
largely O
unknown O
. O

to O
investigate O
the O
actions O
of O
these O
transcription O
factors O
, O
both O
p O
##ax O
##3 O
and O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
were O
introduced O
into O
ni O
##h O
3 O
##t O
##3 O
cells O
, O
and O
the O
result O
##ant O
gene O
expression O
changes O
were O
analyzed O
with O
a O
m O
##uri O
##ne O
c O
##dn O
##a O
micro O
##arra O
##y O
containing O
2 O
, O
225 O
elements O
. O

we O
found O
that O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
but O
not O
p O
##ax O
##3 O
activated O
a O
my O
##ogenic O
transcription O
program O
including O
the O
induction O
of O
transcription O
factors O
my O
##od O
, O
my O
##ogen O
##in O
, O
six O
##1 O
, O
and O
s O
##lug O
as O
well O
as O
a O
battery O
of O
genes O
involved O
in O
several O
aspects O
of O
muscle O
function O
. O

notable O
among O
this O
group O
were O
the O
growth O
factor O
gene O
i O
##g O
##f O
##2 O
and O
its O
binding O
protein O
i O
##g O
##f O
##b O
##p O
##5 O
. O

relevance O
of O
this O
model O
was O
suggested O
by O
ve O
##rification O
that O
three O
of O
these O
genes O
( O
i O
##g O
##f O
##b O
##p O
##5 O
, O
h O
##si O
##x O
##1 O
, O
and O
s O
##lug O
) O
were O
also O
expressed O
in O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
cell O
lines O
. O

this O
study O
utilizes O
c O
##dn O
##a O
micro O
##arra O
##ys O
to O
el O
##uc O
##ida O
##te O
the O
pattern O
of O
gene O
expression O
induced O
by O
an O
on O
##co O
##genic O
transcription O
factor O
and O
demonstrates O
the O
profound O
my O
##ogenic O
properties O
of O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
in O
ni O
##h O
3 O
##t O
##3 O
cells O
. O
. O

experimental O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
due O
to O
m O
##h O
##c O
class O
i O
h B-Disease
##fe I-Disease
deficiency I-Disease
: O
immune O
status O
and O
iron O
metabolism O
. O

the O
pu O
##zzling O
link O
##age O
between O
genetic O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
and O
his O
##to O
##com O
##pa O
##ti O
##bility O
lo O
##ci O
became O
even O
more O
so O
when O
the O
gene O
involved O
, O
h O
##fe O
, O
was O
identified O
. O

indeed O
, O
within O
the O
well O
defined O
, O
mainly O
p O
##eptide O
- O
binding O
, O
m O
##h O
##c O
class O
i O
family O
of O
molecules O
, O
h O
##fe O
seems O
to O
perform O
an O
unusual O
yet O
essential O
function O
. O

as O
yet O
, O
our O
understanding O
of O
h O
##fe O
function O
in O
iron O
home O
##ost O
##asis O
is O
only O
partial O
; O
an O
even O
more O
open O
question O
is O
its O
possible O
role O
in O
the O
immune O
system O
. O

to O
advance O
on O
both O
of O
these O
avenue O
##s O
, O
we O
report O
the O
del O
##eti O
##on O
of O
h O
##fe O
alpha O
##1 O
and O
alpha O
##2 O
put O
##ative O
l O
##igan O
##d O
binding O
domains O
in O
v O
##ivo O
. O

h B-Disease
##fe I-Disease
- I-Disease
def I-Disease
##icient I-Disease
animals O
were O
analyzed O
for O
a O
comprehensive O
set O
of O
metabolic O
and O
immune O
parameters O
. O

faithful O
##ly O
mimic O
##king O
human O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
, O
mice O
ho O
##mo O
##zy O
##go O
##us O
for O
this O
del O
##eti O
##on O
develop O
iron O
over O
##load O
, O
characterized O
by O
a O
higher O
plasma O
iron O
content O
and O
a O
raised O
transfer O
##rin O
sat O
##uration O
as O
well O
as O
an O
elevated O
he O
##pa O
##tic O
iron O
load O
. O

the O
primary O
defect O
could O
, O
indeed O
, O
be O
traced O
to O
an O
augmented O
duo O
##den O
##al O
iron O
absorption O
. O

in O
parallel O
, O
measurement O
of O
the O
gut O
m O
##uc O
##osa O
##l O
iron O
content O
as O
well O
as O
iron O
regulatory O
proteins O
allows O
a O
more O
informed O
evaluation O
of O
various O
h O
##y O
##pot O
##heses O
regarding O
the O
precise O
role O
of O
h O
##fe O
in O
iron O
home O
##ost O
##asis O
. O

finally O
, O
an O
extensive O
p O
##hen O
##ot O
##y O
##ping O
of O
primary O
and O
secondary O
l O
##ymph O
##oid O
organs O
including O
the O
gut O
provides O
no O
compelling O
evidence O
for O
an O
obvious O
immune O
- O
linked O
function O
for O
h O
##fe O
. O
. O

so O
##matic O
rear O
##rang O
##ement O
of O
chromosome O
14 O
in O
human O
l O
##ymph O
##ocytes O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
is O
a O
rare O
genetic B-Disease
disorder I-Disease
associated O
with O
immune B-Disease
deficiency I-Disease
, O
chromosome B-Disease
instability I-Disease
, O
and O
a O
pre O
##dis O
##position O
to O
l B-Disease
##ymph I-Disease
##oid I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
. O

we O
have O
detected O
ch O
##rom O
##oso O
##mal O
##ly O
an O
##oma O
##lous O
clone O
##s O
of O
l O
##ymph O
##ocytes O
in O
eight O
patients O
with O
this O
disorder O
. O

chromosome O
band O
##ing O
disclosed O
that O
the O
clone O
##s O
are O
consistently O
marked O
by O
structural O
rear O
##rang O
##ement O
of O
the O
long O
arm O
( O
q O
) O
of O
chromosome O
14 O
. O

a O
trans O
##location O
involving O
14 O
##q O
was O
found O
in O
clone O
##s O
obtained O
from O
seven O
of O
the O
eight O
patients O
whereas O
a O
ring O
14 O
chromosome O
was O
found O
in O
a O
clone O
obtained O
from O
the O
other O
. O

these O
findings O
as O
well O
as O
data O
obtained O
by O
others O
for O
patients O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
suggest O
that O
structural O
rear O
##rang O
##ement O
of O
14 O
##q O
is O
the O
initial O
ch O
##rom O
##oso O
##mal O
change O
in O
l O
##ymph O
##oc O
##yte O
clone O
##s O
of O
patients O
with O
this O
disorder O
. O

chromosome O
##s O
of O
l O
##ymph O
##ocytes O
from O
one O
of O
the O
patients O
were O
studied O
before O
and O
after O
the O
onset O
of O
chronic B-Disease
l I-Disease
##ymph I-Disease
##oc I-Disease
##ytic I-Disease
le I-Disease
##uke I-Disease
##mia I-Disease
. O

before O
le B-Disease
##uke I-Disease
##mia I-Disease
was O
diagnosed O
, O
the O
patient O
had O
a O
l O
##ymph O
##oc O
##yte O
clone O
with O
a O
14 O
##q O
trans O
##location O
. O

this O
clone O
appears O
to O
have O
given O
rise O
to O
the O
le B-Disease
##uke I-Disease
##mic I-Disease
cells O
. O

we O
h O
##y O
##pot O
##hes O
##ize O
that O
structural O
rear O
##rang O
##ement O
of O
14 O
##q O
is O
directly O
related O
to O
abnormal O
growth O
of O
l O
##ymph O
##ocytes O
and O
that O
it O
may O
be O
a O
step O
toward O
the O
development O
of O
l B-Disease
##ymph I-Disease
##oid I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncies I-Disease
. O

increasing O
evidence O
, O
provided O
by O
others O
, O
for O
the O
non O
##rand O
##om O
involvement O
of O
14 O
##q O
in O
a O
##f O
##rica O
##n O
- O
type O
b B-Disease
##ur I-Disease
##ki I-Disease
##tts I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
and O
other O
l B-Disease
##ymph I-Disease
##oid I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
further O
strengthen O
##s O
this O
hypothesis O
. O
. O

ex O
##on O
9 O
mutations O
in O
the O
w O
##t O
##1 O
gene O
, O
without O
in O
##f O
##lue O
##ncing O
k O
##ts O
s O
##p O
##lice O
is O
##of O
##orms O
, O
are O
also O
responsible O
for O
f B-Disease
##ras I-Disease
##ier I-Disease
syndrome I-Disease
. O

we O
report O
new O
mutations O
in O
ex O
##on O
9 O
of O
the O
w O
##t O
##1 O
gene O
that O
did O
not O
alter O
the O
ratio O
of O
+ O
/ O
- O
k O
##ts O
s O
##p O
##lice O
is O
##of O
##orms O
in O
two O
unrelated O
patients O
with O
f B-Disease
##ras I-Disease
##ier I-Disease
syndrome I-Disease
( O
f B-Disease
##s I-Disease
) O
. O

the O
mutation O
of O
intro O
##n O
9 O
in O
##ducing O
defect O
##ive O
alternative O
s O
##p O
##licing O
was O
reported O
to O
be O
responsible O
for O
this O
syndrome O
. O

the O
mutations O
found O
in O
our O
cases O
occurred O
in O
the O
same O
ex O
##on O
of O
the O
w O
##t O
##1 O
gene O
as O
detected O
in O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
( O
d B-Disease
##ds I-Disease
) O
and O
could O
not O
be O
explained O
by O
the O
previously O
proposed O
mechanism O
. O

the O
results O
suggest O
that O
the O
two O
syndrome O
##s O
originate O
from O
the O
same O
w B-Disease
##t I-Disease
##1 I-Disease
gene I-Disease
abnormal I-Disease
##ity I-Disease
. O

from O
a O
molecular O
biological O
point O
of O
view O
, O
we O
concluded O
that O
the O
two O
diseases O
were O
not O
se O
##par O
##able O
, O
and O
that O
f B-Disease
##s I-Disease
should O
be O
included O
as O
an O
at O
##y O
##pical O
form O
of O
d B-Disease
##ds I-Disease
. O
. O

s O
##p O
##lice O
- O
site O
mutation O
in O
the O
p B-Disease
##ds I-Disease
gene O
may O
result O
in O
in O
##tra O
##fa O
##mi O
##lial O
var O
##iability O
for O
deaf B-Disease
##ness I-Disease
in O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
is O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
inherited I-Disease
disorder I-Disease
that O
consists O
of O
developmental B-Disease
abnormal I-Disease
##ities I-Disease
of I-Disease
the I-Disease
co I-Disease
##ch I-Disease
##lea I-Disease
, O
sensor B-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
, O
and O
di B-Disease
##ff I-Disease
##use I-Disease
thy I-Disease
##roid I-Disease
en I-Disease
##lar I-Disease
##gement I-Disease
( O
go B-Disease
##iter I-Disease
) O
. O

this O
disorder O
may O
account O
for O
up O
to O
10 O
% O
of O
cases O
of O
hereditary B-Disease
deaf I-Disease
##ness I-Disease
. O

the O
disease O
gene O
( O
p B-Disease
##ds I-Disease
) O
has O
been O
mapped O
to O
chromosome O
7 O
##q O
##22 O
- O
q O
##31 O
, O
and O
en O
##codes O
a O
chloride O
- O
i O
##od O
##ide O
transport O
protein O
. O

we O
performed O
mutation O
analysis O
of O
individual O
ex O
##ons O
of O
the O
p B-Disease
##ds I-Disease
gene O
in O
one O
span O
##ish O
family O
that O
shows O
in O
##tra O
##fa O
##mi O
##lial O
var O
##iability O
of O
the O
deaf B-Disease
##ness I-Disease
p O
##hen O
##otype O
( O
two O
patients O
with O
profound O
and O
one O
with O
moderate O
- O
severe O
deaf B-Disease
##ness I-Disease
) O
. O

we O
identified O
a O
new O
s O
##p O
##lice O
- O
site O
mutation O
affecting O
intro O
##n O
4 O
of O
the O
p B-Disease
##ds I-Disease
gene O
, O
at O
n O
##uc O
##leo O
##tide O
position O
63 O
##9 O
+ O
7 O
. O

r O
##na O
analysis O
from O
l O
##ymph O
##ocytes O
of O
the O
affected O
patients O
showed O
that O
mutation O
63 O
##9 O
+ O
7 O
##a O
- O
- O
[UNK] O
g O
generates O
a O
new O
donor O
s O
##p O
##lice O
site O
, O
leading O
to O
an O
m O
##rna O
with O
an O
insertion O
of O
six O
n O
##uc O
##leo O
##tide O
##s O
from O
intro O
##n O
4 O
of O
p O
##ds O
. O

since O
the O
newly O
created O
donor O
s O
##p O
##lice O
site O
is O
likely O
to O
compete O
with O
the O
normal O
one O
, O
variations O
of O
the O
levels O
of O
normal O
and O
a O
##ber O
##rant O
trans O
##cripts O
of O
the O
p B-Disease
##ds I-Disease
gene O
in O
the O
co O
##ch O
##lea O
may O
explain O
the O
var O
##iability O
in O
the O
deaf B-Disease
##ness I-Disease
presentation O
. O
. O

the O
molecular O
basis O
of O
s B-Disease
##jo I-Disease
##gren I-Disease
- I-Disease
la I-Disease
##rs I-Disease
##son I-Disease
syndrome I-Disease
: O
mutation O
analysis O
of O
the O
fatty O
al O
##de O
##hy O
##de O
de O
##hy O
##dr O
##ogen O
##ase O
gene O
. O

s B-Disease
##jo I-Disease
##gren I-Disease
- I-Disease
la I-Disease
##rs I-Disease
##son I-Disease
syndrome I-Disease
( O
s B-Disease
##ls I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
i B-Disease
##cht I-Disease
##hy I-Disease
##osis I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
spa B-Disease
##stic I-Disease
##ity I-Disease
, O
and O
def B-Disease
##icient I-Disease
activity I-Disease
of I-Disease
fatty I-Disease
al I-Disease
##de I-Disease
##hy I-Disease
##de I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( O
f O
##ald O
##h O
) O
. O

to O
define O
the O
molecular O
defects O
causing O
s B-Disease
##ls I-Disease
, O
we O
performed O
mutation O
analysis O
of O
the O
f O
##ald O
##h O
gene O
in O
pro O
##band O
##s O
from O
63 O
kind O
##red O
##s O
with O
s B-Disease
##ls I-Disease
. O

among O
these O
patients O
, O
49 O
different O
mutations O
- O
including O
10 O
del O
##eti O
##ons O
, O
2 O
insertion O
##s O
, O
22 O
amino O
acid O
substitution O
##s O
, O
3 O
nonsense O
mutations O
, O
9 O
s O
##p O
##lice O
- O
site O
defects O
, O
and O
3 O
complex O
mutations O
- O
were O
found O
. O

all O
of O
the O
patients O
with O
s B-Disease
##ls I-Disease
were O
found O
to O
carry O
mutations O
. O

nineteen O
of O
the O
miss O
##ense O
mutations O
resulted O
in O
a O
severe O
reduction O
of O
f O
##ald O
##h O
enzyme O
cat O
##alytic O
activity O
when O
expressed O
in O
ma O
##mmal O
##ian O
cells O
, O
but O
one O
mutation O
( O
79 O
##8 O
##g O
- O
- O
[UNK] O
c O
[ O
k O
##26 O
##6 O
##n O
] O
) O
seemed O
to O
have O
a O
greater O
effect O
on O
m O
##rna O
stability O
. O

the O
s O
##p O
##lice O
- O
site O
mutations O
led O
to O
ex O
##on O
skip O
##ping O
or O
u O
##til O
##ization O
of O
cry O
##ptic O
accept O
##or O
- O
s O
##p O
##lice O
sites O
. O

thirty O
- O
seven O
mutations O
were O
private O
, O
and O
12 O
mutations O
were O
seen O
in O
two O
or O
more O
pro O
##band O
##s O
of O
euro O
##pe O
##an O
or O
middle O
eastern O
descent O
. O

four O
single O
- O
n O
##uc O
##leo O
##tide O
p O
##oly O
##mor O
##phism O
##s O
( O
s O
##n O
##ps O
) O
were O
found O
in O
the O
f O
##ald O
##h O
gene O
. O

at O
least O
four O
of O
the O
common O
mutations O
( O
55 O
##1 O
##c O
- O
- O
[UNK] O
t O
, O
68 O
##2 O
##c O
- O
- O
[UNK] O
t O
, O
73 O
##3 O
##g O
- O
- O
[UNK] O
a O
, O
and O
79 O
##8 O
+ O
1 O
##del O
##g O
) O
were O
associated O
with O
multiple O
s O
##n O
##p O
ha O
##p O
##lot O
##ype O
##s O
, O
suggesting O
that O
these O
mutations O
originated O
independently O
on O
more O
than O
one O
occasion O
or O
were O
ancient O
s B-Disease
##ls I-Disease
genes O
that O
had O
undergone O
in O
##tra O
##genic O
re O
##comb O
##ination O
. O

our O
results O
demonstrate O
that O
s B-Disease
##ls I-Disease
is O
caused O
by O
a O
striking O
##ly O
he O
##tero O
##gene O
##ous O
group O
of O
mutations O
in O
the O
f O
##ald O
##h O
gene O
and O
provide O
a O
framework O
for O
understanding O
the O
genetic O
basis O
of O
s B-Disease
##ls I-Disease
and O
the O
development O
of O
d O
##na O
- O
based O
diagnostic O
tests O
. O
. O

loss O
- O
of O
- O
function O
mutations O
in O
the O
cat O
##he O
##ps O
##in O
c O
gene O
result O
in O
period B-Disease
##ont I-Disease
##al I-Disease
disease I-Disease
and O
palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
k I-Disease
##era I-Disease
##tosis I-Disease
. O

p B-Disease
##ap I-Disease
##illo I-Disease
##n I-Disease
- I-Disease
le I-Disease
##fe I-Disease
##vre I-Disease
syndrome I-Disease
, O
or O
k B-Disease
##era I-Disease
##tosis I-Disease
palm I-Disease
##op I-Disease
##lant I-Disease
##aris I-Disease
with O
period B-Disease
##ont I-Disease
##op I-Disease
##ath I-Disease
##ia I-Disease
( O
p B-Disease
##ls I-Disease
, O
mi O
##m O
245 O
##00 O
##0 O
) O
, O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
that O
is O
mainly O
as O
##cer O
##tain O
##ed O
by O
den O
##tist O
##s O
because O
of O
the O
severe O
period B-Disease
##ont I-Disease
##itis I-Disease
that O
a O
##ff O
##lic O
##ts O
patients O
. O

both O
the O
deciduous O
and O
permanent O
den O
##ti O
##tions O
are O
affected O
, O
resulting O
in O
premature O
tooth B-Disease
loss I-Disease
. O

palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
k I-Disease
##era I-Disease
##tosis I-Disease
, O
varying O
from O
mild O
ps O
##oria O
##si O
##form O
s O
##cal O
##y O
skin O
to O
over O
##t O
h B-Disease
##yper I-Disease
##ker I-Disease
##ato I-Disease
##sis I-Disease
, O
typically O
develops O
within O
the O
first O
three O
years O
of O
life O
. O

k B-Disease
##era I-Disease
##tosis I-Disease
also O
affects O
other O
sites O
such O
as O
elbows O
and O
knees O
. O

most O
p B-Disease
##ls I-Disease
patients O
display O
both O
period B-Disease
##ont I-Disease
##itis I-Disease
and O
h B-Disease
##yper I-Disease
##ker I-Disease
##ato I-Disease
##sis I-Disease
. O

some O
patients O
have O
only O
palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
k I-Disease
##era I-Disease
##tosis I-Disease
or O
period B-Disease
##ont I-Disease
##itis I-Disease
, O
and O
in O
rare O
individuals O
the O
period B-Disease
##ont I-Disease
##itis I-Disease
is O
mild O
and O
of O
late O
onset O
. O

the O
p O
##ls O
lo O
##cus O
has O
been O
mapped O
to O
chromosome O
11 O
##q O
##14 O
- O
q O
##21 O
( O
re O
##fs O
7 O
, O
8 O
, O
9 O
) O
. O

using O
ho O
##mo O
##zy O
##gos O
##ity O
mapping O
in O
eight O
small O
con O
##sang O
##uin O
##eous O
families O
, O
we O
have O
narrowed O
the O
candidate O
region O
to O
a O
1 O
. O

2 O
- O
cm O
interval O
between O
d O
##11 O
##s O
##40 O
##8 O
##2 O
and O
d O
##11 O
##s O
##9 O
##31 O
. O

the O
gene O
( O
c O
##ts O
##c O
) O
encoding O
the O
l O
##ys O
##oso O
##mal O
pro O
##te O
##ase O
cat O
##he O
##ps O
##in O
c O
( O
or O
dip O
##ept O
##idy O
##l O
amino O
##pe O
##pt O
##idas O
##e O
i O
) O
lies O
within O
this O
interval O
. O

we O
defined O
the O
g O
##eno O
##mic O
structure O
of O
c O
##ts O
##c O
and O
found O
mutations O
in O
all O
eight O
families O
. O

in O
two O
of O
these O
families O
we O
used O
a O
functional O
ass O
##ay O
to O
demonstrate O
an O
almost O
total O
loss O
of O
cat O
##he O
##ps O
##in O
c O
activity O
in O
p B-Disease
##ls I-Disease
patients O
and O
reduced O
activity O
in O
o O
##b O
##liga O
##te O
carriers O
. O

confirmation O
of O
link O
##age O
of O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
to O
chromosome O
1 O
##q O
##32 O
: O
evidence O
of O
association O
with O
s O
##tr O
all O
##ele O
##s O
suggests O
possible O
unique O
origin O
of O
the O
disease O
mutation O
. O

van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
( O
v B-Disease
##ws I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
c I-Disease
##rani I-Disease
##of I-Disease
##ac I-Disease
##ial I-Disease
disorder I-Disease
with O
high O
pen O
##et O
##rance O
and O
variable O
expression O
. O

its O
clinical O
features O
are O
var O
##iably O
expressed O
, O
but O
include O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
and O
/ O
or O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
, O
lip B-Disease
pits I-Disease
and O
h B-Disease
##y I-Disease
##po I-Disease
##don I-Disease
##tia I-Disease
. O

all O
v B-Disease
##ws I-Disease
families O
studied O
to O
date O
map O
the O
disease O
gene O
to O
a O
[UNK] O
2 O
cm O
region O
of O
chromosome O
1 O
##q O
##32 O
, O
with O
no O
evidence O
of O
lo O
##cus O
he O
##tero O
##gene O
##ity O
. O

the O
aim O
of O
this O
study O
is O
to O
re O
##fine O
the O
local O
##ization O
of O
the O
v B-Disease
##ws I-Disease
gene O
and O
to O
further O
assess O
possible O
he O
##tero O
##gene O
##ity O
. O

we O
analyzed O
four O
multiple O
##x O
v B-Disease
##ws I-Disease
families O
. O

all O
available O
members O
were O
clinical O
##ly O
assessed O
and O
g O
##eno O
##type O
##d O
for O
19 O
short O
tandem O
repeat O
markers O
on O
chromosome O
1 O
in O
the O
v B-Disease
##ws I-Disease
candidate O
gene O
region O
. O

we O
performed O
two O
- O
point O
and O
multi O
##point O
limit O
of O
detection O
( O
lo O
##d O
) O
score O
analyses O
using O
a O
high O
pen O
##et O
##rance O
auto O
##so O
##mal O
dominant O
model O
. O

all O
families O
showed O
positive O
lo O
##d O
scores O
without O
any O
re O
##comb O
##ination O
in O
the O
candidate O
region O
. O

the O
largest O
two O
- O
point O
lo O
##d O
score O
was O
5 O
. O

87 O
87 O
. O

our O
ass O
##ay O
method O
for O
short O
tandem O
repeat O
( O
s O
##tr O
) O
markers O
provided O
highly O
accurate O
size O
est O
##imation O
of O
marker O
all O
##ele O
fragment O
sizes O
, O
and O
therefore O
enabled O
us O
to O
determine O
the O
specific O
all O
##ele O
##s O
se O
##g O
##re O
##gating O
with O
the O
v B-Disease
##ws I-Disease
gene O
in O
each O
of O
our O
four O
families O
. O

we O
observed O
a O
striking O
pattern O
of O
s O
##tr O
all O
##ele O
sharing O
at O
several O
closely O
linked O
lo O
##ci O
among O
our O
four O
ca O
##uca O
##sian O
v B-Disease
##ws I-Disease
families O
recruited O
at O
three O
different O
locations O
in O
the O
us O
. O

these O
results O
suggest O
the O
possibility O
of O
a O
unique O
origin O
for O
a O
mutation O
responsible O
for O
many O
or O
most O
cases O
of O
v B-Disease
##ws I-Disease
. O

a O
point O
mutation O
th O
##r O
( O
79 O
##9 O
) O
met O
on O
the O
alpha O
( O
2 O
) O
in O
##te O
##g O
##rin O
leads O
to O
the O
formation O
of O
new O
human O
plate O
##let O
all O
##oan O
##ti O
##gen O
sit O
( O
a O
) O
and O
affects O
co O
##lla O
##gen O
- O
induced O
a O
##gg O
##regation O
. O

a O
new O
plate O
##let O
- O
specific O
all O
##oan O
##ti O
##gen O
, O
termed O
sit O
( O
a O
) O
, O
was O
identified O
in O
a O
severe O
case O
of O
neon B-Disease
##ata I-Disease
##l I-Disease
all I-Disease
##oi I-Disease
##mm I-Disease
##une I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

the O
sit O
( O
a O
) O
all O
##oan O
##ti O
##gen O
is O
of O
low O
frequency O
( O
1 O
/ O
400 O
) O
in O
the O
g O
##erman O
population O
. O

im O
##mu O
##no O
##chemical O
studies O
demonstrated O
that O
the O
sit O
( O
a O
) O
e O
##pit O
##ope O
##s O
reside O
on O
plate O
##let O
g O
##ly O
##co O
##p O
##rote O
##in O
( O
g O
##p O
) O
i O
##a O
. O

n O
##uc O
##leo O
##tide O
sequence O
analysis O
of O
g O
##pia O
c O
##dn O
##a O
derived O
from O
sit O
( O
a O
) O
- O
positive O
plate O
##lets O
showed O
c O
( O
253 O
##1 O
) O
- O
- O
[UNK] O
t O
( O
253 O
##1 O
) O
point O
mutation O
, O
resulting O
in O
th O
##r O
( O
79 O
##9 O
) O
met O
dim O
##or O
##phism O
. O

analysis O
of O
g O
##eno O
##mic O
d O
##na O
from O
22 O
sit O
( O
a O
) O
- O
negative O
normal O
individuals O
showed O
that O
the O
th O
##r O
( O
79 O
##9 O
) O
is O
encoded O
by O
a O
##c O
##g O
( O
253 O
##2 O
) O
( O
90 O
. O
9 O
% O
) O
or O
a O
##ca O
( O
253 O
##2 O
) O
( O
9 O
. O
1 O
% O
) O
. O

to O
establish O
a O
d O
##na O
typing O
technique O
, O
we O
el O
##uc O
##idated O
the O
organization O
of O
the O
g O
##pia O
gene O
adjacent O
to O
the O
p O
##oly O
##morphic O
bases O
. O

the O
intro O
##ns O
( O
42 O
##1 O
b O
##p O
and O
1 O
. O
2 O
k O
##b O
) O
en O
##com O
##pass O
a O
142 O
- O
b O
##p O
ex O
##on O
with O
the O
2 O
p O
##oly O
##morphic O
bases O
253 O
##1 O
and O
253 O
##2 O
. O

polymer O
##ase O
chain O
reaction O
- O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
analysis O
on O
d O
##na O
derived O
from O
100 O
donors O
using O
the O
restriction O
enzyme O
ma O
##e O
ii O
##i O
showed O
that O
the O
met O
( O
79 O
##9 O
) O
form O
of O
g O
##pia O
is O
restricted O
to O
sit O
( O
a O
) O
( O
+ O
) O
p O
##hen O
##otype O
. O

analysis O
of O
stable O
chin O
##ese O
ha O
##ms O
##ter O
o O
##vary O
trans O
##fect O
##ants O
expressing O
all O
##ele O
- O
specific O
re O
##comb O
##ina O
##nt O
forms O
of O
g O
##pia O
showed O
that O
anti O
- O
sit O
( O
a O
) O
exclusively O
reacted O
with O
the O
g O
##lu O
( O
50 O
##5 O
) O
met O
( O
79 O
##9 O
) O
, O
but O
not O
with O
the O
g O
##lu O
( O
50 O
##5 O
) O
th O
##r O
( O
79 O
##9 O
) O
and O
the O
l O
##ys O
( O
50 O
##5 O
) O
th O
##r O
( O
79 O
##9 O
) O
is O
##of O
##orms O
. O

in O
contrast O
, O
anti O
- O
br O
( O
a O
) O
( O
hp O
##a O
- O
5 O
##b O
) O
only O
recognized O
the O
l O
##ys O
( O
50 O
##5 O
) O
th O
##r O
( O
79 O
##9 O
) O
form O
, O
whereas O
anti O
- O
br O
( O
b O
) O
( O
hp O
##a O
- O
5 O
##a O
) O
reacted O
with O
both O
g O
##lu O
( O
50 O
##5 O
) O
th O
##r O
( O
79 O
##9 O
) O
and O
g O
##lu O
( O
50 O
##5 O
) O
met O
( O
79 O
##9 O
) O
is O
##of O
##orms O
. O

these O
results O
demonstrated O
that O
the O
met O
( O
79 O
##9 O
) O
is O
responsible O
for O
formation O
of O
the O
sit O
( O
a O
) O
all O
##oan O
##ti O
##genic O
de O
##ter O
##mina O
##nts O
, O
whereas O
amino O
acid O
50 O
##5 O
( O
l O
##ys O
or O
g O
##lu O
) O
specifically O
controls O
the O
expression O
of O
br O
( O
a O
) O
and O
br O
( O
b O
) O
e O
##pit O
##ope O
##s O
, O
respectively O
. O

plate O
##let O
a O
##gg O
##regation O
responses O
of O
sit O
( O
a O
) O
( O
+ O
) O
individuals O
were O
diminished O
in O
response O
to O
co O
##lla O
##gen O
, O
indicating O
that O
the O
th O
##r O
( O
79 O
##9 O
) O
met O
mutation O
affects O
the O
function O
of O
the O
g O
##pia O
/ O
ii O
##a O
complex O

mutations O
of O
the O
cat O
##he O
##ps O
##in O
c O
gene O
are O
responsible O
for O
p B-Disease
##ap I-Disease
##illo I-Disease
##n I-Disease
- I-Disease
le I-Disease
##fe I-Disease
##vre I-Disease
syndrome I-Disease
. O

p B-Disease
##ap I-Disease
##illo I-Disease
##n I-Disease
- I-Disease
le I-Disease
##fe I-Disease
##vre I-Disease
syndrome I-Disease
( O
p B-Disease
##ls I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterised O
by O
palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
h I-Disease
##yper I-Disease
##ker I-Disease
##ato I-Disease
##sis I-Disease
and O
severe O
early O
onset O
period B-Disease
##ont I-Disease
##itis I-Disease
that O
results O
in O
the O
premature O
loss O
of O
the O
primary O
and O
secondary O
den O
##ti O
##tions O
. O

a O
major O
gene O
lo O
##cus O
for O
p B-Disease
##ls I-Disease
has O
been O
mapped O
to O
a O
2 O
. O

8 O
cm O
interval O
on O
chromosome O
11 O
##q O
##14 O
. O

correlation O
of O
physical O
and O
genetic O
maps O
of O
this O
interval O
indicate O
it O
includes O
at O
least O
40 O
est O
##s O
and O
six O
known O
genes O
including O
the O
l O
##ys O
##oso O
##mal O
pro O
##te O
##ase O
cat O
##he O
##ps O
##in O
c O
gene O
( O
c O
##ts O
##c O
) O
. O

the O
c O
##ts O
##c O
message O
is O
expressed O
at O
high O
levels O
in O
a O
variety O
of O
immune O
cells O
including O
p O
##oly O
##mor O
##phon O
##uc O
##lea O
##r O
le O
##uc O
##ocytes O
, O
mac O
##rop O
##hage O
##s O
, O
and O
their O
precursor O
##s O
. O

by O
r O
##t O
- O
p O
##c O
##r O
, O
we O
found O
c O
##ts O
##c O
is O
also O
expressed O
in O
e O
##pit O
##hel O
##ial O
regions O
commonly O
affected O
by O
p B-Disease
##ls I-Disease
, O
including O
the O
palms O
, O
sole O
##s O
, O
knees O
, O
and O
oral O
k O
##era O
##tin O
##ised O
g O
##ing O
##iva O
. O

the O
4 O
. O

7 O
k O
##b O
c O
##ts O
##c O
gene O
consists O
of O
two O
ex O
##ons O
. O

sequence O
analysis O
of O
c O
##ts O
##c O
from O
subjects O
affected O
with O
p B-Disease
##ls I-Disease
from O
five O
con O
##sang O
##uin O
##eous O
t O
##ur O
##kis O
##h O
families O
identified O
four O
different O
mutations O
. O

an O
ex O
##on O
1 O
nonsense O
mutation O
( O
85 O
##6 O
##c O
- O
- O
[UNK] O
t O
) O
introduces O
a O
premature O
stop O
co O
##don O
at O
amino O
acid O
286 O
. O

three O
ex O
##on O
2 O
mutations O
were O
identified O
, O
including O
a O
single O
n O
##uc O
##leo O
##tide O
del O
##eti O
##on O
( O
26 O
##9 O
##2 O
##dela O
) O
of O
co O
##don O
34 O
##9 O
introducing O
a O
frames O
##hi O
##ft O
and O
premature O
termination O
co O
##don O
, O
a O
2 O
b O
##p O
del O
##eti O
##on O
( O
26 O
##7 O
##3 O
- O
26 O
##7 O
##4 O
##del O
##ct O
) O
that O
results O
in O
introduction O
of O
a O
stop O
co O
##don O
at O
amino O
acid O
34 O
##3 O
, O
and O
a O
g O
- O
- O
[UNK] O
a O
substitution O
in O
co O
##don O
42 O
##9 O
( O
29 O
##31 O
##g O
- O
- O
[UNK] O
a O
) O
introducing O
a O
premature O
termination O
co O
##don O
. O

all O
p B-Disease
##ls I-Disease
patients O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
cat O
##he O
##ps O
##in O
c O
mutations O
inherited O
from O
a O
common O
ancestor O
. O

parents O
and O
si O
##bs O
he O
##tero O
##zy O
##go O
##us O
for O
cat O
##he O
##ps O
##in O
c O
mutations O
do O
not O
show O
either O
the O
palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
h I-Disease
##yper I-Disease
##ker I-Disease
##ato I-Disease
##sis I-Disease
or O
severe O
early O
onset O
period B-Disease
##ont I-Disease
##itis I-Disease
characteristic O
of O
p B-Disease
##ls I-Disease
. O

a O
more O
complete O
understanding O
of O
the O
functional O
physiology O
of O
cat O
##he O
##ps O
##in O
c O
carries O
significant O
implications O
for O
understanding O
normal O
and O
abnormal O
skin O
development O
and O
period B-Disease
##ont I-Disease
##al I-Disease
disease I-Disease
su O
##s O
##ce O
##pt O
##ibility O

mutation O
##al O
analysis O
of O
the O
h O
##go O
gene O
in O
fin O
##nish O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
patients O
. O

al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
) O
, O
the O
pro O
##to O
##ty O
##pic O
in B-Disease
##born I-Disease
error I-Disease
of I-Disease
metabolism I-Disease
, O
has O
recently O
been O
shown O
to O
be O
caused O
by O
loss O
of O
function O
mutations O
in O
the O
ho O
##mo O
##gent O
##isa O
##te O
- O
1 O
, O
2 O
- O
di O
##ox O
##y O
##gen O
##ase O
gene O
( O
h O
##go O
) O
. O

so O
far O
17 O
mutations O
have O
been O
characterised O
in O
a B-Disease
##ku I-Disease
patients O
of O
different O
ethnic O
origin O
. O

we O
describe O
three O
novel O
mutations O
( O
r O
##5 O
##8 O
##fs O
, O
r O
##33 O
##0s O
, O
and O
h O
##37 O
##1 O
##r O
) O
and O
one O
common O
a B-Disease
##ku I-Disease
mutation O
( O
m O
##36 O
##8 O
##v O
) O
, O
detected O
by O
mutation O
##al O
and O
p O
##oly O
##mor O
##phism O
analysis O
of O
the O
h O
##go O
gene O
in O
five O
fin O
##nish O
a B-Disease
##ku I-Disease
p O
##ed O
##ig O
##ree O
##s O
. O

the O
three O
novel O
a B-Disease
##ku I-Disease
mutations O
are O
most O
likely O
specific O
for O
the O
fin O
##nish O
population O
and O
have O
originated O
recently O
. O
. O

the O
identical O
5 O
' O
s O
##p O
##lice O
- O
site O
accept O
##or O
mutation O
in O
five O
at B-Disease
##ten I-Disease
##uated I-Disease
a I-Disease
##p I-Disease
##c I-Disease
families O
from O
new O
##found O
##land O
demonstrates O
a O
founder O
effect O
. O

inherited O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
pre O
##dis O
##pose O
carriers O
to O
multiple O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
of I-Disease
the I-Disease
co I-Disease
##lon I-Disease
and I-Disease
re I-Disease
##ct I-Disease
##um I-Disease
and O
to O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

mutations O
located O
at O
the O
extreme O
5 O
end O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
however O
, O
are O
associated O
with O
a O
less O
severe O
disease O
known O
as O
at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##ap I-Disease
##c I-Disease
) O
. O

many O
individuals O
with O
a B-Disease
##ap I-Disease
##c I-Disease
develop O
relatively O
few O
color B-Disease
##ec I-Disease
##tal I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
but O
are O
still O
at O
high O
risk O
for O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

we O
report O
here O
the O
identification O
of O
a O
5 O
a B-Disease
##p I-Disease
##c I-Disease
g O
##er O
##m O
##line O
mutation O
in O
five O
separately O
as O
##cer O
##tain O
##ed O
a B-Disease
##ap I-Disease
##c I-Disease
families O
from O
new O
##found O
##land O
, O
can O
##ada O
. O

this O
disease O
- O
causing O
mutation O
is O
a O
single O
base O
##pair O
change O
( O
g O
to O
a O
) O
in O
the O
s O
##p O
##lice O
- O
accept O
##or O
region O
of O
a B-Disease
##p I-Disease
##c I-Disease
intro O
##n O
3 O
that O
creates O
a O
mutant O
r O
##na O
without O
ex O
##on O
4 O
of O
a O
##p O
##c O
. O

the O
observation O
of O
the O
same O
a B-Disease
##p I-Disease
##c I-Disease
mutation O
in O
five O
families O
from O
the O
same O
geographic O
area O
demonstrates O
a O
founder O
effect O
. O

further O
##more O
, O
the O
identification O
of O
this O
g O
##er O
##m O
##line O
mutation O
strengthen O
##s O
the O
correlation O
between O
the O
5 O
location O
of O
an O
a B-Disease
##p I-Disease
##c I-Disease
disease O
- O
causing O
mutation O
and O
the O
at B-Disease
##ten I-Disease
##uated I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
p O
##hen O
##otype O
. O
. O

al B-Disease
##strom I-Disease
syndrome I-Disease
: O
further O
evidence O
for O
link O
##age O
to O
human O
chromosome O
2 O
##p O
##13 O
. O

al B-Disease
##strom I-Disease
syndrome I-Disease
is O
a O
rare O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
, O
sensor B-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
, O
early O
- O
onset O
o B-Disease
##besity I-Disease
, O
and O
non B-Disease
- I-Disease
insulin I-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
. O

the O
gene O
for O
al B-Disease
##strom I-Disease
syndrome I-Disease
( O
al O
##ms O
##1 O
) O
has O
been O
previously O
localized O
to O
human O
chromosome O
2 O
##p O
##13 O
by O
ho O
##mo O
##zy O
##gos O
##ity O
mapping O
in O
two O
distinct O
isolated O
populations O
- O
f O
##rench O
a O
##ca O
##dian O
and O
north O
a O
##f O
##rica O
##n O
. O

pair O
- O
wise O
analyses O
resulted O
in O
maximum O
lo O
##d O
( O
log O
##ari O
##th O
##m O
of O
the O
odds O
ratio O
) O
scores O
of O
3 O
. O

84 O
and O
2 O
. O

9 O
, O
respectively O
. O

to O
confirm O
these O
findings O
, O
a O
large O
link O
##age O
study O
was O
performed O
in O
twelve O
additional O
families O
se O
##g O
##re O
##gating O
for O
al B-Disease
##strom I-Disease
syndrome I-Disease
. O

a O
maximum O
two O
- O
point O
lo O
##d O
score O
of O
7 O
. O

13 O
( O
the O
##ta O
= O
0 O
. O
00 O
) O
for O
marker O
d O
##2 O
##s O
##21 O
##10 O
and O
a O
maximum O
cumulative O
multi O
##point O
lo O
##d O
score O
of O
9 O
. O

16 O
for O
marker O
d O
##2 O
##s O
##21 O
##10 O
were O
observed O
, O
further O
supporting O
link O
##age O
to O
chromosome O
2 O
##p O
##13 O
. O

no O
evidence O
of O
genetic O
he O
##tero O
##gene O
##ity O
was O
observed O
in O
these O
families O
. O

me O
##iot O
##ic O
re O
##comb O
##ination O
events O
have O
localized O
the O
critical O
region O
containing O
al O
##ms O
##1 O
to O
a O
6 O
. O

1 O
- O
cm O
interval O
flanked O
by O
markers O
d O
##2 O
##s O
##32 O
##7 O
and O
d O
##2 O
##s O
##28 O
##6 O
. O

a O
fine O
resolution O
radiation O
hybrid O
map O
of O
31 O
genes O
and O
markers O
has O
been O
constructed O
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
: O
p O
##hen O
##otypic O
var O
##iability O
in O
two O
families O
carrying O
the O
same O
p B-Disease
##ds I-Disease
miss O
##ense O
mutation O
. O

pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
comprises O
con B-Disease
##gen I-Disease
##ital I-Disease
sensor I-Disease
##ine I-Disease
##ural I-Disease
hearing I-Disease
loss I-Disease
, O
thy B-Disease
##roid I-Disease
go I-Disease
##iter I-Disease
, O
and O
positive O
perch O
##lora O
##te O
discharge O
test O
. O

recently O
, O
this O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
was O
shown O
to O
be O
caused O
by O
mutations O
in O
the O
p B-Disease
##ds I-Disease
gene O
, O
which O
en O
##codes O
an O
an O
##ion O
transport O
##er O
called O
pen O
##dr O
##in O
. O

molecular O
analysis O
of O
the O
p B-Disease
##ds I-Disease
gene O
was O
performed O
in O
two O
con O
##sang O
##uin O
##eous O
large O
families O
from O
southern O
t O
##uni O
##sia O
comprising O
a O
total O
of O
23 O
individuals O
affected O
with O
profound O
con B-Disease
##gen I-Disease
##ital I-Disease
deaf I-Disease
##ness I-Disease
; O
the O
same O
miss O
##ense O
mutation O
, O
l O
##44 O
##5 O
##w O
, O
was O
identified O
in O
all O
affected O
individuals O
. O

a O
widened B-Disease
vest I-Disease
##ib I-Disease
##ular I-Disease
a I-Disease
##queduct I-Disease
was O
found O
in O
all O
patients O
who O
underwent O
com O
##puted O
to O
##mo O
##graphy O
( O
c O
##t O
) O
scan O
exploration O
of O
the O
inner O
ear O
. O

in O
contrast O
, O
go B-Disease
##iter I-Disease
was O
present O
in O
only O
11 O
affected O
individuals O
, O
who O
interesting O
##ly O
had O
a O
normal O
result O
of O
the O
perch O
##lora O
##te O
discharge O
test O
whenever O
performed O
. O

the O
present O
results O
question O
the O
sensitivity O
of O
the O
perch O
##lora O
##te O
test O
for O
the O
diagnosis O
of O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
and O
support O
the O
use O
of O
a O
molecular O
analysis O
of O
the O
p B-Disease
##ds I-Disease
gene O
in O
the O
assessment O
of O
individuals O
with O
severe O
to O
profound O
con B-Disease
##gen I-Disease
##ital I-Disease
hearing I-Disease
loss I-Disease
associated O
with O
inner B-Disease
ear I-Disease
m I-Disease
##or I-Disease
##phological I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
even O
in O
the O
absence O
of O
a O
thy B-Disease
##roid I-Disease
go I-Disease
##iter I-Disease
. O
. O

knob B-Disease
##loc I-Disease
##h I-Disease
syndrome I-Disease
involving O
mid B-Disease
##line I-Disease
scalp I-Disease
defect I-Disease
of I-Disease
the I-Disease
frontal I-Disease
region I-Disease
. O

we O
report O
on O
a O
4 O
- O
year O
- O
old O
boy O
with O
knob B-Disease
##loc I-Disease
##h I-Disease
syndrome I-Disease
. O

he O
has O
v B-Disease
##it I-Disease
##re I-Disease
##ore I-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
, O
high B-Disease
my I-Disease
##op I-Disease
##ia I-Disease
, O
cat B-Disease
##ara I-Disease
##ct I-Disease
, O
te B-Disease
##le I-Disease
##can I-Disease
##thus I-Disease
, O
h B-Disease
##yper I-Disease
##tel I-Disease
##oris I-Disease
##m I-Disease
, O
and O
a O
high B-Disease
- I-Disease
arched I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
. O

he O
also O
has O
a O
defect B-Disease
of I-Disease
the I-Disease
anterior I-Disease
mid I-Disease
##line I-Disease
scalp I-Disease
with O
involvement O
of O
the O
frontal O
bone O
as O
documented O
by O
a O
com O
##puted O
to O
##mo O
##graphy O
( O
c O
##t O
) O
scan O
. O

the O
brain O
was O
normal O
on O
c O
##t O
scan O
and O
magnetic O
resonance O
imaging O
. O

we O
present O
a O
review O
of O
the O
23 O
published O
cases O
with O
this O
syndrome O
. O

our O
patient O
illustrate O
##s O
the O
importance O
of O
investigating O
for O
underlying O
o O
##cular O
and O
central O
nervous O
system O
path O
##ology O
whenever O
mid B-Disease
##line I-Disease
scalp I-Disease
defects I-Disease
are O
present O
. O
. O

the O
d O
##na O
double O
- O
strand O
break O
repair O
gene O
h O
##m O
##re O
##11 O
is O
m O
##uta O
##ted O
in O
individuals O
with O
an O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
- I-Disease
like I-Disease
disorder I-Disease
. O

we O
show O
that O
h O
##y O
##po O
##morphic O
mutations O
in O
h O
##m O
##re O
##11 O
, O
but O
not O
in O
at O
##m O
, O
are O
present O
in O
certain O
individuals O
with O
an O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
- I-Disease
like I-Disease
disorder I-Disease
( O
at B-Disease
##ld I-Disease
) O
. O

the O
cellular O
features O
resulting O
from O
these O
h O
##m O
##re O
##11 O
mutations O
are O
similar O
to O
those O
seen O
in O
a B-Disease
- I-Disease
t I-Disease
as O
well O
as O
n B-Disease
##bs I-Disease
and O
include O
h B-Disease
##yper I-Disease
##sen I-Disease
##si I-Disease
##ti I-Disease
##vity I-Disease
to I-Disease
ion I-Disease
##izing I-Disease
radiation I-Disease
, O
radio O
##res O
##istan O
##t O
d O
##na O
synthesis O
, O
and O
a O
##bro O
##gation O
of O
at O
##m O
- O
dependent O
events O
, O
such O
as O
the O
activation O
of O
j O
##un O
kinase O
following O
exposure O
to O
gamma O
i O
##rra O
##diation O
. O

although O
the O
mutant O
h O
##m O
##re O
##11 O
proteins O
retain O
some O
ability O
to O
interact O
with O
h O
##rad O
##50 O
and O
n O
##bs O
##1 O
, O
formation O
of O
ion O
##izing O
radiation O
- O
induced O
h O
##m O
##re O
##11 O
and O
n O
##bs O
##1 O
f O
##oc O
##i O
was O
absent O
in O
h O
##m O
##re O
##11 O
mutant O
cells O
. O

these O
data O
demonstrate O
that O
at O
##m O
and O
the O
h O
##m O
##re O
##11 O
/ O
h O
##rad O
##50 O
/ O
n O
##bs O
##1 O
protein O
complex O
act O
in O
the O
same O
d O
##na O
damage O
response O
pathway O
and O
link O
h O
##m O
##re O
##11 O
to O
the O
complex O
path O
##ology O
of O
a B-Disease
- I-Disease
t I-Disease
. O
. O

mutations O
in O
t O
##n O
##f O
##rs O
##f O
##11 O
##a O
, O
affecting O
the O
signal O
p O
##eptide O
of O
rank O
, O
cause O
f B-Disease
##ami I-Disease
##lial I-Disease
ex I-Disease
##pan I-Disease
##si I-Disease
##le I-Disease
o I-Disease
##ste I-Disease
##oly I-Disease
##sis I-Disease
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ex I-Disease
##pan I-Disease
##si I-Disease
##le I-Disease
o I-Disease
##ste I-Disease
##oly I-Disease
##sis I-Disease
( O
f B-Disease
##eo I-Disease
, O
mi O
##m O
1748 O
##10 O
) O
is O
a O
rare O
, O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
bone I-Disease
disorder I-Disease
characterized O
by O
focal O
areas O
of O
increased B-Disease
bone I-Disease
re I-Disease
##mo I-Disease
##dell I-Disease
##ing I-Disease
. O

the O
o B-Disease
##ste I-Disease
##oly I-Disease
##tic I-Disease
lesions I-Disease
, O
which O
develop O
usually O
in O
the O
long O
bones O
during O
early O
adulthood O
, O
show O
increased O
o O
##ste O
##ob O
##last O
and O
o O
##ste O
##oc O
##last O
activity O
. O

our O
previous O
link O
##age O
studies O
mapped O
the O
gene O
responsible O
for O
f B-Disease
##eo I-Disease
to O
an O
interval O
of O
less O
than O
5 O
cm O
between O
d O
##18 O
##s O
##64 O
and O
d O
##18 O
##s O
##51 O
on O
chromosome O
18 O
##q O
##21 O
. O

2 O
- O
21 O
2 O
- O
21 O
. O

3 O
in O
a O
large O
northern O
i O
##ris O
##h O
family O
. O

the O
gene O
encoding O
receptor O
act O
##iva O
##tor O
of O
nuclear O
factor O
- O
ka O
##ppa O
b O
( O
rank O
; O
re O
##f O
. O
5 O
) O
, O
t O
##n O
##f O
##rs O
##f O
##11 O
##a O
, O
maps O
to O
this O
region O
. O

rank O
is O
essential O
in O
o O
##ste O
##oc O
##last O
formation O
. O

we O
identified O
two O
he O
##tero O
##zy O
##go O
##us O
insertion O
mutations O
in O
ex O
##on O
1 O
of O
t O
##n O
##f O
##rs O
##f O
##11 O
##a O
in O
affected O
members O
of O
four O
families O
with O
f B-Disease
##eo I-Disease
or O
f B-Disease
##ami I-Disease
##lial I-Disease
page I-Disease
##t I-Disease
disease I-Disease
of I-Disease
bone I-Disease
( O
p B-Disease
##d I-Disease
##b I-Disease
) O
. O

one O
was O
a O
du O
##plication O
of O
18 O
bases O
and O
the O
other O
a O
du O
##plication O
of O
27 O
bases O
, O
both O
of O
which O
affected O
the O
signal O
p O
##eptide O
region O
of O
the O
rank O
molecule O
. O

expression O
of O
re O
##comb O
##ina O
##nt O
forms O
of O
the O
mutant O
rank O
proteins O
revealed O
per O
##tur O
##bation O
##s O
in O
expression O
levels O
and O
lack O
of O
normal O
c O
##lea O
##vage O
of O
the O
signal O
p O
##eptide O
. O

both O
mutations O
caused O
an O
increase O
in O
rank O
- O
mediated O
nuclear O
factor O
- O
ka O
##ppa O
##b O
( O
n O
##f O
- O
ka O
##ppa O
##b O
) O
signalling O
in O
v O
##it O
##ro O
, O
consistent O
with O
the O
presence O
of O
an O
act O
##ivating O
mutation O
. O

cardiac O
na O
( O
+ O
) O
channel O
d O
##ys O
##function O
in O
br B-Disease
##uga I-Disease
##da I-Disease
syndrome I-Disease
is O
a O
##gg O
##ra O
##vated O
by O
beta O
( O
1 O
) O
- O
subunit O
. O

background O
mutations O
in O
the O
gene O
encoding O
the O
human O
cardiac O
na O
( O
+ O
) O
channel O
alpha O
- O
subunit O
( O
h O
##h O
##1 O
) O
are O
responsible O
for O
chromosome O
3 O
- O
linked O
con B-Disease
##gen I-Disease
##ital I-Disease
long I-Disease
- I-Disease
q I-Disease
##t I-Disease
syndrome I-Disease
( O
l B-Disease
##q I-Disease
##t I-Disease
##3 I-Disease
) O
and O
id B-Disease
##io I-Disease
##pathic I-Disease
vent I-Disease
##ric I-Disease
##ular I-Disease
fi I-Disease
##bri I-Disease
##lla I-Disease
##tion I-Disease
( O
i B-Disease
##v I-Disease
##f I-Disease
) O
. O

an O
auxiliary O
beta O
( O
1 O
) O
- O
subunit O
, O
widely O
expressed O
in O
ex O
##ci O
##table O
tissues O
, O
shifts O
the O
voltage O
dependence O
of O
steady O
- O
state O
in O
##act O
##ivation O
toward O
more O
negative O
potential O
##s O
and O
restore O
##s O
normal O
g O
##ating O
kinetic O
##s O
of O
brain O
and O
skeletal O
muscle O
na O
( O
+ O
) O
channels O
expressed O
in O
x O
##eno O
##pus O
o O
##ocytes O
but O
has O
little O
if O
any O
functional O
effect O
on O
the O
cardiac O
is O
##of O
##orm O
. O

here O
, O
we O
character O
##ize O
the O
altered O
effects O
of O
a O
human O
beta O
( O
1 O
) O
- O
subunit O
( O
h O
##bet O
##a O
( O
1 O
) O
) O
on O
the O
he O
##tero O
##log O
##ously O
expressed O
h O
##h O
##1 O
mutation O
( O
t O
##16 O
##20 O
##m O
) O
previously O
associated O
with O
i B-Disease
##v I-Disease
##f I-Disease
. O

methods O
and O
results O
when O
expressed O
alone O
in O
x O
##eno O
##pus O
o O
##ocytes O
, O
t O
##16 O
##20 O
##m O
exhibited O
no O
persistent O
currents O
, O
in O
contrast O
to O
the O
l B-Disease
##q I-Disease
##t I-Disease
##3 I-Disease
mutant O
channels O
, O
but O
the O
mid O
##point O
of O
steady O
- O
state O
in O
##act O
##ivation O
( O
v O
( O
1 O
/ O
2 O
) O
) O
was O
significantly O
shifted O
toward O
more O
positive O
potential O
##s O
than O
for O
wild O
- O
type O
h O
##h O
##1 O
. O

co O
##ex O
##press O
##ion O
of O
h O
##bet O
##a O
( O
1 O
) O
did O
not O
significantly O
alter O
current O
decay O
or O
recovery O
from O
in O
##act O
##ivation O
of O
wild O
- O
type O
h O
##h O
##1 O
; O
however O
, O
it O
further O
shifted O
the O
v O
( O
1 O
/ O
2 O
) O
and O
accelerated O
the O
recovery O
from O
in O
##act O
##ivation O
of O
t O
##16 O
##20 O
##m O
. O

o O
##oc O
##yte O
mac O
##rop O
##atch O
analysis O
revealed O
that O
the O
activation O
kinetic O
##s O
of O
t O
##16 O
##20 O
##m O
were O
normal O
. O

conclusions O
it O
is O
suggested O
that O
co O
##ex O
##press O
##ion O
of O
h O
##bet O
##a O
( O
1 O
) O
expose O
##s O
a O
more O
severe O
functional O
defect O
that O
results O
in O
a O
greater O
overlap O
in O
the O
relationship O
between O
channel O
in O
##act O
##ivation O
and O
activation O
( O
window O
current O
) O
in O
t O
##16 O
##20 O
##m O
, O
which O
is O
proposed O
to O
be O
a O
potential O
path O
##op O
##hy O
##sio O
##logical O
mechanism O
of O
i B-Disease
##v I-Disease
##f I-Disease
in O
v O
##ivo O
. O

one O
possible O
explanation O
for O
our O
finding O
is O
an O
altered O
alpha O
- O
/ O
beta O
( O
1 O
) O
- O
subunit O
association O
in O
the O
mutant O
. O
. O

me O
##iot O
##ic O
segregation O
analysis O
of O
r O
##b O
##1 O
all O
##ele O
##s O
in O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
p O
##ed O
##ig O
##ree O
##s O
by O
use O
of O
single O
- O
sperm O
typing O
. O

in O
hereditary B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
, O
different O
e O
##pid O
##em O
##iol O
##ogical O
studies O
have O
indicated O
a O
prefer O
##ential O
paternal O
transmission O
of O
mutant O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
all O
##ele O
##s O
to O
offspring O
, O
suggesting O
the O
occurrence O
of O
a O
me O
##iot O
##ic O
drive O
. O

to O
investigate O
this O
mechanism O
, O
we O
analyzed O
sperm O
samples O
from O
six O
individuals O
from O
five O
unrelated O
families O
affected O
with O
hereditary B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

single O
- O
sperm O
typing O
techniques O
were O
performed O
for O
each O
sample O
by O
study O
of O
two O
inform O
##ative O
short O
tandem O
repeats O
located O
either O
in O
or O
close O
to O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
gene O
( O
r O
##b O
##1 O
) O
. O

the O
segregation O
probability O
of O
mutant O
r O
##b O
##1 O
all O
##ele O
##s O
in O
sperm O
samples O
was O
assessed O
by O
use O
of O
the O
sperm O
##se O
##g O
program O
, O
which O
includes O
experimental O
parameters O
, O
re O
##comb O
##ination O
fraction O
##s O
between O
the O
markers O
, O
and O
segregation O
parameters O
. O

a O
total O
of O
2 O
, O
95 O
##2 O
single O
sperm O
from O
the O
six O
donors O
were O
analyzed O
. O

we O
detected O
a O
significant O
segregation O
distortion O
in O
the O
data O
as O
a O
whole O
( O
p O
= O
. O
00 O
##9 O
##9 O
) O
and O
a O
significant O
he O
##tero O
##gene O
##ity O
in O
the O
segregation O
rate O
across O
donors O
( O
. O
00 O
##9 O
##2 O
) O
. O

further O
analysis O
shows O
that O
this O
result O
can O
be O
explained O
by O
segregation O
distortion O
in O
favor O
of O
the O
normal O
all O
##ele O
in O
one O
donor O
only O
and O
that O
it O
does O
not O
provide O
evidence O
of O
a O
significant O
segregation O
distortion O
in O
the O
other O
donors O
. O

the O
segregation O
distortion O
favor O
##ing O
the O
mutant O
r O
##b O
##1 O
all O
##ele O
does O
not O
seem O
to O
occur O
during O
sperm O
##ato O
##genesis O
, O
and O
, O
thus O
, O
me O
##iot O
##ic O
drive O
may O
result O
either O
from O
various O
mechanisms O
, O
including O
a O
f O
##ert O
##ilization O
advantage O
or O
a O
better O
mobility O
in O
sperm O
bearing O
a O
mutant O
r O
##b O
##1 O
gene O
, O
or O
from O
the O
existence O
of O
a O
defect O
##ively O
imprint O
##ed O
gene O
located O
on O
the O
human O
x O
chromosome O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
: O
an O
overview O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
, O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disease I-Disease
, O
is O
the O
most O
common O
of O
the O
inherited B-Disease
at I-Disease
##ax I-Disease
##ias I-Disease
. O

the O
recent O
discovery O
of O
the O
gene O
that O
is O
m O
##uta O
##ted O
in O
this O
condition O
, O
f O
##rda O
, O
has O
led O
to O
rapid O
advances O
in O
the O
understanding O
of O
the O
path O
##ogen O
##esis O
of O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

about O
98 O
% O
of O
mutant O
all O
##ele O
##s O
have O
an O
expansion O
of O
a O
g O
##aa O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
intro O
##n O
1 O
of O
the O
gene O
. O

this O
leads O
to O
reduced O
levels O
of O
the O
protein O
, O
f O
##rata O
##xin O
. O

there O
is O
mounting O
evidence O
to O
suggest O
that O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
is O
the O
result O
of O
accumulation O
of O
iron O
in O
mit O
##och O
##ond O
##ria O
leading O
to O
excess O
production O
of O
free O
radical O
##s O
, O
which O
then O
results O
in O
cellular O
damage O
and O
death O
. O

currently O
there O
is O
no O
known O
treatment O
that O
alter O
##s O
the O
natural O
course O
of O
the O
disease O
. O

the O
discovery O
of O
the O
f B-Disease
##rda I-Disease
gene O
and O
its O
possible O
function O
has O
raised O
hope O
that O
rational O
therapeutic O
strategies O
will O
be O
developed O
. O
. O

x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
with O
point O
mutations O
in O
the O
x O
##l O
##rs O
##1 O
gene O
. O

background O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
( O
x B-Disease
##l I-Disease
##rs I-Disease
) O
is O
a O
relatively O
rare O
v B-Disease
##it I-Disease
##re I-Disease
##ore I-Disease
##tina I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
that O
causes O
visual B-Disease
loss I-Disease
in O
young O
men O
. O

recently O
, O
a O
gene O
responsible O
for O
this O
disease O
, O
designated O
x O
##l O
##rs O
##1 O
, O
was O
identified O
, O
and O
several O
del O
##eter O
##ious O
gene O
mutations O
were O
reported O
. O

objective O
to O
analyze O
j O
##apa O
##nese O
patients O
clinical O
##ly O
diagnosed O
as O
having O
x B-Disease
##l I-Disease
##rs I-Disease
form O
##uta O
##tional O
changes O
in O
the O
x O
##l O
##rs O
##1 O
gene O
. O

methods O
ten O
patients O
with O
x B-Disease
##l I-Disease
##rs I-Disease
underwent O
full O
op O
##ht O
##hal O
##mo O
##log O
##ic O
examination O
, O
including O
slit O
##lamp O
bio O
##mic O
##ros O
##copy O
and O
di O
##lated O
fund O
##us O
##copy O
. O

g O
##eno O
##mic O
d O
##na O
was O
isolated O
from O
le O
##uk O
##ocytes O
, O
and O
all O
ex O
##ons O
of O
the O
x O
##l O
##rs O
##1 O
gene O
were O
am O
##plified O
by O
polymer O
##ase O
chain O
reaction O
and O
analyzed O
using O
a O
direct O
se O
##quencing O
method O
. O

results O
point O
mutations O
in O
the O
x O
##l O
##rs O
##1 O
gene O
were O
identified O
in O
all O
10 O
patients O
. O

the O
mutations O
were O
identical O
in O
each O
of O
2 O
pairs O
of O
brothers O
. O

six O
of O
the O
point O
mutations O
represented O
miss O
##ense O
mutations O
, O
1 O
was O
a O
nonsense O
mutation O
, O
and O
1 O
was O
a O
frames O
##hi O
##ft O
mutation O
. O

five O
of O
the O
mutations O
are O
newly O
reported O
here O
##in O
. O

conclusions O
the O
discovery O
of O
new O
point O
mutations O
in O
this O
study O
increases O
the O
available O
information O
regarding O
the O
spectrum O
of O
genetic B-Disease
abnormal I-Disease
##ities I-Disease
and O
clinical O
manifest O
##ations O
of O
x B-Disease
##l I-Disease
##rs I-Disease
. O

however O
, O
the O
limited O
data O
failed O
to O
reveal O
a O
correlation O
between O
mutation O
and O
disease O
p O
##hen O
##otype O
. O

clinical O
relevance O
identification O
of O
mutations O
in O
the O
x O
##l O
##rs O
##1 O
gene O
and O
expanded O
information O
on O
clinical O
manifest O
##ations O
will O
facilitate O
early O
diagnosis O
, O
appropriate O
early O
therapy O
, O
and O
genetic O
counseling O
regarding O
the O
pro O
##gno O
##sis O
of O
x B-Disease
##l I-Disease
##rs I-Disease
. O
. O

at O
##m O
and O
b O
##ax O
cooperate O
in O
ion O
##izing O
radiation O
- O
induced O
a O
##pop O
##tosis O
in O
the O
central O
nervous O
system O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
is O
a O
hereditary B-Disease
multi I-Disease
##sy I-Disease
##ste I-Disease
##mic I-Disease
disease I-Disease
resulting O
from O
mutations O
of O
at B-Disease
##ax I-Disease
##ia I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
, O
m O
##uta O
##ted O
( O
at O
##m O
) O
and O
is O
characterized O
by O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##ration I-Disease
, O
cancer B-Disease
, O
immune B-Disease
defects I-Disease
, O
and O
h B-Disease
##yper I-Disease
##sen I-Disease
##si I-Disease
##ti I-Disease
##vity I-Disease
to I-Disease
ion I-Disease
##izing I-Disease
radiation I-Disease
. O

the O
molecular O
details O
of O
at O
##m O
function O
in O
the O
nervous O
system O
are O
unclear O
, O
although O
the O
ne B-Disease
##uro I-Disease
##logical I-Disease
les I-Disease
##ion I-Disease
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
becomes O
apparent O
early O
in O
life O
, O
suggesting O
a O
developmental O
origin O
. O

the O
central O
nervous O
system O
( O
c O
##ns O
) O
of O
at O
##m O
- O
null O
mice O
shows O
a O
pronounced O
defect O
in O
a O
##pop O
##tosis O
induced O
by O
g O
##eno O
##to O
##xi O
##c O
stress O
, O
suggesting O
at O
##m O
functions O
to O
eliminate O
neurons O
with O
excessive O
g O
##eno O
##mic O
damage O
. O

here O
, O
we O
report O
that O
the O
death O
effect O
##or O
b O
##ax O
is O
required O
for O
a O
large O
proportion O
of O
at O
##m O
- O
dependent O
a O
##pop O
##tosis O
in O
the O
developing O
c O
##ns O
after O
ion O
##izing O
radiation O
( O
i O
##r O
) O
. O

although O
many O
of O
the O
same O
regions O
of O
the O
c O
##ns O
in O
both O
b O
##ax O
- O
/ O
- O
and O
at O
##m O
- O
/ O
- O
mice O
were O
radio O
##res O
##istan O
##t O
, O
mice O
null O
##iz O
##y O
##go O
##us O
for O
both O
b O
##ax O
and O
at O
##m O
showed O
additional O
reduction O
in O
i O
##r O
- O
induced O
a O
##pop O
##tosis O
in O
the O
c O
##ns O
. O

therefore O
, O
although O
the O
major O
i O
##r O
- O
induced O
a O
##pop O
##to O
##tic O
pathway O
in O
the O
c O
##ns O
requires O
at O
##m O
and O
b O
##ax O
, O
a O
p O
##53 O
- O
dependent O
co O
##lla O
##teral O
pathway O
exists O
that O
has O
both O
at O
##m O
- O
and O
b O
##ax O
- O
independent O
branches O
. O

further O
, O
at O
##m O
- O
and O
b O
##ax O
- O
dependent O
a O
##pop O
##tosis O
in O
the O
c O
##ns O
also O
required O
ca O
##sp O
##ase O
- O
3 O
activation O
. O

these O
data O
imp O
##lica O
##te O
b O
##ax O
and O
ca O
##sp O
##ase O
- O
3 O
as O
death O
effect O
##ors O
in O
ne O
##uro O
##de O
##gene O
##rative O
pathways O
. O
. O

ha B-Disease
##im I-Disease
- I-Disease
m I-Disease
##unk I-Disease
syndrome I-Disease
and O
p B-Disease
##ap I-Disease
##illo I-Disease
##n I-Disease
- I-Disease
le I-Disease
##fe I-Disease
##vre I-Disease
syndrome I-Disease
are O
all O
##eli O
##c O
mutations O
in O
cat O
##he O
##ps O
##in O
c O
. O

of O
the O
many O
palm B-Disease
##op I-Disease
##lant I-Disease
##ar I-Disease
k I-Disease
##era I-Disease
##to I-Disease
##der I-Disease
##ma I-Disease
( I-Disease
pp I-Disease
##k I-Disease
) I-Disease
conditions I-Disease
, O
only O
p B-Disease
##ap I-Disease
##illo I-Disease
##n I-Disease
- I-Disease
le I-Disease
##fe I-Disease
##vre I-Disease
syndrome I-Disease
( O
p B-Disease
##ls I-Disease
) O
and O
ha B-Disease
##im I-Disease
- I-Disease
m I-Disease
##unk I-Disease
syndrome I-Disease
( O
h B-Disease
##ms I-Disease
) O
are O
associated O
with O
premature O
period O
##ont O
##al O
destruction O
. O

although O
both O
p B-Disease
##ls I-Disease
and O
h B-Disease
##ms I-Disease
share O
the O
cardinal O
features O
of O
pp B-Disease
##k I-Disease
and O
severe O
period B-Disease
##ont I-Disease
##itis I-Disease
, O
a O
number O
of O
additional O
findings O
are O
reported O
in O
h B-Disease
##ms I-Disease
including O
a B-Disease
##rac I-Disease
##hn I-Disease
##oda I-Disease
##ct I-Disease
##yl I-Disease
##y I-Disease
, O
a B-Disease
##c I-Disease
##ro I-Disease
- I-Disease
o I-Disease
##ste I-Disease
##oly I-Disease
##sis I-Disease
, O
at B-Disease
##rop I-Disease
##hic I-Disease
changes I-Disease
of I-Disease
the I-Disease
nails I-Disease
, O
and O
a O
radio B-Disease
##graphic I-Disease
def I-Disease
##orm I-Disease
##ity I-Disease
of I-Disease
the I-Disease
fingers I-Disease
. O

while O
p B-Disease
##ls I-Disease
cases O
have O
been O
identified O
throughout O
the O
world O
, O
h B-Disease
##ms I-Disease
has O
only O
been O
described O
among O
descendants O
of O
a O
religious O
is O
##olate O
originally O
from O
co O
##chin O
, O
in O
##dia O
. O

parental O
con O
##sang O
##uin O
##ity O
is O
a O
characteristic O
of O
many O
cases O
of O
both O
conditions O
. O

although O
auto O
##so O
##mal O
re O
##cess O
##ive O
transmission O
of O
p B-Disease
##ls I-Disease
is O
evident O
, O
a O
more O
" O
complex O
" O
auto O
##so O
##mal O
re O
##cess O
##ive O
pattern O
of O
inheritance O
with O
p O
##hen O
##otypic O
influences O
from O
a O
closely O
linked O
modify O
##ing O
lo O
##cus O
has O
been O
hypothesis O
##ed O
for O
h B-Disease
##ms I-Disease
. O

recently O
, O
mutations O
of O
the O
cat O
##he O
##ps O
##in O
c O
gene O
have O
been O
identified O
as O
the O
underlying O
genetic B-Disease
defect I-Disease
in O
p B-Disease
##ls I-Disease
. O

to O
determine O
if O
a O
cat O
##he O
##ps O
##in O
c O
mutation O
is O
also O
responsible O
for O
h B-Disease
##ms I-Disease
, O
we O
sequence O
##d O
the O
gene O
in O
affected O
and O
un O
##af O
##fected O
subjects O
from O
the O
co O
##chin O
is O
##olate O
in O
which O
both O
the O
p B-Disease
##ls I-Disease
and O
h B-Disease
##ms I-Disease
p O
##hen O
##otype O
##s O
appear O
. O

here O
we O
report O
identification O
of O
a O
mutation O
of O
cat O
##he O
##ps O
##in O
c O
( O
ex O
##on O
6 O
, O
212 O
##7 O
##a O
- O
- O
[UNK] O
g O
) O
that O
changes O
a O
highly O
conserved O
amino O
acid O
in O
the O
cat O
##he O
##ps O
##in O
c O
p O
##eptide O
. O

this O
mutation O
se O
##g O
##re O
##gate O
##s O
with O
h B-Disease
##ms I-Disease
in O
four O
nuclear O
families O
. O

additionally O
, O
the O
existence O
of O
a O
shared O
common O
ha O
##p O
##lot O
##ype O
for O
genetic O
lo O
##ci O
flank O
##ing O
the O
cat O
##he O
##ps O
##in O
c O
gene O
suggests O
that O
affected O
subjects O
descended O
from O
the O
co O
##chin O
is O
##olate O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
mutation O
inherited O
" O
identical O
by O
descent O
" O
from O
a O
common O
ancestor O
. O

this O
finding O
supports O
simple O
auto O
##so O
##mal O
re O
##cess O
##ive O
inheritance O
for O
h B-Disease
##ms I-Disease
in O
these O
families O
. O

we O
also O
report O
a O
mutation O
of O
the O
same O
ex O
##on O
6 O
c O
##ts O
##c O
co O
##don O
( O
212 O
##6 O
##c O
- O
- O
[UNK] O
t O
) O
in O
a O
t O
##ur O
##kis O
##h O
family O
with O
classical O
p B-Disease
##ls I-Disease
. O

these O
findings O
provide O
evidence O
that O
p B-Disease
##ls I-Disease
and O
h B-Disease
##ms I-Disease
are O
all O
##eli O
##c O
variants O
of O
cat O
##he O
##ps O
##in O
c O
gene O
mutations O
. O
. O

at O
##m O
- O
he O
##tero O
##zy O
##go O
##us O
g O
##er O
##m O
##line O
mutations O
contribute O
to O
breast B-Disease
cancer I-Disease
- O
su O
##s O
##ce O
##pt O
##ibility O
. O

approximately O
0 O
. O

5 O
% O
- O
1 O
% O
of O
the O
general O
population O
has O
been O
estimated O
to O
be O
he O
##tero O
##zy O
##go O
##us O
for O
a O
g O
##er O
##m O
##line O
mutation O
in O
the O
at O
##m O
gene O
. O

mutations O
in O
the O
at O
##m O
gene O
are O
responsible O
for O
the O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
( O
mi O
##m O
208 O
##90 O
##0 O
) O
. O

the O
finding O
that O
at O
##m O
- O
he O
##tero O
##zy O
##got O
##es O
have O
an O
increased O
relative O
risk O
for O
breast B-Disease
cancer I-Disease
was O
supported O
by O
some O
studies O
but O
not O
confirmed O
by O
others O
. O

in O
view O
of O
this O
disc O
##re O
##pan O
##cy O
, O
we O
examined O
the O
frequency O
of O
at O
##m O
g O
##er O
##m O
##line O
mutations O
in O
a O
selected O
group O
of O
du O
##tch O
patients O
with O
breast B-Disease
cancer I-Disease
. O

we O
have O
analyzed O
at O
##m O
g O
##er O
##m O
##line O
mutations O
in O
normal O
blood O
l O
##ymph O
##ocytes O
, O
using O
the O
protein O
- O
t O
##run O
##cation O
test O
followed O
by O
g O
##eno O
##mic O
- O
sequence O
analysis O
. O

a O
high O
percentage O
of O
at O
##m O
g O
##er O
##m O
##line O
mutations O
was O
demonstrated O
among O
patients O
with O
s B-Disease
##poradic I-Disease
breast I-Disease
cancer I-Disease
. O

the O
82 O
patients O
included O
in O
this O
study O
had O
developed O
breast B-Disease
cancer I-Disease
at O
age O
[UNK] O
45 O
and O
had O
survived O
[UNK] O
/ O
= O
5 O
years O
( O
mean O
15 O
years O
) O
, O
and O
in O
33 O
( O
40 O
% O
) O
of O
the O
patients O
a O
con O
##tral O
##ater O
##al O
breast O
tumor O
had O
been O
diagnosed O
. O

among O
these O
patients O
we O
identified O
seven O
( O
8 O
. O
5 O
% O
) O
at O
##m O
g O
##er O
##m O
##line O
mutations O
, O
of O
which O
five O
are O
distinct O
. O

one O
s O
##p O
##lice O
- O
site O
mutation O
( O
i O
##v O
##s O
##10 O
- O
6 O
##t O
- O
- O
[UNK] O
g O
) O
was O
detected O
three O
times O
in O
our O
series O
. O

four O
he O
##tero O
##zy O
##go O
##us O
carriers O
were O
patients O
with O
bilateral O
breast O
cancer O
. O

our O
results O
indicate O
that O
the O
mutations O
identified O
in O
this O
study O
are O
" O
a O
- O
t O
disease O
- O
causing O
" O
mutations O
that O
might O
be O
associated O
with O
an O
increased O
risk O
of O
breast O
cancer O
in O
he O
##tero O
##zy O
##got O
##es O
. O

we O
conclude O
that O
at O
##m O
he O
##tero O
##zy O
##got O
##es O
have O
an O
approximately O
nine O
##fold O
- O
increased O
risk O
of O
developing O
a O
type O
of O
breast O
cancer O
characterized O
by O
frequent O
bilateral O
occurrence O
, O
early O
age O
at O
onset O
, O
and O
long O
- O
term O
survival O
. O

the O
specific O
characteristics O
of O
our O
population O
of O
patients O
may O
explain O
why O
such O
a O
high O
frequency O
was O
not O
found O
in O
other O
series O
. O

human O
mutations O
in O
glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
reflect O
evolutionary O
history O
. O

glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
is O
a O
c O
##yt O
##oso O
##lic O
enzyme O
encoded O
by O
a O
house O
##keeping O
x O
- O
linked O
gene O
whose O
main O
function O
is O
to O
produce O
na O
##d O
##ph O
, O
a O
key O
electron O
donor O
in O
the O
defense O
against O
o O
##xi O
##di O
##zing O
agents O
and O
in O
red O
##uctive O
bio O
##sy O
##nt O
##hetic O
reactions O
. O

inherited O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
associated O
with O
either O
e B-Disease
##pis I-Disease
##od I-Disease
##ic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
( O
triggered O
by O
f O
##ava O
beans O
or O
other O
agents O
) O
or O
life B-Disease
- I-Disease
long I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
. O

we O
show O
here O
that O
an O
evolutionary O
analysis O
is O
a O
key O
to O
understanding O
the O
biology O
of O
a O
house O
##keeping O
gene O
. O

from O
the O
alignment O
of O
the O
amino O
acid O
( O
a O
##a O
) O
sequence O
of O
52 O
glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
species O
from O
42 O
different O
organisms O
, O
we O
found O
a O
striking O
correlation O
between O
the O
a O
##a O
replacement O
##s O
that O
cause O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
humans O
and O
the O
sequence O
conservation O
of O
g O
##6 O
##p O
##d O
two O
- O
thirds O
of O
such O
replacement O
##s O
are O
in O
highly O
and O
moderately O
conserved O
( O
50 O
- O
99 O
% O
) O
a O
##a O
; O
relatively O
few O
are O
in O
fully O
conserved O
a O
##a O
( O
where O
they O
might O
be O
lethal O
) O
or O
in O
poorly O
conserved O
a O
##a O
, O
where O
presumably O
they O
simply O
would O
not O
cause O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

this O
is O
consistent O
with O
the O
notion O
that O
all O
human O
mutant O
##s O
have O
residual O
enzyme O
activity O
and O
that O
null O
mutations O
are O
lethal O
at O
some O
stage O
of O
development O
. O

comparing O
the O
distribution O
of O
mutations O
in O
a O
human O
house O
##keeping O
gene O
with O
evolutionary O
conservation O
is O
a O
useful O
tool O
for O
pin O
##point O
##ing O
amino O
acid O
residues O
important O
for O
the O
stability O
or O
the O
function O
of O
the O
corresponding O
protein O
. O

in O
view O
of O
the O
current O
explosive O
increase O
in O
full O
genome O
se O
##quencing O
projects O
, O
this O
tool O
will O
become O
rapidly O
available O
for O
numerous O
other O
genes O
. O
. O

con O
##st O
##it O
##utive O
and O
regulated O
modes O
of O
s O
##p O
##licing O
produce O
six O
major O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
( O
d O
##mp O
##k O
) O
is O
##of O
##orms O
with O
distinct O
properties O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
the O
most O
prevalent O
inherited B-Disease
ne I-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
disease I-Disease
in O
adults O
. O

the O
genetic B-Disease
defect I-Disease
is O
a O
c O
##t O
##g O
triple O
##t O
repeat O
expansion O
in O
the O
3 O
- O
un O
##tra O
##ns O
##lated O
region O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
( O
d O
##mp O
##k O
) O
gene O
, O
consisting O
of O
15 O
ex O
##ons O
. O

using O
a O
trans O
##genic O
d O
##mp O
##k O
- O
over O
##ex O
##press O
##or O
mouse O
model O
, O
we O
demonstrate O
here O
that O
the O
end O
##ogen O
##ous O
mouse O
d O
##mp O
##k O
gene O
and O
the O
human O
d O
##mp O
##k O
trans O
##gene O
produce O
six O
major O
alternatively O
s O
##p O
##lice O
##d O
m O
##rna O
##s O
which O
have O
almost O
identical O
cell O
type O
- O
dependent O
distribution O
frequencies O
and O
expression O
patterns O
. O

use O
of O
a O
cry O
##ptic O
5 O
s O
##p O
##lice O
site O
in O
ex O
##on O
8 O
, O
which O
results O
in O
absence O
or O
presence O
of O
15 O
n O
##uc O
##leo O
##tide O
##s O
specify O
##ing O
a O
vs O
##gg O
##g O
p O
##eptide O
motif O
, O
and O
/ O
or O
use O
of O
a O
cry O
##ptic O
3 O
s O
##p O
##lice O
site O
in O
ex O
##on O
14 O
, O
which O
leads O
to O
a O
frames O
##hi O
##ft O
in O
the O
m O
##rna O
reading O
frame O
, O
occur O
as O
independent O
s O
##to O
##cha O
##stic O
events O
in O
all O
tissues O
examined O
. O

in O
contrast O
, O
the O
ex O
##cision O
of O
ex O
##ons O
13 O
/ O
14 O
that O
causes O
a O
frames O
##hi O
##ft O
and O
creates O
a O
c O
- O
terminal O
##ly O
t O
##runcated O
protein O
is O
clearly O
cell O
type O
dependent O
and O
occurs O
predominantly O
in O
smooth O
muscle O
. O

we O
generated O
all O
six O
full O
- O
length O
mouse O
c O
##dn O
##as O
that O
result O
from O
combinations O
of O
these O
three O
major O
s O
##p O
##licing O
events O
and O
show O
that O
their O
trans O
##fect O
##ion O
into O
cells O
in O
culture O
leads O
to O
production O
of O
four O
different O
approximately O
74 O
k O
##da O
full O
- O
length O
( O
heart O
- O
, O
skeletal O
muscle O
- O
or O
brain O
- O
specific O
) O
and O
two O
c O
- O
terminal O
##ly O
t O
##runcated O
approximately O
68 O
k O
##da O
( O
smooth O
muscle O
- O
specific O
) O
is O
##of O
##orms O
. O

information O
on O
d O
##mp O
##k O
m O
##rna O
and O
protein O
is O
##of O
##orm O
expression O
patterns O
will O
be O
useful O
for O
recognizing O
differential O
effects O
of O
( O
c O
##t O
##g O
) O
( O
n O
) O
expansion O
in O
d B-Disease
##m I-Disease
manifest O
##ation O
. O
. O

genetic O
analysis O
, O
p O
##hen O
##otypic O
diagnosis O
, O
and O
risk O
of O
ve B-Disease
##nous I-Disease
th I-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
in O
families O
with O
inherited O
def B-Disease
##ici I-Disease
##encies I-Disease
of I-Disease
protein I-Disease
s I-Disease
. O

protein B-Disease
s I-Disease
deficiency I-Disease
is O
a O
recognized O
risk O
factor O
for O
ve B-Disease
##nous I-Disease
th I-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
. O

of O
all O
the O
inherited O
th B-Disease
##rom I-Disease
##bo I-Disease
##phi I-Disease
##lic I-Disease
conditions I-Disease
, O
it O
remains O
the O
most O
difficult O
to O
di O
##ag O
##nose O
because O
of O
p O
##hen O
##otypic O
var O
##iability O
, O
which O
can O
lead O
to O
in O
##con O
##clusive O
results O
. O

we O
have O
overcome O
this O
problem O
by O
studying O
a O
co O
##hor O
##t O
of O
patients O
from O
a O
single O
center O
where O
the O
diagnosis O
was O
confirmed O
at O
the O
genetic O
level O
. O

twenty O
- O
eight O
index O
patients O
with O
protein B-Disease
s I-Disease
deficiency I-Disease
and O
a O
pro B-Disease
##s I-Disease
##1 I-Disease
gene I-Disease
defect I-Disease
were O
studied O
, O
together O
with O
109 O
first O
- O
degree O
relatives O
. O

to O
avoid O
selection O
bias O
, O
we O
confined O
analysis O
of O
total O
and O
free O
protein O
s O
levels O
and O
th O
##rom O
##bot O
##ic O
risk O
to O
the O
patients O
relatives O
. O

in O
this O
group O
of O
relatives O
, O
a O
low O
free O
protein O
s O
level O
was O
the O
most O
reliable O
predict O
##or O
of O
a O
pro B-Disease
##s I-Disease
##1 I-Disease
gene I-Disease
defect I-Disease
( O
sensitivity O
97 O
. O
7 O
% O
, O
specific O
##ity O
100 O
% O
) O
. O

first O
- O
degree O
relatives O
with O
a O
pro B-Disease
##s I-Disease
##1 I-Disease
gene I-Disease
defect I-Disease
had O
a O
5 O
. O

0 O
- O
fold O
higher O
risk O
of O
th B-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
( O
95 O
% O
confidence O
interval O
, O
1 O
. O
5 O
- O
16 O
. O
8 O
) O
than O
those O
with O
a O
normal O
pro O
##s O
##1 O
gene O
and O
no O
other O
recognized O
th B-Disease
##rom I-Disease
##bo I-Disease
##phi I-Disease
##lic I-Disease
defect I-Disease
. O

although O
pregnancy O
/ O
pu O
##er O
##per O
##ium O
and O
im O
##mo O
##bility O
/ O
trauma B-Disease
were O
important O
pre O
##ci O
##pit O
##ating O
factors O
for O
th B-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
, O
almost O
half O
of O
the O
events O
were O
spontaneous O
. O

relatives O
with O
s O
##p O
##lice O
- O
site O
or O
major O
structural O
defects B-Disease
in I-Disease
the I-Disease
pro I-Disease
##s I-Disease
##1 I-Disease
gene I-Disease
were O
more O
likely O
to O
have O
had O
a O
th O
##rom O
##bot O
##ic O
event O
and O
had O
significantly O
lower O
total O
and O
free O
protein O
s O
levels O
than O
those O
relatives O
having O
miss O
##ense O
mutations O
. O

we O
conclude O
that O
persons O
with O
pro B-Disease
##s I-Disease
##1 I-Disease
gene I-Disease
defects I-Disease
and O
protein B-Disease
s I-Disease
deficiency I-Disease
are O
at O
increased O
risk O
of O
th B-Disease
##rom I-Disease
##bos I-Disease
##is I-Disease
and O
that O
free O
protein O
s O
est O
##imation O
offers O
the O
most O
reliable O
way O
of O
di O
##ag O
##nos O
##ing O
the O
deficiency O
. O

( O
blood O
. O
2000 O
; O
95 O
1935 O
- O
1941 O
) O
. O

auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
( O
al B-Disease
##ps I-Disease
) O
in O
a O
child O
from O
con O
##sang O
##uin O
##eous O
parents O
: O
a O
dominant O
or O
re O
##cess O
##ive O
disease O
? O

auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
( O
al B-Disease
##ps I-Disease
) O
is O
characterized O
by O
auto O
##im O
##mu O
##ne O
features O
and O
l O
##ymph O
##op O
##rol O
##ifer O
##ations O
and O
is O
generally O
caused O
by O
defect O
##ive O
f O
##as O
- O
mediated O
a O
##pop O
##tosis O
. O

this O
report O
describes O
a O
child O
with O
clinical O
features O
of O
al B-Disease
##ps I-Disease
without O
detect O
##able O
f O
##as O
expression O
on O
freshly O
isolated O
blood O
le O
##uk O
##ocytes O
. O

detection O
of O
f O
##as O
trans O
##cripts O
via O
real O
- O
time O
quantitative O
p O
##c O
##r O
made O
a O
severe O
transcription O
##al O
defect O
unlikely O
. O

se O
##quencing O
of O
the O
f O
##as O
gene O
revealed O
a O
20 O
- O
n O
##uc O
##leo O
##tide O
du O
##plication O
in O
the O
last O
ex O
##on O
affecting O
the O
c O
##yt O
##op O
##las O
##mic O
signaling O
domain O
. O

the O
patient O
was O
ho O
##mo O
##zy O
##go O
##us O
for O
this O
mutation O
, O
whereas O
the O
con O
##sang O
##uin O
##eous O
parents O
and O
the O
siblings O
were O
he O
##tero O
##zy O
##go O
##us O
. O

the O
patient O
reported O
here O
is O
a O
human O
ho O
##mo O
##logue O
of O
the O
f O
##as O
- O
null O
mouse O
, O
in O
##as O
##mu O
##ch O
as O
she O
carries O
an O
auto O
##so O
##mal O
ho O
##mo O
##zy O
##go O
##us O
mutation O
in O
the O
f O
##as O
gene O
and O
she O
shows O
the O
severe O
and O
accelerated O
al B-Disease
##ps I-Disease
p O
##hen O
##otype O
. O

the O
he O
##tero O
##zy O
##go O
##us O
family O
members O
did O
not O
have O
the O
al B-Disease
##ps I-Disease
p O
##hen O
##otype O
, O
indicating O
that O
the O
disease O
- O
causing O
f O
##as O
mutation O
in O
this O
family O
is O
auto O
##so O
##mal O
re O
##cess O
##ive O
. O
. O

identification O
of O
novel O
imprint O
##ed O
trans O
##cripts O
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
and O
angel B-Disease
##man I-Disease
syndrome I-Disease
del O
##eti O
##on O
region O
: O
further O
evidence O
for O
regional O
imprint O
##ing O
control O
. O

del O
##eti O
##ons O
and O
other O
abnormal O
##ities O
of O
human O
chromosome O
15 O
##q O
##11 O
- O
q O
##13 O
are O
associated O
with O
two O
developmental O
disorders O
, O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
and O
angel B-Disease
##man I-Disease
syndrome I-Disease
( O
as B-Disease
) O
. O

loss O
of O
expression O
of O
imprint O
##ed O
, O
paternal O
##ly O
expressed O
genes O
has O
been O
implicated O
in O
p B-Disease
##ws I-Disease
. O

however O
, O
the O
number O
of O
imprint O
##ed O
genes O
that O
contribute O
to O
p B-Disease
##ws I-Disease
, O
and O
the O
range O
over O
which O
the O
imprint O
##ing O
signal O
acts O
to O
silence O
one O
copy O
of O
the O
gene O
in O
a O
parent O
- O
of O
- O
origin O
- O
specific O
manner O
, O
are O
unknown O
. O

to O
identify O
additional O
imprint O
##ed O
genes O
that O
could O
contribute O
to O
the O
p B-Disease
##ws I-Disease
p O
##hen O
##otype O
and O
to O
understand O
the O
regional O
control O
of O
imprint O
##ing O
in O
15 O
##q O
##11 O
- O
q O
##13 O
, O
we O
have O
constructed O
an O
imprint O
##ed O
trans O
##cript O
map O
of O
the O
p O
##ws O
- O
as O
del O
##eti O
##on O
interval O
. O

the O
imprint O
##ing O
status O
of O
22 O
expressed O
sequence O
tags O
derived O
from O
the O
radiation O
- O
hybrid O
human O
trans O
##cript O
maps O
or O
physical O
maps O
was O
determined O
in O
a O
reverse O
trans O
##cript O
##ase O
- O
p O
##c O
##r O
ass O
##ay O
and O
correlated O
with O
the O
position O
of O
the O
trans O
##cripts O
on O
the O
physical O
map O
. O

seven O
new O
paternal O
##ly O
expressed O
trans O
##cripts O
local O
##ize O
to O
an O
approximately O
1 O
. O

5 O
- O
m O
##b O
domain O
surrounding O
the O
s O
##n O
##rp O
##n O
- O
associated O
imprint O
##ing O
center O
, O
which O
already O
includes O
four O
imprint O
##ed O
, O
paternal O
##ly O
expressed O
genes O
. O

all O
other O
tested O
new O
trans O
##cripts O
in O
the O
del O
##eti O
##on O
region O
were O
expressed O
from O
both O
all O
##ele O
##s O
. O

a O
domain O
of O
exclusive O
paternal O
expression O
surrounding O
the O
imprint O
##ing O
center O
suggests O
strong O
regional O
control O
of O
the O
imprint O
##ing O
process O
. O

this O
study O
provides O
the O
means O
for O
further O
investigation O
of O
additional O
genes O
that O
cause O
or O
modify O
the O
p O
##hen O
##otype O
##s O
associated O
with O
rear O
##rang O
##ement O
##s O
of O
15 O
##q O
##11 O
- O
q O
##13 O
. O

combined O
analysis O
of O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
link O
##age O
to O
1 O
##q O
##24 O
- O
25 O
: O
results O
from O
77 O
##2 O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
families O
from O
the O
international O
consortium O
for O
pro B-Disease
##state I-Disease
cancer I-Disease
genetics O
. O

a O
previous O
link O
##age O
study O
provided O
evidence O
for O
a O
pro B-Disease
##state I-Disease
cancer I-Disease
- O
su O
##s O
##ce O
##pt O
##ibility O
lo O
##cus O
at O
1 O
##q O
##24 O
- O
25 O
. O

subsequent O
reports O
in O
additional O
collections O
of O
families O
have O
yielded O
conflicting O
results O
. O

in O
addition O
, O
evidence O
for O
lo O
##cus O
he O
##tero O
##gene O
##ity O
has O
been O
provided O
by O
the O
identification O
of O
other O
put O
##ative O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
lo O
##ci O
on O
x O
##q O
##27 O
- O
28 O
, O
1 O
##q O
##42 O
- O
43 O
, O
and O
1 O
##p O
##36 O
. O

the O
present O
study O
describes O
a O
combined O
analysis O
for O
six O
markers O
in O
the O
1 O
##q O
##24 O
- O
25 O
region O
in O
77 O
##2 O
families O
affected O
by O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
and O
as O
##cer O
##tain O
##ed O
by O
the O
members O
of O
the O
international O
consortium O
for O
pro B-Disease
##state I-Disease
cancer I-Disease
genetics O
( O
i O
##c O
##p O
##c O
##g O
) O
from O
north O
am O
##eric O
##a O
, O
au O
##stra O
##lia O
, O
fin O
##land O
, O
nor O
##way O
, O
s O
##wed O
##en O
, O
and O
the O
united O
kingdom O
. O

overall O
, O
there O
was O
some O
evidence O
for O
link O
##age O
, O
with O
a O
peak O
para O
##metric O
multi O
##point O
lo O
##d O
score O
assuming O
he O
##tero O
##gene O
##ity O
( O
h O
##lo O
##d O
) O
of O
1 O
. O

40 O
( O
p O
= O
. O
01 O
) O
at O
d O
##1 O
##s O
##21 O
##2 O
. O

the O
estimated O
proportion O
of O
families O
( O
alpha O
) O
linked O
to O
the O
lo O
##cus O
was O
. O

06 O
( O
1 O
- O
lo O
##d O
support O
interval O
. O
01 O
- O
. O
12 O
) O
. O

this O
evidence O
was O
not O
observed O
by O
a O
non O
##par O
##ame O
##tric O
approach O
, O
presumably O
because O
of O
the O
extensive O
he O
##tero O
##gene O
##ity O
. O

further O
para O
##metric O
analysis O
revealed O
a O
significant O
effect O
of O
the O
presence O
of O
male O
- O
to O
- O
male O
disease O
transmission O
within O
the O
families O
. O

in O
the O
subset O
of O
49 O
##1 O
such O
families O
, O
the O
peak O
h O
##lo O
##d O
was O
2 O
. O

in O
the O
subset O
of O
49 O
##1 O
such O
families O
, O
the O
peak O
h O
##lo O
##d O
was O
2 O
. O

56 O
( O
p O
= O
. O
000 O
##6 O
) O
and O
alpha O
= O
. O

11 O
( O
1 O
- O
lo O
##d O
support O
interval O
. O
04 O
- O
. O
19 O
) O
, O
compared O
with O
h O
##lo O
##ds O
of O
0 O
in O
the O
remaining O
281 O
families O
. O

within O
the O
families O
with O
male O
- O
to O
- O
male O
disease O
transmission O
, O
alpha O
increased O
with O
the O
early O
mean O
age O
at O
diagnosis O
( O
[UNK] O
65 O
years O
, O
alpha O
= O
. O
19 O
, O
with O
1 O
- O
lo O
##d O
support O
interval O
. O
06 O
- O
. O
34 O
) O
and O
the O
number O
of O
affected O
family O
members O
( O
five O
or O
more O
family O
members O
, O
alpha O
= O
. O
15 O
, O
with O
1 O
- O
lo O
##d O
support O
interval O
. O
04 O
- O
. O
28 O
) O
. O

the O
highest O
value O
of O
alpha O
was O
observed O
for O
the O
48 O
families O
that O
met O
all O
three O
criteria O
( O
peak O
h O
##lo O
##d O
= O
2 O
. O
25 O
, O
p O
= O
. O
00 O
##1 O
, O
alpha O
= O
. O
29 O
, O
with O
1 O
- O
lo O
##d O
support O
interval O
. O
08 O
- O
. O
53 O
) O
. O

these O
results O
support O
the O
finding O
of O
a O
pro B-Disease
##state I-Disease
cancer I-Disease
- O
su O
##s O
##ce O
##pt O
##ibility O
gene O
linked O
to O
1 O
##q O
##24 O
- O
25 O
, O
albeit O
in O
a O
defined O
subset O
of O
pro B-Disease
##state I-Disease
cancer I-Disease
families O
. O

although O
hp O
##c O
##1 O
accounts O
for O
only O
a O
small O
proportion O
of O
all O
families O
affected O
by O
hereditary B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
, O
it O
appears O
to O
play O
a O
more O
prominent O
role O
in O
the O
subset O
of O
families O
with O
several O
members O
affected O
at O
an O
early O
age O
and O
with O
male O
- O
to O
- O
male O
disease O
transmission O
. O

a O
re O
##current O
expansion O
of O
a O
maternal O
all O
##ele O
with O
36 O
ca O
##g O
repeats O
causes O
hunting B-Disease
##ton I-Disease
disease I-Disease
in O
two O
sisters O
. O

large O
inter O
##gene O
##ration O
##al O
repeat O
expansion O
##s O
of O
the O
ca O
##g O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
the O
h B-Disease
##d I-Disease
gene O
have O
been O
well O
documented O
for O
the O
male O
g O
##er O
##m O
##line O
. O

we O
describe O
a O
re O
##current O
large O
expansion O
of O
a O
maternal O
all O
##ele O
with O
36 O
ca O
##g O
repeats O
( O
to O
66 O
and O
57 O
repeats O
, O
respectively O
, O
in O
two O
daughters O
) O
associated O
with O
onset O
of O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
in O
the O
second O
and O
third O
decade O
in O
a O
family O
without O
history O
of O
h B-Disease
##d I-Disease
. O

our O
findings O
give O
evidence O
of O
a O
go O
##na O
##dal O
mosaic O
##ism O
in O
the O
un O
##af O
##fected O
mother O
. O

we O
h O
##y O
##pot O
##hes O
##ize O
that O
large O
expansion O
##s O
also O
occur O
in O
the O
female O
g O
##er O
##m O
##line O
and O
that O
a O
negative O
selection O
of O
o O
##ocytes O
with O
long O
repeats O
might O
explain O
the O
different O
instability O
behavior O
of O
the O
male O
and O
the O
female O
g O
##er O
##m O
##lines O
. O
. O

abnormal O
development O
of O
pu O
##rkin O
##je O
cells O
and O
l O
##ymph O
##ocytes O
in O
at O
##m O
mutant O
mice O
. O

motor B-Disease
in I-Disease
##co I-Disease
##ordination I-Disease
, O
immune B-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
, O
and O
an O
increased O
risk O
of O
cancer B-Disease
are O
the O
characteristic O
features O
of O
the O
hereditary B-Disease
disease I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
which O
is O
caused O
by O
mutations O
in O
the O
at O
##m O
gene O
. O

through O
gene O
targeting O
, O
we O
have O
generated O
a O
line O
of O
at O
##m O
mutant O
mice O
, O
at O
##m O
( O
y O
/ O
y O
) O
mice O
. O

in O
contrast O
to O
other O
at O
##m O
mutant O
mice O
, O
at O
##m O
( O
y O
/ O
y O
) O
mice O
show O
a O
lower O
incidence O
of O
thy B-Disease
##mic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
and O
survive O
beyond O
a O
few O
months O
of O
age O
. O

at O
##m O
( O
y O
/ O
y O
) O
mice O
exhibit O
deficit O
##s O
in O
motor O
learning O
in O
##dicative O
of O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
. O

even O
though O
we O
found O
no O
gross O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
in O
older O
at O
##m O
( O
y O
/ O
y O
) O
animals O
, O
e O
##ct O
##op O
##ic O
and O
abnormal O
##ly O
differentiated O
pu O
##rkin O
##je O
cells O
were O
apparent O
in O
mutant O
mice O
of O
all O
ages O
. O

these O
findings O
establish O
that O
some O
ne B-Disease
##uro I-Disease
##path I-Disease
##ological I-Disease
abnormal I-Disease
##ities I-Disease
seen O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
also O
are O
present O
in O
at O
##m O
mutant O
mice O
. O

in O
addition O
, O
we O
report O
a O
previously O
un O
##re O
##co O
##gni O
##zed O
effect O
of O
at B-Disease
##m I-Disease
deficiency I-Disease
on O
development O
or O
maintenance O
of O
c O
##d O
##4 O
( O
+ O
) O
8 O
( O
+ O
) O
thy O
##mo O
##cy O
##tes O
. O

we O
discuss O
these O
findings O
in O
the O
context O
of O
the O
hypothesis O
that O
abnormal O
development O
of O
pu O
##rkin O
##je O
cells O
and O
l O
##ymph O
##ocytes O
contributes O
to O
the O
path O
##ogen O
##esis O
of O
a B-Disease
- I-Disease
t I-Disease
. O
. O

novel O
mutations O
of O
the O
at O
##p O
##7 O
##b O
gene O
in O
j O
##apa O
##nese O
patients O
with O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
( O
w B-Disease
##d I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
copper O
accumulation O
in O
the O
liver O
, O
brain O
, O
kidney O
##s O
, O
and O
corn O
##eas O
, O
and O
culminating O
in O
copper O
toxic O
##ation O
in O
these O
organs O
. O

in O
this O
study O
, O
we O
analyzed O
mutations O
of O
the O
responsible O
gene O
, O
at O
##p O
##7 O
##b O
, O
in O
four O
j O
##apa O
##nese O
patients O
with O
w B-Disease
##d I-Disease
. O

by O
direct O
se O
##quencing O
, O
we O
identified O
five O
mutations O
, O
of O
which O
two O
were O
novel O
, O
and O
16 O
p O
##oly O
##mor O
##phism O
##s O
, O
of O
which O
6 O
were O
novel O
. O

the O
mutations O
287 O
##1 O
##del O
##c O
and O
251 O
##3 O
##dela O
shift O
the O
reading O
frame O
so O
that O
t O
##runcated O
abnormal O
protein O
is O
expected O
. O

in O
contrast O
to O
these O
mutations O
found O
in O
patients O
with O
he O
##pa O
##tic O
- O
type O
of O
early O
onset O
, O
the O
mutations O
a O
##8 O
##7 O
##4 O
##v O
, O
r O
##7 O
##7 O
##8 O
##l O
, O
and O
38 O
##9 O
##2 O
##del O
##gt O
##c O
were O
either O
miss O
##ense O
mutations O
or O
in O
frame O
1 O
- O
amino O
acid O
del O
##eti O
##on O
, O
and O
occurred O
in O
the O
patients O
with O
he O
##pa O
##to O
- O
ne O
##uro O
##log O
##ic O
type O
of O
late O
onset O
. O

the O
mutations O
287 O
##1 O
##del O
##c O
and O
r O
##7 O
##7 O
##8 O
##l O
have O
been O
previously O
reported O
in O
a O
relatively O
large O
number O
of O
j O
##apa O
##nese O
patients O
. O

in O
particular O
, O
r O
##7 O
##7 O
##8 O
##l O
is O
known O
to O
be O
more O
prevalent O
in O
as O
##ian O
countries O
than O
in O
other O
countries O
of O
the O
world O
. O

our O
data O
are O
compatible O
with O
the O
hypothesis O
that O
the O
mutations O
tend O
to O
occur O
in O
a O
population O
- O
specific O
manner O
. O

therefore O
, O
the O
accumulation O
of O
the O
types O
of O
mutations O
in O
j O
##apa O
##nese O
patients O
with O
w B-Disease
##d I-Disease
will O
facilitate O
the O
fast O
and O
effective O
genetic O
diagnosis O
of O
w B-Disease
##d I-Disease
in O
j O
##apa O
##nese O
patients O
. O
. O

auto O
##in O
##hibition O
and O
activation O
mechanisms O
of O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
. O

the O
r O
##ho O
- O
family O
g O
##t O
##pas O
##e O
, O
c O
##d O
##c O
##42 O
, O
can O
regulate O
the O
act O
##in O
c O
##yt O
##os O
##kel O
##eton O
through O
activation O
of O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
( O
was O
##p O
) O
family O
members O
. O

activation O
relieve O
##s O
an O
auto O
##in O
##hibit O
##ory O
contact O
between O
the O
g O
##t O
##pas O
##e O
- O
binding O
domain O
and O
the O
car O
##box O
##y O
- O
terminal O
region O
of O
was O
##p O
proteins O
. O

here O
we O
report O
the O
auto O
##in O
##hibit O
##ed O
structure O
of O
the O
g O
##t O
##pas O
##e O
- O
binding O
domain O
of O
was O
##p O
, O
which O
can O
be O
induced O
by O
the O
c O
- O
terminal O
region O
or O
by O
organic O
co O
- O
solvent O
##s O
. O

in O
the O
auto O
##in O
##hibit O
##ed O
complex O
, O
in O
##tra O
##mo O
##le O
##cular O
interactions O
with O
the O
g O
##t O
##pas O
##e O
- O
binding O
domain O
o O
##cc O
##lude O
residues O
of O
the O
c O
terminus O
that O
regulate O
the O
a O
##rp O
##2 O
/ O
3 O
act O
##in O
- O
n O
##uc O
##lea O
##ting O
complex O
. O

binding O
of O
c O
##d O
##c O
##42 O
to O
the O
g O
##t O
##pas O
##e O
- O
binding O
domain O
causes O
a O
dramatic O
conform O
##ational O
change O
, O
resulting O
in O
disruption O
of O
the O
h O
##ydro O
##phobic O
core O
and O
release O
of O
the O
c O
terminus O
, O
enabling O
its O
interaction O
with O
the O
act O
##in O
regulatory O
machinery O
. O

these O
data O
show O
that O
intrinsic O
##ally O
un O
##structure O
##d O
p O
##eptide O
##s O
such O
as O
the O
g O
##t O
##pas O
##e O
- O
binding O
domain O
of O
was O
##p O
can O
be O
induced O
into O
distinct O
structural O
and O
functional O
states O
depending O
on O
context O
. O
. O

h O
##c O
##ds O
##1 O
- O
mediated O
p O
##hos O
##ph O
##ory O
##lation O
of O
br O
##ca O
##1 O
regulate O
##s O
the O
d O
##na O
damage O
response O
. O

mutations O
in O
the O
br O
##ca O
##1 O
( O
re O
##f O
. O
1 O
) O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
are O
found O
in O
almost O
all O
of O
the O
families O
with O
inherited B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
and O
about O
half O
of O
the O
families O
with O
only O
breast B-Disease
cancer I-Disease
. O

although O
the O
bio O
##chemical O
function O
of O
br O
##ca O
##1 O
is O
not O
well O
understood O
, O
it O
is O
important O
for O
d O
##na O
damage O
repair O
and O
cell O
- O
cycle O
check O
##point O
. O

br O
##ca O
##1 O
exists O
in O
nuclear O
f O
##oc O
##i O
but O
is O
h O
##yper O
##ph O
##os O
##ph O
##ory O
##lated O
and O
di O
##sper O
##ses O
after O
d O
##na O
damage O
. O

it O
is O
not O
known O
whether O
br O
##ca O
##1 O
p O
##hos O
##ph O
##ory O
##lation O
and O
di O
##sper O
##sion O
and O
its O
function O
in O
d O
##na O
damage O
response O
are O
related O
. O

in O
yeast O
the O
d O
##na O
damage O
response O
and O
the O
replication O
- O
block O
check O
##point O
are O
mediated O
partly O
through O
the O
c O
##ds O
##1 O
kinase O
family O
. O

here O
we O
report O
that O
the O
human O
c O
##ds O
##1 O
kinase O
( O
h O
##c O
##ds O
##1 O
/ O
ch O
##k O
##2 O
) O
regulate O
##s O
br O
##ca O
##1 O
function O
after O
d O
##na O
damage O
by O
p O
##hos O
##ph O
##ory O
##lating O
se O
##rine O
98 O
##8 O
of O
br O
##ca O
##1 O
. O

we O
show O
that O
h O
##c O
##ds O
##1 O
and O
br O
##ca O
##1 O
interact O
and O
co O
- O
local O
##ize O
within O
discrete O
nuclear O
f O
##oc O
##i O
but O
separate O
after O
gamma O
i O
##rra O
##diation O
. O

p O
##hos O
##ph O
##ory O
##lation O
of O
br O
##ca O
##1 O
at O
se O
##rine O
98 O
##8 O
is O
required O
for O
the O
release O
of O
br O
##ca O
##1 O
from O
h O
##c O
##ds O
##1 O
. O

this O
p O
##hos O
##ph O
##ory O
##lation O
is O
also O
important O
for O
the O
ability O
of O
br O
##ca O
##1 O
to O
restore O
survival O
after O
d O
##na O
damage O
in O
the O
br O
##ca O
##1 O
- O
m O
##uta O
##ted O
cell O
line O
h O
##cc O
##19 O
##37 O
. O
. O

characterization O
of O
the O
rat O
spin O
##oc O
##ere O
##bella O
##r O
at O
##ax O
##ia O
type O
3 O
gene O
. O

mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
belongs O
to O
a O
group O
of O
clinical O
##ly O
and O
genetically O
he O
##tero O
##gene O
##ous O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disorders I-Disease
characterized O
by O
progressive B-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

the O
disease O
- O
causing O
mutation O
has O
recently O
been O
identified O
as O
an O
unstable O
and O
expanded O
( O
ca O
##g O
) O
n O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
a O
novel O
gene O
of O
unknown O
function O
. O

in O
ca O
##uca O
##sian O
##s O
, O
repeat O
expansion O
##s O
in O
the O
m O
##j O
##d O
##1 O
gene O
have O
also O
been O
found O
in O
patients O
with O
the O
clinical O
##ly O
distinct O
auto O
##so O
##mal O
dominant O
spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
type I-Disease
3 I-Disease
( O
s B-Disease
##ca I-Disease
##3 I-Disease
) O
. O

in O
order O
to O
gain O
insight O
into O
the O
biology O
of O
the O
m O
##j O
##d O
##1 O
/ O
s O
##ca O
##3 O
gene O
we O
clone O
##d O
the O
rat O
ho O
##mo O
##logue O
and O
studied O
its O
expression O
. O

the O
rat O
and O
human O
at O
##ax O
##in O
- O
3 O
genes O
are O
highly O
ho O
##mo O
##log O
##ous O
with O
an O
overall O
sequence O
identity O
of O
approximately O
88 O
% O
. O

however O
, O
the O
c O
- O
terminal O
end O
of O
the O
put O
##ative O
protein O
differs O
strongly O
from O
the O
published O
human O
sequence O
. O

the O
( O
ca O
##g O
) O
n O
block O
in O
the O
rat O
c O
##dn O
##a O
consists O
of O
just O
three O
interrupted O
units O
suggesting O
that O
a O
long O
p O
##oly O
##g O
##lut O
##amine O
stretch O
is O
not O
essential O
for O
the O
normal O
function O
of O
the O
at O
##ax O
##in O
- O
3 O
protein O
in O
rode O
##nts O
. O

the O
expression O
pattern O
of O
the O
s O
##ca O
##3 O
gene O
in O
various O
rat O
and O
human O
tissues O
was O
investigated O
by O
northern O
b O
##lot O
analyses O
. O

the O
mature O
trans O
##cript O
is O
approximately O
6 O
k O
##b O
in O
length O
. O

in O
rat O
test O
##is O
, O
a O
smaller O
trans O
##cript O
of O
1 O
. O

3 O
k O
##b O
was O
identified O
. O

transcription O
of O
r O
##sca O
##3 O
was O
detected O
in O
most O
rat O
tissues O
including O
brain O
. O

analyzing O
the O
expression O
level O
of O
the O
s O
##ca O
##3 O
gene O
in O
several O
human O
brain O
sections O
revealed O
no O
significant O
higher O
m O
##rna O
level O
in O
regions O
predominantly O
affected O
in O
m B-Disease
##j I-Disease
##d I-Disease
. O

thus O
additional O
molecules O
and O
/ O
or O
regulatory O
events O
are O
necessary O
to O
explain O
the O
exclusive O
de B-Disease
##gene I-Disease
##ration I-Disease
of I-Disease
certain I-Disease
brain I-Disease
areas I-Disease
. O

em B-Disease
##eri I-Disease
##n I-Disease
, I-Disease
deficiency I-Disease
of O
which O
causes O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
is O
localized O
at O
the O
inner O
nuclear O
membrane O
. O

x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
is O
an O
inherited B-Disease
muscle I-Disease
disorder I-Disease
characterized O
by O
the O
clinical O
t O
##riad O
of O
progressive O
wasting B-Disease
of I-Disease
hum I-Disease
##ero I-Disease
- I-Disease
per I-Disease
##one I-Disease
##al I-Disease
muscles I-Disease
, O
early O
contract B-Disease
##ures I-Disease
of I-Disease
the I-Disease
elbows I-Disease
, I-Disease
a I-Disease
##chi I-Disease
##lles I-Disease
tend I-Disease
##ons I-Disease
and I-Disease
post I-Disease
##cer I-Disease
##vic I-Disease
##al I-Disease
muscles I-Disease
, O
and O
cardiac B-Disease
conduct I-Disease
##ion I-Disease
block I-Disease
with O
a O
high O
risk O
of O
sudden B-Disease
death I-Disease
. O

the O
gene O
for O
ed B-Disease
##m I-Disease
##d I-Disease
on O
x O
##q O
##28 O
en O
##codes O
a O
novel O
protein O
named O
em O
##eri O
##n O
that O
local O
##izes O
at O
the O
nuclear O
membrane O
of O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
and O
some O
other O
non O
- O
muscle O
tissues O
. O

to O
investigate O
a O
possible O
physiological O
role O
for O
em O
##eri O
##n O
, O
we O
examined O
the O
ultra O
##st O
##ructural O
local O
##ization O
of O
the O
protein O
in O
human O
skeletal O
muscle O
and O
he O
##la O
cells O
, O
using O
ultra O
##thin O
cry O
##ose O
##ctions O
. O

we O
found O
that O
the O
immune O
- O
labeled O
co O
##llo O
##idal O
gold O
particles O
were O
localized O
on O
the O
n O
##uc O
##leo O
##p O
##las O
##mic O
surface O
of O
the O
inner O
nuclear O
membrane O
, O
but O
not O
on O
the O
nuclear O
p O
##ore O
. O

em O
##eri O
##n O
stayed O
on O
the O
c O
##yt O
##op O
##las O
##mic O
surface O
of O
the O
nuclear O
la O
##mina O
, O
even O
after O
de O
##ter O
##gent O
treatment O
that O
so O
##lub O
##ilize O
##s O
membrane O
lip O
##ids O
and O
wash O
##es O
out O
membrane O
proteins O
. O

these O
results O
suggest O
that O
em O
##eri O
##n O
anchor O
##s O
at O
the O
inner O
nuclear O
membrane O
through O
the O
h O
##ydro O
##phobic O
stretch O
, O
and O
pro O
##tr O
##udes O
from O
the O
h O
##ydro O
##phi O
##lic O
region O
to O
the O
n O
##uc O
##leo O
##p O
##las O
##m O
where O
it O
interact O
##s O
with O
the O
nuclear O
la O
##mina O
. O

we O
s O
##pec O
##ulate O
that O
em O
##eri O
##n O
contributes O
to O
maintain O
the O
nuclear O
structure O
and O
stability O
, O
as O
well O
as O
nuclear O
functions O
, O
particularly O
in O
muscle O
tissues O
that O
have O
severe O
stress O
with O
rigorous O
contraction O
- O
relaxation O
movements O
and O
calcium O
flux O
. O
. O

lo O
##cus O
he O
##tero O
##gene O
##ity O
in O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
is O
the O
most O
common O
form O
of O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

the O
disease O
lo O
##cus O
was O
assigned O
to O
chromosome O
9 O
and O
the O
disease O
gene O
, O
s O
##t O
##m O
##7 O
/ O
x O
##25 O
, O
has O
been O
isolated O
. O

to O
date O
most O
data O
suggest O
lo O
##cus O
ho O
##mo O
##gene O
##ity O
in O
f B-Disease
##rda I-Disease
. O

we O
now O
provide O
strong O
evidence O
of O
a O
second O
f B-Disease
##rda I-Disease
lo O
##cus O
. O

studying O
two O
siblings O
with O
f B-Disease
##rda I-Disease
from O
two O
families O
we O
did O
not O
detect O
a O
mutation O
in O
s O
##t O
##m O
##7 O
/ O
x O
##25 O
. O

ha O
##p O
##lot O
##ype O
analysis O
of O
the O
s O
##t O
##m O
##7 O
/ O
x O
##25 O
region O
of O
chromosome O
9 O
demonstrated O
that O
the O
relevant O
portion O
of O
chromosome O
9 O
differs O
in O
the O
patients O
. O

although O
the O
patients O
studied O
had O
typical O
f B-Disease
##rda I-Disease
, O
one O
si O
##b O
##pair O
had O
the O
uncommon O
s O
##ym O
##pt O
##om O
of O
retained O
tend O
##on O
reflex O
##es O
. O

in O
order O
to O
investigate O
whether O
retained O
tend O
##on O
reflex O
##es O
are O
characteristic O
of O
f B-Disease
##rda I-Disease
caused O
by O
the O
second O
lo O
##cus O
, O
f O
##rda O
##2 O
, O
we O
studied O
an O
unrelated O
f B-Disease
##rda I-Disease
patient O
with O
retained O
tend O
##on O
reflex O
##es O
. O

the O
observation O
of O
typical O
mutations O
in O
s O
##t O
##m O
##7 O
/ O
x O
##25 O
( O
g O
##aa O
expansion O
##s O
) O
in O
this O
patient O
demonstrates O
that O
the O
two O
genetically O
different O
forms O
of O
f B-Disease
##rda I-Disease
cannot O
be O
distinguished O
clinical O
##ly O
. O
. O

g O
##ly O
##cer O
##ol O
as O
a O
co O
##rrel O
##ate O
of O
impaired B-Disease
glucose I-Disease
tolerance I-Disease
: O
di O
##sse O
##ction O
of O
a O
complex O
system O
by O
use O
of O
a O
simple O
genetic O
trait O
. O

g O
##ly O
##cer O
##ol O
kinase O
( O
g O
##k O
) O
represents O
the O
primary O
entry O
of O
g O
##ly O
##cer O
##ol O
into O
glucose O
and O
t O
##rig O
##ly O
##cer O
##ide O
metabolism O
. O

impaired B-Disease
glucose I-Disease
tolerance I-Disease
( O
i B-Disease
##gt I-Disease
) O
and O
h B-Disease
##yper I-Disease
##tri I-Disease
##gly I-Disease
##cer I-Disease
##ide I-Disease
##mia I-Disease
are O
associated O
with O
an O
increased O
risk O
of O
diabetes B-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
and O
card B-Disease
##iovascular I-Disease
disease I-Disease
. O

the O
relationship O
between O
g O
##ly O
##cer O
##ol O
and O
the O
risk O
of O
i B-Disease
##gt I-Disease
, O
however O
, O
is O
poorly O
understood O
. O

we O
therefore O
undertook O
the O
study O
of O
fast O
##ing O
plasma O
g O
##ly O
##cer O
##ol O
levels O
in O
a O
co O
##hor O
##t O
of O
1 O
, O
05 O
##6 O
unrelated O
men O
and O
women O
of O
f O
##rench O
- O
can O
##adia O
##n O
descent O
. O

family O
screening O
in O
the O
initial O
co O
##hor O
##t O
identified O
18 O
men O
from O
five O
families O
with O
severe O
h B-Disease
##yper I-Disease
##gly I-Disease
##cer I-Disease
##ole I-Disease
##mia I-Disease
( O
values O
above O
2 O
. O
0 O
mm O
##ol O
/ O
liter O
) O
and O
demonstrated O
an O
x O
- O
linked O
pattern O
of O
inheritance O
. O

link O
##age O
analysis O
of O
the O
data O
from O
12 O
micro O
##sat O
##elli O
##te O
markers O
surrounding O
the O
x O
##p O
##21 O
. O

3 O
g O
##k O
gene O
resulted O
in O
a O
peak O
lo O
##d O
score O
of O
3 O
. O

46 O
, O
centered O
around O
marker O
d O
##x O
##s O
##80 O
##39 O
. O

in O
addition O
, O
since O
all O
of O
the O
families O
originated O
in O
a O
population O
with O
a O
proven O
founder O
effect O
- O
the O
sa O
##gue O
##nay O
la O
##c O
- O
s O
##t O
. O

- O
j O
##ean O
region O
of O
que O
##be O
##c O
- O
a O
common O
disease O
ha O
##p O
##lot O
##ype O
was O
sought O
. O

indeed O
, O
a O
six O
- O
marker O
ha O
##p O
##lot O
##ype O
extending O
over O
a O
region O
of O
5 O
. O

5 O
cm O
was O
observed O
in O
all O
families O
. O

re O
##se O
##quencing O
of O
the O
g O
##k O
gene O
in O
family O
members O
led O
to O
the O
discovery O
of O
a O
n O
##28 O
##8 O
##d O
miss O
##ense O
mutation O
in O
ex O
##on O
10 O
, O
which O
resulted O
in O
the O
substitution O
of O
a O
highly O
conserved O
as O
##par O
##agi O
##ne O
residue O
by O
a O
negatively O
charged O
as O
##par O
##tic O
acid O
. O

clinical O
and O
molecular O
genetics O
of O
primary B-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ias I-Disease
. O

primary B-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ias I-Disease
are O
movement B-Disease
disorders I-Disease
with O
d B-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
as O
a O
major O
s O
##ym O
##pt O
##om O
. O

they O
are O
frequently O
inherited O
as O
men O
##del O
##ian O
traits O
. O

there O
are O
at O
least O
eight O
clinical O
##ly O
distinct O
auto O
##so O
##mal O
dominant O
and O
two O
x O
- O
linked O
re O
##cess O
##ive O
forms O
. O

in O
addition O
, O
p O
##ed O
##ig O
##ree O
analyses O
suggest O
the O
occurrence O
of O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
variant O
. O

the O
clinical O
classification O
is O
increasingly O
being O
replaced O
by O
a O
genetic O
one O
. O

to O
date O
gene O
lo O
##ci O
have O
been O
identified O
in O
at O
least O
six O
auto O
##so O
##mal O
dominant O
forms O
, O
i O
. O
e O
. O
, O
in O
id B-Disease
##io I-Disease
##pathic I-Disease
to I-Disease
##rs I-Disease
##ion I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
( O
9 O
##q O
##34 O
) O
, O
focal B-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
( O
18 O
##p O
) O
, O
adult O
- O
onset O
id B-Disease
##io I-Disease
##pathic I-Disease
to I-Disease
##rs I-Disease
##ion I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
of O
mixed O
type O
( O
8 O
##p O
##21 O
- O
q O
##22 O
) O
, O
do B-Disease
##pa I-Disease
- I-Disease
re I-Disease
##sp I-Disease
##ons I-Disease
##ive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
( O
14 O
##q O
##22 O
. O
1 O
- O
q O
##22 O
. O
2 O
) O
, O
and O
par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ic I-Disease
ch I-Disease
##ore I-Disease
##oat I-Disease
##he I-Disease
##tosis I-Disease
( O
2 O
##q O
##25 O
- O
q O
##33 O
; O
1 O
##p O
##21 O
- O
p O
##13 O
. O
3 O
) O
. O

gene O
lo O
##ci O
in O
the O
x O
- O
linked O
re O
##cess O
##ive O
forms O
have O
been O
assigned O
to O
x O
##q O
##13 O
. O

1 O
in O
the O
x B-Disease
- I-Disease
linked I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
park I-Disease
##ins I-Disease
##oni I-Disease
##sm I-Disease
syndrome I-Disease
and O
to O
x O
##q O
##22 O
in O
x B-Disease
- I-Disease
linked I-Disease
sensor I-Disease
##ine I-Disease
##ural I-Disease
deaf I-Disease
##ness I-Disease
, O
d B-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
, O
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
. O

the O
disease O
genes O
have O
been O
identified O
in O
two O
auto O
##so O
##mal O
dominant O
forms O
and O
in O
one O
x O
- O
linked O
re O
##cess O
##ive O
form O
. O

mutations O
in O
a O
gene O
coding O
for O
an O
at O
##p O
- O
binding O
protein O
were O
detected O
in O
id B-Disease
##io I-Disease
##pathic I-Disease
to I-Disease
##rs I-Disease
##ion I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
( O
d O
##yt O
##1 O
) O
, O
and O
the O
g O
##t O
##p O
c O
##y O
##c O
##lo O
##hy O
##dr O
##ola O
##se O
1 O
gene O
is O
m O
##uta O
##ted O
in O
do B-Disease
##pa I-Disease
- I-Disease
re I-Disease
##sp I-Disease
##ons I-Disease
##ive I-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
( O
d O
##yt O
##5 O
) O
. O

in O
sensor B-Disease
##ine I-Disease
##ural I-Disease
deaf I-Disease
##ness I-Disease
, O
d B-Disease
##ys I-Disease
##ton I-Disease
##ia I-Disease
, O
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
mutations O
were O
found O
in O
the O
gene O
d O
##d O
##p O
coding O
for O
a O
p O
##oly O
##pe O
##pt O
##ide O
of O
unknown O
function O
. O

this O
article O
reviews O
the O
clinical O
and O
molecular O
genetics O
of O
primary B-Disease
d I-Disease
##ys I-Disease
##ton I-Disease
##ias I-Disease
, O
critically O
discusses O
present O
findings O
, O
and O
proposes O
referring O
to O
the O
known O
forms O
, O
most O
of O
which O
can O
be O
distinguished O
by O
genetic O
criteria O
, O
as O
d B-Disease
##ys I-Disease
##ton I-Disease
##ias I-Disease
1 I-Disease
- I-Disease
12 I-Disease
. O

determination O
of O
30 O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
mutations O
, O
including O
15 O
not O
previously O
described O
. O

x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
) O
is O
the O
most O
frequent O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disease I-Disease
. O

it O
mainly O
involves O
the O
nervous O
system O
white O
matter O
, O
ad O
##rena O
##l O
cortex O
and O
test O
##es O
. O

several O
distinct O
clinical O
p O
##hen O
##otype O
##s O
are O
known O
. O

the O
principal O
bio O
##chemical O
abnormal O
##ity O
is O
the O
accumulation O
of O
saturated O
very O
- O
long O
- O
chain O
fatty O
acids O
( O
v O
##l O
##c O
##fa O
##s O
[UNK] O
c O
##22 O
0 O
, O
mainly O
c O
##26 O
0 O
) O
, O
which O
is O
due O
to O
impaired O
capacity O
for O
beta O
- O
oxidation O
in O
per O
##ox O
##is O
##ome O
##s O
. O

diagnosis O
is O
usually O
based O
on O
the O
v O
##l O
##c O
##fa O
levels O
in O
plasma O
or O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
in O
both O
patients O
and O
carriers O
. O

in O
0 O
. O

1 O
% O
of O
affected O
males O
, O
however O
, O
the O
plasma O
c O
##26 O
0 O
level O
is O
border O
##line O
normal O
, O
and O
15 O
% O
of O
o O
##b O
##liga O
##te O
female O
carriers O
have O
normal O
results O
. O

effective O
mutation O
detection O
in O
these O
families O
is O
therefore O
fundamental O
to O
un O
##am O
##bi O
##guous O
##ly O
determine O
the O
genetic O
status O
of O
each O
individual O
at O
risk O
. O

of O
particular O
concern O
are O
female O
members O
of O
kind O
##red O
##s O
se O
##g O
##re O
##gating O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
mutations O
, O
because O
normal O
v O
##l O
##c O
##fa O
levels O
do O
not O
guarantee O
lack O
of O
carrier O
status O
. O

we O
describe O
a O
fast O
method O
for O
detection O
of O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
mutations O
. O

the O
method O
is O
based O
on O
s O
##s O
##c O
##p O
analysis O
of O
nest O
##ed O
p O
##c O
##r O
fragments O
followed O
by O
sequence O
- O
determination O
reactions O
. O

using O
this O
methodology O
we O
have O
found O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
mutations O
in O
30 O
kind O
##red O
##s O
, O
including O
15 O
not O
previously O
reported O
. O

beta O
- O
gal O
##act O
##os O
##idas O
##e O
gene O
mutations O
affecting O
the O
l O
##ys O
##oso O
##mal O
enzyme O
and O
the O
el O
##ast O
##in O
- O
binding O
protein O
in O
g B-Disease
##m I-Disease
##1 I-Disease
- I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
patients O
with O
cardiac B-Disease
involvement I-Disease
. O

g B-Disease
##m I-Disease
##1 I-Disease
- I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
is O
a O
l B-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
acid I-Disease
beta I-Disease
- I-Disease
gal I-Disease
##act I-Disease
##os I-Disease
##idas I-Disease
##e I-Disease
( O
g O
##l O
##b O
##1 O
) O
. O

we O
report O
five O
new O
beta O
- O
gal O
##act O
##os O
##idas O
##e O
gene O
mutations O
in O
nine O
it O
##alia O
##n O
patients O
and O
one O
f O
##etus O
, O
se O
##g O
##re O
##gating O
in O
seven O
unrelated O
families O
. O

six O
of O
the O
eight O
patients O
with O
the O
infant O
##ile O
, O
severe O
form O
of O
the O
disease O
presented O
cardiac B-Disease
involvement I-Disease
, O
a O
feature O
rarely O
associated O
with O
g B-Disease
##m I-Disease
##1 I-Disease
- I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
. O

molecular O
analysis O
of O
the O
patients O
r O
##na O
and O
d O
##na O
identified O
two O
new O
r O
##na O
s O
##p O
##licing O
defects O
, O
three O
new O
and O
three O
previously O
described O
amino O
acid O
substitution O
##s O
. O

interesting O
##ly O
, O
all O
patients O
with O
cardiac B-Disease
involvement I-Disease
were O
ho O
##mo O
##zy O
##go O
##us O
for O
one O
of O
these O
mutations O
r O
##5 O
##9 O
##h O
, O
y O
##5 O
##9 O
##1 O
##c O
, O
y O
##5 O
##9 O
##1 O
##n O
, O
or O
i O
##v O
##s O
##14 O
- O
2 O
##a O
[UNK] O
g O
. O

in O
contrast O
, O
all O
other O
patients O
were O
compound O
he O
##tero O
##zy O
##go O
##us O
for O
one O
of O
the O
following O
mutations O
r O
##20 O
##1 O
##h O
, O
r O
##48 O
##2 O
##h O
, O
g O
##5 O
##7 O
##9 O
##d O
, O
i O
##v O
##s O
##8 O
+ O
2 O
##t O
[UNK] O
c O
. O

although O
we O
could O
not O
directly O
co O
##rrel O
##ate O
the O
presence O
of O
cardiac B-Disease
abnormal I-Disease
##ities I-Disease
with O
specific O
genetic B-Disease
lesions I-Disease
, O
the O
mutations O
identified O
in O
patients O
with O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
fell O
in O
the O
g O
##l O
##b O
##1 O
c O
##dn O
##a O
region O
common O
to O
the O
l O
##ys O
##oso O
##mal O
enzyme O
and O
the O
h O
##bet O
##a O
- O
gal O
- O
related O
protein O
, O
also O
known O
as O
the O
el O
##ast O
##in O
binding O
protein O
( O
e O
##b O
##p O
) O
. O

consequently O
, O
both O
molecules O
are O
affected O
by O
the O
mutations O
, O
and O
they O
may O
contribute O
differently O
to O
the O
occurrence O
of O
specific O
clinical O
manifest O
##ations O
. O
. O

in O
v O
##ivo O
m O
##od O
##ulation O
of O
h O
##m O
##gic O
reduces O
o B-Disease
##besity I-Disease
. O

the O
h O
##m O
##gi O
family O
of O
proteins O
consists O
of O
three O
members O
, O
h O
##m O
##gic O
, O
h O
##m O
##gi O
and O
h O
##m O
##gi O
( O
y O
) O
, O
that O
function O
as O
architectural O
factors O
and O
are O
essential O
components O
of O
the O
enhance O
##some O
. O

h O
##m O
##gic O
is O
predominantly O
expressed O
in O
pro O
##life O
##rating O
, O
und O
##iff O
##ere O
##nti O
##ated O
me O
##sen O
##chy O
##mal O
cells O
and O
is O
not O
detected O
in O
adult O
tissues O
. O

it O
is O
disrupted O
and O
mi O
##sex O
##pressed O
in O
a O
number O
of O
me B-Disease
##sen I-Disease
##chy I-Disease
##mal I-Disease
t I-Disease
##umour I-Disease
cell O
types O
, O
including O
fat B-Disease
- I-Disease
cell I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
( O
lip B-Disease
##oma I-Disease
##s I-Disease
) O
. O

in O
addition O
h O
##m O
##gic O
- O
/ O
- O
mice O
have O
a O
deficiency O
in O
fat O
tissue O
. O

to O
study O
its O
role O
in O
ad O
##ip O
##ogen O
##esis O
and O
o B-Disease
##besity I-Disease
, O
we O
examined O
h O
##m O
##gic O
expression O
in O
the O
ad O
##ip O
##ose O
tissue O
of O
adult O
, O
o B-Disease
##bes I-Disease
##e I-Disease
mice O
. O

mice O
with O
a O
partial B-Disease
or I-Disease
complete I-Disease
deficiency I-Disease
of I-Disease
h I-Disease
##m I-Disease
##gic I-Disease
resisted O
diet O
- O
induced O
o B-Disease
##besity I-Disease
. O

disruption O
of O
h O
##m O
##gic O
caused O
a O
reduction O
in O
the O
o B-Disease
##besity I-Disease
induced O
by O
le B-Disease
##pt I-Disease
##in I-Disease
deficiency I-Disease
( O
le O
##po O
##b O
/ O
le O
##po O
##b O
) O
in O
a O
gene O
- O
dose O
- O
dependent O
manner O
. O

our O
studies O
imp O
##lica O
##te O
a O
role O
for O
h O
##m O
##gic O
in O
fat O
- O
cell O
proliferation O
, O
indicating O
that O
it O
may O
be O
an O
ad O
##ip O
##ose O
- O
specific O
target O
for O
the O
treatment O
of O
o B-Disease
##besity I-Disease
. O
. O

molecular O
analysis O
of O
the O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
relationship O
in O
factor B-Disease
x I-Disease
deficiency I-Disease
. O

factor B-Disease
x I-Disease
deficiency I-Disease
is O
a O
rare O
ha B-Disease
##em I-Disease
##or I-Disease
##r I-Disease
##ha I-Disease
##gic I-Disease
condition I-Disease
, O
normally O
inherited O
as O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
, O
in O
which O
a O
variable O
clinical O
presentation O
co O
##rrel O
##ates O
poorly O
with O
laboratory O
p O
##hen O
##otype O
. O

the O
factor O
x O
( O
f O
##10 O
) O
genes O
of O
14 O
unrelated O
individuals O
with O
factor B-Disease
x I-Disease
deficiency I-Disease
( O
12 O
f O
##ami O
##lial O
and O
two O
s O
##poradic O
cases O
) O
were O
sequence O
##d O
yielding O
a O
total O
of O
13 O
novel O
mutations O
. O

family O
studies O
were O
performed O
in O
order O
to O
distinguish O
the O
contributions O
of O
individual O
mutant O
f O
##10 O
all O
##ele O
##s O
to O
the O
clinical O
and O
laboratory O
p O
##hen O
##otype O
##s O
. O

miss O
##ense O
mutations O
were O
studied O
by O
means O
of O
molecular O
modelling O
, O
whereas O
single O
base O
##pair O
substitution O
##s O
in O
s O
##p O
##lice O
sites O
and O
the O
5 O
flank O
##ing O
region O
were O
examined O
by O
in O
v O
##it O
##ro O
s O
##p O
##licing O
ass O
##ay O
and O
l O
##uc O
##ifer O
##ase O
reporter O
gene O
ass O
##ay O
respectively O
. O

the O
del O
##eti O
##on O
all O
##ele O
of O
a O
novel O
he O
##xa O
##nu O
##cle O
##ot O
##ide O
insertion O
/ O
del O
##eti O
##on O
p O
##oly O
##mor O
##phism O
in O
the O
f O
##10 O
gene O
promoter O
region O
was O
shown O
by O
reporter O
gene O
ass O
##ay O
, O
to O
reduce O
promoter O
activity O
by O
approximately O
20 O
% O
. O

one O
family O
manifest O
##ing O
an O
auto O
##so O
##mal O
dominant O
pattern O
of O
inheritance O
possessed O
three O
clinical O
##ly O
affected O
members O
who O
were O
he O
##tero O
##zy O
##go O
##us O
for O
a O
s O
##p O
##lice O
- O
site O
mutation O
that O
was O
predicted O
to O
lead O
to O
the O
production O
of O
a O
t O
##runcated O
protein O
product O
. O

a O
model O
which O
accounts O
for O
the O
dominant O
negative O
effect O
of O
this O
les O
##ion O
is O
presented O
. O

variation O
in O
the O
anti O
##gen O
level O
of O
he O
##tero O
##zy O
##go O
##us O
relatives O
of O
pro O
##band O
##s O
was O
found O
to O
be O
significantly O
higher O
between O
families O
than O
within O
families O
, O
consistent O
with O
the O
view O
that O
the O
nature O
of O
the O
f O
##10 O
les O
##ion O
( O
s O
) O
se O
##g O
##re O
##gating O
in O
a O
given O
family O
is O
a O
prime O
de O
##ter O
##mina O
##nt O
of O
the O
laboratory O
p O
##hen O
##otype O
. O

by O
contrast O
, O
no O
such O
relationship O
could O
be O
disc O
##erne O
##d O
between O
laboratory O
p O
##hen O
##otype O
and O
p O
##oly O
##mor O
##phism O
g O
##eno O
##type O
. O
. O

trans O
##genic O
mice O
expressing O
a O
t O
##runcated O
form O
of O
the O
high O
mobility O
group O
i O
- O
c O
protein O
develop O
ad O
##ip O
##os O
##ity O
and O
an O
abnormal O
##ly O
high O
prevalence O
of O
lip B-Disease
##oma I-Disease
##s I-Disease
. O

ch O
##rom O
##oso O
##mal O
trans O
##location O
##s O
in O
human O
lip B-Disease
##oma I-Disease
##s I-Disease
frequently O
create O
fusion O
trans O
##cripts O
encoding O
high O
mobility O
group O
( O
h O
##m O
##g O
) O
i O
- O
c O
d O
##na O
- O
binding O
domains O
and O
c O
- O
terminal O
sequences O
from O
different O
presumed O
transcription O
factors O
, O
suggesting O
a O
potential O
role O
for O
h O
##m O
##g O
i O
- O
c O
in O
the O
development O
of O
lip B-Disease
##oma I-Disease
##s I-Disease
. O

to O
evaluate O
the O
role O
of O
the O
h O
##m O
##g O
i O
- O
c O
component O
, O
the O
three O
d O
##na O
- O
binding O
domains O
of O
h O
##m O
##g O
i O
- O
c O
have O
now O
been O
expressed O
in O
trans O
##genic O
mice O
. O

despite O
the O
u O
##bi O
##quito O
##us O
expression O
of O
the O
t O
##runcated O
h O
##m O
##g O
i O
- O
c O
protein O
, O
the O
trans O
##genic O
mice O
develop O
a O
selective O
abundance O
of O
fat O
tissue O
early O
in O
life O
, O
show O
marked O
ad B-Disease
##ip I-Disease
##ose I-Disease
tissue I-Disease
inflammation I-Disease
, O
and O
have O
an O
abnormal O
##ly O
high O
incidence O
of O
lip B-Disease
##oma I-Disease
##s I-Disease
. O

these O
findings O
demonstrate O
that O
the O
d O
##na O
- O
binding O
domains O
of O
h O
##m O
##g O
i O
- O
c O
, O
in O
the O
absence O
of O
a O
c O
- O
terminal O
fusion O
partner O
, O
are O
sufficient O
to O
per O
##tur O
##b O
ad O
##ip O
##ogen O
##esis O
and O
pre O
##dis O
##pose O
to O
lip B-Disease
##oma I-Disease
##s I-Disease
. O

we O
provide O
data O
supporting O
the O
central O
utility O
of O
this O
animal O
model O
as O
a O
tool O
to O
understand O
the O
molecular O
mechanisms O
underlying O
the O
development O
of O
one O
of O
the O
most O
common O
kind O
of O
human O
ben B-Disease
##ign I-Disease
tumors I-Disease
. O
. O

at O
##m O
p O
##hos O
##ph O
##ory O
##lates O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
in O
an O
s O
- O
phase O
check O
##point O
pathway O
. O

the O
rare B-Disease
diseases I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
at B-Disease
) O
, O
caused O
by O
mutations O
in O
the O
at O
##m O
gene O
, O
and O
ni B-Disease
##j I-Disease
##me I-Disease
##gen I-Disease
break I-Disease
##age I-Disease
syndrome I-Disease
( O
n B-Disease
##bs I-Disease
) O
, O
with O
mutations O
in O
the O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
gene O
, O
share O
a O
variety O
of O
p B-Disease
##hen I-Disease
##otypic I-Disease
abnormal I-Disease
##ities I-Disease
such O
as O
ch B-Disease
##rom I-Disease
##oso I-Disease
##mal I-Disease
instability I-Disease
, O
radiation O
sensitivity O
and O
defects O
in O
cell O
- O
cycle O
check O
##points O
in O
response O
to O
ion O
##izing O
radiation O
. O

the O
at O
##m O
gene O
en O
##codes O
a O
protein O
kinase O
that O
is O
activated O
by O
ion O
##izing O
radiation O
or O
radio O
##mi O
##met O
##ic O
drugs O
, O
whereas O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
is O
part O
of O
a O
protein O
complex O
that O
is O
involved O
in O
responses O
to O
d O
##na O
double O
- O
strand O
breaks O
. O

here O
, O
because O
of O
the O
similarities O
between O
at B-Disease
and O
n B-Disease
##bs I-Disease
, O
we O
evaluated O
the O
functional O
interactions O
between O
at O
##m O
and O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
. O

activation O
of O
the O
at O
##m O
kinase O
by O
ion O
##izing O
radiation O
and O
induction O
of O
at O
##m O
- O
dependent O
responses O
in O
n B-Disease
##bs I-Disease
cells O
indicated O
that O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
may O
not O
be O
required O
for O
signalling O
to O
at O
##m O
after O
ion O
##izing O
radiation O
. O

however O
, O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
was O
p O
##hos O
##ph O
##ory O
##lated O
on O
se O
##rine O
34 O
##3 O
in O
an O
at O
##m O
- O
dependent O
manner O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
after O
ion O
##izing O
radiation O
. O

a O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
construct O
m O
##uta O
##ted O
at O
the O
at O
##m O
p O
##hos O
##ph O
##ory O
##lation O
site O
a O
##bro O
##gated O
an O
s O
- O
phase O
check O
##point O
induced O
by O
ion O
##izing O
radiation O
in O
normal O
cells O
and O
failed O
to O
compensate O
for O
this O
functional O
deficiency O
in O
n B-Disease
##bs I-Disease
cells O
. O

these O
observations O
link O
at O
##m O
and O
p O
##9 O
##5 O
/ O
n O
##bs O
##1 O
in O
a O
common O
signalling O
pathway O
and O
provide O
an O
explanation O
for O
p O
##hen O
##otypic O
similarities O
in O
these O
two O
diseases O
. O
. O

understanding O
the O
molecular O
basis O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
, O
a O
common O
form O
of O
inherited B-Disease
mental I-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
is O
mainly O
caused O
by O
massive O
expansion O
of O
c O
##gg O
triple O
##t O
repeats O
located O
in O
the O
5 O
- O
un O
##tra O
##ns O
##lated O
region O
of O
the O
fragile B-Disease
x I-Disease
mental I-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
- O
1 O
( O
f O
##m O
##r O
##1 O
) O
gene O
. O

in O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
the O
expanded O
c O
##gg O
triple O
##t O
repeats O
are O
h O
##yper O
##met O
##hyl O
##ated O
and O
the O
expression O
of O
the O
f O
##m O
##r O
##1 O
gene O
is O
re O
##pressed O
, O
which O
leads O
to O
the O
absence O
of O
f O
##m O
##r O
##1 O
protein O
( O
f O
##m O
##rp O
) O
and O
subsequent O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
. O

f O
##m O
##rp O
is O
an O
r O
##na O
- O
binding O
protein O
that O
shuttle O
##s O
between O
the O
nucleus O
and O
c O
##yt O
##op O
##las O
##m O
. O

this O
protein O
has O
been O
implicated O
in O
protein O
translation O
as O
it O
is O
found O
associated O
with O
p O
##oly O
##ri O
##bos O
##ome O
##s O
and O
the O
rough O
end O
##op O
##las O
##mic O
re O
##tic O
##ulum O
. O

we O
discuss O
here O
the O
recent O
progress O
made O
towards O
understanding O
the O
molecular O
mechanism O
of O
c O
##gg O
repeat O
expansion O
and O
physiological O
function O
( O
s O
) O
of O
f O
##m O
##rp O
. O

these O
studies O
will O
not O
only O
help O
to O
ill O
##umi O
##nate O
the O
molecular O
basis O
of O
the O
general O
class O
of O
human O
diseases O
with O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
expansion O
but O
also O
provide O
an O
avenue O
to O
understand O
aspects O
of O
human O
co O
##gnition O
and O
intelligence O
. O
. O

ha B-Disease
##p I-Disease
##lo I-Disease
##ins I-Disease
##uff I-Disease
##iciency I-Disease
of I-Disease
the I-Disease
transcription I-Disease
factors I-Disease
fox I-Disease
##c I-Disease
##1 I-Disease
and I-Disease
fox I-Disease
##c I-Disease
##2 I-Disease
results O
in O
a O
##ber O
##rant O
o O
##cular O
development O
. O

anterior B-Disease
segment I-Disease
developmental I-Disease
disorders I-Disease
, O
including O
axe B-Disease
##n I-Disease
##feld I-Disease
- I-Disease
r I-Disease
##ie I-Disease
##ger I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
( O
a B-Disease
##ra I-Disease
) O
, O
var O
##iably O
associate O
with O
harmful O
##ly O
elevated O
in O
##tra O
##oc O
##ular O
pressure O
( O
i O
##op O
) O
, O
which O
causes O
g B-Disease
##lau I-Disease
##com I-Disease
##a I-Disease
. O

clinical O
##ly O
observed O
d O
##ys O
##genesis O
does O
not O
co O
##rrel O
##ate O
with O
i O
##op O
, O
however O
, O
and O
the O
et O
##iology O
of O
g B-Disease
##lau I-Disease
##com I-Disease
##a I-Disease
development O
is O
not O
understood O
. O

the O
fork O
##head O
transcription O
factor O
genes O
fox O
##c O
##1 O
( O
formerly O
m O
##f O
##1 O
) O
and O
fox O
##c O
##2 O
( O
formerly O
m O
##f O
##h O
##1 O
) O
are O
expressed O
in O
the O
me O
##sen O
##chy O
##me O
from O
which O
the O
o O
##cular O
drainage O
structures O
derive O
. O

mutations O
in O
the O
human O
ho O
##mo O
##log O
of O
fox O
##c O
##1 O
, O
f O
##kh O
##l O
##7 O
, O
cause O
dominant O
anterior B-Disease
segment I-Disease
defects I-Disease
and O
g B-Disease
##lau I-Disease
##com I-Disease
##a I-Disease
in O
various O
families O
. O

we O
show O
that O
fox O
##c O
##1 O
( O
+ O
/ O
- O
) O
mice O
have O
anterior B-Disease
segment I-Disease
abnormal I-Disease
##ities I-Disease
similar O
to O
those O
reported O
in O
human O
patients O
. O

these O
abnormal O
##ities O
include O
small O
or O
absent O
s O
##ch O
##lem O
##ms O
canal O
, O
a O
##ber O
##rant O
##ly O
developed O
t O
##rab O
##ec O
##ular O
mesh O
##work O
, O
i B-Disease
##ris I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
severely O
eccentric O
pupils O
and O
displaced O
s O
##ch O
##wal O
##bes O
line O
. O

the O
pen O
##et O
##rance O
of O
clinical O
##ly O
obvious O
abnormal O
##ities O
varies O
with O
genetic O
background O
. O

in O
some O
affected O
eyes O
, O
co O
##lla O
##gen O
bundle O
##s O
were O
half O
normal O
diameter O
, O
or O
co O
##lla O
##gen O
and O
elastic O
tissue O
were O
very O
sparse O
. O

thus O
, O
abnormal O
##ities O
in O
extra O
##cellular O
matrix O
synthesis O
or O
organization O
may O
contribute O
to O
development O
of O
the O
o O
##cular O
p O
##hen O
##otype O
##s O
. O

despite O
the O
abnormal O
##ities O
in O
o O
##cular O
drainage O
structures O
in O
fox O
##c O
##1 O
( O
+ O
/ O
- O
) O
mice O
, O
i O
##op O
was O
normal O
in O
almost O
all O
mice O
analyzed O
, O
on O
all O
genetic O
backgrounds O
and O
at O
all O
ages O
. O

similar O
abnormal O
##ities O
were O
found O
in O
fox O
##c O
##2 O
( O
+ O
/ O
- O
) O
mice O
, O
but O
no O
disease O
- O
associated O
mutations O
were O
identified O
in O
the O
human O
ho O
##mo O
##log O
f O
##kh O
##l O
##14 O
in O
32 O
a B-Disease
##ra I-Disease
patients O
. O

fox O
##c O
##1 O
( O
+ O
/ O
- O
) O
and O
fox O
##c O
##2 O
( O
+ O
/ O
- O
) O
mice O
are O
useful O
models O
for O
studying O
anterior O
segment O
development O
and O
its O
an O
##oma O
##lies O
, O
and O
may O
allow O
identification O
of O
genes O
that O
interact O
with O
fox O
##c O
##1 O
and O
fox O
##c O
##2 O
( O
or O
f O
##kh O
##l O
##7 O
and O
f O
##kh O
##l O
##14 O
) O
to O
produce O
a O
p O
##hen O
##otype O
with O
elevated O
i O
##op O
and O
g B-Disease
##lau I-Disease
##com I-Disease
##a I-Disease
. O
. O

( O
over O
) O
correction O
of O
f B-Disease
##m I-Disease
##r I-Disease
##1 I-Disease
deficiency I-Disease
with O
ya O
##c O
trans O
##genic O
##s O
: O
behavioral O
and O
physical O
features O
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
is O
a O
common O
cause O
of O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
involving O
loss O
of O
expression O
of O
the O
f O
##m O
##r O
##1 O
gene O
. O

the O
role O
of O
f O
##m O
##r O
##1 O
remains O
und O
##eter O
##mined O
but O
the O
protein O
appears O
to O
be O
involved O
in O
r O
##na O
metabolism O
. O

f O
##m O
##r O
##1 O
knockout O
mice O
exhibit O
a O
p O
##hen O
##otype O
with O
some O
similarities O
to O
humans O
, O
such O
as O
mac B-Disease
##roo I-Disease
##rch I-Disease
##id I-Disease
##ism I-Disease
and O
behavioral O
abnormal O
##ities O
. O

as O
a O
step O
toward O
understanding O
the O
function O
of O
f O
##m O
##r O
##1 O
and O
the O
determination O
of O
the O
potential O
for O
therapeutic O
approaches O
to O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
yeast O
artificial O
chromosome O
( O
ya O
##c O
) O
trans O
##genic O
mice O
were O
generated O
in O
order O
to O
determine O
whether O
the O
f O
##m O
##r O
##1 O
knockout O
mouse O
p O
##hen O
##otype O
could O
be O
rescued O
. O

several O
trans O
##genic O
lines O
were O
generated O
that O
carried O
the O
entire O
f O
##m O
##r O
##1 O
lo O
##cus O
with O
extensive O
amounts O
of O
flank O
##ing O
sequence O
. O

we O
observed O
that O
the O
ya O
##c O
trans O
##gene O
supported O
production O
of O
the O
human O
protein O
( O
f O
##m O
##rp O
) O
which O
was O
present O
at O
levels O
10 O
to O
15 O
times O
that O
of O
end O
##ogen O
##ous O
protein O
and O
was O
expressed O
in O
a O
cell O
- O
and O
tissue O
- O
specific O
manner O
. O

mac O
##ro O
- O
orchid O
##ism O
was O
absent O
in O
knockout O
mice O
carrying O
the O
ya O
##c O
trans O
##gene O
indicating O
functional O
rescue O
by O
the O
human O
protein O
. O

given O
the O
complex O
behavioral O
p O
##hen O
##otype O
in O
fragile B-Disease
x I-Disease
patients O
and O
the O
mild O
p O
##hen O
##otype O
previously O
reported O
for O
the O
f O
##m O
##r O
##1 O
knockout O
mouse O
, O
we O
performed O
a O
more O
thorough O
evaluation O
of O
the O
f O
##m O
##r O
##1 O
knockout O
p O
##hen O
##otype O
using O
additional O
behavioral O
ass O
##ays O
that O
had O
not O
previously O
been O
reported O
for O
this O
animal O
model O
. O

the O
mouse O
displayed O
reduced O
anxiety B-Disease
- O
related O
responses O
with O
increased O
ex O
##p O
##lora O
##tory O
behavior O
. O

f O
##m O
##r O
##1 O
ya O
##c O
trans O
##genic O
mice O
over O
##ex O
##pressing O
the O
human O
protein O
did O
produce O
opposing O
behavioral O
responses O
and O
additional O
abnormal O
behaviors O
were O
also O
observed O
. O

these O
findings O
have O
significant O
implications O
for O
gene O
therapy O
for O
fragile B-Disease
x I-Disease
syndrome I-Disease
since O
over O
##ex O
##press O
##ion O
of O
the O
gene O
may O
harbor O
its O
own O
p O
##hen O
##otype O
. O
. O

trans O
##genic O
mice O
carrying O
large O
human O
g O
##eno O
##mic O
sequences O
with O
expanded O
c O
##t O
##g O
repeat O
mimic O
closely O
the O
d B-Disease
##m I-Disease
c O
##t O
##g O
repeat O
inter O
##gene O
##ration O
##al O
and O
so O
##matic O
instability O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
caused O
by O
a O
c O
##t O
##g O
repeat O
expansion O
in O
the O
3 O
##ut O
##r O
of O
the O
d B-Disease
##m I-Disease
protein O
kinase O
( O
d O
##mp O
##k O
) O
gene O
. O

a O
very O
high O
level O
of O
instability O
is O
observed O
through O
successive O
generations O
and O
the O
size O
of O
the O
repeat O
is O
generally O
correlated O
with O
the O
severity O
of O
the O
disease O
and O
with O
age O
at O
onset O
. O

further O
##more O
, O
tissues O
from O
d B-Disease
##m I-Disease
patients O
exhibit O
so O
##matic O
mosaic O
##ism O
that O
increases O
with O
age O
. O

we O
generated O
trans O
##genic O
mice O
carrying O
large O
human O
g O
##eno O
##mic O
sequences O
with O
20 O
, O
55 O
or O
[UNK] O
300 O
c O
##t O
##g O
, O
clone O
##d O
from O
patients O
from O
the O
same O
affected O
d B-Disease
##m I-Disease
family O
. O

using O
large O
human O
flank O
##ing O
sequences O
and O
a O
large O
am O
##p O
##lification O
, O
we O
demonstrate O
that O
the O
inter O
##gene O
##ration O
##al O
c O
##t O
##g O
repeat O
instability O
is O
reproduced O
in O
mice O
, O
with O
a O
strong O
bias O
towards O
expansion O
##s O
and O
with O
the O
same O
sex O
- O
and O
size O
- O
dependent O
characteristics O
as O
in O
humans O
. O

more O
##over O
, O
a O
high O
level O
of O
instability O
, O
increasing O
with O
age O
, O
can O
be O
observed O
in O
tissues O
and O
in O
sperm O
. O

although O
we O
did O
not O
observe O
dramatic O
expansion O
##s O
( O
or O
big O
jumps O
over O
several O
hundred O
c O
##t O
##g O
repeats O
) O
as O
in O
con O
##gen O
##ital O
forms O
of O
d B-Disease
##m I-Disease
, O
our O
model O
carrying O
[UNK] O
300 O
c O
##t O
##g O
is O
the O
first O
to O
show O
instability O
so O
close O
to O
the O
human O
d B-Disease
##m I-Disease
situation O
. O

our O
three O
models O
carrying O
different O
sizes O
of O
c O
##t O
##g O
repeat O
provide O
insight O
on O
the O
different O
factors O
m O
##od O
##ulating O
the O
c O
##t O
##g O
repeat O
instability O
. O
. O

in O
##act O
##ivation O
of O
the O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
mouse O
gene O
leads O
to O
early O
em B-Disease
##b I-Disease
##ryo I-Disease
##nic I-Disease
lethal I-Disease
##ity I-Disease
without O
iron O
accumulation O
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
, O
the O
most O
common O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
, O
is O
caused O
in O
almost O
all O
cases O
by O
ho O
##mo O
##zy O
##go O
##us O
intro O
##nic O
expansion O
##s O
resulting O
in O
the O
loss O
of O
f O
##rata O
##xin O
, O
a O
mitochondrial O
protein O
conserved O
through O
evolution O
, O
and O
involved O
in O
mitochondrial O
iron O
home O
##ost O
##asis O
. O

yeast O
knockout O
models O
, O
and O
his O
##to O
##logical O
and O
bio O
##chemical O
data O
from O
patient O
heart O
bio O
##ps O
##ies O
or O
auto O
##ps O
##ies O
indicate O
that O
the O
f O
##rata O
##xin O
defect O
causes O
a O
specific O
iron B-Disease
- I-Disease
sulfur I-Disease
protein I-Disease
deficiency I-Disease
and O
mitochondrial O
iron O
accumulation O
leading O
to O
the O
path O
##ological O
changes O
. O

affected O
human O
tissues O
are O
rarely O
available O
to O
further O
examine O
this O
hypothesis O
. O

to O
study O
the O
mechanism O
of O
the O
disease O
, O
we O
generated O
a O
mouse O
model O
by O
del O
##eti O
##on O
of O
ex O
##on O
4 O
leading O
to O
in O
##act O
##ivation O
of O
the O
f B-Disease
##rda I-Disease
gene O
product O
. O

we O
show O
that O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
cause O
em B-Disease
##b I-Disease
##ryo I-Disease
##nic I-Disease
lethal I-Disease
##ity I-Disease
a O
few O
days O
after O
imp O
##lant O
##ation O
, O
demonstrating O
an O
important O
role O
for O
f O
##rata O
##xin O
during O
early O
development O
. O

these O
results O
suggest O
that O
the O
mild O
##er O
p O
##hen O
##otype O
in O
humans O
is O
due O
to O
residual O
f O
##rata O
##xin O
expression O
associated O
with O
the O
expansion O
mutations O
. O

surprisingly O
, O
in O
the O
f O
##rata O
##xin O
knockout O
mouse O
, O
no O
iron O
accumulation O
was O
observed O
during O
em O
##b O
##ryo O
##nic O
re O
##sor O
##ption O
, O
suggesting O
that O
cell O
death O
could O
be O
due O
to O
a O
mechanism O
independent O
of O
iron O
accumulation O
. O
. O

g B-Disease
##au I-Disease
##cher I-Disease
disease I-Disease
: O
the O
origins O
of O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
n O
##37 O
##0s O
and O
84 O
##gg O
acid O
beta O
- O
g O
##lu O
##cos O
##idas O
##e O
mutations O
. O

type O
1 O
g B-Disease
##au I-Disease
##cher I-Disease
disease I-Disease
( O
g B-Disease
##d I-Disease
) O
, O
a O
non O
- O
ne O
##uron O
##op O
##ath O
##ic O
l B-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
, O
results O
from O
the O
def O
##icient O
activity O
of O
acid O
beta O
- O
g O
##lu O
##cos O
##idas O
##e O
( O
g O
##ba O
) O
. O

type O
1 O
disease O
is O
pan O
##eth O
##nic O
but O
is O
more O
prevalent O
in O
individuals O
of O
ash O
##ken O
##azi O
j O
##ew O
##ish O
( O
a O
##j O
) O
descent O
. O

of O
the O
ca O
##usa O
##tive O
g O
##ba O
mutations O
, O
n O
##37 O
##0s O
is O
particularly O
frequent O
in O
the O
a O
##j O
population O
, O
( O
q O
approximately O
. O
03 O
) O
, O
whereas O
the O
84 O
##gg O
insertion O
( O
q O
approximately O
. O
00 O
##3 O
) O
occurs O
exclusively O
in O
the O
ash O
##ken O
##azi O
##m O
. O

to O
investigate O
the O
genetic O
history O
of O
these O
mutations O
in O
the O
a O
##j O
population O
, O
short O
tandem O
repeat O
( O
s O
##tr O
) O
markers O
were O
used O
to O
map O
a O
9 O
. O

3 O
- O
cm O
region O
containing O
the O
g O
##ba O
lo O
##cus O
and O
to O
g O
##eno O
##type O
261 O
a O
##j O
n O
##37 O
##0s O
chromosome O
##s O
, O
60 O
euro O
##pe O
##an O
non O
- O
j O
##ew O
##ish O
n O
##37 O
##0s O
chromosome O
##s O
, O
and O
62 O
a O
##j O
84 O
##gg O
chromosome O
##s O
. O

a O
highly O
conserved O
ha O
##p O
##lot O
##ype O
at O
four O
markers O
flank O
##ing O
g O
##ba O
( O
p O
##k O
##l O
##r O
, O
d O
##1 O
##s O
##15 O
##9 O
##5 O
, O
d O
##1 O
##s O
##27 O
##21 O
, O
and O
d O
##1 O
##s O
##27 O
##7 O
##7 O
) O
was O
observed O
on O
both O
the O
a O
##j O
chromosome O
##s O
and O
the O
non O
- O
j O
##ew O
##ish O
n O
##37 O
##0s O
chromosome O
##s O
, O
suggesting O
the O
occurrence O
of O
a O
founder O
common O
to O
both O
populations O
. O

of O
note O
, O
the O
presence O
of O
different O
diver O
##gent O
ha O
##p O
##lot O
##ype O
##s O
suggested O
the O
occurrence O
of O
de O
no O
##vo O
, O
re O
##current O
n O
##37 O
##0s O
mutations O
. O

in O
contrast O
, O
a O
different O
conserved O
ha O
##p O
##lot O
##ype O
at O
these O
markers O
was O
identified O
on O
the O
84 O
##gg O
chromosome O
##s O
, O
which O
was O
unique O
to O
the O
a O
##j O
population O
. O

on O
the O
basis O
of O
the O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
( O
l O
##d O
) O
delta O
values O
, O
the O
non O
- O
j O
##ew O
##ish O
euro O
##pe O
##an O
n O
##37 O
##0s O
chromosome O
##s O
had O
greater O
ha O
##p O
##lot O
##ype O
diversity O
and O
less O
l O
##d O
at O
the O
markers O
flank O
##ing O
the O
conserved O
ha O
##p O
##lot O
##ype O
than O
did O
the O
a O
##j O
n O
##37 O
##0s O
chromosome O
##s O
. O

this O
finding O
is O
consistent O
with O
the O
presence O
of O
the O
n O
##37 O
##0s O
mutation O
in O
the O
non O
- O
j O
##ew O
##ish O
euro O
##pe O
##an O
population O
prior O
to O
the O
founding O
of O
the O
a O
##j O
population O
. O

coal O
##es O
##cence O
analyses O
for O
the O
n O
##37 O
##0s O
and O
84 O
##gg O
mutations O
estimated O
similar O
coal O
##es O
##cence O
times O
, O
of O
48 O
and O
55 O
. O
5 O
generations O
ago O
, O
respectively O
. O

the O
results O
of O
these O
studies O
are O
consistent O
with O
a O
significant O
bottle O
##neck O
occurring O
in O
the O
a O
##j O
population O
during O
the O
first O
millennium O
, O
when O
the O
population O
became O
established O
in O
euro O
##pe O
. O

h O
##la O
b O
##27 O
and O
the O
genetics O
of O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
. O

one O
hundred O
and O
twenty O
- O
eight O
of O
145 O
patients O
with O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
( O
as B-Disease
) O
were O
found O
to O
be O
h O
##la O
b O
##27 O
positive O
. O

five O
patients O
had O
evidence O
of O
a O
se O
##ro O
- O
negative O
peripheral B-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
resembling O
peripheral B-Disease
ps I-Disease
##oria I-Disease
##tic I-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
and O
3 O
of O
these O
were O
b O
##27 O
negative O
. O

one O
further O
b O
##27 O
negative O
patients O
had O
a O
sister O
with O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
and O
ul B-Disease
##cer I-Disease
##ative I-Disease
co I-Disease
##lit I-Disease
##is I-Disease
and O
a O
mother O
with O
ul B-Disease
##cer I-Disease
##ative I-Disease
co I-Disease
##lit I-Disease
##is I-Disease
. O

there O
was O
evidence O
of O
a O
somewhat O
later O
age O
of O
onset O
of O
symptoms O
in O
b O
##27 O
negative O
patients O
. O

these O
findings O
are O
interpreted O
as O
suggesting O
some O
degree O
of O
clinical O
and O
genetic O
he O
##tero O
##gene O
##ity O
in O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
with O
genes O
for O
ps B-Disease
##oria I-Disease
##sis I-Disease
and O
inflammatory B-Disease
bow I-Disease
##el I-Disease
disease I-Disease
being O
important O
in O
some O
individuals O
, O
particularly O
those O
who O
are O
b O
##27 O
negative O
. O

twenty O
- O
five O
first O
- O
degree O
relatives O
with O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
were O
all O
b O
##27 O
positive O
. O

the O
only O
instance O
of O
di O
##sa O
##sso O
##ciation O
of O
b O
##27 O
and O
s B-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
in O
a O
family O
was O
where O
the O
pro O
##band O
had O
ul B-Disease
##cer I-Disease
##ative I-Disease
co I-Disease
##lit I-Disease
##is I-Disease
as O
well O
as O
s B-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
. O

of O
13 O
b O
##27 O
positive O
fathers O
3 O
could O
be O
diagnosed O
as O
having O
definite O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
( O
23 O
% O
) O
. O

these O
findings O
are O
thought O
to O
provide O
evidence O
against O
the O
concept O
that O
the O
gene O
for O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
is O
not O
b O
##27 O
but O
a O
closely O
linked O
gene O
and O
favour O
the O
occurrence O
of O
an O
environmental O
event O
affecting O
approximately O
one O
- O
fifth O
of O
b O
##27 O
positive O
males O
to O
result O
in O
disease O
. O
. O

founder O
mutations O
in O
the O
br O
##ca O
##1 O
gene O
in O
p O
##olis O
##h O
families O
with O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

we O
have O
undertaken O
a O
hospital O
- O
based O
study O
, O
to O
identify O
possible O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
founder O
mutations O
in O
the O
p O
##olis O
##h O
population O
. O

the O
study O
group O
consisted O
of O
66 O
p O
##olis O
##h O
families O
with O
cancer B-Disease
who O
have O
at O
least O
three O
related O
females O
affected O
with O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
who O
had O
cancer B-Disease
diagnosed O
, O
in O
at O
least O
one O
of O
the O
three O
affected O
females O
, O
at O
age O
[UNK] O
50 O
years O
. O

a O
total O
of O
26 O
families O
had O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
, O
4 O
families O
had O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
only O
, O
and O
36 O
families O
had O
breast B-Disease
cancer I-Disease
##s I-Disease
only O
. O

g O
##eno O
##mic O
d O
##na O
was O
prepared O
from O
the O
peripheral O
blood O
le O
##uk O
##ocytes O
of O
at O
least O
one O
affected O
woman O
from O
each O
family O
. O

the O
entire O
coding O
region O
of O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
was O
screened O
for O
the O
presence O
of O
g O
##er O
##m O
##line O
mutations O
, O
by O
use O
of O
s O
##s O
##c O
##p O
followed O
by O
direct O
se O
##quencing O
of O
observed O
variants O
. O

mutations O
were O
found O
in O
35 O
( O
53 O
% O
) O
of O
the O
66 O
families O
studied O
. O

all O
but O
one O
of O
the O
mutations O
were O
detected O
within O
the O
br O
##ca O
##1 O
gene O
. O

br B-Disease
##ca I-Disease
##1 I-Disease
abnormal I-Disease
##ities I-Disease
were O
identified O
in O
all O
four O
families O
with O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
only O
, O
in O
67 O
% O
of O
27 O
families O
with O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
and O
in O
34 O
% O
of O
35 O
families O
with O
breast B-Disease
cancer I-Disease
only O
. O

the O
single O
family O
with O
a O
br O
##ca O
##2 O
mutation O
had O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
syndrome I-Disease
. O

seven O
distinct O
mutations O
were O
identified O
; O
five O
of O
these O
occurred O
in O
two O
or O
more O
families O
. O

in O
total O
, O
re O
##current O
mutations O
were O
found O
in O
33 O
( O
94 O
% O
) O
of O
the O
35 O
families O
with O
detected O
mutations O
. O

three O
br B-Disease
##ca I-Disease
##1 I-Disease
abnormal I-Disease
##ities I-Disease
- O
53 O
##8 O
##2 O
##ins O
##c O
, O
c O
##6 O
##1 O
##g O
, O
and O
415 O
##3 O
##dela O
- O
accounted O
for O
51 O
% O
, O
20 O
% O
, O
and O
11 O
% O
of O
the O
identified O
mutations O
, O
respectively O
. O
. O

molecular O
basis O
of O
very B-Disease
long I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
three O
is O
##rae O
##li O
patients O
: O
identification O
of O
a O
complex O
mutant O
all O
##ele O
with O
p O
##65 O
##l O
and O
k O
##24 O
##7 O
##q O
mutations O
, O
the O
former O
being O
an O
ex O
##onic O
mutation O
causing O
ex O
##on O
3 O
skip O
##ping O
. O

very B-Disease
long I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
v I-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
is O
a O
life O
- O
threatening O
disorder O
of O
mitochondrial O
fatty O
acid O
beta O
- O
oxidation O
. O

we O
identified O
four O
novel O
mutations O
in O
three O
unrelated O
patients O
. O

all O
patients O
had O
the O
severe O
childhood O
form O
of O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
with O
early O
onset O
and O
high O
mortality O
. O

im O
##mu O
##nob O
##lot O
analysis O
revealed O
that O
v O
##l O
##ca O
##d O
protein O
was O
und O
##ete O
##ct O
##able O
in O
patients O
2 O
and O
3 O
, O
whereas O
normal O
- O
size O
v O
##l O
##ca O
##d O
protein O
and O
an O
a O
##ber O
##rant O
form O
of O
v O
##l O
##ca O
##d O
( O
4 O
##k O
##da O
smaller O
) O
were O
detected O
in O
patient O
1 O
. O

as O
expected O
, O
null O
mutations O
were O
found O
in O
patients O
2 O
and O
3 O
patient O
2 O
is O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
frames O
##hi O
##ft O
mutation O
, O
del O
4 O
b O
##p O
at O
79 O
##8 O
- O
80 O
##1 O
, O
and O
patient O
3 O
is O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
nonsense O
mutation O
65 O
##c O
[UNK] O
a O
( O
s O
##22 O
##x O
) O
. O

patient O
1 O
was O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
complex O
mutant O
all O
##ele O
containing O
two O
alterations O
, O
including O
a O
194 O
##c O
[UNK] O
t O
transition O
( O
p O
##65 O
##l O
) O
and O
73 O
##9 O
##a O
[UNK] O
c O
trans O
##version O
( O
k O
##24 O
##7 O
##q O
) O
; O
in O
the O
case O
of O
p O
##65 O
##l O
, O
the O
amino O
acid O
change O
does O
not O
reduce O
enzyme O
activity O
. O

however O
, O
the O
n O
##uc O
##leo O
##tide O
change O
resulted O
in O
ex O
##on O
3 O
skip O
##ping O
, O
whereas O
the O
latter O
k O
##24 O
##7 O
##q O
mutation O
had O
a O
drastic O
effect O
on O
enzyme O
activity O
. O

we O
verified O
these O
events O
by O
in O
v O
##ivo O
s O
##p O
##licing O
experiments O
and O
trans O
##ient O
expression O
analysis O
of O
mutant O
c O
##dn O
##as O
. O

the O
p O
##65 O
##l O
mutation O
locate O
##s O
11 O
bases O
upstream O
of O
a O
s O
##p O
##lice O
donor O
site O
of O
intro O
##n O
3 O
. O

this O
is O
an O
example O
of O
an O
ex O
##onic O
mutation O
which O
affects O
ex O
##on O
- O
s O
##p O
##licing O
. O
. O

sub O
##mic O
##ros O
##copic O
del O
##eti O
##on O
in O
cousins O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
causes O
a O
grand O
##mat O
##ril O
##ine O
##al O
inheritance O
pattern O
: O
effects O
of O
imprint O
##ing O
. O

the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
critical O
region O
on O
15 O
##q O
##11 O
- O
q O
##13 O
is O
subject O
to O
imprint O
##ing O
. O

p B-Disease
##ws I-Disease
becomes O
apparent O
when O
genes O
on O
the O
paternal O
##ly O
inherited O
chromosome O
are O
not O
expressed O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
p I-Disease
##ws I-Disease
is O
rare O
. O

we O
report O
on O
a O
family O
in O
which O
a O
male O
and O
a O
female O
paternal O
first O
cousin O
both O
have O
p B-Disease
##ws I-Disease
with O
c O
##yt O
##ogen O
##etic O
##ally O
normal O
ka O
##ryo O
##type O
##s O
. O

flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
( O
fish O
) O
analysis O
shows O
a O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##on O
of O
s O
##n O
##rp O
##n O
, O
but O
not O
the O
closely O
associated O
lo O
##ci O
d O
##15 O
##s O
##10 O
, O
d O
##15 O
##s O
##11 O
, O
d O
##15 O
##s O
##6 O
##3 O
, O
and O
g O
##ab O
##rb O
##3 O
. O

the O
cousins O
fathers O
and O
two O
paternal O
aunt O
##s O
have O
the O
same O
del O
##eti O
##on O
and O
are O
clinical O
##ly O
normal O
. O

the O
grandmother O
of O
the O
cousins O
is O
deceased O
and O
not O
available O
for O
study O
, O
and O
their O
grandfather O
is O
not O
deleted O
for O
s O
##n O
##rp O
##n O
. O

d O
##na O
met O
##hyl O
##ation O
analysis O
of O
d O
##15 O
##s O
##6 O
##3 O
is O
consistent O
with O
an O
abnormal O
##ity O
of O
the O
imprint O
##ing O
center O
associated O
with O
p B-Disease
##ws I-Disease
. O

" O
grand O
##mat O
##ril O
##ine O
##al O
" O
inheritance O
occurs O
when O
a O
woman O
with O
del O
##eti O
##on O
of O
an O
imprint O
##ed O
, O
paternal O
##ly O
expressed O
gene O
is O
at O
risk O
of O
having O
affected O
grandchildren O
through O
her O
sons O
. O

in O
this O
case O
, O
p B-Disease
##ws I-Disease
does O
not O
become O
evident O
as O
long O
as O
the O
del O
##eti O
##on O
is O
passed O
through O
the O
mat O
##ril O
##ine O
##al O
line O
. O

this O
represents O
a O
unique O
inheritance O
pattern O
due O
to O
imprint O
##ing O
. O
. O

human O
g O
##ly O
##cine O
de O
##car O
##box O
##yla O
##se O
gene O
( O
g O
##ld O
##c O
) O
and O
its O
highly O
conserved O
processed O
pseudo O
##gene O
( O
ps O
##ig O
##ld O
##c O
) O
: O
their O
structure O
and O
expression O
, O
and O
the O
identification O
of O
a O
large O
del O
##eti O
##on O
in O
a O
family O
with O
non B-Disease
##ket I-Disease
##otic I-Disease
h I-Disease
##yper I-Disease
##gly I-Disease
##cine I-Disease
##mia I-Disease
. O

mutations O
in O
the O
g O
##ly O
##cine O
de O
##car O
##box O
##yla O
##se O
gene O
( O
g O
##ld O
##c O
) O
cause O
non B-Disease
##ket I-Disease
##otic I-Disease
h I-Disease
##yper I-Disease
##gly I-Disease
##cine I-Disease
##mia I-Disease
( O
n B-Disease
##kh I-Disease
) O
, O
an O
in B-Disease
- I-Disease
born I-Disease
error I-Disease
of I-Disease
metabolism I-Disease
characterized O
by O
severe O
ne B-Disease
##uro I-Disease
##logical I-Disease
disturbance I-Disease
. O

we O
have O
determined O
the O
structure O
of O
g O
##ld O
##c O
and O
of O
its O
pseudo O
##gene O
( O
ps O
##ig O
##ld O
##c O
) O
and O
studied O
their O
expression O
for O
a O
molecular O
analysis O
of O
n B-Disease
##kh I-Disease
. O

the O
g O
##ld O
##c O
gene O
spans O
at O
least O
135 O
k O
##b O
and O
consists O
of O
25 O
ex O
##ons O
. O

all O
donor O
and O
accept O
##or O
sites O
ad O
##here O
to O
the O
canonical O
g O
##t O
- O
a O
##g O
rule O
, O
except O
for O
the O
donor O
site O
of O
intro O
##n O
21 O
, O
where O
a O
variant O
form O
g O
##c O
is O
used O
instead O
of O
g O
##t O
. O

the O
transcription O
initiation O
site O
has O
been O
assigned O
to O
a O
residue O
163 O
b O
##p O
upstream O
from O
the O
translation O
initiation O
triple O
##t O
by O
prime O
##r O
extension O
analysis O
. O

the O
ps O
##ig O
##ld O
##c O
gene O
has O
no O
intro O
##n O
and O
shares O
97 O
. O

5 O
% O
ho O
##mology O
with O
the O
coding O
region O
of O
functional O
g O
##ld O
##c O
, O
suggesting O
that O
ps O
##ig O
##ld O
##c O
is O
a O
processed O
pseudo O
##gene O
that O
arose O
from O
the O
g O
##ld O
##c O
trans O
##cript O
about O
4 O
- O
8 O
million O
years O
ago O
. O

r O
##na O
b O
##lot O
##ting O
analysis O
has O
revealed O
that O
g O
##ld O
##c O
is O
expressed O
in O
human O
liver O
, O
kidney O
, O
brain O
, O
and O
place O
##nta O
. O

we O
have O
also O
examined O
a O
patient O
with O
n B-Disease
##kh I-Disease
with O
no O
detect O
##able O
g O
##ld O
##c O
m O
##rna O
in O
his O
l O
##ymph O
##ob O
##last O
##s O
. O

ex O
##ons O
1 O
- O
3 O
of O
the O
functional O
g O
##ld O
##c O
gene O
from O
this O
patient O
are O
not O
am O
##plified O
by O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
, O
whereas O
those O
from O
control O
subjects O
are O
. O

these O
results O
suggest O
a O
large O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##on O
( O
at O
least O
30 O
k O
##b O
) O
in O
the O
patient O
. O

further O
##more O
, O
we O
have O
devised O
a O
semi O
- O
quantitative O
p O
##c O
##r O
to O
estimate O
the O
number O
of O
g O
##ld O
##c O
all O
##ele O
##s O
by O
using O
ps O
##ig O
##ld O
##c O
as O
an O
internal O
control O
and O
have O
confirmed O
the O
ho O
##mo O
##zy O
##gos O
##ity O
and O
he O
##tero O
##zy O
##gos O
##ity O
of O
the O
del O
##eti O
##on O
in O
the O
patient O
and O
his O
parents O
, O
respectively O
. O

structural O
information O
of O
g O
##ld O
##c O
and O
ps O
##ig O
##ld O
##c O
should O
facilitate O
the O
molecular O
analysis O
of O
n B-Disease
##kh I-Disease
. O

de O
no O
##vo O
del O
##eti O
##ons O
of O
s O
##n O
##rp O
##n O
ex O
##on O
1 O
in O
early O
human O
and O
mouse O
em O
##b O
##ryo O
##s O
result O
in O
a O
paternal O
to O
maternal O
imprint O
switch O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
is O
a O
ne B-Disease
##uro I-Disease
##gene I-Disease
##tic I-Disease
disease I-Disease
characterized O
by O
infant B-Disease
##ile I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
, O
go B-Disease
##na I-Disease
##dal I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
o O
##bs O
##ess O
##ive O
behaviour O
and O
neon O
##ata O
##l O
feeding O
difficulties O
followed O
by O
h B-Disease
##yper I-Disease
##pha I-Disease
##gia I-Disease
, O
leading O
to O
profound O
o B-Disease
##besity I-Disease
. O

p B-Disease
##ws I-Disease
is O
due O
to O
a O
lack O
of O
paternal O
genetic O
information O
at O
15 O
##q O
##11 O
- O
q O
##13 O
( O
re O
##f O
. O
2 O
) O
. O

five O
imprint O
##ed O
, O
paternal O
##ly O
expressed O
genes O
map O
to O
the O
p B-Disease
##ws I-Disease
region O
, O
m O
##k O
##rn O
##3 O
( O
re O
##f O
. O
3 O
) O
, O
n O
##dn O
( O
re O
##f O
. O
4 O
) O
, O
n O
##dn O
##l O
##1 O
( O
re O
##f O
. O
5 O
) O
, O
s O
##n O
##rp O
##n O
( O
re O
##fs O
6 O
- O
8 O
) O
and O
i O
##p O
##w O
( O
re O
##f O
. O
9 O
) O
, O
as O
well O
as O
two O
poorly O
characterized O
frame O
##nts O
designated O
par O
- O
1 O
and O
par O
- O
5 O
( O
re O
##f O
. O
10 O
) O
. O

imprint O
##ing O
of O
this O
region O
involves O
a O
bi O
##par O
##tite O
imprint O
##ing O
centre O
( O
i O
##c O
) O
, O
which O
overlap O
##s O
s O
##n O
##rp O
##n O
( O
re O
##fs O
10 O
, O
11 O
) O
. O

del O
##eti O
##on O
of O
the O
s O
##n O
##rp O
##n O
promoter O
/ O
ex O
##on O
1 O
region O
( O
the O
p B-Disease
##ws I-Disease
i O
##c O
element O
) O
appears O
to O
imp O
##air O
the O
establishment O
of O
the O
paternal O
imprint O
in O
the O
male O
g O
##er O
##m O
line O
and O
leads O
to O
p B-Disease
##ws I-Disease
. O

here O
we O
report O
a O
p B-Disease
##ws I-Disease
family O
in O
which O
the O
father O
is O
mosaic O
for O
an O
i O
##c O
del O
##eti O
##on O
on O
his O
paternal O
chromosome O
. O

the O
del O
##eti O
##on O
chromosome O
has O
acquired O
a O
maternal O
met O
##hyl O
##ation O
imprint O
in O
his O
so O
##matic O
cells O
. O

we O
have O
made O
identical O
findings O
in O
ch O
##ima O
##eric O
mice O
generated O
from O
two O
independent O
em O
##b O
##ryo O
##nic O
stem O
( O
es O
) O
cell O
lines O
harbour O
##ing O
a O
similar O
del O
##eti O
##on O
. O

our O
studies O
demonstrate O
that O
the O
p B-Disease
##ws I-Disease
i O
##c O
element O
is O
not O
only O
required O
for O
the O
establishment O
of O
the O
paternal O
imprint O
, O
but O
also O
for O
its O
post O
##zy O
##got O
##ic O
maintenance O
. O
. O

mice O
def B-Disease
##icient I-Disease
in I-Disease
six I-Disease
##5 I-Disease
develop O
cat B-Disease
##ara I-Disease
##cts I-Disease
: O
implications O
for O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

expansion O
of O
a O
c O
##t O
##g O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
the O
3 O
u O
##tr O
of O
the O
gene O
d O
##mp O
##k O
at O
the O
d O
##m O
##1 O
lo O
##cus O
on O
chromosome O
19 O
causes O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
a O
dominant B-Disease
##ly I-Disease
inherited I-Disease
disease I-Disease
characterized O
by O
skeletal O
muscle B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
my B-Disease
##oto I-Disease
##nia I-Disease
, O
cat B-Disease
##ara I-Disease
##cts I-Disease
and O
cardiac B-Disease
conduct I-Disease
##ion I-Disease
defects I-Disease
. O

targeted O
del O
##eti O
##on O
of O
d O
##m O
##15 O
, O
the O
mouse O
or O
##th O
##olo O
##gue O
of O
human O
d O
##mp O
##k O
, O
produced O
mice O
with O
a O
mild O
my B-Disease
##op I-Disease
##athy I-Disease
and O
cardiac B-Disease
conduct I-Disease
##ion I-Disease
abnormal I-Disease
##ities I-Disease
, O
but O
without O
other O
features O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
such O
as O
my B-Disease
##oto I-Disease
##nia I-Disease
and O
cat B-Disease
##ara I-Disease
##cts I-Disease
. O

we O
, O
and O
others O
, O
have O
demonstrated O
that O
repeat O
expansion O
decreases O
expression O
of O
the O
adjacent O
gene O
six O
##5 O
( O
re O
##fs O
7 O
, O
8 O
) O
, O
which O
en O
##codes O
a O
home O
##od O
##oma O
##in O
transcription O
factor O
. O

to O
determine O
whether O
six B-Disease
##5 I-Disease
deficiency I-Disease
contributes O
to O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
p O
##hen O
##otype O
, O
we O
disrupted O
mouse O
six O
##5 O
by O
replacing O
the O
first O
ex O
##on O
with O
a O
beta O
- O
gal O
##act O
##os O
##idas O
##e O
reporter O
. O

six O
##5 O
- O
mutant O
mice O
showed O
reporter O
expression O
in O
multiple O
tissues O
, O
including O
the O
developing O
lens O
. O

ho O
##mo O
##zy O
##go O
##us O
mutant O
mice O
had O
no O
apparent O
abnormal B-Disease
##ities I-Disease
of I-Disease
skeletal I-Disease
muscle I-Disease
function I-Disease
, O
but O
developed O
lent B-Disease
##icular I-Disease
op I-Disease
##ac I-Disease
##ities I-Disease
at O
a O
higher O
rate O
than O
controls O
. O

our O
results O
suggest O
that O
six B-Disease
##5 I-Disease
deficiency I-Disease
contributes O
to O
the O
cat B-Disease
##ara I-Disease
##ct I-Disease
p O
##hen O
##otype O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
and O
that O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
represents O
a O
multi B-Disease
##genic I-Disease
disorder I-Disease
. O
. O

he O
##tero O
##zy O
##go O
##us O
loss O
of O
six O
##5 O
in O
mice O
is O
sufficient O
to O
cause O
o O
##cular O
cat B-Disease
##ara I-Disease
##cts I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
skeletal O
muscle B-Disease
wasting I-Disease
, O
my B-Disease
##oto I-Disease
##nia I-Disease
, O
cardiac B-Disease
a I-Disease
##rr I-Disease
##hy I-Disease
##th I-Disease
##mia I-Disease
, O
h B-Disease
##yper I-Disease
##ins I-Disease
##ulin I-Disease
##ae I-Disease
##mia I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
and O
o O
##cular O
cat B-Disease
##ara I-Disease
##cts I-Disease
. O

the O
genetic B-Disease
defect I-Disease
in O
d B-Disease
##m I-Disease
is O
a O
c O
##t O
##g O
repeat O
expansion O
located O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
d O
##mp O
##k O
and O
5 O
of O
a O
home O
##od O
##oma O
##in O
- O
encoding O
gene O
, O
six O
##5 O
( O
formerly O
d O
##mah O
##p O
; O
re O
##fs O
2 O
- O
5 O
) O
. O

there O
are O
three O
mechanisms O
by O
which O
c O
##t O
##g O
expansion O
can O
result O
in O
d B-Disease
##m I-Disease
. O

first O
, O
repeat O
expansion O
may O
alter O
the O
processing O
or O
transport O
of O
the O
mutant O
d O
##mp O
##k O
m O
##rna O
and O
consequently O
reduce O
d O
##mp O
##k O
levels O
. O

second O
, O
c O
##t O
##g O
expansion O
may O
establish O
a O
region O
of O
he O
##tero O
##ch O
##roma O
##tin O
3 O
of O
the O
repeat O
sequence O
and O
decrease O
six O
##5 O
transcription O
. O

third O
, O
toxic O
effects O
of O
the O
repeat O
expansion O
may O
be O
intrinsic O
to O
the O
repeated O
elements O
at O
the O
level O
of O
d O
##na O
or O
r O
##na O
( O
re O
##fs O
10 O
, O
11 O
) O
. O

previous O
studies O
have O
demonstrated O
that O
a O
dose O
- O
dependent O
loss O
of O
d O
##m O
##15 O
( O
the O
mouse O
d O
##mp O
##k O
ho O
##mo O
##logue O
) O
in O
mice O
produces O
a O
partial O
d B-Disease
##m I-Disease
p O
##hen O
##otype O
characterized O
by O
decreased O
development O
of O
skeletal O
muscle O
force O
and O
cardiac B-Disease
conduct I-Disease
##ion I-Disease
disorders I-Disease
. O

to O
test O
the O
role O
of O
six O
##5 O
loss O
in O
d B-Disease
##m I-Disease
, O
we O
have O
anal O
##ys O
##ed O
a O
strain O
of O
mice O
in O
which O
six O
##5 O
was O
deleted O
. O

our O
results O
demonstrate O
that O
the O
rate O
and O
severity O
of O
cat B-Disease
##ara I-Disease
##ct I-Disease
formation O
is O
inverse O
##ly O
related O
to O
six O
##5 O
dos O
##age O
and O
is O
temporal O
##ly O
progressive O
. O

six O
##5 O
+ O
/ O
- O
and O
six O
##5 O
- O
/ O
- O
mice O
show O
increased O
steady O
- O
state O
levels O
of O
the O
na O
+ O
/ O
k O
+ O
- O
at O
##pas O
##e O
alpha O
- O
1 O
subunit O
and O
decreased O
d O
##m O
##15 O
m O
##rna O
levels O
. O

thus O
, O
altered O
ion O
home O
##ost O
##asis O
within O
the O
lens O
may O
contribute O
to O
cat B-Disease
##ara I-Disease
##ct I-Disease
formation O
. O

as O
o O
##cular O
cat B-Disease
##ara I-Disease
##cts I-Disease
are O
a O
characteristic O
feature O
of O
d B-Disease
##m I-Disease
, O
these O
results O
demonstrate O
that O
decreased O
six O
##5 O
transcription O
is O
important O
in O
the O
a O
##eti O
##ology O
of O
d B-Disease
##m I-Disease
. O

our O
data O
support O
the O
hypothesis O
that O
d B-Disease
##m I-Disease
is O
a O
con O
##ti O
##guous O
gene O
syndrome O
associated O
with O
the O
partial O
loss O
of O
both O
d O
##mp O
##k O
and O
six O
##5 O
. O
. O

at O
##m O
- O
dependent O
p O
##hos O
##ph O
##ory O
##lation O
of O
ni O
##bri O
##n O
in O
response O
to O
radiation O
exposure O
. O

mutations O
in O
the O
gene O
at O
##m O
are O
responsible O
for O
the O
genetic B-Disease
disorder I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
which O
is O
characterized O
by O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
, O
radios O
##ens O
##iti O
##vity O
, O
ch O
##rom O
##oso O
##mal O
instability O
and O
cancer B-Disease
pre O
##dis O
##position O
. O

both O
the O
a B-Disease
- I-Disease
t I-Disease
p O
##hen O
##otype O
and O
the O
similarity O
of O
the O
at O
##m O
protein O
to O
other O
d O
##na O
- O
damage O
sensors O
suggests O
a O
role O
for O
at O
##m O
in O
bio O
##chemical O
pathways O
involved O
in O
the O
recognition O
, O
signalling O
and O
repair O
of O
d O
##na O
double O
- O
strand O
breaks O
( O
d O
##s O
##bs O
) O
. O

there O
are O
strong O
parallels O
between O
the O
pattern O
of O
radios O
##ens O
##iti O
##vity O
, O
ch O
##rom O
##oso O
##mal O
instability O
and O
cancer B-Disease
pre O
##dis O
##position O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
and O
that O
in O
patients O
with O
ni B-Disease
##j I-Disease
##me I-Disease
##gen I-Disease
break I-Disease
##age I-Disease
syndrome I-Disease
( O
n B-Disease
##bs I-Disease
) O
. O

the O
protein O
defect O
##ive O
in O
n B-Disease
##bs I-Disease
, O
ni O
##bri O
##n O
( O
encoded O
by O
n O
##bs O
##1 O
) O
, O
forms O
a O
complex O
with O
m O
##re O
##11 O
and O
r O
##ad O
##50 O
( O
re O
##fs O
1 O
, O
2 O
) O
. O

this O
complex O
local O
##izes O
to O
d O
##s O
##bs O
within O
30 O
minutes O
after O
cellular O
exposure O
to O
ion O
##izing O
radiation O
( O
i O
##r O
) O
and O
is O
observed O
in O
brightly O
stain O
##ing O
nuclear O
f O
##oc O
##i O
after O
a O
longer O
period O
of O
time O
. O

the O
overlap O
between O
clinical O
and O
cellular O
p O
##hen O
##otype O
##s O
in O
a B-Disease
- I-Disease
t I-Disease
and O
n B-Disease
##bs I-Disease
suggests O
that O
at O
##m O
and O
ni O
##bri O
##n O
may O
function O
in O
the O
same O
bio O
##chemical O
pathway O
. O

here O
we O
demonstrate O
that O
ni O
##bri O
##n O
is O
p O
##hos O
##ph O
##ory O
##lated O
within O
one O
hour O
of O
treatment O
of O
cells O
with O
i O
##r O
. O

this O
response O
is O
a O
##bro O
##gated O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
that O
either O
do O
not O
express O
at O
##m O
protein O
or O
express O
near O
full O
- O
length O
mutant O
protein O
. O

we O
also O
show O
that O
at O
##m O
physically O
interact O
##s O
with O
and O
p O
##hos O
##ph O
##ory O
##lates O
ni O
##bri O
##n O
on O
se O
##rine O
34 O
##3 O
both O
in O
v O
##ivo O
and O
in O
v O
##it O
##ro O
. O

p O
##hos O
##ph O
##ory O
##lation O
of O
this O
site O
appears O
to O
be O
functional O
##ly O
important O
because O
m O
##uta O
##ted O
ni O
##bri O
##n O
( O
s O
##34 O
##3 O
##a O
) O
does O
not O
completely O
complement O
radios O
##ens O
##iti O
##vity O
in O
n B-Disease
##bs I-Disease
cells O
. O

at O
##m O
p O
##hos O
##ph O
##ory O
##lation O
of O
ni O
##bri O
##n O
does O
not O
affect O
ni O
##bri O
##n O
- O
m O
##re O
##11 O
- O
r O
##ad O
##50 O
association O
as O
revealed O
by O
radiation O
- O
induced O
f O
##oc O
##i O
formation O
. O

our O
data O
provide O
a O
bio O
##chemical O
explanation O
for O
the O
similarity O
in O
p O
##hen O
##otype O
between O
a B-Disease
- I-Disease
t I-Disease
and O
n B-Disease
##bs I-Disease
. O
. O

clinic O
##op O
##ath O
##olo O
##gic O
features O
of O
br B-Disease
##ca I-Disease
- I-Disease
linked I-Disease
and I-Disease
s I-Disease
##poradic I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

context O
most O
hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
are O
associated O
with O
g O
##er O
##m O
##line O
mutations O
in O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
. O

attempts O
to O
define O
the O
clinical O
significance O
of O
br O
##ca O
mutation O
status O
in O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
have O
produced O
conflicting O
results O
, O
especially O
regarding O
survival O
. O

objective O
to O
determine O
whether O
hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
have O
distinct O
clinical O
and O
path O
##ological O
features O
compared O
with O
s B-Disease
##poradic I-Disease
( I-Disease
non I-Disease
##hered I-Disease
##ita I-Disease
##ry I-Disease
) I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

design O
and O
setting O
retrospective O
co O
##hor O
##t O
study O
of O
a O
consecutive O
series O
of O
93 O
##3 O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
diagnosed O
and O
treated O
at O
our O
institution O
, O
which O
is O
a O
comprehensive O
cancer B-Disease
center O
as O
designated O
by O
the O
national O
cancer B-Disease
institute O
, O
over O
a O
12 O
- O
year O
period O
( O
de O
##ce O
##mber O
1986 O
to O
au O
##gus O
##t O
1998 O
) O
. O

patients O
the O
study O
was O
restricted O
to O
patients O
of O
j O
##ew O
##ish O
origin O
because O
of O
the O
ease O
of O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
g O
##eno O
##ty O
##ping O
in O
this O
ethnic O
group O
. O

from O
the O
189 O
patients O
who O
identified O
themselves O
as O
j O
##ew O
##ish O
, O
88 O
hereditary O
cases O
were O
identified O
with O
the O
presence O
of O
a O
g O
##er O
##m O
##line O
founder O
mutation O
in O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
. O

the O
remaining O
101 O
cases O
from O
the O
same O
series O
not O
associated O
with O
a O
br O
##ca O
mutation O
and O
2 O
additional O
groups O
( O
g O
##yne O
##co O
##log O
##ic O
on O
##cology O
group O
protocols O
52 O
and O
111 O
) O
with O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
from O
clinical O
trials O
( O
for O
the O
survival O
analysis O
) O
were O
included O
for O
comparison O
. O

main O
outcome O
measures O
age O
at O
diagnosis O
, O
surgical O
stage O
, O
his O
##to O
##log O
##ic O
cell O
type O
and O
grade O
, O
and O
surgical O
outcome O
; O
and O
response O
to O
ch O
##em O
##otherapy O
and O
survival O
for O
advanced O
- O
stage O
( O
ii O
and O
i O
##v O
) O
cases O
. O

results O
hereditary B-Disease
cancer I-Disease
##s I-Disease
were O
rarely O
diagnosed O
before O
age O
40 O
years O
and O
were O
common O
after O
age O
60 O
years O
, O
with O
mean O
age O
at O
diagnosis O
being O
significantly O
younger O
for O
br O
##ca O
##1 O
- O
vs O
br O
##ca O
##2 O
- O
linked O
patients O
( O
54 O
vs O
62 O
years O
; O
p O
= O
. O
04 O
) O
. O

his O
##tology O
, O
grade O
, O
stage O
, O
and O
success O
of O
c O
##yt O
##ored O
##uctive O
surgery O
were O
similar O
for O
hereditary O
and O
s O
##poradic O
cases O
. O

the O
hereditary O
group O
had O
a O
longer O
disease O
- O
free O
interval O
following O
primary O
ch O
##em O
##otherapy O
in O
comparison O
with O
the O
non O
##hered O
##ita O
##ry O
group O
, O
with O
a O
median O
time O
to O
re O
##cu O
##rrence O
of O
14 O
months O
and O
7 O
months O
, O
respectively O
( O
p O
[UNK] O
. O
00 O
##1 O
) O
. O

those O
with O
hereditary B-Disease
cancer I-Disease
##s I-Disease
had O
improved O
survival O
compared O
with O
the O
non O
##hered O
##ita O
##ry O
group O
( O
p O
= O
. O
00 O
##4 O
) O
. O

for O
stage B-Disease
ii I-Disease
##i I-Disease
cancer I-Disease
##s I-Disease
, O
br O
##ca O
mutation O
status O
was O
an O
independent O
pro O
##gno O
##stic O
variable O
( O
p O
= O
. O
03 O
) O
. O

conclusions O
although O
br B-Disease
##ca I-Disease
- I-Disease
associated I-Disease
hereditary I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
in O
this O
population O
have O
surgical O
and O
path O
##ological O
characteristics O
similar O
to O
those O
of O
s B-Disease
##poradic I-Disease
cancer I-Disease
##s I-Disease
, O
advanced B-Disease
- I-Disease
stage I-Disease
hereditary I-Disease
cancer I-Disease
patients O
survive O
longer O
than O
non B-Disease
##hered I-Disease
##ita I-Disease
##ry I-Disease
cancer I-Disease
patients O
. O

age O
pen O
##et O
##rance O
is O
greater O
for O
br B-Disease
##ca I-Disease
##1 I-Disease
- I-Disease
linked I-Disease
than I-Disease
for I-Disease
br I-Disease
##ca I-Disease
##2 I-Disease
- I-Disease
linked I-Disease
cancer I-Disease
##s I-Disease
in O
this O
population O
. O

the O
gene O
for O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
, O
me O
##f O
##v O
, O
is O
expressed O
in O
early O
le O
##uk O
##oc O
##yte O
development O
and O
is O
regulated O
in O
response O
to O
inflammatory O
media O
##tors O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
is O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever B-Disease
and O
ne B-Disease
##ut I-Disease
##rop I-Disease
##hil I-Disease
- I-Disease
mediated I-Disease
se I-Disease
##ros I-Disease
##al I-Disease
inflammation I-Disease
. O

we O
recently O
identified O
the O
gene O
causing O
f B-Disease
##m I-Disease
##f I-Disease
, O
designated O
me O
##f O
##v O
, O
and O
found O
it O
to O
be O
expressed O
in O
mature O
ne O
##ut O
##rop O
##hil O
##s O
, O
suggesting O
that O
it O
functions O
as O
an O
inflammatory O
regulator O
. O

to O
facilitate O
our O
understanding O
of O
the O
normal O
function O
of O
me O
##f O
##v O
, O
we O
extended O
our O
previous O
studies O
. O

me O
##f O
##v O
messenger O
r O
##na O
was O
detected O
by O
reverse O
trans O
##cript O
##ase O
- O
polymer O
##ase O
chain O
reaction O
in O
bone O
ma O
##rrow O
le O
##uk O
##ocytes O
, O
with O
differential O
expression O
observed O
among O
cells O
by O
in O
sit O
##u O
hybrid O
##ization O
. O

c O
##d O
##34 O
hem O
##ato O
##po O
##iet O
##ic O
stem O
- O
cell O
cultures O
induced O
toward O
the O
g O
##ran O
##ulo O
##cy O
##tic O
lineage O
expressed O
me O
##f O
##v O
at O
the O
my O
##elo O
##cy O
##te O
stage O
, O
concurrently O
with O
lineage O
commitment O
. O

the O
pre O
##p O
##rom O
##ye O
##loc O
##ytic O
cell O
line O
h O
##l O
##60 O
expressed O
me O
##f O
##v O
only O
at O
g O
##ran O
##ulo O
##cy O
##tic O
and O
mon O
##oc O
##ytic O
differentiation O
. O

me O
##f O
##v O
was O
also O
expressed O
in O
the O
mon O
##oc O
##ytic O
cell O
lines O
u O
##9 O
##37 O
and O
th O
##p O
- O
1 O
. O

among O
peripheral O
blood O
le O
##uk O
##ocytes O
, O
me O
##f O
##v O
expression O
was O
detected O
in O
ne O
##ut O
##rop O
##hil O
##s O
, O
e O
##os O
##ino O
##phi O
##ls O
, O
and O
to O
varying O
degrees O
, O
mon O
##ocytes O
. O

consistent O
with O
the O
tissue O
specific O
##ity O
of O
expression O
, O
complete O
se O
##quencing O
and O
analysis O
of O
upstream O
regulatory O
regions O
of O
me O
##f O
##v O
revealed O
ho O
##mology O
to O
my O
##elo O
##id O
- O
specific O
promoter O
##s O
and O
to O
more O
broadly O
expressed O
inflammatory O
promoter O
elements O
. O

in O
v O
##it O
##ro O
stimulation O
of O
mon O
##ocytes O
with O
the O
pro O
##in O
##f O
##lam O
##mat O
##ory O
agents O
inter O
##fer O
##on O
( O
if O
##n O
) O
gamma O
, O
tumor B-Disease
ne O
##c O
##rosis O
factor O
, O
and O
lip O
##op O
##oly O
##sa O
##cc O
##hari O
##de O
induced O
me O
##f O
##v O
expression O
, O
whereas O
the O
anti O
##in O
##f O
##lam O
##mat O
##ory O
c O
##yt O
##oki O
##nes O
inter O
##le O
##uki O
##n O
( O
il O
) O
4 O
, O
il O
- O
10 O
, O
and O
transforming O
growth O
factor O
beta O
in O
##hibit O
##ed O
such O
expression O
. O

induction O
by O
if O
##n O
- O
gamma O
occurred O
rapidly O
and O
was O
resistant O
to O
c O
##y O
##c O
##lo O
##he O
##xi O
##mi O
##de O
. O

if O
##n O
- O
alpha O
also O
induced O
me O
##f O
##v O
expression O
. O

in O
g O
##ran O
##ulo O
##cy O
##tes O
, O
me O
##f O
##v O
was O
up O
- O
regulated O
by O
if O
##n O
- O
gamma O
and O
the O
combination O
of O
if O
##n O
- O
alpha O
and O
co O
##l O
##chi O
##cine O
. O

these O
results O
re O
##fine O
understanding O
of O
me O
##f O
##v O
by O
placing O
the O
gene O
in O
the O
my O
##elo O
##mon O
##oc O
##ytic O
- O
specific O
pro O
##in O
##f O
##lam O
##mat O
##ory O
pathway O
and O
identifying O
it O
as O
an O
if O
##n O
- O
gamma O
immediate O
early O
gene O
. O
. O

bio O
##chemical O
and O
structural O
analysis O
of O
miss O
##ense O
mutations O
in O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##osa O
##mine O
- O
6 O
- O
su O
##lf O
##ate O
su O
##lf O
##ata O
##se O
causing O
m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
p O
##hen O
##otype O
##s O
. O

m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
( O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
; O
o O
##mi O
##m O
# O
253 O
##00 O
##0 O
) O
, O
a O
l B-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
n I-Disease
- I-Disease
ace I-Disease
##ty I-Disease
##l I-Disease
##gal I-Disease
##act I-Disease
##osa I-Disease
##mine I-Disease
- I-Disease
6 I-Disease
- I-Disease
su I-Disease
##lf I-Disease
##ate I-Disease
su I-Disease
##lf I-Disease
##ata I-Disease
##se I-Disease
( O
gal O
##ns O
) O
, O
has O
variable O
clinical O
p O
##hen O
##otype O
##s O
. O

to O
date O
we O
have O
identified O
65 O
miss O
##ense O
mutations O
in O
the O
gal O
##ns O
gene O
from O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
patients O
, O
but O
the O
correlation O
between O
g O
##eno O
##type O
and O
p O
##hen O
##otype O
has O
remained O
unclear O
. O

we O
studied O
17 O
miss O
##ense O
mutations O
using O
bio O
##chemical O
approaches O
and O
32 O
miss O
##ense O
mutations O
, O
using O
structural O
analyses O
. O

fifteen O
miss O
##ense O
mutations O
and O
two O
newly O
engineered O
active O
site O
mutations O
( O
c O
##7 O
##9 O
##s O
, O
c O
##7 O
##9 O
##t O
) O
were O
characterized O
by O
trans O
##ient O
expression O
analysis O
. O

mutant O
proteins O
, O
except O
for O
c O
##7 O
##9 O
##s O
and O
c O
##7 O
##9 O
##t O
, O
were O
des O
##ta O
##bil O
##ized O
and O
detected O
as O
ins O
##ol O
##ub O
##le O
precursor O
forms O
while O
the O
c O
##7 O
##9 O
##s O
and O
c O
##7 O
##9 O
##t O
mutant O
##s O
were O
of O
a O
soluble O
mature O
size O
. O

mutant O
##s O
found O
in O
the O
severe O
p O
##hen O
##otype O
had O
no O
activity O
. O

mutant O
##s O
found O
in O
the O
mild O
p O
##hen O
##otype O
had O
a O
considerable O
residual O
activity O
( O
1 O
. O
3 O
- O
13 O
. O
3 O
% O
of O
wild O
- O
type O
gal O
##ns O
activity O
) O
. O

su O
##lf O
##ata O
##ses O
, O
including O
gal O
##ns O
, O
are O
members O
of O
a O
highly O
conserved O
gene O
family O
sharing O
an O
extensive O
sequence O
ho O
##mology O
. O

thus O
, O
a O
tertiary O
structural O
model O
of O
human O
gal O
##ns O
was O
constructed O
from O
the O
x O
- O
ray O
crystal O
structure O
of O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##o O
- O
sa O
##mine O
- O
4 O
- O
su O
##lf O
##ata O
##se O
and O
a O
##ryl O
##sul O
##fa O
##tase O
a O
, O
using O
ho O
##mology O
modeling O
, O
and O
32 O
miss O
##ense O
mutations O
were O
investigated O
. O

consequently O
, O
we O
propose O
that O
there O
are O
at O
least O
three O
different O
reasons O
for O
the O
severe O
p O
##hen O
##otype O
( O
i O
) O
destruction O
of O
the O
h O
##ydro O
##phobic O
core O
or O
modification O
of O
the O
packing O
; O
( O
ii O
) O
removal O
of O
a O
salt O
bridge O
to O
des O
##ta O
##bil O
##ize O
the O
entire O
conform O
##ation O
; O
( O
ii O
##i O
) O
modification O
of O
the O
active O
site O
. O

in O
contrast O
, O
mild O
mutations O
were O
mostly O
located O
on O
the O
surface O
of O
the O
gal O
##ns O
protein O
. O

these O
studies O
shed O
further O
light O
on O
the O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
of O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
and O
structure O
- O
function O
relationship O
in O
the O
su O
##lf O
##ata O
##se O
family O
. O

mutations O
at O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
lo O
##cus O
and O
clinical O
p O
##hen O
##otype O
##s O
of O
a B-Disease
- I-Disease
t I-Disease
patients O
. O

mutations O
at O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
lo O
##cus O
on O
chromosome O
band O
11 O
##q O
##22 O
cause O
a O
distinctive O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
syndrome I-Disease
in O
ho O
##mo O
##zy O
##got O
##es O
and O
pre O
##dis O
##pose O
he O
##tero O
##zy O
##got O
##es O
to O
cancer B-Disease
, O
is B-Disease
##che I-Disease
##mic I-Disease
heart I-Disease
disease I-Disease
, O
and O
early O
mortality O
. O

p O
##c O
##r O
am O
##p O
##lification O
from O
g O
##eno O
##mic O
d O
##na O
and O
automated O
se O
##quencing O
of O
the O
entire O
coding O
region O
( O
66 O
ex O
##ons O
) O
and O
s O
##p O
##lice O
junction O
##s O
detected O
77 O
mutations O
( O
85 O
% O
) O
in O
90 O
a B-Disease
- I-Disease
t I-Disease
chromosome O
##s O
. O

he O
##tero O
##du O
##plex O
analysis O
detected O
another O
42 O
mutations O
at O
the O
a B-Disease
- I-Disease
t I-Disease
lo O
##cus O
. O

out O
of O
a O
total O
of O
71 O
unique O
mutations O
, O
50 O
were O
found O
only O
in O
a O
single O
family O
, O
and O
51 O
had O
not O
been O
reported O
previously O
. O

most O
( O
58 O
/ O
71 O
, O
82 O
% O
) O
mutations O
were O
frames O
##hi O
##ft O
and O
nonsense O
mutations O
that O
are O
predicted O
to O
cause O
t O
##run O
##cation O
of O
the O
a B-Disease
- I-Disease
t I-Disease
protein O
; O
the O
less O
common O
mutation O
types O
were O
miss O
##ense O
( O
9 O
/ O
71 O
, O
13 O
% O
) O
, O
s O
##p O
##licing O
( O
3 O
/ O
71 O
, O
4 O
% O
) O
and O
one O
in O
- O
frame O
del O
##eti O
##on O
, O
254 O
##6 O
3 O
( O
1 O
/ O
71 O
, O
1 O
% O
) O
. O

the O
mean O
survival O
and O
height O
distribution O
of O
134 O
a B-Disease
- I-Disease
t I-Disease
patients O
correlated O
significantly O
with O
the O
specific O
mutations O
present O
in O
the O
patients O
. O

patients O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
single O
t O
##run O
##cating O
mutation O
, O
typically O
near O
the O
n O
- O
terminal O
end O
of O
the O
gene O
, O
or O
he O
##tero O
##zy O
##go O
##us O
for O
the O
in O
- O
frame O
del O
##eti O
##on O
254 O
##6 O
3 O
, O
were O
shorter O
and O
had O
significantly O
shorter O
survival O
than O
those O
he O
##tero O
##zy O
##go O
##us O
for O
a O
s O
##p O
##lice O
site O
or O
miss O
##ense O
mutation O
, O
or O
he O
##tero O
##zy O
##go O
##us O
for O
two O
t O
##run O
##cating O
mutations O
. O

alterations O
of O
the O
length O
or O
amino O
acid O
composition O
of O
the O
a B-Disease
- I-Disease
t I-Disease
gene O
product O
affect O
the O
a B-Disease
- I-Disease
t I-Disease
clinical O
p O
##hen O
##otype O
in O
different O
ways O
. O

mutation O
analysis O
at O
the O
a B-Disease
- I-Disease
t I-Disease
lo O
##cus O
may O
help O
estimate O
the O
pro O
##gno O
##sis O
of O
a B-Disease
- I-Disease
t I-Disease
patients O
. O
. O

isolation O
, O
g O
##eno O
##mic O
organization O
, O
and O
expression O
analysis O
of O
the O
mouse O
and O
rat O
ho O
##mo O
##log O
##s O
of O
me O
##f O
##v O
, O
the O
gene O
for O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
. O

f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
is O
a O
re B-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever B-Disease
with O
se B-Disease
##ros I-Disease
##itis I-Disease
or O
s B-Disease
##yn I-Disease
##ov I-Disease
##itis I-Disease
. O

recently O
the O
f B-Disease
##m I-Disease
##f I-Disease
gene O
( O
me O
##f O
##v O
) O
was O
clone O
##d O
; O
the O
protein O
product O
, O
p O
##yr O
##in O
/ O
mare O
##nos O
##tri O
##n O
, O
is O
thought O
to O
regulate O
inflammation O
in O
my O
##elo O
##id O
cells O
. O

in O
this O
manuscript O
we O
report O
the O
mouse O
and O
rat O
ho O
##mo O
##log O
##s O
of O
me O
##f O
##v O
. O

the O
m O
##uri O
##ne O
gene O
contains O
ten O
ex O
##ons O
with O
a O
coding O
sequence O
of O
230 O
##4 O
b O
##p O
, O
while O
the O
rat O
ho O
##mo O
##log O
has O
nine O
ex O
##ons O
with O
a O
coding O
sequence O
of O
225 O
##3 O
b O
##p O
. O

a O
considerable O
amino O
acid O
sequence O
ho O
##mology O
was O
observed O
between O
the O
mouse O
and O
human O
( O
47 O
. O
6 O
% O
identity O
and O
65 O
. O
5 O
% O
similarity O
) O
and O
between O
the O
mouse O
and O
rat O
genes O
( O
73 O
. O
5 O
% O
identity O
and O
82 O
. O
1 O
% O
similarity O
) O
. O

the O
predicted O
rode O
##nt O
proteins O
have O
several O
important O
domains O
and O
signals O
found O
in O
human O
p O
##yr O
##in O
, O
including O
a O
b O
- O
box O
zinc O
finger O
domain O
, O
r O
##ob O
##bin O
##s O
- O
din O
##g O
##wall O
nuclear O
local O
##ization O
signal O
, O
and O
coil O
##ed O
- O
coil O
domain O
. O

however O
, O
perhaps O
because O
of O
an O
ancient O
frame O
- O
shift O
mutation O
, O
neither O
the O
mouse O
nor O
the O
rat O
protein O
has O
an O
intact O
c O
- O
terminal O
b O
##30 O
. O

2 O
domain O
, O
in O
which O
most O
f B-Disease
##m I-Disease
##f I-Disease
- O
associated O
mutations O
have O
been O
found O
in O
human O
me O
##f O
##v O
. O

nevertheless O
, O
like O
the O
human O
gene O
, O
mouse O
me O
##f O
##v O
is O
expressed O
in O
peripheral O
blood O
g O
##ran O
##ulo O
##cy O
##tes O
but O
not O
l O
##ymph O
##ocytes O
. O

consistent O
with O
its O
expression O
in O
g O
##ran O
##ulo O
##cy O
##tes O
, O
me O
##f O
##v O
was O
detected O
at O
high O
levels O
in O
the O
primary O
f O
##oll O
##icles O
and O
marginal O
zones O
of O
the O
s O
##ple O
##nic O
white O
pulp O
. O

me O
##f O
##v O
is O
localized O
on O
mouse O
chromosome O
( O
ch O
##r O
) O
16 O
, O
region O
a O
##3 O
- O
b O
##1 O
, O
extending O
a O
region O
of O
s O
##yn O
##ten O
##y O
with O
human O
ch O
##r O
16 O
##p O
##13 O
. O

3 O
. O

development O
of O
knockout O
and O
knock O
##in O
mouse O
models O
may O
provide O
further O
insights O
into O
the O
functional O
evolution O
of O
this O
gene O
. O

additional O
copies O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
causing O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
arise O
by O
separate O
integration O
into O
the O
x O
chromosome O
. O

the O
pro O
##te O
##oli O
##pid O
protein O
gene O
( O
p O
##l O
##p O
) O
is O
normally O
present O
at O
chromosome O
x O
##q O
##22 O
. O

mutations O
and O
du O
##plication O
##s O
of O
this O
gene O
are O
associated O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
. O

here O
we O
describe O
two O
new O
families O
in O
which O
males O
affected O
with O
pm B-Disease
##d I-Disease
were O
found O
to O
have O
a O
copy O
of O
p O
##l O
##p O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
, O
in O
addition O
to O
a O
normal O
copy O
on O
x O
##q O
##22 O
. O

in O
the O
first O
family O
, O
the O
extra O
copy O
was O
first O
detected O
by O
the O
presence O
of O
he O
##tero O
##zy O
##gos O
##ity O
of O
the O
ah O
##ai O
##i O
dim O
##or O
##phism O
within O
the O
p O
##l O
##p O
gene O
. O

the O
results O
of O
fish O
analysis O
showed O
an O
additional O
copy O
of O
p O
##l O
##p O
in O
x O
##p O
##22 O
. O

1 O
, O
although O
no O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
##s O
could O
be O
detected O
by O
standard O
ka O
##ryo O
##type O
analysis O
. O

another O
three O
affected O
males O
from O
the O
family O
had O
similar O
findings O
. O

in O
a O
second O
unrelated O
family O
with O
signs O
of O
pm B-Disease
##d I-Disease
, O
c O
##yt O
##ogen O
##etic O
analysis O
showed O
a O
per O
##ice O
##nt O
##ric O
in O
##version O
of O
the O
x O
chromosome O
. O

in O
the O
in O
##v O
( O
x O
) O
carried O
by O
several O
affected O
family O
members O
, O
fish O
showed O
p O
##l O
##p O
signals O
at O
x O
##p O
##11 O
. O

4 O
and O
x O
##q O
##22 O
. O

a O
third O
family O
has O
previously O
been O
reported O
, O
in O
which O
affected O
members O
had O
an O
extra O
copy O
of O
the O
p O
##l O
##p O
gene O
detected O
at O
x O
##q O
##26 O
in O
a O
chromosome O
with O
an O
otherwise O
normal O
band O
##ing O
pattern O
. O

the O
identification O
of O
three O
separate O
families O
in O
which O
p O
##l O
##p O
is O
du O
##plicate O
##d O
at O
a O
non O
##con O
##ti O
##guous O
site O
suggests O
that O
such O
du O
##plication O
##s O
could O
be O
a O
relatively O
common O
but O
previously O
und O
##ete O
##cted O
cause O
of O
genetic B-Disease
disorders I-Disease
. O

the O
ex O
##on O
13 O
du O
##plication O
in O
the O
br O
##ca O
##1 O
gene O
is O
a O
founder O
mutation O
present O
in O
geographically O
diverse O
populations O
. O

the O
br O
##ca O
##1 O
ex O
##on O
13 O
du O
##plication O
screening O
group O
. O

recently O
, O
a O
6 O
- O
k O
##b O
du O
##plication O
of O
ex O
##on O
13 O
, O
which O
creates O
a O
frames O
##hi O
##ft O
in O
the O
coding O
sequence O
of O
the O
br O
##ca O
##1 O
gene O
, O
has O
been O
described O
in O
three O
unrelated O
u O
. O

s O
s O
. O
families O
of O
euro O
##pe O
##an O
ancestry O
and O
in O
one O
port O
##ug O
##ues O
##e O
family O
. O

here O
, O
our O
goal O
was O
to O
estimate O
the O
frequency O
and O
geographic O
diversity O
of O
carriers O
of O
this O
du O
##plication O
. O

to O
do O
this O
, O
a O
collaborative O
screening O
study O
was O
set O
up O
that O
involved O
39 O
institutions O
from O
19 O
countries O
and O
included O
3 O
, O
580 O
unrelated O
individuals O
with O
a O
family O
history O
of O
the O
disease O
and O
93 O
##4 O
early O
- O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
. O

a O
total O
of O
11 O
additional O
families O
carrying O
this O
mutation O
were O
identified O
in O
au O
##stra O
##lia O
( O
1 O
) O
, O
be O
##l O
##gi O
##um O
( O
1 O
) O
, O
can O
##ada O
( O
1 O
) O
, O
great O
br O
##ita O
##in O
( O
6 O
) O
, O
and O
the O
united O
states O
( O
2 O
) O
. O

ha O
##p O
##lot O
##y O
##ping O
showed O
that O
they O
are O
likely O
to O
derive O
from O
a O
common O
ancestor O
, O
possibly O
of O
northern O
br O
##itis O
##h O
origin O
. O

our O
results O
demonstrate O
that O
it O
is O
strongly O
ad O
##vis O
##able O
, O
for O
laboratories O
carrying O
out O
screening O
either O
in O
en O
##gli O
##sh O
- O
speaking O
countries O
or O
in O
countries O
with O
historical O
links O
with O
br O
##ita O
##in O
, O
to O
include O
within O
their O
br O
##ca O
##1 O
screening O
protocols O
the O
polymer O
##ase O
chain O
reaction O
- O
based O
ass O
##ay O
described O
in O
this O
report O
. O

g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
families O
with O
del O
##eti O
##ons O
in O
the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( O
v B-Disease
##hl I-Disease
) O
gene O
. O

von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
disease I-Disease
is O
a O
hereditary B-Disease
tumor I-Disease
syndrome I-Disease
characterized O
by O
pre O
##dis O
##position O
for O
bilateral B-Disease
and I-Disease
multi I-Disease
- I-Disease
cent I-Disease
##ric I-Disease
hem I-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
in O
the O
re O
##tina O
and O
central O
nervous O
system O
, O
p B-Disease
##he I-Disease
##och I-Disease
##rom I-Disease
##oc I-Disease
##yt I-Disease
##oma I-Disease
, O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
, O
and O
c B-Disease
##ys I-Disease
##ts I-Disease
in I-Disease
the I-Disease
kidney I-Disease
, I-Disease
pan I-Disease
##cre I-Disease
##as I-Disease
, I-Disease
and I-Disease
e I-Disease
##pid I-Disease
##idy I-Disease
##mis I-Disease
. O

we O
describe O
five O
families O
for O
which O
direct O
se O
##quencing O
of O
the O
coding O
region O
of O
the O
v B-Disease
##hl I-Disease
gene O
had O
failed O
to O
identify O
the O
family O
- O
specific O
mutation O
. O

further O
molecular O
analysis O
revealed O
del O
##eti O
##ons O
involving O
the O
v B-Disease
##hl I-Disease
gene O
in O
each O
of O
these O
families O
. O

in O
four O
families O
, O
partial O
del O
##eti O
##ons O
of O
one O
or O
more O
ex O
##ons O
were O
detected O
by O
southern O
b O
##lot O
analysis O
. O

in O
the O
fifth O
family O
, O
fish O
analysis O
demonstrated O
the O
del O
##eti O
##on O
of O
the O
entire O
v B-Disease
##hl I-Disease
gene O
. O

our O
results O
show O
that O
( O
quantitative O
) O
southern O
b O
##lot O
analysis O
is O
a O
sensitive O
method O
for O
detect O
##ing O
g O
##er O
##m O
##line O
del O
##eti O
##ons O
of O
the O
v B-Disease
##hl I-Disease
gene O
and O
should O
be O
implemented O
in O
routine O
d O
##na O
diagnosis O
for O
v B-Disease
##hl I-Disease
disease I-Disease
. O

our O
data O
support O
the O
previously O
established O
observation O
that O
families O
with O
a O
g O
##er O
##m O
##line O
del O
##eti O
##on O
have O
a O
low O
risk O
for O
p B-Disease
##he I-Disease
##och I-Disease
##rom I-Disease
##oc I-Disease
##yt I-Disease
##oma I-Disease
. O

further O
un O
##rave O
##ling O
of O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
v B-Disease
##hl I-Disease
disease I-Disease
has O
revealed O
that O
families O
with O
a O
full O
or O
partial O
del O
##eti O
##on O
of O
the O
v B-Disease
##hl I-Disease
gene O
exhibit O
a O
p O
##hen O
##otype O
with O
a O
pre O
##po O
##nder O
##ance O
of O
central B-Disease
nervous I-Disease
system I-Disease
hem I-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
. O
. O

age O
of O
the O
intro O
##nic O
g O
##aa O
triple O
##t O
repeat O
expansion O
mutation O
in O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
, O
the O
most O
frequently O
inherited B-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
, O
is O
due O
in O
the O
vast O
majority O
of O
cases O
to O
a O
large O
expansion O
of O
an O
intro O
##nic O
g O
##aa O
repeat O
. O

using O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
analysis O
based O
on O
ha O
##p O
##lot O
##ype O
data O
of O
seven O
p O
##oly O
##morphic O
markers O
close O
to O
the O
f O
##rata O
##xin O
gene O
, O
the O
age O
of O
f B-Disease
##rda I-Disease
founding O
mutation O
##al O
event O
( O
s O
) O
is O
estimated O
to O
be O
at O
least O
68 O
##2 O
+ O
/ O
- O
203 O
generations O
( O
95 O
% O
confidence O
interval O
56 O
##4 O
- O
80 O
##1 O
g O
) O
, O
a O
dating O
which O
is O
consistent O
with O
little O
or O
no O
negative O
selection O
and O
provides O
further O
evidence O
for O
an O
ancient O
spread O
of O
a O
pre O
- O
mutation O
( O
at O
- O
risk O
all O
##ele O
##s O
) O
in O
western O
euro O
##pe O
. O
. O

functional O
link O
between O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
and O
ni B-Disease
##j I-Disease
##me I-Disease
##gen I-Disease
break I-Disease
##age I-Disease
syndrome I-Disease
gene O
products O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
and O
ni B-Disease
##j I-Disease
##me I-Disease
##gen I-Disease
break I-Disease
##age I-Disease
syndrome I-Disease
( O
n B-Disease
##bs I-Disease
) O
are O
re B-Disease
##cess I-Disease
##ive I-Disease
genetic I-Disease
disorders I-Disease
with O
su O
##s O
##ce O
##pt O
##ibility O
to O
cancer B-Disease
and O
similar O
cellular O
p O
##hen O
##otype O
##s O
. O

the O
protein O
product O
of O
the O
gene O
responsible O
for O
a B-Disease
- I-Disease
t I-Disease
, O
designated O
at O
##m O
, O
is O
a O
member O
of O
a O
family O
of O
kinase O
##s O
characterized O
by O
a O
car O
##box O
##y O
- O
terminal O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
3 O
- O
kinase O
- O
like O
domain O
. O

the O
n O
##bs O
##1 O
protein O
is O
specifically O
m O
##uta O
##ted O
in O
patients O
with O
ni B-Disease
##j I-Disease
##me I-Disease
##gen I-Disease
break I-Disease
##age I-Disease
syndrome I-Disease
and O
forms O
a O
complex O
with O
the O
d O
##na O
repair O
proteins O
r O
##ad O
##50 O
and O
m O
##rel O
##1 O
. O

here O
we O
show O
that O
p O
##hos O
##ph O
##ory O
##lation O
of O
n O
##bs O
##1 O
, O
induced O
by O
ion O
##izing O
radiation O
, O
requires O
cat O
##alytic O
##ally O
active O
at O
##m O
. O

complexes O
containing O
at O
##m O
and O
n O
##bs O
##1 O
exist O
in O
v O
##ivo O
in O
both O
un O
##tre O
##ated O
cells O
and O
cells O
treated O
with O
ion O
##izing O
radiation O
. O

we O
have O
identified O
two O
residues O
of O
n O
##bs O
##1 O
, O
se O
##r O
278 O
and O
se O
##r O
34 O
##3 O
that O
are O
p O
##hos O
##ph O
##ory O
##lated O
in O
v O
##it O
##ro O
by O
at O
##m O
and O
whose O
modification O
in O
v O
##ivo O
is O
essential O
for O
the O
cellular O
response O
to O
d O
##na O
damage O
. O

this O
response O
includes O
s O
- O
phase O
check O
##point O
activation O
, O
formation O
of O
the O
n O
##bs O
##1 O
/ O
m O
##rel O
##1 O
/ O
r O
##ad O
##50 O
nuclear O
f O
##oc O
##i O
and O
rescue O
of O
h B-Disease
##yper I-Disease
##sen I-Disease
##si I-Disease
##ti I-Disease
##vity I-Disease
to I-Disease
ion I-Disease
##izing I-Disease
radiation I-Disease
. O

together O
, O
these O
results O
demonstrate O
a O
bio O
##chemical O
link O
between O
cell O
- O
cycle O
check O
##points O
activated O
by O
d O
##na O
damage O
and O
d O
##na O
repair O
in O
two O
genetic B-Disease
diseases I-Disease
with O
overlapping O
p O
##hen O
##otype O
##s O
. O
. O

ho O
##mo O
##zy O
##gos O
##ity O
mapping O
in O
a O
family O
with O
micro B-Disease
##ce I-Disease
##pha I-Disease
##ly I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
short B-Disease
stature I-Disease
to O
a O
co B-Disease
##hen I-Disease
syndrome I-Disease
region O
on O
8 O
##q O
##21 O
. O
3 O
- O
8 O
##q O
##22 O
. O
1 O
: O
red O
##ef O
##ining O
a O
clinical O
entity O
. O

a O
syndrome O
of O
micro B-Disease
##ce I-Disease
##pha I-Disease
##ly I-Disease
, O
progressive O
post B-Disease
##nat I-Disease
##al I-Disease
growth I-Disease
deficiency I-Disease
, O
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
was O
observed O
in O
two O
brothers O
and O
their O
cousin O
from O
a O
multi O
##p O
##ly O
con O
##sang O
##uin O
##eous O
kind O
##red O
of O
le O
##ban O
##ese O
descent O
. O

h B-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
, O
ch B-Disease
##orio I-Disease
##ret I-Disease
##inal I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
and O
my B-Disease
##op I-Disease
##ia I-Disease
were O
also O
identified O
. O

the O
severity O
of O
the O
condition O
varied O
among O
the O
closely O
related O
patients O
. O

because O
of O
absence O
of O
a O
distinctive O
facial O
appearance O
, O
the O
degree O
of O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
short B-Disease
stature I-Disease
, O
the O
initially O
considered O
clinical O
diagnosis O
of O
co B-Disease
##hen I-Disease
syndrome I-Disease
was O
withdrawn O
and O
a O
novel O
genetic O
entity O
was O
assumed O
. O

ho O
##mo O
##zy O
##gos O
##ity O
mapping O
in O
this O
family O
assigned O
the O
gene O
to O
a O
26 O
. O

8 O
- O
cm O
region O
on O
the O
chromosome O
band O
8 O
##q O
##21 O
. O

3 O
- O
22 O
. O

1 O
, O
between O
the O
micro O
##sat O
##elli O
##tes O
at O
d O
##8 O
##s O
##27 O
##0 O
and O
d O
##8 O
##s O
##51 O
##4 O
. O

the O
maximum O
two O
- O
point O
lo O
##d O
score O
was O
found O
for O
marker O
at O
d O
##8 O
##s O
##26 O
##7 O
( O
z O
##max O
= O
3 O
. O
. O
237 O
at O
o O
##max O
= O
0 O
. O
00 O
) O
. O

intriguing O
##ly O
enough O
, O
the O
identified O
gene O
region O
overlap O
##s O
the O
refined O
gene O
region O
for O
co B-Disease
##hen I-Disease
syndrome I-Disease
( O
co O
##h O
##1 O
) O
[ O
k O
##ole O
##hm O
##aine O
##n O
et O
al O
. O
, O
1997 O
euro O
j O
hum O
gene O
##t O
5 O
206 O
- O
213 O
] O
. O

this O
fact O
encourages O
the O
hypothesis O
that O
the O
described O
kind O
##red O
se O
##g O
##re O
##gate O
##s O
for O
a O
variant O
of O
co B-Disease
##hen I-Disease
syndrome I-Disease
and O
suggests O
a O
red O
##ef O
##ini O
##tion O
of O
its O
p O
##hen O
##otype O

p O
##oly O
##mor O
##phism O
##s O
of O
the O
c O
##y O
##p O
##2 O
##d O
##6 O
gene O
increase O
su O
##s O
##ce O
##pt O
##ibility O
to O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
. O

an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
( O
as B-Disease
) O
is O
a O
common O
and O
highly O
f O
##ami O
##lial O
r B-Disease
##he I-Disease
##umatic I-Disease
disorder I-Disease
. O

the O
sibling O
re O
##cu O
##rrence O
risk O
ratio O
for O
the O
disease O
is O
63 O
and O
her O
##ita O
##bility O
assessed O
in O
twins O
[UNK] O
90 O
% O
. O

although O
m O
##h O
##c O
genes O
, O
including O
h O
##la O
- O
b O
##27 O
, O
contribute O
only O
20 O
- O
50 O
% O
of O
the O
genetic O
risk O
for O
the O
disease O
, O
no O
non O
- O
m O
##h O
##c O
gene O
has O
yet O
been O
convincing O
##ly O
demonstrated O
to O
influence O
either O
su O
##s O
##ce O
##pt O
##ibility O
to O
the O
disease O
or O
its O
p O
##hen O
##otypic O
expression O
. O

previous O
link O
##age O
and O
association O
studies O
have O
suggested O
the O
presence O
of O
a O
su O
##s O
##ce O
##pt O
##ibility O
gene O
for O
as B-Disease
close O
to O
, O
or O
within O
, O
the O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
2d O
##6 O
gene O
( O
c O
##y O
##p O
##2 O
##d O
##6 O
, O
debris O
##o O
##quin O
##e O
h O
##ydro O
##xy O
##lase O
) O
located O
at O
chromosome O
22 O
##q O
##13 O
. O
1 O
. O

we O
performed O
a O
link O
##age O
study O
of O
chromosome O
22 O
in O
200 O
families O
with O
as B-Disease
affected O
sibling O
- O
pairs O
. O

association O
of O
all O
##ele O
##s O
of O
the O
c O
##y O
##p O
##2 O
##d O
##6 O
gene O
was O
examined O
by O
both O
case O
- O
control O
and O
within O
- O
family O
means O
. O

for O
case O
- O
control O
studies O
, O
61 O
##7 O
unrelated O
individuals O
with O
as B-Disease
( O
36 O
##1 O
pro O
##band O
##s O
from O
sibling O
- O
pair O
and O
parent O
- O
case O
trio O
families O
and O
256 O
unrelated O
non O
- O
f O
##ami O
##lial O
s O
##poradic O
cases O
) O
and O
40 O
##2 O
healthy O
ethnic O
##ally O
matched O
controls O
were O
employed O
. O

for O
within O
- O
family O
association O
studies O
, O
36 O
##1 O
families O
including O
161 O
parent O
- O
case O
trio O
##s O
and O
200 O
affected O
sibling O
- O
pair O
families O
were O
employed O
. O

ho O
##mo O
##zy O
##gos O
##ity O
for O
poor O
meta O
##bol O
##izer O
all O
##ele O
##s O
was O
found O
to O
be O
associated O
with O
as B-Disease
. O

he O
##tero O
##zy O
##gos O
##ity O
for O
the O
most O
frequent O
poor O
meta O
##bol O
##izer O
all O
##ele O
( O
c O
##y O
##p O
##2 O
##d O
##6 O
* O
4 O
) O
was O
not O
associated O
with O
increased O
su O
##s O
##ce O
##pt O
##ibility O
to O
as B-Disease
. O

significant O
within O
- O
family O
association O
of O
c O
##y O
##p O
##2 O
##d O
##6 O
* O
4 O
all O
##ele O
##s O
and O
as B-Disease
was O
demonstrated O
. O

weak O
link O
##age O
was O
also O
demonstrated O
between O
c O
##y O
##p O
##2 O
##d O
##6 O
and O
as B-Disease
. O

we O
post O
##ulate O
that O
altered O
metabolism O
of O
a O
natural O
to O
##xin O
or O
anti O
##gen O
by O
the O
c O
##y O
##p O
##2 O
##d O
##6 O
gene O
may O
increase O
su O
##s O
##ce O
##pt O
##ibility O
to O
as B-Disease
. O

functional O
differences O
of O
the O
p B-Disease
##ds I-Disease
gene O
product O
are O
associated O
with O
p O
##hen O
##otypic O
variation O
in O
patients O
with O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
and O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
( O
d B-Disease
##f I-Disease
##n I-Disease
##b I-Disease
##4 I-Disease
) O
. O

the O
p B-Disease
##ds I-Disease
gene O
en O
##codes O
a O
trans O
##me O
##mb O
##rane O
protein O
, O
known O
as O
pen O
##dr O
##in O
, O
which O
functions O
as O
a O
transport O
##er O
of O
i O
##od O
##ide O
and O
chloride O
. O

mutations O
in O
this O
gene O
are O
responsible O
for O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
and O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
non I-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
at O
the O
d B-Disease
##f I-Disease
##n I-Disease
##b I-Disease
##4 I-Disease
lo O
##cus O
on O
chromosome O
7 O
##q O
##31 O
. O

a O
screen O
of O
20 O
individuals O
from O
the O
mid O
##wes O
##tern O
us O
##a O
with O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
and O
di O
##lated O
vest O
##ib O
##ular O
a O
##queduct O
##s O
identified O
three O
people O
( O
15 O
% O
) O
with O
p B-Disease
##ds I-Disease
mutations O
. O

to O
determine O
whether O
p B-Disease
##ds I-Disease
mutations O
in O
individuals O
with O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
differ O
functional O
##ly O
from O
p B-Disease
##ds I-Disease
mutations O
in O
individuals O
with O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
, O
we O
compared O
three O
common O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
all O
##ele O
variants O
( O
l O
##23 O
##6 O
##p O
, O
t O
##41 O
##6 O
##p O
and O
e O
##38 O
##4 O
##g O
) O
, O
with O
three O
p B-Disease
##ds I-Disease
mutations O
reported O
only O
in O
individuals O
with O
non B-Disease
- I-Disease
s I-Disease
##yn I-Disease
##dr I-Disease
##omi I-Disease
##c I-Disease
hearing I-Disease
loss I-Disease
( O
v O
##48 O
##0 O
##d O
, O
v O
##65 O
##3 O
##a O
and O
i O
##4 O
##90 O
##l O
/ O
g O
##4 O
##9 O
##7 O
##s O
) O
. O

the O
mutations O
associated O
with O
pen B-Disease
##dre I-Disease
##d I-Disease
syndrome I-Disease
have O
complete O
loss O
of O
pen O
##dr O
##in O
- O
induced O
chloride O
and O
i O
##od O
##ide O
transport O
, O
while O
all O
##ele O
##s O
unique O
to O
people O
with O
d B-Disease
##f I-Disease
##n I-Disease
##b I-Disease
##4 I-Disease
are O
able O
to O
transport O
both O
i O
##od O
##ide O
and O
chloride O
, O
albeit O
at O
a O
much O
lower O
level O
than O
wild O
- O
type O
pen O
##dr O
##in O
. O

we O
h O
##y O
##pot O
##hes O
##ize O
that O
this O
residual O
level O
of O
an O
##ion O
transport O
is O
sufficient O
to O
eliminate O
or O
post O
##po O
##ne O
the O
onset O
of O
go B-Disease
##iter I-Disease
in O
individuals O
with O
d B-Disease
##f I-Disease
##n I-Disease
##b I-Disease
##4 I-Disease
. O

we O
propose O
a O
model O
for O
pen O
##dr O
##in O
function O
in O
the O
thy O
##roid O
in O
which O
pen O
##dr O
##in O
transports O
i O
##od O
##ide O
across O
the O
a O
##pical O
membrane O
of O
the O
thy O
##ro O
##cy O
##te O
into O
the O
co O
##llo O
##id O
space O
. O
. O

the O
human O
factor O
i O
##x O
gene O
as O
g O
##er O
##m O
##line O
m O
##uta O
##gen O
test O
: O
samples O
from O
mainland O
chin O
##a O
have O
the O
put O
##ative O
##ly O
end O
##ogen O
##ous O
pattern O
of O
mutation O
. O

g O
##er O
##m O
##line O
mutations O
are O
the O
major O
source O
of O
genetic O
variation O
that O
allows O
a O
species O
to O
evolve O
over O
time O
but O
at O
the O
cost O
of O
men B-Disease
##del I-Disease
##ian I-Disease
disease I-Disease
and O
genetic O
pre O
##dis O
##position O
to O
multi B-Disease
##fa I-Disease
##ctor I-Disease
##ial I-Disease
diseases I-Disease
. O

previous O
analyses O
have O
revealed O
that O
the O
pattern O
of O
g O
##er O
##m O
##line O
mutations O
in O
the O
factor O
i O
##x O
gene O
( O
f O
##9 O
) O
is O
similar O
among O
a O
variety O
of O
ethnic O
##ally O
and O
geographically O
diverse O
populations O
and O
compatible O
with O
the O
ancient O
pattern O
that O
has O
shaped O
the O
ma O
##mmal O
##ian O
genome O
. O

here O
, O
we O
compare O
the O
pattern O
of O
g O
##er O
##m O
##line O
mutation O
in O
a O
population O
of O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
b I-Disease
patients O
from O
mainland O
chin O
##a O
( O
n O
= O
66 O
) O
to O
that O
in O
u O
. O

s O
. O

ca O
##uca O
##sian O
##s O
, O
blacks O
, O
and O
me O
##xi O
##can O
his O
##pan O
##ics O
and O
s O
##tra O
##ti O
##fy O
by O
disease O
severity O
and O
ethnicity O
. O

the O
similar O
pattern O
of O
g O
##er O
##m O
##line O
mutation O
in O
all O
ethnic O
groups O
studied O
to O
date O
provides O
additional O
data O
compatible O
with O
the O
in O
##ference O
that O
end O
##ogen O
##ous O
processes O
pre O
##dom O
##inate O
in O
g O
##er O
##m O
##line O
mutations O
. O

f O
##as O
pre O
##ass O
##oc O
##iation O
required O
for O
a O
##pop O
##tosis O
signaling O
and O
dominant O
in O
##hibition O
by O
path O
##ogenic O
mutations O
. O

he O
##tero O
##zy O
##go O
##us O
mutations O
encoding O
abnormal O
forms O
of O
the O
death O
receptor O
f O
##as O
dominant O
##ly O
interfere O
with O
f O
##as O
- O
induced O
l O
##ymph O
##oc O
##yte O
a O
##pop O
##tosis O
in O
human O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
. O

this O
effect O
, O
rather O
than O
depending O
on O
l O
##igan O
##d O
- O
induced O
receptor O
o O
##li O
##go O
##mer O
##ization O
, O
was O
found O
to O
stem O
from O
l O
##igan O
##d O
- O
independent O
interaction O
of O
wild O
- O
type O
and O
mutant O
f O
##as O
receptors O
through O
a O
specific O
region O
in O
the O
extra O
##cellular O
domain O
. O

pre O
##ass O
##oc O
##iated O
f O
##as O
complexes O
were O
found O
in O
living O
cells O
by O
means O
of O
flu O
##ores O
##cence O
resonance O
energy O
transfer O
between O
variants O
of O
green O
fluorescent O
protein O
. O

these O
results O
show O
that O
formation O
of O
pre O
##ass O
##oc O
##iated O
receptor O
complexes O
is O
necessary O
for O
f O
##as O
signaling O
and O
dominant O
interference O
in O
human O
disease O
. O
. O

determination O
of O
carrier O
status O
for O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
by O
flow O
c O
##yt O
##ometric O
analysis O
of O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
expression O
in O
peripheral O
blood O
mon O
##on O
##uc O
##lea O
##r O
cells O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
caused O
by O
defects O
in O
the O
was B-Disease
protein O
( O
was O
##p O
) O
gene O
on O
the O
x O
chromosome O
. O

previous O
study O
disclosed O
that O
flow O
c O
##yt O
##ometric O
analysis O
of O
in O
##tra O
##cellular O
was O
##p O
expression O
( O
f O
##c O
##m O
- O
was O
##p O
analysis O
) O
in O
l O
##ymph O
##ocytes O
was O
useful O
for O
the O
diagnosis O
of O
was B-Disease
patients O
. O

l O
##ymph O
##ocytes O
from O
all O
was B-Disease
patients O
showed O
was O
##p O
##di O
##m O
instead O
of O
was O
##p O
##bright O
. O

here O
we O
report O
that O
f O
##c O
##m O
- O
was O
##p O
analysis O
in O
mon O
##ocytes O
could O
be O
a O
useful O
tool O
for O
the O
was B-Disease
carrier O
diagnosis O
. O

mon O
##ocytes O
from O
all O
nine O
was B-Disease
carriers O
showed O
varied O
population O
of O
was O
##p O
##di O
##m O
together O
with O
was O
##p O
##bright O
. O

none O
of O
control O
individuals O
possessed O
the O
was O
##p O
##di O
##m O
population O
. O

in O
contrast O
, O
l O
##ymph O
##ocytes O
from O
all O
the O
carriers O
except O
two O
lacked O
the O
was O
##p O
##di O
##m O
population O
. O

the O
difference O
of O
the O
was O
##p O
##di O
##m O
population O
in O
mon O
##ocytes O
and O
l O
##ymph O
##ocytes O
observed O
in O
was B-Disease
carriers O
suggests O
that O
was O
##p O
plays O
a O
more O
critical O
role O
in O
the O
development O
of O
l O
##ymph O
##ocytes O
than O
in O
that O
of O
mon O
##ocytes O
. O

the O
present O
studies O
suggest O
that O
a O
s O
##ke O
##wed O
x O
- O
ch O
##rom O
##oso O
##mal O
in O
##act O
##ivation O
pattern O
observed O
in O
was B-Disease
carrier O
peripheral O
blood O
cells O
is O
not O
fixed O
at O
the O
hem O
##op O
##oi O
##etic O
stem O
cell O
level O
but O
progresses O
after O
the O
lineage O
commitment O
. O
. O

restoration O
of O
photo O
##re O
##ceptor O
ultra O
##structure O
and O
function O
in O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
slow O
mice O
by O
gene O
therapy O
. O

the O
gene O
p O
##rp O
##h O
##2 O
en O
##codes O
a O
photo O
##re O
##ceptor O
- O
specific O
membrane O
g O
##ly O
##co O
##p O
##rote O
##in O
, O
per O
##ip O
##her O
##in O
- O
2 O
( O
also O
known O
as O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
) O
, O
which O
is O
inserted O
into O
the O
rim O
##s O
of O
photo O
##re O
##ceptor O
outer O
segment O
discs O
in O
a O
complex O
with O
r O
##om O
- O
1 O
( O
re O
##f O
. O
2 O
) O
. O

the O
complex O
is O
necessary O
for O
the O
stab O
##ilization O
of O
the O
discs O
, O
which O
are O
renewed O
constantly O
throughout O
life O
, O
and O
which O
contain O
the O
visual O
pig O
##ments O
necessary O
for O
photo O
##n O
capture O
. O

mutations O
in O
p O
##rp O
##h O
##2 O
have O
been O
shown O
to O
result O
in O
a O
variety O
of O
photo B-Disease
##re I-Disease
##ceptor I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##es I-Disease
, O
including O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
re I-Disease
##tin I-Disease
##itis I-Disease
pig I-Disease
##mento I-Disease
##sa I-Disease
and O
mac B-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

a O
common O
feature O
of O
these O
diseases O
is O
the O
loss O
of O
photo O
##re O
##ceptor O
function O
, O
also O
seen O
in O
the O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
slow O
( O
r O
##ds O
or O
p O
##rp O
##h O
##2 O
r O
##d O
##2 O
/ O
r O
##d O
##2 O
) O
mouse O
, O
which O
is O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
null O
mutation O
in O
p O
##rp O
##h O
##2 O
. O

it O
is O
characterized O
by O
a O
complete O
failure O
to O
develop O
photo O
##re O
##ceptor O
discs O
and O
outer O
segments O
, O
down O
##re O
##gu O
##lation O
of O
r O
##ho O
##do O
##ps O
##in O
and O
a O
##pop O
##to O
##tic O
loss O
of O
photo O
##re O
##ceptor O
cells O
. O

the O
electro O
##ret O
##ino O
##gram O
##s O
( O
er O
##gs O
) O
of O
p O
##rp O
##h O
##2 O
##rd O
##2 O
/ O
r O
##d O
##2 O
mice O
have O
greatly O
diminished O
a O
- O
wave O
and O
b O
- O
wave O
amplitude O
##s O
, O
which O
decline O
to O
virtually O
und O
##ete O
##ct O
##able O
concentrations O
by O
two O
months O
. O

sub O
##ret O
##inal O
injection O
of O
re O
##comb O
##ina O
##nt O
ad O
##eno O
- O
associated O
virus O
( O
a O
##av O
) O
encoding O
a O
p O
##rp O
##h O
##2 O
trans O
##gene O
results O
in O
stable O
generation O
of O
outer O
segment O
structures O
and O
formation O
of O
new O
stacks O
of O
discs O
containing O
both O
per O
##pher O
##in O
- O
2 O
and O
r O
##ho O
##do O
##ps O
##in O
, O
which O
in O
many O
cases O
are O
m O
##or O
##phological O
##ly O
similar O
to O
normal O
outer O
segments O
. O

more O
##over O
, O
the O
re O
- O
establishment O
of O
the O
structural O
integrity O
of O
the O
photo O
##re O
##ceptor O
layer O
also O
results O
in O
electro O
##phy O
##sio O
##logical O
correction O
. O

these O
studies O
demonstrate O
for O
the O
first O
time O
that O
a O
complex O
ultra O
##st O
##ructural O
cell O
defect O
can O
be O
corrected O
both O
m O
##or O
##phological O
##ly O
and O
functional O
##ly O
by O
in O
v O
##ivo O
gene O
transfer O
. O
. O

mutations O
in O
the O
fi O
##bri O
##no O
##gen O
a O
##al O
##pha O
gene O
account O
for O
the O
majority O
of O
cases O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
a I-Disease
##fi I-Disease
##bri I-Disease
##no I-Disease
##gene I-Disease
##mia I-Disease
. O

con B-Disease
##gen I-Disease
##ital I-Disease
a I-Disease
##fi I-Disease
##bri I-Disease
##no I-Disease
##gene I-Disease
##mia I-Disease
is O
a O
rare O
, O
auto B-Disease
##so I-Disease
##mal I-Disease
, I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
the O
complete O
absence O
of O
detect O
##able O
fi O
##bri O
##no O
##gen O
. O

we O
previously O
identified O
the O
first O
ca O
##usa O
##tive O
mutations O
in O
a O
non O
##con O
##sang O
##uin O
##eous O
s O
##wi O
##ss O
family O
; O
the O
4 O
affected O
persons O
have O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
of O
approximately O
11 O
k O
##b O
of O
the O
fi O
##bri O
##no O
##gen O
alpha O
( O
f O
##ga O
) O
gene O
. O

ha O
##p O
##lot O
##ype O
data O
implied O
that O
these O
del O
##eti O
##ons O
occurred O
on O
distinct O
ancestral O
chromosome O
##s O
, O
suggesting O
that O
this O
region O
may O
be O
susceptible O
to O
del O
##eti O
##on O
by O
a O
common O
mechanism O
. O

we O
subsequently O
showed O
that O
all O
the O
del O
##eti O
##ons O
were O
identical O
to O
the O
base O
pair O
and O
probably O
resulted O
from O
a O
non O
##hom O
##olo O
##go O
##us O
re O
##comb O
##ination O
mediated O
by O
7 O
- O
b O
##p O
direct O
repeats O
. O

in O
this O
study O
, O
we O
have O
collected O
data O
on O
13 O
additional O
unrelated O
patients O
to O
identify O
the O
ca O
##usa O
##tive O
mutations O
and O
to O
determine O
the O
prevalence O
of O
the O
11 O
- O
k O
##b O
del O
##eti O
##on O
. O

a O
common O
re O
##current O
mutation O
, O
at O
the O
donor O
s O
##p O
##lice O
site O
of O
f O
##ga O
intro O
##n O
4 O
( O
i O
##v O
##s O
##4 O
+ O
1 O
g O
[UNK] O
t O
) O
, O
accounted O
for O
14 O
of O
the O
26 O
( O
54 O
% O
) O
all O
##ele O
##s O
. O

one O
patient O
was O
he O
##tero O
##zy O
##go O
##us O
for O
the O
previously O
identified O
del O
##eti O
##on O
. O

three O
more O
frames O
##hi O
##ft O
mutations O
, O
2 O
nonsense O
mutations O
, O
and O
a O
second O
s O
##p O
##lice O
site O
mutation O
were O
also O
identified O
. O

consequently O
, O
86 O
% O
of O
a B-Disease
##fi I-Disease
##bri I-Disease
##no I-Disease
##gene I-Disease
##mia I-Disease
all O
##ele O
##s O
analyzed O
to O
date O
have O
t O
##run O
##cating O
mutations O
of O
f O
##ga O
, O
though O
mutations O
in O
all O
3 O
fi O
##bri O
##no O
##gen O
genes O
, O
f O
##gg O
, O
f O
##ga O
, O
and O
f O
##g O
##b O
, O
might O
be O
predicted O
to O
cause O
con B-Disease
##gen I-Disease
##ital I-Disease
a I-Disease
##fi I-Disease
##bri I-Disease
##no I-Disease
##gene I-Disease
##mia I-Disease
. O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
: O
the O
role O
of O
the O
cu O
##g O
triple O
##t O
repeats O
in O
s O
##p O
##licing O
of O
a O
novel O
d O
##mp O
##k O
ex O
##on O
and O
altered O
c O
##yt O
##op O
##las O
##mic O
d O
##mp O
##k O
m O
##rna O
is O
##of O
##orm O
ratios O
. O

the O
mechanism O
by O
which O
( O
c O
##t O
##g O
) O
n O
expansion O
in O
the O
3 O
u O
##tr O
of O
the O
d O
##mp O
##k O
gene O
causes O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
unknown O
. O

we O
identified O
four O
r O
##na O
s O
##p O
##licing O
factors O
- O
- O
h O
##n O
##rn O
##p O
c O
, O
u O
##2 O
##af O
( O
u O
##2 O
auxiliary O
factor O
) O
, O
p O
##t O
##b O
( O
p O
##oly O
##py O
##rim O
##id O
##ine O
tract O
binding O
protein O
) O
, O
and O
ps O
##f O
( O
p O
##t O
##b O
associated O
s O
##p O
##licing O
factor O
) O
- O
- O
that O
bind O
to O
two O
short O
regions O
3 O
of O
the O
( O
cu O
##g O
) O
n O
, O
and O
found O
a O
novel O
3 O
d O
##mp O
##k O
ex O
##on O
resulting O
in O
an O
m O
##rna O
lacking O
the O
repeats O
. O

we O
propose O
that O
the O
( O
cu O
##g O
) O
n O
is O
an O
essential O
c O
##is O
acting O
element O
for O
this O
s O
##p O
##licing O
event O
. O

in O
contrast O
to O
( O
cu O
##g O
) O
n O
containing O
m O
##rna O
##s O
, O
the O
novel O
is O
##of O
##orm O
is O
not O
retained O
in O
the O
nucleus O
in O
d B-Disease
##m I-Disease
cells O
, O
resulting O
in O
im O
##bal O
##ance O
##s O
in O
relative O
levels O
of O
c O
##yt O
##op O
##las O
##mic O
d O
##mp O
##k O
m O
##rna O
is O
##of O
##orms O
and O
a O
new O
dominant O
effect O
of O
the O
mutation O
on O
d O
##mp O
##k O
. O
. O

expression O
and O
imprint O
##ing O
of O
mage O
##l O
##2 O
suggest O
a O
role O
in O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
and O
the O
ho O
##mo O
##log O
##ous O
m O
##uri O
##ne O
imprint O
##ing O
p O
##hen O
##otype O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
is O
caused O
by O
the O
loss O
of O
expression O
of O
imprint O
##ed O
genes O
in O
chromosome O
15 O
##q O
##11 O
- O
q O
##13 O
. O

affected O
individuals O
exhibit O
neon B-Disease
##ata I-Disease
##l I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
, O
developmental B-Disease
delay I-Disease
and O
childhood B-Disease
- I-Disease
onset I-Disease
o I-Disease
##besity I-Disease
. O

ne O
##c O
##din O
, O
a O
protein O
implicated O
in O
the O
terminal O
differentiation O
of O
neurons O
, O
is O
the O
only O
p B-Disease
##ws I-Disease
candidate O
gene O
to O
reduce O
via O
##bility O
when O
disrupted O
in O
a O
mouse O
model O
. O

in O
this O
study O
, O
we O
have O
characterized O
mage O
##l O
##2 O
( O
also O
known O
as O
n O
##dn O
##l O
##1 O
) O
, O
a O
gene O
with O
51 O
% O
amino O
acid O
sequence O
similarity O
to O
ne O
##c O
##din O
and O
located O
41 O
k O
##b O
di O
##stal O
to O
n O
##dn O
in O
the O
p B-Disease
##ws I-Disease
del O
##eti O
##on O
region O
. O

mage O
##l O
##2 O
is O
expressed O
predominantly O
in O
brain O
, O
the O
primary O
tissue O
affected O
in O
p B-Disease
##ws I-Disease
and O
in O
several O
f O
##etal O
tissues O
as O
shown O
by O
northern O
b O
##lot O
analysis O
. O

mage O
##l O
##2 O
is O
imprint O
##ed O
with O
mon O
##oa O
##lle O
##lic O
expression O
in O
control O
brain O
, O
and O
paternal O
- O
only O
expression O
in O
the O
central O
nervous O
system O
as O
demonstrated O
by O
its O
lack O
of O
expression O
in O
brain O
from O
a O
p B-Disease
##ws I-Disease
- O
affected O
individual O
. O

the O
or O
##th O
##olo O
##go O
##us O
mouse O
gene O
( O
mage O
##l O
##2 O
) O
is O
located O
within O
150 O
k O
##b O
of O
n O
##dn O
, O
is O
imprint O
##ed O
with O
paternal O
- O
only O
expression O
and O
is O
expressed O
predominantly O
in O
late O
developmental O
stages O
and O
adult O
brain O
as O
shown O
by O
northern O
b O
##lot O
##ting O
, O
r O
##t O
- O
p O
##c O
##r O
and O
whole O
- O
mount O
r O
##na O
in O
sit O
##u O
hybrid O
##ization O
. O

mage O
##l O
##2 O
distribution O
partially O
overlap O
##s O
that O
of O
n O
##dn O
, O
with O
strong O
expression O
being O
detected O
in O
the O
central O
nervous O
system O
in O
mid O
- O
g O
##esta O
##tion O
mouse O
em O
##b O
##ryo O
##s O
by O
in O
sit O
##u O
hybrid O
##ization O
. O

we O
h O
##y O
##pot O
##hes O
##ize O
that O
, O
although O
loss O
of O
ne O
##c O
##din O
expression O
may O
be O
important O
in O
the O
neon O
##ata O
##l O
presentation O
of O
p B-Disease
##ws I-Disease
, O
loss O
of O
mage O
##l O
##2 O
may O
be O
critical O
to O
abnormal B-Disease
##ities I-Disease
in I-Disease
brain I-Disease
development I-Disease
and O
d B-Disease
##ys I-Disease
##morphic I-Disease
features I-Disease
in O
individuals O
with O
p B-Disease
##ws I-Disease
. O
. O

re O
##tino O
##sch O
##isi O
##n O
, O
the O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
protein O
, O
is O
a O
secret O
##ed O
photo O
##re O
##ceptor O
protein O
, O
and O
is O
expressed O
and O
released O
by O
we O
##ri O
- O
r O
##b O
##1 O
cells O
. O

x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
is O
characterized O
by O
micro O
##cy O
##stic O
- O
like O
changes O
of O
the O
mac O
##ular O
region O
and O
s O
##chi O
##sis O
within O
the O
inner O
re O
##tina O
##l O
layers O
, O
leading O
to O
visual B-Disease
de I-Disease
##ter I-Disease
##ior I-Disease
##ation I-Disease
in O
males O
. O

many O
miss O
##ense O
and O
protein O
- O
t O
##run O
##cating O
mutations O
of O
the O
ca O
##usa O
##tive O
gene O
r O
##s O
##1 O
have O
now O
been O
identified O
and O
are O
thought O
to O
be O
in O
##act O
##ivating O
. O

r O
##s O
##1 O
en O
##codes O
a O
224 O
amino O
acid O
protein O
, O
re O
##tino O
##sch O
##isi O
##n O
, O
which O
contains O
a O
disco O
##id O
##in O
domain O
but O
is O
of O
unknown O
function O
. O

we O
have O
generated O
a O
p O
##oly O
##c O
##lon O
##al O
anti O
##body O
against O
a O
p O
##eptide O
from O
a O
unique O
region O
within O
re O
##tino O
##sch O
##isi O
##n O
, O
which O
detect O
##s O
a O
protein O
of O
approximately O
28 O
k O
##da O
in O
re O
##tina O
##l O
samples O
reduced O
with O
di O
##thi O
##oth O
##re O
##ito O
##l O
, O
but O
multi O
##mers O
sized O
[UNK] O
40 O
k O
##da O
under O
non O
- O
reducing O
conditions O
. O

a O
screen O
of O
human O
tissues O
with O
this O
anti O
##body O
reveals O
re O
##tino O
##sch O
##isi O
##n O
to O
be O
re O
##tina O
specific O
and O
the O
anti O
##body O
detect O
##s O
a O
protein O
of O
similar O
size O
in O
b O
##ov O
##ine O
and O
m O
##uri O
##ne O
re O
##tina O
##e O
. O

we O
investigated O
the O
expression O
pattern O
in O
the O
re O
##tina O
of O
both O
r O
##s O
##1 O
m O
##rna O
( O
using O
in O
sit O
##u O
hybrid O
##ization O
with O
rib O
##op O
##robe O
##s O
) O
and O
re O
##tino O
##sch O
##isi O
##n O
( O
using O
im O
##mu O
##no O
##his O
##to O
##chemistry O
) O
. O

the O
anti O
##sen O
##se O
rib O
##op O
##robe O
detected O
r O
##s O
##1 O
m O
##rna O
only O
in O
the O
photo O
##re O
##ceptor O
layer O
but O
the O
protein O
product O
of O
the O
gene O
was O
present O
both O
in O
the O
photo O
##re O
##ceptor O
##s O
and O
within O
the O
inner O
portions O
of O
the O
re O
##tina O
. O

further O
##more O
, O
differentiated O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
cells O
( O
we O
##ri O
- O
r O
##b O
##1 O
cells O
) O
were O
found O
to O
express O
r O
##s O
##1 O
m O
##rna O
and O
to O
release O
re O
##tino O
##sch O
##isi O
##n O
. O

these O
results O
suggest O
that O
re O
##tino O
##sch O
##isi O
##n O
is O
released O
by O
photo O
- O
receptors O
and O
has O
functions O
within O
the O
inner O
re O
##tina O
##l O
layers O
. O

thus O
, O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##tino I-Disease
##sch I-Disease
##isi I-Disease
##s I-Disease
is O
caused O
by O
abnormal O
##ities O
in O
a O
put O
##ative O
secret O
##ed O
photo O
##re O
##ceptor O
protein O
and O
is O
the O
first O
example O
of O
a O
secret O
##ed O
photo O
- O
receptor O
protein O
associated O
with O
a O
re B-Disease
##tina I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O
. O

study O
of O
the O
voltage O
- O
gate O
##d O
sodium O
channel O
beta O
1 O
subunit O
gene O
( O
s O
##c O
##n O
##1 O
##b O
) O
in O
the O
ben B-Disease
##ign I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
infant I-Disease
##ile I-Disease
con I-Disease
##vu I-Disease
##ls I-Disease
##ions I-Disease
syndrome I-Disease
( O
b B-Disease
##fic I-Disease
) O
. O

ben B-Disease
##ign I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
infant I-Disease
##ile I-Disease
con I-Disease
##vu I-Disease
##ls I-Disease
##ions I-Disease
( O
b B-Disease
##fic I-Disease
) O
is O
a O
rare O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
e I-Disease
##pile I-Disease
##psy I-Disease
syndrome I-Disease
. O

this O
syndrome O
has O
been O
recently O
described O
in O
it O
##alia O
##n O
and O
f O
##rench O
p O
##ed O
##ig O
##ree O
##s O
. O

patients O
present O
with O
partial O
, O
then O
generalized O
seizure O
##s O
, O
with O
onset O
at O
age O
three O
months O
. O

the O
seizure O
##s O
usually O
spontaneous O
##ly O
cease O
after O
one O
year O
without O
treatment O
, O
leaving O
no O
ne B-Disease
##uro I-Disease
##logical I-Disease
abnormal I-Disease
##ities I-Disease
. O

we O
have O
mapped O
b B-Disease
##fic I-Disease
to O
chromosome O
19 O
##q O
in O
five O
it O
##alia O
##n O
p O
##ed O
##ig O
##ree O
##s O
. O

the O
sodium O
channel O
beta O
##1 O
subunit O
gene O
( O
s O
##c O
##n O
##1 O
##b O
) O
maps O
to O
this O
candidate O
region O
and O
has O
been O
shown O
to O
be O
involved O
in O
one O
au O
##stra O
##lian O
p O
##ed O
##ig O
##ree O
with O
generalized B-Disease
e I-Disease
##pile I-Disease
##psy I-Disease
and I-Disease
f I-Disease
##eb I-Disease
##ril I-Disease
##e I-Disease
seizure I-Disease
##s I-Disease
" I-Disease
plus I-Disease
" I-Disease
( O
g O
##ef O
##s O
+ O
) O
. O

in O
this O
family O
, O
a O
miss O
##ense O
mutation O
in O
s O
##c O
##n O
##1 O
##b O
co O
##se O
##g O
##re O
##gate O
##s O
with O
the O
g O
##ef O
##s O
+ O
p O
##hen O
##otype O
. O

b B-Disease
##fic I-Disease
and O
g O
##ef O
##s O
+ O
have O
clinical O
features O
in O
common O
, O
therefore O
s O
##c O
##n O
##1 O
##b O
is O
a O
candidate O
gene O
for O
b B-Disease
##fic I-Disease
. O

we O
studied O
s O
##c O
##n O
##1 O
##b O
ex O
##ons O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
and O
5 O
, O
using O
four O
s O
##s O
##c O
##p O
methods O
in O
10 O
ca O
##uca O
##sian O
b B-Disease
##fic I-Disease
pro O
##band O
##s O
of O
western O
euro O
##pe O
. O

we O
found O
no O
ex O
##on O
variants O
. O

one O
variant O
was O
identified O
in O
intro O
##n O
5 O
( O
i O
##v O
##s O
##5 O
- O
10 O
##c O
[UNK] O
g O
) O
, O
which O
did O
not O
se O
##g O
##re O
##gate O
with O
b B-Disease
##fic I-Disease
and O
was O
observed O
in O
9 O
. O

2 O
% O
controls O
. O

a O
second O
variant O
in O
intro O
##n O
5 O
was O
identified O
( O
i O
##v O
##s O
##5 O
+ O
30 O
##g O
[UNK] O
a O
) O
. O

it O
was O
rare O
, O
as O
not O
observed O
in O
controls O
, O
but O
not O
se O
##g O
##re O
##gating O
with O
the O
b B-Disease
##fic I-Disease
p O
##hen O
##otype O
. O

in O
##act O
##ivation O
of O
g O
##er O
##m O
##line O
mutant O
a B-Disease
##p I-Disease
##c I-Disease
all O
##ele O
##s O
by O
at O
##ten O
##uated O
so O
##matic O
mutations O
: O
a O
molecular O
genetic O
mechanism O
for O
at B-Disease
##ten I-Disease
##uated I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
. O

g O
##er O
##m O
##line O
mutations O
of O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( I-Disease
a I-Disease
##p I-Disease
##c I-Disease
) I-Disease
tumor I-Disease
- O
suppress O
##or O
gene O
result O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

patients O
with O
f B-Disease
##ap I-Disease
typically O
develop O
hundreds O
to O
thousands O
of O
ben B-Disease
##ign I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
and O
early O
- O
onset O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

a O
subset O
of O
g O
##er O
##m O
##line O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
results O
in O
an O
at B-Disease
##ten I-Disease
##uated I-Disease
f I-Disease
##ap I-Disease
( O
a B-Disease
##fa I-Disease
##p I-Disease
) O
p O
##hen O
##otype O
, O
in O
which O
patients O
develop O
fewer O
tumors B-Disease
and O
develop O
them O
at O
an O
older O
age O
. O

although O
a O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
between O
the O
locations O
of O
a B-Disease
##p I-Disease
##c I-Disease
g O
##er O
##m O
##line O
mutations O
and O
the O
development O
of O
a B-Disease
##fa I-Disease
##p I-Disease
has O
been O
well O
documented O
, O
the O
mechanism O
for O
a B-Disease
##fa I-Disease
##p I-Disease
has O
not O
been O
well O
defined O
. O

we O
investigated O
the O
mechanism O
for O
a B-Disease
##fa I-Disease
##p I-Disease
in O
patients O
carrying O
a O
mutant O
a B-Disease
##p I-Disease
##c I-Disease
all O
##ele O
( O
a O
##p O
##c O
( O
as O
##9 O
) O
) O
that O
has O
a O
mutation O
in O
the O
alternatively O
s O
##p O
##lice O
##d O
region O
of O
ex O
##on O
9 O
. O

a O
##p O
##c O
( O
as O
##9 O
) O
was O
found O
to O
down O
- O
regulate O
beta O
- O
cat O
##eni O
##n O
- O
regulated O
transcription O
, O
the O
major O
tumor B-Disease
- O
suppress O
##or O
function O
of O
a O
##p O
##c O
, O
as O
did O
the O
wild O
- O
type O
a O
##p O
##c O
. O

mutation O
analysis O
showed O
that O
both O
a O
##p O
##c O
( O
as O
##9 O
) O
and O
the O
wild O
- O
type O
a B-Disease
##p I-Disease
##c I-Disease
all O
##ele O
##s O
were O
so O
##matical O
##ly O
m O
##uta O
##ted O
in O
most O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
from O
these O
patients O
. O

functional O
analysis O
showed O
that O
46 O
##6 O
##6 O
##ins O
##a O
, O
a O
common O
so O
##matic O
mutation O
in O
a O
##p O
##c O
( O
as O
##9 O
) O
in O
these O
tumors B-Disease
, O
did O
not O
in O
##act O
##ivate O
the O
wild O
- O
type O
a O
##p O
##c O
. O

our O
results O
indicate O
that O
carriers O
of O
a O
##p O
##c O
( O
as O
##9 O
) O
develop O
fewer O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
than O
do O
typical O
patients O
with O
f B-Disease
##ap I-Disease
because O
so O
##matic O
in O
##act O
##ivation O
of O
both O
a B-Disease
##p I-Disease
##c I-Disease
all O
##ele O
##s O
is O
necessary O
for O
color O
##ec O
##tal O
tumor O
##ige O
##nes O
##is O
. O

however O
, O
these O
patients O
develop O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
more O
frequently O
than O
does O
the O
general O
population O
because O
a O
##p O
##c O
( O
as O
##9 O
) O
is O
inactivated O
by O
mutations O
that O
do O
not O
in O
##act O
##ivate O
the O
wild O
- O
type O
a O
##p O
##c O
. O
. O

iron O
- O
dependent O
self O
- O
assembly O
of O
re O
##comb O
##ina O
##nt O
yeast O
f O
##rata O
##xin O
: O
implications O
for O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

f B-Disease
##rata I-Disease
##xin I-Disease
deficiency I-Disease
is O
the O
primary O
cause O
of O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
, O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
card I-Disease
##io I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
and I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disease I-Disease
. O

f O
##rata O
##xin O
is O
a O
nuclear O
- O
encoded O
mitochondrial O
protein O
that O
is O
widely O
conserved O
among O
e O
##uka O
##ryo O
##tes O
. O

genetic O
in O
##act O
##ivation O
of O
the O
yeast O
f O
##rata O
##xin O
ho O
##mo O
##logue O
( O
y O
##f O
##h O
##1 O
##p O
) O
results O
in O
mitochondrial B-Disease
iron I-Disease
accumulation I-Disease
and O
h B-Disease
##yper I-Disease
##sen I-Disease
##si I-Disease
##ti I-Disease
##vity I-Disease
to I-Disease
o I-Disease
##xi I-Disease
##da I-Disease
##tive I-Disease
stress I-Disease
. O

increased O
iron O
deposition O
and O
evidence O
of O
o O
##xi O
##da O
##tive O
damage O
have O
also O
been O
observed O
in O
cardiac O
tissue O
and O
culture O
##d O
fi O
##bro O
##blast O
##s O
from O
patients O
with O
f B-Disease
##rda I-Disease
. O

these O
findings O
indicate O
that O
f O
##rata O
##xin O
is O
essential O
for O
mitochondrial O
iron O
home O
##ost O
##asis O
and O
protection O
from O
iron O
- O
induced O
formation O
of O
free O
radical O
##s O
. O

the O
functional O
mechanism O
of O
f O
##rata O
##xin O
, O
however O
, O
is O
still O
unknown O
. O

we O
have O
expressed O
the O
mature O
form O
of O
y O
##f O
##h O
##1 O
##p O
( O
my O
##f O
##h O
##1 O
##p O
) O
in O
es O
##cher O
##ichi O
##a O
co O
##li O
and O
have O
analyzed O
its O
function O
in O
v O
##it O
##ro O
. O

isolated O
my O
##f O
##h O
##1 O
##p O
is O
a O
soluble O
mon O
##omer O
( O
13 O
, O
78 O
##3 O
da O
) O
that O
contains O
no O
iron O
and O
shows O
no O
significant O
tendency O
to O
self O
- O
associate O
. O

a O
##ero O
##bic O
addition O
of O
f O
##er O
##rous O
iron O
to O
my O
##f O
##h O
##1 O
##p O
results O
in O
assembly O
of O
regular O
spherical O
multi O
##mers O
with O
a O
molecular O
mass O
of O
approximately O
1 O
. O

1 O
m O
##da O
( O
me O
##ga O
##dal O
##tons O
) O
and O
a O
diameter O
of O
13 O
+ O
/ O
- O
2 O
nm O
. O

each O
multi O
##mer O
consists O
of O
approximately O
60 O
subunit O
##s O
and O
can O
se O
##quest O
##er O
[UNK] O
3 O
, O
000 O
atoms O
of O
iron O
. O

t O
##it O
##ration O
of O
my O
##f O
##h O
##1 O
##p O
with O
increasing O
iron O
concentrations O
supports O
a O
step O
##wise O
mechanism O
of O
multi O
##mer O
assembly O
. O

se O
##quential O
addition O
of O
an O
iron O
ch O
##ela O
##tor O
and O
a O
reducing O
agent O
results O
in O
quantitative O
iron O
release O
with O
con O
##com O
##ita O
##nt O
di O
##sa O
##sse O
##mb O
##ly O
of O
the O
multi O
##mer O
, O
indicating O
that O
my O
##f O
##h O
##1 O
##p O
se O
##quest O
##ers O
iron O
in O
an O
available O
form O
. O

in O
yeast O
mit O
##och O
##ond O
##ria O
, O
native O
my O
##f O
##h O
##1 O
##p O
exists O
as O
mon O
##omer O
and O
a O
higher O
- O
order O
species O
with O
a O
molecular O
weight O
[UNK] O
600 O
, O
000 O
. O

after O
addition O
of O
( O
55 O
) O
f O
##e O
to O
the O
medium O
, O
im O
##mu O
##no O
##p O
##re O
##ci O
##pit O
##ates O
of O
this O
species O
contain O
[UNK] O
16 O
atoms O
of O
( O
55 O
) O
f O
##e O
per O
molecule O
of O
my O
##f O
##h O
##1 O
##p O
. O

we O
propose O
that O
iron O
- O
dependent O
self O
- O
assembly O
of O
re O
##comb O
##ina O
##nt O
my O
##f O
##h O
##1 O
##p O
reflects O
a O
physiological O
role O
for O
f O
##rata O
##xin O
in O
mitochondrial O
iron O
se O
##quest O
##ration O
and O
bio O
##ava O
##ila O
##bility O
. O
. O

a O
mutation O
in O
the O
p O
##le O
##cks O
##tri O
##n O
ho O
##mology O
( O
p O
##h O
) O
domain O
of O
the O
f O
##g O
##d O
##1 O
gene O
in O
an O
it O
##alia O
##n O
family O
with O
f B-Disease
##ac I-Disease
##io I-Disease
##gen I-Disease
##ital I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
( O
a B-Disease
##ars I-Disease
##ko I-Disease
##g I-Disease
- I-Disease
s I-Disease
##cott I-Disease
syndrome I-Disease
) O
. O

a B-Disease
##ars I-Disease
##ko I-Disease
##g I-Disease
- I-Disease
s I-Disease
##cott I-Disease
syndrome I-Disease
( O
a B-Disease
##as I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
characterised O
by O
short B-Disease
stature I-Disease
and O
multiple O
facial B-Disease
, I-Disease
limb I-Disease
and I-Disease
g I-Disease
##eni I-Disease
##tal I-Disease
abnormal I-Disease
##ities I-Disease
. O

a O
gene O
, O
f O
##g O
##d O
##1 O
, O
altered O
in O
a O
patient O
with O
a B-Disease
##as I-Disease
p O
##hen O
##otype O
, O
has O
been O
identified O
and O
found O
to O
en O
##code O
a O
protein O
with O
ho O
##mology O
to O
r O
##ho O
/ O
r O
##ac O
g O
##uan O
##ine O
n O
##uc O
##leo O
##tide O
exchange O
factors O
( O
r O
##ho O
/ O
r O
##ac O
g O
##ef O
) O
. O

however O
, O
since O
this O
original O
report O
on O
identification O
of O
a O
m O
##uta O
##ted O
f O
##g O
##d O
##1 O
gene O
in O
an O
a B-Disease
##as I-Disease
patient O
, O
no O
additional O
mutations O
in O
the O
f O
##g O
##d O
##1 O
gene O
have O
been O
described O
. O

we O
anal O
##ys O
##ed O
13 O
independent O
patients O
with O
clinical O
diagnosis O
of O
a B-Disease
##as I-Disease
. O

one O
patient O
presented O
a O
mutation O
that O
results O
in O
a O
n O
##uc O
##leo O
##tide O
change O
in O
ex O
##on O
10 O
of O
the O
f O
##g O
##d O
##1 O
gene O
( O
g O
##25 O
##5 O
##9 O
[UNK] O
a O
) O
sub O
##stituting O
a O
g O
##ln O
for O
a O
##rg O
in O
position O
610 O
. O

the O
mutation O
was O
found O
to O
se O
##g O
##re O
##gate O
with O
the O
a B-Disease
##as I-Disease
p O
##hen O
##otype O
in O
affected O
males O
and O
carrier O
females O
in O
the O
family O
of O
this O
patient O
. O

interesting O
##ly O
, O
a O
##rg O
- O
610 O
is O
located O
within O
one O
of O
the O
two O
p O
##le O
##cks O
##tri O
##n O
ho O
##mology O
( O
p O
##h O
) O
domains O
of O
the O
f O
##g O
##d O
##1 O
gene O
and O
it O
corresponds O
to O
a O
highly O
conserved O
residue O
which O
has O
been O
involved O
in O
ins O
##p O
binding O
in O
p O
##h O
domains O
of O
other O
proteins O
. O

the O
same O
residue O
is O
often O
m O
##uta O
##ted O
in O
the O
br O
##uto O
##ns O
t O
##yr O
##os O
##ine O
kinase O
( O
b O
##t O
##k O
) O
gene O
in O
patients O
with O
an O
x B-Disease
- I-Disease
linked I-Disease
a I-Disease
##gam I-Disease
##ma I-Disease
##g I-Disease
##lo I-Disease
##bul I-Disease
##ine I-Disease
##mia I-Disease
. O

the O
a O
##rg O
##6 O
##10 O
##g O
##ln O
mutation O
represents O
the O
first O
case O
of O
a O
mutation O
in O
the O
p O
##h O
domain O
of O
the O
f O
##g O
##d O
##1 O
gene O
and O
additional O
evidence O
that O
mutations O
in O
p O
##h O
domains O
can O
be O
associated O
to O
human O
diseases O
. O
. O

amino O
- O
terminal O
fragments O
of O
mutant O
hunting O
##tin O
show O
selective O
accumulation O
in O
s O
##tri O
##ata O
##l O
neurons O
and O
s O
##yna O
##ptic O
toxicity O
. O

hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
is O
caused O
by O
expansion O
of O
a O
g O
##lut O
##amine O
repeat O
in O
the O
amino O
- O
terminal O
region O
of O
hunting O
##tin O
. O

despite O
its O
widespread O
expression O
, O
mutant O
hunting O
##tin O
induce O
##s O
selective O
ne O
##uron O
##al O
loss O
in O
s O
##tri O
##ata O
##l O
neurons O
. O

here O
we O
report O
that O
, O
in O
mutant O
mice O
expressing O
h B-Disease
##d I-Disease
repeats O
, O
the O
production O
and O
a O
##gg O
##regation O
of O
n O
- O
terminal O
hunting O
##tin O
fragments O
prefer O
##ential O
##ly O
occur O
in O
h B-Disease
##d I-Disease
- O
affected O
neurons O
and O
their O
processes O
and O
a O
##xon O
##al O
terminals O
. O

n O
- O
terminal O
fragments O
of O
mutant O
hunting O
##tin O
form O
aggregate O
##s O
and O
induce O
ne B-Disease
##uri I-Disease
##tic I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
in O
culture O
##d O
s O
##tri O
##ata O
##l O
neurons O
. O

n O
- O
terminal O
mutant O
hunting O
##tin O
also O
binds O
to O
s O
##yna O
##ptic O
ve O
##si O
##cles O
and O
in O
##hibit O
##s O
their O
g O
##lut O
##ama O
##te O
up O
##take O
in O
v O
##it O
##ro O
. O

the O
specific O
processing O
and O
accumulation O
of O
toxic O
fragments O
of O
n O
- O
terminal O
hunting O
##tin O
in O
h B-Disease
##d I-Disease
- O
affected O
s O
##tri O
##ata O
##l O
neurons O
, O
especially O
in O
their O
ne O
##uron O
##al O
processes O
and O
a O
##xon O
##al O
terminals O
, O
may O
contribute O
to O
the O
selective O
ne O
##uro O
##path O
##ology O
of O
h B-Disease
##d I-Disease
. O
. O

br O
##ca O
##1 O
is O
associated O
with O
a O
human O
s O
##wi O
/ O
s O
##n O
##f O
- O
related O
complex O
: O
linking O
ch O
##roma O
##tin O
re O
##mo O
##del O
##ing O
to O
breast B-Disease
cancer I-Disease
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
tumor B-Disease
suppress O
##or O
gene O
, O
br O
##ca O
##1 O
, O
pre O
##dis O
##pose O
individuals O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

using O
a O
combination O
of O
affinity O
- O
and O
conventional O
ch O
##roma O
##to O
##graphic O
techniques O
, O
we O
have O
isolated O
a O
predominant O
form O
of O
a O
multi O
##p O
##rote O
##in O
br O
##ca O
##1 O
- O
containing O
complex O
from O
human O
cells O
displaying O
ch O
##roma O
##tin O
- O
re O
##mo O
##del O
##ing O
activity O
. O

mass O
s O
##pect O
##rome O
##tric O
se O
##quencing O
of O
components O
of O
this O
complex O
indicated O
that O
br O
##ca O
##1 O
is O
associated O
with O
a O
s O
##wi O
/ O
s O
##n O
##f O
- O
related O
complex O
. O

we O
show O
that O
br O
##ca O
##1 O
can O
directly O
interact O
with O
the O
br O
##g O
##1 O
subunit O
of O
the O
s O
##wi O
/ O
s O
##n O
##f O
complex O
. O

more O
##over O
, O
p O
##53 O
- O
mediated O
stimulation O
of O
transcription O
by O
br O
##ca O
##1 O
was O
completely O
a O
##bro O
##gated O
by O
either O
a O
dominant O
- O
negative O
mutant O
of O
br O
##g O
##1 O
or O
the O
cancer B-Disease
- O
causing O
del O
##eti O
##on O
in O
ex O
##on O
11 O
of O
br O
##ca O
##1 O
. O

these O
findings O
reveal O
a O
direct O
function O
for O
br O
##ca O
##1 O
in O
transcription O
##al O
control O
through O
m O
##od O
##ulation O
of O
ch O
##roma O
##tin O
structure O
. O
. O

as O
##ef O
, O
a O
link O
between O
the O
tumor B-Disease
suppress O
##or O
a O
##p O
##c O
and O
g O
- O
protein O
signaling O
. O

the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
gene O
( O
a O
##p O
##c O
) O
is O
m O
##uta O
##ted O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
and O
in O
s O
##poradic O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
. O

here O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
product O
is O
shown O
to O
bind O
through O
its O
arm O
##adi O
##llo O
repeat O
domain O
to O
a O
r O
##ac O
- O
specific O
g O
##uan O
##ine O
n O
##uc O
##leo O
##tide O
exchange O
factor O
( O
g O
##ef O
) O
, O
termed O
as O
##ef O
. O

end O
##ogen O
##ous O
a O
##p O
##c O
co O
##loc O
##ali O
##zed O
with O
as O
##ef O
in O
mouse O
co O
##lon O
e O
##pit O
##hel O
##ial O
cells O
and O
ne O
##uron O
##al O
cells O
. O

further O
##more O
, O
a O
##p O
##c O
enhanced O
the O
g O
##ef O
activity O
of O
as O
##ef O
and O
stimulate O
##d O
as O
##ef O
- O
mediated O
cell O
flat O
##ten O
##ing O
, O
membrane O
r O
##uff O
##ling O
, O
and O
lame O
##lli O
##po O
##dia O
formation O
in O
m O
##d O
##ck O
cells O
. O

these O
results O
suggest O
that O
the O
a O
##p O
##c O
- O
as O
##ef O
complex O
may O
regulate O
the O
act O
##in O
c O
##yt O
##os O
##kel O
##etal O
network O
, O
cell O
morphology O
and O
migration O
, O
and O
ne O
##uron O
##al O
function O
. O
. O

function O
of O
an O
a O
##xon O
##al O
ch O
##em O
##oat O
##tract O
##ant O
m O
##od O
##ulated O
by O
metal O
##lop O
##rote O
##ase O
activity O
. O

the O
a O
##xon O
##al O
ch O
##em O
##oat O
##tract O
##ant O
net O
##rin O
- O
1 O
guides O
spinal O
com O
##mis O
##su O
##ral O
a O
##xon O
##s O
by O
act O
##ivating O
its O
receptor O
d O
##cc O
( O
deleted O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
) O
. O

we O
have O
found O
that O
chemical O
inhibitor O
##s O
of O
metal O
##lop O
##rote O
##ases O
potent O
##iate O
net O
##rin O
- O
mediated O
a O
##xon O
out O
##gro O
##wth O
in O
v O
##it O
##ro O
. O

we O
have O
also O
found O
that O
d O
##cc O
is O
a O
substrate O
for O
metal O
##lop O
##rote O
##ase O
- O
dependent O
e O
##ct O
##od O
##oma O
##in O
shed O
##ding O
, O
and O
that O
the O
inhibitor O
##s O
block O
pro O
##te O
##oly O
##tic O
processing O
of O
d O
##cc O
and O
cause O
an O
increase O
in O
d O
##cc O
protein O
levels O
on O
a O
##xon O
##s O
within O
spinal O
cord O
ex O
##p O
##lants O
. O

thus O
, O
potent O
##iation O
of O
net O
##rin O
activity O
by O
inhibitor O
##s O
may O
result O
from O
stab O
##ilization O
of O
d O
##cc O
on O
the O
a O
##xon O
##s O
, O
and O
pro O
##te O
##oly O
##tic O
activity O
may O
regulate O
a O
##xon O
migration O
by O
controlling O
the O
number O
of O
functional O
extra O
##cellular O
a O
##xon O
guidance O
receptors O
. O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
in O
trans O
##genic O
mice O
expressing O
an O
expanded O
cu O
##g O
repeat O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
, O
the O
most O
common O
form O
of O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
in O
adult O
humans O
, O
results O
from O
expansion O
of O
a O
c O
##t O
##g O
repeat O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
the O
d O
##mp O
##k O
gene O
. O

the O
mutant O
d O
##mp O
##k O
messenger O
r O
##na O
( O
m O
##rna O
) O
contains O
an O
expanded O
cu O
##g O
repeat O
and O
is O
retained O
in O
the O
nucleus O
. O

we O
have O
expressed O
an O
un O
##tra O
##ns O
##lated O
cu O
##g O
repeat O
in O
an O
unrelated O
m O
##rna O
in O
trans O
##genic O
mice O
. O

mice O
that O
expressed O
expanded O
cu O
##g O
repeats O
developed O
my B-Disease
##oto I-Disease
##nia I-Disease
and O
my B-Disease
##op I-Disease
##athy I-Disease
, O
whereas O
mice O
expressing O
a O
none O
##x O
##pan O
##ded O
repeat O
did O
not O
. O

thus O
, O
trans O
##cripts O
with O
expanded O
cu O
##g O
repeats O
are O
sufficient O
to O
generate O
a O
d B-Disease
##m I-Disease
p O
##hen O
##otype O
. O

this O
result O
supports O
a O
role O
for O
r O
##na O
gain O
of O
function O
in O
disease O
path O
##ogen O
##esis O
. O
. O

g O
##eno O
##mic O
rear O
##rang O
##ement O
##s O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
tumor I-Disease
- O
suppress O
##or O
gene O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
. O

g O
##er O
##m O
##line O
mutations O
of O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( I-Disease
a I-Disease
##p I-Disease
##c I-Disease
) I-Disease
tumor I-Disease
- O
suppress O
##or O
gene O
result O
in O
the O
hereditary B-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
syndrome I-Disease
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

almost O
all O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
that O
have O
been O
identified O
are O
single O
- O
n O
##uc O
##leo O
##tide O
alterations O
, O
small O
insertion O
##s O
, O
or O
small O
del O
##eti O
##ons O
that O
would O
t O
##run O
##cate O
the O
protein O
product O
of O
the O
gene O
. O

no O
well O
- O
characterized O
in O
##tra O
##genic O
rear O
##rang O
##ement O
of O
a O
##p O
##c O
has O
been O
described O
, O
and O
the O
prevalence O
of O
this O
type O
of O
mutation O
in O
f B-Disease
##ap I-Disease
patients O
is O
not O
clear O
. O

we O
screened O
49 O
potential O
f B-Disease
##ap I-Disease
families O
and O
identified O
26 O
different O
g O
##er O
##m O
##line O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
in O
30 O
families O
. O

four O
of O
these O
mutations O
were O
g O
##eno O
##mic O
rear O
##rang O
##ement O
##s O
resulting O
from O
ho O
##mo O
##log O
##ous O
and O
non O
##hom O
##olo O
##go O
##us O
re O
##comb O
##ination O
##s O
mediated O
by O
al O
##u O
elements O
. O

two O
of O
these O
four O
rear O
##rang O
##ement O
##s O
were O
complex O
, O
involving O
del O
##eti O
##on O
and O
insertion O
of O
n O
##uc O
##leo O
##tide O
##s O
. O

of O
these O
four O
rear O
##rang O
##ement O
##s O
, O
one O
resulted O
in O
the O
del O
##eti O
##on O
of O
ex O
##ons O
11 O
and O
12 O
and O
two O
others O
resulted O
in O
either O
complete O
or O
partial O
del O
##eti O
##on O
of O
ex O
##on O
14 O
. O

the O
fourth O
rear O
##rang O
##ement O
gross O
##ly O
altered O
the O
sequence O
within O
intro O
##n O
14 O
. O

although O
this O
rear O
##rang O
##ement O
did O
not O
affect O
any O
coding O
sequence O
of O
a O
##p O
##c O
at O
the O
g O
##eno O
##mic O
d O
##na O
level O
, O
it O
caused O
inappropriate O
s O
##p O
##licing O
of O
ex O
##on O
14 O
. O

these O
rear O
##rang O
##ement O
##s O
were O
initially O
revealed O
by O
analyzing O
c O
##dn O
##as O
and O
could O
not O
have O
been O
identified O
by O
using O
mutation O
detection O
methods O
that O
screened O
each O
ex O
##on O
individually O
. O

the O
identification O
of O
a O
rear O
##rang O
##ement O
that O
did O
not O
alter O
any O
coding O
ex O
##ons O
yet O
affected O
the O
s O
##p O
##licing O
further O
under O
##sco O
##res O
the O
importance O
of O
using O
c O
##dn O
##a O
for O
mutation O
analysis O
. O

the O
identification O
of O
four O
g O
##eno O
##mic O
rear O
##rang O
##ement O
##s O
among O
30 O
mutations O
suggests O
that O
g O
##eno O
##mic O
rear O
##rang O
##ement O
##s O
are O
frequent O
g O
##er O
##m O
##line O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
. O
. O

detection O
of O
a O
novel O
miss O
##ense O
mutation O
and O
second O
re O
##current O
mutation O
in O
the O
ca O
##c O
##na O
##1 O
##a O
gene O
in O
individuals O
with O
e B-Disease
##a I-Disease
- I-Disease
2 I-Disease
and O
f B-Disease
##hm I-Disease
. O

mutations O
in O
the O
brain O
specific O
p O
/ O
q O
type O
ca O
##2 O
+ O
channel O
alpha O
##1 O
subunit O
gene O
, O
ca O
##c O
##na O
##1 O
##a O
, O
have O
been O
identified O
in O
three O
clinical O
##ly O
distinct O
disorders O
, O
v O
##iz O
. O
e B-Disease
##pis I-Disease
##od I-Disease
##ic I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
type I-Disease
2 I-Disease
( O
e B-Disease
##a I-Disease
- I-Disease
2 I-Disease
) O
, O
f B-Disease
##ami I-Disease
##lial I-Disease
hem I-Disease
##ip I-Disease
##leg I-Disease
##ic I-Disease
mi I-Disease
##gra I-Disease
##ine I-Disease
( O
f B-Disease
##hm I-Disease
) O
and O
spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
6 I-Disease
( O
s B-Disease
##ca I-Disease
##6 I-Disease
) O
. O

for O
individuals O
with O
e B-Disease
##a I-Disease
- I-Disease
2 I-Disease
, O
the O
mutations O
described O
thus O
far O
are O
presumed O
to O
result O
in O
a O
t O
##runcated O
protein O
product O
. O

several O
different O
miss O
##ense O
mutations O
have O
been O
identified O
in O
patients O
with O
f B-Disease
##hm I-Disease
. O

at O
least O
two O
of O
these O
mutations O
have O
been O
identified O
on O
two O
different O
chromosome O
19 O
##p O
##13 O
ha O
##p O
##lot O
##ype O
##s O
and O
thus O
represent O
re O
##current O
mutations O
. O

in O
the O
present O
study O
, O
we O
have O
screened O
several O
individuals O
for O
mutations O
in O
all O
47 O
ex O
##ons O
in O
the O
ca O
##c O
##na O
##1 O
##a O
gene O
by O
single O
- O
strand O
conform O
##ation O
analysis O
. O

we O
have O
characterised O
a O
novel O
miss O
##ense O
mutation O
, O
g O
##5 O
##26 O
##0 O
##a O
, O
in O
ex O
##on O
32 O
in O
a O
family O
se O
##g O
##re O
##gating O
for O
e B-Disease
##a I-Disease
- I-Disease
2 I-Disease
. O

the O
consequence O
of O
this O
mutation O
is O
an O
amino O
acid O
substitution O
at O
a O
highly O
conserved O
position O
within O
the O
ca O
##c O
##na O
##1 O
##a O
gene O
. O

this O
represents O
the O
first O
point O
mutation O
not O
resulting O
in O
a O
proposed O
t O
##runcated O
protein O
. O

further O
##more O
, O
this O
mutation O
has O
been O
detected O
in O
a O
family O
member O
with O
mild O
clinical O
signs O
including O
only O
mi B-Disease
##gra I-Disease
##ine I-Disease
. O

additionally O
, O
a O
second O
previously O
identified O
re O
##current O
m O
##uta O
t O
##ion O
, O
c O
##22 O
##7 O
##2 O
##t O
, O
in O
ex O
##on O
16 O
has O
been O
discovered O
in O
a O
patient O
with O
f B-Disease
##hm I-Disease
. O
. O

anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
in O
a O
neon O
##ate O
. O

a O
small O
- O
for O
- O
g O
##esta O
##tional O
- O
age O
infant O
, O
found O
to O
have O
anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
in O
the O
neon O
##ata O
##l O
period O
, O
is O
reported O
and O
the O
twelve O
cases O
recorded O
in O
the O
world O
literature O
are O
reviewed O
. O

patients O
lacking O
this O
serum O
protein O
are O
essentially O
as O
##ym O
##pt O
##oma O
##tic O
, O
apart O
from O
minimal O
ankle B-Disease
ed I-Disease
##ema I-Disease
and O
ease B-Disease
of I-Disease
fatigue I-Disease
. O

apparent O
com O
##pen O
##sat O
##ory O
mechanisms O
which O
come O
into O
play O
when O
serum O
album O
##in O
is O
low O
include O
prolonged O
half O
- O
life O
of O
album O
##in O
and O
transfer O
##rin O
, O
an O
increase O
in O
serum O
g O
##lo O
##bul O
##ins O
, O
beta O
lip O
##op O
##rote O
##in O
, O
and O
g O
##ly O
##co O
##p O
##rote O
##ins O
, O
art B-Disease
##erial I-Disease
h I-Disease
##y I-Disease
##pot I-Disease
##ens I-Disease
##ion I-Disease
with O
reduced O
cap O
##illa O
##ry O
h O
##ydro O
##static O
pressure O
, O
and O
the O
ability O
to O
respond O
with O
rapid O
sodium O
and O
chloride O
di O
##ures O
##is O
in O
response O
to O
small O
volume O
changes O
. O

examination O
of O
plasma O
amino O
acids O
, O
an O
investigation O
not O
previously O
reported O
, O
revealed O
an O
extremely O
low O
plasma O
try O
##pt O
##op O
##han O
level O
, O
a O
finding O
which O
may O
be O
important O
in O
view O
of O
the O
role O
of O
try O
##pt O
##op O
##han O
in O
album O
##in O
synthesis O
. O
. O

his B-Disease
##ti I-Disease
##dine I-Disease
##mia I-Disease
. O

classical O
and O
at O
##y O
##pical O
form O
in O
siblings O
. O

two O
brothers O
, O
6 O
and O
13 O
years O
old O
, O
had O
his B-Disease
##ti I-Disease
##dine I-Disease
##mia I-Disease
. O

on O
the O
basis O
of O
clinical O
and O
bio O
##chemical O
observations O
, O
the O
younger O
boy O
was O
considered O
to O
have O
a O
classical O
type O
of O
the O
disease O
, O
while O
the O
older O
boy O
had O
an O
at O
##y O
##pical O
form O
characterized O
by O
partial O
imp O
##air O
##ment O
of O
the O
skin O
his O
##ti O
##das O
##e O
activity O
and O
a O
moderately O
prolonged O
half O
- O
life O
of O
blood O
his O
##ti O
##dine O
. O

the O
mother O
is O
a O
he O
##tero O
##zy O
##go O
##us O
carrier O
, O
while O
the O
father O
and O
sister O
seem O
to O
be O
normal O
. O
. O

carrier O
detection O
of O
p B-Disease
##yr I-Disease
##u I-Disease
##vate I-Disease
car I-Disease
##box I-Disease
##yla I-Disease
##se I-Disease
deficiency I-Disease
in O
fi O
##bro O
##blast O
##s O
and O
l O
##ymph O
##ocytes O
. O

p O
##yr O
##u O
##vate O
car O
##box O
##yla O
##se O
( O
e O
. O
c O
. O
6 O
. O
4 O
. O
1 O
. O
1 O
) O
activity O
was O
determined O
in O
the O
circulating O
peripheral O
l O
##ymph O
##ocytes O
and O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
from O
the O
family O
of O
a O
patient O
with O
he O
##pa O
##tic O
, O
cerebral O
, O
re O
##nal O
co O
##rt O
##ical O
, O
le O
##uk O
##oc O
##yte O
, O
and O
fi O
##bro O
##blast O
p B-Disease
##yr I-Disease
##u I-Disease
##vate I-Disease
car I-Disease
##box I-Disease
##yla I-Disease
##se I-Disease
deficiency I-Disease
( O
p B-Disease
##c I-Disease
port I-Disease
##land I-Disease
deficiency I-Disease
) O
. O

l O
##ymph O
##oc O
##yte O
activities O
were O
mother O
, O
33 O
- O
- O
39 O
% O
; O
father O
, O
11 O
- O
- O
29 O
% O
; O
brother O
, O
82 O
- O
- O
103 O
% O
; O
and O
sister O
, O
38 O
- O
- O
48 O
% O
of O
the O
lowest O
normal O
. O

fi O
##bro O
##blast O
##s O
from O
the O
patients O
mother O
and O
father O
had O
42 O
and O
34 O
% O
, O
respectively O
, O
of O
the O
activity O
of O
the O
lowest O
normal O
. O

these O
data O
demonstrate O
that O
the O
disease O
is O
inherited O
in O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
manner O
and O
that O
l O
##ymph O
##ocytes O
and O
fi O
##bro O
##blast O
##s O
can O
be O
used O
to O
detect O
carriers O
. O

neither O
p O
##yr O
##u O
##vate O
car O
##box O
##yla O
##se O
nor O
mitochondrial O
p O
##ep O
##ck O
activity O
in O
l O
##ymph O
##ocytes O
was O
increased O
by O
a O
21 O
- O
h O
##r O
fast O
. O

glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variants O
from O
it O
##alia O
##n O
subjects O
associated O
with O
severe B-Disease
neon I-Disease
##ata I-Disease
##l I-Disease
j I-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
. O

screening O
for O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
was O
carried O
out O
at O
the O
mater O
##nity O
division O
of O
the O
gal O
##lier O
##a O
hospital O
in O
g O
##eno O
##a O
, O
it O
##aly O
. O

two O
groups O
of O
subjects O
with O
h B-Disease
##yper I-Disease
##bil I-Disease
##ir I-Disease
##ubi I-Disease
##nae I-Disease
##mia I-Disease
of O
non O
- O
im O
##mu O
##nological O
origin O
were O
examined O
( O
a O
) O
302 O
newborn O
babies O
of O
sa O
##rdi O
##nian O
extraction O
( O
on O
cord O
blood O
) O
and O
( O
b O
) O
201 O
newborn O
babies O
of O
south O
it O
##alia O
##n O
ancestry O
( O
on O
peripheral O
blood O
) O
. O

among O
50 O
##3 O
subjects O
, O
43 O
showed O
an O
enzyme O
deficiency O
; O
in O
39 O
the O
defect O
was O
of O
the O
me O
##dit O
##er O
##rane O
##an O
type O
. O

in O
one O
case O
, O
previously O
described O
, O
the O
enzyme O
was O
of O
the O
a O
- O
type O
. O

in O
the O
remaining O
cases O
three O
different O
variants O
were O
identified O
. O

in O
the O
present O
work O
these O
three O
cases O
, O
each O
with O
severe B-Disease
neon I-Disease
##ata I-Disease
##l I-Disease
j I-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
, O
are O
reported O
. O

their O
parents O
originated O
from O
ca O
##la O
##bria O
, O
from O
sa O
##rdi O
##nia O
and O
from O
sic O
##ily O
. O

the O
abnormal O
enzymes O
are O
respectively O
designated O
as O
g O
##dd O
##c O
##bro O
##uss O
##e O
- O
like O
, O
g O
##d O
##gall O
##ura O
and O
g O
##da O
##g O
##rig O
##ent O
##o O
. O
. O

c O
##yt O
##ogen O
##etic O
investigations O
in O
families O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
. O

ch O
##rom O
##oso O
##mal O
studies O
were O
performed O
on O
peripheral O
blood O
l O
##ymph O
##ocytes O
and O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
from O
five O
is O
##rae O
##li O
- O
m O
##oro O
##cca O
##n O
families O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
. O

a O
total O
of O
24 O
individuals O
, O
including O
seven O
prop O
##os O
##iti O
, O
was O
investigated O
. O

among O
the O
pro O
##band O
##s O
, O
significantly O
elevated O
rates O
of O
chromosome O
damage O
were O
observed O
in O
both O
blood O
and O
skin O
. O

skin O
fi O
##bro O
##blast O
##s O
of O
affected O
individuals O
showed O
several O
orders O
of O
magnitude O
more O
chromosome O
break O
##age O
than O
l O
##ymph O
##ocytes O
. O

increased O
rates O
of O
chromosome O
damage O
were O
also O
observed O
in O
the O
fi O
##bro O
##blast O
##s O
of O
some O
p O
##hen O
##otypic O
##ally O
normal O
family O
members O
( O
o O
##b O
##liga O
##te O
he O
##tero O
##zy O
##got O
##es O
and O
si O
##bs O
) O
when O
compared O
to O
normal O
controls O
. O

an O
apparent O
abnormal O
clone O
of O
cells O
, O
possessing O
a O
large O
a O
##c O
##ro O
##centric O
marker O
chromosome O
( O
14 O
##q O
+ O
) O
, O
was O
observed O
in O
varying O
proportions O
among O
cells O
of O
all O
the O
prop O
##os O
##iti O
( O
2 O
- O
5 O
% O
of O
l O
##ymph O
##ocytes O
; O
1 O
- O
9 O
% O
of O
fi O
##bro O
##blast O
##s O
) O
. O
. O

pre O
##nat O
##al O
diagnosis O
of O
w B-Disease
##olm I-Disease
##an I-Disease
disease I-Disease
. O

two O
pre O
##gna O
##ncies O
at O
risk O
for O
w B-Disease
##olm I-Disease
##an I-Disease
disease I-Disease
were O
monitored O
by O
ass O
##ay O
and O
electro O
##ph O
##ores O
##is O
of O
acid O
lip O
##ase O
in O
culture O
##d O
am O
##nio O
##tic O
- O
fluid O
cells O
. O

cells O
from O
patient O
1 O
had O
5 O
% O
of O
control O
levels O
of O
acid O
lip O
##ase O
, O
using O
14 O
##c O
- O
trio O
##lein O
as O
substrate O
; O
however O
, O
when O
artificial O
substrates O
( O
est O
##ers O
of O
4 O
- O
met O
##hyl O
##um O
##bell O
##ifer O
##one O
and O
p O
- O
ni O
##tro O
##phe O
##no O
##l O
) O
were O
used O
to O
measure O
acid O
lip O
##ase O
, O
these O
cells O
had O
30 O
% O
of O
control O
levels O
. O

electro O
##ph O
##ores O
##is O
of O
cell O
extract O
##s O
revealed O
the O
absence O
of O
the O
a O
form O
of O
acid O
lip O
##ase O
, O
consistent O
with O
the O
diagnosis O
of O
w B-Disease
##olm I-Disease
##an I-Disease
disease I-Disease
. O

analysis O
of O
f O
##etal O
tissues O
following O
pro O
##sta O
##g O
##land O
##in O
termination O
of O
this O
pregnancy O
confirmed O
the O
diagnosis O
. O

ass O
##ay O
of O
f O
##etal O
- O
skin O
fi O
##bro O
##blast O
##s O
with O
14 O
##c O
- O
trio O
##lein O
, O
as O
well O
as O
with O
artificial O
substrates O
, O
showed O
marked O
deficiency O
of O
acid O
lip O
##ase O
activity O
. O

electro O
##ph O
##ores O
##is O
of O
f O
##etal O
- O
tissue O
extract O
##s O
also O
demonstrated O
the O
absence O
of O
the O
a O
form O
of O
acid O
lip O
##ase O
. O

am O
##nio O
##tic O
- O
fluid O
cells O
from O
patient O
2 O
showed O
normal O
levels O
of O
acid O
lip O
##ase O
with O
all O
substrates O
tested O
; O
the O
electro O
##ph O
##ore O
##tic O
pattern O
of O
acid O
lip O
##ase O
was O
normal O
. O

the O
results O
suggest O
that O
the O
pre O
##nat O
##al O
diagnosis O
of O
w B-Disease
##olm I-Disease
##an I-Disease
disease I-Disease
be O
made O
using O
the O
radio O
##ass O
##ay O
of O
acid O
lip O
##ase O
and O
/ O
or O
electro O
##ph O
##ores O
##is O
. O
. O

ma B-Disease
##li I-Disease
##gnant I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
in O
the O
families O
of O
patients O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
syndrome I-Disease
associated O
with O
a O
greatly O
increased O
incidence O
of O
ma B-Disease
##li I-Disease
##gnant I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
in O
ho O
##mo O
##zy O
##go O
##us O
affected O
individuals O
. O

he O
##tero O
##zy O
##got O
##es O
for O
the O
gene O
for O
a B-Disease
- I-Disease
t I-Disease
are O
thought O
to O
comprise O
about O
1 O
% O
of O
the O
general O
population O
and O
, O
therefore O
, O
it O
is O
important O
to O
know O
whether O
this O
gene O
also O
pre O
##dis O
##pose O
##s O
the O
he O
##tero O
##zy O
##go O
##us O
carrier O
to O
cancer B-Disease
##s I-Disease
. O

he O
##tero O
##zy O
##go O
##us O
carriers O
of O
this O
gene O
are O
common O
among O
the O
close O
relatives O
of O
patients O
with O
a B-Disease
- I-Disease
t I-Disease
, O
although O
individual O
carriers O
cannot O
be O
identified O
by O
any O
clinical O
criterion O
or O
laboratory O
test O
. O

for O
this O
reason O
, O
we O
compared O
the O
incidence O
of O
death O
from O
ma B-Disease
##li I-Disease
##gnant I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
in O
2 O
families O
of O
patients O
with O
a B-Disease
- I-Disease
t I-Disease
to O
that O
expected O
in O
a O
random O
sample O
of O
the O
general O
population O
. O

there O
were O
59 O
deaths O
from O
ma B-Disease
##li I-Disease
##gnant I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
in O
relatives O
dying O
before O
age O
75 O
, O
compared O
to O
42 O
. O

6 O
expected O
( O
p O
less O
than O
0 O
. O
02 O
) O
. O

for O
a B-Disease
- I-Disease
t I-Disease
he O
##tero O
##zy O
##got O
##es O
younger O
than O
age O
45 O
, O
the O
risk O
of O
dying O
from O
a O
ma B-Disease
##li I-Disease
##gnant I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##m I-Disease
was O
estimated O
to O
be O
greater O
than O
5 O
times O
the O
risk O
for O
the O
general O
population O
. O

a B-Disease
- I-Disease
t I-Disease
he O
##tero O
##zy O
##got O
##es O
may O
comprise O
more O
than O
5 O
% O
of O
all O
persons O
dying O
from O
a O
cancer B-Disease
before O
age O
45 O
. O

the O
incidence O
of O
o B-Disease
##var I-Disease
##ian I-Disease
, I-Disease
gas I-Disease
##tric I-Disease
, I-Disease
and I-Disease
bi I-Disease
##lia I-Disease
##ry I-Disease
system I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
and O
of O
le B-Disease
##uke I-Disease
##mia I-Disease
and O
l B-Disease
##ymph I-Disease
##oma I-Disease
was O
increased O
in O
these O
a B-Disease
- I-Disease
t I-Disease
families O
. O

other O
neo B-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
that O
may O
be O
associated O
with O
this O
gene O
in O
he O
##tero O
##zy O
##got O
##es O
include O
pan B-Disease
##cre I-Disease
##atic I-Disease
, I-Disease
basal I-Disease
cell I-Disease
, I-Disease
co I-Disease
##lon I-Disease
##ic I-Disease
, I-Disease
breast I-Disease
, I-Disease
and I-Disease
c I-Disease
##er I-Disease
##vic I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

striking O
prevalence O
of O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
in O
" O
healthy O
" O
w O
##27 O
positive O
males O
and O
females O
. O

an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
is O
diagnosed O
once O
or O
twice O
in O
each O
1000 O
males O
and O
one O
tenth O
as O
frequently O
in O
females O
, O
but O
the O
true O
prevalence O
is O
unknown O
. O

in O
##dent O
##ification O
of O
genetic O
marker O
, O
h O
##l O
- O
a O
w O
##27 O
, O
for O
susceptible O
persons O
has O
provided O
a O
tool O
f O
##ac O
##ilitating O
e O
##pid O
##em O
##iol O
##og O
##ic O
studies O
and O
allowing O
identification O
of O
" O
control O
" O
populations O
without O
the O
marker O
. O

evaluation O
by O
postal O
question O
##naire O
##s O
, O
and O
p O
##el O
##vic O
radio O
##graphy O
of O
78 O
h O
##l O
- O
a O
27 O
##w O
- O
positive O
blood O
donors O
selected O
from O
a O
group O
of O
apparently O
healthy O
subjects O
revealed O
14 O
who O
satisfied O
the O
criteria O
for O
definite O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
. O

the O
prevalence O
was O
similar O
in O
both O
sexes O
. O

one O
hundred O
and O
twenty O
- O
six O
w O
##27 O
- O
negative O
controls O
matched O
for O
race O
, O
sex O
, O
and O
age O
failed O
to O
yield O
a O
single O
case O
. O

for O
a O
person O
of O
either O
sex O
with O
h O
##l O
- O
a O
w O
##27 O
, O
there O
appears O
to O
be O
about O
a O
20 O
per O
cent O
chance O
that O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
will O
develop O
, O
suggesting O
a O
prevalence O
of O
10 O
to O
15 O
per O
thousand O
. O

hit O
##her O
##to O
accepted O
figures O
may O
under O
##est O
##imate O
the O
frequency O
by O
a O
factor O
of O
10 O
to O
20 O
. O
. O

anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
in O
an O
am O
##eric O
##an O
in O
##dian O
girl O
. O

anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
was O
fort O
##uit O
##ously O
detected O
in O
a O
none O
##de O
##mat O
##ous O
12 O
- O
year O
- O
old O
am O
##eric O
##an O
in O
##dian O
girl O
with O
atop B-Disease
##ic I-Disease
der I-Disease
##mat I-Disease
##itis I-Disease
, O
mild O
br B-Disease
##on I-Disease
##chia I-Disease
##l I-Disease
as I-Disease
##th I-Disease
##ma I-Disease
, O
a O
mild O
seizure B-Disease
disorder I-Disease
, O
and O
h B-Disease
##yper I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
with O
a O
corn B-Disease
##eal I-Disease
arc I-Disease
##us I-Disease
. O

im O
##mu O
##no O
##log O
##ic O
methods O
revealed O
trace O
amounts O
( O
17 O
mg O
/ O
100 O
m O
##l O
) O
of O
apparently O
normal O
serum O
album O
##in O
. O

the O
patients O
parents O
were O
remotely O
related O
. O

the O
p O
##ed O
##ig O
##ree O
and O
clinical O
findings O
were O
compatible O
with O
auto O
##so O
##mal O
re O
##cess O
##ive O
transmission O
of O
anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
. O

he O
##tero O
##zy O
##got O
##es O
had O
sub O
##nor O
##mal O
levels O
of O
serum O
album O
##in O
. O

the O
g O
##c O
- O
lo O
##cus O
is O
closely O
linked O
to O
the O
structural O
album O
##in O
lo O
##cus O
. O

g O
##c O
- O
protein O
levels O
were O
normal O
in O
the O
patient O
and O
together O
with O
normal O
ch O
##rom O
##oso O
##mal O
band O
##ing O
studies O
make O
it O
unlikely O
that O
a O
ch O
##rom O
##oso O
##mal O
del O
##eti O
##on O
caused O
anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
. O

g O
##c O
- O
types O
in O
the O
family O
were O
compatible O
with O
, O
but O
did O
not O
prove O
, O
link O
##age O
of O
anal B-Disease
##bu I-Disease
##mine I-Disease
##mia I-Disease
to O
the O
g O
##c O
- O
lo O
##cus O
. O

these O
findings O
suggest O
a O
" O
th B-Disease
##ala I-Disease
##sse I-Disease
##mia I-Disease
" O
- O
like O
mutation O
for O
this O
disorder O
. O
. O

del O
##eti O
##on O
of O
the O
kit O
and O
p O
##d O
##g O
##fra O
genes O
in O
a O
patient O
with O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
. O

we O
have O
previously O
shown O
that O
human O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
results O
from O
mutations O
of O
the O
kit O
gene O
, O
which O
en O
##codes O
the O
receptor O
for O
the O
mast O
/ O
stem O
cell O
growth O
factor O
and O
is O
located O
in O
chromosome O
segment O
4 O
##q O
##12 O
. O

using O
d O
##na O
of O
a O
patient O
with O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
multiple B-Disease
con I-Disease
##gen I-Disease
##ital I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
associated O
with O
a O
46 O
, O
x O
##y O
, O
del O
( O
4 O
) O
( O
q O
##12 O
##q O
##21 O
. O
1 O
) O
ka O
##ryo O
##type O
, O
we O
carried O
out O
quantitative O
southern O
b O
##lot O
hybrid O
##ization O
analyses O
of O
the O
kit O
gene O
and O
the O
adjacent O
p O
##d O
##g O
##fra O
( O
plate O
##let O
- O
derived O
growth O
factor O
receptor O
alpha O
subunit O
) O
genes O
. O

the O
patient O
was O
hem O
##iz O
##y O
##go O
##us O
for O
both O
the O
kit O
and O
p O
##d O
##g O
##fra O
genes O
, O
indicating O
that O
both O
of O
these O
genes O
are O
included O
within O
the O
deleted O
region O
. O

therefore O
, O
del O
##eti O
##on O
of O
the O
kit O
and O
p O
##d O
##g O
##fra O
genes O
may O
account O
for O
the O
pie B-Disease
##bal I-Disease
##d I-Disease
p O
##hen O
##otype O
in O
this O
patient O
. O

a O
g O
##er O
##m O
line O
mutation O
within O
the O
coding O
sequence O
for O
the O
put O
##ative O
5 O
- O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
- O
1 O
- O
p O
##yr O
##op O
##hos O
##phate O
binding O
site O
of O
h O
##y O
##pox O
##ant O
##hine O
- O
g O
##uan O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
hp O
##rt O
) O
in O
a O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patient O
: O
miss O
##ense O
mutations O
within O
a O
functional O
##ly O
important O
region O
probably O
cause O
disease O
. O

les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
caused O
by O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
h I-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
g I-Disease
##uan I-Disease
##ine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
##tra I-Disease
##ns I-Disease
##fer I-Disease
##ase I-Disease
( O
hp O
##rt O
) O
is O
the O
result O
of O
a O
he O
##tero O
##gene O
##ous O
group O
of O
g O
##er O
##m O
line O
mutations O
. O

identification O
of O
each O
mutant O
gene O
provides O
valuable O
information O
as O
to O
the O
type O
of O
mutation O
that O
occurs O
spontaneous O
##ly O
. O

we O
report O
here O
a O
newly O
identified O
hp O
##rt O
mutation O
in O
a O
j O
##apa O
##nese O
patient O
with O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

this O
gene O
, O
designated O
hp O
##rt O
to O
##ky O
##o O
, O
had O
a O
single O
n O
##uc O
##leo O
##tide O
change O
from O
g O
to O
a O
, O
as O
identified O
by O
se O
##quencing O
c O
##dn O
##a O
am O
##plified O
by O
the O
polymer O
##ase O
chain O
reaction O
. O

all O
##ele O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
hybrid O
##ization O
analysis O
using O
am O
##plified O
g O
##eno O
##mic O
d O
##na O
showed O
that O
the O
mutant O
gene O
was O
transmitted O
from O
the O
maternal O
g O
##er O
##m O
line O
. O

this O
mutation O
would O
lead O
to O
an O
amino O
acid O
substitution O
of O
as O
##p O
for O
g O
##ly O
at O
the O
amino O
acid O
position O
140 O
located O
within O
the O
put O
##ative O
5 O
- O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
- O
1 O
- O
p O
##yr O
##op O
##hos O
##phate O
( O
p O
##rp O
##p O
) O
binding O
region O
. O

miss O
##ense O
mutations O
in O
human O
hp B-Disease
##rt I-Disease
def I-Disease
##icient I-Disease
patients O
thus O
far O
reported O
tend O
to O
a O
##cc O
##um O
##ulate O
in O
this O
functional O
##ly O
active O
region O
. O

however O
, O
a O
comparison O
of O
the O
data O
suggested O
that O
both O
miss O
##ense O
and O
synonymous O
mutations O
can O
occur O
at O
any O
coding O
sequence O
of O
the O
human O
g O
##er O
##m O
line O
hp O
##rt O
gene O
, O
but O
that O
a O
limited O
percentage O
of O
all O
the O
miss O
##ense O
mutations O
cause O
disease O
. O

the O
probability O
that O
a O
mutation O
will O
cause O
disease O
tends O
to O
be O
higher O
when O
the O
miss O
##ense O
mutation O
is O
within O
a O
functional O
##ly O
important O
sequence O
. O
. O

character O
##isation O
of O
a O
new O
rare O
fragile O
site O
easily O
confused O
with O
the O
fragile B-Disease
x I-Disease
. O

a O
new O
fragile O
site O
( O
f O
##rax O
##e O
) O
in O
x O
##q O
##28 O
is O
described O
. O

it O
appears O
to O
be O
a O
typical O
f O
##olate O
sensitive O
fragile O
site O
. O

the O
fragile O
site O
is O
not O
associated O
with O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
it O
does O
not O
give O
abnormal O
results O
when O
subjected O
to O
southern O
analysis O
with O
probe O
p O
##f O
##xa O
##3 O
which O
detect O
##s O
the O
unstable O
d O
##na O
sequence O
characteristic O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

in O
sit O
##u O
hybrid O
##ization O
mapping O
locate O
##s O
the O
fragile O
site O
between O
150 O
k O
##b O
and O
600 O
k O
##b O
di O
##stal O
to O
f O
##rax O
##a O
. O

the O
distinction O
between O
the O
two O
fragile O
sites O
is O
important O
clinical O
##ly O
since O
c O
##yt O
##ogen O
##etic O
detection O
of O
f O
##rax O
##e O
, O
without O
molecular O
analysis O
, O
could O
result O
in O
mi O
##s O
##dia O
##gno O
##sis O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O
. O

the O
nor B-Disease
##rie I-Disease
disease I-Disease
gene O
maps O
to O
a O
150 O
k O
##b O
region O
on O
chromosome O
x O
##p O
##11 O
. O
3 O
. O

nor B-Disease
##rie I-Disease
disease I-Disease
is O
a O
human O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
of O
unknown O
et O
##iology O
characterized O
by O
con B-Disease
##gen I-Disease
##ital I-Disease
blind I-Disease
##ness I-Disease
, O
sensory B-Disease
neural I-Disease
deaf I-Disease
##ness I-Disease
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
. O

this O
disease O
gene O
was O
previously O
linked O
to O
the O
d O
##x O
##s O
##7 O
( O
l O
##1 O
. O
28 O
) O
lo O
##cus O
and O
the O
ma O
##o O
genes O
in O
band O
x O
##p O
##11 O
. O

3 O
3 O
. O

we O
report O
here O
fine O
physical O
mapping O
of O
the O
o O
##b O
##liga O
##te O
region O
containing O
the O
nor B-Disease
##rie I-Disease
disease I-Disease
gene O
( O
n O
##d O
##p O
) O
defined O
by O
a O
re O
##comb O
##ination O
and O
by O
the O
smallest O
sub O
##mic O
##ros O
##copic O
ch O
##rom O
##oso O
##mal O
del O
##eti O
##on O
associated O
with O
nor B-Disease
##rie I-Disease
disease I-Disease
identified O
to O
date O
. O

analysis O
, O
using O
in O
addition O
two O
overlapping O
ya O
##c O
clone O
##s O
from O
this O
region O
, O
allowed O
orientation O
of O
the O
ma O
##oa O
and O
ma O
##ob O
genes O
in O
a O
5 O
- O
3 O
- O
3 O
- O
5 O
configuration O
. O

a O
re O
##comb O
##ination O
event O
between O
a O
( O
g O
##t O
) O
n O
p O
##oly O
##mor O
##phism O
in O
intro O
##n O
2 O
of O
the O
ma O
##ob O
gene O
and O
the O
n O
##d O
##p O
lo O
##cus O
, O
in O
a O
family O
previously O
reported O
to O
have O
a O
re O
##comb O
##ination O
between O
d O
##x O
##s O
##7 O
and O
n O
##d O
##p O
, O
del O
##ine O
##ates O
a O
flank O
##ing O
marker O
te O
##lo O
##mer O
##ic O
to O
this O
disease O
gene O
. O

an O
anonymous O
d O
##na O
probe O
, O
d O
##c O
##12 O
, O
present O
in O
one O
of O
the O
ya O
##cs O
and O
in O
a O
patient O
with O
a O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##on O
which O
includes O
ma O
##oa O
and O
ma O
##ob O
but O
not O
l O
##1 O
. O

28 O
, O
serves O
as O
a O
flank O
##ing O
marker O
cent O
##rome O
##ric O
to O
the O
disease O
gene O
. O

an O
al O
##u O
- O
p O
##c O
##r O
fragment O
from O
the O
right O
arm O
of O
the O
ma O
##o O
ya O
##c O
( O
y O
##ma O
##o O
. O
al O
##ur O
) O
is O
not O
deleted O
in O
this O
patient O
and O
also O
del O
##ine O
##ates O
the O
cent O
##rome O
##ric O
extent O
of O
the O
o O
##b O
##liga O
##te O
disease O
region O
. O

the O
apparent O
order O
of O
these O
lo O
##ci O
is O
te O
##lo O
##mere O
. O

d O
##x O
##s O
##7 O
- O
ma O
##oa O
- O
ma O
##ob O
- O
n O
##d O
##p O
- O
d O
##c O
##12 O
- O
y O
##ma O
##o O
d O
##x O
##s O
##7 O
- O
ma O
##oa O
- O
ma O
##ob O
- O
n O
##d O
##p O
- O
d O
##c O
##12 O
- O
y O
##ma O
##o O
. O

al O
##ur O
. O
cent O
##rome O
##re O
. O

together O
these O
data O
define O
the O
o O
##b O
##liga O
##te O
region O
containing O
the O
n O
##d O
##p O
gene O
to O
a O
ch O
##rom O
##oso O
##mal O
segment O
less O
than O
150 O
k O
##b O
. O

molecular O
basis O
of O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
and O
related O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
##s I-Disease
: O
mutations O
and O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
human O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
. O

mutations O
in O
the O
human O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
producing O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
or O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

these O
mutations O
all O
exhibit O
a O
high O
degree O
of O
association O
with O
specific O
restriction O
fragment O
- O
length O
p O
##oly O
##mor O
##phism O
ha O
##p O
##lot O
##ype O
##s O
at O
the O
p O
##ah O
lo O
##cus O
. O

about O
50 O
of O
these O
mutations O
are O
single O
- O
base O
substitution O
##s O
, O
including O
six O
nonsense O
mutations O
and O
eight O
s O
##p O
##licing O
mutations O
, O
with O
the O
remainder O
being O
miss O
##ense O
mutations O
. O

one O
s O
##p O
##licing O
mutation O
results O
in O
a O
3 O
amino O
acid O
in O
- O
frame O
insertion O
. O

two O
or O
3 O
large O
del O
##eti O
##ons O
, O
2 O
single O
co O
##don O
del O
##eti O
##ons O
, O
and O
2 O
single O
base O
del O
##eti O
##ons O
have O
been O
found O
. O

twelve O
of O
the O
miss O
##ense O
mutations O
apparently O
result O
from O
the O
met O
##hyl O
##ation O
and O
subsequent O
de O
##ami O
##nation O
of O
highly O
m O
##uta O
##genic O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
##s O
. O

re O
##current O
mutation O
has O
been O
observed O
at O
several O
of O
these O
sites O
, O
producing O
associations O
with O
different O
ha O
##p O
##lot O
##ype O
##s O
in O
different O
populations O
. O

about O
half O
of O
all O
miss O
##ense O
mutations O
have O
been O
examined O
by O
in O
v O
##it O
##ro O
expression O
analysis O
, O
and O
a O
significant O
correlation O
has O
been O
observed O
between O
residual O
p O
##ah O
activity O
and O
disease O
p O
##hen O
##otype O
. O

since O
continuing O
advances O
in O
molecular O
method O
##ologies O
have O
dramatically O
accelerated O
the O
rate O
in O
which O
new O
mutations O
are O
being O
identified O
and O
characterized O
, O
this O
register O
of O
mutations O
will O
be O
updated O
periodically O
. O
. O

a O
g O
##ly O
##cine O
##25 O
##0 O
- O
- O
[UNK] O
as O
##par O
##tate O
substitution O
in O
the O
alpha O
- O
subunit O
of O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
causes O
juvenile O
- O
onset O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
in O
a O
le O
##ban O
##ese O
- O
can O
##adia O
##n O
family O
. O

the O
mutation O
causing O
juvenile O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
in O
two O
si O
##bs O
of O
le O
##ban O
##ese O
- O
ma O
##ron O
##ite O
origin O
is O
described O
. O

an O
m O
##rna O
- O
containing O
extract O
of O
culture O
##d O
fi O
##bro O
##blast O
##s O
obtained O
from O
one O
of O
the O
pro O
##band O
##s O
was O
used O
as O
a O
template O
to O
am O
##p O
##lify O
the O
coding O
sequence O
of O
the O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##x O
a O
) O
alpha O
- O
subunit O
. O

se O
##quencing O
of O
am O
##plified O
c O
##dn O
##a O
fragments O
revealed O
a O
single O
alter O
##ation O
, O
g O
##uan O
##ine O
to O
ad O
##eni O
##ne O
at O
n O
##t O
74 O
##9 O
creating O
a O
g O
##25 O
##0 O
##d O
mutation O
. O

the O
mutation O
introduces O
a O
new O
recognition O
site O
for O
the O
restriction O
enzyme O
e O
##co O
r O
##v O
, O
permitting O
identification O
of O
he O
##tero O
##zy O
##got O
##es O
for O
this O
all O
##ele O
following O
p O
##c O
##r O
am O
##p O
##lification O
and O
e O
##co O
r O
##v O
dig O
##est O
##ion O
of O
ex O
##on O
7 O
sequences O
from O
g O
##eno O
##mic O
d O
##na O
template O
##s O
. O

in O
order O
to O
test O
the O
effect O
of O
this O
substitution O
, O
an O
in O
v O
##it O
##ro O
m O
##uta O
##gen O
##ized O
c O
##dn O
##a O
construct O
was O
introduced O
into O
a O
ma O
##mmal O
##ian O
expression O
vector O
and O
trans O
##fected O
into O
monkey O
co O
##s O
- O
1 O
cells O
separately O
or O
along O
with O
a O
beta O
- O
c O
##dn O
##a O
expression O
vector O
. O

when O
the O
mutant O
alpha O
- O
c O
##dn O
##a O
was O
the O
only O
gene O
introduced O
into O
co O
##s O
cells O
no O
en O
##zy O
##matic O
activity O
above O
end O
##ogen O
##ous O
co O
##s O
cell O
activity O
was O
detected O
. O

co O
##tra O
##ns O
##fect O
##ion O
of O
normal O
alpha O
- O
c O
##dn O
##a O
and O
beta O
- O
c O
##dn O
##a O
followed O
by O
im O
##mu O
##no O
##p O
##re O
##ci O
##pit O
##ation O
of O
human O
he O
##x O
a O
resulted O
in O
20 O
- O
fold O
increase O
in O
the O
ratio O
between O
positive O
and O
negative O
( O
mock O
trans O
##fect O
##ion O
) O
control O
values O
. O

this O
allowed O
the O
detection O
of O
some O
residual O
activity O
( O
12 O
% O
of O
the O
positive O
control O
) O
when O
the O
mutant O
alpha O
- O
c O
##dn O
##a O
replaced O
its O
wild O
- O
type O
counterpart O
. O

the O
predicted O
protein O
environment O
in O
which O
the O
mutation O
occurs O
is O
compared O
to O
that O
of O
the O
adult O
- O
onset O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
mutation O
caused O
by O
a O
g O
##ly O
##26 O
##9 O
- O
- O
[UNK] O
se O
##r O
substitution O
in O
ex O
##on O
7 O
. O

( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
. O

novel O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
mutations O
from O
chin O
##a O
. O

we O
describe O
three O
he O
##xa O
mutations O
associated O
with O
infant O
##ile O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
in O
three O
unrelated O
non O
##con O
##sang O
##uin O
##eous O
chin O
##ese O
families O
. O

novel O
mutations O
were O
found O
in O
two O
of O
these O
families O
. O

the O
third O
is O
a O
previously O
reported O
mutation O
( O
g O
- O
- O
[UNK] O
a O
transition O
at O
n O
##t O
144 O
##4 O
) O
( O
nak O
##ano O
et O
al O
. O
, O
1988 O
) O
. O

direct O
se O
##quencing O
of O
p O
##c O
##r O
products O
identified O
a O
novel O
insertion O
of O
an O
a O
after O
n O
##t O
54 O
##7 O
in O
family O
1 O
. O

this O
change O
generates O
an O
early O
termination O
co O
##don O
6 O
b O
##p O
downstream O
from O
the O
insertion O
site O
. O

all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
hybrid O
##ization O
confirmed O
ho O
##mo O
##zy O
##gos O
##ity O
in O
the O
pro O
##band O
. O

single O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
analysis O
and O
direct O
se O
##quencing O
of O
am O
##plified O
ex O
##on O
13 O
revealed O
a O
t O
- O
- O
[UNK] O
c O
transition O
at O
n O
##t O
145 O
##3 O
with O
the O
corresponding O
amino O
acid O
substitution O
w O
##48 O
##5 O
##r O
in O
the O
second O
family O
. O

this O
mutation O
creates O
an O
f O
##nu O
##4 O
##hi O
restriction O
site O
. O

the O
pro O
##band O
is O
ho O
##mo O
##zy O
##go O
##us O
for O
this O
all O
##ele O
. O

when O
the O
site O
- O
specific O
m O
##uta O
##gen O
##ized O
alpha O
c O
##dn O
##a O
carrying O
the O
t O
- O
- O
[UNK] O
c O
transition O
at O
n O
##t O
145 O
##3 O
was O
expressed O
in O
co O
##s O
1 O
cells O
he O
##x O
##osa O
##mini O
##das O
##e O
s O
activity O
was O
not O
detect O
##able O
above O
background O
. O

a O
g O
- O
- O
[UNK] O
a O
transition O
at O
n O
##t O
144 O
##4 O
( O
ex O
##on O
13 O
) O
corresponding O
to O
the O
e O
##48 O
##2 O
##k O
substitution O
was O
found O
in O
the O
third O
family O
. O

this O
mutation O
occurs O
at O
a O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
. O

it O
has O
been O
reported O
in O
an O
it O
##alia O
##n O
t B-Disease
##s I-Disease
##d I-Disease
pro O
##band O
and O
causes O
defect O
##ive O
in O
##tra O
##cellular O
transport O
of O
the O
alpha O
- O
subunit O
from O
the O
rough O
end O
##op O
##las O
##mic O
re O
##tic O
##ulum O
to O
the O
go O
##l O
##gi O
apparatus O
. O

two O
miss O
##ense O
mutations O
causing O
mild O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
associated O
with O
d O
##na O
ha O
##p O
##lot O
##ype O
12 O
. O

the O
genetic B-Disease
defects I-Disease
responsible O
for O
most O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
and O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
( O
hp B-Disease
##a I-Disease
) O
cases O
are O
located O
in O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
gene O
. O

approximately O
50 O
- O
60 O
mutations O
have O
been O
reported O
in O
ca O
##uca O
##sian O
##s O
and O
are O
reflected O
in O
a O
wide O
range O
of O
clinical O
se O
##ver O
##ities O
. O

most O
mutations O
are O
linked O
to O
specific O
ha O
##p O
##lot O
##ype O
##s O
, O
as O
defined O
by O
eight O
p O
##oly O
##morphic O
restriction O
sites O
in O
the O
p O
##ah O
gene O
. O

we O
h O
##y O
##pot O
##hes O
##ized O
that O
there O
is O
at O
least O
one O
mild O
mutation O
linked O
to O
ha O
##p O
##lot O
##ype O
12 O
in O
the O
s O
##wed O
##ish O
p B-Disease
##ku I-Disease
/ O
hp B-Disease
##a I-Disease
population O
, O
since O
7 O
of O
8 O
patients O
carrying O
ha O
##p O
##lot O
##ype O
12 O
had O
mild O
hp B-Disease
##a I-Disease
. O

sequence O
analysis O
revealed O
a O
c O
- O
to O
- O
g O
trans O
##version O
at O
the O
second O
base O
of O
co O
##don O
322 O
, O
resulting O
in O
a O
substitution O
of O
g O
##ly O
##cine O
for O
al O
##ani O
##ne O
, O
in O
four O
mutant O
ha O
##p O
##lot O
##ype O
12 O
genes O
, O
and O
a O
g O
- O
to O
- O
a O
transition O
at O
the O
second O
base O
of O
co O
##don O
40 O
##8 O
, O
resulting O
in O
a O
substitution O
of O
g O
##lut O
##amine O
for O
a O
##rg O
##ini O
##ne O
, O
in O
another O
three O
mutant O
ha O
##p O
##lot O
##ype O
12 O
genes O
. O

these O
mutations O
segregated O
with O
mutant O
ha O
##p O
##lot O
##ype O
12 O
all O
##ele O
##s O
in O
nuclear O
families O
but O
were O
not O
present O
on O
normal O
or O
other O
mutant O
all O
##ele O
##s O
. O

both O
mutations O
were O
tested O
in O
a O
e O
##uka O
##ryo O
##tic O
expression O
system O
in O
which O
enzyme O
activities O
of O
different O
mutant O
p O
##ah O
enzymes O
reflect O
the O
relative O
se O
##ver O
##ities O
of O
the O
mutations O
, O
although O
these O
in O
v O
##it O
##ro O
activities O
cannot O
be O
translated O
directly O
into O
in O
v O
##ivo O
he O
##pa O
##tic O
activities O
. O

the O
a O
##32 O
##2 O
##g O
mutant O
p O
##ah O
had O
about O
75 O
% O
and O
the O
r O
##40 O
##8 O
##q O
mutant O
p O
##ah O
about O
55 O
% O
of O
the O
wild O
- O
type O
p O
##ah O
enzyme O
activity O
. O

these O
in O
v O
##it O
##ro O
activities O
are O
the O
highest O
reported O
for O
mutant O
p O
##ah O
enzymes O
produced O
in O
the O
same O
expression O
system O
. O

( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
. O

in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
correlation O
##s O
for O
i O
##65 O
##t O
and O
m O
##1 O
##v O
mutations O
at O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
lo O
##cus O
. O

mutations O
at O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
lo O
##cus O
are O
the O
major O
cause O
of O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mia I-Disease
. O

we O
have O
previously O
described O
four O
mutations O
( O
m O
##1 O
##v O
, O
i O
##v O
##s O
##12 O
##nt O
##1 O
, O
r O
##40 O
##8 O
##w O
, O
and O
s O
##34 O
##9 O
##p O
) O
at O
the O
p O
##ah O
lo O
##cus O
in O
f O
##rench O
can O
##adia O
##ns O
with O
ancestry O
in O
eastern O
que O
##be O
##c O
. O

here O
we O
report O
( O
1 O
) O
identification O
of O
another O
mutation O
, O
on O
a O
ha O
##p O
##lot O
##ype O
9 O
chromosome O
, O
which O
converts O
co O
##don O
65 O
from O
is O
##ole O
##uc O
##ine O
( O
at O
##t O
) O
to O
th O
##re O
##oni O
##ne O
( O
act O
) O
, O
( O
2 O
) O
expression O
analysis O
of O
the O
i O
##65 O
##t O
mutation O
in O
co O
##s O
cells O
demonstrating O
75 O
% O
loss O
of O
both O
im O
##mu O
##nor O
##ea O
##ctive O
protein O
and O
enzyme O
activity O
, O
and O
( O
3 O
) O
expression O
analysis O
of O
the O
most O
prevalent O
p B-Disease
##ku I-Disease
all O
##ele O
( O
m O
##1 O
##v O
) O
in O
eastern O
que O
##be O
##c O
, O
showing O
non O
##det O
##ec O
##table O
levels O
of O
p O
##ah O
protein O
and O
activity O
, O
a O
finding O
compatible O
with O
a O
mutation O
in O
the O
translation O
initiation O
co O
##don O
. O

ho O
##mo O
##zy O
##gos O
##ity O
for O
m O
##1 O
##v O
and O
co O
##dom O
##ina O
##nt O
inheritance O
of O
i O
##65 O
##t O
/ O
r O
##40 O
##8 O
##w O
were O
both O
associated O
with O
classical B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O
. O

molecular O
basis O
of O
he B-Disease
##x I-Disease
##osa I-Disease
##mini I-Disease
##das I-Disease
##e I-Disease
a I-Disease
deficiency I-Disease
and O
pseudo O
##de O
##ficiency O
in O
the O
be O
##rks O
county O
pen O
##ns O
##yl O
##vani O
##a O
du O
##tch O
. O

following O
the O
birth O
of O
two O
infants O
with O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
, O
a O
non O
- O
j O
##ew O
##ish O
, O
pen O
##ns O
##yl O
##vani O
##a O
du O
##tch O
kind O
##red O
was O
screened O
for O
t B-Disease
##s I-Disease
##d I-Disease
carriers O
using O
the O
bio O
##chemical O
ass O
##ay O
. O

a O
high O
frequency O
of O
individuals O
who O
appeared O
to O
be O
t B-Disease
##s I-Disease
##d I-Disease
he O
##tero O
##zy O
##got O
##es O
was O
detected O
( O
k O
##elly O
et O
al O
. O
, O
1975 O
) O
. O

clinical O
and O
bio O
##chemical O
evidence O
suggested O
that O
the O
increased O
carrier O
frequency O
was O
due O
to O
at O
least O
two O
altered O
all O
##ele O
##s O
for O
the O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
alpha O
- O
subunit O
. O

we O
now O
report O
two O
mutant O
all O
##ele O
##s O
in O
this O
pen O
##ns O
##yl O
##vani O
##a O
du O
##tch O
kind O
##red O
, O
and O
one O
p O
##oly O
##mor O
##phism O
. O

one O
all O
##ele O
, O
reported O
originally O
in O
a O
f O
##rench O
t B-Disease
##s I-Disease
##d I-Disease
patient O
( O
a O
##k O
##li O
et O
al O
. O
, O
1991 O
) O
, O
is O
a O
g O
##t O
- O
- O
[UNK] O
at O
transition O
at O
the O
donor O
s O
##p O
##lice O
- O
site O
of O
intro O
##n O
9 O
. O

the O
second O
, O
a O
c O
- O
- O
[UNK] O
t O
transition O
at O
n O
##uc O
##leo O
##tide O
73 O
##9 O
( O
a O
##rg O
##24 O
##7 O
##tr O
##p O
) O
, O
has O
been O
shown O
by O
t O
##rig O
##gs O
- O
rain O
##e O
et O
al O
. O

( O
1992 O
) O
to O
be O
a O
clinical O
##ly O
ben O
##ign O
" O
pseudo O
##de O
##ficient O
" O
all O
##ele O
associated O
with O
reduced O
enzyme O
activity O
against O
artificial O
substrate O
. O

finally O
, O
a O
p O
##oly O
##mor O
##phism O
[ O
g O
- O
- O
[UNK] O
a O
( O
75 O
##9 O
) O
] O
, O
which O
leaves O
v O
##ali O
##ne O
at O
co O
##don O
253 O
unchanged O
, O
is O
described O
. O

a O
mutation O
common O
in O
non O
- O
j O
##ew O
##ish O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
: O
frequency O
and O
r O
##na O
studies O
. O

ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
genetic I-Disease
disorder I-Disease
resulting O
from O
mutation O
of O
the O
he O
##xa O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
l O
##ys O
##oso O
##mal O
enzyme O
, O
beta O
- O
n O
- O
ace O
##ty O
##l O
##he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##x O
a O
) O
. O

we O
have O
discovered O
that O
a O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
mutation O
, O
i O
##v O
##s O
- O
9 O
+ O
1 O
g O
- O
- O
[UNK] O
a O
, O
first O
detected O
by O
a O
##k O
##li O
et O
al O
. O

( O
g O
##eno O
##mic O
##s O
11 O
124 O
- O
134 O
, O
1991 O
) O
, O
is O
a O
common O
disease O
all O
##ele O
in O
non O
- O
j O
##ew O
##ish O
ca O
##uca O
##sian O
##s O
( O
10 O
/ O
58 O
all O
##ele O
##s O
examined O
) O
. O

a O
p O
##c O
##r O
- O
based O
diagnostic O
test O
, O
which O
detect O
##s O
an O
n O
##lai O
##ii O
site O
generated O
by O
the O
mutation O
, O
revealed O
a O
frequency O
among O
enzyme O
- O
defined O
carriers O
of O
9 O
/ O
64 O
( O
14 O
% O
) O
. O

most O
of O
those O
carrying O
the O
all O
##ele O
trace O
their O
origins O
to O
the O
united O
kingdom O
, O
i O
##rel O
##and O
, O
or O
western O
euro O
##pe O
. O

it O
was O
not O
identified O
among O
12 O
black O
am O
##eric O
##an O
t B-Disease
##s I-Disease
##d I-Disease
all O
##ele O
##s O
or O
in O
any O
of O
18 O
ash O
##ken O
##azi O
j O
##ew O
##ish O
, O
enzyme O
- O
defined O
carriers O
who O
did O
not O
carry O
any O
of O
the O
mutations O
common O
to O
this O
population O
. O

no O
normally O
s O
##p O
##lice O
##d O
r O
##na O
was O
detected O
in O
p O
##c O
##r O
products O
generated O
from O
reverse O
transcription O
of O
r O
##na O
carrying O
the O
i O
##v O
##s O
- O
9 O
mutation O
. O

instead O
, O
the O
low O
levels O
of O
m O
##rna O
from O
this O
all O
##ele O
were O
comprised O
of O
a O
##ber O
##rant O
species O
resulting O
from O
the O
use O
of O
either O
of O
two O
cry O
##ptic O
donor O
sites O
, O
one O
t O
##run O
##cating O
ex O
##on O
9 O
and O
the O
other O
within O
i O
##v O
##s O
- O
9 O
, O
s O
##p O
##lice O
##d O
to O
ex O
##on O
10 O
. O

numerous O
additional O
s O
##p O
##lice O
products O
were O
detected O
, O
most O
involving O
skip O
##ping O
of O
one O
or O
more O
surrounding O
ex O
##ons O
. O

together O
with O
a O
recently O
identified O
all O
##ele O
responsible O
for O
he O
##x O
a O
pseudo O
##de O
##ficiency O
( O
t O
##rig O
##gs O
- O
rain O
##e O
et O
al O
. O
am O
j O
hum O
gene O
##t O
, O
1992 O
) O
, O
these O
two O
all O
##ele O
##s O
accounted O
for O
almost O
50 O
% O
( O
29 O
/ O
64 O
) O
of O
t B-Disease
##s I-Disease
##d I-Disease
or O
carrier O
all O
##ele O
##s O
as O
##cer O
##tain O
##ed O
by O
enzyme O
screening O
tests O
in O
non O
- O
j O
##ew O
##ish O
ca O
##uca O
##sian O
##s O
. O
. O

a O
##ber O
##rant O
s O
##p O
##licing O
of O
the O
ch B-Disease
##m I-Disease
gene O
is O
a O
significant O
cause O
of O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
. O

ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
( O
ch B-Disease
##m I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
progressive I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
of I-Disease
the I-Disease
ch I-Disease
##oro I-Disease
##id I-Disease
and I-Disease
re I-Disease
##tina I-Disease
. O

12 O
% O
of O
unrelated O
male O
patients O
carry O
del O
##eti O
##ons O
of O
the O
partially O
clone O
##d O
ch B-Disease
##m I-Disease
gene O
. O

in O
fin O
##land O
, O
there O
are O
more O
than O
120 O
living O
ch B-Disease
##m I-Disease
patients O
belonging O
to O
eight O
apparently O
unrelated O
p O
##ed O
##ig O
##ree O
##s O
. O

molecular O
del O
##eti O
##ons O
involving O
the O
ch B-Disease
##m I-Disease
gene O
have O
been O
detected O
in O
three O
families O
. O

we O
have O
screened O
the O
remaining O
five O
families O
for O
point O
mutations O
. O

in O
one O
large O
family O
a O
single O
n O
##uc O
##leo O
##tide O
( O
t O
) O
insertion O
into O
the O
donor O
s O
##p O
##lice O
site O
of O
ex O
##on O
c O
leads O
to O
two O
a O
##ber O
##rant O
##ly O
s O
##p O
##lice O
##d O
m O
##rna O
##s O
both O
producing O
a O
premature O
stop O
co O
##don O
. O

the O
mutation O
can O
be O
ass O
##ay O
##ed O
easily O
by O
am O
##p O
##lification O
and O
dig O
##est O
##ion O
with O
m O
##sel O
. O

our O
findings O
provide O
additional O
evidence O
for O
the O
path O
##ogen O
##etic O
role O
of O
ch B-Disease
##m I-Disease
mutations O
and O
provide O
a O
diagnostic O
tool O
for O
one O
fifth O
of O
the O
worlds O
known O
ch B-Disease
##m I-Disease
patients O
. O
. O

g O
##er O
##m O
##line O
intro O
##nic O
and O
ex O
##onic O
mutations O
in O
the O
w B-Disease
##il I-Disease
##ms I-Disease
' I-Disease
t I-Disease
##umour I-Disease
gene O
( O
w O
##t O
##1 O
) O
affecting O
u O
##rogen O
##ital O
development O
. O

deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
is O
a O
rare O
human O
developmental B-Disease
disorder I-Disease
affecting O
the O
u O
##rogen O
##ital O
system O
and O
leading O
to O
re B-Disease
##nal I-Disease
failure I-Disease
, O
inter B-Disease
##sex I-Disease
disorders I-Disease
and O
w B-Disease
##il I-Disease
##ms I-Disease
t I-Disease
##umour I-Disease
. O

in O
this O
report O
, O
four O
individuals O
with O
this O
syndrome O
are O
described O
carrying O
g O
##er O
##m O
##line O
point O
mutations O
in O
the O
w B-Disease
##il I-Disease
##ms I-Disease
t I-Disease
##umour I-Disease
suppress O
##or O
gene O
, O
w O
##t O
##1 O
. O

three O
of O
these O
mutations O
were O
in O
the O
zinc O
finger O
domains O
of O
w O
##t O
##1 O
. O

the O
fourth O
occurred O
within O
intro O
##n O
9 O
, O
preventing O
s O
##p O
##licing O
at O
one O
of O
the O
alternatively O
chosen O
s O
##p O
##lice O
donor O
sites O
of O
ex O
##on O
9 O
when O
ass O
##ay O
##ed O
in O
v O
##it O
##ro O
. O

these O
results O
provide O
genetic O
evidence O
for O
distinct O
functional O
roles O
of O
the O
w O
##t O
##1 O
is O
##of O
##orms O
in O
u O
##rogen O
##ital O
development O
. O
. O

characterization O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
region O
predict O
##s O
multiple O
protein O
is O
##of O
##orm O
- O
encoding O
m O
##rna O
##s O
. O

the O
mutation O
underlying O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
has O
been O
identified O
as O
an O
expansion O
of O
a O
p O
##oly O
##morphic O
c O
##t O
##g O
- O
repeat O
in O
a O
gene O
encoding O
protein O
kinase O
activity O
. O

brain O
and O
heart O
trans O
##cripts O
of O
the O
d O
##m O
- O
kinase O
( O
d O
##m O
##r O
- O
b O
##15 O
) O
gene O
are O
subject O
to O
alternative O
r O
##na O
s O
##p O
##licing O
in O
both O
human O
and O
mouse O
. O

the O
unstable O
[ O
c O
##t O
##g O
] O
5 O
- O
30 O
motif O
is O
found O
uniquely O
in O
humans O
, O
although O
the O
flank O
##ing O
n O
##uc O
##leo O
##tide O
##s O
are O
also O
present O
in O
mouse O
. O

characterization O
of O
the O
d B-Disease
##m I-Disease
region O
of O
both O
species O
reveals O
another O
active O
gene O
( O
d O
##m O
##r O
- O
n O
##9 O
) O
in O
close O
proximity O
to O
the O
kinase O
gene O
. O

d O
##m O
##r O
- O
n O
##9 O
trans O
##cripts O
, O
mainly O
expressed O
in O
brain O
and O
test O
##is O
, O
possess O
a O
single O
, O
large O
open O
reading O
frame O
, O
but O
the O
function O
of O
its O
protein O
product O
is O
unknown O
. O

clinical O
manifest O
##ation O
of O
d B-Disease
##m I-Disease
may O
be O
caused O
by O
the O
expanded O
c O
##t O
##g O
- O
repeat O
com O
##p O
##rom O
##ising O
the O
( O
alternative O
) O
expression O
of O
d O
##m O
- O
kinase O
or O
d O
##m O
##r O
- O
n O
##9 O
proteins O
. O
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
without O
cc O
##g O
am O
##p O
##lification O
has O
an O
f O
##m O
##r O
##1 O
del O
##eti O
##on O
. O

we O
describe O
a O
patient O
with O
typical O
clinical O
features O
of O
the O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
but O
without O
c O
##yt O
##ogen O
##etic O
expression O
of O
the O
fragile B-Disease
x I-Disease
or O
an O
am O
##plified O
cc O
##g O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
fragment O
. O

the O
patient O
has O
a O
previously O
un O
##cha O
##rac O
##ter O
##ized O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##on O
encompassing O
the O
cc O
##g O
repeat O
, O
the O
entire O
f O
##m O
##r O
##1 O
gene O
and O
about O
2 O
. O

5 O
me O
##ga O
##base O
##s O
of O
flank O
##ing O
sequences O
. O

this O
finding O
confirms O
that O
the O
fragile B-Disease
x I-Disease
p O
##hen O
##otype O
can O
exist O
, O
without O
am O
##p O
##lification O
of O
the O
cc O
##g O
repeat O
or O
c O
##yt O
##ogen O
##etic O
expression O
of O
the O
fragile B-Disease
x I-Disease
, O
and O
that O
fragile B-Disease
x I-Disease
syndrome I-Disease
is O
a O
genetically O
ho O
##mogeneous O
disorder O
involving O
f O
##m O
##r O
##1 O
. O

we O
also O
found O
random O
x O
- O
in O
##act O
##ivation O
in O
the O
mother O
of O
the O
patient O
who O
was O
shown O
to O
be O
a O
carrier O
of O
this O
del O
##eti O
##on O
. O

c O
##lon O
##ing O
of O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
region O
in O
yeast O
artificial O
chromosome O
##s O
. O

the O
gene O
responsible O
for O
hunting B-Disease
##ton I-Disease
disease I-Disease
has O
been O
localized O
to O
a O
2 O
. O

5 O
million O
base O
pair O
( O
m O
##b O
) O
region O
between O
the O
lo O
##ci O
d O
##4 O
##s O
##10 O
and O
d O
##4 O
##s O
##16 O
##8 O
on O
the O
short O
arm O
of O
chromosome O
4 O
. O

as O
part O
of O
a O
strategy O
to O
clone O
the O
h B-Disease
##d I-Disease
gene O
on O
the O
basis O
of O
its O
ch O
##rom O
##oso O
##mal O
location O
, O
we O
isolated O
g O
##eno O
##mic O
d O
##na O
from O
the O
h B-Disease
##d I-Disease
region O
as O
a O
set O
of O
overlapping O
yeast O
artificial O
chromosome O
( O
ya O
##c O
) O
clone O
##s O
. O

twenty O
- O
eight O
ya O
##c O
clone O
##s O
were O
identified O
by O
screening O
human O
ya O
##c O
libraries O
with O
twelve O
p O
##c O
##r O
- O
based O
sequence O
- O
tag O
##ged O
sites O
( O
sts O
##s O
) O
from O
the O
region O
. O

we O
assembled O
the O
ya O
##c O
clone O
##s O
into O
overlapping O
sets O
by O
hybrid O
##izing O
them O
to O
a O
large O
number O
of O
d O
##na O
probe O
##s O
from O
the O
h B-Disease
##d I-Disease
region O
, O
including O
the O
sts O
##s O
. O

in O
addition O
, O
we O
isolated O
the O
ends O
of O
the O
human O
d O
##na O
insert O
##s O
of O
most O
of O
the O
ya O
##c O
clone O
##s O
to O
assist O
in O
the O
construction O
of O
the O
con O
##ti O
##g O
. O

although O
almost O
half O
of O
the O
ya O
##cs O
appear O
to O
contain O
ch O
##ime O
##ric O
insert O
##s O
and O
several O
contain O
internal O
del O
##eti O
##ons O
or O
other O
rear O
##rang O
##ement O
##s O
, O
we O
were O
able O
to O
obtain O
over O
2 O
. O

2 O
m O
##b O
of O
the O
h B-Disease
##d I-Disease
region O
in O
ya O
##cs O
, O
including O
one O
continuous O
segment O
of O
2 O
. O

0 O
m O
##b O
covering O
the O
region O
that O
most O
likely O
contains O
the O
h B-Disease
##d I-Disease
gene O
. O

ten O
of O
the O
twenty O
eight O
ya O
##c O
clone O
##s O
comprise O
a O
minimal O
set O
spanning O
the O
2 O
. O

2 O
m O
##b O
. O

these O
clone O
##s O
provide O
re O
##age O
##nts O
for O
the O
complete O
characterization O
of O
this O
region O
of O
the O
genome O
and O
for O
the O
eventual O
isolation O
of O
the O
h B-Disease
##d I-Disease
gene O
. O

characterization O
of O
a O
ya O
##c O
containing O
part O
or O
all O
of O
the O
nor B-Disease
##rie I-Disease
disease I-Disease
lo O
##cus O
. O

it O
has O
been O
shown O
from O
pulsed O
- O
field O
gel O
electro O
##ph O
##ores O
##is O
( O
p O
##f O
##ge O
) O
that O
the O
mon O
##oam O
##ine O
o O
##xi O
##das O
##e O
genes O
a O
and O
b O
( O
ma O
##oa O
[UNK] O
ma O
##ob O
) O
and O
d O
##x O
##s O
##7 O
lo O
##ci O
are O
physically O
very O
close O
. O

we O
have O
therefore O
extended O
studies O
on O
their O
relationship O
through O
the O
character O
##isation O
of O
a O
650 O
k O
##b O
ya O
##c O
isolated O
using O
l O
##1 O
. O

28 O
( O
re O
##co O
##gni O
##sing O
the O
d O
##x O
##s O
##7 O
lo O
##cus O
) O
as O
a O
probe O
. O

restriction O
mapping O
of O
the O
ya O
##c O
indicates O
that O
it O
contains O
both O
ma O
##oa O
and O
ma O
##ob O
genes O
in O
addition O
to O
the O
d O
##x O
##s O
##7 O
lo O
##cus O
. O

the O
map O
derived O
from O
the O
y O
##l O
##1 O
. O

28 O
- O
ya O
##c O
is O
compatible O
both O
with O
the O
map O
from O
an O
independently O
derived O
ya O
##c O
carrying O
ma O
##oa O
and O
b O
genes O
and O
with O
the O
long O
range O
g O
##eno O
##mic O
map O
for O
the O
region O
. O

a O
series O
of O
sub O
##c O
##lone O
##s O
prepared O
from O
a O
p O
##hage O
library O
( O
la O
##mb O
##da O
dash O
ii O
) O
of O
the O
ya O
##c O
have O
been O
characterised O
and O
have O
been O
employed O
to O
determine O
the O
end O
point O
of O
the O
del O
##eti O
##on O
of O
a O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
##p I-Disease
) O
patient O
who O
has O
been O
shown O
to O
lack O
both O
d O
##x O
##s O
##7 O
and O
ma O
##o O
coding O
sequences O
. O

the O
pattern O
of O
retention O
of O
sub O
##c O
##lone O
##s O
in O
the O
del O
##eti O
##on O
patient O
place O
the O
end O
point O
of O
the O
del O
##eti O
##on O
within O
30 O
- O
130 O
k O
##b O
of O
the O
pro O
##ximal O
end O
of O
the O
ya O
##c O
. O

by O
combining O
the O
data O
with O
established O
re O
##comb O
##ination O
analysis O
, O
we O
provide O
evidence O
that O
all O
or O
part O
of O
the O
n O
##d O
##p O
lies O
in O
the O
interval O
of O
approximately O
250 O
##k O
##b O
within O
the O
ya O
##c O
. O

both O
mutations O
in O
g O
##6 O
##p O
##d O
a O
- O
are O
necessary O
to O
produce O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
def I-Disease
##icient I-Disease
p O
##hen O
##otype O
. O

the O
high O
prevalence O
of O
glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
a O
##f O
##rica O
##n O
populations O
is O
due O
almost O
entirely O
to O
the O
enzyme O
variant O
a O
- O
, O
which O
differs O
from O
the O
wild O
- O
type O
g O
##6 O
##p O
##d O
b O
by O
two O
amino O
acid O
replacement O
##s O
, O
68 O
v O
##al O
- O
- O
[UNK] O
met O
and O
126 O
as O
##n O
- O
- O
[UNK] O
as O
##p O
. O

the O
non O
- O
def O
##icient O
p O
##oly O
##morphic O
variant O
g O
##6 O
##p O
##d O
a O
contains O
only O
the O
mutation O
126 O
as O
##n O
- O
- O
[UNK] O
as O
##p O
. O

the O
frequencies O
of O
the O
g O
##6 O
##p O
##d O
a O
and O
of O
the O
g O
##6 O
##p O
##d O
a O
- O
genes O
in O
parts O
of O
a O
##f O
##rica O
are O
both O
about O
0 O
. O

2 O
. O

the O
68 O
v O
##al O
- O
- O
[UNK] O
met O
mutation O
has O
not O
been O
found O
in O
a O
b O
background O
. O

this O
could O
be O
because O
the O
68 O
v O
##al O
- O
- O
[UNK] O
met O
mutation O
happened O
to O
arise O
in O
an O
a O
gene O
in O
the O
first O
instance O
, O
or O
because O
the O
68 O
v O
##al O
- O
- O
[UNK] O
met O
mutation O
alone O
is O
not O
sufficient O
to O
cause O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

we O
have O
approached O
this O
question O
by O
producing O
g O
##6 O
##p O
##d O
b O
, O
a O
, O
a O
- O
, O
and O
g O
##6 O
##p O
##d O
68 O
v O
##al O
- O
- O
[UNK] O
met O
in O
a O
bacterial O
expression O
system O
and O
anal O
##ys O
##ing O
their O
bio O
##chemical O
properties O
. O

with O
each O
single O
mutation O
we O
found O
a O
slight O
decrease O
in O
both O
the O
specific O
activity O
and O
the O
yield O
of O
enzyme O
when O
compared O
to O
g O
##6 O
##p O
##d O
b O
. O

when O
both O
mutations O
were O
introduced O
together O
, O
there O
was O
a O
roughly O
add O
##itive O
effect O
on O
specific O
activity O
, O
but O
a O
much O
more O
drastic O
effect O
on O
enzyme O
yield O
( O
4 O
% O
of O
normal O
) O
. O

this O
s O
##yne O
##rg O
##istic O
effect O
was O
also O
demonstrated O
on O
thermal O
stability O
, O
especially O
at O
low O
na O
##d O
##p O
concentrations O
. O

comparable O
results O
were O
produced O
when O
the O
replacement O
119 O
g O
##ln O
- O
- O
[UNK] O
g O
##lu O
was O
studied O
instead O
of O
126 O
as O
##n O
- O
- O
[UNK] O
as O
##p O
. O

we O
in O
##fer O
that O
the O
co O
##ex O
##ist O
##ence O
of O
the O
two O
mutations O
is O
responsible O
for O
enzyme B-Disease
deficiency I-Disease
in I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
a O
- O
because O
they O
act O
s O
##yne O
##rg O
##istic O
##ally O
in O
causing O
instability O
of O
the O
enzyme O
. O

small O
nuclear O
rib O
##on O
##uc O
##leo O
##p O
##rote O
##in O
p O
##oly O
##pe O
##pt O
##ide O
n O
( O
s O
##n O
##rp O
##n O
) O
, O
an O
expressed O
gene O
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
critical O
region O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
is O
associated O
with O
paternal O
##ly O
derived O
ch O
##rom O
##oso O
##mal O
del O
##eti O
##ons O
in O
region O
15 O
##q O
##11 O
- O
13 O
or O
with O
maternal B-Disease
di I-Disease
##so I-Disease
##my I-Disease
for I-Disease
chromosome I-Disease
15 I-Disease
. O

therefore O
, O
loss O
of O
the O
expressed O
paternal O
all O
##ele O
##s O
of O
maternal O
##ly O
imprint O
##ed O
genes O
must O
be O
responsible O
for O
the O
p B-Disease
##ws I-Disease
p O
##hen O
##otype O
. O

we O
have O
mapped O
the O
gene O
encoding O
the O
small O
nuclear O
r O
##na O
associated O
p O
##oly O
##pe O
##pt O
##ide O
s O
##m O
##n O
( O
s O
##n O
##rp O
##n O
) O
to O
human O
chromosome O
15 O
##q O
##12 O
and O
a O
processed O
pseudo O
##gene O
s O
##n O
##rp O
##n O
##p O
##1 O
to O
chromosome O
region O
6 O
##pt O
##er O
- O
p O
##21 O
. O

further O
##more O
, O
s O
##n O
##rp O
##n O
was O
mapped O
to O
the O
minimal O
del O
##eti O
##on O
interval O
that O
is O
critical O
for O
p B-Disease
##ws I-Disease
. O

the O
fact O
that O
the O
mouse O
s O
##n O
##rp O
##n O
gene O
is O
maternal O
##ly O
imprint O
##ed O
in O
brain O
suggests O
that O
loss O
of O
the O
paternal O
##ly O
derived O
s O
##n O
##rp O
##n O
all O
##ele O
may O
be O
involved O
in O
the O
p B-Disease
##ws I-Disease
p O
##hen O
##otype O
. O
. O

the O
presence O
of O
two O
different O
infant O
##ile O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
mutations O
in O
a O
ca O
##jun O
population O
. O

a O
study O
was O
undertaken O
to O
character O
##ize O
the O
mutation O
( O
s O
) O
responsible O
for O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
in O
a O
ca O
##jun O
population O
in O
southwest O
lo O
##ui O
##sian O
##a O
and O
to O
identify O
the O
origins O
of O
these O
mutations O
. O

eleven O
of O
12 O
infant O
##ile O
t B-Disease
##s I-Disease
##d I-Disease
all O
##ele O
##s O
examined O
in O
six O
families O
had O
the O
beta O
- O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##x O
a O
) O
alpha O
- O
subunit O
ex O
##on O
11 O
insertion O
mutation O
that O
is O
present O
in O
approximately O
70 O
% O
of O
ash O
##ken O
##azi O
j O
##ew O
##ish O
t B-Disease
##s I-Disease
##d I-Disease
he O
##tero O
##zy O
##got O
##es O
. O

the O
mutation O
in O
the O
remaining O
all O
##ele O
was O
a O
single O
- O
base O
transition O
in O
the O
donor O
s O
##p O
##lice O
site O
of O
the O
alpha O
- O
subunit O
intro O
##n O
9 O
. O

to O
determine O
the O
origins O
of O
these O
two O
mutations O
in O
the O
ca O
##jun O
population O
, O
the O
t B-Disease
##s I-Disease
##d I-Disease
carrier O
status O
was O
en O
##zy O
##matical O
##ly O
determined O
for O
90 O
members O
of O
four O
of O
the O
six O
families O
, O
and O
extensive O
p O
##ed O
##ig O
##ree O
##s O
were O
constructed O
for O
all O
carriers O
. O

a O
single O
ancestral O
couple O
from O
f O
##rance O
was O
found O
to O
be O
common O
to O
most O
of O
the O
carriers O
of O
the O
ex O
##on O
11 O
insertion O
. O

p O
##ed O
##ig O
##ree O
data O
suggest O
that O
this O
mutation O
has O
been O
in O
the O
ca O
##jun O
population O
since O
its O
founding O
over O
2 O
centuries O
ago O
and O
that O
it O
may O
be O
widely O
distributed O
within O
the O
population O
. O

in O
contrast O
, O
the O
intro O
##n O
9 O
mutation O
apparently O
was O
introduced O
within O
the O
last O
century O
and O
probably O
is O
limited O
to O
a O
few O
lo O
##ui O
##sian O
##a O
families O
. O
. O

mutations O
in O
the O
candidate O
gene O
for O
nor B-Disease
##rie I-Disease
disease I-Disease
. O

recently O
, O
we O
and O
others O
have O
isolated O
a O
candidate O
gene O
for O
x B-Disease
linked I-Disease
nor I-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
) O
which O
was O
found O
to O
be O
deleted O
or O
disrupted O
in O
several O
patients O
. O

as O
a O
pre O
##re O
##quisite O
for O
the O
identification O
of O
point O
mutations O
in O
the O
n B-Disease
##d I-Disease
gene O
we O
have O
established O
the O
ex O
##on O
- O
intro O
##n O
structure O
of O
this O
gene O
. O

in O
17 O
unrelated O
patients O
and O
15 O
controls O
, O
p O
##c O
##r O
products O
derived O
from O
the O
promoter O
region O
, O
ex O
##ons O
1 O
and O
2 O
as O
well O
as O
the O
coding O
part O
of O
ex O
##on O
3 O
were O
anal O
##ys O
##ed O
with O
the O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
technique O
. O

in O
12 O
patients O
altered O
p O
##c O
##r O
fragments O
were O
detected O
which O
were O
studied O
in O
detail O
by O
direct O
se O
##quencing O
. O

eleven O
different O
mutations O
were O
found O
, O
and O
all O
but O
one O
are O
likely O
to O
give O
rise O
to O
significant O
structural O
changes O
in O
the O
predicted O
protein O
. O

these O
findings O
, O
and O
the O
absence O
of O
functional O
##ly O
relevant O
base O
changes O
in O
healthy O
controls O
, O
emphasize O
the O
ca O
##usal O
role O
of O
this O
candidate O
gene O
in O
nor B-Disease
##rie I-Disease
disease I-Disease
and O
p O
##ave O
the O
way O
for O
reliable O
diagnosis O
and O
carrier O
detection O
. O
. O

detection O
of O
a O
nonsense O
mutation O
in O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
by O
multiple O
s O
##s O
##c O
##p O
. O

a O
combination O
of O
multiple O
##x O
p O
##c O
##r O
with O
the O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
technique O
was O
employed O
to O
screen O
for O
point O
mutations O
in O
the O
human O
d O
##ys O
##tro O
##phi O
##n O
gene O
. O

co O
- O
am O
##p O
##lification O
of O
11 O
ex O
##ons O
from O
g O
##eno O
##mic O
d O
##na O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
) O
patients O
with O
no O
del O
##eti O
##on O
or O
du O
##plication O
was O
performed O
and O
the O
samples O
subjected O
to O
multiple O
s O
##s O
##c O
##p O
analysis O
. O

we O
report O
the O
case O
of O
a O
nonsense O
mutation O
in O
a O
du B-Disease
##chen I-Disease
##ne I-Disease
patient O
identified O
by O
this O
approach O
. O

the O
mutation O
introduces O
a O
termination O
co O
##don O
within O
ex O
##on O
8 O
of O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
. O

it O
is O
predicted O
to O
cause O
a O
very O
premature O
translation O
##al O
termination O
accounting O
for O
the O
severe O
p O
##hen O
##otype O
observed O
. O

the O
patient O
inherited O
this O
mutation O
from O
his O
mother O
. O

in O
addition O
the O
analysis O
revealed O
5 O
p O
##oly O
##mor O
##phism O
##s O
useful O
for O
internal O
control O
. O
. O

proliferation O
- O
related O
expression O
of O
p O
##19 O
/ O
nm O
##23 O
n O
##uc O
##leo O
##side O
dip O
##hos O
##phate O
kinase O
. O

high O
level O
expression O
of O
the O
nm O
##23 O
- O
h O
##1 O
gene O
, O
which O
en O
##codes O
for O
a O
n O
##uc O
##leo O
##side O
dip O
##hos O
##phate O
kinase O
, O
has O
been O
found O
to O
co O
##rrel O
##ate O
with O
diminished O
meta O
##sta O
##sis O
in O
some O
tumors B-Disease
but O
not O
in O
others O
. O

we O
have O
previously O
identified O
the O
protein O
product O
of O
the O
nm O
##23 O
- O
h O
##1 O
gene O
in O
two O
- O
dimensional O
electro O
##ph O
##ore O
##tic O
gel O
##s O
and O
have O
designated O
it O
p O
##19 O
/ O
nm O
##23 O
. O

in O
ne B-Disease
##uro I-Disease
##blast I-Disease
##oma I-Disease
, O
higher O
levels O
of O
p O
##19 O
/ O
nm O
##23 O
, O
which O
are O
associated O
with O
am O
##p O
##lification O
of O
the O
n O
- O
my O
##c O
on O
##co O
##gene O
, O
large O
tumor B-Disease
mass O
, O
and O
meta O
##sta O
##sis O
, O
were O
observed O
in O
advanced O
stage O
tumors B-Disease
compared O
with O
limited O
stage O
disease O
. O

because O
of O
the O
variable O
expression O
of O
nm O
##23 O
- O
h O
##1 O
in O
different O
tumors B-Disease
, O
we O
have O
investigated O
the O
relationship O
between O
amounts O
of O
the O
protein O
and O
cell O
proliferation O
. O

the O
levels O
of O
p O
##19 O
/ O
nm O
##23 O
were O
compared O
between O
resting O
and O
mit O
##otic O
##ally O
stimulate O
##d O
normal O
human O
p O
##b O
##ls O
and O
in O
le B-Disease
##uke I-Disease
##mia I-Disease
cells O
. O

the O
amount O
of O
p O
##19 O
/ O
nm O
##23 O
increased O
in O
normal O
l O
##ymph O
##ocytes O
in O
response O
to O
mit O
##otic O
stimulation O
and O
parallel O
##ed O
the O
increase O
in O
d O
##na O
synthesis O
. O

in O
le B-Disease
##uke I-Disease
##mia I-Disease
cells O
obtained O
from O
patients O
with O
different O
sub O
##type O
##s O
of O
acute B-Disease
le I-Disease
##uke I-Disease
##mia I-Disease
, O
p O
##19 O
/ O
nm O
##23 O
levels O
were O
also O
increased O
relative O
to O
resting O
normal O
l O
##ymph O
##ocytes O
. O

treatment O
of O
mit O
##otic O
##ally O
stimulate O
##d O
l O
##ymph O
##ocytes O
with O
c O
##y O
##c O
##los O
##por O
##in O
, O
which O
in O
##hibit O
##s O
proliferation O
, O
blocked O
the O
increase O
in O
p O
##19 O
/ O
nm O
##23 O
; O
treatment O
of O
the O
le B-Disease
##uke I-Disease
##mia I-Disease
cell O
line O
h O
##l O
- O
60 O
with O
dim O
##eth O
##yl O
##sul O
##fo O
##xi O
##de O
, O
which O
induce O
##s O
terminal O
differentiation O
, O
resulted O
in O
diminished O
levels O
of O
p O
##19 O
/ O
nm O
##23 O
. O

our O
data O
therefore O
provide O
evidence O
that O
nm O
##23 O
- O
h O
##1 O
expression O
is O
related O
to O
cell O
pro O
##life O
##rative O
activity O
. O
. O

an O
in O
##tra O
##ch O
##rom O
##oso O
##mal O
insertion O
causing O
5 O
##q O
##22 O
del O
##eti O
##on O
and O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
in O
two O
generations O
. O

we O
report O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
f B-Disease
##ap I-Disease
##c I-Disease
) O
with O
e B-Disease
##pid I-Disease
##er I-Disease
##mo I-Disease
##id I-Disease
c I-Disease
##ys I-Disease
##ts I-Disease
, O
o B-Disease
##ste I-Disease
##oma I-Disease
##ta I-Disease
, O
and O
areas O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##yper I-Disease
##tro I-Disease
##phy I-Disease
of I-Disease
the I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
pig I-Disease
##ment I-Disease
e I-Disease
##pit I-Disease
##hel I-Disease
##ium I-Disease
( O
ch B-Disease
##rp I-Disease
##es I-Disease
) O
in O
a O
male O
patient O
and O
his O
maternal O
aunt O
, O
both O
of O
whom O
suffered O
a O
mild O
to O
moderate O
degree O
of O
mental B-Disease
hand I-Disease
##ica I-Disease
##p I-Disease
. O

both O
had O
an O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
of O
the O
long O
arm O
of O
chromosome O
5 O
( O
del O
( O
5 O
) O
( O
q O
##22 O
##q O
##23 O
. O
2 O
) O
) O
. O

two O
other O
normal O
family O
members O
had O
the O
underlying O
direct O
insertion O
of O
chromosome O
5 O
( O
dir O
ins O
( O
5 O
) O
( O
q O
##31 O
. O
3 O
##q O
##22 O
##q O
##23 O
3 O
##q O
##22 O
##q O
##23 O
. O
2 O
) O
) O
. O

molecular O
genetic O
and O
fluorescent O
hybrid O
##isation O
studies O
have O
shown O
that O
lo O
##ci O
d O
##5 O
##s O
##37 O
and O
d O
##5 O
##s O
##9 O
##8 O
are O
outside O
the O
del O
##eti O
##on O
whereas O
lo O
##ci O
detected O
by O
probe O
##s O
e O
##f O
##5 O
. O

44 O
and O
y O
##n O
##5 O
. O

48 O
are O
lost O
. O

as O
expected O
, O
the O
molecular O
analyses O
indicate O
loss O
of O
one O
all O
##ele O
at O
the O
m O
##cc O
and O
a B-Disease
##p I-Disease
##c I-Disease
lo O
##ci O
. O

the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
is O
located O
within O
band O
5 O
##q O
##22 O
. O

f O
##ami O
##lial O
direct O
insertion O
##s O
should O
be O
considered O
as O
a O
cause O
of O
re O
##current O
micro O
##del O
##eti O
##on O
syndrome O
##s O
. O

chromosome O
mapping O
of O
the O
rod O
photo O
##re O
##ceptor O
c O
##g O
##mp O
p O
##hos O
##ph O
##odies O
##tera O
##se O
beta O
- O
subunit O
gene O
in O
mouse O
and O
human O
: O
tight O
link O
##age O
to O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
region O
( O
4 O
##p O
##16 O
. O
3 O
) O
. O

the O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
mouse O
( O
gene O
symbol O
, O
r O
##d O
) O
is O
an O
animal O
model O
for O
certain O
forms O
of O
human O
hereditary B-Disease
re I-Disease
##tino I-Disease
##path I-Disease
##ies I-Disease
. O

recent O
findings O
of O
a O
nonsense O
mutation O
in O
the O
r O
##d O
mouse O
p O
##de O
beta O
- O
subunit O
gene O
( O
p O
##de O
##b O
) O
prompted O
us O
to O
investigate O
the O
chromosome O
locations O
of O
the O
mouse O
and O
human O
genes O
. O

we O
have O
utilized O
back O
##cross O
analysis O
in O
mice O
to O
verify O
and O
define O
more O
precisely O
the O
location O
of O
the O
p O
##de O
##b O
lo O
##cus O
6 O
. O

1 O
+ O
/ O
- O
2 O
. O

3 O
cm O
di O
##stal O
of O
mg O
##sa O
on O
mouse O
chromosome O
5 O
. O

we O
have O
determined O
that O
the O
human O
gene O
( O
p O
##de O
##b O
) O
maps O
to O
4 O
##p O
##16 O
. O

3 O
, O
very O
close O
to O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
region O
. O

analysis O
of O
the O
comparative O
map O
for O
mice O
and O
humans O
shows O
that O
the O
mouse O
ho O
##mo O
##logue O
of O
the O
h B-Disease
##d I-Disease
gene O
will O
reside O
on O
chromosome O
5 O
. O

link O
##age O
of O
the O
mouse O
p O
##de O
##b O
lo O
##cus O
with O
other O
ho O
##mo O
##logue O
##s O
in O
the O
human O
4 O
##p O
##16 O
. O

3 O
region O
is O
maintained O
but O
gene O
order O
is O
not O
, O
suggesting O
at O
least O
three O
possible O
sites O
for O
the O
corresponding O
mouse O
h B-Disease
##d I-Disease
gene O
. O

coincide O
##nt O
ka B-Disease
##po I-Disease
##si I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
and O
t B-Disease
- I-Disease
cell I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
in O
a O
patient O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O

a O
24 O
year O
old O
male O
with O
a O
history O
of O
e B-Disease
##cz I-Disease
##ema I-Disease
, O
re O
##current O
mild O
infections O
, O
and O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
consistent O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
presented O
with O
a O
media O
##st O
##inal O
mass O
, O
generalized O
l B-Disease
##ymph I-Disease
##ade I-Disease
##no I-Disease
##pathy I-Disease
, O
s B-Disease
##ple I-Disease
##no I-Disease
##me I-Disease
##gal I-Disease
##y I-Disease
, O
and O
severe O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

studies O
of O
immune O
function O
including O
im O
##mu O
##no O
##g O
##lo O
##bul O
##in O
levels O
and O
t O
- O
cell O
subset O
##s O
were O
normal O
. O

further O
##more O
, O
his O
t O
l O
##ymph O
##ocytes O
pro O
##life O
##rated O
normally O
in O
response O
to O
p O
##hy O
##to O
##hem O
##ag O
##g O
##lut O
##ini O
##n O
, O
con O
##can O
##ava O
##lin O
a O
, O
and O
the O
combination O
of O
ne O
##ura O
##mini O
##das O
##e O
/ O
gal O
##act O
##ose O
o O
##xi O
##das O
##e O
. O

however O
, O
their O
pro O
##life O
##rative O
responses O
to O
anti O
- O
c O
##d O
##43 O
anti O
##body O
and O
period O
##ate O
were O
diminished O
, O
consistent O
with O
the O
clinical O
diagnosis O
of O
was B-Disease
. O

an O
initial O
ing O
##uin O
##al O
l O
##ymph O
node O
bio O
##psy O
surprisingly O
revealed O
ka B-Disease
##po I-Disease
##si I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
. O

however O
, O
following O
s O
##ple O
##nect O
##omy O
to O
increase O
the O
plate O
##let O
count O
, O
bio O
##psy O
of O
the O
media O
##st O
##inal O
mass O
revealed O
t B-Disease
- I-Disease
cell I-Disease
large I-Disease
cell I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
. O

studies O
of O
bio O
##ps O
##ied O
tissue O
for O
the O
presence O
of O
e B-Disease
##ps I-Disease
##tein I-Disease
- I-Disease
bar I-Disease
##r I-Disease
virus I-Disease
and O
c B-Disease
##yt I-Disease
##ome I-Disease
##gal I-Disease
##ov I-Disease
##ir I-Disease
##us I-Disease
were O
negative O
, O
as O
were O
studies O
of O
blood O
, O
including O
the O
polymer O
##ase O
chain O
reaction O
, O
for O
the O
presence O
of O
the O
human B-Disease
im I-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
virus I-Disease
( O
hi B-Disease
##v I-Disease
) O
. O

this O
is O
the O
first O
report O
of O
ka B-Disease
##po I-Disease
##si I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
arising O
in O
a O
patient O
with O
a O
con B-Disease
##gen I-Disease
##ital I-Disease
im I-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
syndrome I-Disease
. O

although O
ka B-Disease
##po I-Disease
##si I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
can O
arise O
in O
the O
face O
of O
the O
severe O
im O
##mu O
##nos O
##up O
##press O
##ion O
that O
follows O
all O
##og O
##raft O
transplant O
##ation O
and O
in O
patients O
infected O
with O
hi B-Disease
##v I-Disease
, O
we O
post O
##ulate O
that O
long O
##evity O
in O
the O
face O
of O
mild O
im O
##mu O
##nos O
##up O
##press O
##ion O
was O
the O
major O
factor O
in O
the O
development O
of O
ka B-Disease
##po I-Disease
##si I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
in O
this O
patient O
. O
. O

the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
responsible O
for O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
, O
is O
m O
##uta O
##ted O
in O
human O
gas B-Disease
##tric I-Disease
cancer I-Disease
. O

although O
gas B-Disease
##tric I-Disease
cancer I-Disease
is O
the O
most O
common O
cancer B-Disease
in O
the O
world O
, O
genetic O
changes O
during O
its O
car O
##cin O
##ogen O
##esis O
are O
not O
well O
understood O
. O

since O
some O
gas B-Disease
##tric I-Disease
cancer I-Disease
##s I-Disease
are O
considered O
to O
originate O
from O
the O
in O
##test O
##inal O
meta O
##p O
##lasia O
, O
it O
is O
likely O
that O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
, O
the O
mutation O
of O
which O
causes O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
in I-Disease
the I-Disease
co I-Disease
##lon I-Disease
, O
is O
associated O
with O
car O
##cin O
##ogen O
##esis O
of O
gas B-Disease
##tric I-Disease
cancer I-Disease
. O

based O
on O
this O
idea O
, O
d O
##nas O
isolated O
from O
gas B-Disease
##tric I-Disease
cancer I-Disease
##s I-Disease
were O
examined O
by O
means O
of O
a O
r O
##nas O
##e O
protection O
analysis O
coupled O
with O
polymer O
##ase O
chain O
reaction O
followed O
by O
se O
##quencing O
of O
the O
polymer O
##ase O
chain O
reaction O
products O
. O

by O
screening O
nearly O
one O
- O
half O
of O
the O
coding O
region O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
44 O
tumors B-Disease
, O
so O
##matic O
mutations O
were O
detected O
in O
three O
tumors B-Disease
a O
miss O
##ense O
mutation O
, O
a O
nonsense O
mutation O
, O
and O
a O
5 O
- O
base O
pair O
del O
##eti O
##on O
resulting O
in O
a O
frame O
shift O
which O
causes O
t O
##run O
##cation O
of O
the O
gene O
product O
. O

these O
results O
suggest O
that O
the O
mutation O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
also O
plays O
an O
important O
role O
during O
the O
car O
##cin O
##ogen O
##esis O
of O
at O
least O
some O
gas B-Disease
##tric I-Disease
cancer I-Disease
##s I-Disease
. O
. O

a O
71 O
- O
k O
##ilo O
##dal O
##ton O
protein O
is O
a O
major O
product O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
in O
brain O
and O
other O
non O
##mus O
##cle O
tissues O
. O

the O
known O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
products O
, O
the O
muscle O
- O
and O
brain O
- O
type O
d O
##ys O
##tro O
##phi O
##n O
is O
##of O
##orms O
, O
are O
42 O
##7 O
- O
k O
##da O
proteins O
translated O
from O
14 O
- O
k O
##ilo O
##base O
( O
k O
##b O
) O
m O
##rna O
##s O
. O

recently O
we O
described O
a O
6 O
. O

5 O
- O
k O
##b O
m O
##rna O
that O
also O
is O
trans O
##cribed O
from O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

c O
##lon O
##ing O
and O
in O
v O
##it O
##ro O
transcription O
and O
translation O
of O
the O
entire O
coding O
region O
show O
that O
the O
6 O
. O

5 O
- O
k O
##b O
m O
##rna O
en O
##codes O
a O
70 O
. O

8 O
- O
k O
##da O
protein O
that O
is O
a O
major O
product O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

it O
contains O
the O
c O
- O
terminal O
and O
the O
c O
##ys O
##tein O
##e O
- O
rich O
domains O
of O
d O
##ys O
##tro O
##phi O
##n O
, O
seven O
additional O
amino O
acids O
at O
the O
n O
terminus O
, O
and O
some O
modifications O
formed O
by O
alternative O
s O
##p O
##licing O
in O
the O
c O
- O
terminal O
domain O
. O

it O
lacks O
the O
entire O
large O
domain O
of O
s O
##pect O
##rin O
- O
like O
repeats O
and O
the O
act O
##in O
- O
binding O
n O
- O
terminal O
domain O
of O
d O
##ys O
##tro O
##phi O
##n O
. O

this O
protein O
is O
the O
major O
d B-Disease
##m I-Disease
##d I-Disease
gene O
product O
in O
brain O
and O
other O
non O
##mus O
##cle O
tissues O
but O
is O
und O
##ete O
##ct O
##able O
in O
skeletal O
muscle O
extract O
##s O
. O

correlation O
between O
the O
location O
of O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
and O
the O
number O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
patients O
. O

recently O
we O
have O
isolated O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
which O
causes O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
, O
and O
its O
g O
##er O
##m O
- O
line O
mutations O
in O
a O
substantial O
number O
of O
f B-Disease
##ap I-Disease
patients O
have O
been O
identified O
. O

on O
the O
basis O
of O
this O
information O
, O
we O
compared O
the O
location O
of O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
22 O
unrelated O
patients O
( O
12 O
of O
whom O
have O
been O
reported O
previously O
) O
with O
the O
number O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
developed O
in O
f B-Disease
##ap I-Disease
patients O
; O
17 O
were O
sparse O
types O
and O
five O
were O
pro O
##fuse O
types O
. O

all O
but O
one O
of O
the O
mutations O
were O
considered O
to O
cause O
t O
##run O
##cation O
of O
the O
gene O
product O
by O
frame O
- O
shift O
due O
to O
del O
##eti O
##on O
( O
14 O
cases O
) O
or O
nonsense O
mutation O
( O
seven O
cases O
) O
. O

the O
location O
of O
the O
g O
##er O
##m O
- O
line O
mutations O
seems O
to O
co O
##rrel O
##ate O
with O
the O
two O
clinical O
types O
; O
g O
##er O
##m O
- O
line O
mutations O
in O
five O
f B-Disease
##ap I-Disease
patients O
with O
pro O
##fuse O
p B-Disease
##oly I-Disease
##ps I-Disease
were O
observed O
between O
co O
##don O
125 O
##0 O
and O
co O
##don O
146 O
##4 O
, O
whereas O
mutations O
in O
17 O
f B-Disease
##ap I-Disease
patients O
with O
fewer O
p B-Disease
##oly I-Disease
##ps I-Disease
were O
observed O
in O
the O
other O
regions O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

the O
result O
suggests O
that O
the O
number O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
in O
f B-Disease
##ap I-Disease
patients O
may O
be O
associated O
with O
a O
difference O
in O
the O
stability O
or O
biological O
function O
of O
the O
t O
##runcated O
a B-Disease
##p I-Disease
##c I-Disease
protein O
. O
. O

identification O
and O
rapid O
detection O
of O
three O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
mutations O
in O
the O
m O
##oro O
##cca O
##n O
j O
##ew O
##ish O
population O
. O

infant O
##ile O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
is O
caused O
by O
mutations O
in O
the O
he O
##xa O
gene O
that O
result O
in O
the O
complete O
absence O
of O
beta O
- O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
activity O
. O

it O
is O
well O
known O
that O
an O
elevated O
frequency O
of O
t B-Disease
##s I-Disease
##d I-Disease
mutations O
exists O
among O
ash O
##ken O
##azi O
j O
##ews O
. O

more O
recently O
it O
has O
become O
apparent O
that O
elevated O
carrier O
frequencies O
for O
t B-Disease
##s I-Disease
##d I-Disease
also O
occur O
in O
several O
other O
ethnic O
groups O
, O
including O
m O
##oro O
##cca O
##n O
j O
##ews O
, O
a O
subgroup O
of O
se O
##pha O
##rdi O
##c O
j O
##ews O
. O

elsewhere O
we O
reported O
an O
in O
- O
frame O
del O
##eti O
##on O
of O
one O
of O
the O
two O
adjacent O
p O
##hen O
##yla O
##lani O
##ne O
co O
##don O
##s O
at O
position O
304 O
or O
305 O
( O
delta O
f O
##30 O
##4 O
/ O
305 O
) O
in O
one O
he O
##xa O
all O
##ele O
of O
a O
m O
##oro O
##cca O
##n O
j O
##ew O
##ish O
t B-Disease
##s I-Disease
##d I-Disease
patient O
and O
in O
three O
o O
##b O
##liga O
##te O
carriers O
from O
six O
unrelated O
m O
##oro O
##cca O
##n O
j O
##ew O
##ish O
families O
. O

we O
have O
now O
identified O
two O
additional O
mutations O
within O
ex O
##on O
5 O
of O
the O
he O
##xa O
gene O
that O
account O
for O
the O
remaining O
t B-Disease
##s I-Disease
##d I-Disease
all O
##ele O
##s O
in O
the O
patient O
and O
carriers O
. O

one O
of O
the O
mutations O
is O
a O
novel O
c O
- O
to O
- O
g O
trans O
##version O
, O
resulting O
in O
a O
replacement O
of O
t O
##yr O
##18 O
##0 O
by O
a O
stop O
co O
##don O
. O

the O
other O
mutation O
is O
a O
g O
- O
to O
- O
a O
transition O
resulting O
in O
an O
a O
##rg O
##17 O
##0 O
- O
to O
- O
g O
##ln O
substitution O
. O

this O
mutation O
is O
at O
a O
c O
##p O
##g O
site O
in O
a O
j O
##apa O
##nese O
infant O
with O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
and O
was O
described O
elsewhere O
. O

analysis O
of O
nine O
o O
##b O
##liga O
##te O
carriers O
from O
seven O
unrelated O
families O
showed O
that O
four O
harbor O
the O
delta O
f O
##30 O
##4 O
/ O
305 O
mutation O
, O
two O
the O
a O
##rg O
##17 O
##0 O
- O
- O
- O
- O
g O
##ln O
mutation O
, O
and O
one O
the O
t O
##yr O
##18 O
##0 O
- O
- O
- O
- O
stop O
mutation O
. O

we O
also O
have O
developed O
rapid O
, O
non O
##rad O
##io O
##active O
ass O
##ays O
for O
the O
detection O
of O
each O
mutation O
, O
which O
should O
be O
helpful O
for O
carrier O
screening O
. O
. O

molecular O
characterization O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
by O
natural O
and O
am O
##p O
##lification O
created O
restriction O
sites O
: O
five O
mutations O
account O
for O
most O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
cases O
in O
ta O
##i O
##wan O
. O

we O
have O
developed O
a O
rapid O
and O
simple O
method O
to O
di O
##ag O
##nose O
the O
molecular O
defects O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
chin O
##ese O
in O
ta O
##i O
##wan O
. O

this O
method O
involves O
the O
selective O
am O
##p O
##lification O
of O
a O
d O
##na O
fragment O
from O
human O
g O
##6 O
##p O
##d O
gene O
with O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
prime O
##rs O
followed O
by O
dig O
##est O
##ion O
with O
restriction O
enzymes O
that O
recognize O
artificial O
##ly O
created O
or O
naturally O
occurring O
restriction O
sites O
. O

ninety O
- O
four O
chin O
##ese O
males O
with O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
were O
studied O
. O

the O
results O
show O
that O
50 O
% O
( O
47 O
of O
94 O
) O
were O
g O
to O
t O
mutation O
at O
n O
##uc O
##leo O
##tide O
( O
n O
##t O
) O
137 O
##6 O
, O
21 O
. O

3 O
% O
( O
20 O
of O
94 O
) O
were O
g O
to O
a O
mutation O
at O
n O
##t O
138 O
##8 O
, O
7 O
. O

4 O
% O
( O
7 O
of O
94 O
) O
were O
a O
to O
g O
mutation O
at O
n O
##t O
49 O
##3 O
, O
7 O
. O

4 O
% O
( O
7 O
of O
94 O
) O
were O
a O
to O
g O
mutation O
at O
n O
##t O
95 O
, O
4 O
. O

2 O
% O
( O
4 O
of O
94 O
) O
were O
c O
to O
t O
mutation O
at O
n O
##t O
102 O
##4 O
, O
1 O
. O

1 O
% O
( O
1 O
of O
94 O
) O
was O
g O
to O
t O
mutation O
at O
n O
##t O
39 O
##2 O
, O
and O
1 O
. O

1 O
% O
( O
1 O
of O
94 O
) O
was O
g O
to O
a O
mutation O
at O
n O
##t O
48 O
##7 O
. O

these O
results O
show O
that O
the O
former O
five O
mutations O
account O
for O
more O
than O
90 O
% O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
cases O
in O
ta O
##i O
##wan O
. O

aside O
from O
showing O
that O
g O
to O
t O
change O
at O
n O
##t O
137 O
##6 O
is O
the O
most O
common O
mutation O
, O
our O
research O
indicates O
that O
n O
##t O
49 O
##3 O
mutation O
is O
a O
frequent O
mutation O
among O
chin O
##ese O
in O
ta O
##i O
##wan O
. O

we O
compared O
g O
##6 O
##p O
##d O
activity O
among O
different O
mutations O
, O
without O
discovering O
significant O
differences O
between O
them O
. O

eight O
novel O
in O
##act O
##ivating O
g O
##er O
##m O
line O
mutations O
at O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
identified O
by O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
is O
a O
dominant O
##ly O
inherited O
condition O
pre O
##dis O
##po O
##sing O
to O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

the O
recent O
isolation O
of O
the O
responsible O
gene O
( O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
or O
a B-Disease
##p I-Disease
##c I-Disease
) O
has O
facilitated O
the O
search O
for O
g O
##er O
##m O
line O
mutations O
in O
affected O
individuals O
. O

previous O
authors O
have O
used O
the O
r O
##nas O
##e O
protection O
ass O
##ay O
and O
the O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
##s O
procedure O
to O
screen O
for O
mutations O
. O

in O
this O
study O
we O
used O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
( O
d O
##gg O
##e O
) O
. O

d O
##gg O
##e O
analysis O
of O
10 O
a B-Disease
##p I-Disease
##c I-Disease
ex O
##ons O
( O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
12 O
, O
13 O
, O
14 O
, O
and O
part O
of O
15 O
) O
in O
33 O
unrelated O
du O
##tch O
f B-Disease
##ap I-Disease
patients O
has O
led O
to O
the O
identification O
of O
eight O
novel O
g O
##er O
##m O
line O
mutations O
resulting O
in O
stop O
co O
##don O
##s O
or O
frames O
##hi O
##fts O
. O

the O
results O
reported O
here O
indicate O
that O
( O
1 O
) O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
is O
caused O
by O
an O
extremely O
he O
##tero O
##gene O
##ous O
spectrum O
of O
point O
mutations O
; O
( O
2 O
) O
all O
the O
mutations O
found O
in O
this O
study O
are O
chain O
terminating O
; O
and O
( O
3 O
) O
d O
##gg O
##e O
represents O
a O
rapid O
and O
sensitive O
technique O
for O
the O
detection O
of O
mutations O
in O
the O
unusually O
large O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

an O
extension O
of O
the O
d O
##gg O
##e O
analysis O
to O
the O
entire O
coding O
region O
in O
a O
sufficient O
number O
of O
clinical O
##ly O
well O
- O
characterized O
, O
unrelated O
patients O
will O
facilitate O
the O
establishment O
of O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
. O

on O
the O
other O
hand O
, O
the O
occurrence O
of O
an O
extremely O
he O
##tero O
##gene O
##ous O
spectrum O
of O
mutations O
spread O
throughout O
the O
entire O
length O
of O
the O
large O
a B-Disease
##p I-Disease
##c I-Disease
gene O
among O
the O
f B-Disease
##ap I-Disease
patients O
indicates O
that O
this O
approach O
may O
not O
be O
useful O
as O
a O
rapid O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnostic O
procedure O
in O
a O
routine O
laboratory O
. O

nevertheless O
, O
the O
above O
d O
##gg O
##e O
approach O
has O
incident O
##ally O
led O
to O
the O
identification O
of O
a O
common O
p O
##oly O
##mor O
##phism O
in O
ex O
##on O
13 O
. O

such O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
##s O
offer O
a O
practical O
approach O
to O
a O
more O
rapid O
procedure O
for O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnosis O
of O
f B-Disease
##ap I-Disease
by O
link O
##age O
analysis O
in O
inform O
##ative O
families O
. O
. O

yeast O
artificial O
chromosome O
##s O
for O
the O
molecular O
analysis O
of O
the O
f B-Disease
##ami I-Disease
##lial I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
a I-Disease
##p I-Disease
##c I-Disease
gene O
region O
. O

two O
yeast O
artificial O
chromosome O
##s O
( O
ya O
##cs O
) O
spanning O
a O
total O
distance O
of O
1 O
. O

1 O
me O
##ga O
##base O
pairs O
of O
d O
##na O
around O
the O
m O
##cc O
( O
for O
m O
##uta O
##ted O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
) O
and O
a B-Disease
##p I-Disease
##c I-Disease
( O
for O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
) O
genes O
at O
5 O
##q O
##21 O
have O
been O
isolated O
and O
characterized O
. O

starting O
from O
the O
m O
##cc O
gene O
, O
a O
strategy O
was O
undertaken O
to O
identify O
constitutional O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##ons O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
patients O
that O
might O
considerably O
narrow O
down O
the O
position O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

to O
this O
end O
, O
ya O
##cs O
identified O
by O
the O
m O
##cc O
gene O
were O
screened O
across O
a O
chromosome O
5 O
- O
specific O
co O
##sm O
##id O
library O
to O
provide O
a O
source O
of O
d O
##na O
probe O
##s O
for O
g O
##eno O
##mic O
scanning O
. O

the O
co O
##sm O
##ids O
isolated O
from O
these O
experiments O
were O
used O
to O
screen O
a O
panel O
of O
so O
##matic O
cell O
hybrid O
##s O
containing O
chromosome O
5 O
segregated O
from O
patients O
suspected O
to O
carry O
put O
##ative O
inter O
##st O
##iti O
##al O
del O
##eti O
##ons O
. O

this O
screening O
approach O
led O
to O
the O
confirmation O
of O
a O
small O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##on O
in O
a O
p B-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
patient O
that O
overlap O
##s O
one O
of O
the O
two O
isolated O
ya O
##cs O
. O

this O
ya O
##c O
has O
been O
shown O
to O
contain O
the O
entire O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
in O
addition O
to O
a O
significant O
portion O
of O
d O
##na O
flank O
##ing O
the O
5 O
end O
of O
the O
gene O
, O
and O
should O
therefore O
prove O
a O
valuable O
resource O
for O
functional O
studies O
by O
transfer O
to O
color B-Disease
##ec I-Disease
##tal I-Disease
tumor I-Disease
- O
derived O
cell O
lines O
. O

inherited O
w O
##t O
##1 O
mutation O
in O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
. O

patients O
with O
the O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
( O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
, O
g B-Disease
##eni I-Disease
##tal I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
, O
and O
ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
) O
have O
been O
demonstrated O
to O
carry O
de O
no O
##vo O
constitutional O
mutations O
in O
w O
##t O
##1 O
, O
the O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
gene O
at O
chromosome O
11 O
##p O
##13 O
. O

we O
report O
three O
new O
cases O
, O
two O
carrying O
a O
previously O
described O
w O
##t O
##1 O
ex O
##on O
9 O
mutation O
and O
one O
with O
a O
novel O
w O
##t O
##1 O
ex O
##on O
8 O
mutation O
. O

however O
, O
unlike O
patients O
in O
previous O
reports O
, O
one O
of O
our O
three O
patients O
inherited O
the O
affected O
all O
##ele O
from O
his O
p O
##hen O
##otypic O
##ally O
un O
##af O
##fected O
father O
. O

this O
observation O
indicates O
that O
the O
w O
##t O
##1 O
ex O
##on O
9 O
mutation O
affecting O
39 O
##4 O
##ar O
##g O
demonstrated O
in O
over O
one O
- O
half O
of O
the O
patients O
with O
the O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
may O
exhibit O
incomplete O
pen O
##et O
##rance O
. O

consequently O
, O
f O
##ami O
##lial O
studies O
in O
patients O
affected O
by O
this O
syndrome O
are O
recommended O
. O
. O

sub O
##mic O
##ros O
##copic O
del O
##eti O
##ons O
at O
the O
wa B-Disease
##g I-Disease
##r I-Disease
lo O
##cus O
, O
revealed O
by O
non O
##rad O
##io O
##active O
in O
sit O
##u O
hybrid O
##ization O
. O

flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
( O
fish O
) O
with O
bio O
##tin O
- O
labeled O
probe O
##s O
mapping O
to O
11 O
##p O
##13 O
has O
been O
used O
for O
the O
molecular O
analysis O
of O
del O
##eti O
##ons O
of O
the O
wa B-Disease
##g I-Disease
##r I-Disease
( O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
, O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
g B-Disease
##eni I-Disease
##tour I-Disease
##ina I-Disease
##ry I-Disease
abnormal I-Disease
##ities I-Disease
, O
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
) O
lo O
##cus O
. O

we O
have O
detected O
a O
sub O
##mic O
##ros O
##copic O
11 O
##p O
##13 O
del O
##eti O
##on O
in O
a O
child O
with O
inherited O
an B-Disease
##iri I-Disease
##dia I-Disease
who O
subsequently O
presented O
with O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
in O
a O
horses O
##hoe O
kidney O
, O
only O
revealed O
at O
surgery O
. O

the O
mother O
, O
who O
has O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
was O
also O
found O
to O
carry O
a O
del O
##eti O
##on O
including O
both O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
candidate O
gene O
( O
an O
##2 O
) O
and O
the O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
pre O
##dis O
##position O
gene O
( O
w O
##t O
##1 O
) O
. O

this O
is O
therefore O
a O
rare O
case O
of O
an O
inherited O
wa B-Disease
##g I-Disease
##r I-Disease
del O
##eti O
##on O
. O

w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
has O
so O
far O
only O
been O
associated O
with O
s O
##poradic O
de O
no O
##vo O
an B-Disease
##iri I-Disease
##dia I-Disease
cases O
. O

we O
have O
shown O
that O
a O
co O
##sm O
##id O
probe O
for O
a O
candidate O
an B-Disease
##iri I-Disease
##dia I-Disease
gene O
, O
ho O
##mo O
##log O
##ous O
to O
the O
mouse O
p O
##ax O
- O
6 O
gene O
, O
is O
deleted O
in O
cell O
lines O
from O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
with O
previously O
characterized O
del O
##eti O
##ons O
at O
11 O
##p O
##13 O
, O
while O
another O
co O
##sm O
##id O
marker O
mapping O
between O
two O
an B-Disease
##iri I-Disease
##dia I-Disease
- O
associated O
trans O
##location O
break O
##points O
( O
and O
hence O
a O
second O
candidate O
marker O
) O
is O
present O
on O
both O
chromosome O
##s O
. O

these O
results O
support O
the O
p O
##ax O
- O
6 O
ho O
##mo O
##logue O
as O
a O
strong O
candidate O
for O
the O
an O
##2 O
gene O
. O

fish O
with O
co O
##sm O
##id O
probe O
##s O
has O
proved O
to O
be O
a O
fast O
and O
reliable O
technique O
for O
the O
molecular O
analysis O
of O
del O
##eti O
##ons O
. O

it O
can O
be O
used O
with O
limited O
amounts O
of O
material O
and O
has O
strong O
potential O
for O
clinical O
applications O
. O
. O

link O
##age O
of O
gene O
for O
c B-Disease
##2 I-Disease
deficiency I-Disease
and O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
complex O
m O
##h O
##c O
in O
man O
. O

family O
study O
of O
a O
further O
case O
. O

close O
link O
##age O
between O
h O
##l O
- O
a O
and O
c B-Disease
##2 I-Disease
deficiency I-Disease
was O
first O
reported O
by O
f O
##u O
and O
co O
- O
workers O
in O
1974 O
. O

we O
present O
here O
a O
p O
##ed O
##ig O
##ree O
of O
a O
31 O
- O
year O
- O
old O
c B-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individual O
with O
clinical O
manifest O
##ations O
of O
ho B-Disease
##d I-Disease
##g I-Disease
##kins I-Disease
disease I-Disease
. O

the O
following O
markers O
were O
tested O
c O
##2 O
levels O
, O
factor O
b O
p O
##oly O
##mor O
##phism O
, O
blood O
groups O
, O
and O
enzyme O
typing O
. O

in O
addition O
to O
close O
link O
##age O
between O
h O
##l O
- O
a O
and O
c B-Disease
##2 I-Disease
deficiency I-Disease
, O
both O
parents O
were O
he O
##tero O
##zy O
##go O
##us O
for O
b O
##f O
( O
h O
##l O
- O
a O
linked O
, O
electro O
##ph O
##ore O
##tic O
variation O
of O
b O
) O
. O

the O
two O
h O
##l O
- O
a O
ha O
##p O
##lot O
##ype O
##s O
closely O
linked O
to O
c B-Disease
##2 I-Disease
deficiency I-Disease
are O
different O
2 O
, O
w O
##18 O
and O
w O
##24 O
, O
w O
##18 O
. O

they O
share O
, O
however O
, O
the O
s O
##d O
##2 O
anti O
##gen O
w O
##18 O
and O
the O
l O
##d O
type O
7 O
##a O
. O
. O

screening O
for O
g O
##er O
##m O
- O
line O
mutations O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
patients O
: O
61 O
new O
patients O
and O
a O
summary O
of O
150 O
unrelated O
patients O
. O

we O
report O
here O
the O
result O
of O
a O
screening O
for O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
in O
61 O
new O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
patients O
as O
well O
as O
a O
summary O
of O
the O
results O
of O
150 O
patients O
. O

examination O
of O
the O
entire O
coding O
region O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
based O
on O
a O
rib O
##on O
##uc O
##lea O
##se O
protection O
ass O
##ay O
coupled O
with O
the O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
, O
disclosed O
mutations O
that O
were O
considered O
to O
cause O
significant O
defects O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
product O
in O
97 O
of O
150 O
unrelated O
f B-Disease
##ap I-Disease
patients O
. O

our O
findings O
revealed O
the O
following O
characteristics O
of O
the O
g O
##er O
##m O
- O
line O
mutations O
of O
a O
##p O
##c O
1 O
) O
the O
great O
majority O
of O
the O
mutations O
were O
found O
to O
t O
##run O
##cate O
the O
a B-Disease
##p I-Disease
##c I-Disease
product O
; O
2 O
) O
almost O
all O
of O
the O
mutations O
were O
located O
within O
the O
first O
half O
of O
the O
coding O
region O
; O
3 O
) O
no O
correlation O
was O
observed O
between O
the O
locations O
of O
g O
##er O
##m O
- O
line O
mutations O
and O
extra O
##co O
##lon O
##ic O
manifest O
##ations O
in O
f B-Disease
##ap I-Disease
patients O
; O
4 O
) O
more O
than O
80 O
% O
of O
base O
substitution O
##s O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
were O
from O
c O
##yt O
##os O
##ine O
to O
other O
n O
##uc O
##leo O
##tide O
##s O
, O
nearly O
one O
- O
third O
of O
which O
occurred O
at O
the O
g O
##p O
##g O
site O
. O

our O
results O
provide O
information O
helpful O
to O
an O
understanding O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
and O
will O
also O
contribute O
to O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnosis O
of O
members O
in O
f B-Disease
##ap I-Disease
families O
. O
. O

so O
##matic O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
: O
mutation O
cluster O
region O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

we O
examined O
so O
##matic O
mutations O
of O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
in O
63 O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
( O
16 O
ad B-Disease
##eno I-Disease
##mas I-Disease
and O
47 O
car B-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
) O
developed O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
and O
non O
- O
f O
##ap O
patients O
. O

in O
addition O
to O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
( O
lo O
##h O
) O
at O
the O
a B-Disease
##p I-Disease
##c I-Disease
lo O
##cus O
in O
30 O
tumors B-Disease
, O
43 O
other O
so O
##matic O
mutations O
were O
detected O
. O

twenty O
- O
one O
of O
them O
were O
point O
mutations O
; O
16 O
nonsense O
and O
two O
miss O
##ense O
mutations O
, O
and O
three O
occurred O
in O
intro O
##ns O
at O
the O
s O
##p O
##licing O
site O
. O

twenty O
- O
two O
tumors B-Disease
had O
frames O
##hi O
##ft O
mutations O
due O
to O
del O
##eti O
##on O
or O
insertion O
; O
nineteen O
of O
them O
were O
del O
##eti O
##ons O
of O
one O
to O
31 O
b O
##p O
and O
three O
were O
a O
1 O
- O
b O
##p O
insertion O
. O

one O
tumor B-Disease
had O
a O
1 O
- O
b O
##p O
del O
##eti O
##on O
in O
an O
intro O
##n O
near O
the O
s O
##p O
##licing O
site O
. O

hence O
, O
41 O
( O
95 O
% O
) O
of O
43 O
mutations O
resulted O
in O
t O
##run O
##cation O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
protein O
. O

over O
60 O
% O
of O
the O
so O
##matic O
mutations O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
were O
cluster O
##ed O
within O
a O
small O
region O
of O
ex O
##on O
15 O
, O
designated O
as O
m O
##c O
##r O
( O
mutation O
cluster O
region O
) O
, O
which O
accounted O
for O
less O
than O
10 O
% O
of O
the O
coding O
region O
. O

combining O
these O
data O
and O
the O
results O
of O
lo O
##h O
, O
more O
than O
80 O
% O
of O
tumors B-Disease
( O
14 O
ad B-Disease
##eno I-Disease
##mas I-Disease
and O
39 O
car B-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
) O
had O
at O
least O
one O
mutation O
in O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
, O
of O
which O
more O
than O
60 O
% O
( O
9 O
ad B-Disease
##eno I-Disease
##mas I-Disease
and O
23 O
car B-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
) O
had O
two O
mutations O
. O

these O
results O
strongly O
suggest O
that O
so O
##matic O
mutations O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
are O
associated O
with O
development O
of O
a O
great O
majority O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
tumors I-Disease
. O
. O

constitutional O
mutations O
in O
the O
w O
##t O
##1 O
gene O
in O
patients O
with O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
. O

the O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
is O
characterised O
by O
a O
typical O
ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
, O
g B-Disease
##eni I-Disease
##tal I-Disease
abnormal I-Disease
##ities I-Disease
and O
also O
pre O
##dis O
##pose O
##s O
to O
the O
development O
of O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
. O

these O
patients O
eventually O
go O
into O
end O
stage O
re B-Disease
##nal I-Disease
failure I-Disease
. O

a O
candidate O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
gene O
, O
w O
##t O
##1 O
, O
from O
the O
11 O
##p O
##13 O
chromosome O
region O
has O
recently O
been O
clone O
##d O
. O

we O
have O
anal O
##ys O
##ed O
the O
d O
##na O
sequence O
in O
constitutional O
cells O
from O
eight O
patients O
and O
have O
shown O
he O
##tero O
##zy O
##go O
##us O
mutations O
in O
six O
of O
them O
. O

four O
of O
the O
mutations O
were O
in O
ex O
##on O
9 O
, O
all O
resulting O
in O
miss O
##ense O
mutations O
. O

three O
were O
at O
n O
##uc O
##leo O
##tide O
position O
118 O
##0 O
resulting O
in O
an O
a O
##rg O
[UNK] O
t O
##rp O
amino O
acid O
change O
. O

the O
other O
was O
at O
position O
118 O
##6 O
converting O
an O
as O
##p O
[UNK] O
as O
##n O
in O
the O
predicted O
result O
##ant O
protein O
. O

one O
patient O
had O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
8 O
, O
converting O
an O
a O
##rg O
[UNK] O
his O
. O

a O
single O
base O
pair O
insertion O
at O
n O
##uc O
##leo O
##tide O
position O
82 O
##1 O
in O
ex O
##on O
6 O
resulted O
in O
the O
generation O
of O
a O
premature O
stop O
co O
##don O
in O
the O
last O
patient O
. O

we O
were O
unable O
to O
find O
a O
mutation O
in O
one O
patient O
despite O
complete O
se O
##quencing O
of O
the O
g O
##eno O
##mic O
sequence O
of O
the O
gene O
. O

the O
last O
patient O
carried O
a O
constitutional O
del O
##eti O
##on O
of O
the O
11 O
##p O
##13 O
region O
and O
no O
additional O
mutation O
was O
found O
. O

there O
was O
no O
obvious O
correlation O
between O
the O
type O
of O
mutation O
and O
p O
##hen O
##otypic O
expression O
. O

these O
results O
further O
demonstrate O
that O
the O
w O
##t O
##1 O
gene O
is O
important O
in O
both O
the O
development O
of O
the O
kidney O
and O
the O
g O
##eni O
##to O
- O
u O
##rina O
##ry O
system O
. O
. O

link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
mapping O
in O
isolated O
founder O
populations O
: O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
in O
fin O
##land O
. O

link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
mapping O
in O
isolated O
populations O
provides O
a O
powerful O
tool O
for O
fine O
structure O
local O
##ization O
of O
disease O
genes O
. O

here O
, O
l O
##uria O
and O
del O
##bruck O
##s O
classical O
methods O
for O
anal O
##ys O
##ing O
bacterial O
cultures O
are O
adapted O
to O
the O
study O
of O
human O
isolated O
founder O
populations O
in O
order O
to O
estimate O
( O
i O
) O
the O
re O
##comb O
##ination O
fraction O
between O
a O
disease O
lo O
##cus O
and O
a O
marker O
; O
( O
ii O
) O
the O
expected O
degree O
of O
all O
##eli O
##c O
ho O
##mo O
##gene O
##ity O
in O
a O
population O
; O
and O
( O
ii O
##i O
) O
the O
mutation O
rate O
of O
marker O
lo O
##ci O
. O

using O
these O
methods O
, O
we O
report O
striking O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
for O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
( O
d B-Disease
##t I-Disease
##d I-Disease
) O
in O
fin O
##land O
indicating O
that O
the O
d B-Disease
##t I-Disease
##d I-Disease
gene O
should O
lie O
within O
0 O
. O

06 O
cent O
##imo O
##rgan O
##s O
( O
or O
about O
60 O
k O
##ilo O
##base O
##s O
) O
of O
the O
c O
##s O
##f O
##1 O
##r O
gene O
. O

predictions O
about O
all O
##eli O
##c O
ho O
##mo O
##gene O
##ity O
in O
fin O
##land O
and O
mutation O
rates O
in O
simple O
sequence O
repeats O
are O
confirmed O
by O
independent O
observations O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
: O
re O
##fine O
##ment O
of O
the O
local O
##ization O
on O
x O
##p O
and O
identification O
of O
another O
closely O
linked O
marker O
lo O
##cus O
, O
o O
##at O
##l O
##1 O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
has O
previously O
been O
mapped O
to O
the O
pro O
##ximal O
short O
arm O
of O
the O
x O
chromosome O
between O
the O
d O
##x O
##s O
##14 O
and O
d O
##x O
##s O
##7 O
lo O
##ci O
. O

in O
this O
study O
, O
further O
segregation O
analysis O
has O
been O
performed O
using O
a O
newly O
identified O
was B-Disease
family O
as O
well O
as O
an O
additional O
marker O
probe O
, O
ho O
##at O
##l O
##1 O
. O

the O
results O
indicate O
close O
link O
##age O
between O
the O
was B-Disease
and O
o O
##at O
##l O
##1 O
lo O
##ci O
( O
z O
= O
6 O
. O
08 O
at O
the O
##ta O
= O
0 O
. O
00 O
) O
and O
local O
##ize O
the O
t O
##im O
##p O
, O
o O
##at O
##l O
##1 O
, O
d O
##x O
##s O
##25 O
##5 O
, O
and O
was B-Disease
lo O
##ci O
di O
##stal O
to O
d O
##x O
##s O
##14 O
##6 O
and O
the O
o O
##at O
##l O
##1 O
and O
was B-Disease
lo O
##ci O
pro O
##ximal O
to O
t O
##im O
##p O
. O

these O
link O
##age O
data O
narrow O
the O
boundaries O
within O
which O
the O
was B-Disease
lo O
##cus O
maps O
to O
the O
ch O
##rom O
##oso O
##mal O
region O
bracket O
##ed O
by O
t O
##im O
##p O
and O
d O
##x O
##s O
##14 O
##6 O
and O
support O
the O
lo O
##ci O
order O
x O
##pt O
##er O
- O
d O
##x O
##s O
##7 O
- O
t O
##im O
##p O
- O
( O
o O
##at O
##l O
##1 O
, O
was O
, O
d O
##x O
##s O
##25 O
##5 O
) O
- O
d O
##x O
##s O
##14 O
##6 O
. O

detection O
of O
an O
unstable O
fragment O
of O
d O
##na O
specific O
to O
individuals O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
with O
a O
prevalence O
of O
2 O
- O
14 O
per O
100 O
, O
000 O
individuals O
. O

the O
disease O
is O
characterized O
by O
progressive O
muscle B-Disease
weakness I-Disease
and O
sustained B-Disease
muscle I-Disease
contraction I-Disease
, O
often O
with O
a O
wide O
range O
of O
accompanying O
symptoms O
. O

the O
age O
at O
onset O
and O
severity O
of O
the O
disease O
show O
extreme O
variation O
, O
both O
within O
and O
between O
families O
. O

despite O
its O
clinical O
var O
##iability O
, O
this O
dominant O
condition O
se O
##g O
##re O
##gate O
##s O
as O
a O
single O
lo O
##cus O
at O
chromosome O
19 O
##q O
##13 O
. O

3 O
in O
every O
population O
studied O
. O

it O
is O
flanked O
by O
the O
tightly O
linked O
genetic O
markers O
er O
##cc O
##1 O
pro O
##ximal O
##ly O
and O
d O
##19 O
##s O
##51 O
di O
##stal O
##ly O
; O
these O
define O
the O
d B-Disease
##m I-Disease
critical O
region O
. O

we O
report O
the O
isolation O
of O
an O
expressed O
sequence O
from O
this O
region O
which O
detect O
##s O
a O
d O
##na O
fragment O
that O
is O
larger O
in O
affected O
individuals O
than O
in O
normal O
siblings O
or O
un O
##af O
##fected O
controls O
. O

the O
size O
of O
this O
fragment O
varies O
between O
affected O
siblings O
, O
and O
increases O
in O
size O
through O
generations O
in O
parallel O
with O
increasing O
severity O
of O
the O
disease O
. O

we O
post O
##ulate O
that O
this O
unstable O
d O
##na O
sequence O
is O
the O
molecular O
feature O
that O
under O
##lies O
d B-Disease
##m I-Disease
. O

common O
sequence O
motifs O
at O
the O
rear O
##rang O
##ement O
sites O
of O
a O
constitutional O
x O
/ O
auto O
##some O
trans O
##location O
and O
associated O
del O
##eti O
##on O
. O

re O
##ci O
##p O
##ro O
##cal O
chromosome O
trans O
##location O
##s O
are O
common O
de O
no O
##vo O
rear O
##rang O
##ement O
##s O
that O
occur O
randomly O
throughout O
the O
human O
genome O
. O

to O
learn O
about O
ca O
##usa O
##tive O
mechanisms O
, O
we O
have O
clone O
##d O
and O
sequence O
##d O
the O
break O
##points O
of O
a O
c O
##yt O
##ological O
##ly O
balanced O
constitutional O
re O
##ci O
##p O
##ro O
##cal O
trans O
##location O
, O
t O
( O
x O
; O
4 O
) O
( O
p O
##21 O
. O
2 O
; O
q O
##31 O
. O
22 O
) O
, O
present O
in O
a O
girl O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

physical O
mapping O
of O
the O
derivative O
chromosome O
##s O
, O
after O
their O
separation O
in O
so O
##matic O
cell O
hybrid O
##s O
, O
reveals O
that O
the O
trans O
##location O
disrupt O
##s O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
in O
x O
##p O
##21 O
within O
the O
18 O
- O
k O
##b O
intro O
##n O
16 O
. O

restriction O
mapping O
and O
se O
##quencing O
of O
clone O
##s O
that O
span O
both O
trans O
##location O
break O
##points O
as O
well O
as O
the O
corresponding O
normal O
regions O
indicate O
the O
loss O
of O
approximately O
5 O
k O
##b O
in O
the O
formation O
of O
the O
derivative O
x O
chromosome O
, O
with O
4 O
- O
6 O
b O
##p O
deleted O
from O
chromosome O
4 O
. O

r O
##f O
##l O
##p O
and O
southern O
analyses O
indicate O
that O
the O
de O
no O
##vo O
trans O
##location O
is O
a O
paternal O
origin O
and O
that O
the O
fathers O
x O
chromosome O
contains O
the O
d O
##na O
that O
is O
deleted O
in O
the O
derivative O
x O
. O

most O
likely O
, O
del O
##eti O
##on O
and O
translation O
arose O
simultaneously O
from O
a O
complex O
rear O
##rang O
##ement O
event O
that O
involves O
three O
ch O
##rom O
##oso O
##mal O
break O
##points O
. O

short O
regions O
of O
sequence O
ho O
##mology O
were O
present O
at O
the O
three O
sites O
. O

a O
5 O
- O
b O
##p O
sequence O
, O
g O
##ga O
##at O
, O
found O
exactly O
at O
the O
trans O
##location O
break O
##points O
on O
both O
normal O
chromosome O
##s O
x O
and O
4 O
, O
has O
been O
preserved O
only O
on O
the O
der O
( O
4 O
) O
chromosome O
. O

it O
is O
likely O
that O
the O
x O
- O
derived O
sequence O
g O
##ga O
##at O
##ca O
has O
been O
lost O
in O
the O
formation O
of O
the O
der O
( O
x O
) O
chromosome O
, O
as O
it O
matches O
an O
inverted O
g O
##aa O
##t O
##ca O
sequence O
present O
on O
the O
opposite O
strand O
exactly O
at O
the O
other O
end O
of O
the O
deleted O
5 O
- O
k O
##b O
fragment O
. O

a O
genetic O
et O
##iology O
for O
dig B-Disease
##eor I-Disease
##ge I-Disease
syndrome I-Disease
: O
consistent O
del O
##eti O
##ons O
and O
micro O
##del O
##eti O
##ons O
of O
22 O
##q O
##11 O
. O

dig B-Disease
##eor I-Disease
##ge I-Disease
syndrome I-Disease
( O
d B-Disease
##gs I-Disease
) O
, O
a O
developmental O
field O
defect O
of O
the O
third O
and O
fourth O
p O
##har O
##yn O
##ge O
##al O
pouch O
##es O
, O
is O
characterized O
by O
a B-Disease
##p I-Disease
##lasia I-Disease
or I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
of I-Disease
the I-Disease
thy I-Disease
##mus I-Disease
and I-Disease
para I-Disease
##thy I-Disease
##roid I-Disease
glands I-Disease
and O
by O
con B-Disease
##ot I-Disease
##run I-Disease
##cal I-Disease
cardiac I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ations I-Disease
. O

c O
##yt O
##ogen O
##etic O
studies O
support O
the O
presence O
of O
a O
d B-Disease
##gs I-Disease
critical O
region O
in O
band O
22 O
##q O
##11 O
. O

in O
the O
present O
study O
, O
we O
report O
the O
results O
of O
clinical O
, O
c O
##yt O
##ogen O
##etic O
, O
and O
molecular O
studies O
of O
14 O
patients O
with O
d B-Disease
##gs I-Disease
. O

chromosome O
analysis O
, O
utilizing O
high O
- O
resolution O
band O
##ing O
techniques O
, O
detected O
inter O
##st O
##iti O
##al O
del O
##eti O
##ons O
in O
five O
pro O
##band O
##s O
and O
was O
in O
##con O
##clusive O
for O
a O
del O
##eti O
##on O
in O
three O
pro O
##band O
##s O
. O

the O
remaining O
six O
patients O
had O
normal O
ka O
##ryo O
##type O
##s O
. O

in O
contrast O
, O
molecular O
analysis O
detected O
d O
##na O
del O
##eti O
##ons O
in O
all O
14 O
pro O
##band O
##s O
. O

two O
of O
10 O
lo O
##ci O
tested O
, O
d O
##22 O
##s O
##75 O
and O
d O
##22 O
##s O
##25 O
##9 O
, O
are O
deleted O
in O
all O
14 O
patients O
. O

a O
third O
lo O
##cus O
, O
d O
##22 O
##s O
##6 O
##6 O
, O
is O
deleted O
in O
the O
eight O
d B-Disease
##gs I-Disease
pro O
##band O
##s O
tested O
. O

physical O
mapping O
using O
so O
##matic O
cell O
hybrid O
##s O
places O
d O
##22 O
##s O
##6 O
##6 O
between O
d O
##22 O
##s O
##75 O
and O
d O
##22 O
##s O
##25 O
##9 O
, O
suggesting O
that O
it O
should O
be O
deleted O
in O
the O
remaining O
six O
cases O
. O

parent O
- O
of O
- O
origin O
studies O
were O
performed O
in O
five O
families O
. O

four O
pro O
##band O
##s O
failed O
to O
inherit O
a O
maternal O
all O
##ele O
, O
and O
one O
failed O
to O
inherit O
a O
paternal O
all O
##ele O
. O

on O
the O
basis O
of O
these O
families O
, O
and O
of O
six O
maternal O
##ly O
and O
five O
paternal O
##ly O
derived O
un O
##bal O
##ance O
##d O
- O
trans O
##location O
d B-Disease
##gs I-Disease
pro O
##band O
##s O
in O
the O
literature O
, O
parent O
of O
origin O
or O
imprint O
##ing O
does O
not O
appear O
to O
play O
an O
important O
role O
in O
the O
path O
##ogen O
##esis O
of O
d B-Disease
##gs I-Disease
. O

del O
##eti O
##on O
of O
the O
same O
three O
lo O
##ci O
in O
all O
14 O
d B-Disease
##gs I-Disease
pro O
##band O
##s O
begins O
to O
del O
##ine O
##ate O
the O
region O
of O
chromosome O
22 O
critical O
for O
d B-Disease
##gs I-Disease
and O
confirms O
the O
hypothesis O
that O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##ons O
of O
22 O
##q O
##11 O
are O
et O
##iol O
##og O
##ic O
in O
the O
vast O
majority O
of O
cases O
. O
. O

loss O
of O
normal O
all O
##ele O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
in O
an O
ad B-Disease
##ren I-Disease
##oc I-Disease
##ort I-Disease
##ical I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
from O
a O
patient O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
. O

end B-Disease
##oc I-Disease
##rine I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
have O
been O
reported O
occasionally O
in O
patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

an O
ad B-Disease
##ren I-Disease
##oc I-Disease
##oro I-Disease
##tical I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
was O
studied O
in O
a O
patient O
with O
a O
family O
history O
of O
f B-Disease
##ap I-Disease
. O

loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
( O
lo O
##h O
) O
in O
the O
region O
close O
to O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
was O
detected O
in O
this O
car B-Disease
##cin I-Disease
##oma I-Disease
, O
and O
evidence O
was O
obtained O
that O
there O
was O
a O
loss O
of O
the O
normal O
all O
##ele O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

this O
is O
the O
first O
demonstration O
of O
lo O
##h O
at O
the O
a B-Disease
##p I-Disease
##c I-Disease
lo O
##cus O
in O
ad B-Disease
##ren I-Disease
##oc I-Disease
##ort I-Disease
##ical I-Disease
tumors I-Disease
. O

the O
present O
results O
and O
our O
previous O
data O
on O
lo O
##h O
in O
a O
recurring O
des B-Disease
##mo I-Disease
##id I-Disease
tumor I-Disease
suggest O
that O
the O
he O
##tero O
##zy O
##go O
##us O
mutant O
/ O
wild O
- O
type O
condition O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
may O
give O
rise O
to O
ben B-Disease
##ign I-Disease
tumors I-Disease
, O
and O
that O
functional O
loss O
of O
this O
gene O
leads O
to O
development O
of O
tumors B-Disease
not O
only O
in O
the O
co O
##lon O
but O
also O
in O
other O
various O
parts O
of O
the O
body O
in O
f B-Disease
##ap I-Disease
patients O
. O
. O

on O
##co O
##genic O
point O
mutations O
in O
ex O
##on O
20 O
of O
the O
r O
##b O
##1 O
gene O
in O
families O
showing O
incomplete O
pen O
##et O
##rance O
and O
mild O
expression O
of O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
p O
##hen O
##otype O
. O

the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
- O
pre O
##dis O
##position O
gene O
, O
r O
##b O
##1 O
, O
se O
##g O
##re O
##gate O
##s O
as O
an O
auto O
##so O
##mal O
dominant O
trait O
with O
high O
( O
90 O
% O
) O
pen O
##et O
##rance O
. O

certain O
families O
, O
however O
, O
show O
an O
unusual O
low O
- O
pen O
##et O
##rance O
p O
##hen O
##otype O
with O
many O
individuals O
being O
un O
##af O
##fected O
, O
un O
##ila O
##teral O
##ly O
affected O
, O
or O
with O
evidence O
of O
spontaneous O
##ly O
re O
##g O
##ressed O
tumors B-Disease
. O

we O
have O
used O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
and O
p O
##c O
##r O
se O
##quencing O
to O
study O
two O
such O
families O
. O

mutations O
were O
found O
in O
ex O
##on O
20 O
of O
r O
##b O
##1 O
in O
both O
cases O
. O

in O
one O
family O
a O
c O
- O
- O
- O
- O
t O
transition O
in O
co O
##don O
66 O
##1 O
converts O
an O
a O
##rg O
##ini O
##ne O
( O
c O
##gg O
) O
to O
a O
try O
##pt O
##op O
##han O
( O
t O
##gg O
) O
co O
##don O
. O

in O
this O
family O
, O
incomplete O
pen O
##et O
##rance O
and O
mild O
p O
##hen O
##otypic O
expression O
were O
observed O
in O
virtually O
all O
patients O
, O
possibly O
indicating O
that O
single O
amino O
acid O
changes O
may O
modify O
protein O
structure O
/ O
function O
such O
that O
tumor O
##ige O
##nes O
##is O
is O
not O
inevitable O
. O

in O
the O
second O
family O
the O
mutation O
in O
co O
##don O
67 O
##5 O
is O
a O
g O
- O
- O
- O
- O
t O
trans O
##version O
that O
converts O
a O
g O
##lut O
##amine O
( O
g O
##aa O
) O
to O
a O
stop O
( O
ta O
##a O
) O
co O
##don O
. O

however O
, O
this O
mutation O
also O
occurs O
near O
a O
potential O
cry O
##ptic O
s O
##p O
##lice O
accept O
##or O
site O
, O
raising O
the O
possibility O
of O
alternative O
s O
##p O
##licing O
resulting O
in O
a O
less O
severely O
disrupted O
protein O
. O
. O

late O
- O
onset O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
: O
molecular O
path O
##ology O
in O
two O
siblings O
. O

we O
report O
on O
a O
new O
all O
##ele O
at O
the O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
lo O
##cus O
causing O
late O
- O
onset O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
. O

in O
that O
all O
##ele O
a O
##rg O
##ini O
##ne O
##8 O
##4 O
, O
a O
residue O
that O
is O
highly O
conserved O
in O
the O
a O
##ryl O
##sul O
##fa O
##tase O
gene O
family O
, O
is O
replaced O
by O
g O
##lut O
##amine O
. O

in O
contrast O
to O
all O
##ele O
##s O
that O
cause O
early O
- O
onset O
m B-Disease
##ld I-Disease
, O
the O
a O
##rg O
##ini O
##ne O
##8 O
##4 O
to O
g O
##lut O
##amine O
substitution O
is O
associated O
with O
some O
residual O
a O
##rsa O
activity O
. O

a O
comparison O
of O
g O
##eno O
##type O
##s O
, O
a O
##rsa O
activities O
, O
and O
clinical O
data O
on O
4 O
individuals O
carrying O
the O
all O
##ele O
of O
81 O
patients O
with O
m B-Disease
##ld I-Disease
examined O
, O
further O
valid O
##ates O
the O
concept O
that O
different O
degrees O
of O
residual O
a O
##rsa O
activity O
are O
the O
basis O
of O
p O
##hen O
##otypic O
##al O
variation O
in O
m B-Disease
##ld I-Disease
. O
. O

t B-Disease
##ris I-Disease
##omy I-Disease
15 I-Disease
with O
loss O
of O
the O
paternal O
15 O
as O
a O
cause O
of O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
due O
to O
maternal B-Disease
di I-Disease
##so I-Disease
##my I-Disease
. O

un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
has O
recently O
been O
recognized O
to O
cause O
human O
disorders O
, O
including O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

we O
describe O
a O
particularly O
ins O
##truct O
##ive O
case O
which O
raises O
important O
issues O
concerning O
the O
mechanisms O
producing O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
and O
whose O
evaluation O
provides O
evidence O
that O
t O
##ris O
##omy O
may O
pre O
##cede O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
in O
a O
f O
##etus O
. O

ch O
##orio O
##nic O
v O
##ill O
##us O
sampling O
performed O
for O
advanced O
maternal O
age O
revealed O
t B-Disease
##ris I-Disease
##omy I-Disease
15 I-Disease
in O
all O
direct O
and O
culture O
##d O
cells O
, O
though O
the O
f O
##etus O
appeared O
normal O
. O

chromosome O
analysis O
of O
am O
##nio O
##cy O
##tes O
obtained O
at O
15 O
w O
##k O
was O
normal O
in O
over O
100 O
cells O
studied O
. O

the O
child O
was O
h B-Disease
##y I-Disease
##pot I-Disease
##onic I-Disease
at O
birth O
, O
and O
high O
- O
resolution O
band O
##ing O
failed O
to O
reveal O
the O
del O
##eti O
##on O
of O
15 O
##q O
##11 O
- O
13 O
, O
a O
del O
##eti O
##on O
which O
is O
found O
in O
50 O
% O
- O
70 O
% O
of O
patients O
with O
p B-Disease
##ws I-Disease
. O

over O
time O
, O
typical O
features O
of O
p B-Disease
##ws I-Disease
developed O
. O

molecular O
genetic O
analysis O
using O
probe O
##s O
for O
chromosome O
15 O
revealed O
maternal O
di O
##so O
##my O
. O

maternal O
non O
##dis O
##junct O
##ion O
with O
f O
##ert O
##ilization O
of O
a O
di O
##so O
##mic O
egg O
by O
a O
normal O
sperm O
, O
followed O
by O
loss O
of O
the O
paternal O
15 O
, O
is O
a O
likely O
cause O
of O
confined O
place O
##ntal O
mosaic O
##ism O
and O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
in O
this O
case O
of O
p B-Disease
##ws I-Disease
, O
and O
advanced O
maternal O
age O
may O
be O
a O
pre O
##dis O
##po O
##sing O
factor O
. O
. O

genetic O
he O
##tero O
##gene O
##ity O
in O
x B-Disease
- I-Disease
linked I-Disease
am I-Disease
##elo I-Disease
##genesis I-Disease
imp I-Disease
##er I-Disease
##fect I-Disease
##a I-Disease
. O

the O
am O
##el O
##x O
gene O
located O
at O
x O
##p O
##22 O
. O

1 O
- O
p O
##22 O
. O

3 O
en O
##codes O
for O
the O
en O
##amel O
protein O
am O
##elo O
##gen O
##in O
and O
has O
been O
implicated O
as O
the O
gene O
responsible O
for O
the O
inherited B-Disease
dental I-Disease
abnormal I-Disease
##ity I-Disease
x B-Disease
- I-Disease
linked I-Disease
am I-Disease
##elo I-Disease
##genesis I-Disease
imp I-Disease
##er I-Disease
##fect I-Disease
##a I-Disease
( O
x B-Disease
##ai I-Disease
) O
. O

three O
families O
with O
x B-Disease
##ai I-Disease
have O
been O
investigated O
using O
p O
##oly O
##morphic O
d O
##na O
markers O
flank O
##ing O
the O
position O
of O
am O
##el O
##x O
. O

using O
two O
- O
point O
link O
##age O
analysis O
, O
link O
##age O
was O
established O
between O
x B-Disease
##ai I-Disease
and O
several O
of O
these O
markers O
in O
two O
families O
, O
with O
a O
combined O
lo O
##d O
score O
of O
6 O
. O

05 O
for O
d O
##x O
##s O
##16 O
at O
the O
##ta O
= O
0 O
. O

04 O
04 O
. O

this O
supports O
the O
involvement O
of O
am O
##el O
##x O
, O
located O
close O
to O
d O
##x O
##s O
##16 O
, O
in O
the O
x B-Disease
##ai I-Disease
disease I-Disease
process O
( O
a O
##ih O
##1 O
) O
in O
those O
families O
. O

using O
multi O
##point O
link O
##age O
analysis O
, O
the O
combined O
maximum O
lo O
##d O
score O
for O
these O
two O
families O
was O
7 O
. O

30 O
for O
a O
location O
of O
a O
##ih O
##1 O
at O
2 O
cm O
di O
##stal O
to O
d O
##x O
##s O
##16 O
. O

the O
support O
interval O
around O
this O
location O
extended O
about O
8 O
cm O
pro O
##ximal O
to O
d O
##x O
##s O
##9 O
##2 O
, O
and O
the O
a O
##ih O
##1 O
location O
could O
not O
be O
precisely O
defined O
by O
multi O
##point O
mapping O
. O

study O
of O
re O
##comb O
##ination O
events O
indicated O
that O
a O
##ih O
##1 O
lies O
in O
the O
interval O
between O
d O
##x O
##s O
##14 O
##3 O
and O
d O
##x O
##s O
##8 O
##5 O
. O

there O
was O
significant O
evidence O
against O
link O
##age O
to O
this O
region O
in O
the O
third O
family O
, O
indicating O
lo O
##cus O
he O
##tero O
##gene O
##ity O
in O
x B-Disease
##ai I-Disease
. O

further O
analysis O
with O
markers O
on O
the O
long O
arm O
of O
the O
x O
chromosome O
showed O
evidence O
of O
link O
##age O
to O
d O
##x O
##s O
##14 O
##4 O
##e O
and O
f O
##9 O
with O
no O
re O
##comb O
##ination O
with O
either O
of O
these O
markers O
. O

two O
- O
point O
analysis O
gave O
a O
peak O
lo O
##d O
score O
at O
d O
##x O
##s O
##14 O
##4 O
##e O
with O
a O
maximum O
lo O
##d O
score O
of O
2 O
. O

83 O
at O
the O
##ta O
= O
0 O
, O
with O
a O
peak O
lo O
##d O
score O
in O
multi O
##point O
link O
##age O
analysis O
of O
2 O
. O

84 O
at O
the O
##ta O
= O
0 O
. O

the O
support O
interval O
extended O
9 O
cm O
pro O
##ximal O
to O
d O
##x O
##s O
##14 O
##4 O
##e O
and O
14 O
cm O
di O
##stal O
to O
f O
##9 O
. O

( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
. O

multiple O
origins O
for O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
in O
euro O
##pe O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
, O
a O
disorder B-Disease
of I-Disease
amino I-Disease
acid I-Disease
metabolism I-Disease
prevalent O
among O
ca O
##uca O
##sian O
##s O
and O
other O
ethnic O
groups O
, O
is O
caused O
primarily O
by O
a O
deficiency B-Disease
of I-Disease
the I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
enzyme I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

p B-Disease
##ku I-Disease
is O
a O
highly O
he O
##tero O
##gene O
##ous O
disorder O
, O
with O
more O
than O
60 O
molecular O
lesions O
identified O
in O
the O
p O
##ah O
gene O
. O

the O
ha O
##p O
##lot O
##ype O
associations O
, O
relative O
frequencies O
, O
and O
distributions O
of O
five O
prevalent O
p O
##ah O
mutations O
( O
r O
##15 O
##8 O
##q O
, O
r O
##26 O
##1 O
##q O
, O
i O
##v O
##s O
##10 O
##nt O
##5 O
##46 O
, O
r O
##40 O
##8 O
##w O
, O
and O
i O
##v O
##s O
##12 O
##n O
##1 O
) O
were O
established O
in O
a O
comprehensive O
euro O
##pe O
##an O
sample O
population O
and O
subsequently O
were O
examined O
to O
determine O
the O
potential O
roles O
of O
several O
genetic O
mechanisms O
in O
explaining O
the O
present O
distribution O
of O
the O
major O
p B-Disease
##ku I-Disease
all O
##ele O
##s O
. O

each O
of O
these O
five O
mutations O
was O
strongly O
associated O
with O
only O
one O
of O
the O
more O
than O
70 O
ch O
##rom O
##oso O
##mal O
ha O
##p O
##lot O
##ype O
##s O
defined O
by O
eight O
r O
##f O
##l O
##ps O
in O
or O
near O
the O
p O
##ah O
gene O
. O

these O
findings O
suggest O
that O
each O
of O
these O
mutations O
arose O
through O
a O
single O
founding O
event O
that O
occurred O
within O
time O
periods O
ranging O
from O
several O
hundred O
to O
several O
thousand O
years O
ago O
. O

from O
the O
significant O
differences O
observed O
in O
the O
relative O
frequencies O
and O
distributions O
of O
these O
five O
all O
##ele O
##s O
throughout O
euro O
##pe O
, O
four O
of O
these O
put O
##ative O
founding O
events O
could O
be O
localized O
to O
specific O
ethnic O
subgroup O
##s O
. O

together O
, O
these O
data O
suggest O
that O
there O
were O
multiple O
, O
geographically O
and O
ethnic O
##ally O
distinct O
origins O
for O
p B-Disease
##ku I-Disease
within O
the O
euro O
##pe O
##an O
population O
. O
. O

complement B-Disease
factor I-Disease
2 I-Disease
deficiency I-Disease
: O
a O
clinical O
and O
se O
##rol O
##ogical O
family O
study O
. O

inherited B-Disease
complement I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
are O
associated O
with O
a O
variety O
of O
connect O
##ive O
tissue O
diseases O
. O

a O
family O
with O
inherited B-Disease
deficiency I-Disease
of I-Disease
complement I-Disease
factor I-Disease
2 I-Disease
( O
c O
##2 O
) O
is O
described O
in O
which O
two O
family O
members O
with O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
developed O
cut B-Disease
##aneous I-Disease
v I-Disease
##as I-Disease
##cu I-Disease
##lit I-Disease
##is I-Disease
and O
sic B-Disease
##ca I-Disease
syndrome I-Disease
. O

the O
other O
family O
members O
had O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
and O
each O
member O
had O
the O
h O
##la O
- O
a O
##25 O
, O
b O
##18 O
, O
d O
##r O
##2 O
( O
w O
##15 O
) O
ha O
##p O
##lot O
##ype O
. O

the O
mother O
had O
se B-Disease
##rop I-Disease
##os I-Disease
##itive I-Disease
r I-Disease
##he I-Disease
##uma I-Disease
##to I-Disease
##id I-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
. O

further O
studies O
showed O
the O
presence O
of O
cry O
##og O
##lo O
##bul O
##ins O
, O
antibodies O
against O
end O
##oth O
##eli O
##al O
cells O
, O
and O
anti O
##card O
##iol O
##ip O
##in O
antibodies O
. O
. O

new O
variant O
in O
ex O
##on O
3 O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
in O
a O
family O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

a O
c O
- O
- O
greater O
than O
g O
trans O
##version O
has O
been O
found O
in O
ex O
##on O
3 O
of O
the O
p O
##l O
##p O
gene O
of O
affected O
males O
and O
their O
mother O
in O
a O
single O
si O
##bs O
##hip O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
. O

the O
trans O
##version O
should O
not O
result O
in O
an O
amino O
acid O
change O
in O
the O
protein O
but O
it O
does O
result O
in O
the O
loss O
of O
a O
ha O
##ei O
##ii O
restriction O
end O
##on O
##uc O
##lea O
##se O
c O
##lea O
##vage O
site O
. O

it O
is O
con O
##cor O
##dant O
with O
the O
disease O
in O
this O
family O
. O

one O
- O
hundred O
- O
ten O
unrelated O
x O
chromosome O
##s O
are O
negative O
for O
this O
mutation O
. O

no O
other O
sequence O
defect O
was O
found O
in O
the O
p O
##l O
##p O
ex O
##ons O
of O
the O
affected O
males O
. O

the O
cause O
of O
disease O
in O
this O
family O
remains O
unknown O
, O
but O
the O
association O
between O
this O
rare O
mutation O
and O
pm B-Disease
##d I-Disease
is O
intriguing O
. O

the O
mutation O
can O
serve O
as O
a O
marker O
for O
following O
segregation O
of O
the O
p O
##l O
##p O
gene O
. O
. O

un O
##co O
##up O
##ling O
of O
h B-Disease
##y I-Disease
##po I-Disease
##my I-Disease
##elin I-Disease
##ation I-Disease
and O
g B-Disease
##lial I-Disease
cell I-Disease
death I-Disease
by O
a O
mutation O
in O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
. O

pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
; O
m O
( O
r O
) O
30 O
, O
000 O
) O
is O
a O
highly O
conserved O
major O
p O
##oly O
##top O
##ic O
membrane O
protein O
in O
my O
##elin O
but O
its O
cellular O
function O
remains O
obscure O
. O

ne O
##uro O
##logical O
mutant O
mice O
can O
often O
provide O
model O
systems O
for O
human O
genetic B-Disease
disorders I-Disease
. O

mutations O
of O
the O
x O
- O
chromosome O
- O
linked O
p O
##l O
##p O
gene O
are O
lethal O
, O
identified O
first O
in O
the O
ji O
##mp O
##y O
mouse O
and O
subsequently O
in O
patients O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

the O
une O
##x O
##plain O
##ed O
p O
##hen O
##otype O
of O
these O
mutations O
includes O
de B-Disease
##gene I-Disease
##ration I-Disease
and I-Disease
premature I-Disease
cell I-Disease
death I-Disease
of I-Disease
o I-Disease
##li I-Disease
##go I-Disease
##den I-Disease
##dr I-Disease
##ocytes I-Disease
with O
associated O
h B-Disease
##y I-Disease
##po I-Disease
##my I-Disease
##elin I-Disease
##ation I-Disease
. O

here O
we O
show O
that O
a O
new O
mouse O
mutant O
r O
##ump O
##sha O
##ker O
is O
defined O
by O
the O
amino O
- O
acid O
substitution O
il O
##e O
- O
to O
- O
th O
##r O
at O
residue O
186 O
in O
a O
membrane O
- O
embedded O
domain O
of O
p O
##l O
##p O
. O

surprisingly O
, O
r O
##ump O
##sha O
##ker O
mice O
, O
although O
my B-Disease
##elin I-Disease
- I-Disease
def I-Disease
##icient I-Disease
, O
have O
normal O
long O
##evity O
and O
a O
full O
complement O
of O
m O
##or O
##phological O
##ly O
normal O
o O
##li O
##go O
##den O
##dr O
##ocytes O
. O

h B-Disease
##y I-Disease
##po I-Disease
##my I-Disease
##elin I-Disease
##ation I-Disease
can O
thus O
be O
genetically O
separated O
from O
the O
p O
##l O
##p O
- O
dependent O
o B-Disease
##li I-Disease
##go I-Disease
##den I-Disease
##dr I-Disease
##oc I-Disease
##yte I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
. O

we O
suggest O
that O
p O
##l O
##p O
has O
a O
vital O
function O
in O
g O
##lial O
cell O
development O
, O
distinct O
from O
its O
later O
role O
in O
my O
##elin O
assembly O
, O
and O
that O
this O
di O
##cho O
##tom O
##y O
of O
action O
may O
explain O
the O
clinical O
spectrum O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O
. O

a O
pseudo O
##de O
##ficiency O
all O
##ele O
common O
in O
non O
- O
j O
##ew O
##ish O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
carriers O
: O
implications O
for O
carrier O
screening O
. O

deficiency B-Disease
of I-Disease
beta I-Disease
- I-Disease
he I-Disease
##x I-Disease
##osa I-Disease
##mini I-Disease
##das I-Disease
##e I-Disease
a I-Disease
( O
he O
##x O
a O
) O
activity O
typically O
results O
in O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
. O

however O
, O
healthy O
subjects O
found O
to O
be O
def B-Disease
##icient I-Disease
in I-Disease
he I-Disease
##x I-Disease
a I-Disease
activity O
( O
i O
. O
e O
. O
, O
pseudo O
##de O
##ficient O
) O
by O
means O
of O
in O
v O
##it O
##ro O
bio O
##chemical O
tests O
have O
been O
described O
. O

we O
analyzed O
the O
he O
##xa O
gene O
of O
one O
pseudo O
##de O
##ficient O
subject O
and O
identified O
both O
a O
c O
##7 O
##39 O
- O
to O
- O
t O
substitution O
that O
changes O
a O
##rg O
##24 O
##7 O
- O
- O
- O
- O
t O
##rp O
on O
one O
all O
##ele O
and O
a O
previously O
identified O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
mutation O
on O
the O
second O
all O
##ele O
. O

six O
additional O
pseudo O
##de O
##ficient O
subjects O
were O
found O
to O
have O
the O
c O
##7 O
##39 O
- O
to O
- O
t O
mutation O
. O

this O
all O
##ele O
accounted O
for O
32 O
% O
( O
20 O
/ O
62 O
) O
of O
non O
- O
j O
##ew O
##ish O
enzyme O
- O
defined O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
carriers O
but O
for O
none O
of O
36 O
j O
##ew O
##ish O
enzyme O
- O
defined O
carriers O
who O
did O
not O
have O
one O
of O
three O
known O
mutations O
common O
to O
this O
group O
. O

the O
c O
##7 O
##39 O
- O
to O
- O
t O
all O
##ele O
, O
together O
with O
a O
" O
true O
" O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
all O
##ele O
, O
causes O
he O
##x O
a O
pseudo O
##de O
##ficiency O
. O

given O
both O
the O
large O
proportion O
of O
non O
- O
j O
##ew O
##ish O
carriers O
with O
this O
all O
##ele O
and O
that O
standard O
bio O
##chemical O
screening O
cannot O
differentiate O
between O
he O
##tero O
##zy O
##got O
##es O
for O
the O
c O
##7 O
##39 O
- O
to O
- O
t O
mutations O
and O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
carriers O
, O
d O
##na O
testing O
for O
this O
mutation O
in O
at O
- O
risk O
couples O
is O
essential O
. O

p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
: O
detection O
of O
mutations O
th O
##r O
##18 O
##1 O
- O
- O
- O
- O
pro O
and O
le O
##u O
##22 O
##3 O
- O
- O
- O
- O
pro O
in O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
, O
and O
pre O
##nat O
##al O
diagnosis O
. O

a O
family O
with O
an O
apparent O
history O
of O
x O
- O
linked O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
presented O
for O
genetic O
counseling O
, O
requesting O
carrier O
detection O
and O
pre O
##nat O
##al O
diagnosis O
. O

r O
##f O
##l O
##p O
analysis O
using O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
probe O
was O
un O
##in O
##form O
##ative O
in O
this O
family O
. O

a O
pre O
##nat O
##al O
diagnosis O
on O
a O
ch O
##orio O
##nic O
v O
##ill O
##us O
sample O
( O
c O
##v O
##s O
) O
was O
carried O
out O
using O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
analysis O
of O
a O
variant O
in O
ex O
##on O
4 O
of O
the O
p O
##l O
##p O
gene O
. O

the O
f O
##etus O
was O
predicted O
to O
be O
un O
##af O
##fected O
. O

se O
##quencing O
of O
the O
ex O
##on O
from O
the O
c O
##v O
##s O
, O
the O
predicted O
- O
carrier O
mother O
, O
and O
the O
o O
##b O
##liga O
##te O
- O
carrier O
grandmother O
revealed O
an O
a O
- O
to O
- O
c O
change O
at O
n O
##uc O
##leo O
##tide O
54 O
##1 O
in O
the O
two O
women O
but O
not O
in O
the O
f O
##etus O
. O

as O
this O
change O
results O
in O
a O
th O
##r O
- O
to O
- O
pro O
change O
at O
amino O
acid O
181 O
in O
a O
region O
of O
the O
gene O
predicted O
to O
be O
part O
of O
a O
trans O
##me O
##mb O
##rane O
segment O
, O
it O
was O
concluded O
that O
this O
was O
the O
mutation O
causing O
the O
disease O
in O
this O
family O
. O

in O
addition O
, O
in O
a O
second O
family O
, O
an O
ex O
##on O
5 O
variant O
band O
pattern O
on O
s O
##s O
##c O
##p O
analysis O
was O
shown O
by O
se O
##quencing O
to O
be O
due O
to O
a O
t O
- O
to O
- O
c O
change O
at O
n O
##uc O
##leo O
##tide O
66 O
##8 O
. O

this O
results O
in O
a O
le O
##u O
- O
to O
- O
pro O
change O
in O
a O
carrier O
mother O
and O
in O
her O
two O
affected O
sons O
. O

these O
results O
provide O
further O
examples O
of O
mutations O
in O
p O
##l O
##p O
that O
cause O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
and O
illustrate O
the O
value O
of O
s O
##s O
##c O
##p O
in O
genetic O
analysis O
. O
. O

von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
type I-Disease
b I-Disease
: O
a O
miss O
##ense O
mutation O
selective O
##ly O
a O
##bol O
##ishes O
r O
##ist O
##oc O
##eti O
##n O
- O
induced O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
binding O
to O
plate O
##let O
g O
##ly O
##co O
##p O
##rote O
##in O
i O
##b O
. O

von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
( O
v O
##w O
##f O
) O
is O
a O
multi O
##mer O
##ic O
g O
##ly O
##co O
##p O
##rote O
##in O
that O
media O
##tes O
the O
ad O
##hesion O
of O
plate O
##lets O
to O
the O
sub O
##end O
##oth O
##eli O
##um O
by O
binding O
to O
plate O
##let O
g O
##ly O
##co O
##p O
##rote O
##in O
i O
##b O
. O

for O
human O
v O
##w O
##f O
, O
this O
interaction O
can O
be O
induced O
in O
v O
##it O
##ro O
by O
the O
anti O
##biotic O
r O
##ist O
##oc O
##eti O
##n O
or O
the O
snake O
venom O
protein O
b O
##ot O
##ro O
##ce O
##tin O
. O

a O
miss O
##ense O
mutation O
, O
g O
##ly O
- O
56 O
##1 O
- O
- O
[UNK] O
se O
##r O
, O
was O
identified O
within O
the O
proposed O
g O
##ly O
##co O
##p O
##rote O
##in O
i O
##b O
binding O
domain O
of O
v O
##w O
##f O
in O
the O
pro O
##band O
with O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
type I-Disease
b I-Disease
, O
a O
unique O
variant O
characterized O
by O
no O
r O
##ist O
##oc O
##eti O
##n O
- O
induced O
, O
but O
normal O
b O
##ot O
##ro O
##ce O
##tin O
- O
induced O
, O
binding O
to O
g O
##ly O
##co O
##p O
##rote O
##in O
i O
##b O
. O

the O
corresponding O
mutant O
re O
##comb O
##ina O
##nt O
protein O
, O
r O
##v O
##w O
##f O
( O
g O
##5 O
##6 O
##1 O
##s O
) O
, O
formed O
normal O
multi O
##mers O
and O
exhibited O
the O
same O
functional O
defect O
as O
the O
patients O
plasma O
v O
##w O
##f O
, O
confirming O
that O
this O
mutation O
causes O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
type I-Disease
b I-Disease
. O

these O
data O
show O
that O
b O
##ot O
##ro O
##ce O
##tin O
and O
r O
##ist O
##oc O
##eti O
##n O
co O
##fa O
##ctor O
activities O
of O
v O
##w O
##f O
can O
be O
di O
##sso O
##cia O
##ted O
by O
a O
point O
mutation O
and O
confirm O
that O
these O
media O
##tors O
promote O
v O
##w O
##f O
binding O
to O
plate O
##lets O
by O
different O
mechanisms O
. O

the O
normal O
b O
##ot O
##ro O
##ce O
##tin O
- O
induced O
binding O
and O
the O
defect O
##ive O
r O
##ist O
##oc O
##eti O
##n O
- O
induced O
binding O
of O
r O
##v O
##w O
##f O
( O
g O
##5 O
##6 O
##1 O
##s O
) O
suggest O
that O
the O
primary O
defect O
in O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
type I-Disease
b I-Disease
may O
be O
a O
failure O
of O
normal O
all O
##ost O
##eric O
regulation O
of O
the O
g O
##ly O
##co O
##p O
##rote O
##in O
i O
##b O
binding O
function O
of O
v O
##w O
##f O
. O
. O

typical O
and O
partial O
cat B-Disease
eye I-Disease
syndrome I-Disease
: O
identification O
of O
the O
marker O
chromosome O
by O
fish O
. O

three O
children O
are O
reported O
with O
typical O
cat B-Disease
eye I-Disease
syndrome I-Disease
( O
c B-Disease
##es I-Disease
) O
and O
three O
more O
children O
with O
partial O
c B-Disease
##es I-Disease
because O
of O
absence O
of O
co O
##lo O
##bo O
##ma O
, O
in O
which O
the O
super O
##num O
##era O
##ry O
marker O
chromosome O
was O
studied O
by O
fish O
. O

using O
a O
g O
##eno O
##mic O
library O
, O
and O
also O
a O
cent O
##rome O
##ric O
and O
particularly O
a O
co O
##sm O
##id O
probe O
of O
22 O
##q O
##11 O
, O
partial O
te B-Disease
##tras I-Disease
##omy I-Disease
was O
shown O
in O
all O
cases O
. O
. O

[ O
genetic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
: O
mutant O
all O
##ele O
##s O
of O
g O
##6 O
##p O
##d O
in O
the O
she O
##ki O
##i O
district O
of O
a O
##zer O
##ba O
##ija O
##n O
] O

examination O
on O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
34 O
##9 O
patients O
of O
she O
##ki O
##i O
district O
hospital O
( O
a O
##zer O
##ba O
##ija O
##n O
) O
revealed O
16 O
hem O
##i O
- O
, O
4 O
ho O
##mo O
- O
and O
9 O
he O
##tero O
##zy O
##got O
##ic O
carriers O
of O
the O
defect O
. O

g O
##d O
- O
frequency O
, O
calculated O
from O
the O
data O
obtained O
( O
7 O
. O
7 O
% O
) O
, O
may O
be O
compared O
to O
neighbouring O
regions O
frequencies O
( O
6 O
- O
30 O
% O
) O
. O

carriers O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
are O
residents O
of O
11 O
villages O
located O
in O
al O
##asa O
##ni O
- O
a O
##ph O
##tal O
##an O
valley O
, O
highly O
endemic O
with O
malaria B-Disease
in O
the O
past O
; O
nearly O
all O
marriages O
are O
end O
##oga O
##mic O
. O

p O
##hy O
##si O
##co O
- O
chemical O
and O
kinetic O
study O
of O
10 O
mutant O
forms O
of O
g O
##6 O
##p O
##d O
, O
according O
to O
who O
program O
, O
led O
to O
identification O
of O
5 O
variants O
of O
the O
ii O
class O
( O
she O
##ki O
##i O
, O
bid O
##ei O
##z O
, O
s O
##hir O
##in O
- O
b O
##ula O
##kh O
, O
ok O
##hu O
##t O
i O
and O
z O
##aka O
##tal O
##y O
) O
and O
2 O
variants O
of O
the O
ii O
##i O
class O
( O
ok O
##hu O
##t O
ii O
and O
ma O
##rt O
##ini O
##que O
- O
like O
) O
. O

resemblance O
of O
the O
majority O
of O
variants O
in O
electro O
##ph O
##ore O
##tic O
mobility O
and O
the O
level O
of O
er O
##yt O
##hr O
##oc O
##yte O
enzyme O
activity O
permit O
to O
suggest O
the O
existence O
of O
a O
common O
parental O
mutant O
g O
##6 O
##p O
##d O
all O
##ele O
distributed O
in O
this O
area O
. O

c B-Disease
##rani I-Disease
##of I-Disease
##ron I-Disease
##ton I-Disease
##asa I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

we O
report O
on O
nine O
patients O
with O
c B-Disease
##rani I-Disease
##of I-Disease
##ron I-Disease
##ton I-Disease
##asa I-Disease
##l I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
( O
c B-Disease
##f I-Disease
##nd I-Disease
) O
. O

seven O
classical O
cases O
had O
facial O
features O
suggest O
##ive O
of O
front B-Disease
##ona I-Disease
##sal I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
and O
co B-Disease
##rona I-Disease
##l I-Disease
c I-Disease
##rani I-Disease
##osy I-Disease
##nos I-Disease
##tosis I-Disease
. O

extra B-Disease
##c I-Disease
##rani I-Disease
##al I-Disease
abnormal I-Disease
##ities I-Disease
such O
as O
br B-Disease
##ittle I-Disease
nails I-Disease
with I-Disease
prominent I-Disease
longitudinal I-Disease
groove I-Disease
##s I-Disease
or O
s B-Disease
##yn I-Disease
##da I-Disease
##ct I-Disease
##yl I-Disease
##y I-Disease
of I-Disease
fingers I-Disease
and I-Disease
toes I-Disease
were O
observed O
in O
individual O
patients O
. O

in O
two O
families O
the O
father O
of O
classical O
cases O
showed O
a O
mild O
##er O
pattern O
of O
abnormal O
##ities O
, O
consistent O
with O
the O
diagnosis O
. O

we O
present O
a O
2 O
- O
to O
13 O
- O
year O
follow O
- O
up O
on O
our O
patients O
. O

h B-Disease
##y I-Disease
##pot I-Disease
##onia I-Disease
and O
la B-Disease
##xi I-Disease
##ty I-Disease
of I-Disease
joints I-Disease
are O
common O
and O
may O
ne O
##cess O
##itate O
supportive O
measures O
. O

mild O
developmental B-Disease
delay I-Disease
was O
noted O
in O
three O
out O
of O
six O
classical O
cases O
studied O
in O
detail O
. O

unlike O
almost O
all O
other O
x B-Disease
- I-Disease
linked I-Disease
disorders I-Disease
, O
clinical O
expression O
in O
c B-Disease
##f I-Disease
##nd I-Disease
is O
generally O
much O
more O
severe O
in O
females O
than O
in O
males O
. O

in O
contrast O
to O
previous O
reports O
of O
this O
condition O
, O
one O
of O
our O
severely O
affected O
cases O
is O
a O
male O
. O
. O

the O
intro O
##n O
7 O
donor O
s O
##p O
##lice O
site O
transition O
: O
a O
second O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
mutation O
in O
f O
##rench O
can O
##ada O
. O

mutations O
at O
the O
he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
he O
##xa O
) O
gene O
which O
cause O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
have O
elevated O
frequency O
in O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
and O
f O
##rench O
- O
can O
##adia O
##n O
populations O
. O

we O
report O
a O
novel O
t B-Disease
##s I-Disease
##d I-Disease
all O
##ele O
in O
the O
f O
##rench O
- O
can O
##adia O
##n O
population O
associated O
with O
the O
infant O
##ile O
form O
of O
the O
disease O
. O

the O
mutation O
, O
a O
g O
- O
- O
[UNK] O
a O
transition O
at O
the O
+ O
1 O
position O
of O
intro O
##n O
7 O
, O
a O
##bol O
##ishes O
the O
donor O
s O
##p O
##lice O
site O
. O

culture O
##d O
human O
fi O
##bro O
##blast O
##s O
from O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
for O
this O
transition O
( O
and O
for O
a O
del O
##eti O
##on O
mutation O
) O
produce O
no O
detect O
##able O
he O
##xa O
m O
##rna O
. O

the O
intro O
##n O
7 O
+ O
1 O
mutation O
occurs O
in O
the O
base O
adjacent O
to O
the O
site O
of O
the O
adult O
- O
onset O
t B-Disease
##s I-Disease
##d I-Disease
mutation O
( O
g O
##80 O
##5 O
##a O
) O
. O

in O
both O
mutations O
a O
restriction O
site O
for O
the O
end O
##on O
##uc O
##lea O
##se O
e O
##cor O
##ii O
is O
abolished O
. O

un O
##am O
##bi O
##guous O
diagnosis O
, O
therefore O
, O
requires O
all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
hybrid O
##ization O
to O
distinguish O
between O
these O
two O
mutant O
all O
##ele O
##s O
. O

the O
intro O
##n O
7 O
+ O
1 O
mutation O
has O
been O
detected O
in O
three O
unrelated O
families O
. O

o O
##b O
##liga O
##te O
he O
##tero O
##zy O
##got O
##es O
for O
the O
intro O
##n O
7 O
+ O
1 O
mutation O
were O
born O
in O
the O
sa O
##gue O
##nay O
- O
la O
##c O
- O
s O
##t O
- O
j O
##ean O
region O
of O
que O
##be O
##c O
. O

the O
most O
recent O
ancestors O
common O
to O
o O
##b O
##liga O
##te O
carriers O
of O
this O
mutation O
were O
from O
the O
ch O
##ar O
##lev O
##oi O
##x O
region O
of O
the O
province O
of O
que O
##be O
##c O
. O

this O
mutation O
thus O
has O
a O
different O
geographic O
centre O
of O
diffusion O
and O
is O
probably O
less O
common O
than O
the O
ex O
##on O
1 O
del O
##eti O
##on O
t B-Disease
##s I-Disease
##d I-Disease
mutation O
in O
f O
##rench O
can O
##adia O
##ns O
. O

neither O
mutation O
has O
been O
detected O
in O
f O
##rance O
, O
the O
ancestral O
homeland O
of O
f O
##rench O
can O
##ada O
. O
. O

assignment O
of O
the O
as O
##par O
##ty O
##l O
##g O
##lu O
##cos O
##ami O
##ni O
##das O
##e O
gene O
( O
a O
##ga O
) O
to O
4 O
##q O
##33 O
- O
- O
- O
- O
q O
##35 O
based O
on O
decreased O
activity O
in O
a O
girl O
with O
a O
46 O
, O
x O
##x O
, O
del O
( O
4 O
) O
( O
q O
##33 O
) O
ka O
##ryo O
##type O
. O

as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
( O
a B-Disease
##gu I-Disease
) O
is O
a O
re O
##cess O
##ive O
auto O
##so O
##mal O
##ly O
inherited O
l B-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
due O
to O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
as I-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##ni I-Disease
##das I-Disease
##e I-Disease
( O
a O
##ga O
) O
. O

the O
structural O
gene O
for O
this O
human O
enzyme O
( O
a O
##ga O
) O
has O
been O
assigned O
to O
the O
region O
4 O
##q O
##21 O
- O
- O
- O
- O
q O
##ter O
. O

we O
determined O
the O
a O
##ga O
activity O
in O
culture O
##d O
fi O
##bro O
##blast O
##s O
of O
a O
girl O
with O
a O
46 O
, O
x O
##x O
, O
del O
( O
4 O
) O
( O
q O
##33 O
) O
ka O
##ryo O
##type O
. O

the O
results O
indicate O
that O
the O
girl O
is O
a O
hem O
##iz O
##y O
##got O
##e O
for O
a O
##ga O
, O
permitting O
the O
assignment O
of O
human O
a O
##ga O
to O
the O
region O
4 O
##q O
##33 O
- O
- O
- O
- O
q O
##ter O
. O
. O

resolution O
of O
the O
two O
lo O
##ci O
for O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
an O
##1 O
and O
an O
##2 O
, O
to O
a O
single O
lo O
##cus O
on O
chromosome O
11 O
##p O
##13 O
. O

two O
distinct O
lo O
##ci O
have O
been O
proposed O
for O
an B-Disease
##iri I-Disease
##dia I-Disease
; O
an O
##1 O
for O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
on O
chromosome O
2 O
##p O
and O
an O
##2 O
for O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
in O
the O
wa B-Disease
##g I-Disease
##r I-Disease
con I-Disease
##ti I-Disease
##guous I-Disease
gene I-Disease
syndrome I-Disease
on O
chromosome O
11 O
##p O
##13 O
. O

in O
this O
report O
, O
the O
kind O
##red O
se O
##g O
##re O
##gating O
for O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
which O
suggested O
link O
##age O
to O
acid O
p O
##hos O
##pha O
##tase O
- O
1 O
( O
a O
##c O
##p O
##1 O
) O
and O
led O
to O
the O
assignment O
of O
the O
an O
##1 O
lo O
##cus O
on O
chromosome O
2 O
##p O
, O
has O
been O
updated O
and O
expanded O
. O

link O
##age O
analysis O
between O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
p O
##hen O
##otype O
and O
a O
##c O
##p O
##1 O
does O
not O
support O
the O
original O
link O
##age O
results O
, O
excluding O
link O
##age O
up O
to O
the O
##ta O
= O
0 O
. O

17 O
with O
z O
= O
- O
2 O
. O

tests O
for O
link O
##age O
to O
other O
chromosome O
2 O
##p O
markers O
. O

a O
##po O
##b O
, O
d O
##2 O
##s O
##7 O
##1 O
, O
d O
##2 O
##s O
##5 O
, O
and O
d O
##2 O
##s O
##1 O
, O
also O
excluded O
link O
##age O
to O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

markers O
that O
have O
been O
isolated O
from O
the O
chromosome O
11 O
##p O
##13 O
region O
were O
then O
analyzed O
in O
this O
an B-Disease
##iri I-Disease
##dia I-Disease
family O
. O

two O
r O
##f O
##l O
##ps O
at O
the O
d O
##11 O
##s O
##32 O
##3 O
lo O
##cus O
give O
significant O
evidence O
for O
link O
##age O
. O

the O
p O
##vu O
##ii O
p O
##oly O
##mor O
##phism O
detected O
by O
probe O
p O
##5 O
##s O
##1 O
. O

6 O
detect O
##s O
no O
re O
##comb O
##ina O
##nts O
, O
with O
a O
maximum O
lo O
##d O
score O
of O
z O
= O
6 O
. O

97 O
at O
the O
##ta O
= O
0 O
. O

00 O
00 O
. O

the O
ha O
##ei O
##ii O
p O
##oly O
##mor O
##phism O
detected O
by O
the O
probe O
p O
##5 O
##be O
##1 O
. O

2 O
gives O
a O
maximum O
lo O
##d O
score O
of O
z O
= O
2 O
. O

57 O
at O
the O
##ta O
= O
0 O
. O

00 O
00 O
. O

lo O
##cus O
d O
##11 O
##s O
##32 O
##5 O
gives O
a O
lo O
##d O
score O
of O
z O
= O
1 O
. O

53 O
at O
the O
##ta O
= O
0 O
. O

00 O
00 O
. O

these O
data O
suggest O
that O
a O
lo O
##cus O
for O
an B-Disease
##iri I-Disease
##dia I-Disease
( O
an O
##1 O
) O
on O
chromosome O
2 O
##p O
has O
been O
mi O
##sa O
##ssi O
##gned O
and O
that O
this O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
family O
is O
se O
##g O
##re O
##gating O
for O
an O
an B-Disease
##iri I-Disease
##dia I-Disease
mutation O
linked O
to O
markers O
in O
the O
11 O
##p O
##13 O
region O
. O

fatal O
p B-Disease
##yo I-Disease
##der I-Disease
##ma I-Disease
gang I-Disease
##ren I-Disease
##os I-Disease
##um I-Disease
in O
association O
with O
c B-Disease
##7 I-Disease
deficiency I-Disease
. O

although O
p B-Disease
##yo I-Disease
##der I-Disease
##ma I-Disease
gang I-Disease
##ren I-Disease
##os I-Disease
##um I-Disease
( O
p B-Disease
##g I-Disease
) O
is O
often O
associated O
with O
systemic B-Disease
diseases I-Disease
, O
it O
has O
not O
been O
reported O
in O
association O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
complement I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
. O

we O
describe O
an O
aggressive O
and O
ultimately O
fatal O
case O
of O
p B-Disease
##g I-Disease
in O
a O
patient O
with O
a O
con O
##gen O
##ital O
c B-Disease
##7 I-Disease
deficiency I-Disease
. O

def B-Disease
##ici I-Disease
##encies I-Disease
of I-Disease
c I-Disease
##7 I-Disease
can O
be O
associated O
with O
decreased O
ne O
##ut O
##rop O
##hil O
ch O
##em O
##ota O
##xi O
##s O
, O
p O
##ha O
##go O
##cy O
##tosis O
, O
and O
op O
##son O
##ization O
, O
similar O
to O
the O
im B-Disease
##mu I-Disease
##no I-Disease
##log I-Disease
##ic I-Disease
abnormal I-Disease
##ities I-Disease
described O
in O
patients O
with O
p B-Disease
##g I-Disease
. O

our O
patients O
decreased O
complement O
level O
, O
if O
not O
directly O
related O
to O
the O
development O
of O
p B-Disease
##g I-Disease
, O
may O
have O
contributed O
to O
the O
aggressive O
nature O
of O
her O
disease O
. O
. O

diverse O
point O
mutations O
result O
in O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
p O
##oly O
##mor O
##phism O
in O
ta O
##i O
##wan O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
; I-Disease
e I-Disease
##c I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
the O
most O
common O
human O
en B-Disease
##zy I-Disease
##mo I-Disease
##pathy I-Disease
, O
affecting O
more O
than O
200 O
million O
people O
worldwide O
. O

although O
greater O
than O
400 O
variants O
have O
been O
described O
based O
on O
clinical O
and O
bio O
##chemical O
criteria O
, O
little O
is O
known O
about O
the O
molecular O
basis O
of O
these O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
. O

recently O
, O
the O
gene O
that O
en O
##codes O
human O
g O
##6 O
##p O
##d O
has O
been O
clone O
##d O
and O
sequence O
##d O
, O
which O
enables O
us O
to O
examine O
directly O
the O
he O
##tero O
##gene O
##ity O
of O
g O
##6 O
##p O
##d O
at O
the O
d O
##na O
level O
. O

during O
the O
past O
10 O
years O
, O
we O
examined O
the O
g O
##6 O
##p O
##d O
activity O
in O
21 O
, O
27 O
##1 O
newborn O
chin O
##ese O
infants O
( O
11 O
, O
400 O
males O
and O
9 O
, O
87 O
##1 O
females O
) O
and O
identified O
31 O
##4 O
( O
2 O
. O
8 O
% O
) O
males O
and O
246 O
( O
2 O
. O
5 O
% O
) O
females O
having O
low O
g O
##6 O
##p O
##d O
activity O
. O

the O
g O
##6 O
##p O
##d O
gene O
from O
10 O
randomly O
selected O
affected O
individuals O
and O
their O
relatives O
was O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
am O
##plified O
, O
sub O
##c O
##lone O
##d O
, O
and O
sequence O
##d O
. O

our O
results O
indicate O
that O
at O
least O
four O
types O
of O
mutation O
are O
responsible O
for O
the O
g O
##6 O
##p O
##d O
p O
##oly O
##mor O
##phism O
in O
ta O
##i O
##wan O
. O

the O
first O
type O
of O
mutation O
( O
48 O
##7 O
g O
- O
- O
- O
- O
a O
) O
was O
found O
in O
an O
affected O
chin O
##ese O
with O
a O
g O
to O
a O
change O
at O
n O
##uc O
##leo O
##tide O
48 O
##7 O
, O
which O
results O
in O
a O
( O
163 O
) O
g O
##ly O
to O
se O
##r O
substitution O
. O

the O
second O
type O
of O
mutation O
( O
49 O
##3 O
a O
- O
- O
- O
- O
g O
) O
is O
a O
novel O
mutation O
that O
has O
not O
been O
reported O
in O
any O
other O
ethnic O
group O
and O
was O
identified O
in O
two O
affected O
chin O
##ese O
. O

this O
mutation O
causes O
an O
a O
to O
g O
change O
at O
n O
##uc O
##leo O
##tide O
position O
49 O
##3 O
, O
producing O
an O
( O
165 O
) O
as O
##n O
to O
as O
##p O
substitution O
. O

interesting O
##ly O
, O
the O
48 O
##7 O
g O
- O
- O
- O
- O
a O
and O
49 O
##3 O
a O
- O
- O
- O
- O
g O
mutations O
create O
al O
##u O
i O
and O
a O
##va O
ii O
recognition O
sites O
, O
respectively O
, O
which O
enabled O
us O
to O
rapidly O
detect O
these O
two O
mutations O
by O
p O
##c O
##r O
/ O
restriction O
enzyme O
( O
re O
) O
dig O
##est O
##ion O
method O
. O

the O
third O
mutation O
( O
137 O
##6 O
g O
- O
- O
- O
- O
t O
) O
was O
found O
in O
four O
affected O
chin O
##ese O
. O

this O
mutation O
causes O
a O
g O
to O
t O
change O
at O
n O
##uc O
##leo O
##tide O
position O
137 O
##6 O
that O
results O
in O
an O
( O
45 O
##9 O
) O
a O
##rg O
to O
le O
##u O
substitution O
. O

the O
137 O
##6 O
g O
- O
- O
- O
- O
t O
mutation O
seems O
to O
be O
the O
dominant O
all O
##ele O
that O
causes O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
ta O
##i O
##wan O
. O

finally O
, O
two O
affected O
chin O
##ese O
were O
identified O
as O
having O
the O
fourth O
mutation O
( O
138 O
##8 O
g O
- O
- O
- O
- O
a O
) O
. O

this O
mutation O
causes O
a O
g O
to O
a O
change O
at O
n O
##uc O
##leo O
##tide O
138 O
##8 O
that O
produces O
an O
( O
46 O
##3 O
) O
a O
##rg O
to O
his O
substitution O
. O

our O
studies O
provide O
the O
direct O
proof O
of O
the O
genetic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
the O
chin O
##ese O
populations O
of O
ta O
##i O
##wan O
and O
the O
p O
##c O
##r O
/ O
re O
dig O
##est O
##ion O
method O
is O
suitable O
for O
simultaneous O
detection O
of O
the O
48 O
##7 O
g O
- O
- O
- O
- O
a O
and O
49 O
##3 O
a O
- O
- O
- O
- O
g O
mutations O
. O

an O
error O
in O
d O
##ys O
##tro O
##phi O
##n O
m O
##rna O
processing O
in O
golden B-Disease
retrieve I-Disease
##r I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
an O
animal O
ho O
##mo O
##logue O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

golden B-Disease
retrieve I-Disease
##r I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
g B-Disease
##rm I-Disease
##d I-Disease
) O
is O
a O
spontaneous O
, O
x O
- O
linked O
, O
progressively O
fatal O
disease O
of O
dogs O
and O
is O
also O
a O
ho O
##mo O
##logue O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

two O
- O
thirds O
of O
d B-Disease
##m I-Disease
##d I-Disease
patients O
carry O
detect O
##able O
del O
##eti O
##ons O
in O
their O
d O
##ys O
##tro O
##phi O
##n O
gene O
. O

the O
defect O
underlying O
the O
remaining O
one O
- O
third O
of O
d B-Disease
##m I-Disease
##d I-Disease
patients O
is O
und O
##eter O
##mined O
. O

analysis O
of O
the O
can O
##ine O
d O
##ys O
##tro O
##phi O
##n O
gene O
in O
normal O
and O
g B-Disease
##rm I-Disease
##d I-Disease
dogs O
has O
failed O
to O
demonstrate O
any O
detect O
##able O
loss O
of O
ex O
##ons O
. O

here O
, O
we O
have O
demonstrated O
a O
r O
##na O
processing O
error O
in O
g B-Disease
##rm I-Disease
##d I-Disease
that O
results O
from O
a O
single O
base O
change O
in O
the O
3 O
consensus O
s O
##p O
##lice O
site O
of O
intro O
##n O
6 O
. O

the O
seventh O
ex O
##on O
is O
then O
skipped O
, O
which O
predict O
##s O
a O
termination O
of O
the O
d O
##ys O
##tro O
##phi O
##n O
reading O
frame O
within O
its O
n O
- O
terminal O
domain O
in O
ex O
##on O
8 O
. O

this O
is O
the O
first O
example O
of O
d B-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##n I-Disease
deficiency I-Disease
caused O
by O
a O
s O
##p O
##lice O
- O
site O
mutation O
. O
. O

type B-Disease
i I-Disease
human I-Disease
complement I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
. O

a O
28 O
- O
base O
pair O
gene O
del O
##eti O
##on O
causes O
skip O
##ping O
of O
ex O
##on O
6 O
during O
r O
##na O
s O
##p O
##licing O
. O

two O
variants O
of O
a O
genetic O
deficiency B-Disease
of I-Disease
complement I-Disease
protein I-Disease
c I-Disease
##2 I-Disease
( O
c O
##2 O
##d O
) O
have O
been O
previously O
identified O
. O

no O
c O
##2 O
protein O
translation O
is O
detected O
in O
type O
i O
deficiency O
, O
while O
type O
ii O
deficiency O
is O
characterized O
by O
a O
selective O
block O
in O
c O
##2 O
secret O
##ion O
. O

type B-Disease
i I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
was O
described O
in O
a O
family O
in O
which O
the O
c O
##2 O
null O
all O
##ele O
( O
c O
##2 O
##q O
##0 O
) O
is O
associated O
with O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
ha O
##p O
##lot O
##ype O
/ O
com O
##p O
##lot O
##ype O
h O
##la O
- O
a O
##25 O
, O
b O
##18 O
, O
c O
##2 O
##q O
##0 O
, O
b O
##fs O
, O
c O
##4 O
##a O
##4 O
, O
c O
##4 O
##b O
##2 O
, O
d O
##r O
##w O
##2 O
; O
this O
extended O
ha O
##p O
##lot O
##ype O
occurs O
in O
over O
90 O
% O
of O
c B-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individuals O
( O
common O
com O
##p O
##lot O
##ype O
/ O
ha O
##p O
##lot O
##ype O
) O
. O

to O
determine O
the O
molecular O
basis O
of O
type B-Disease
i I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
, O
the O
c O
##2 O
gene O
and O
c O
##dn O
##a O
were O
characterized O
from O
a O
ho O
##mo O
##zy O
##go O
##us O
type B-Disease
i I-Disease
c I-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individual O
with O
the O
common O
associated O
ha O
##p O
##lot O
##ype O
/ O
com O
##p O
##lot O
##ype O
. O

we O
found O
a O
28 O
- O
base O
pair O
del O
##eti O
##on O
in O
the O
type O
i O
c O
##2 O
##q O
##0 O
gene O
, O
beginning O
9 O
base O
pairs O
upstream O
of O
the O
3 O
- O
end O
of O
ex O
##on O
6 O
, O
that O
generates O
a O
c O
##2 O
trans O
##cript O
with O
a O
complete O
del O
##eti O
##on O
of O
ex O
##on O
6 O
( O
134 O
base O
pair O
) O
and O
a O
premature O
termination O
co O
##don O
. O

in O
studies O
of O
eight O
kind O
##red O
, O
the O
28 O
- O
base O
pair O
del O
##eti O
##on O
was O
observed O
in O
all O
c O
##2 O
##q O
##0 O
all O
##ele O
##s O
associated O
with O
the O
common O
type O
i O
def O
##icient O
com O
##p O
##lot O
##ype O
/ O
ha O
##p O
##lot O
##ype O
; O
this O
del O
##eti O
##on O
was O
not O
present O
in O
normal O
c O
##2 O
nor O
in O
type B-Disease
ii I-Disease
c I-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
genes O
. O

these O
data O
demonstrate O
that O
1 O
) O
type B-Disease
i I-Disease
human I-Disease
complement I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
is O
caused O
by O
a O
28 O
- O
base O
pair O
g O
##eno O
##mic O
del O
##eti O
##on O
that O
causes O
skip O
##ping O
of O
ex O
##on O
6 O
during O
r O
##na O
s O
##p O
##licing O
, O
resulting O
in O
generation O
of O
a O
premature O
termination O
co O
##don O
, O
2 O
) O
the O
28 O
- O
base O
pair O
del O
##eti O
##on O
in O
the O
type O
i O
c O
##2 O
##q O
##0 O
gene O
is O
strongly O
associated O
with O
the O
h O
##la O
ha O
##p O
##lot O
##ype O
/ O
com O
##p O
##lot O
##ype O
a O
##25 O
, O
b O
##18 O
, O
c O
##2 O
##q O
##0 O
, O
b O
##fs O
, O
c O
##4 O
##a O
##4 O
, O
c O
##4 O
##b O
##2 O
, O
d O
##r O
##w O
##2 O
, O
suggesting O
that O
all O
c B-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individuals O
with O
this O
ha O
##p O
##lot O
##ype O
/ O
com O
##p O
##lot O
##ype O
will O
harbor O
the O
28 O
- O
base O
pair O
c O
##2 O
gene O
del O
##eti O
##on O
, O
and O
3 O
) O
type B-Disease
ii I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
is O
caused O
by O
a O
different O
, O
as O
yet O
un O
##cha O
##rac O
##ter O
##ized O
, O
molecular O
genetic B-Disease
defect I-Disease
. O
. O

molecular O
characterization O
of O
two O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
and O
one O
p O
##oly O
##mor O
##phism O
: O
implications O
for O
structure O
- O
function O
analysis O
of O
human O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
. O

we O
report O
here O
the O
molecular O
characterization O
of O
two O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
, O
l O
##7 O
##4 O
##p O
and O
f O
##17 O
##1 O
##s O
, O
and O
one O
p O
##oly O
##mor O
##phism O
, O
s O
##13 O
##5 O
##l O
, O
in O
human O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
gal O
##t O
) O
. O

both O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
result O
in O
reduced O
en O
##zy O
##matic O
activity O
when O
reconstructed O
in O
the O
c O
##dn O
##a O
and O
over O
##ex O
##pressed O
. O

the O
p O
##oly O
##mor O
##phism O
, O
in O
contrast O
, O
has O
near O
normal O
activity O
. O

both O
mutations O
affect O
evolution O
##arily O
conserved O
residues O
, O
suggesting O
that O
they O
are O
functional O
##ly O
important O
, O
while O
the O
p O
##oly O
##mor O
##phism O
occurs O
in O
a O
non O
##con O
##serve O
##d O
domain O
which O
is O
presumably O
not O
critical O
for O
en O
##zy O
##matic O
function O
. O

the O
f O
##17 O
##1 O
##s O
mutation O
is O
close O
to O
the O
put O
##ative O
active O
- O
site O
n O
##uc O
##leo O
##phi O
##le O
. O

our O
data O
further O
support O
the O
notion O
of O
molecular O
he O
##tero O
##gene O
##ity O
of O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
and O
suggest O
that O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
and O
gal O
##t O
p O
##oly O
##mor O
##phism O
##s O
may O
be O
useful O
tools O
in O
highlighting O
different O
functional O
domains O
in O
human O
gal O
##t O
. O
. O

link O
##age O
relationship O
of O
c B-Disease
##2 I-Disease
deficiency I-Disease
, O
h O
##la O
and O
g O
##ly O
##ox O
##ala O
##se O
i O
lo O
##ci O
. O

im O
##mu O
##no O
##gene O
##tic O
analysis O
of O
a O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
individual O
and O
family O
members O
demonstrated O
link O
##age O
of O
h O
##la O
- O
a O
##25 O
, O
b O
##18 O
and O
c O
##2 O
##o O
. O

h O
##la O
- O
d O
typing O
showed O
that O
5 O
members O
typed O
with O
ho O
##mo O
##zy O
##go O
##us O
d O
##w O
##2 O
typing O
cells O
from O
an O
individual O
with O
c B-Disease
##2 I-Disease
deficiency I-Disease
but O
not O
with O
d O
##w O
##2 O
typing O
cells O
from O
2 O
individuals O
with O
normal O
c O
##2 O
. O

the O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
prop O
##os O
##it O
##us O
and O
brother O
were O
h O
##la O
- O
a O
and O
b O
ho O
##mo O
##zy O
##go O
##us O
but O
he O
##tero O
##zy O
##go O
##us O
at O
the O
h O
##la O
- O
d O
and O
g O
##ly O
##ox O
##ala O
##se O
i O
lo O
##ci O
. O

therefore O
, O
in O
this O
family O
, O
the O
c O
##2 O
##o O
gene O
is O
linked O
with O
two O
distinct O
ha O
##p O
##lot O
##ype O
##s O
h O
##la O
- O
a O
##25 O
, O
b O
##18 O
, O
d O
##w O
##2 O
, O
g O
##lo O
##1 O
and O
h O
##la O
- O
a O
##25 O
, O
b O
##18 O
, O
d O
unknown O
, O
g O
##l O
##0 O
##2 O
. O

these O
results O
could O
be O
explained O
by O
an O
ancestral O
re O
##comb O
##ina O
##nt O
event O
, O
which O
occurred O
between O
the O
c O
##2 O
##o O
lo O
##cus O
and O
h O
##la O
- O
d O
lo O
##cus O
in O
which O
c O
##2 O
##o O
segregated O
with O
h O
##la O
- O
b O
. O

this O
would O
suggest O
that O
the O
lo O
##cus O
for O
the O
c O
##2 O
##o O
gene O
maps O
between O
h O
##la O
- O
b O
and O
h O
##la O
- O
d O
on O
the O
sixth O
chromosome O
. O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
w B-Disease
##il I-Disease
##ms I-Disease
' I-Disease
tumor I-Disease
suppress O
##or O
gene O
are O
associated O
with O
abnormal O
u O
##rogen O
##ital O
development O
in O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
. O

deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
is O
a O
rare O
human O
condition O
in O
which O
severe O
u B-Disease
##rogen I-Disease
##ital I-Disease
a I-Disease
##ber I-Disease
##rations I-Disease
result O
in O
re B-Disease
##nal I-Disease
failure I-Disease
, O
pseudo B-Disease
##her I-Disease
##ma I-Disease
##ph I-Disease
##rod I-Disease
##itis I-Disease
##m I-Disease
, O
and O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
( O
ne B-Disease
##ph I-Disease
##ro I-Disease
##blast I-Disease
##oma I-Disease
) O
. O

to O
investigate O
its O
possible O
role O
, O
we O
have O
analyzed O
the O
coding O
ex O
##ons O
of O
the O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
suppress O
##or O
gene O
( O
w O
##t O
##1 O
) O
for O
g O
##er O
##m O
##line O
mutations O
. O

in O
ten O
independent O
cases O
of O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
, O
point O
mutations O
in O
the O
zinc O
finger O
domains O
of O
one O
w O
##t O
##1 O
gene O
copy O
were O
found O
. O

nine O
of O
these O
mutations O
are O
found O
within O
ex O
##on O
9 O
( O
zinc O
finger O
ii O
##i O
) O
; O
the O
remaining O
mutation O
is O
in O
ex O
##on O
8 O
( O
zinc O
finger O
ii O
) O
. O

these O
mutations O
directly O
affect O
d O
##na O
sequence O
recognition O
. O

in O
two O
families O
analyzed O
, O
the O
mutations O
were O
shown O
to O
arise O
de O
no O
##vo O
. O

w B-Disease
##il I-Disease
##ms I-Disease
tumors I-Disease
from O
three O
individuals O
and O
one O
juvenile O
g O
##ran O
##ulos O
##a O
cell O
tumor B-Disease
demonstrate O
reduction O
to O
ho O
##mo O
##zy O
##gos O
##ity O
for O
the O
m O
##uta O
##ted O
w O
##t O
##1 O
all O
##ele O
. O

our O
results O
provide O
evidence O
of O
a O
direct O
role O
for O
w O
##t O
##1 O
in O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
and O
thus O
u O
##rogen O
##ital O
system O
development O
. O
. O

link O
##age O
analysis O
in O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
and O
application O
in O
post O
- O
and O
pre O
##nat O
##al O
diagnosis O
. O

we O
have O
performed O
link O
##age O
analysis O
with O
the O
d O
##na O
markers O
d O
##x O
##s O
##5 O
##2 O
and O
the O
c O
##lot O
##ting O
factor O
v O
##ii O
##i O
gene O
( O
f O
##8 O
##c O
) O
, O
in O
several O
large O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
. O

the O
tight O
link O
##age O
to O
d O
##x O
##s O
##5 O
##2 O
could O
be O
extended O
giving O
a O
ma O
##ximal O
lo O
##d O
score O
of O
22 O
. O

5 O
at O
1 O
cm O
. O

f O
##8 O
##c O
was O
also O
tightly O
linked O
to O
al B-Disease
##d I-Disease
with O
a O
ma O
##ximal O
lo O
##d O
score O
of O
7 O
. O

8 O
without O
re O
##comb O
##ination O
. O

multi O
##point O
link O
##age O
analysis O
with O
the O
markers O
d O
##x O
##s O
##30 O
##4 O
, O
d O
##x O
##s O
##5 O
##2 O
, O
and O
f O
##8 O
##c O
indicated O
that O
both O
the O
gene O
for O
al B-Disease
##d I-Disease
and O
for O
f O
##8 O
##c O
are O
di O
##stal O
to O
d O
##x O
##s O
##5 O
##2 O
. O

in O
four O
patients O
with O
al B-Disease
##d I-Disease
, O
no O
major O
structural O
rear O
##rang O
##ement O
in O
the O
x O
##q O
##ter O
region O
was O
observed O
; O
in O
particular O
, O
there O
were O
no O
abnormal B-Disease
##ities I-Disease
in I-Disease
the I-Disease
vision I-Disease
blind I-Disease
##ness I-Disease
genes I-Disease
. O

d O
##na O
analysis O
appeared O
to O
be O
of O
use O
in O
determination O
of O
the O
carrier O
status O
of O
females O
at O
risk O
, O
for O
the O
determination O
of O
the O
origin O
of O
the O
mutation O
in O
a O
particular O
family O
, O
and O
for O
pre O
##nat O
##al O
diagnosis O
. O

two O
distinct O
mutations O
at O
a O
single O
b O
##am O
##hi O
site O
in O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

classical B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

the O
abolition O
of O
an O
invariant O
b O
##am O
##hi O
site O
located O
in O
the O
coding O
sequence O
of O
the O
p O
##ah O
gene O
( O
ex O
##on O
7 O
) O
led O
to O
the O
recognition O
of O
two O
new O
point O
mutations O
at O
co O
##don O
272 O
and O
27 O
##3 O
( O
272 O
##gly O
- O
- O
- O
- O
stop O
and O
27 O
##3 O
##ser O
- O
- O
- O
- O
p O
##he O
, O
respectively O
) O
. O

both O
mutations O
were O
detected O
in O
north O
eastern O
f O
##rance O
or O
be O
##l O
##gi O
##um O
and O
occurred O
on O
the O
background O
of O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
7 O
all O
##ele O
##s O
. O

the O
present O
study O
supports O
the O
view O
that O
the O
clinical O
he O
##tero O
##gene O
##ity O
in O
p B-Disease
##ku I-Disease
is O
accounted O
for O
by O
the O
large O
variety O
of O
mutant O
g O
##eno O
##type O
##s O
associated O
with O
p B-Disease
##ah I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
. O
. O

a O
detailed O
multi O
##point O
map O
of O
human O
chromosome O
4 O
provides O
evidence O
for O
link O
##age O
he O
##tero O
##gene O
##ity O
and O
position O
- O
specific O
re O
##comb O
##ination O
rates O
. O

utilizing O
the O
c O
##ep O
##h O
reference O
panel O
and O
g O
##eno O
##ty O
##pic O
data O
for O
53 O
markers O
, O
we O
have O
constructed O
a O
20 O
- O
lo O
##cus O
multi O
##point O
genetic O
map O
of O
human O
chromosome O
4 O
. O

new O
r O
##f O
##l O
##ps O
are O
reported O
for O
four O
lo O
##ci O
. O

the O
map O
integrate O
##s O
a O
high O
- O
resolution O
genetic O
map O
of O
4 O
##p O
##16 O
into O
a O
continuous O
map O
extending O
to O
4 O
##q O
##31 O
and O
an O
un O
##link O
##ed O
cluster O
of O
three O
lo O
##ci O
at O
4 O
##q O
##35 O
. O

the O
20 O
linked O
markers O
form O
a O
continuous O
link O
##age O
group O
of O
152 O
cm O
in O
males O
and O
202 O
cm O
in O
females O
. O

likely O
genetic O
locations O
are O
provided O
for O
25 O
p O
##oly O
##morphic O
anonymous O
sequences O
and O
28 O
gene O
- O
specific O
r O
##f O
##l O
##ps O
. O

the O
map O
was O
constructed O
employing O
the O
link O
##age O
and O
c O
##rima O
##p O
computational O
method O
##ologies O
to O
build O
the O
multi O
##point O
map O
via O
a O
step O
##wise O
algorithm O
. O

a O
detailed O
10 O
- O
point O
map O
of O
the O
4 O
##p O
##16 O
region O
constructed O
from O
the O
c O
##ep O
##h O
panel O
provides O
evidence O
for O
he O
##tero O
##gene O
##ity O
in O
the O
link O
##age O
maps O
constructed O
from O
families O
se O
##g O
##re O
##gating O
for O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
. O

it O
additionally O
provides O
evidence O
for O
position O
- O
specific O
re O
##comb O
##ination O
frequencies O
in O
the O
te O
##lo O
##mer O
##ic O
region O
of O
4 O
##p O
. O
. O

carrier O
detection O
and O
pre O
##nat O
##al O
diagnosis O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
using O
a O
combination O
of O
anonymous O
d O
##na O
p O
##oly O
##mor O
##phism O
##s O
and O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
c O
##dn O
##a O
. O

we O
report O
carrier O
identification O
and O
a O
pre O
##nat O
##al O
diagnosis O
using O
d O
##na O
p O
##oly O
##mor O
##phism O
##s O
in O
2 O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
p I-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
. O

in O
both O
families O
, O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
in O
the O
single O
affected O
male O
could O
be O
traced O
back O
to O
his O
un O
##af O
##fected O
maternal O
grandfather O
. O

therefore O
, O
each O
family O
contains O
a O
new O
mutation O
. O

in O
the O
case O
of O
the O
pre O
##nat O
##al O
diagnosis O
, O
the O
f O
##etus O
was O
shown O
by O
c O
##yt O
##ogen O
##etic O
analysis O
to O
be O
a O
female O
, O
who O
we O
predict O
will O
be O
a O
non O
##car O
##rier O
of O
pm B-Disease
##d I-Disease
based O
on O
her O
g O
##eno O
##type O
with O
the O
p O
##l O
##p O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
. O
. O

identification O
of O
del O
##eti O
##on O
mutations O
and O
three O
new O
genes O
at O
the O
f B-Disease
##ami I-Disease
##lial I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
lo O
##cus O
. O

small O
( O
100 O
- O
260 O
k O
##b O
) O
, O
nest O
##ed O
del O
##eti O
##ons O
were O
characterized O
in O
d O
##na O
from O
two O
unrelated O
patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
. O

three O
candidate O
genes O
located O
within O
the O
deleted O
region O
were O
as O
##cer O
##tain O
##ed O
and O
a O
previous O
candidate O
gene O
, O
m O
##cc O
, O
was O
shown O
to O
be O
located O
outside O
the O
deleted O
region O
. O

one O
of O
the O
new O
genes O
contained O
sequence O
identical O
to O
s O
##rp O
##19 O
, O
the O
gene O
coding O
for O
the O
19 O
k O
##d O
component O
of O
the O
rib O
##oso O
##mal O
signal O
recognition O
particle O
. O

the O
second O
, O
provisional O
##ly O
designated O
d O
##p O
##1 O
( O
deleted O
in O
p O
##oly O
##po O
##sis O
1 O
) O
, O
was O
found O
to O
be O
trans O
##cribed O
in O
the O
same O
orientation O
as O
m O
##cc O
. O

two O
other O
c O
##dn O
##as O
, O
d O
##p O
##2 O
and O
d O
##p O
##3 O
, O
were O
found O
to O
overlap O
, O
forming O
a O
single O
gene O
, O
d O
##p O
##2 O
. O

5 O
, O
that O
is O
trans O
##cribed O
in O
the O
same O
orientation O
as O
s O
##rp O
##19 O
. O

exclusion O
of O
link O
##age O
between O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
and O
the O
human O
serum O
am O
##yl O
##oid O
a O
( O
sa O
##a O
) O
gene O
cluster O
. O

we O
studied O
the O
relationship O
between O
the O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
and O
the O
serum O
am O
##yl O
##oid O
a O
( O
sa O
##a O
) O
genes O
by O
comparing O
all O
##ele O
##s O
of O
a O
highly O
p O
##oly O
##morphic O
din O
##uc O
##leo O
##tide O
repeat O
and O
a O
conventional O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
( O
r O
##f O
##l O
##p O
) O
in O
the O
sa O
##a O
gene O
cluster O
in O
is O
##rae O
##li O
f B-Disease
##m I-Disease
##f I-Disease
kind O
##red O
##s O
. O

by O
ha O
##p O
##lot O
##ype O
analysis O
, O
our O
data O
indicate O
a O
minimum O
crossover O
frequency O
of O
22 O
% O
between O
the O
sa O
##a O
gene O
marker O
and O
f B-Disease
##m I-Disease
##f I-Disease
. O

by O
conventional O
link O
##age O
analysis O
this O
eliminate O
##s O
a O
minimum O
of O
10 O
. O

4 O
cm O
including O
and O
surrounding O
the O
sa O
##a O
gene O
cluster O
as O
the O
site O
of O
the O
f B-Disease
##m I-Disease
##f I-Disease
mutation O
although O
sa O
##a O
proteins O
are O
prominent O
p O
##hy O
##sio O
##log O
##ic O
markers O
of O
the O
acute O
attacks O
. O

p O
##rad O
##1 O
, O
a O
candidate O
b O
##c O
##l O
##1 O
on O
##co O
##gene O
: O
mapping O
and O
expression O
in O
cent B-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
. O

rear O
##rang O
##ement O
of O
the O
b O
##c O
##l O
##1 O
( O
b O
- O
cell O
l O
##ymph O
##oma O
1 O
) O
region O
on O
chromosome O
11 O
##q O
##13 O
appears O
to O
be O
highly O
characteristic O
of O
cent B-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
and O
also O
is O
found O
in O
##f O
##re O
##quent O
##ly O
in O
other O
b B-Disease
- I-Disease
cell I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
. O

rear O
##rang O
##ement O
is O
thought O
to O
der O
##eg O
##ulate O
a O
nearby O
pro O
##toon O
##co O
##gene O
, O
but O
trans O
##cribed O
sequences O
in O
the O
immediate O
vicinity O
of O
b O
##c O
##l O
##1 O
break O
##points O
had O
not O
been O
identified O
. O

p O
##rad O
##1 O
, O
previously O
designated O
d O
##11 O
##s O
##28 O
##7 O
##e O
, O
was O
identified O
on O
11 O
##q O
##13 O
as O
a O
ch O
##rom O
##oso O
##mal O
break O
##point O
region O
rear O
##ranged O
with O
the O
para O
##thy O
##roid O
hormone O
gene O
in O
a O
subset O
of O
para B-Disease
##thy I-Disease
##roid I-Disease
ad I-Disease
##eno I-Disease
##mas I-Disease
; O
this O
highly O
conserved O
put O
##ative O
on O
##co O
##gene O
, O
which O
en O
##codes O
a O
novel O
c O
##y O
##c O
##lin O
, O
has O
been O
linked O
to O
b O
##c O
##l O
##1 O
and O
implicated O
also O
in O
subset O
##s O
of O
breast B-Disease
and I-Disease
sq I-Disease
##ua I-Disease
##mous I-Disease
cell I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
with O
11 O
##q O
##13 O
am O
##p O
##lification O
. O

we O
report O
pulsed O
- O
field O
gel O
electro O
##ph O
##ores O
##is O
data O
showing O
b O
##c O
##l O
##1 O
and O
p O
##rad O
##1 O
to O
be O
no O
more O
than O
130 O
k O
##ilo O
##base O
##s O
apart O
. O

p O
##rad O
##1 O
m O
##rna O
is O
abundant O
##ly O
expressed O
in O
seven O
of O
seven O
cent B-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
( O
k O
##iel O
classification O
) O
, O
in O
contrast O
to O
13 O
closely O
related O
but O
non B-Disease
##cent I-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
. O

three O
of O
the O
seven O
cent B-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
had O
detect O
##able O
b O
##c O
##l O
##1 O
d O
##na O
rear O
##rang O
##ement O
. O

also O
, O
two O
unusual O
cases O
of O
c O
##ll O
with O
b O
##c O
##l O
##1 O
rear O
##rang O
##ement O
over O
##ex O
##pressed O
p O
##rad O
##1 O
, O
in O
contrast O
to O
five O
c O
##ll O
controls O
. O

thus O
, O
p O
##rad O
##1 O
is O
an O
excellent O
candidate O
" O
b O
##c O
##l O
##1 O
on O
##co O
##gene O
. O

" O
its O
over O
##ex O
##press O
##ion O
may O
be O
a O
key O
consequence O
of O
rear O
##rang O
##ement O
of O
the O
b O
##c O
##l O
##1 O
vicinity O
in O
b B-Disease
- I-Disease
cell I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
and O
a O
un O
##ifying O
path O
##ogen O
##etic O
feature O
in O
cent B-Disease
##ro I-Disease
##cy I-Disease
##tic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
. O

two O
new O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
mutations O
in O
a O
juvenile O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
patient O
. O

fragments O
of O
the O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
gene O
from O
a O
patient O
with O
juvenile O
- O
onset O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
were O
am O
##plified O
by O
p O
##c O
##r O
and O
l O
##igate O
##d O
into O
m O
##p O
##13 O
c O
##lon O
##ing O
vectors O
. O

clone O
##s O
hybrid O
##izing O
with O
c O
##dn O
##a O
for O
human O
a O
##rsa O
were O
selected O
, O
examined O
for O
appropriate O
size O
insert O
##s O
, O
and O
used O
to O
prepare O
single O
- O
stranded O
p O
##hage O
d O
##na O
. O

examination O
of O
the O
entire O
coding O
and O
most O
of O
the O
intro O
##nic O
sequence O
revealed O
two O
put O
##ative O
disease O
- O
related O
mutations O
. O

one O
, O
a O
point O
mutation O
in O
ex O
##on O
3 O
, O
resulted O
in O
the O
substitution O
of O
is O
##ole O
##uc O
##ine O
by O
se O
##rine O
. O

introduction O
of O
this O
alter O
##ation O
into O
the O
normal O
a O
##rsa O
c O
##dn O
##a O
sequence O
resulted O
in O
a O
substantial O
decrease O
in O
a O
##rsa O
activity O
on O
trans O
##ient O
expression O
in O
culture O
##d O
baby O
ha O
##ms O
##ter O
kidney O
cells O
. O

about O
5 O
% O
of O
the O
control O
expression O
was O
observed O
, O
suggesting O
a O
small O
residual O
activity O
in O
the O
m O
##uta O
##ted O
a O
##rsa O
. O

the O
second O
mutation O
, O
a O
g O
- O
to O
- O
a O
transition O
, O
occurred O
in O
the O
other O
all O
##ele O
and O
resulted O
in O
an O
altered O
s O
##p O
##lice O
- O
recognition O
sequence O
between O
ex O
##on O
7 O
and O
the O
following O
intro O
##n O
. O

the O
mutation O
also O
resulted O
in O
the O
loss O
of O
a O
restriction O
site O
. O

apparently O
normal O
levels O
of O
m O
##rna O
were O
generated O
from O
this O
all O
##ele O
, O
but O
no O
a O
##rsa O
activity O
or O
im O
##mu O
##no O
- O
cross O
- O
reactive O
material O
could O
be O
detected O
. O

a O
collection O
of O
d O
##na O
samples O
from O
known O
or O
suspected O
m B-Disease
##ld I-Disease
patients O
, O
members O
of O
their O
families O
, O
and O
normal O
controls O
was O
screened O
for O
these O
mutations O
. O

four O
additional O
individuals O
carrying O
each O
of O
the O
mutations O
were O
found O
among O
the O
nearly O
100 O
m B-Disease
##ld I-Disease
patients O
in O
the O
sample O
. O

gene O
segregation O
in O
the O
original O
patients O
family O
was O
consistent O
with O
available O
clinical O
and O
bio O
##chemical O
data O
. O

no O
individuals O
ho O
##mo O
##zy O
##go O
##us O
for O
either O
of O
these O
two O
mutations O
were O
identified O
. O

however O
, O
combinations O
with O
other O
m B-Disease
##ld I-Disease
mutations O
suggest O
that O
the O
point O
mutation O
in O
ex O
##on O
3 O
does O
result O
in O
some O
residual O
enzyme O
activity O
and O
is O
associated O
with O
late O
- O
onset O
forms O
of O
the O
disease O
. O

the O
s O
##p O
##lice O
- O
site O
mutation O
following O
ex O
##on O
7 O
produces O
late O
- O
infant O
##ile O
m B-Disease
##ld I-Disease
when O
combined O
with O
other O
enzyme O
- O
null O
mutations O
, O
implying O
that O
it O
is O
completely O
silent O
en O
##zy O
##matical O
##ly O
. O
. O

analysis O
of O
x O
- O
chromosome O
in O
##act O
##ivation O
and O
pre O
##su O
##mpt O
##ive O
expression O
of O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
gene O
in O
hem O
##ato O
##po O
##iet O
##ic O
cell O
lineage O
##s O
of O
a O
th O
##rom O
##bo O
##cy O
##top O
##eni O
##c O
carrier O
female O
of O
was B-Disease
. O

we O
report O
on O
a O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##eni I-Disease
##c I-Disease
female O
belonging O
to O
a O
p O
##ed O
##ig O
##ree O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
( O
r O
##f O
##l O
##p O
) O
analysis O
with O
probe O
m O
##27 O
beta O
, O
closely O
linked O
to O
the O
was B-Disease
gene O
, O
demonstrated O
that O
she O
is O
a O
carrier O
of O
was B-Disease
. O

both O
small O
- O
sized O
and O
normal O
- O
sized O
plate O
##lets O
were O
present O
, O
suggesting O
that O
, O
unlike O
the O
vast O
majority O
of O
was B-Disease
carriers O
, O
she O
does O
not O
manifest O
non O
##rand O
##om O
x O
- O
chromosome O
in O
##act O
##ivation O
in O
the O
th O
##rom O
##bo O
##po O
##iet O
##ic O
cell O
lineage O
. O

study O
of O
x O
- O
chromosome O
in O
##act O
##ivation O
by O
means O
of O
r O
##f O
##l O
##p O
and O
met O
##hyl O
##ation O
analysis O
demonstrated O
that O
the O
pattern O
of O
x O
- O
chromosome O
in O
##act O
##ivation O
was O
non O
##rand O
##om O
in O
t O
l O
##ymph O
##ocytes O
, O
but O
random O
in O
g O
##ran O
##ulo O
##cy O
##tes O
. O

while O
this O
is O
the O
first O
complete O
report O
on O
the O
occurrence O
of O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
in O
a O
carrier O
female O
of O
was B-Disease
as O
the O
result O
of O
at O
##y O
##pical O
l O
##yon O
##ization O
, O
it O
also O
suggests O
that O
expression O
of O
the O
was B-Disease
gene O
occurs O
at O
( O
or O
extends O
up O
to O
) O
a O
later O
stage O
than O
the O
multi O
##pot O
##ent O
stem O
cell O
along O
the O
hem O
##ato O
##po O
##iet O
##ic O
differentiation O
pathway O
. O
. O

a O
new O
mutation O
in O
the O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
in O
a O
g O
##erman O
family O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

a O
c O
- O
to O
- O
t O
transition O
in O
ex O
##on O
4 O
of O
the O
p O
##l O
##p O
gene O
was O
found O
in O
2 O
affected O
males O
and O
two O
o O
##b O
##liga O
##te O
carriers O
in O
a O
g O
##erman O
family O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

the O
mutation O
, O
which O
causes O
loss O
of O
an O
hp O
##hi O
site O
and O
changes O
amino O
acid O
155 O
from O
th O
##re O
##oni O
##ne O
to O
is O
##ole O
##uc O
##ine O
, O
was O
absent O
from O
108 O
normal O
chromosome O
##s O
. O

there O
are O
5 O
con O
##cor O
##dance O
##s O
and O
1 O
disc O
##re O
##pan O
##cy O
between O
these O
results O
and O
those O
obtained O
by O
magnetic O
resonance O
imaging O
in O
this O
family O
. O
. O

a O
3 O
- O
base O
pair O
in O
- O
frame O
del O
##eti O
##on O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
results O
in O
a O
kinetic O
variant O
of O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
due O
to O
deficiency B-Disease
of I-Disease
a I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
enzyme I-Disease
, I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

the O
absence O
of O
p O
##ah O
activity O
results O
in O
typical O
p B-Disease
##ku I-Disease
while O
per O
##sistence O
of O
a O
residual O
enzyme O
activity O
gives O
rise O
to O
variant O
forms O
of O
the O
disease O
. O

we O
report O
here O
a O
3 O
- O
base O
pair O
in O
- O
frame O
del O
##eti O
##on O
of O
the O
p O
##ah O
gene O
( O
delta O
194 O
) O
in O
a O
mild O
variant O
, O
with O
marked O
##ly O
reduced O
affinity O
of O
the O
enzyme O
for O
p O
##hen O
##yla O
##lani O
##ne O
( O
km O
= O
160 O
nm O
) O
, O
and O
we O
provide O
functional O
evidence O
for O
responsibility O
of O
the O
del O
##eti O
##on O
in O
the O
mutant O
p O
##hen O
##otype O
. O

since O
the O
del O
##eti O
##on O
was O
located O
in O
the O
third O
ex O
##on O
of O
the O
gene O
, O
which O
presents O
no O
ho O
##mology O
with O
other O
h O
##ydro O
##xy O
##lase O
##s O
, O
we O
suggest O
that O
ex O
##on O
3 O
is O
involved O
in O
the O
specific O
##ity O
of O
the O
enzyme O
for O
p O
##hen O
##yla O
##lani O
##ne O
. O

finally O
, O
since O
none O
of O
the O
98 O
p B-Disease
##ku I-Disease
patients O
tested O
were O
found O
to O
carry O
this O
particular O
del O
##eti O
##on O
, O
our O
study O
suggests O
that O
this O
molecular O
event O
probably O
occurred O
recently O
on O
the O
background O
of O
a O
ha O
##p O
##lot O
##ype O
2 O
gene O
in O
port O
##uga O
##l O
. O
. O

mutation O
of O
the O
kit O
( O
mast O
/ O
stem O
cell O
growth O
factor O
receptor O
) O
pro O
##toon O
##co O
##gene O
in O
human O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
. O

pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
genetic I-Disease
disorder I-Disease
characterized O
by O
co O
##gen O
##ital O
patches O
of O
skin O
and O
hair O
from O
which O
me O
##lan O
##ocytes O
are O
completely O
absent O
. O

a O
similar O
disorder O
of O
mouse O
, O
dominant O
white O
spot O
##ting O
( O
w O
) O
, O
results O
from O
mutations O
of O
the O
c O
- O
kit O
pro O
##toon O
##co O
##gene O
, O
which O
en O
##codes O
and O
receptor O
for O
mast O
/ O
stem O
cell O
growth O
factor O
. O

we O
identified O
a O
kit O
gene O
mutation O
in O
a O
pro O
##band O
with O
classic O
auto O
##so O
##mal O
dominant O
pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
. O

this O
mutation O
results O
in O
a O
g O
##ly O
- O
- O
- O
- O
a O
##rg O
substitution O
at O
co O
##don O
66 O
##4 O
, O
within O
the O
t O
##yr O
##os O
##ine O
kinase O
domain O
. O

this O
substitution O
was O
not O
seen O
in O
any O
normal O
individuals O
and O
was O
completely O
linked O
to O
the O
pie B-Disease
##bal I-Disease
##d I-Disease
p O
##hen O
##otype O
in O
the O
pro O
##band O
##s O
family O
. O

pie B-Disease
##bal I-Disease
##dis I-Disease
##m I-Disease
in O
this O
family O
thus O
appears O
to O
be O
the O
human O
ho O
##mo O
##logue O
to O
dominant O
white O
spot O
##ting O
( O
w O
) O
of O
the O
mouse O
. O
. O

genetic O
analysis O
of O
a O
j O
##apa O
##nese O
family O
with O
norm B-Disease
##ot I-Disease
##rig I-Disease
##ly I-Disease
##cer I-Disease
##ide I-Disease
##mic I-Disease
a I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
indicates O
a O
lack O
of O
link O
##age O
to O
the O
a O
##poli O
##pop O
##rote O
##in O
b O
gene O
. O

norm B-Disease
##ot I-Disease
##rig I-Disease
##ly I-Disease
##cer I-Disease
##ide I-Disease
##mic I-Disease
a I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
is O
a O
rare O
f B-Disease
##ami I-Disease
##lial I-Disease
disorder I-Disease
characterized O
by O
an O
isolated O
deficiency B-Disease
of I-Disease
a I-Disease
##po I-Disease
##b I-Disease
- I-Disease
100 I-Disease
. O

we O
have O
previously O
reported O
a O
patient O
with O
this O
disease O
, O
who O
had O
normal O
a O
##po O
##b O
- O
48 O
but O
no O
a O
##po O
##b O
- O
100 O
. O

to O
el O
##uc O
##ida O
##te O
the O
genetic B-Disease
abnormal I-Disease
##ities I-Disease
in O
this O
family O
, O
we O
studied O
the O
link O
##age O
of O
a O
##po O
##b O
gene O
using O
three O
genetic O
markers O
. O

the O
pro O
##band O
and O
her O
affected O
brother O
showed O
completely O
different O
a O
##po O
##b O
gene O
all O
##ele O
##s O
, O
suggesting O
that O
the O
a O
##po O
##b O
gene O
itself O
is O
not O
related O
to O
this O
disorder O
in O
this O
family O
. O

by O
contrast O
, O
an O
am O
##eric O
##an O
case O
had O
a O
point O
substitution O
in O
the O
a O
##po O
##b O
gene O
generating O
an O
in O
- O
frame O
stop O
co O
##don O
. O

these O
results O
indicate O
that O
this O
disorder O
can O
be O
caused O
by O
defect O
( O
s O
) O
of O
either O
an O
a O
##po O
##b O
gene O
or O
other O
genes O
. O
. O

local O
##isation O
of O
the O
gene O
for O
nor B-Disease
##rie I-Disease
disease I-Disease
to O
between O
d O
##x O
##s O
##7 O
and O
d O
##x O
##s O
##42 O
##6 O
on O
x O
##p O
. O

a O
highly O
inform O
##ative O
micro O
##sat O
##elli O
##te O
marker O
, O
d O
##x O
##s O
##42 O
##6 O
, O
which O
maps O
pro O
##ximal O
to O
d O
##x O
##s O
##7 O
in O
the O
interval O
x O
##p O
##11 O
. O

4 O
- O
x O
##p O
##11 O
4 O
- O
x O
##p O
##11 O
. O

23 O
, O
has O
been O
used O
to O
re O
##fine O
further O
the O
local O
##isation O
of O
the O
gene O
for O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
##p I-Disease
) O
. O

the O
results O
from O
a O
multi O
##p O
##ly O
inform O
##ative O
crossover O
local O
##ize O
the O
n B-Disease
##d I-Disease
##p I-Disease
gene O
pro O
##ximal O
to O
d O
##x O
##s O
##7 O
. O

in O
conjunction O
with O
information O
from O
2 O
n B-Disease
##d I-Disease
##p I-Disease
patients O
who O
have O
a O
del O
##eti O
##on O
for O
d O
##x O
##s O
##7 O
but O
not O
for O
d O
##s O
##x O
##42 O
##6 O
, O
our O
data O
indicate O
that O
the O
n B-Disease
##d I-Disease
##p I-Disease
gene O
lies O
between O
d O
##x O
##s O
##7 O
and O
d O
##x O
##s O
##42 O
##6 O
on O
pro O
##ximal O
x O
##p O
. O

a O
##ber O
##rant O
s O
##p O
##licing O
of O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
m O
##rna O
: O
the O
major O
cause O
for O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
in O
parts O
of O
southern O
euro O
##pe O
. O

we O
report O
a O
mutation O
within O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
gene O
that O
causes O
a O
##ber O
##rant O
s O
##p O
##licing O
of O
the O
m O
##rna O
and O
that O
is O
in O
tight O
association O
with O
ch O
##rom O
##oso O
##mal O
ha O
##p O
##lot O
##ype O
##s O
6 O
, O
10 O
, O
and O
36 O
. O

because O
of O
the O
high O
frequency O
of O
these O
particular O
ha O
##p O
##lot O
##ype O
##s O
in O
b O
##ul O
##gar O
##ia O
, O
it O
##aly O
, O
and O
turkey O
, O
it O
appears O
to O
be O
one O
of O
the O
more O
frequent O
defects O
in O
the O
p O
##ah O
gene O
causing O
classical O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
in O
this O
part O
of O
euro O
##pe O
. O

the O
mutation O
is O
a O
g O
to O
a O
transition O
at O
position O
54 O
##6 O
in O
intro O
##n O
10 O
of O
the O
p O
##ah O
gene O
, O
11 O
b O
##p O
upstream O
from O
the O
intro O
##n O
10 O
/ O
ex O
##on O
11 O
boundary O
. O

it O
activate O
##s O
a O
cry O
##ptic O
s O
##p O
##lice O
site O
and O
results O
in O
an O
in O
- O
frame O
insertion O
of O
9 O
n O
##uc O
##leo O
##tide O
##s O
between O
ex O
##on O
10 O
and O
ex O
##on O
11 O
of O
the O
processed O
m O
##rna O
. O

normal O
amounts O
of O
liver O
p O
##ah O
protein O
are O
present O
in O
ho O
##mo O
##zy O
##go O
##us O
patients O
, O
but O
no O
cat O
##alytic O
activity O
can O
be O
detected O
. O

this O
loss O
of O
enzyme O
activity O
is O
probably O
caused O
by O
conform O
##ational O
changes O
resulting O
from O
the O
insertion O
of O
three O
additional O
amino O
acids O
( O
g O
##ly O
- O
le O
##u O
- O
g O
##ln O
) O
between O
the O
normal O
sequences O
encoded O
by O
ex O
##on O
10 O
and O
ex O
##on O
11 O
. O
. O

g B-Disease
##ard I-Disease
##ner I-Disease
syndrome I-Disease
in O
a O
boy O
with O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
of O
the O
long O
arm O
of O
chromosome O
5 O
. O

we O
described O
a O
15 O
- O
year O
- O
old O
boy O
with O
g B-Disease
##ard I-Disease
##ner I-Disease
syndrome I-Disease
( O
g B-Disease
##s I-Disease
) O
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
c B-Disease
##rani I-Disease
##of I-Disease
##ac I-Disease
##ial I-Disease
abnormal I-Disease
##ities I-Disease
. O

high O
- O
resolution O
band O
##ing O
analysis O
showed O
an O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
of O
the O
long O
arm O
of O
chromosome O
5 O
( O
q O
##22 O
. O
1 O
- O
- O
- O
- O
q O
##31 O
1 O
- O
- O
- O
- O
q O
##31 O
. O
1 O
) O
. O

the O
break O
##points O
in O
the O
present O
case O
and O
in O
3 O
previously O
reported O
5 O
##q O
- O
patients O
with O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
suggest O
that O
the O
gene O
responsible O
for O
g B-Disease
##s I-Disease
/ O
or O
f B-Disease
##ami I-Disease
##lial I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
f B-Disease
##p I-Disease
##c I-Disease
) O
is O
in O
the O
5 O
##q O
##22 O
region O
, O
a O
result O
consistent O
with O
the O
findings O
of O
link O
##age O
studies O

hunting B-Disease
##ton I-Disease
disease I-Disease
and O
childhood O
- O
onset O
tour B-Disease
##ette I-Disease
syndrome I-Disease
. O

a O
40 O
- O
year O
- O
old O
man O
with O
childhood O
- O
onset O
tour B-Disease
##ette I-Disease
syndrome I-Disease
( O
t B-Disease
##s I-Disease
) O
developed O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
. O

we O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
childhood O
- O
onset O
t B-Disease
##s I-Disease
with O
adult O
onset O
h B-Disease
##d I-Disease
. O

discovery O
of O
other O
cases O
with O
both O
disorders O
may O
provide O
clues O
to O
the O
path O
##op O
##hy O
##sio O
##logy O
of O
both O
conditions O
. O
. O

sequence O
of O
d O
##na O
flank O
##ing O
the O
ex O
##ons O
of O
the O
he O
##xa O
gene O
, O
and O
identification O
of O
mutations O
in O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
. O

the O
rapid O
identification O
of O
mutations O
causing O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
requires O
the O
capacity O
to O
readily O
screen O
the O
regions O
of O
the O
he O
##xa O
gene O
most O
likely O
to O
be O
affected O
by O
mutation O
. O

we O
have O
sequence O
##d O
the O
portions O
of O
the O
intro O
##ns O
flank O
##ing O
each O
of O
the O
14 O
he O
##xa O
ex O
##ons O
in O
order O
to O
specify O
o O
##li O
##gon O
##uc O
##leo O
##tide O
prime O
##rs O
for O
the O
p O
##c O
##r O
- O
dependent O
am O
##p O
##lification O
of O
each O
ex O
##on O
and O
s O
##p O
##lice O
- O
junction O
sequence O
. O

the O
am O
##plified O
products O
were O
analyzed O
, O
by O
electro O
##ph O
##ores O
##is O
in O
non O
##den O
##at O
##uring O
p O
##oly O
##ac O
##ryl O
##ami O
##de O
gel O
##s O
, O
for O
the O
presence O
of O
either O
he O
##tero O
##du O
##plex O
##es O
, O
derived O
from O
the O
an O
##nea O
##ling O
of O
normal O
and O
mutant O
d O
##na O
strands O
, O
or O
single O
- O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
##s O
( O
s O
##s O
##c O
##p O
) O
, O
derived O
from O
the O
re O
##nat O
##uration O
of O
single O
- O
stranded O
d O
##na O
. O

five O
novel O
mutations O
from O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
patients O
were O
detected O
a O
5 O
- O
b O
##p O
del O
##eti O
##on O
of O
t O
##ct O
##cc O
in O
i O
##v O
##s O
- O
9 O
; O
a O
2 O
- O
b O
##p O
del O
##eti O
##on O
of O
t O
##g O
in O
ex O
##on O
5 O
; O
g O
##7 O
##8 O
to O
a O
, O
giving O
a O
stop O
co O
##don O
in O
ex O
##on O
1 O
; O
g O
##53 O
##3 O
to O
t O
in O
ex O
##on O
5 O
, O
producing O
the O
third O
amino O
acid O
substitution O
detected O
at O
this O
site O
; O
and O
g O
to O
c O
at O
position O
1 O
of O
i O
##v O
##s O
- O
2 O
, O
expected O
to O
produce O
abnormal O
s O
##p O
##licing O
. O

in O
addition O
, O
two O
mutations O
, O
( O
g O
##14 O
##9 O
##6 O
to O
a O
in O
ex O
##on O
13 O
and O
a O
4 O
- O
b O
##p O
insertion O
in O
ex O
##on O
11 O
) O
that O
have O
previously O
been O
reported O
were O
identified O
. O
. O

molecular O
characterization O
of O
two O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
: O
correlation O
of O
mutations O
with O
highly O
conserved O
domains O
in O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
transfer O
##ase O
. O

gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
of I-Disease
human I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
metabolism I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
- I-Disease
1 I-Disease
- I-Disease
phosphate I-Disease
u I-Disease
##rid I-Disease
##yl I-Disease
transfer I-Disease
##ase I-Disease
( O
gal O
##t O
) O
. O

the O
molecular O
basis O
of O
this O
disorder O
is O
at O
present O
not O
well O
understood O
. O

we O
report O
here O
two O
miss O
##ense O
mutations O
which O
result O
in O
low O
or O
und O
##ete O
##ct O
##able O
en O
##zy O
##matic O
activity O
. O

first O
, O
we O
identified O
at O
n O
##uc O
##leo O
##tide O
59 O
##1 O
a O
transition O
which O
substitute O
##s O
g O
##lut O
##amine O
188 O
by O
a O
##rg O
##ini O
##ne O
. O

the O
m O
##uta O
##ted O
g O
##lut O
##amine O
is O
not O
only O
highly O
conserved O
in O
evolution O
( O
conserved O
also O
in O
es O
##cher O
##ichi O
##a O
co O
##li O
and O
sa O
##cc O
##har O
##omy O
##ces O
c O
##ere O
##vis O
##iae O
) O
, O
but O
is O
also O
two O
amino O
acid O
residues O
downstream O
from O
the O
active O
site O
his O
##ti O
##dine O
- O
pro O
##line O
- O
his O
##ti O
##dine O
t O
##riad O
and O
results O
in O
about O
10 O
% O
of O
normal O
en O
##zy O
##matic O
activity O
. O

the O
a O
##rg O
##ini O
##ne O
188 O
mutation O
is O
the O
most O
common O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutation O
characterized O
to O
date O
. O

it O
accounts O
for O
one O
- O
fourth O
of O
the O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
all O
##ele O
##s O
studied O
. O

second O
, O
we O
report O
the O
substitution O
of O
a O
##rg O
##ini O
##ne O
333 O
by O
try O
##pt O
##op O
##han O
, O
caused O
by O
a O
transition O
at O
n O
##uc O
##leo O
##tide O
102 O
##5 O
. O

the O
area O
surrounding O
this O
miss O
##ense O
mutation O
is O
the O
most O
highly O
conserved O
domain O
in O
the O
ho O
##mo O
##log O
##ous O
enzymes O
from O
e O
. O
co O
##li O
, O
yeast O
, O
and O
humans O
, O
and O
this O
mutation O
results O
in O
und O
##ete O
##ct O
##able O
en O
##zy O
##matic O
activity O
, O
suggesting O
that O
this O
is O
a O
severe O
mutation O
. O

this O
second O
mutation O
appears O
to O
be O
rare O
, O
since O
it O
was O
found O
only O
in O
the O
patient O
we O
sequence O
##d O
. O

our O
data O
provide O
further O
evidence O
for O
the O
he O
##tero O
##gene O
##ity O
of O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
at O
the O
molecular O
level O
, O
he O
##tero O
##gene O
##ity O
which O
might O
be O
related O
to O
the O
variable O
clinical O
outcome O
observed O
in O
this O
disorder O
. O
. O

h B-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
- I-Disease
g I-Disease
##uan I-Disease
##ine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
##tra I-Disease
##ns I-Disease
##fer I-Disease
##ase I-Disease
deficiency I-Disease
: O
analysis O
of O
hp O
##rt O
mutations O
by O
direct O
se O
##quencing O
and O
all O
##ele O
- O
specific O
am O
##p O
##lification O
. O

the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
is O
a O
severe O
x B-Disease
chromosome I-Disease
- I-Disease
linked I-Disease
human I-Disease
disease I-Disease
caused O
by O
a O
virtual O
absence B-Disease
of I-Disease
h I-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
- I-Disease
g I-Disease
##uan I-Disease
##ine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
##tra I-Disease
##ns I-Disease
##fer I-Disease
##ase I-Disease
( I-Disease
hp I-Disease
##rt I-Disease
) I-Disease
activity I-Disease
. O

a O
partial O
deficiency O
in O
the O
activity O
of O
this O
enzyme O
can O
result O
in O
go B-Disease
##ut I-Disease
##y I-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
. O

to O
determine O
the O
genetic O
basis O
for O
reduction O
or O
loss O
of O
enzyme O
activity O
, O
we O
have O
am O
##plified O
and O
sequence O
##d O
the O
coding O
region O
of O
hp O
##rt O
c O
##dn O
##a O
from O
four O
patients O
one O
with O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
( O
hp O
##rt O
##pert O
##h O
) O
and O
three O
with O
partial B-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
of I-Disease
hp I-Disease
##rt I-Disease
activity I-Disease
, O
which O
have O
been O
designated O
hp O
##rt O
##ura O
##nga O
##n O
, O
hp O
##rts O
##wan O
and O
hp O
##rt O
##to O
##ow O
##ong O
. O

in O
all O
four O
patients O
, O
the O
only O
mutation O
identified O
was O
a O
single O
base O
substitution O
in O
ex O
##ons O
2 O
or O
3 O
of O
the O
coding O
region O
, O
which O
in O
each O
case O
predict O
##s O
a O
single O
amino O
acid O
substitution O
in O
the O
translated O
protein O
. O

each O
base O
change O
was O
confirmed O
by O
all O
##ele O
- O
specific O
am O
##p O
##lification O
of O
the O
patients O
g O
##eno O
##mic O
d O
##na O
. O

it O
is O
interesting O
to O
note O
that O
the O
mutation O
found O
for O
hp O
##rt O
##pert O
##h O
is O
identical O
to O
that O
reported O
for O
hp O
##rt O
##f O
##lint O
. O

it O
appears O
that O
the O
two O
mutations O
are O
de O
no O
##vo O
events O
. O
. O

molecular O
and O
metabolic O
basis O
for O
the O
metabolic B-Disease
disorder I-Disease
norm B-Disease
##ot I-Disease
##rig I-Disease
##ly I-Disease
##cer I-Disease
##ide I-Disease
##mic I-Disease
a I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
. O

we O
have O
previously O
described O
a O
disorder O
, O
norm B-Disease
##ot I-Disease
##rig I-Disease
##ly I-Disease
##cer I-Disease
##ide I-Disease
##mic I-Disease
a I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
, O
that O
is O
characterized O
by O
the O
virtual O
absence O
of O
plasma O
low O
density O
lip O
##op O
##rote O
##ins O
and O
complete O
absence O
of O
a O
##po O
##b O
- O
100 O
, O
but O
with O
apparently O
normal O
secret O
##ion O
of O
t O
##rig O
##ly O
##cer O
##ide O
- O
rich O
lip O
##op O
##rote O
##ins O
containing O
a O
##po O
##b O
- O
48 O
. O

the O
patients O
plasma O
lip O
##op O
##rote O
##ins O
were O
shown O
on O
p O
##oly O
##ac O
##ryl O
##ami O
##de O
gel O
##s O
and O
by O
anti O
##body O
mapping O
to O
have O
a O
new O
t O
##runcated O
a O
##po O
##b O
variant O
, O
a O
##po O
##b O
- O
50 O
, O
circulating O
along O
with O
her O
a O
##po O
##b O
- O
48 O
. O

we O
have O
found O
this O
individual O
to O
be O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
single O
c O
- O
to O
- O
t O
n O
##uc O
##leo O
##tide O
substitution O
at O
a O
##po O
##b O
co O
##don O
225 O
##2 O
, O
which O
produces O
a O
premature O
in O
- O
frame O
stop O
co O
##don O
. O

thus O
, O
this O
is O
a O
rare O
example O
of O
ho B-Disease
##mo I-Disease
##zy I-Disease
##go I-Disease
##us I-Disease
h I-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
. O

electron O
photo O
##mic O
##rog O
##rap O
##hs O
revealed O
that O
the O
diameter O
##s O
of O
particles O
in O
the O
d O
less O
than O
1 O
. O

00 O
##6 O
g O
/ O
m O
##l O
lip O
##op O
##rote O
##in O
fraction O
, O
in O
both O
the O
post O
##pra O
##ndi O
##al O
and O
post O
##ab O
##sor O
##pt O
##ive O
state O
, O
are O
bi O
##mo O
##dal O
##ly O
distributed O
. O

the O
m O
##olar O
ratio O
of O
a O
##po O
##e O
to O
a O
##po O
##b O
in O
these O
particles O
is O
3 O
. O

5 O
1 O
, O
similar O
to O
normal O
v O
##ld O
##l O
. O

the O
plasma O
l O
##dl O
interval O
contains O
both O
spherical O
and O
cu O
##bo O
##idal O
particles O
. O

auto O
##log O
##ous O
re O
##in O
##fusion O
of O
labeled O
d O
less O
than O
1 O
. O

00 O
##6 O
g O
/ O
m O
##l O
lip O
##op O
##rote O
##ins O
showed O
ex O
##po O
##nent O
##ial O
disappearance O
from O
plasma O
, O
with O
an O
apparent O
half O
- O
removal O
time O
of O
50 O
min O
, O
somewhat O
slower O
than O
for O
normal O
ch O
##yl O
##omi O
##c O
##rons O
but O
within O
the O
normal O
range O
for O
v O
##ld O
##l O
. O

the O
calculated O
production O
rate O
for O
a O
##po O
##b O
was O
within O
the O
normal O
range O
in O
this O
subject O
. O

a O
single O
origin O
of O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
in O
ye O
##men O
##ite O
j O
##ews O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
a O
metabolic B-Disease
disease I-Disease
caused O
by O
re O
##cess O
##ive O
mutations O
of O
the O
gene O
encoding O
the O
he O
##pa O
##tic O
enzyme O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
. O

the O
incidence O
of O
p B-Disease
##ku I-Disease
varies O
widely O
across O
different O
geographic O
areas O
, O
and O
is O
highest O
( O
about O
1 O
in O
5 O
, O
000 O
live O
births O
) O
in O
i O
##rel O
##and O
and O
western O
s O
##cot O
##land O
, O
and O
among O
ye O
##men O
##ite O
j O
##ews O
. O

a O
limited O
number O
of O
point O
mutations O
account O
for O
most O
of O
the O
p B-Disease
##ku I-Disease
cases O
in O
the O
euro O
##pe O
##an O
population O
. O

here O
we O
report O
that O
a O
single O
molecular O
defect O
- O
- O
a O
del O
##eti O
##on O
spanning O
the O
third O
ex O
##on O
of O
the O
p O
##ah O
gene O
- O
- O
is O
responsible O
for O
all O
the O
p B-Disease
##ku I-Disease
cases O
among O
the O
ye O
##men O
##ite O
j O
##ews O
. O

examination O
of O
a O
random O
sample O
of O
ye O
##men O
##ite O
j O
##ews O
using O
a O
molecular O
probe O
that O
detect O
##s O
the O
carriers O
of O
this O
del O
##eti O
##on O
indicated O
a O
high O
frequency O
of O
the O
defect O
##ive O
gene O
in O
this O
community O
. O

although O
the O
deleted O
p O
##ah O
gene O
was O
traced O
to O
25 O
different O
locations O
throughout O
ye O
##men O
, O
family O
histories O
and O
official O
documents O
of O
the O
ye O
##men O
##ite O
j O
##ew O
##ish O
community O
showed O
that O
the O
common O
ancestor O
of O
all O
the O
carriers O
of O
this O
genetic B-Disease
defect I-Disease
lived O
in O
sa O
##na O
, O
the O
capital O
of O
ye O
##men O
, O
before O
the O
eighteenth O
century O
. O
. O

link O
##age O
of O
as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
( O
a B-Disease
##gu I-Disease
) O
to O
marker O
lo O
##ci O
on O
the O
long O
arm O
of O
chromosome O
4 O
. O

as B-Disease
##par I-Disease
##ty I-Disease
##l I-Disease
##g I-Disease
##lu I-Disease
##cos I-Disease
##ami I-Disease
##nu I-Disease
##ria I-Disease
( O
a B-Disease
##gu I-Disease
) O
is O
caused O
by O
def O
##icient O
activity O
of O
the O
enzyme O
as O
##par O
##ty O
##l O
##g O
##lu O
##cos O
##ami O
##ni O
##das O
##e O
( O
a O
##ga O
) O
. O

the O
structural O
gene O
for O
a O
##ga O
has O
been O
assigned O
to O
the O
region O
4 O
##q O
##21 O
- O
q O
##ter O
of O
chromosome O
4 O
. O

we O
have O
studied O
the O
map O
position O
of O
the O
a O
##gu O
lo O
##cus O
in O
relation O
to O
other O
marker O
lo O
##ci O
on O
the O
long O
arm O
of O
chromosome O
4 O
using O
link O
##age O
analyses O
. O

restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
all O
##ele O
##s O
for O
the O
ad O
##h O
##2 O
, O
ad O
##h O
##3 O
, O
e O
##g O
##f O
, O
f O
##g O
alpha O
and O
f O
##g O
beta O
lo O
##ci O
and O
blood O
group O
anti O
##gens O
for O
the O
m O
##ns O
lo O
##cus O
were O
determined O
in O
a O
panel O
of O
12 O
fin O
##nish O
a B-Disease
##gu I-Disease
families O
. O

the O
he O
##tero O
##zy O
##go O
##us O
family O
members O
were O
identified O
by O
reduced O
activity O
of O
a O
##ga O
in O
l O
##ymph O
##ocytes O
. O

link O
##age O
studies O
were O
performed O
using O
both O
pair O
##wise O
and O
multi O
##point O
analyses O
. O

loose O
link O
##age O
of O
the O
a B-Disease
##gu I-Disease
lo O
##cus O
to O
the O
f O
##g O
and O
m O
##ns O
lo O
##ci O
was O
observed O
( O
z O
= O
1 O
. O
16 O
, O
z O
= O
1 O
. O
39 O
, O
respectively O
) O
. O

multi O
##point O
analysis O
to O
the O
fixed O
map O
[ O
ad O
##h O
- O
( O
0 O
. O
03 O
) O
- O
e O
##g O
##f O
- O
( O
0 O
. O
35 O
) O
- O
f O
##g O
- O
( O
0 O
. O
11 O
) O
- O
m O
##ns O
] O
suggests O
that O
the O
location O
of O
the O
a O
##gu O
lo O
##cus O
is O
0 O
. O

05 O
- O
0 O
. O

30 O
re O
##comb O
##ination O
units O
di O
##stal O
to O
m O
##ns O
( O
z O
= O
3 O
. O
03 O
) O
. O

the O
order O
c O
##en O
- O
ad O
##h O
- O
e O
##g O
##f O
- O
f O
##g O
- O
m O
##ns O
- O
a O
##gu O
is O
35 O
times O
more O
likely O
than O
the O
next O
best O
order O
c O
##en O
- O
ad O
##h O
- O
e O
##g O
##f O
- O
a O
##gu O
- O
f O
##g O
- O
m O
##ns O
. O

link O
##age O
relationships O
of O
the O
a O
##poli O
##pop O
##rote O
##in O
c O
##1 O
gene O
and O
a O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
gene O
( O
c O
##y O
##p O
##2 O
##a O
) O
to O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

we O
have O
studied O
the O
genetic O
link O
##age O
of O
two O
markers O
, O
the O
a O
##poli O
##pop O
##rote O
##in O
c O
##1 O
( O
a O
##po O
##c O
##1 O
) O
gene O
and O
a O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
( O
c O
##y O
##p O
##2 O
##a O
) O
gene O
, O
in O
relation O
to O
the O
gene O
for O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

a O
peak O
lo O
##d O
score O
of O
9 O
. O

29 O
at O
2 O
cm O
was O
observed O
for O
a O
##po O
##c O
##1 O
- O
d O
##m O
, O
with O
a O
lo O
##d O
score O
of O
8 O
. O

55 O
at O
4 O
cm O
for O
c O
##y O
##p O
##2 O
##a O
- O
d O
##m O
. O

these O
two O
markers O
also O
show O
close O
link O
##age O
to O
each O
other O
( O
the O
##ta O
ma O
##x O
= O
0 O
. O
05 O
, O
z O
##max O
= O
9 O
. O
09 O
) O
. O

from O
examination O
of O
the O
g O
##eno O
##type O
##s O
of O
the O
re O
##comb O
##ina O
##nt O
individuals O
, O
c O
##y O
##p O
##2 O
##a O
appears O
to O
map O
pro O
##ximal O
to O
d O
##m O
because O
in O
one O
re O
##comb O
##ina O
##nt O
individual O
c O
##y O
##p O
##2 O
##a O
, O
a O
##po O
##c O
##2 O
and O
c O
##k O
##mm O
had O
all O
re O
##comb O
##ined O
with O
d O
##m O
. O

evidence O
from O
another O
c O
##y O
##p O
##2 O
##a O
- O
d O
##m O
re O
##comb O
##ina O
##nt O
individual O
places O
c O
##y O
##p O
##2 O
##a O
pro O
##ximal O
to O
a O
##po O
##c O
##2 O
and O
c O
##k O
##mm O
. O

local O
##isation O
of O
c O
##y O
##p O
##2 O
##a O
on O
a O
panel O
of O
so O
##matic O
cell O
hybrid O
##s O
also O
suggests O
that O
it O
is O
pro O
##ximal O
to O
d O
##m O
and O
a O
##po O
##c O
##2 O
/ O
c O
##1 O
/ O
e O
gene O
cluster O
. O

genetic O
link O
##age O
map O
of O
six O
p O
##oly O
##morphic O
d O
##na O
markers O
around O
the O
gene O
for O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
on O
chromosome O
5 O
. O

a O
genetic O
link O
##age O
map O
of O
six O
p O
##oly O
##morphic O
d O
##na O
markers O
close O
to O
the O
gene O
( O
a O
##p O
##c O
) O
for O
f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
on O
chromosome O
5 O
##q O
is O
reported O
. O

one O
hundred O
fifty O
- O
five O
typed O
members O
of O
nine O
f B-Disease
##ap I-Disease
kind O
##red O
provided O
more O
than O
90 O
me O
##ios O
##es O
for O
link O
##age O
analysis O
. O

a O
number O
of O
crucial O
re O
##comb O
##ination O
events O
have O
been O
identified O
which O
are O
inform O
##ative O
at O
three O
or O
more O
lo O
##ci O
, O
allowing O
confident O
ordering O
of O
parts O
of O
the O
map O
. O

there O
was O
no O
evidence O
of O
genetic O
he O
##tero O
##gene O
##ity O
, O
with O
all O
families O
showing O
link O
##age O
of O
at O
least O
one O
chromosome O
5 O
marker O
to O
the O
gene O
. O

re O
##comb O
##ination O
data O
and O
two O
- O
point O
link O
##age O
analysis O
support O
a O
lo O
##cus O
order O
of O
cent O
##rome O
##re O
- O
p O
##i O
227 O
- O
c O
##11 O
##p O
##11 O
- O
e O
##c O
##b O
##27 O
- O
l O
##5 O
. O

62 O
- O
a O
##p O
##c O
- O
e O
##f O
##5 O
62 O
- O
a O
##p O
##c O
- O
e O
##f O
##5 O
. O

44 O
- O
y O
##n O
##5 O
44 O
- O
y O
##n O
##5 O
. O

48 O
- O
te O
##lo O
##mer O
e O
, O
although O
e O
##f O
##5 O
. O

44 O
could O
lie O
in O
the O
interval O
l O
##5 O
. O

62 O
- O
a O
##p O
##c O
or O
e O
##c O
##b O
##27 O
- O
l O
##5 O
. O

62 O
. O

no O
re O
##comb O
##ina O
##nts O
were O
identified O
between O
a O
##p O
##c O
and O
either O
e O
##f O
##5 O
. O

44 O
or O
y O
##n O
##5 O
. O

48 O
, O
but O
published O
del O
##eti O
##on O
mapping O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
and O
link O
##age O
analysis O
in O
f B-Disease
##ap I-Disease
suggest O
that O
y O
##n O
##5 O
. O

48 O
is O
1 O
- O
3 O
cm O
from O
a O
##p O
##c O
. O

the O
present O
study O
suggests O
that O
y O
##n O
##5 O
. O

48 O
and O
l O
##5 O
. O

62 O
del O
##ine O
##ate O
a O
small O
region O
of O
chromosome O
5 O
within O
which O
the O
e O
##f O
##5 O
. O

44 O
lo O
##cus O
lies O
very O
close O
to O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
. O

these O
data O
not O
only O
allow O
use O
of O
flank O
##ing O
markers O
for O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnosis O
of O
f B-Disease
##ap I-Disease
but O
also O
provide O
a O
high O
- O
density O
map O
of O
the O
region O
for O
isolation O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
itself O
and O
for O
further O
assessment O
of O
the O
role O
of O
chromosome O
5 O
del O
##eti O
##ons O
in O
the O
biology O
of O
s O
##poradic O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

serum O
am O
##yl O
##oid O
a O
and O
p O
protein O
genes O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
. O

two O
recent O
studies O
have O
suggested O
the O
involvement O
of O
serum O
am O
##yl O
##oid O
a O
( O
sa O
##a O
) O
and O
p O
( O
a O
##p O
##cs O
) O
genes O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
me B-Disease
##f I-Disease
) O
. O

to O
test O
the O
role O
of O
sa O
##a O
and O
a O
##p O
##cs O
in O
me B-Disease
##f I-Disease
and O
me B-Disease
##f I-Disease
- I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
, O
we O
studied O
17 O
inform O
##ative O
families O
( O
15 O
arm O
##enia O
##ns O
, O
2 O
non O
- O
ash O
##ken O
##azi O
j O
##ews O
) O
and O
8 O
me B-Disease
##f I-Disease
patients O
with O
am B-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
using O
a O
candidate O
gene O
approach O
. O

no O
evidence O
for O
any O
me B-Disease
##f I-Disease
- O
associated O
p O
##oly O
##mor O
##phism O
was O
found O
in O
any O
of O
the O
41 O
arm O
##enia O
##n O
and O
j O
##ew O
##ish O
me B-Disease
##f I-Disease
patients O
tested O
. O

our O
family O
studies O
allowed O
us O
to O
rule O
out O
tight O
link O
##age O
between O
sa O
##a O
and O
me B-Disease
##f I-Disease
( O
lo O
##d O
score O
= O
- O
2 O
. O
16 O
, O
the O
##ta O
less O
than O
or O
equal O
to O
0 O
. O
06 O
) O
. O

for O
a O
##p O
##cs O
we O
found O
that O
the O
all O
##ele O
frequency O
in O
the O
me B-Disease
##f I-Disease
- I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
patients O
was O
similar O
to O
that O
in O
18 O
unrelated O
me B-Disease
##f I-Disease
patients O
without O
am B-Disease
##yl I-Disease
##oid I-Disease
##osis I-Disease
and O
their O
33 O
healthy O
parents O
. O

some O
me O
##xi O
##can O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variants O
re O
##vis O
##ited O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
appears O
to O
be O
fairly O
common O
in O
me O
##xi O
##co O
. O

we O
have O
now O
examined O
the O
d O
##na O
of O
three O
previously O
reported O
electro O
##ph O
##ore O
##tically O
fast O
me O
##xi O
##can O
g O
##6 O
##p O
##d O
variants O
, O
- O
g O
##6 O
##p O
##d O
di O
##st O
##rito O
federal O
, O
g O
##6 O
##p O
##d O
te O
##pic O
, O
and O
g O
##6 O
##p O
##d O
cast O
##illa O
. O

all O
three O
of O
these O
variants O
, O
believed O
on O
the O
basis O
of O
bio O
##chemical O
characterization O
and O
population O
origin O
to O
be O
unique O
, O
have O
the O
g O
- O
- O
- O
- O
a O
transition O
at O
n O
##uc O
##leo O
##tide O
202 O
and O
the O
a O
- O
- O
- O
- O
g O
transition O
at O
n O
##uc O
##leo O
##tide O
37 O
##6 O
, O
mutations O
that O
we O
now O
recognize O
to O
be O
characteristic O
of O
g O
##6 O
##p O
##d O
a O
- O
. O

two O
other O
me O
##xi O
##can O
males O
with O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
were O
found O
to O
have O
the O
same O
mutation O
. O

all O
five O
have O
the O
( O
n O
##lai O
##ii O
/ O
f O
##oki O
/ O
p O
##vu O
##ii O
/ O
ps O
##ti O
) O
ha O
##p O
##lot O
##ype O
characteristic O
of O
g O
##6 O
##p O
##d O
a O
- O
in O
a O
##f O
##rica O
. O

since O
the O
p O
##vu O
##ii O
+ O
g O
##eno O
##type O
seems O
to O
be O
rare O
in O
euro O
##pe O
, O
we O
conclude O
that O
all O
of O
these O
g O
##6 O
##p O
##d O
a O
- O
genes O
had O
their O
ancient O
origin O
in O
a O
##f O
##rica O
, O
although O
in O
many O
of O
the O
me O
##xi O
##can O
patients O
with O
g O
##6 O
##p O
##d O
a O
- O
202 O
##a O
/ O
37 O
##6 O
##g O
the O
gene O
may O
have O
been O
imported O
more O
recently O
from O
spa O
##in O
, O
where O
this O
variant O
, O
formerly O
known O
as O
g O
##6 O
##p O
##d O
bet O
##ica O
, O
is O
also O
prevalent O
. O
. O

hereditary O
deficiency B-Disease
of I-Disease
c I-Disease
##5 I-Disease
in O
association O
with O
disco B-Disease
##id I-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
. O

a O
29 O
- O
year O
- O
old O
woman O
with O
disco B-Disease
##id I-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
had O
und O
##ete O
##ct O
##able O
classic O
pathway O
complement O
activity O
. O

h B-Disease
##y I-Disease
##po I-Disease
##com I-Disease
##ple I-Disease
##ment I-Disease
##emia I-Disease
was O
due O
to O
selective O
deficiency B-Disease
of I-Disease
c I-Disease
##5 I-Disease
. O

one O
of O
her O
children O
was O
also O
def O
##icient O
. O

to O
our O
knowledge O
this O
is O
the O
first O
documented O
case O
of O
an O
association O
between O
disco B-Disease
##id I-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
and O
c B-Disease
##5 I-Disease
deficiency I-Disease
. O
. O

founder O
effect O
of O
a O
prevalent O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
mutation O
in O
the O
or O
##ient O
##al O
population O
. O

a O
miss O
##ense O
mutation O
has O
been O
identified O
in O
the O
human O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
[ O
p O
##ah O
; O
p O
##hen O
##yla O
##lani O
##ne O
4 O
- O
mon O
##oo O
##xy O
##gen O
##ase O
; O
l O
- O
p O
##hen O
##yla O
##lani O
##ne O
, O
te O
##tra O
##hy O
##dr O
##ob O
##io O
##pt O
##eri O
##n O
oxygen O
o O
##xi O
##dor O
##ed O
##uc O
##tase O
( O
4 O
- O
h O
##ydro O
##xy O
##lating O
) O
, O
e O
##c O
1 O
. O
14 O
. O
16 O
. O
1 O
] O
gene O
in O
a O
chin O
##ese O
patient O
with O
classic O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
. O

a O
g O
- O
to O
- O
c O
transition O
at O
the O
second O
base O
of O
co O
##don O
41 O
##3 O
in O
ex O
##on O
12 O
of O
the O
gene O
results O
in O
the O
substitution O
of O
pro O
##41 O
##3 O
for O
a O
##rg O
##41 O
##3 O
in O
the O
mutant O
protein O
. O

this O
mutation O
( O
r O
##41 O
##3 O
##p O
) O
results O
in O
ne O
##gli O
##gible O
en O
##zy O
##matic O
activity O
when O
expressed O
in O
he O
##tero O
##log O
##ous O
ma O
##mmal O
##ian O
cells O
and O
is O
compatible O
with O
a O
classic O
p B-Disease
##ku I-Disease
p O
##hen O
##otype O
in O
the O
patient O
. O

population O
genetic O
studies O
reveal O
that O
this O
mutation O
is O
tightly O
linked O
to O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
ha O
##p O
##lot O
##ype O
4 O
, O
which O
is O
the O
predominant O
ha O
##p O
##lot O
##ype O
of O
the O
p O
##ah O
lo O
##cus O
in O
the O
or O
##ient O
##al O
population O
. O

it O
accounts O
for O
13 O
. O

8 O
% O
of O
northern O
chin O
##ese O
and O
27 O
% O
of O
j O
##apa O
##nese O
p B-Disease
##ku I-Disease
all O
##ele O
##s O
, O
but O
it O
is O
rare O
in O
southern O
chin O
##ese O
( O
2 O
. O
2 O
% O
) O
and O
is O
absent O
in O
the O
ca O
##uca O
##sian O
population O
. O

the O
data O
demonstrate O
un O
##am O
##bi O
##guous O
##ly O
that O
the O
mutation O
occurred O
after O
racial O
diver O
##gence O
of O
or O
##ient O
##als O
and O
ca O
##uca O
##sian O
##s O
and O
suggest O
that O
the O
all O
##ele O
has O
spread O
throughout O
the O
or O
##ient O
by O
a O
founder O
effect O
. O

previous O
protein O
p O
##oly O
##mor O
##phism O
studies O
in O
eastern O
as O
##ia O
have O
led O
to O
the O
hypothesis O
that O
" O
northern O
mon O
##gol O
##oids O
" O
represented O
a O
founding O
population O
in O
as O
##ia O
. O

our O
results O
are O
compatible O
with O
this O
hypothesis O
in O
that O
the O
p B-Disease
##ku I-Disease
mutation O
might O
have O
occurred O
in O
northern O
mon O
##gol O
##oids O
and O
subsequently O
spread O
to O
the O
chin O
##ese O
and O
j O
##apa O
##nese O
populations O
. O

glucose B-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
caused O
by O
a O
defect O
in O
the O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
. O

glucose B-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
( O
g B-Disease
##g I-Disease
##m I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
manifest O
##ing O
within O
the O
first O
weeks O
of O
life O
and O
characterized O
by O
a O
selective O
failure O
to O
absorb O
diet O
##ary O
glucose O
and O
gal O
##act O
##ose O
from O
the O
in O
##test O
##ine O
. O

the O
con O
##se O
##quent O
severe O
di B-Disease
##ar I-Disease
##r I-Disease
##hoe I-Disease
##a I-Disease
and O
de B-Disease
##hy I-Disease
##dra I-Disease
##tion I-Disease
are O
usually O
fatal O
unless O
these O
sugar O
##s O
are O
eliminated O
from O
the O
diet O
. O

in O
##test O
##inal O
bio O
##ps O
##ies O
of O
g B-Disease
##g I-Disease
##m I-Disease
patients O
have O
revealed O
a O
specific O
defect O
in O
na O
( O
+ O
) O
- O
dependent O
absorption O
of O
glucose O
in O
the O
brush O
border O
. O

normal O
glucose O
absorption O
is O
mediated O
by O
the O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
in O
the O
brush O
border O
membrane O
of O
the O
in O
##test O
##inal O
e O
##pit O
##hel O
##ium O
. O

cellular O
influx O
is O
driven O
by O
the O
trans O
##me O
##mb O
##rane O
na O
+ O
electro O
##chemical O
potential O
gradient O
; O
thereafter O
the O
sugar O
moves O
to O
the O
blood O
across O
the O
b O
##as O
##olate O
##ral O
membrane O
via O
the O
facilitated O
glucose O
carrier O
. O

we O
have O
previously O
clone O
##d O
and O
sequence O
##d O
a O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
from O
normal O
human O
il O
##eum O
and O
shown O
that O
this O
gene O
, O
s O
##g O
##lt O
##1 O
, O
resides O
on O
the O
di O
##stal O
q O
arm O
of O
chromosome O
22 O
. O

we O
have O
now O
am O
##plified O
s O
##g O
##lt O
##1 O
complementary O
d O
##na O
and O
g O
##eno O
##mic O
d O
##na O
from O
members O
of O
a O
family O
affected O
with O
g B-Disease
##g I-Disease
##m I-Disease
by O
the O
polymer O
##ase O
chain O
reaction O
. O

sequence O
analysis O
of O
the O
am O
##plified O
products O
has O
revealed O
a O
single O
miss O
##ense O
mutation O
in O
s O
##g O
##lt O
##1 O
which O
co O
##se O
##g O
##re O
##gate O
##s O
with O
the O
g B-Disease
##g I-Disease
##m I-Disease
p O
##hen O
##otype O
and O
results O
in O
a O
complete O
loss O
of O
na O
( O
+ O
) O
- O
dependent O
glucose O
transport O
in O
x O
##eno O
##pus O
o O
##ocytes O
injected O
with O
this O
complementary O
r O
##na O
. O
. O

a O
de O
no O
##vo O
un O
##bal O
##ance O
##d O
re O
##ci O
##p O
##ro O
##cal O
trans O
##location O
identified O
as O
paternal O
in O
origin O
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

inter O
##st O
##iti O
##al O
c O
##yt O
##ogen O
##etic O
del O
##eti O
##ons O
involving O
the O
paternal O
##ly O
derived O
chromosome O
15 O
##q O
##11 O
- O
13 O
have O
been O
described O
in O
patients O
with O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

we O
report O
a O
child O
with O
p B-Disease
##ws I-Disease
and O
a O
de O
no O
##vo O
un O
##bal O
##ance O
##d O
ka O
##ryo O
##type O
- O
45 O
, O
x O
##y O
, O
- O
9 O
, O
- O
15 O
, O
+ O
der O
( O
9 O
) O
t O
( O
9 O
; O
15 O
) O
( O
q O
##34 O
; O
q O
##13 O
) O
. O

molecular O
studies O
with O
the O
d O
##na O
probe O
pm O
##l O
##34 O
confirmed O
that O
only O
a O
single O
p B-Disease
##rade I-Disease
##r I-Disease
will I-Disease
##i I-Disease
critical O
region O
( O
p O
##w O
##c O
##r O
15 O
##q O
##11 O
. O
2 O
- O
q O
##12 O
) O
copy O
was O
present O
. O

hybrid O
##isation O
of O
patient O
and O
parental O
d O
##na O
with O
the O
multi O
- O
all O
##eli O
##c O
probe O
cm O
##w O
##1 O
, O
which O
maps O
to O
p O
##ter O
- O
15 O
##q O
##13 O
, O
showed O
that O
the O
chromosome O
involved O
in O
the O
trans O
##location O
was O
paternal O
in O
origin O
. O

this O
is O
the O
first O
example O
of O
a O
paternal O
##ly O
- O
derived O
p O
##w O
##c O
##r O
all O
##ele O
loss O
caused O
by O
an O
un O
##bal O
##ance O
##d O
trans O
##location O
that O
has O
arise O
##n O
de O
no O
##vo O
. O

local O
##isation O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
to O
19 O
##q O
##13 O
. O
2 O
- O
19 O
##q O
##13 O
. O
3 O
and O
its O
relationship O
to O
twelve O
p O
##oly O
##morphic O
lo O
##ci O
on O
19 O
##q O
. O

the O
order O
of O
fourteen O
p O
##oly O
##morphic O
markers O
local O
##ised O
to O
the O
long O
arm O
of O
human O
chromosome O
19 O
has O
been O
established O
by O
multi O
##point O
mapping O
in O
a O
set O
of O
40 O
c O
##ep O
##h O
( O
centre O
de O
##tude O
de O
p O
##oly O
##mor O
##phism O
##e O
hum O
##ain O
, O
par O
##is O
) O
reference O
families O
. O

we O
report O
here O
the O
link O
##age O
relationship O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
lo O
##cus O
to O
twelve O
of O
these O
markers O
as O
studied O
in O
45 O
families O
with O
d B-Disease
##m I-Disease
. O

the O
resulting O
genetic O
map O
is O
supported O
by O
the O
local O
##isation O
of O
the O
d O
##na O
markers O
in O
a O
panel O
of O
so O
##matic O
cell O
hybrid O
##s O
. O

ten O
of O
the O
twelve O
markers O
have O
been O
shown O
to O
be O
pro O
##ximal O
to O
the O
d B-Disease
##m I-Disease
gene O
and O
two O
, O
p O
##rk O
##c O
##g O
and O
d O
##19 O
##s O
##22 O
, O
di O
##stal O
but O
at O
distances O
of O
approximately O
25 O
cm O
and O
15 O
cm O
, O
respectively O
. O

the O
closest O
pro O
##ximal O
markers O
are O
a O
##po O
##c O
##2 O
( O
a O
##poli O
##pop O
##rote O
##in O
c O
- O
ii O
) O
and O
c O
##k O
##m O
( O
c O
##rea O
##tine O
kinase O
, O
muscle O
) O
approximately O
3 O
cm O
and O
2 O
cm O
from O
the O
d B-Disease
##m I-Disease
gene O
respectively O
, O
in O
the O
order O
a O
##po O
##c O
##2 O
- O
c O
##k O
##m O
- O
d O
##m O
. O

the O
distance O
between O
a O
##po O
##c O
##2 O
, O
c O
##k O
##m O
and O
d B-Disease
##m I-Disease
( O
of O
the O
order O
of O
2 O
million O
base O
pairs O
) O
and O
their O
known O
orientation O
should O
permit O
directional O
chromosome O
walking O
and O
jumping O
. O

the O
data O
presented O
here O
should O
enable O
us O
to O
determine O
whether O
or O
not O
new O
markers O
are O
di O
##stal O
to O
a O
##po O
##c O
##2 O
/ O
c O
##k O
##m O
and O
thus O
potentially O
flank O
the O
d B-Disease
##m I-Disease
gene O
. O
. O

local O
##ization O
of O
his O
##ti O
##das O
##e O
to O
human O
chromosome O
region O
12 O
##q O
##22 O
- O
- O
- O
- O
q O
##24 O
. O
1 O
and O
mouse O
chromosome O
region O
10 O
##c O
##2 O
- O
- O
- O
- O
d O
##1 O
. O

the O
human O
gene O
for O
his O
##ti O
##das O
##e O
( O
his O
##ti O
##dine O
am O
##monia O
- O
l O
##yas O
##e O
; O
ha O
##l O
) O
, O
the O
enzyme O
def O
##icient O
in O
his B-Disease
##ti I-Disease
##dine I-Disease
##mia I-Disease
, O
was O
assigned O
to O
human O
chromosome O
12 O
by O
southern O
b O
##lot O
analysis O
of O
human O
x O
mouse O
so O
##matic O
cell O
hybrid O
d O
##na O
. O

the O
gene O
was O
sub O
##loc O
##ali O
##zed O
to O
region O
12 O
##q O
##22 O
- O
- O
- O
- O
q O
##24 O
. O

1 O
by O
in O
sit O
##u O
hybrid O
##ization O
, O
using O
a O
human O
his O
##ti O
##das O
##e O
c O
##dn O
##a O
. O

the O
ho O
##mo O
##log O
##ous O
lo O
##cus O
in O
the O
mouse O
( O
ha O
##l O
) O
was O
mapped O
to O
region O
10 O
##c O
##2 O
- O
- O
- O
- O
d O
##1 O
by O
in O
sit O
##u O
hybrid O
##ization O
, O
using O
a O
cell O
line O
from O
a O
mouse O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
1 O
. O

10 O
robe O
##rts O
##onia O
##n O
trans O
##location O
. O

these O
assignments O
extend O
the O
conserved O
s O
##yn O
##ten O
##ic O
region O
between O
human O
chromosome O
12 O
and O
mouse O
chromosome O
10 O
that O
includes O
the O
genes O
for O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
, O
gamma O
inter O
##fer O
##on O
, O
p O
##ept O
##idas O
##e O
, O
and O
c O
##it O
##rate O
s O
##ynth O
##ase O
. O

the O
local O
##ization O
of O
his O
##ti O
##das O
##e O
to O
mouse O
chromosome O
10 O
suggests O
that O
the O
his O
##ti O
##das O
##e O
regulatory O
lo O
##cus O
( O
h O
##s O
##d O
) O
and O
the O
his O
##ti O
##dine O
##mia O
mutation O
( O
his O
) O
, O
which O
are O
both O
known O
to O
be O
on O
chromosome O
10 O
, O
may O
be O
all O
##ele O
##s O
of O
the O
his O
##ti O
##das O
##e O
structural O
gene O
lo O
##cus O
. O

determination O
of O
the O
mutations O
responsible O
for O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
in O
17 O
subjects O
. O

h O
##y O
##pox O
##ant O
##hine O
- O
- O
g O
##uan O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
hp O
##rt O
) O
is O
a O
pu O
##rine O
salvage O
enzyme O
that O
cat O
##aly O
##zes O
the O
conversion O
of O
h O
##y O
##pox O
##ant O
##hine O
to O
in O
##os O
##ine O
mon O
##op O
##hos O
##phate O
and O
g O
##uan O
##ine O
to O
g O
##uan O
##os O
##ine O
mon O
##op O
##hos O
##phate O
. O

previous O
studies O
of O
mutant O
hp O
##rt O
proteins O
analyzed O
at O
the O
molecular O
level O
have O
shown O
a O
significant O
he O
##tero O
##gene O
##ity O
. O

this O
investigation O
further O
ve O
##ri O
##fies O
this O
he O
##tero O
##gene O
##ity O
and O
identifies O
insertion O
##s O
, O
del O
##eti O
##ons O
, O
and O
point O
mutations O
. O

the O
direct O
se O
##quencing O
of O
the O
polymer O
##ase O
chain O
reaction O
- O
am O
##plified O
product O
of O
reverse O
- O
trans O
##cribed O
hp O
##rt O
m O
##rna O
enabled O
the O
rapid O
identification O
of O
the O
mutations O
found O
in O
17 O
previously O
un O
##cha O
##rac O
##ter O
##ized O
cell O
lines O
derived O
from O
patients O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O
. O

link O
##age O
of O
d O
##na O
markers O
at O
x O
##q O
##28 O
to O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
and O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
present O
within O
the O
same O
family O
. O

we O
present O
a O
large O
kind O
##red O
that O
contained O
patients O
with O
either O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
or O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
. O

the O
p O
##ed O
##ig O
##ree O
clearly O
supported O
the O
x O
- O
linked O
mode O
of O
inheritance O
of O
the O
non O
##ne O
##ona O
##tal O
form O
of O
al B-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
. O

analysis O
with O
d O
##na O
markers O
at O
x O
##q O
##28 O
suggested O
segregation O
of O
both O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
with O
an O
identical O
ha O
##p O
##lot O
##ype O
. O

this O
indicated O
that O
non O
##ne O
##ona O
##tal O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
are O
caused O
by O
a O
mutation O
in O
the O
same O
gene O
at O
x O
##q O
##28 O
. O

it O
showed O
, O
further O
##more O
, O
that O
p O
##hen O
##otypic O
differences O
between O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
are O
not O
necessarily O
the O
consequence O
of O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
due O
to O
different O
mutations O
within O
the O
same O
gene O
. O

the O
ma O
##ximal O
lo O
##d O
score O
for O
link O
##age O
of O
the O
al B-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
gene O
and O
the O
multi O
##alle O
##lic O
anonymous O
d O
##na O
marker O
at O
d O
##x O
##s O
##5 O
##2 O
was O
3 O
. O

0 O
at O
a O
re O
##comb O
##ination O
fraction O
of O
0 O
. O

00 O
. O

this O
made O
a O
pre O
##nat O
##al O
or O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnosis O
and O
he O
##tero O
##zy O
##got O
##e O
detection O
by O
d O
##na O
analysis O
with O
this O
marker O
reliable O
. O

s O
##ke O
##wed O
x O
in O
##act O
##ivation O
in O
a O
female O
m O
##z O
twin O
results O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

one O
of O
female O
m O
##z O
twins O
presented O
with O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

physical O
examination O
, O
c O
##rea O
##tine O
p O
##hos O
##ph O
##oki O
##nas O
##e O
levels O
, O
and O
muscle O
bio O
##psy O
were O
consistent O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

however O
, O
because O
of O
her O
sex O
she O
was O
diagnosed O
as O
having O
limb B-Disease
- I-Disease
g I-Disease
##ir I-Disease
##dle I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

with O
c O
##dn O
##a O
probe O
##s O
to O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
, O
a O
gene O
del O
##eti O
##on O
was O
detected O
in O
the O
twins O
and O
their O
mother O
. O

the O
de O
no O
##vo O
mutation O
which O
arose O
in O
the O
mother O
was O
shown O
by O
novel O
junction O
fragments O
generated O
by O
hind O
##ii O
##i O
, O
ps O
##ti O
, O
or O
ta O
##qi O
when O
probe O
##d O
with O
c O
##dn O
##a O
##8 O
. O

additional O
evidence O
of O
a O
large O
gene O
del O
##eti O
##on O
was O
given O
by O
novel O
s O
##fi O
##i O
junction O
fragments O
detected O
by O
probe O
##s O
p O
##20 O
, O
j O
- O
bi O
##r O
, O
and O
j O
- O
66 O
on O
pulsed O
- O
field O
gel O
electro O
##ph O
##ores O
##is O
( O
p O
##f O
##ge O
) O
. O

im O
##mu O
##nob O
##lot O
analysis O
of O
muscle O
from O
the O
affected O
twin O
showed O
d O
##ys O
##tro O
##phi O
##n O
of O
normal O
size O
but O
of O
reduced O
amount O
. O

im O
##mu O
##no O
##f O
##lu O
##ores O
##cent O
visual O
##ization O
of O
d O
##ys O
##tro O
##phi O
##n O
revealed O
f O
##oc O
##i O
of O
d O
##ys O
##tro O
##phi O
##n O
- O
positive O
fibers O
adjacent O
to O
f O
##oc O
##i O
of O
d O
##ys O
##tro O
##phi O
##n O
- O
negative O
fibers O
. O

these O
data O
indicate O
that O
the O
affected O
twin O
is O
a O
manifest O
##ing O
carrier O
of O
an O
abnormal O
d B-Disease
##m I-Disease
##d I-Disease
gene O
, O
her O
my B-Disease
##op I-Disease
##athy I-Disease
being O
a O
direct O
result O
of O
under O
##ex O
##press O
##ion O
of O
d O
##ys O
##tro O
##phi O
##n O
. O

c O
##yt O
##ogen O
##etic O
analysis O
revealed O
normal O
ka O
##ryo O
##type O
##s O
, O
eliminating O
the O
possibility O
of O
a O
trans O
##location O
affecting O
d B-Disease
##m I-Disease
##d I-Disease
gene O
function O
. O

both O
link O
##age O
analysis O
and O
d O
##na O
finger O
##print O
analysis O
revealed O
that O
each O
twin O
has O
two O
different O
x O
chromosome O
##s O
, O
eliminating O
the O
possibility O
of O
un B-Disease
##ip I-Disease
##are I-Disease
##ntal I-Disease
di I-Disease
##so I-Disease
##my I-Disease
as O
a O
mechanism O
for O
d B-Disease
##m I-Disease
##d I-Disease
expression O
. O

on O
the O
basis O
of O
met O
##hyl O
##ation O
differences O
of O
the O
paternal O
and O
maternal O
x O
chromosome O
##s O
in O
these O
m O
##z O
twins O
, O
we O
propose O
uneven O
l O
##yon O
##ization O
( O
x O
chromosome O
in O
##act O
##ivation O
) O
as O
the O
underlying O
mechanism O
for O
disease O
expression O
in O
the O
affected O
female O
. O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
and O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
associated O
with O
partial O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
in O
three O
generations O
of O
a O
kind O
##red O
. O

four O
cases O
of O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
and O
one O
case O
of O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
have O
developed O
in O
a O
kind O
##red O
over O
three O
generations O
demonstrating O
that O
am B-Disease
##n I-Disease
is O
a O
clinical O
variant O
of O
al B-Disease
##d I-Disease
. O

pit O
##uit O
##ary O
- O
ad O
##rena O
##l O
function O
studies O
were O
performed O
in O
10 O
family O
members O
, O
including O
two O
affected O
males O
and O
four O
females O
identified O
as O
carriers O
of O
al B-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
. O

no O
pit B-Disease
##uit I-Disease
##ary I-Disease
- I-Disease
ad I-Disease
##rena I-Disease
##l I-Disease
abnormal I-Disease
##ity I-Disease
was O
found O
in O
the O
carriers O
. O

however O
, O
basal O
morning O
plasma O
ad O
##ren O
##oc O
##ort O
##ico O
##tro O
##pic O
hormone O
( O
act O
##h O
) O
levels O
were O
marked O
##ly O
elevated O
in O
the O
two O
males O
with O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
, O
despite O
the O
fact O
that O
they O
had O
no O
clinical O
signs O
of O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
and O
that O
morning O
plasma O
co O
##rt O
##is O
##ol O
levels O
and O
their O
response O
to O
ma O
##ximal O
ex O
##ogen O
##ous O
act O
##h O
stimulation O
appeared O
to O
be O
normal O
. O

in O
addition O
, O
the O
integrated O
24 O
- O
hour O
response O
to O
the O
administration O
were O
also O
sub O
##nor O
##mal O
in O
these O
two O
cases O
. O

thus O
, O
people O
with O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
may O
have O
sub O
##c O
##lini O
##cal O
partial O
ad B-Disease
##ren I-Disease
##oc I-Disease
##rot I-Disease
##ical I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
. O

no O
other O
end B-Disease
##oc I-Disease
##rino I-Disease
##log I-Disease
##ic I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
was O
identified O
. O
. O

regional O
local O
##isation O
of O
the O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
lo O
##cus O
to O
human O
chromosome O
9 O
##q O
##13 O
- O
- O
- O
- O
q O
##21 O
. O
1 O
. O

we O
have O
previously O
assigned O
the O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
lo O
##cus O
( O
f O
##rda O
) O
to O
chromosome O
9 O
; O
the O
current O
ma O
##ximal O
lo O
##d O
score O
between O
f O
##rda O
and O
m O
##ct O
##11 O
##2 O
( O
d O
##9 O
##s O
##15 O
) O
is O
greater O
than O
50 O
at O
a O
re O
##comb O
##ination O
fraction O
of O
the O
##ta O
= O
0 O
. O

the O
physical O
assignment O
of O
the O
lo O
##cus O
defined O
by O
m O
##ct O
##11 O
##2 O
, O
and O
hence O
f O
##rda O
, O
has O
not O
been O
determined O
, O
although O
link O
##age O
analysis O
of O
m O
##ct O
##11 O
##2 O
with O
other O
chromosome O
9 O
markers O
in O
##ferred O
a O
location O
close O
to O
the O
cent O
##rome O
##re O
. O

we O
have O
used O
in O
sit O
##u O
hybrid O
##isation O
with O
m O
##ct O
##11 O
##2 O
, O
a O
corresponding O
co O
##sm O
##id O
m O
##j O
##1 O
, O
and O
d O
##r O
##47 O
( O
d O
##9 O
##s O
##5 O
) O
, O
coupled O
with O
mapping O
studies O
on O
hybrid O
cell O
panels O
, O
to O
define O
more O
precisely O
the O
location O
of O
the O
disease O
lo O
##cus O
. O

the O
in O
sit O
##u O
location O
of O
all O
three O
probe O
##s O
is O
9 O
##q O
##13 O
- O
- O
- O
- O
q O
##21 O
. O

1 O
, O
di O
##stal O
to O
the O
variable O
he O
##tero O
##ch O
##roma O
##tin O
region O
. O

physical O
assignment O
of O
f O
##rda O
will O
allow O
us O
to O
identify O
hybrid O
cell O
lines O
containing O
the O
m O
##uta O
##ted O
gene O
. O

increased O
high O
- O
density O
lip O
##op O
##rote O
##in O
levels O
caused O
by O
a O
common O
ch O
##ole O
##ster O
##yl O
- O
est O
##er O
transfer O
protein O
gene O
mutation O
. O

background O
and O
methods O
. O

the O
plasma O
ch O
##ole O
##ster O
##yl O
- O
est O
##er O
transfer O
protein O
( O
c O
##et O
##p O
) O
cat O
##aly O
##zes O
the O
transfer O
of O
ch O
##ole O
##ster O
##yl O
est O
##ers O
from O
high O
- O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
to O
other O
lip O
##op O
##rote O
##ins O
. O

we O
recently O
described O
a O
j O
##apa O
##nese O
family O
with O
increased O
h O
##dl O
levels O
and O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
due O
to O
a O
s O
##p O
##licing O
defect O
of O
the O
c O
##et O
##p O
gene O
. O

to O
assess O
the O
frequency O
and O
p O
##hen O
##otype O
of O
this O
condition O
, O
we O
screened O
11 O
additional O
families O
with O
high O
h O
##dl O
levels O
by O
means O
of O
a O
radio O
##im O
##mu O
##no O
##ass O
##ay O
for O
c O
##et O
##p O
and O
d O
##na O
analysis O
. O

results O
. O

we O
found O
the O
same O
c O
##et O
##p O
gene O
mutation O
in O
four O
families O
from O
three O
different O
regions O
of O
j O
##apa O
##n O
. O

analysis O
of O
restriction O
- O
fragment O
- O
length O
p O
##oly O
##mor O
##phism O
##s O
of O
the O
mutant O
c O
##et O
##p O
all O
##ele O
showed O
that O
all O
pro O
##band O
##s O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
identical O
ha O
##p O
##lot O
##ype O
. O

family O
members O
ho O
##mo O
##zy O
##go O
##us O
for O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
( O
n O
= O
10 O
) O
had O
moderate O
h B-Disease
##yper I-Disease
##cho I-Disease
##les I-Disease
##tero I-Disease
##lem I-Disease
##ia I-Disease
( O
mean O
total O
ch O
##ole O
##ster O
##ol O
level O
[ O
+ O
/ O
- O
s O
##d O
] O
, O
7 O
. O
01 O
+ O
/ O
- O
0 O
. O
83 O
mm O
##ol O
per O
liter O
) O
, O
marked O
##ly O
increased O
levels O
of O
h O
##dl O
ch O
##ole O
##ster O
##ol O
( O
4 O
. O
24 O
+ O
/ O
- O
1 O
. O
01 O
mm O
##ol O
per O
liter O
) O
and O
a O
##poli O
##pop O
##rote O
##in O
a O
- O
i O
, O
and O
decreased O
levels O
of O
low O
- O
density O
lip O
##op O
##rote O
##in O
ch O
##ole O
##ster O
##ol O
( O
1 O
. O
99 O
+ O
/ O
- O
0 O
. O
80 O
mm O
##ol O
per O
liter O
) O
and O
a O
##poli O
##pop O
##rote O
##in O
b O
. O

members O
he O
##tero O
##zy O
##go O
##us O
for O
the O
deficiency O
( O
n O
= O
20 O
) O
, O
whose O
c O
##et O
##p O
levels O
were O
in O
the O
lower O
part O
of O
the O
normal O
range O
, O
had O
moderately O
increased O
levels O
of O
h O
##dl O
ch O
##ole O
##ster O
##ol O
and O
a O
##poli O
##pop O
##rote O
##in O
a O
- O
i O
and O
an O
increased O
ratio O
of O
h O
##dl O
sub O
##c O
##lass O
2 O
to O
h O
##dl O
sub O
##c O
##lass O
3 O
, O
as O
compared O
with O
un O
##af O
##fected O
family O
members O
( O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
8 O
vs O
. O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
4 O
) O
. O

c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
was O
not O
found O
in O
six O
unrelated O
subjects O
with O
elevated O
h O
##dl O
ch O
##ole O
##ster O
##ol O
levels O
who O
were O
from O
different O
parts O
of O
the O
united O
states O
. O

conclusions O
. O

c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
appears O
to O
be O
a O
frequent O
cause O
of O
increased O
h O
##dl O
levels O
in O
the O
population O
of O
j O
##apa O
##n O
, O
possibly O
because O
of O
a O
founder O
effect O
. O

the O
results O
that O
we O
observed O
in O
he O
##tero O
##zy O
##got O
##es O
suggest O
that O
c O
##et O
##p O
normally O
plays O
a O
part O
in O
the O
regulation O
of O
levels O
of O
h O
##dl O
sub O
##c O
##lass O
2 O
. O

there O
was O
no O
evidence O
of O
premature B-Disease
at I-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rosis I-Disease
in O
the O
families O
with O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
. O

in O
fact O
, O
the O
lip O
##op O
##rote O
##in O
profile O
of O
persons O
with O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
is O
potentially O
anti O
##ather O
##ogenic O
and O
may O
be O
associated O
with O
an O
increased O
life O
span O
. O

further O
mapping O
of O
an O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
lo O
##cus O
to O
the O
chromosome O
11 O
##q O
##23 O
region O
. O

we O
recently O
mapped O
the O
gene O
for O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
group O
a O
( O
at O
##a O
) O
to O
chromosome O
11 O
##q O
##22 O
- O
23 O
by O
link O
##age O
analysis O
, O
using O
the O
genetic O
markers O
thy O
##1 O
and O
p O
##yn O
##b O
##3 O
. O

12 O
( O
d O
##11 O
##s O
##14 O
##4 O
) O
. O

the O
most O
likely O
order O
was O
cent O
- O
at O
- O
s O
##14 O
##4 O
- O
thy O
##1 O
. O

the O
present O
paper O
describes O
further O
mapping O
of O
the O
at B-Disease
lo O
##cus O
by O
means O
of O
a O
panel O
of O
10 O
markers O
that O
span O
approximately O
60 O
cm O
in O
the O
11 O
##q O
##22 O
- O
23 O
region O
centered O
around O
s O
##14 O
##4 O
and O
thy O
##1 O
. O

location O
scores O
indicate O
that O
three O
con O
##ti O
##guous O
sub O
##se O
##gment O
##s O
within O
the O
[ O
s O
##14 O
##4 O
- O
thy O
##1 O
] O
segment O
, O
as O
well O
as O
three O
con O
##ti O
##guous O
segments O
te O
##lo O
##mer O
##ic O
to O
thy O
##1 O
, O
are O
each O
unlikely O
to O
contain O
the O
at B-Disease
lo O
##cus O
, O
while O
the O
more O
cent O
##rome O
##ric O
[ O
s O
##t O
##my O
- O
s O
##14 O
##4 O
] O
segment O
is O
most O
likely O
to O
contain O
the O
at B-Disease
lo O
##cus O
. O

these O
data O
, O
together O
with O
recent O
re O
##fine O
##ments O
in O
the O
link O
##age O
and O
physical O
maps O
of O
11 O
##q O
##22 O
- O
23 O
, O
place O
the O
at B-Disease
lo O
##cus O
at O
11 O
##q O
##23 O
. O

re O
##current O
men B-Disease
##ing I-Disease
##itis I-Disease
in O
a O
patient O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
deficiency I-Disease
of I-Disease
the I-Disease
c I-Disease
##9 I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

first O
case O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
in O
euro O
##pe O
. O

we O
describe O
the O
first O
cases O
, O
to O
our O
knowledge O
, O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
in O
euro O
##pe O
that O
were O
detected O
in O
a O
s O
##wi O
##ss O
family O
, O
of O
which O
two O
members O
- O
- O
one O
with O
a O
complete O
deficiency O
and O
the O
other O
with O
approximately O
half O
- O
normal O
c O
##9 O
levels O
- O
- O
experienced O
bacterial B-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
. O

the O
index O
patient O
, O
a O
56 O
- O
year O
- O
old O
white O
man O
with O
a O
history O
of O
pu B-Disease
##ru I-Disease
##lent I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
at O
the O
age O
of O
23 O
years O
, O
presented O
with O
an O
acute B-Disease
men I-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
. O

no O
imp B-Disease
##air I-Disease
##ment I-Disease
of I-Disease
cellular I-Disease
immunity I-Disease
or O
im B-Disease
##mu I-Disease
##no I-Disease
##g I-Disease
##lo I-Disease
##bul I-Disease
##in I-Disease
deficiency I-Disease
could O
be O
found O
. O

complement O
ass O
##ays O
showed O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
c I-Disease
##9 I-Disease
component I-Disease
, O
while O
the O
other O
individual O
component O
levels O
were O
normal O
and O
the O
hem O
##oly O
##tic O
activity O
( O
measured O
using O
the O
ch O
##50 O
ass O
##ay O
) O
was O
only O
slightly O
reduced O
. O

a O
family O
study O
revealed O
complete B-Disease
c I-Disease
##9 I-Disease
deficiency I-Disease
in O
the O
patients O
healthy O
brother O
and O
half O
- O
normal O
c O
##9 O
concentrations O
in O
his O
sister O
, O
his O
son O
( O
who O
also O
had O
experienced O
an O
episode O
of O
bacterial B-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
) O
, O
and O
his O
niece O
, O
consistent O
with O
an O
inherited O
c B-Disease
##9 I-Disease
deficiency I-Disease
. O

this O
first O
case O
of O
re B-Disease
##current I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
in O
a O
white O
patient O
with O
complete B-Disease
c I-Disease
##9 I-Disease
deficiency I-Disease
suggests O
that O
this O
complement B-Disease
defect I-Disease
may O
also O
be O
a O
risk O
factor O
for O
bacterial B-Disease
, I-Disease
especially I-Disease
ne I-Disease
##isse I-Disease
##rial I-Disease
, I-Disease
infections I-Disease
. O
. O

detection O
of O
98 O
% O
of O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
gene O
del O
##eti O
##ons O
by O
polymer O
##ase O
chain O
reaction O
. O

we O
describe O
o O
##li O
##gon O
##uc O
##leo O
##tide O
prime O
##r O
sequences O
that O
can O
be O
used O
to O
am O
##p O
##lify O
eight O
ex O
##ons O
plus O
the O
muscle O
promoter O
of O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
in O
a O
single O
multiple O
##x O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
. O

when O
used O
in O
conjunction O
with O
an O
existing O
prime O
##r O
set O
, O
these O
two O
multiple O
##x O
reactions O
detect O
about O
98 O
% O
of O
del O
##eti O
##ons O
in O
patients O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
or I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
, O
b B-Disease
##m I-Disease
##d I-Disease
) O
. O

further O
##more O
, O
these O
prime O
##rs O
am O
##p O
##lify O
most O
of O
the O
ex O
##ons O
in O
the O
del O
##eti O
##on O
prone O
" O
hot O
spot O
" O
region O
around O
ex O
##ons O
44 O
to O
53 O
, O
allowing O
determination O
of O
del O
##eti O
##on O
end O
##points O
and O
prediction O
of O
mutation O
##al O
effects O
on O
the O
translation O
##al O
reading O
frame O
. O

thus O
, O
use O
of O
these O
p O
##c O
##r O
- O
based O
ass O
##ays O
will O
allow O
del O
##eti O
##on O
detection O
and O
pre O
##nat O
##al O
diagnosis O
for O
most O
d B-Disease
##m I-Disease
##d I-Disease
/ O
b B-Disease
##m I-Disease
##d I-Disease
patients O
in O
a O
fraction O
of O
the O
time O
required O
for O
southern O
b O
##lot O
analysis O
. O
. O

genetic O
he O
##tero O
##gene O
##ity O
at O
the O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
lo O
##cus O
in O
southern O
it O
##aly O
: O
a O
study O
on O
a O
population O
from O
the O
mater O
##a O
district O
. O

glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
has O
been O
analyzed O
by O
gel O
electro O
##ph O
##ores O
##is O
and O
by O
quantitative O
ass O
##ay O
in O
an O
un O
##sel O
##ec O
##ted O
sample O
of O
152 O
##4 O
school O
##boy O
##s O
from O
the O
province O
of O
mater O
##a O
( O
l O
##uca O
##nia O
) O
in O
southern O
it O
##aly O
. O

we O
have O
identified O
43 O
subjects O
with O
a O
g O
##6 O
##p O
##d O
variant O
. O

of O
these O
, O
31 O
had O
severe O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
nine O
had O
mild O
to O
moderate O
deficiency O
, O
and O
three O
had O
a O
non O
- O
def O
##icient O
electro O
##ph O
##ore O
##tic O
variant O
. O

the O
overall O
rate O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
was O
2 O
. O

6 O
% O
. O

the O
frequency O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
ranging O
from O
7 O
. O

2 O
% O
on O
the O
ion O
##ian O
coast O
to O
zero O
on O
the O
eastern O
side O
of O
the O
l O
##uca O
##nian O
a O
##pen O
##nine O
##s O
, O
appears O
to O
be O
inverse O
##ly O
related O
to O
the O
distance O
of O
each O
town O
examined O
from O
the O
ion O
##ian O
coast O
, O
suggesting O
that O
this O
geographic O
distribution O
may O
reflect O
, O
at O
least O
in O
part O
, O
gene O
flow O
from O
g O
##ree O
##k O
settlers O
. O

bio O
##chemical O
characterization O
has O
shown O
that O
most O
of O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
this O
population O
is O
accounted O
for O
by O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
. O

in O
addition O
, O
we O
have O
found O
several O
examples O
of O
two O
other O
known O
p O
##oly O
##morphic O
variants O
( O
g O
##6 O
##p O
##d O
ca O
##glia O
##ri O
and O
g O
##6 O
##p O
##d O
a O
- O
) O
; O
three O
new O
p O
##oly O
##morphic O
variants O
, O
g O
##6 O
##p O
##d O
meta O
##pont O
##o O
( O
class O
ii O
##i O
) O
, O
g O
##6 O
##p O
##d O
mon O
##tal O
##ban O
##o O
( O
class O
ii O
##i O
) O
, O
and O
g O
##6 O
##p O
##d O
p O
##istic O
##ci O
( O
class O
i O
##v O
) O
; O
and O
two O
s O
##poradic O
variants O
, O
g O
##6 O
##p O
##d O
t O
##urs O
##i O
( O
class O
ii O
##i O
) O
and O
g O
##6 O
##p O
##d O
f O
##er O
##rand O
##ina O
( O
class O
ii O
) O
. O

these O
data O
provide O
further O
evidence O
for O
the O
marked O
genetic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
within O
a O
relatively O
narrow O
geographic O
area O
and O
they O
prove O
the O
presence O
in O
the O
it O
##alia O
##n O
peninsula O
of O
a O
gene O
( O
g O
##da O
- O
) O
regarded O
as O
characteristic O
##ally O
a O
##f O
##rica O
##n O
. O

deficiency B-Disease
of I-Disease
the I-Disease
m I-Disease
##uri I-Disease
##ne I-Disease
fifth I-Disease
complement I-Disease
component I-Disease
( I-Disease
c I-Disease
##5 I-Disease
) I-Disease
. O

a O
2 O
- O
base O
pair O
gene O
del O
##eti O
##on O
in O
a O
5 O
' O
- O
ex O
##on O
. O

to O
as O
##cer O
##tain O
the O
molecular O
mechanism O
that O
causes O
m O
##uri O
##ne O
c B-Disease
##5 I-Disease
deficiency I-Disease
, O
g O
##eno O
##mic O
and O
c O
##dn O
##a O
libraries O
were O
constructed O
from O
mouse O
liver O
d O
##na O
and O
m O
##rna O
employing O
the O
con O
##genic O
strains O
b O
##10 O
. O

d O
##2 O
/ O
n O
##s O
##n O
##j O
and O
b O
##10 O
. O

d O
##2 O
/ O
o O
##s O
##n O
##j O
that O
are O
sufficient O
and O
def B-Disease
##icient I-Disease
for I-Disease
c I-Disease
##5 I-Disease
, O
respectively O
. O

g O
##eno O
##mic O
fragments O
were O
isolated O
which O
correspond O
to O
p O
##vu O
##ii O
and O
hind O
##ii O
##i O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
associated O
with O
c B-Disease
##5 I-Disease
deficiency I-Disease
. O

sequence O
analyses O
demonstrated O
that O
each O
of O
these O
p O
##oly O
##mor O
##phism O
##s O
resulted O
from O
single O
base O
pair O
substitution O
##s O
and O
that O
neither O
substitution O
would O
probably O
cause O
or O
contribute O
to O
the O
c B-Disease
##5 I-Disease
deficiency I-Disease
. O

sequence O
analyses O
of O
c O
##5 O
sufficient O
and O
def O
##icient O
c O
##dn O
##as O
revealed O
a O
2 O
base O
- O
pair O
del O
##eti O
##on O
in O
the O
def O
##icient O
c O
##dn O
##as O
. O

the O
" O
ta O
" O
del O
##eti O
##on O
was O
located O
near O
the O
5 O
end O
of O
the O
c O
##dn O
##a O
. O

this O
del O
##eti O
##on O
shifts O
the O
reading O
frame O
of O
the O
c O
##5 O
m O
##rna O
so O
that O
the O
termination O
co O
##don O
u O
##ga O
is O
present O
4 O
base O
pairs O
downstream O
from O
the O
del O
##eti O
##on O
. O

g O
##eno O
##mic O
d O
##na O
was O
am O
##plified O
and O
sequence O
##d O
corresponding O
to O
the O
area O
surrounding O
the O
2 O
- O
base O
pair O
del O
##eti O
##on O
. O

six O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
strains O
, O
a O
/ O
he O
##j O
, O
a O
##k O
##r O
/ O
j O
, O
d O
##ba O
/ O
2 O
##j O
, O
n O
##z O
##b O
/ O
b O
##1 O
##n O
##j O
, O
s O
##w O
##r O
/ O
j O
, O
and O
b O
##10 O
. O

d O
##2 O
/ O
o O
##s O
##n O
##j O
, O
and O
four O
c O
##5 O
- O
sufficient O
strains O
, O
b O
##al O
##b O
/ O
c O
##j O
, O
c O
##5 O
##7 O
##b O
##l O
/ O
6 O
##j O
, O
d O
##ba O
/ O
1 O
##j O
, O
and O
b O
##10 O
. O

d O
##2 O
/ O
n O
##s O
##n O
##j O
, O
were O
analyzed O
. O

the O
se O
##quencing O
data O
revealed O
that O
the O
2 O
base O
pairs O
were O
deleted O
from O
the O
c O
##5 O
gene O
of O
each O
def O
##icient O
mouse O
tested O
but O
not O
from O
the O
c O
##5 O
gene O
of O
any O
sufficient O
mouse O
. O

these O
data O
demonstrate O
that O
1 O
) O
there O
is O
an O
identical O
2 O
- O
base O
pair O
del O
##eti O
##on O
in O
an O
ex O
##on O
of O
the O
c O
##5 O
gene O
in O
several O
different O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mouse O
strains O
; O
2 O
) O
the O
m O
##rna O
trans O
##cribed O
from O
the O
c O
##5 O
##d O
gene O
retains O
this O
del O
##eti O
##on O
; O
and O
3 O
) O
this O
mutation O
should O
result O
in O
c B-Disease
##5 I-Disease
protein I-Disease
deficiency I-Disease
. O

molecular O
genetics O
of O
p B-Disease
##ku I-Disease
in O
eastern O
euro O
##pe O
: O
a O
nonsense O
mutation O
associated O
with O
ha O
##p O
##lot O
##ype O
4 O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
a O
genetic B-Disease
disorder I-Disease
secondary O
to O
a O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

several O
mutations O
in O
the O
p O
##ah O
gene O
have O
recently O
been O
reported O
, O
and O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
was O
observed O
between O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
##s O
and O
specific O
mutations O
. O

a O
new O
molecular B-Disease
les I-Disease
##ion I-Disease
has O
been O
identified O
in O
ex O
##on O
7 O
of O
the O
p O
##ah O
gene O
in O
a O
hung O
##arian O
p B-Disease
##ku I-Disease
patient O
by O
direct O
se O
##quencing O
of O
p O
##c O
##r O
- O
am O
##plified O
d O
##na O
. O

the O
c O
- O
to O
- O
t O
transition O
causes O
the O
substitution O
of O
a O
##rg O
##24 O
##3 O
to O
a O
termination O
co O
##don O
, O
and O
the O
mutant O
all O
##ele O
is O
associated O
with O
ha O
##p O
##lot O
##ype O
4 O
of O
the O
p O
##ah O
gene O
. O

the O
mutation O
is O
present O
in O
two O
of O
nine O
mutant O
ha O
##p O
##lot O
##ype O
4 O
all O
##ele O
##s O
among O
eastern O
euro O
##pe O
##ans O
and O
is O
not O
present O
among O
western O
euro O
##pe O
##ans O
and O
as O
##ians O
. O

the O
r O
##arity O
of O
this O
mutant O
all O
##ele O
and O
its O
restricted O
geographic O
distribution O
suggest O
that O
the O
mutation O
##al O
event O
occurred O
recently O
on O
a O
normal O
ha O
##p O
##lot O
##ype O
4 O
background O
in O
eastern O
euro O
##pe O
. O
. O

the O
red O
- O
green O
visual O
pig O
##ment O
gene O
region O
in O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

although O
recent O
data O
established O
that O
a O
specific O
very O
- O
long O
- O
chain O
fatty O
a O
##cy O
##l O
- O
co O
##a O
s O
##ynth O
##eta O
##se O
is O
defect O
##ive O
in O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
, O
the O
al B-Disease
##d I-Disease
gene O
is O
still O
unidentified O
. O

the O
al B-Disease
##d I-Disease
lo O
##cus O
has O
been O
mapped O
to O
x O
##q O
##28 O
, O
like O
the O
red O
and O
green O
color O
pig O
##ment O
genes O
. O

abnormal B-Disease
color I-Disease
vision I-Disease
has O
been O
observed O
in O
12 O
of O
27 O
patients O
with O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
, O
a O
mild O
##er O
form O
of O
al B-Disease
##d I-Disease
. O

further O
##more O
, O
rear O
##rang O
##ement O
##s O
of O
the O
color O
vision O
gene O
cluster O
were O
found O
in O
four O
of O
eight O
al B-Disease
##d I-Disease
kind O
##red O
##s O
. O

this O
led O
us O
to O
propose O
that O
a O
single O
d O
##na O
rear O
##rang O
##ement O
could O
under O
##lie O
both O
al B-Disease
##d I-Disease
and O
abnormal B-Disease
color I-Disease
vision I-Disease
in O
these O
patients O
. O

study O
of O
34 O
f O
##rench O
al B-Disease
##d I-Disease
patients O
failed O
to O
reveal O
a O
higher O
than O
expected O
frequency O
of O
green O
/ O
red O
visual O
pig O
##ment O
rear O
##rang O
##ement O
##s O
3 O
to O
the O
red O
/ O
green O
color O
vision O
gene O
complex O
. O

the O
previous O
report O
of O
such O
rear O
##rang O
##ement O
##s O
was O
based O
on O
small O
numbers O
and O
lack O
of O
knowledge O
that O
the O
frequency O
of O
" O
abnormal O
" O
color O
vision O
array O
##s O
on O
molecular O
analysis O
was O
twice O
as O
high O
as O
expected O
on O
the O
basis O
of O
the O
frequency O
of O
p B-Disease
##hen I-Disease
##otypic I-Disease
color I-Disease
vision I-Disease
defects I-Disease
. O

the O
red O
/ O
green O
color O
pig O
##ment O
( O
r O
/ O
g O
##c O
##p O
) O
region O
was O
studied O
by O
pulsed O
- O
field O
gel O
electro O
##ph O
##ores O
##is O
in O
14 O
of O
these O
patients O
, O
and O
we O
did O
not O
find O
any O
fragment O
size O
difference O
between O
the O
patients O
and O
normal O
individuals O
who O
have O
the O
same O
number O
of O
pig O
##ment O
genes O
. O

the O
r O
/ O
g O
##c O
##p O
region O
was O
also O
analyzed O
in O
29 O
f O
##rench O
and O
seven O
north O
am O
##eric O
##an O
al B-Disease
##d I-Disease
patients O
by O
using O
six O
g O
##eno O
##mic O
d O
##na O
probe O
##s O
, O
isolated O
from O
a O
co O
##sm O
##id O
walk O
, O
that O
flank O
the O
color O
vision O
genes O
. O

no O
del O
##eti O
##ons O
were O
found O
with O
probe O
##s O
that O
lie O
3 O
of O
the O
green O
pig O
##ment O
genes O
. O

one O
of O
the O
eight O
previously O
reported O
al B-Disease
##d I-Disease
individuals O
has O
a O
long O
del O
##eti O
##on O
5 O
of O
the O
red O
pig O
##ment O
gene O
, O
a O
del O
##eti O
##on O
causing O
blue O
cone O
mon O
##och O
##roma O
##cy O
. O

this O
finding O
and O
the O
previous O
findings O
of O
a O
45 O
% O
frequency O
of O
p O
##hen O
##otypic O
color O
vision O
defects O
in O
patients O
with O
am B-Disease
##n I-Disease
may O
suggest O
that O
the O
al B-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
gene O
lies O
5 O
to O
the O
red O
pig O
##ment O
gene O
and O
that O
the O
frequent O
p O
##hen O
##otypic O
color B-Disease
vision I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
owe O
their O
origin O
to O
deleted O
d O
##na O
that O
includes O
regulatory O
genes O
for O
color O
vision O
. O

it O
is O
possible O
, O
however O
, O
that O
p O
##hen O
##otypic O
color B-Disease
vision I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
in O
am B-Disease
##n I-Disease
may O
be O
p O
##hen O
##oc O
##op O
##ies O
secondary O
to O
re O
##tina O
##l O
or O
neural O
involvement O
by O
the O
disease O
. O

the O
single O
case O
of O
blue O
cone O
mon O
##och O
##roma O
##cy O
may O
therefore O
be O
a O
fort O
##uit O
##ous O
coincidence O
of O
two O
diseases O
. O
. O

par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
no I-Disease
##cturnal I-Disease
ha I-Disease
##em I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
with O
co O
##ex O
##ist O
##ing O
deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
complement I-Disease
: O
lack O
of O
massive O
ha B-Disease
##em I-Disease
##oly I-Disease
##tic I-Disease
attack I-Disease
. O

a O
47 O
- O
year O
- O
old O
woman O
with O
par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
no I-Disease
##cturnal I-Disease
ha I-Disease
##em I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
( O
p B-Disease
##nh I-Disease
) O
was O
found O
to O
have O
an O
inherited B-Disease
deficiency I-Disease
in I-Disease
the I-Disease
ninth I-Disease
complement I-Disease
component I-Disease
( O
c O
##9 O
) O
. O

in O
complement O
- O
sensitivity O
l O
##ys O
##is O
tests O
, O
80 O
% O
of O
her O
er O
##yt O
##hr O
##ocytes O
were O
marked O
##ly O
complement O
- O
sensitive O
( O
p O
##nh O
- O
ii O
##i O
) O
. O

laser O
c O
##yt O
##of O
##lu O
##ori O
##metry O
with O
a O
mon O
##oc O
##lon O
##al O
anti O
##body O
against O
decay O
- O
a O
##cc O
##ele O
##rating O
factor O
( O
da O
##f O
) O
revealed O
that O
95 O
% O
of O
her O
er O
##yt O
##hr O
##ocytes O
were O
da O
##f O
- O
negative O
. O

surprisingly O
, O
she O
has O
suffered O
only O
mild O
ha B-Disease
##em I-Disease
##oly I-Disease
##sis I-Disease
and O
has O
never O
experienced O
massive O
spontaneous O
ha B-Disease
##em I-Disease
##oly I-Disease
##sis I-Disease
. O

gross O
ha B-Disease
##em I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
and O
j B-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
occurred O
only O
after O
receiving O
post O
##oper O
##ative O
trans O
##fusion O
of O
whole O
blood O
. O

in O
her O
serum O
, O
c O
##9 O
was O
not O
detect O
##able O
either O
by O
im O
##mu O
##nological O
or O
by O
functional O
ass O
##ays O
. O

both O
the O
ha O
##m O
test O
and O
the O
sugar O
water O
test O
using O
normal O
human O
serum O
or O
plasma O
yielded O
marked O
ha O
##em O
##oly O
##sis O
of O
the O
patients O
er O
##yt O
##hr O
##ocytes O
. O

when O
the O
patients O
serum O
or O
plasma O
was O
used O
, O
only O
a O
trace O
of O
l O
##ys O
##is O
was O
detected O
. O

addition O
of O
pu O
##rified O
human O
c O
##9 O
to O
her O
plasma O
fully O
restored O
ha O
##em O
##oly O
##sis O
. O

these O
observations O
indicated O
that O
c O
##9 O
may O
play O
a O
critical O
role O
in O
ha B-Disease
##em I-Disease
##oly I-Disease
##tic I-Disease
attacks I-Disease
in O
patients O
with O
p B-Disease
##nh I-Disease
and O
that O
characteristic O
ha B-Disease
##em I-Disease
##oly I-Disease
##sis I-Disease
in O
p B-Disease
##nh I-Disease
may O
be O
tempered O
by O
co O
##ex O
##ist O
##ing O
c B-Disease
##9 I-Disease
deficiency I-Disease
. O
. O

du O
##plication O
##al O
mutation O
at O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
: O
its O
frequency O
, O
distribution O
, O
origin O
, O
and O
p O
##hen O
##otype O
##gen O
##otype O
correlation O
. O

partial O
gene O
del O
##eti O
##on O
is O
the O
major O
cause O
of O
mutation O
leading O
to O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
and O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
b B-Disease
##m I-Disease
##d I-Disease
) O
. O

partial O
gene O
du O
##plication O
has O
also O
been O
recognized O
in O
a O
few O
cases O
. O

we O
have O
conducted O
a O
survey O
for O
du O
##plication O
in O
72 O
unrelated O
non O
##del O
##eti O
##on O
patients O
, O
analyzed O
by O
southern O
b O
##lot O
hybrid O
##ization O
with O
clone O
##s O
representing O
the O
entire O
d B-Disease
##m I-Disease
##d I-Disease
c O
##dn O
##a O
. O

with O
careful O
quantitative O
analysis O
of O
hybrid O
##ization O
band O
intensity O
, O
10 O
cases O
were O
found O
to O
carry O
a O
du O
##plication O
of O
part O
of O
the O
gene O
, O
a O
frequency O
of O
14 O
% O
for O
non O
##del O
##eti O
##on O
cases O
( O
10 O
/ O
72 O
) O
, O
or O
6 O
% O
for O
all O
cases O
( O
10 O
/ O
181 O
) O
. O

the O
extent O
of O
these O
du O
##plication O
##s O
has O
been O
characterized O
according O
to O
the O
published O
ex O
##on O
- O
containing O
hind O
##ii O
##i O
fragment O
map O
, O
and O
in O
six O
of O
the O
10 O
du O
##plication O
##s O
a O
novel O
restriction O
fragment O
that O
spanned O
the O
du O
##plication O
junction O
was O
detected O
. O

the O
resulting O
translation O
##al O
reading O
frame O
of O
m O
##rna O
has O
been O
predicted O
for O
nine O
du O
##plication O
##s O
. O

a O
shift O
of O
the O
reading O
frame O
was O
predicted O
in O
four O
of O
the O
six O
d B-Disease
##m I-Disease
##d I-Disease
cases O
and O
in O
one O
of O
the O
two O
intermediate O
cases O
, O
while O
the O
reading O
frame O
remained O
un O
##int O
##er O
##rup O
##ted O
in O
both O
b B-Disease
##m I-Disease
##d I-Disease
cases O
. O

r O
##f O
##l O
##p O
and O
quantitative O
southern O
b O
##lot O
analyses O
revealed O
a O
grand O
##pate O
##rnal O
origin O
of O
du O
##plication O
in O
four O
families O
and O
grand O
##mate O
##rnal O
origin O
in O
one O
family O
. O

in O
all O
five O
families O
, O
the O
du O
##plication O
was O
found O
to O
originate O
from O
a O
single O
x O
chromosome O
. O

une O
##qua O
##l O
sister O
- O
ch O
##roma O
##ti O
##d O
exchange O
is O
proposed O
to O
be O
the O
mechanism O
for O
the O
formation O
of O
these O
du O
##plication O
##s O
. O
. O

glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variants O
: O
g O
##d O
( O
+ O
) O
ale O
##xa O
##ndra O
associated O
with O
neon B-Disease
##ata I-Disease
##l I-Disease
j I-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
and O
g O
##d O
( O
- O
) O
camp O
##erd O
##own O
in O
a O
young O
man O
with O
lame B-Disease
##llar I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
. O

two O
male O
subjects O
are O
described O
, O
with O
unusual O
clinical O
presentations O
and O
with O
hit O
##her O
##to O
und O
##es O
##cribed O
g O
##6 O
##p O
##d O
variants O
. O

the O
first O
, O
of O
it O
##alia O
##n O
extraction O
, O
suffered O
from O
severe O
neon B-Disease
##ata I-Disease
##l I-Disease
j I-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
following O
maternal O
ing O
##est O
##ion O
of O
fresh O
broad O
beans O
( O
v O
##ici O
##a O
f O
##ava O
) O
both O
pre O
##nat O
##ally O
and O
post O
##nat O
##ally O
the O
expression O
of O
the O
en O
##zy O
##matic O
defect O
was O
much O
more O
severe O
in O
the O
neon O
##ata O
##l O
period O
than O
on O
re O
##test O
##ing O
in O
ad O
##ole O
##scence O
, O
when O
bio O
##chemical O
characterization O
showed O
unique O
features O
which O
justify O
designation O
as O
a O
new O
variant O
g O
##d O
( O
+ O
) O
ale O
##xa O
##ndra O
. O

the O
second O
patient O
, O
a O
boy O
of O
ma O
##lt O
##ese O
extraction O
who O
was O
found O
to O
have O
bilateral B-Disease
lame I-Disease
##llar I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
at O
the O
age O
of O
4 O
years O
, O
was O
identified O
as O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
def I-Disease
##icient I-Disease
only O
as O
a O
result O
of O
a O
survey O
of O
children O
of O
me O
##dit O
##er O
##rane O
##an O
origin O
with O
une O
##x O
##plain O
##ed O
cat B-Disease
##ara I-Disease
##ct I-Disease
formation O
; O
he O
has O
approximately O
15 O
% O
of O
normal O
enzyme O
activity O
, O
with O
another O
unique O
combination O
of O
bio O
##chemical O
characteristics O
which O
has O
led O
to O
its O
designation O
as O
g O
##d O
( O
- O
) O
camp O
##erd O
##own O
. O

although O
this O
association O
may O
be O
coincide O
##ntal O
, O
it O
pro O
##mpt O
##s O
further O
attention O
to O
the O
possibility O
that O
under O
certain O
circumstances O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
may O
favor O
cat B-Disease
##ara I-Disease
##ct I-Disease
formation O
. O

the O
two O
cases O
illustrate O
the O
value O
of O
characterization O
of O
the O
mutant O
enzyme O
whenever O
unexpected O
clinical O
or O
laboratory O
results O
are O
obtained O
. O
. O

statistical O
analysis O
of O
the O
two O
stage O
mutation O
model O
in O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
, O
and O
in O
s B-Disease
##poradic I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
and O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

analysis O
of O
the O
age O
incidence O
curves O
for O
un B-Disease
##ila I-Disease
##teral I-Disease
and I-Disease
bilateral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
led O
kn O
##uds O
##on O
to O
propose O
that O
hereditary B-Disease
t I-Disease
##umour I-Disease
##s I-Disease
may O
arise O
by O
a O
single O
event O
and O
s B-Disease
##poradic I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
by O
a O
two O
stage O
mutation O
process O
. O

it O
has O
been O
suggested O
recently O
that O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
may O
arise O
from O
a O
two O
stage O
mutation O
process O
. O

we O
anal O
##ys O
##ed O
the O
age O
incidence O
curves O
for O
s O
##ym O
##pt O
##oma O
##tic O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
( O
n O
= O
26 O
) O
and O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
( O
n O
= O
68 O
) O
in O
109 O
patients O
with O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
disease I-Disease
, O
and O
compared O
them O
to O
104 O
patients O
with O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
43 O
patients O
with O
s B-Disease
##poradic I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
. O

the O
age O
incidence O
curves O
for O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
in O
v B-Disease
##hl I-Disease
disease I-Disease
were O
compatible O
with O
a O
single O
mutation O
model O
, O
whereas O
the O
age O
incidence O
curves O
for O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
suggested O
a O
two O
stage O
mutation O
process O
. O

these O
data O
are O
compatible O
with O
the O
v B-Disease
##hl I-Disease
gene O
functioning O
as O
a O
re O
##cess O
##ive O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
. O

s B-Disease
##poradic I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
and O
some O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
may O
arise O
from O
so O
##matic O
mutations O
in O
##act O
##ivating O
both O
all O
##ele O
##s O
at O
the O
v B-Disease
##hl I-Disease
lo O
##cus O
. O
. O

screening O
for O
carriers O
of O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
among O
ash O
##ken O
##azi O
j O
##ews O
. O

a O
comparison O
of O
d O
##na O
- O
based O
and O
enzyme O
- O
based O
tests O
. O

background O
and O
methods O
. O

the O
prevention O
of O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
g B-Disease
##m I-Disease
##2 I-Disease
gang I-Disease
##lio I-Disease
##si I-Disease
##dos I-Disease
##is I-Disease
, I-Disease
type I-Disease
1 I-Disease
) O
depends O
on O
the O
identification O
of O
carriers O
of O
the O
gene O
for O
this O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
. O

we O
compared O
the O
enzyme O
- O
based O
test O
widely O
used O
in O
screening O
for O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
with O
a O
test O
based O
on O
analysis O
of O
d O
##na O
. O

we O
developed O
methods O
to O
detect O
the O
three O
mutations O
in O
the O
he O
##xa O
gene O
that O
occur O
with O
high O
frequency O
among O
ash O
##ken O
##azi O
j O
##ews O
two O
mutations O
cause O
infant O
##ile O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
, O
and O
the O
third O
causes O
the O
adult O
- O
onset O
form O
of O
the O
disease O
. O

d O
##na O
segments O
containing O
these O
mutation O
sites O
were O
am O
##plified O
with O
the O
polymer O
##ase O
chain O
reaction O
and O
analyzed O
for O
the O
presence O
of O
the O
mutations O
. O

results O
. O

among O
62 O
ash O
##ken O
##azi O
o O
##b O
##liga O
##te O
carriers O
of O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
, O
the O
three O
specific O
mutations O
accounted O
for O
all O
but O
one O
of O
the O
mutant O
all O
##ele O
##s O
( O
98 O
percent O
) O
. O

in O
216 O
ash O
##ken O
##azi O
carriers O
identified O
by O
the O
enzyme O
test O
, O
d O
##na O
analysis O
showed O
that O
177 O
( O
82 O
percent O
) O
had O
one O
of O
the O
identified O
mutations O
. O

of O
the O
177 O
, O
79 O
percent O
had O
the O
ex O
##on O
11 O
insertion O
mutation O
, O
18 O
percent O
had O
the O
intro O
##n O
12 O
s O
##p O
##lice O
- O
junction O
mutation O
, O
and O
3 O
percent O
had O
the O
less O
severe O
ex O
##on O
7 O
mutation O
associated O
with O
adult O
- O
onset O
disease O
. O

the O
results O
of O
the O
enzyme O
tests O
in O
the O
39 O
subjects O
( O
18 O
percent O
) O
who O
were O
defined O
as O
carriers O
but O
in O
whom O
d O
##na O
analysis O
did O
not O
identify O
a O
mutant O
all O
##ele O
were O
probably O
false O
positive O
( O
although O
there O
remains O
some O
possibility O
of O
unidentified O
mutations O
) O
. O

in O
addition O
, O
of O
152 O
persons O
defined O
as O
non O
##car O
##rier O
##s O
by O
the O
enzyme O
- O
based O
test O
, O
1 O
was O
identified O
as O
a O
carrier O
by O
d O
##na O
analysis O
( O
i O
. O
e O
e O
. O
, O
a O
false O
negative O
enzyme O
- O
test O
result O
) O
. O

conclusions O
. O

the O
increased O
specific O
##ity O
and O
predict O
##ive O
value O
of O
the O
d O
##na O
- O
based O
test O
make O
it O
a O
useful O
ad O
##junct O
to O
the O
diagnostic O
tests O
currently O
used O
to O
screen O
for O
carriers O
of O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
. O

total B-Disease
deficiency I-Disease
of I-Disease
plasma I-Disease
ch I-Disease
##ole I-Disease
##ster I-Disease
##yl I-Disease
est I-Disease
##er I-Disease
transfer I-Disease
protein I-Disease
in O
subjects O
ho O
##mo O
##zy O
##go O
##us O
and O
he O
##tero O
##zy O
##go O
##us O
for O
the O
intro O
##n O
14 O
s O
##p O
##licing O
defect O
. O

the O
molecular O
basis O
of O
ch B-Disease
##ole I-Disease
##ster I-Disease
##yl I-Disease
est I-Disease
##er I-Disease
transfer I-Disease
protein I-Disease
( I-Disease
c I-Disease
##et I-Disease
##p I-Disease
) I-Disease
deficiency I-Disease
was O
investigated O
in O
4 O
unrelated O
c B-Disease
##et I-Disease
##p I-Disease
- I-Disease
def I-Disease
##icient I-Disease
families O
. O

the O
high O
density O
lip O
##op O
##rote O
##in O
- O
ch O
##ole O
##ster O
##ol O
levels O
of O
the O
pro O
##band O
##s O
exceeded O
150 O
mg O
/ O
d O
##l O
. O

the O
plasma O
of O
the O
pro O
##band O
##s O
was O
totally O
def O
##icient O
in O
c O
##et O
##p O
activity O
and O
mass O
. O

the O
g O
##eno O
##mic O
d O
##na O
of O
the O
patients O
was O
am O
##plified O
by O
polymer O
##ase O
chain O
reaction O
, O
using O
two O
o O
##li O
##gon O
##uc O
##leo O
##tide O
prime O
##rs O
located O
in O
the O
intro O
##n O
12 O
and O
14 O
of O
the O
c O
##et O
##p O
gene O
, O
and O
the O
am O
##plified O
products O
were O
directly O
sequence O
##d O
. O

two O
patients O
were O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
g O
- O
to O
- O
a O
change O
at O
the O
5 O
- O
s O
##p O
##lice O
donor O
site O
of O
the O
intro O
##n O
14 O
. O

the O
g O
- O
to O
- O
a O
change O
would O
cause O
impaired O
s O
##p O
##licing O
of O
pre O
- O
messenger O
r O
##na O
. O

the O
other O
two O
pro O
##band O
##s O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
mutation O
, O
but O
totally O
lacked O
c O
##et O
##p O
. O

their O
lip O
##op O
##rote O
##in O
patterns O
were O
also O
similar O
to O
those O
of O
the O
two O
ho O
##mo O
##zy O
##got O
##es O
. O

thus O
, O
other O
genetic B-Disease
defects I-Disease
or O
metabolic O
factors O
in O
##f O
##lue O
##ncing O
c O
##et O
##p O
expression O
are O
implicated O
. O

the O
data O
suggest O
that O
the O
g O
- O
to O
- O
a O
mutation O
may O
be O
common O
in O
human O
plasma O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
. O

further O
##more O
, O
there O
could O
be O
compound O
he O
##tero O
##zy O
##got O
##es O
who O
totally O
lack O
plasma O
c O
##et O
##p O
and O
have O
lip O
##op O
##rote O
##in O
profiles O
similar O
to O
those O
of O
ho O
##mo O
##zy O
##got O
##es O
. O
. O

molecular O
genetics O
of O
the O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
me O
##dit O
##er O
##rane O
##an O
variant O
and O
description O
of O
a O
new O
g O
##6 O
##p O
##d O
mutant O
, O
g O
##6 O
##p O
##d O
and O
##al O
##us O
##13 O
##6 O
##1 O
##a O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
; I-Disease
e I-Disease
. I-Disease
c I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
the O
most O
common O
human O
en B-Disease
##zy I-Disease
##mo I-Disease
##pathy I-Disease
; O
more O
than O
300 O
different O
bio O
##chemical O
variants O
of O
the O
enzyme O
have O
been O
described O
. O

in O
many O
parts O
of O
the O
world O
the O
me O
##dit O
##er O
##rane O
##an O
type O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
prevalent O
. O

however O
, O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
has O
come O
to O
be O
regarded O
as O
a O
generic O
term O
applied O
to O
similar O
g O
##6 O
##p O
##d O
mutations O
thought O
, O
however O
, O
to O
represent O
a O
somewhat O
he O
##tero O
##gene O
##ous O
group O
. O

a O
c O
- O
- O
- O
- O
t O
mutation O
at O
n O
##uc O
##leo O
##tide O
56 O
##3 O
of O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
has O
been O
identified O
by O
v O
##ull O
##iam O
##y O
et O
al O
. O
, O
and O
the O
same O
mutation O
has O
been O
found O
by O
de O
v O
##ita O
et O
al O
. O
in O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
, O
g O
##6 O
##p O
##d O
sa O
##ssa O
##ri O
, O
and O
g O
##6 O
##p O
##d O
ca O
##glia O
##ri O
. O

the O
latter O
subjects O
had O
an O
additional O
mutation O
, O
at O
n O
##uc O
##leo O
##tide O
131 O
##1 O
, O
that O
did O
not O
produce O
a O
coding O
change O
. O

we O
have O
examined O
g O
##eno O
##mic O
d O
##na O
of O
five O
patients O
- O
- O
four O
of O
span O
##ish O
origin O
and O
one O
of O
j O
##ew O
##ish O
origin O
- O
- O
having O
en O
##zy O
##matical O
##ly O
documented O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
. O

all O
had O
both O
the O
mutation O
at O
n O
##uc O
##leo O
##tide O
56 O
##3 O
and O
that O
at O
n O
##uc O
##leo O
##tide O
131 O
##1 O
. O

a O
sixth O
sample O
, O
resembling O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
kinetic O
##ally O
but O
with O
a O
slightly O
rapid O
electro O
##ph O
##ore O
##tic O
mobility O
, O
was O
designated O
g O
##6 O
##p O
##d O
and O
##al O
##us O
and O
was O
found O
to O
have O
a O
different O
mutation O
, O
a O
g O
- O
- O
- O
- O
a O
transition O
at O
n O
##uc O
##leo O
##tide O
136 O
##1 O
, O
producing O
an O
a O
##rg O
##ini O
##ne O
- O
to O
- O
his O
##ti O
##dine O
substitution O
. O

these O
studies O
suggest O
that O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
is O
, O
after O
all O
, O
relatively O
ho O
##mogeneous O
. O

a O
normal O
male O
with O
an O
inherited O
del O
##eti O
##on O
of O
one O
ex O
##on O
within O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

we O
describe O
two O
brothers O
with O
identical O
inherited O
del O
##eti O
##ons O
of O
one O
single O
ex O
##on O
within O
the O
middle O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
; O
one O
brother O
has O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
diagnosed O
at O
11 O
years O
of O
age O
, O
whereas O
the O
older O
brother O
is O
normal O
at O
18 O
. O

these O
results O
have O
implications O
for O
genetic O
counsel O
##ling O
and O
pre O
##nat O
##al O
diagnosis O
in O
families O
with O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O
. O

du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
expression O
in O
normal O
and O
disease O
##d O
human O
muscle O
. O

a O
probe O
for O
the O
5 O
end O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
was O
used O
to O
study O
expression O
of O
the O
gene O
in O
normal O
human O
muscle O
, O
my O
##ogenic O
cell O
cultures O
, O
and O
muscle O
from O
patients O
with O
d B-Disease
##m I-Disease
##d I-Disease
. O

expression O
was O
found O
in O
r O
##na O
from O
normal O
f O
##etal O
muscle O
, O
adult O
cardiac O
and O
skeletal O
muscle O
, O
and O
culture O
##d O
muscle O
after O
my O
##ob O
##last O
fusion O
. O

in O
d B-Disease
##m I-Disease
##d I-Disease
muscle O
, O
expression O
of O
this O
portion O
of O
the O
gene O
was O
also O
revealed O
by O
in O
sit O
##u O
r O
##na O
hybrid O
##ization O
, O
particularly O
in O
re O
##gene O
##rating O
muscle O
fibers O
. O
. O

molecular O
and O
p O
##hen O
##otypic O
analysis O
of O
patients O
with O
del O
##eti O
##ons O
within O
the O
del O
##eti O
##on O
- O
rich O
region O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
. O

eighty O
unrelated O
individuals O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
or O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
b B-Disease
##m I-Disease
##d I-Disease
) O
were O
found O
to O
have O
del O
##eti O
##ons O
in O
the O
major O
del O
##eti O
##on O
- O
rich O
region O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
. O

this O
region O
includes O
the O
last O
five O
ex O
##ons O
detected O
by O
c O
##dn O
##a O
##5 O
##b O
- O
7 O
, O
all O
ex O
##ons O
detected O
by O
c O
##dn O
##a O
##8 O
, O
and O
the O
first O
two O
ex O
##ons O
detected O
by O
c O
##dn O
##a O
##9 O
. O

these O
80 O
individuals O
account O
for O
approximately O
75 O
% O
of O
109 O
del O
##eti O
##ons O
of O
the O
gene O
, O
detected O
among O
181 O
patients O
analyzed O
with O
the O
entire O
d O
##ys O
##tro O
##phi O
##n O
c O
##dn O
##a O
. O

end O
##points O
for O
many O
of O
these O
del O
##eti O
##ons O
were O
further O
characterized O
using O
two O
g O
##eno O
##mic O
probe O
##s O
, O
p O
##20 O
( O
d O
##x O
##s O
##26 O
##9 O
; O
wa O
##pen O
##aar O
et O
al O
. O
) O
and O
g O
##m O
##g O
##x O
##11 O
( O
d O
##x O
##s O
##23 O
##9 O
; O
present O
paper O
) O
. O

clinical O
findings O
are O
presented O
for O
all O
80 O
patients O
allowing O
a O
correlation O
of O
p O
##hen O
##otypic O
severity O
with O
the O
g O
##eno O
##type O
. O

thirty O
- O
eight O
independent O
patients O
were O
old O
enough O
to O
be O
classified O
as O
d B-Disease
##m I-Disease
##d I-Disease
, O
b B-Disease
##m I-Disease
##d I-Disease
, O
or O
intermediate O
p O
##hen O
##otype O
and O
had O
del O
##eti O
##ons O
of O
ex O
##ons O
with O
sequence O
##d O
intro O
##n O
/ O
ex O
##on O
boundaries O
. O

of O
these O
, O
eight O
b B-Disease
##m I-Disease
##d I-Disease
patients O
and O
one O
intermediate O
patient O
had O
gene O
del O
##eti O
##ons O
predicted O
to O
leave O
the O
reading O
frame O
intact O
, O
while O
21 O
d B-Disease
##m I-Disease
##d I-Disease
patients O
, O
7 O
intermediate O
patients O
, O
and O
1 O
b B-Disease
##m I-Disease
##d I-Disease
patient O
had O
gene O
del O
##eti O
##ons O
predicted O
to O
disrupt O
the O
reading O
frame O
. O

thus O
, O
with O
two O
exceptions O
, O
frames O
##hi O
##ft O
del O
##eti O
##ons O
of O
the O
gene O
resulted O
in O
more O
severe O
p O
##hen O
##otype O
than O
did O
in O
- O
frame O
del O
##eti O
##ons O
. O

this O
is O
in O
agreement O
with O
recent O
findings O
by O
b O
##au O
##mba O
##ch O
et O
al O
. O
and O
k O
##oe O
##ni O
##g O
et O
al O
. O
but O
is O
in O
contrast O
to O
findings O
, O
by O
ma O
##l O
##hot O
##ra O
et O
al O
. O
at O
the O
5 O
' O
end O
of O
the O
gene O
. O

c O
##lon O
##ing O
of O
break O
##points O
of O
a O
chromosome O
trans O
##location O
identifies O
the O
an O
##2 O
lo O
##cus O
. O

chromosome O
trans O
##location O
##s O
involving O
11 O
##p O
##13 O
have O
been O
associated O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
in O
two O
kind O
##red O
##s O
highlighting O
the O
ch O
##rom O
##oso O
##mal O
local O
##ization O
of O
the O
an O
##2 O
lo O
##cus O
. O

this O
lo O
##cus O
is O
also O
part O
of O
the O
wa B-Disease
##g I-Disease
##r I-Disease
complex O
( O
w B-Disease
##il I-Disease
##ms I-Disease
tumor I-Disease
, O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
g B-Disease
##eni I-Disease
##tour I-Disease
##ina I-Disease
##ry I-Disease
abnormal I-Disease
##ities I-Disease
, O
and O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
) O
. O

in O
one O
kind O
##red O
, O
the O
trans O
##location O
is O
associated O
with O
a O
del O
##eti O
##on O
, O
and O
probe O
##s O
for O
this O
region O
were O
used O
to O
identify O
and O
clone O
the O
break O
##points O
of O
the O
trans O
##location O
in O
the O
second O
kind O
##red O
. O

comparison O
of O
p O
##hage O
restriction O
maps O
exclude O
the O
presence O
of O
any O
si O
##zable O
del O
##eti O
##on O
in O
this O
case O
. O

sequences O
at O
the O
chromosome O
11 O
break O
##point O
are O
conserved O
in O
multiple O
species O
, O
suggesting O
that O
the O
trans O
##location O
falls O
within O
the O
an O
##2 O
gene O
. O
. O

link O
##age O
analysis O
of O
the O
a O
##poli O
##pop O
##rote O
##in O
c O
##2 O
gene O
and O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
on O
human O
chromosome O
19 O
reveals O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
in O
a O
f O
##rench O
- O
can O
##adia O
##n O
population O
. O

the O
gene O
for O
human O
a O
##poli O
##pop O
##rote O
##in O
c O
##2 O
( O
a O
##po O
##c O
##2 O
) O
, O
situated O
on O
the O
pro O
##ximal O
long O
arm O
of O
chromosome O
19 O
, O
is O
closely O
linked O
to O
the O
gene O
for O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

six O
a O
##po O
##c O
##2 O
r O
##f O
##l O
##ps O
( O
ta O
##qi O
, O
b O
##gli O
, O
ban O
##i O
, O
b O
##am O
##hi O
, O
n O
##co O
##i O
, O
and O
a O
##va O
##ii O
) O
have O
been O
identified O
to O
date O
. O

we O
have O
conducted O
a O
comprehensive O
d B-Disease
##m I-Disease
link O
##age O
study O
utilizing O
all O
six O
r O
##f O
##l O
##ps O
and O
involving O
50 O
families O
and O
37 O
##2 O
individuals O
. O

the O
most O
inform O
##ative O
r O
##f O
##l O
##ps O
are O
, O
in O
descending O
order O
, O
n O
##co O
##i O
( O
lo O
##d O
= O
6 O
. O
64 O
, O
the O
##ta O
= O
0 O
. O
05 O
) O
, O
b O
##gli O
( O
lo O
##d O
= O
6 O
. O
12 O
, O
the O
##ta O
= O
0 O
. O
05 O
) O
, O
a O
##va O
##ii O
( O
lo O
##d O
= O
6 O
. O
02 O
, O
the O
##ta O
= O
0 O
. O
03 O
) O
, O
ban O
##i O
( O
lo O
##d O
= O
5 O
. O
76 O
, O
the O
##ta O
= O
0 O
. O
04 O
) O
, O
ta O
##qi O
( O
lo O
##d O
= O
4 O
. O
29 O
, O
the O
##ta O
= O
0 O
. O
06 O
) O
, O
and O
b O
##am O
##hi O
( O
lo O
##d O
= O
1 O
. O
75 O
, O
the O
##ta O
= O
0 O
. O
01 O
) O
. O

a O
substantial O
increase O
in O
the O
lo O
##d O
scores O
over O
those O
seen O
with O
the O
individual O
r O
##f O
##l O
##ps O
was O
obtained O
when O
the O
link O
##age O
of O
the O
entire O
a O
##po O
##c O
##2 O
ha O
##p O
##lot O
##ype O
( O
composed O
of O
the O
six O
r O
##f O
##l O
##ps O
) O
was O
studied O
( O
lo O
##d O
= O
17 O
. O
87 O
, O
the O
##ta O
= O
0 O
. O
04 O
) O
. O

we O
have O
observed O
significant O
inter O
- O
a O
##po O
##c O
##2 O
r O
##f O
##l O
##p O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
. O

consequently O
, O
the O
three O
most O
inform O
##ative O
r O
##f O
##l O
##ps O
have O
been O
found O
to O
be O
ban O
##i O
, O
ta O
##qi O
, O
and O
either O
b O
##gli O
, O
a O
##va O
##ii O
, O
or O
n O
##co O
##i O
p O
##oly O
##mor O
##phism O
##s O
. O

we O
also O
demonstrate O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
between O
d O
##m O
and O
a O
##po O
##c O
##2 O
in O
our O
f O
##rench O
- O
can O
##adia O
##n O
population O
( O
standardized O
di O
##se O
##qui O
##li O
##bri O
##um O
constant O
p O
##hi O
= O
. O
22 O
, O
ch O
##i O
2 O
= O
5 O
. O
12 O
, O
d O
##f O
= O
1 O
, O
p O
less O
than O
0 O
. O
04 O
) O
. O

this O
represents O
the O
first O
evidence O
of O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
between O
a O
##po O
##c O
##2 O
and O
the O
d B-Disease
##m I-Disease
lo O
##cus O
. O

p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
ha O
##p O
##lot O
##ype O
##s O
in O
p O
##oly O
##nesia O
##ns O
: O
evolutionary O
origins O
and O
absence O
of O
all O
##ele O
##s O
associated O
with O
severe O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

a O
total O
of O
630 O
ha O
##p O
##lot O
##ype O
##s O
for O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
gene O
lo O
##cus O
were O
established O
in O
five O
groups O
of O
p O
##oly O
##nesia O
##ns O
comprising O
sa O
##mo O
##ans O
, O
ton O
##gan O
##s O
, O
cook O
island O
##ers O
, O
ma O
##ori O
, O
and O
ni O
##ue O
##ans O
. O

considerable O
genetic O
continuity O
was O
demonstrated O
between O
these O
widely O
dispersed O
populations O
, O
since O
three O
common O
ha O
##p O
##lot O
##ype O
##s O
( O
4 O
, O
1 O
, O
and O
7 O
) O
constituted O
over O
95 O
% O
of O
all O
##ele O
##s O
. O

a O
control O
group O
of O
individuals O
from O
southeast O
as O
##ia O
shared O
the O
same O
major O
ha O
##p O
##lot O
##ype O
##s O
, O
4 O
, O
1 O
, O
and O
7 O
, O
with O
p O
##oly O
##nesia O
##ns O
. O

these O
data O
provide O
further O
support O
for O
the O
theories O
of O
genetic O
ho O
##mo O
##gene O
##ity O
and O
of O
as O
##ian O
a O
##ffin O
##ities O
of O
the O
p O
##oly O
##nesia O
##n O
precursor O
populations O
. O

the O
absence O
of O
severe O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
in O
both O
p O
##oly O
##nesia O
##ns O
and O
southeast O
as O
##ians O
is O
consistent O
with O
the O
lack O
of O
p O
##ah O
ha O
##p O
##lot O
##ype O
##s O
2 O
and O
3 O
, O
on O
which O
the O
severe O
p B-Disease
##ku I-Disease
mutant O
##s O
have O
arise O
##n O
among O
ca O
##uca O
##sian O
##s O
. O
. O

prefer O
##ential O
g O
##er O
##m O
##line O
mutation O
of O
the O
paternal O
all O
##ele O
in O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

the O
event O
trigger O
##ing O
ma O
##li O
##gnant O
proliferation O
in O
70 O
% O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
is O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
for O
chromosome O
13 O
##q O
##14 O
, O
whereby O
the O
normal O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
gene O
( O
r O
##b O
##1 O
) O
all O
##ele O
is O
lost O
and O
an O
already O
m O
##uta O
##ted O
r O
##b O
##1 O
all O
##ele O
remains O
in O
the O
t B-Disease
##umour I-Disease
. O

the O
first O
all O
##ele O
suffers O
a O
mutation O
##al O
event O
- O
- O
del O
##eti O
##on O
, O
du O
##plication O
or O
point O
mutation O
( O
manuscript O
in O
preparation O
) O
- O
- O
either O
in O
the O
g O
##er O
##m O
line O
( O
all O
bilateral O
patients O
) O
or O
in O
a O
so O
##matic O
re O
##tina O
##l O
cell O
( O
most O
un O
##ila O
##teral O
patients O
) O
. O

most O
bilateral O
patients O
have O
no O
family O
history O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
and O
are O
presumed O
to O
have O
new O
g O
##er O
##m O
##line O
mutations O
which O
arose O
in O
the O
egg O
, O
sperm O
or O
early O
em O
##b O
##ryo O
. O

we O
have O
determined O
the O
parental O
origin O
of O
the O
retained O
all O
##ele O
in O
nine O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
from O
eight O
unrelated O
non O
- O
f O
##ami O
##lial O
cases O
by O
using O
r O
##b O
##1 O
- O
linked O
genetic O
markers O
. O

six O
t B-Disease
##umour I-Disease
##s I-Disease
retained O
the O
paternal O
all O
##ele O
and O
three O
retained O
the O
maternal O
all O
##ele O
. O

of O
the O
three O
un B-Disease
##ila I-Disease
##teral I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
, O
only O
one O
retained O
the O
paternal O
r O
##b O
##1 O
all O
##ele O
. O

thus O
, O
there O
is O
no O
evidence O
that O
the O
paternal O
r O
##b O
##1 O
all O
##ele O
is O
prefer O
##ential O
##ly O
retained O
in O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
, O
as O
has O
been O
suggested O
to O
be O
the O
case O
in O
o B-Disease
##ste I-Disease
##osa I-Disease
##rc I-Disease
##oma I-Disease
. O

by O
contrast O
, O
t B-Disease
##umour I-Disease
##s I-Disease
from O
four O
of O
the O
five O
bilateral O
patients O
retained O
the O
paternal O
r O
##b O
##1 O
all O
##ele O
. O

this O
suggests O
either O
that O
new O
g O
##er O
##m O
##line O
r O
##b O
##1 O
mutations O
arise O
more O
frequently O
during O
sperm O
##ato O
##genesis O
than O
during O
o O
##ogen O
##esis O
, O
or O
that O
imprint O
##ing O
in O
the O
early O
em O
##b O
##ryo O
affects O
ch O
##rom O
##oso O
##mal O
su O
##s O
##ce O
##pt O
##ibility O
to O
mutation O
. O
. O

ha O
##p O
##lot O
##ype O
analysis O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
in O
t O
##ur O
##kis O
##h O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
families O
. O

we O
have O
estimated O
the O
ha O
##p O
##lot O
##ype O
distribution O
of O
mutant O
and O
normal O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
all O
##ele O
##s O
for O
17 O
t O
##ur O
##kis O
##h O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
families O
20 O
normal O
and O
27 O
m O
##uta O
##ted O
p O
##ah O
all O
##ele O
##s O
could O
be O
identified O
. O

of O
the O
latter O
, O
the O
most O
prevalent O
were O
associated O
with O
ha O
##p O
##lot O
##ype O
6 O
( O
29 O
. O
6 O
% O
) O
, O
1 O
( O
18 O
. O
5 O
% O
) O
and O
36 O
( O
11 O
. O
1 O
% O
) O
, O
while O
the O
normal O
all O
##ele O
##s O
were O
prefer O
##ential O
##ly O
associated O
with O
ha O
##p O
##lot O
##ype O
1 O
( O
20 O
% O
) O
. O

of O
the O
19 O
different O
ha O
##p O
##lot O
##ype O
##s O
observed O
, O
5 O
have O
not O
been O
described O
previously O
. O

the O
ha O
##p O
##lot O
##ype O
distribution O
differed O
significantly O
from O
that O
of O
the O
northern O
euro O
##pe O
##an O
population O
. O

two O
of O
the O
eight O
p O
##oly O
##morphic O
sites O
were O
in O
association O
with O
p B-Disease
##ku I-Disease
. O

no O
del O
##eti O
##ons O
of O
ex O
##on O
sequences O
were O
found O
in O
the O
families O
anal O
##ys O
##ed O
. O

hunting B-Disease
##ton I-Disease
disease I-Disease
: O
no O
evidence O
for O
lo O
##cus O
he O
##tero O
##gene O
##ity O
. O

a O
total O
of O
63 O
families O
with O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
were O
examined O
for O
link O
##age O
between O
h B-Disease
##d I-Disease
and O
g O
##8 O
( O
d O
##4 O
##s O
##10 O
) O
. O

the O
families O
included O
57 O
ca O
##uca O
##sian O
, O
four O
black O
am O
##eric O
##an O
, O
and O
two O
j O
##apa O
##nese O
. O

the O
combined O
maximum O
lo O
##d O
score O
was O
87 O
. O

69 O
at O
the O
##ta O
= O
0 O
. O

04 O
( O
99 O
% O
confidence O
interval O
0 O
. O
01 O
##8 O
- O
0 O
. O
07 O
##1 O
) O
. O

the O
maximum O
frequency O
of O
re O
##comb O
##ination O
was O
0 O
. O

03 O
in O
males O
and O
0 O
. O

05 O
in O
females O
. O

fifty O
- O
seven O
families O
gave O
positive O
lo O
##d O
scores O
; O
five O
small O
families O
gave O
mildly O
negative O
lo O
##d O
scores O
. O

the O
maximum O
likelihood O
estimate O
of O
alpha O
, O
the O
proportion O
of O
linked O
lo O
##ci O
, O
was O
1 O
. O

0 O
with O
a O
lower O
99 O
% O
confidence O
interval O
of O
0 O
. O

88 O
. O

these O
data O
suggest O
that O
there O
is O
only O
one O
h B-Disease
##d I-Disease
lo O
##cus O
, O
although O
a O
second O
rare O
lo O
##cus O
cannot O
be O
ruled O
out O
. O

ha O
##p O
##lot O
##ype O
and O
multi O
##point O
link O
##age O
analysis O
in O
fin O
##nish O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
families O
. O

multi O
##point O
link O
##age O
analysis O
of O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
( O
t B-Disease
##c I-Disease
##d I-Disease
) O
and O
seven O
x O
ch O
##rom O
##oso O
##mal O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
( O
r O
##f O
##l O
##ps O
) O
was O
carried O
out O
in O
18 O
fin O
##nish O
t B-Disease
##c I-Disease
##d I-Disease
families O
. O

the O
data O
place O
t B-Disease
##c I-Disease
##d I-Disease
di O
##stal O
to O
p O
##g O
##k O
and O
d O
##x O
##s O
##7 O
##2 O
, O
very O
close O
to O
d O
##xy O
##s O
##1 O
and O
d O
##xy O
##s O
##5 O
( O
z O
##max O
= O
24 O
at O
the O
##ta O
= O
0 O
) O
and O
pro O
##ximal O
to O
d O
##xy O
##s O
##4 O
and O
d O
##xy O
##s O
##12 O
. O

this O
agrees O
with O
the O
data O
obtained O
from O
other O
link O
##age O
studies O
and O
from O
physical O
mapping O
. O

all O
the O
t B-Disease
##c I-Disease
##d I-Disease
males O
and O
carrier O
females O
studied O
have O
the O
same O
d O
##xy O
##s O
##1 O
all O
##ele O
in O
coupling O
with O
t B-Disease
##c I-Disease
##d I-Disease
. O

in O
northeastern O
fin O
##land O
, O
66 O
/ O
69 O
chromosome O
##s O
carrying O
t B-Disease
##c I-Disease
##d I-Disease
had O
the O
same O
ha O
##p O
##lot O
##ype O
at O
lo O
##ci O
d O
##x O
##s O
##7 O
##2 O
, O
d O
##xy O
##s O
##1 O
, O
d O
##xy O
##s O
##4 O
, O
and O
d O
##xy O
##s O
##12 O
. O

the O
same O
ha O
##p O
##lot O
##ype O
is O
seen O
in O
only O
15 O
/ O
99 O
chromosome O
##s O
not O
carrying O
t B-Disease
##c I-Disease
##d I-Disease
. O

more O
##over O
, O
in O
71 O
/ O
104 O
non O
- O
t O
##c O
##d O
chromosome O
##s O
, O
the O
ha O
##p O
##lot O
##ype O
at O
six O
marker O
lo O
##ci O
is O
different O
from O
those O
seen O
in O
any O
of O
the O
76 O
t B-Disease
##c I-Disease
##d I-Disease
chromosome O
##s O
. O

this O
supports O
the O
previously O
described O
hypothesis O
that O
the O
large O
northern O
fin O
##nish O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
p O
##ed O
##ig O
##ree O
##s O
, O
comprising O
a O
total O
of O
over O
80 O
living O
patients O
representing O
more O
than O
a O
fifth O
of O
all O
t B-Disease
##c I-Disease
##d I-Disease
patients O
described O
worldwide O
, O
carry O
the O
same O
mutation O
. O

these O
link O
##age O
and O
ha O
##p O
##lot O
##ype O
data O
provide O
improved O
opportunities O
for O
pre O
##nat O
##al O
diagnosis O
based O
on O
r O
##f O
##l O
##p O
studies O
. O
. O

auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
linked O
to O
the O
chromosome O
11 O
##p O
##13 O
markers O
cat O
##ala O
##se O
and O
d O
##11 O
##s O
##15 O
##1 O
in O
a O
large O
du O
##tch O
family O
. O

in O
a O
large O
p O
##ed O
##ig O
##ree O
with O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
we O
found O
close O
link O
##age O
between O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
lo O
##cus O
an O
##2 O
and O
the O
markers O
cat O
##ala O
##se O
( O
cat O
) O
( O
z O
##eta O
= O
7 O
. O
27 O
at O
the O
##ta O
= O
0 O
. O
00 O
) O
and O
d O
##11 O
##s O
##15 O
##1 O
( O
z O
##eta O
= O
3 O
. O
86 O
at O
the O
##ta O
= O
0 O
. O
10 O
) O
flank O
##ing O
the O
an O
##2 O
lo O
##cus O
on O
11 O
##p O
##13 O
. O

positive O
lo O
##d O
scores O
were O
also O
obtained O
for O
the O
11 O
##p O
##13 O
- O
- O
- O
- O
11 O
##p O
##14 O
markers O
d O
##11 O
##s O
##16 O
and O
f O
##sh O
##b O
with O
the O
link O
##age O
group O
cat O
/ O
an O
##2 O
/ O
d O
##11 O
##s O
##15 O
##1 O
. O

we O
conclude O
that O
the O
auto O
##so O
##mal O
dominant O
an B-Disease
##iri I-Disease
##dia I-Disease
in O
this O
family O
is O
due O
to O
a O
mutation O
at O
the O
an O
##2 O
lo O
##cus O
on O
11 O
##p O
##13 O
. O

we O
have O
excluded O
link O
##age O
( O
z O
##eta O
less O
than O
- O
2 O
at O
the O
##ta O
less O
than O
0 O
. O
18 O
) O
between O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
and O
the O
chromosome O
2 O
##p O
##25 O
marker O
d O
##2 O
##s O
##1 O
( O
linked O
to O
a O
##c O
##p O
##1 O
) O
. O

re O
##comb O
##ination O
events O
that O
locate O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
di O
##stal O
to O
a O
##po O
##c O
##2 O
on O
19 O
##q O
. O

we O
previously O
reported O
a O
re O
##comb O
##ination O
in O
an O
individual O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
which O
placed O
the O
markers O
d O
##19 O
##s O
##19 O
and O
a O
##po O
##c O
##2 O
on O
the O
same O
side O
of O
the O
d B-Disease
##m I-Disease
lo O
##cus O
. O

ha O
##p O
##lot O
##y O
##ping O
of O
this O
family O
with O
more O
recently O
characterized O
probe O
##s O
which O
are O
either O
tightly O
linked O
to O
d B-Disease
##m I-Disease
or O
di O
##stal O
to O
the O
link O
##age O
group O
at O
q O
##13 O
. O

2 O
shows O
that O
the O
d B-Disease
##m I-Disease
lo O
##cus O
is O
di O
##stal O
to O
a O
##po O
##c O
##2 O
. O

this O
is O
confirmed O
by O
other O
re O
##comb O
##ina O
##nts O
where O
d B-Disease
##m I-Disease
se O
##g O
##re O
##gate O
##s O
with O
di O
##stal O
probe O
##s O
. O

additional O
marker O
to O
marker O
re O
##comb O
##ination O
##s O
in O
un O
##af O
##fected O
individuals O
are O
reported O
and O
support O
the O
order O
and O
orientation O
of O
the O
d B-Disease
##m I-Disease
link O
##age O
group O
as O
p O
##ter O
- O
( O
ins O
##r O
, O
l O
##dl O
##r O
, O
s O
##9 O
) O
- O
( O
s O
##19 O
, O
b O
##c O
##l O
##3 O
, O
a O
##po O
##c O
##2 O
) O
- O
( O
c O
##k O
##mm O
, O
d O
##m O
) O
- O
( O
s O
##22 O
, O
+ O
+ O
+ O
p O
##rk O
##c O
##g O
) O
- O
q O
##ter O
. O

the O
data O
presented O
here O
cannot O
determine O
whether O
d B-Disease
##m I-Disease
is O
pro O
##ximal O
or O
di O
##stal O
to O
c O
##k O
##mm O
. O

the O
consequences O
of O
this O
probe O
order O
for O
ant O
##ena O
##tal O
diagnosis O
and O
future O
research O
aiming O
to O
is O
##olate O
the O
gene O
which O
is O
affected O
in O
d B-Disease
##m I-Disease
are O
discussed O
. O

mutations O
in O
the O
r O
##b O
##1 O
gene O
and O
their O
effects O
on O
transcription O
. O

in O
##act O
##ivation O
of O
both O
all O
##ele O
##s O
of O
the O
r O
##b O
##1 O
gene O
during O
normal O
re O
##tina O
##l O
development O
initiate O
##s O
the O
formation O
of O
a O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
( I-Disease
r I-Disease
##b I-Disease
) I-Disease
tumor I-Disease
. O

to O
identify O
the O
mutations O
which O
in O
##act O
##ivate O
r O
##b O
##1 O
, O
21 O
r B-Disease
##b I-Disease
tumors I-Disease
isolated O
from O
19 O
patients O
were O
analyzed O
with O
the O
polymer O
##ase O
chain O
reaction O
or O
an O
r O
##nas O
##e O
protection O
ass O
##ay O
or O
both O
. O

mutations O
were O
identified O
in O
13 O
of O
21 O
r B-Disease
##b I-Disease
tumors I-Disease
; O
in O
8 O
tumors B-Disease
, O
the O
precise O
errors O
in O
n O
##uc O
##leo O
##tide O
sequence O
were O
characterized O
. O

each O
of O
four O
g O
##er O
##m O
line O
mutations O
involved O
a O
small O
del O
##eti O
##on O
or O
du O
##plication O
, O
while O
three O
so O
##matic O
mutations O
were O
point O
mutations O
leading O
to O
s O
##p O
##lice O
alterations O
and O
loss O
of O
an O
ex O
##on O
from O
the O
mature O
r O
##b O
##1 O
m O
##rna O
. O

we O
were O
unable O
to O
detect O
expression O
of O
the O
mutant O
all O
##ele O
in O
l O
##ymph O
##ob O
##last O
##s O
of O
three O
bilateral O
##ly O
affected O
patients O
, O
although O
the O
mutation O
was O
present O
in O
the O
g O
##eno O
##mic O
d O
##na O
and O
trans O
##cripts O
containing O
the O
mutations O
were O
obvious O
in O
the O
r B-Disease
##b I-Disease
tumors I-Disease
in O
the O
absence O
of O
a O
normal O
r O
##b O
##1 O
all O
##ele O
. O

the O
variations O
in O
the O
level O
of O
expression O
of O
mutant O
trans O
##cripts O
suggest O
der O
##eg O
##ulation O
of O
r O
##b O
##1 O
transcription O
in O
the O
absence O
of O
a O
functional O
r O
##b O
##1 O
gene O
product O
. O
. O

partial O
del O
##eti O
##on O
8 O
##q O
without O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
: O
a O
re O
##co O
##gni O
##sable O
syndrome O
. O

we O
report O
two O
de O
no O
##vo O
cases O
of O
del O
( O
8 O
) O
( O
p O
##ter O
- O
- O
- O
- O
q O
##24 O
. O
1 O
) O
with O
break O
##points O
involving O
the O
di O
##stal O
part O
of O
band O
8 O
##q O
##24 O
. O

1 O
1 O
. O

the O
clinical O
features O
were O
similar O
and O
there O
were O
no O
obvious O
s O
##ti O
##gma O
##ta O
of O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
( O
l B-Disease
##gs I-Disease
) O
. O

there O
are O
three O
other O
cases O
reported O
with O
a O
del O
##eti O
##on O
of O
chromosome O
8 O
at O
approximately O
the O
same O
break O
##point O
, O
one O
without O
l B-Disease
##gs I-Disease
and O
some O
similarities O
to O
our O
cases O
, O
the O
other O
two O
with O
l B-Disease
##gs I-Disease
. O

our O
findings O
would O
support O
the O
observation O
that O
the O
critical O
segment O
for O
the O
assignment O
of O
l B-Disease
##gs I-Disease
is O
pro O
##ximal O
to O
or O
involves O
the O
pro O
##ximal O
part O
of O
8 O
##q O
##24 O
. O

1 O
, O
but O
a O
review O
of O
published O
reports O
suggests O
that O
the O
a O
##eti O
##ology O
of O
l B-Disease
##gs I-Disease
may O
be O
a O
more O
complex O
issue O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
is O
closely O
linked O
to O
the O
gene O
for O
muscle O
- O
type O
c O
##rea O
##tine O
kinase O
( O
c O
##k O
##mm O
) O
. O

we O
have O
studied O
genetic O
link O
##age O
between O
the O
gene O
for O
c O
##rea O
##tine O
kinase O
muscle O
type O
( O
c O
##k O
##mm O
) O
and O
the O
gene O
for O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

in O
a O
panel O
of O
65 O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
families O
from O
can O
##ada O
and O
the O
net O
##her O
##lands O
, O
a O
maximum O
lo O
##d O
score O
( O
z O
##max O
) O
of O
22 O
. O

8 O
at O
a O
re O
##comb O
##ination O
frequency O
( O
the O
##ta O
) O
of O
0 O
. O

03 O
was O
obtained O
. O

tight O
link O
##age O
was O
also O
demonstrated O
for O
c O
##k O
##mm O
and O
the O
gene O
for O
a O
##poli O
##pop O
##rote O
##in O
c O
##2 O
( O
a O
##po O
##c O
##2 O
) O
. O

this O
establishes O
c O
##k O
##mm O
as O
a O
useful O
marker O
for O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease

color B-Disease
vision I-Disease
defects I-Disease
in O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
. O

the O
relationship O
between O
abnormal B-Disease
color I-Disease
vision I-Disease
and O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
was O
investigated O
in O
27 O
am B-Disease
##n I-Disease
patients O
and O
31 O
age O
- O
matched O
controls O
by O
using O
the O
far O
##ns O
##worth O
- O
m O
##uns O
##ell O
100 O
h O
##ue O
test O
. O

twelve O
( O
44 O
% O
) O
of O
27 O
patients O
showed O
test O
scores O
significantly O
above O
normal O
. O

the O
axes O
of O
bi O
##pol O
##arity O
determined O
by O
the O
testing O
differed O
widely O
between O
the O
patients O
with O
abnormal O
scores O
, O
compatible O
with O
the O
notion O
that O
different O
alterations O
in O
visual O
pig O
##ment O
genes O
occur O
in O
different O
am B-Disease
##n I-Disease
kind O
##red O
##s O
. O

these O
observations O
confirm O
our O
earlier O
impression O
that O
the O
frequency O
of O
abnormal B-Disease
color I-Disease
vision I-Disease
is O
increased O
in O
these O
kind O
##red O
##s O
, O
and O
it O
supports O
our O
contention O
##s O
that O
( O
1 O
) O
am B-Disease
##n I-Disease
( O
and O
its O
companion O
, O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
) O
are O
very O
closely O
linked O
to O
the O
visual O
pig O
##ment O
lo O
##ci O
at O
x O
##q O
##28 O
and O
( O
2 O
) O
this O
proximity O
might O
provide O
the O
opportunity O
to O
observe O
con B-Disease
##ti I-Disease
##guous I-Disease
gene I-Disease
defects I-Disease
. O
. O

molecular O
analysis O
of O
a O
female O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patient O
. O

we O
report O
the O
identification O
of O
a O
female O
patient O
with O
the O
x O
- O
linked O
re O
##cess O
##ive O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
( O
h B-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
##tra I-Disease
##ns I-Disease
##fer I-Disease
##ase I-Disease
[ I-Disease
hp I-Disease
##rt I-Disease
] I-Disease
deficiency I-Disease
) O
. O

c O
##yt O
##ogen O
##etic O
and O
carrier O
studies O
revealed O
structural O
##ly O
normal O
chromosome O
##s O
for O
this O
patient O
and O
her O
parents O
and O
demonstrated O
that O
this O
mutation O
arose O
through O
a O
de O
no O
##vo O
game O
##tic O
event O
. O

comparison O
of O
this O
patients O
d O
##na O
with O
the O
d O
##na O
of O
her O
parents O
revealed O
that O
a O
micro O
##del O
##eti O
##on O
, O
which O
occurred O
within O
a O
maternal O
game O
##te O
and O
involved O
the O
entire O
hp O
##rt O
gene O
, O
was O
partially O
responsible O
for O
the O
disease O
in O
this O
patient O
. O

so O
##matic O
cell O
hybrid O
##s O
, O
generated O
to O
separate O
maternal O
and O
paternal O
x O
chromosome O
##s O
, O
showed O
that O
expression O
of O
two O
additional O
x O
- O
linked O
enzymes O
, O
p O
##hos O
##ph O
##og O
##ly O
##cer O
##ate O
kinase O
and O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
, O
were O
expressed O
only O
in O
cells O
that O
contained O
the O
maternal O
x O
chromosome O
, O
suggesting O
the O
presence O
of O
a O
functional O
##ly O
inactive O
paternal O
x O
chromosome O
. O

further O
##more O
, O
comparison O
of O
met O
##hyl O
##ation O
patterns O
within O
a O
region O
of O
the O
hp O
##rt O
gene O
known O
to O
be O
important O
in O
gene O
regulation O
revealed O
differences O
between O
d O
##na O
from O
the O
father O
and O
the O
patient O
, O
in O
keeping O
with O
an O
active O
hp O
##rt O
lo O
##cus O
in O
the O
father O
and O
an O
inactive O
hp O
##rt O
lo O
##cus O
in O
the O
patient O
. O

together O
these O
data O
indicate O
that O
non O
##rand O
##om O
in O
##act O
##ivation O
of O
the O
c O
##yt O
##ogen O
##etic O
##ally O
normal O
paternal O
x O
chromosome O
and O
a O
micro O
##del O
##eti O
##on O
of O
the O
hp O
##rt O
gene O
on O
an O
active O
maternal O
x O
chromosome O
were O
responsible O
for O
the O
absence O
of O
hp O
##rt O
in O
this O
patient O
. O
. O

p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
: O
an O
x B-Disease
- I-Disease
linked I-Disease
ne I-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
disorder I-Disease
of I-Disease
my I-Disease
##elin I-Disease
metabolism I-Disease
with O
a O
novel O
mutation O
in O
the O
gene O
encoding O
pro O
##te O
##oli O
##pid O
protein O
. O

the O
no O
##sol O
##ogy O
of O
the O
in B-Disease
##born I-Disease
errors I-Disease
of I-Disease
my I-Disease
##elin I-Disease
metabolism I-Disease
has O
been O
s O
##ty O
##mie O
##d O
by O
the O
lack O
of O
molecular O
genetic O
analysis O
. O

historically O
, O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
has O
encompassed O
a O
host O
of O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
disorders I-Disease
that O
present O
with O
a O
deficit B-Disease
of I-Disease
my I-Disease
##elin I-Disease
, O
the O
membrane O
elaborate O
##d O
by O
g O
##lial O
cells O
that O
en O
##ci O
##rcle O
##s O
and O
successively O
en O
##w O
##rap O
##s O
a O
##xon O
##s O
. O

we O
describe O
here O
a O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
p O
##ed O
##ig O
##ree O
of O
the O
classical O
type O
, O
with O
x O
- O
linked O
inheritance O
, O
a O
typical O
clinical O
progression O
, O
and O
a O
path O
##olo O
##gic O
loss O
of O
my O
##elin O
##ating O
cells O
and O
my O
##elin O
in O
the O
central O
nervous O
system O
. O

to O
disc O
##rim O
##inate O
variants O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
, O
a O
set O
of O
o O
##li O
##gon O
##uc O
##leo O
##tide O
prime O
##rs O
was O
constructed O
to O
polymer O
##ase O
- O
chain O
- O
reaction O
( O
p O
##c O
##r O
) O
am O
##p O
##lify O
and O
sequence O
the O
gene O
encoding O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
, O
a O
structural O
protein O
that O
comprises O
half O
of O
the O
protein O
of O
the O
my O
##elin O
sheath O
. O

the O
p O
##l O
##p O
gene O
in O
one O
of O
two O
affected O
males O
and O
the O
carrier O
mother O
of O
this O
family O
exhibited O
a O
single O
base O
difference O
in O
the O
more O
than O
2 O
k O
##b O
of O
the O
p O
##l O
##p O
gene O
sequence O
##d O
, O
a O
c O
- O
- O
- O
- O
t O
transition O
that O
would O
create O
a O
se O
##rine O
substitution O
for O
pro O
##line O
at O
the O
car O
##box O
##y O
end O
of O
the O
protein O
. O

our O
results O
del O
##ine O
##ate O
the O
clinical O
features O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
, O
define O
the O
possible O
molecular O
path O
##ology O
of O
this O
d B-Disease
##ys I-Disease
##my I-Disease
##elin I-Disease
##ating I-Disease
disorder I-Disease
, O
and O
address O
the O
molecular O
classification O
of O
in B-Disease
##born I-Disease
errors I-Disease
of I-Disease
my I-Disease
##elin I-Disease
metabolism I-Disease
. O

patients O
with O
the O
classical O
form O
( O
type O
i O
) O
and O
the O
more O
severely O
affected O
, O
con O
##nat O
##al O
variant O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( I-Disease
type I-Disease
ii I-Disease
) I-Disease
would O
be O
predicted O
to O
display O
mutation O
at O
the O
p O
##l O
##p O
lo O
##cus O
. O

the O
other O
variants O
( O
types O
ii O
##i O
- O
v O
##i O
) O
, O
which O
have O
sometimes O
been O
categorized O
as O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
, O
may O
represent O
mutations O
in O
genes O
encoding O
other O
structural O
my O
##elin O
proteins O
or O
proteins O
critical O
to O
my O
##elin O
##ation O
. O
. O

molecular O
basis O
of O
human O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
: O
analysis O
of O
plate O
##let O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
m O
##rna O
. O

von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
( O
v B-Disease
##w I-Disease
##d I-Disease
) O
, O
the O
most O
common O
inherited B-Disease
bleeding I-Disease
disorder I-Disease
in O
humans O
, O
can O
result O
from O
either O
a O
quantitative O
or O
a O
q O
##ual O
##itative O
defect O
in O
the O
ad O
##hesive O
g O
##ly O
##co O
##p O
##rote O
##in O
, O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
( O
v O
##w O
##f O
) O
. O

molecular O
studies O
of O
v B-Disease
##w I-Disease
##d I-Disease
have O
been O
limited O
by O
the O
large O
size O
of O
the O
v O
##w O
##f O
gene O
and O
difficulty O
in O
obtaining O
the O
v O
##w O
##f O
m O
##rna O
from O
patients O
. O

by O
use O
of O
an O
adaptation O
of O
the O
polymer O
##ase O
chain O
reaction O
, O
v O
##w O
##f O
m O
##rna O
was O
am O
##plified O
and O
sequence O
##d O
from O
peripheral O
blood O
plate O
##lets O
. O

a O
silent O
v O
##w O
##f O
all O
##ele O
was O
identified O
, O
resulting O
from O
a O
c O
##is O
defect O
in O
v O
##w O
##f O
m O
##rna O
transcription O
or O
processing O
. O

in O
two O
type B-Disease
ii I-Disease
##a I-Disease
v I-Disease
##w I-Disease
##d I-Disease
patients O
, O
two O
different O
but O
adjacent O
miss O
##ense O
mutations O
were O
identified O
, O
the O
locations O
of O
which O
may O
identify O
an O
important O
v O
##w O
##f O
functional O
domain O
. O

expression O
in O
he O
##tero O
##log O
##ous O
cells O
of O
re O
##comb O
##ina O
##nt O
v O
##w O
##f O
containing O
one O
of O
these O
latter O
mutations O
reproduced O
the O
characteristic O
structural O
abnormal O
##ity O
seen O
in O
type B-Disease
ii I-Disease
##a I-Disease
v I-Disease
##w I-Disease
##d I-Disease
plasma O
. O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
deficiency I-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
associated O
with O
re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
infections I-Disease
. O

we O
describe O
an O
11 O
- O
year O
- O
old O
girl O
suffering O
from O
re B-Disease
##current I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
with O
a O
complete O
absence B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##7 O
) O
. O

diagnosis O
was O
established O
by O
ha O
##em O
##oly O
##tic O
t O
##it O
##ration O
and O
western O
b O
##lot O
##ting O
. O

the O
patients O
serum O
lacked O
the O
85 O
k O
##da O
c O
##7 O
chain O
. O

ha O
##em O
##oly O
##tic O
activity O
of O
serum O
was O
re O
##con O
##stituted O
with O
either O
pool O
##ed O
normal O
human O
serum O
or O
with O
pu O
##rified O
c O
##7 O
. O

the O
relatives O
( O
parents O
and O
one O
sister O
) O
had O
half O
- O
normal O
levels O
of O
both O
im O
##mu O
##no O
##chemical O
##ly O
and O
functional O
##ly O
determined O
c O
##7 O
, O
indicating O
a O
he O
##tero O
##zy O
##go O
##us O
state O
for O
c B-Disease
##7 I-Disease
deficiency I-Disease
. O
. O

trans O
##location O
t O
( O
5 O
; O
11 O
) O
( O
q O
##13 O
. O
1 O
; O
p O
##13 O
) O
associated O
with O
f O
##ami O
##lial O
isolated B-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
. O

a O
father O
and O
daughter O
with O
isolated B-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
were O
observed O
to O
have O
an O
apparently O
balanced O
, O
re O
##ci O
##p O
##ro O
##cal O
trans O
##location O
involving O
chromosome O
##s O
5 O
and O
11 O
[ O
t O
( O
5 O
; O
11 O
) O
( O
q O
##13 O
. O
1 O
; O
p O
##13 O
) O
] O
. O

no O
other O
clinical O
characteristics O
often O
associated O
with O
the O
del O
##eti O
##on O
of O
11 O
##p O
##13 O
were O
observed O
in O
this O
family O
. O

this O
finding O
, O
in O
association O
with O
3 O
other O
instances O
of O
single O
breaks O
at O
11 O
##p O
##13 O
and O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
supports O
the O
assignment O
of O
an O
##2 O
to O
11 O
##p O
##13 O
. O

ho B-Disease
##mo I-Disease
##zy I-Disease
##go I-Disease
##us I-Disease
h I-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
: O
a O
disease O
distinct O
from O
a B-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
at O
the O
molecular O
level O
. O

a O
##po O
##b O
d O
##na O
, O
r O
##na O
, O
and O
protein O
from O
two O
patients O
with O
ho B-Disease
##mo I-Disease
##zy I-Disease
##go I-Disease
##us I-Disease
h I-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
( O
h B-Disease
##b I-Disease
##l I-Disease
) O
were O
evaluated O
and O
compared O
with O
normal O
individuals O
. O

southern O
b O
##lot O
analysis O
with O
10 O
different O
c O
##dn O
##a O
probe O
##s O
revealed O
a O
normal O
gene O
without O
major O
insertion O
##s O
, O
del O
##eti O
##ons O
, O
or O
rear O
##rang O
##ement O
##s O
. O

northern O
and O
slot O
b O
##lot O
analyses O
of O
total O
liver O
m O
##rna O
from O
h B-Disease
##b I-Disease
##l I-Disease
patients O
documented O
a O
normal O
size O
a O
##po O
##b O
m O
##rna O
that O
was O
present O
in O
greatly O
reduced O
quantities O
. O

a O
##po O
##b O
protein O
was O
detected O
within O
h B-Disease
##b I-Disease
##l I-Disease
he O
##pa O
##to O
##cy O
##tes O
utilizing O
im O
##mu O
##no O
##his O
##to O
##chemical O
techniques O
; O
however O
, O
it O
was O
marked O
##ly O
reduced O
in O
quantity O
when O
compared O
with O
control O
samples O
. O

no O
a O
##po O
##b O
was O
detect O
##able O
in O
the O
plasma O
of O
h B-Disease
##b I-Disease
##l I-Disease
individuals O
with O
an O
el O
##isa O
ass O
##ay O
. O

these O
data O
are O
most O
consistent O
with O
a O
mutation O
in O
the O
coding O
portion O
of O
the O
a O
##po O
##b O
gene O
in O
h B-Disease
##b I-Disease
##l I-Disease
patients O
, O
leading O
to O
an O
abnormal O
a O
##po O
##b O
protein O
and O
a O
##po O
##b O
m O
##rna O
instability O
. O

these O
results O
are O
distinct O
from O
those O
previously O
noted O
in O
a B-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
, O
which O
was O
characterized O
by O
an O
elevated O
level O
of O
he O
##pa O
##tic O
a O
##po O
##b O
m O
##rna O
and O
accumulation O
of O
in O
##tra O
##cellular O
he O
##pa O
##tic O
a O
##po O
##b O
protein O
. O
. O

spontaneous O
re O
##version O
of O
novel O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
mutation O
by O
hp O
##rt O
gene O
rear O
##rang O
##ement O
. O

molecular O
analysis O
of O
an O
unusual O
patient O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
has O
suggested O
that O
the O
mutation O
is O
due O
to O
a O
partial O
hp O
##rt O
gene O
du O
##plication O
. O

we O
now O
report O
the O
c O
##lon O
##ing O
and O
se O
##quencing O
of O
the O
mutant O
hp O
##rt O
c O
##dn O
##a O
which O
shows O
the O
precise O
du O
##plication O
of O
ex O
##ons O
2 O
and O
3 O
. O

this O
mutation O
is O
the O
result O
of O
an O
internal O
du O
##plication O
of O
16 O
- O
20 O
k O
##ilo O
##base O
##s O
of O
the O
gene O
. O

the O
structure O
of O
the O
mutant O
gene O
suggests O
that O
the O
du O
##plication O
was O
not O
generated O
by O
a O
single O
une O
##qua O
##l O
crossing O
- O
over O
event O
between O
two O
normal O
hp O
##rt O
all O
##ele O
##s O
. O

growth O
of O
e B-Disease
##ps I-Disease
##tein I-Disease
- I-Disease
bar I-Disease
##r I-Disease
virus O
- O
transformed O
l O
##ymph O
##ob O
##last O
##s O
from O
this O
patient O
in O
selective O
medium O
has O
permitted O
isolation O
of O
spontaneous O
hp O
##rt O
+ O
re O
##vert O
##ants O
of O
this O
mutation O
. O

the O
re O
##version O
event O
involves O
a O
second O
major O
hp O
##rt O
gene O
rear O
##rang O
##ement O
where O
most O
or O
all O
of O
the O
du O
##plicate O
##d O
portion O
of O
the O
mutant O
gene O
is O
deleted O
. O

the O
original O
mutation O
therefore O
has O
the O
potential O
for O
spontaneous O
so O
##matic O
re O
##version O
. O

this O
may O
explain O
the O
relatively O
mild O
symptoms O
of O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
exhibited O
by O
this O
patient O
. O
. O

complex B-Disease
g I-Disease
##ly I-Disease
##cer I-Disease
##ol I-Disease
kinase I-Disease
deficiency I-Disease
: O
molecular O
- O
genetic O
, O
c O
##yt O
##ogen O
##etic O
, O
and O
clinical O
studies O
of O
five O
j O
##apa O
##nese O
patients O
. O

five O
male O
j O
##apa O
##nese O
patients O
with O
complex B-Disease
g I-Disease
##ly I-Disease
##cer I-Disease
##ol I-Disease
kinase I-Disease
deficiency I-Disease
( O
c B-Disease
##g I-Disease
##k I-Disease
##d I-Disease
) O
and O
their O
relatives O
were O
studied O
clinical O
##ly O
, O
c O
##yt O
##ogen O
##etic O
##ally O
, O
and O
molecular O
- O
genetically O
. O

all O
patients O
had O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
or O
muscle B-Disease
weakness I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
con B-Disease
##gen I-Disease
##ital I-Disease
ad I-Disease
##rena I-Disease
##l I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
and O
g B-Disease
##ly I-Disease
##cer I-Disease
##ol I-Disease
kinase I-Disease
deficiency I-Disease
. O

high O
- O
resolution O
g O
##t O
##g O
- O
band O
##ed O
chromosome O
##s O
showed O
a O
micro O
##del O
##eti O
##on O
in O
the O
x O
##p O
##21 O
region O
in O
all O
four O
patients O
examined O
and O
in O
all O
five O
mothers O
. O

southern O
hybrid O
##izations O
, O
after O
dig O
##est O
##ions O
by O
restriction O
end O
##on O
##uc O
##lea O
##ses O
, O
with O
various O
clone O
##d O
d O
##nas O
( O
d O
##2 O
, O
99 O
- O
6 O
, O
b O
##24 O
, O
c O
##7 O
, O
l O
##1 O
- O
4 O
, O
c O
##d O
##m O
##d O
##13 O
- O
14 O
, O
j O
##6 O
##6 O
- O
hi O
, O
p O
##20 O
, O
j O
- O
bi O
##r O
, O
er O
##t O
##8 O
##7 O
- O
30 O
, O
er O
##t O
##8 O
##7 O
- O
15 O
, O
er O
##t O
##8 O
##7 O
- O
8 O
, O
er O
##t O
##8 O
##7 O
- O
1 O
, O
x O
##j O
- O
1 O
. O
1 O
, O
75 O
##4 O
, O
c O
##x O
##5 O
. O
7 O
, O
and O
o O
##t O
##c O
- O
1 O
) O
that O
are O
located O
around O
x O
##p O
##21 O
also O
showed O
a O
del O
##eti O
##on O
in O
the O
genome O
of O
all O
patients O
and O
mothers O
. O

although O
the O
del O
##eti O
##on O
differed O
in O
size O
among O
patients O
, O
a O
segment O
commonly O
absent O
was O
located O
between O
the O
g O
##eno O
##mic O
sequences O
corresponding O
to O
l O
##1 O
- O
4 O
and O
c O
##d O
##m O
##d O
##13 O
- O
14 O
. O

this O
finding O
indicated O
that O
the O
gene O
coding O
for O
g O
##ly O
##cer O
##ol O
kinase O
( O
g O
##k O
) O
is O
located O
within O
this O
segment O
. O

a O
comparison O
of O
the O
clinical O
manifest O
##ations O
of O
the O
present O
five O
patients O
and O
reported O
c B-Disease
##g I-Disease
##k I-Disease
##d I-Disease
or O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
patients O
with O
d O
##na O
del O
##eti O
##on O
suggests O
the O
existence O
of O
a O
certain O
gene O
responsible O
for O
go B-Disease
##nado I-Disease
##tro I-Disease
##pin I-Disease
deficiency I-Disease
( O
g B-Disease
##t I-Disease
##d I-Disease
) O
. O

the O
result O
of O
the O
present O
study O
and O
results O
of O
previous O
studies O
suggest O
that O
genes O
for O
or O
##ni O
##thin O
##e O
trans O
##car O
##ba O
##my O
##lase O
( O
o O
##t O
##c O
) O
, O
d B-Disease
##m I-Disease
##d I-Disease
, O
and O
g O
##k O
and O
put O
##ative O
genes O
responsible O
for O
con B-Disease
##gen I-Disease
##ital I-Disease
ad I-Disease
##rena I-Disease
##l I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
( O
ah B-Disease
##c I-Disease
) O
and O
g B-Disease
##t I-Disease
##d I-Disease
are O
arranged O
from O
te O
##lo O
##mere O
to O
cent O
##rome O
##re O
as O
p O
##ter O
- O
- O
g O
##t O
##d O
- O
- O
ah O
##c O
- O
- O
g O
##k O
- O
- O
d O
##m O
##d O
- O
- O
o O
##t O
##c O
- O
- O
c O
##en O

genetically O
determined O
low O
c O
##4 O
: O
a O
pre O
##dis O
##po O
##sing O
factor O
to O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
chronic I-Disease
active I-Disease
he I-Disease
##pa I-Disease
##titis I-Disease
. O

of O
26 O
patients O
with O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
chronic I-Disease
active I-Disease
he I-Disease
##pa I-Disease
##titis I-Disease
( O
ca B-Disease
##h I-Disease
) O
starting O
in O
childhood O
18 O
( O
69 O
% O
) O
had O
low O
c O
##4 O
and O
5 O
( O
19 O
% O
) O
had O
low O
c O
##3 O
serum O
levels O
. O

impaired O
he O
##pa O
##tic O
synthesis O
and O
immune O
- O
consumption O
were O
unlikely O
since O
transfer O
##rin O
levels O
were O
normal O
in O
all O
patients O
, O
album O
##in O
levels O
were O
persistent O
##ly O
low O
in O
only O
3 O
, O
and O
only O
3 O
had O
raised O
levels O
of O
activation O
fragment O
c O
##3 O
##d O
. O

c O
##4 O
##d O
was O
normal O
in O
all O
patients O
studied O
. O

in O
the O
families O
of O
12 O
pro O
##band O
##s O
with O
low O
c O
##4 O
, O
7 O
parents O
had O
low O
c O
##4 O
and O
2 O
had O
levels O
which O
were O
at O
the O
lower O
limit O
of O
normal O
. O

5 O
of O
10 O
siblings O
from O
5 O
families O
had O
low O
c O
##4 O
. O

these O
results O
suggest O
that O
low O
c O
##4 O
levels O
in O
ca B-Disease
##h I-Disease
are O
genetically O
determined O
. O

c O
##4 O
p O
##hen O
##ot O
##y O
##ping O
in O
20 O
patients O
and O
in O
26 O
parents O
showed O
that O
90 O
% O
and O
81 O
% O
, O
respectively O
, O
had O
null O
all O
##otype O
##s O
at O
either O
the O
c O
##4 O
##a O
or O
c O
##4 O
##b O
lo O
##cus O
compared O
with O
59 O
% O
in O
controls O
, O
indicating O
that O
defect O
##ive O
expression O
of O
structural O
genes O
may O
contribute O
to O
the O
observed O
c B-Disease
##4 I-Disease
deficiency I-Disease
. O
. O

an O
amino O
- O
acid O
substitution O
involved O
in O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
is O
in O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
with O
d O
##na O
ha O
##p O
##lot O
##ype O
2 O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
human I-Disease
genetic I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
, O
p O
##hen O
##yla O
##lani O
##ne O
4 O
- O
mon O
##oo O
##xy O
##gen O
##ase O
, O
e O
##c O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

p B-Disease
##ku I-Disease
is O
a O
common O
in B-Disease
##born I-Disease
error I-Disease
of I-Disease
amino I-Disease
- I-Disease
acid I-Disease
metabolism I-Disease
in O
ca O
##uca O
##sian O
populations O
and O
approximately O
1 O
in O
50 O
individuals O
are O
carriers O
of O
a O
p B-Disease
##ku I-Disease
all O
##ele O
. O

to O
define O
the O
molecular O
basis O
of O
p B-Disease
##ku I-Disease
, O
we O
characterized O
twelve O
restriction O
fragment O
- O
length O
p O
##oly O
##mor O
##phism O
( O
r O
##f O
##l O
##p O
) O
ha O
##p O
##lot O
##ype O
##s O
of O
the O
p O
##ah O
lo O
##cus O
in O
the O
northern O
euro O
##pe O
##an O
population O
and O
observed O
that O
90 O
% O
of O
the O
p B-Disease
##ku I-Disease
all O
##ele O
##s O
in O
this O
population O
are O
confined O
to O
four O
common O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
##s O
. O

we O
have O
recently O
reported O
a O
s O
##p O
##licing O
mutation O
in O
the O
p O
##ah O
gene O
that O
is O
associated O
with O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
3 O
which O
is O
present O
at O
about O
40 O
% O
of O
mutant O
all O
##ele O
##s O
. O

we O
now O
report O
the O
molecular B-Disease
les I-Disease
##ion I-Disease
associated O
with O
the O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
2 O
mutant O
all O
##ele O
. O

this O
defect O
is O
caused O
by O
a O
c O
- O
to O
- O
t O
transition O
in O
ex O
##on O
12 O
resulting O
in O
an O
amino O
- O
acid O
substitution O
( O
a O
##rg O
to O
t O
##rp O
) O
at O
residue O
40 O
##8 O
of O
p O
##ah O
. O

direct O
hybrid O
##ization O
analysis O
of O
the O
point O
mutation O
using O
a O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
probe O
demonstrated O
that O
this O
mutation O
is O
also O
in O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
with O
r O
##f O
##l O
##p O
ha O
##p O
##lot O
##ype O
2 O
all O
##ele O
##s O
that O
make O
up O
about O
20 O
% O
of O
mutant O
p O
##ah O
genes O

ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
: O
close O
link O
##age O
to O
d O
##xy O
##s O
##1 O
and O
d O
##xy O
##s O
##12 O
demonstrated O
by O
segregation O
analysis O
and O
historical O
- O
gene O
##alog O
##ical O
evidence O
. O

link O
##age O
studies O
using O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
were O
conducted O
in O
the O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
, O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
, O
designated O
t B-Disease
##c I-Disease
##d I-Disease
for O
progressive B-Disease
tape I-Disease
##to I-Disease
- I-Disease
ch I-Disease
##oro I-Disease
##idal I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

previously O
demonstrated O
close O
link O
##age O
with O
lo O
##cus O
d O
##xy O
##s O
##1 O
was O
confirmed O
( O
lo O
##d O
11 O
. O
44 O
at O
0 O
re O
##comb O
##ination O
distance O
) O
. O

in O
addition O
, O
lo O
##cus O
d O
##xy O
##s O
##12 O
was O
found O
to O
be O
closely O
linked O
with O
t B-Disease
##c I-Disease
##d I-Disease
( O
lo O
##d O
3 O
. O
31 O
at O
0 O
re O
##comb O
##ination O
distance O
) O
. O

the O
disease O
mainly O
occurs O
in O
three O
large O
kind O
##red O
##s O
in O
remote O
northern O
fin O
##land O
. O

while O
formal O
gene O
##alog O
##ical O
proof O
is O
lacking O
, O
all O
presently O
living O
( O
more O
than O
80 O
affected O
males O
and O
120 O
carrier O
females O
) O
probably O
originate O
from O
a O
common O
founder O
couple O
born O
in O
1644 O
and O
164 O
##6 O
, O
twelve O
generations O
ago O
. O

all O
36 O
patients O
and O
48 O
carriers O
tested O
from O
the O
three O
kind O
##red O
##s O
had O
the O
same O
ha O
##p O
##lot O
##ype O
( O
t B-Disease
##c I-Disease
##d I-Disease
/ O
d O
##xy O
##s O
##1 O
, O
11 O
##k O
##b O
/ O
d O
##xy O
##s O
##12 O
, O
1 O
. O
6 O
##k O
##b O
) O
. O

given O
that O
at O
least O
105 O
female O
me O
##ios O
##es O
transmitting O
t B-Disease
##c I-Disease
##d I-Disease
have O
occurred O
since O
1650 O
in O
these O
kind O
##red O
##s O
, O
extremely O
close O
link O
##age O
between O
t B-Disease
##c I-Disease
##d I-Disease
, O
d O
##xy O
##s O
##1 O
and O
d O
##xy O
##s O
##12 O
is O
suggested O
. O

the O
above O
ha O
##p O
##lot O
##ype O
is O
a O
very O
useful O
diagnostic O
tool O
in O
these O
t B-Disease
##c I-Disease
##d I-Disease
families O
. O

we O
suggest O
that O
our O
historical O
- O
gene O
##alog O
##ical O
approach O
to O
link O
##age O
analysis O
may O
be O
possible O
elsewhere O
in O
similar O
isolated O
populations O

von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
maps O
to O
the O
region O
of O
chromosome O
3 O
associated O
with O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
( O
v B-Disease
##hl I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
with O
inherited O
su O
##s O
##ce O
##pt O
##ibility O
to O
various O
forms O
of O
cancer B-Disease
, O
including O
hem B-Disease
##ang I-Disease
##io I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
of O
the O
central O
nervous O
system O
, O
p B-Disease
##ha I-Disease
##eo I-Disease
##ch I-Disease
##rom I-Disease
##oc I-Disease
##yt I-Disease
##oma I-Disease
##s I-Disease
, O
pan B-Disease
##cre I-Disease
##atic I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncies I-Disease
, O
and O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
constitute O
a O
particularly O
frequent O
cause O
of O
death O
in O
this O
disorder O
, O
occurring O
as O
bilateral B-Disease
and I-Disease
multi I-Disease
##fo I-Disease
##cal I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
, O
and O
presenting O
at O
an O
earlier O
age O
than O
in O
s O
##poradic O
, O
non O
- O
f O
##ami O
##lial O
cases O
of O
this O
t B-Disease
##umour I-Disease
type O
. O

we O
report O
here O
that O
the O
v B-Disease
##hl I-Disease
gene O
is O
linked O
to O
the O
lo O
##cus O
encoding O
the O
human O
ho O
##mo O
##log O
##ou O
##e O
of O
the O
r O
##af O
##1 O
on O
##co O
##gene O
, O
which O
maps O
to O
chromosome O
3 O
##p O
##25 O
( O
re O
##f O
. O
4 O
) O
. O

crossover O
##s O
with O
the O
v B-Disease
##hl I-Disease
lo O
##cus O
suggest O
that O
the O
defect O
responsible O
for O
the O
v B-Disease
##hl I-Disease
p O
##hen O
##otype O
is O
not O
a O
mutation O
in O
the O
r O
##af O
##1 O
gene O
itself O
. O

an O
alternative O
or O
prior O
event O
to O
on O
##co O
##gene O
activation O
in O
t B-Disease
##umour I-Disease
formation O
may O
be O
the O
in O
##act O
##ivation O
of O
a O
put O
##ative O
t B-Disease
##umour I-Disease
suppress O
##or O
which O
can O
be O
associated O
with O
both O
the O
inherited B-Disease
and I-Disease
s I-Disease
##poradic I-Disease
forms I-Disease
of I-Disease
the I-Disease
cancer I-Disease
. O

s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
have O
previously O
been O
associated O
with O
the O
loss O
of O
regions O
on O
chromosome O
3 O
##p O
( O
re O
##fs O
5 O
, O
6 O
) O
. O

consequently O
, O
s O
##poradic O
and O
v O
##hl O
- O
associated O
forms O
of O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
might O
both O
result O
from O
alterations O
causing O
loss O
of O
function O
of O
the O
same O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
on O
this O
chromosome O
. O
. O

tightly O
linked O
flank O
##ing O
markers O
for O
the O
low B-Disease
##e I-Disease
o I-Disease
##cu I-Disease
##loc I-Disease
##ere I-Disease
##bro I-Disease
##rena I-Disease
##l I-Disease
syndrome I-Disease
, O
with O
application O
to O
carrier O
assessment O
. O

the O
low B-Disease
##e I-Disease
o I-Disease
##cu I-Disease
##loc I-Disease
##ere I-Disease
##bro I-Disease
##rena I-Disease
##l I-Disease
syndrome I-Disease
( O
o B-Disease
##c I-Disease
##rl I-Disease
) O
is O
characterized O
by O
con O
##gen O
##ital O
cat B-Disease
##ara I-Disease
##ct I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
defect B-Disease
##ive I-Disease
re I-Disease
##nal I-Disease
tub I-Disease
##ular I-Disease
function I-Disease
. O

a O
map O
assignment O
of O
o B-Disease
##c I-Disease
##rl I-Disease
to O
x O
##q O
##24 O
- O
q O
##26 O
has O
been O
made O
previously O
by O
link O
##age O
analysis O
with O
d O
##x O
##s O
##42 O
at O
x O
##q O
##24 O
- O
q O
##26 O
( O
the O
##ta O
= O
0 O
, O
z O
= O
5 O
. O
09 O
) O
and O
with O
d O
##x O
##s O
##10 O
at O
x O
##q O
##26 O
( O
the O
##ta O
= O
0 O
, O
z O
= O
6 O
. O
45 O
) O
. O

two O
additional O
families O
were O
studied O
and O
three O
additional O
p O
##oly O
##mor O
##phism O
##s O
were O
identified O
at O
d O
##x O
##s O
##42 O
by O
using O
a O
35 O
- O
k O
##b O
sequence O
isolated O
with O
the O
probe O
detect O
##ing O
the O
original O
p O
##oly O
##mor O
##phism O
at O
d O
##x O
##s O
##42 O
. O

with O
additional O
o B-Disease
##c I-Disease
##rl I-Disease
families O
made O
inform O
##ative O
for O
d O
##x O
##s O
##42 O
, O
the O
##ta O
remained O
0 O
with O
z O
= O
6 O
. O

63 O
; O
and O
for O
d O
##x O
##s O
##10 O
the O
##ta O
= O
0 O
. O

03 O
and O
z O
= O
7 O
. O

07 O
. O

evidence O
for O
placing O
o O
##c O
##rl O
at O
x O
##q O
##25 O
also O
comes O
from O
a O
female O
with O
low B-Disease
##e I-Disease
syndrome I-Disease
and O
an O
x O
; O
3 O
trans O
##location O
. O

we O
have O
used O
the O
x O
##q O
##25 O
break O
##point O
in O
this O
patient O
to O
determine O
the O
position O
of O
o O
##c O
##rl O
relative O
to O
the O
two O
linked O
markers O
. O

each O
derivative O
chromosome O
was O
isolated O
away O
from O
its O
normal O
counterpart O
in O
so O
##matic O
cell O
hybrid O
##s O
. O

d O
##x O
##s O
##42 O
was O
mapped O
to O
the O
derivative O
chromosome O
x O
containing O
x O
##pt O
##er O
##q O
##25 O
, O
and O
d O
##x O
##s O
##10 O
was O
mapped O
to O
the O
derivative O
chromosome O
3 O
containing O
x O
##q O
##25 O
- O
q O
##ter O
. O

the O
markers O
d O
##x O
##s O
##10 O
and O
d O
##x O
##s O
##42 O
therefore O
show O
tight O
link O
##age O
with O
o B-Disease
##c I-Disease
##rl I-Disease
in O
six O
families O
and O
flank O
the O
x O
##q O
##25 O
break O
##point O
in O
a O
female O
patient O
with O
an O
x O
; O
3 O
trans O
##location O
. O

link O
##age O
analysis O
with O
flank O
##ing O
markers O
was O
used O
to O
assess O
o B-Disease
##c I-Disease
##rl I-Disease
carrier O
status O
in O
women O
at O
risk O
. O

results O
, O
when O
compared O
with O
carrier O
determination O
by O
op O
##ht O
##hal O
##mo O
##log O
##ic O
examination O
, O
indicated O
that O
the O
slit O
- O
lamp O
exam O
can O
be O
a O
sensitive O
and O
specific O
method O
of O
carrier O
determination O
in O
many O
cases O

identification O
of O
a O
single O
n O
##uc O
##leo O
##tide O
change O
in O
the O
h O
##y O
##pox O
##ant O
##hine O
- O
g O
##uan O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
gene O
( O
hp O
##rt O
##yal O
##e O
) O
responsible O
for O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

complete O
deficiency B-Disease
of I-Disease
h I-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
- I-Disease
g I-Disease
##uan I-Disease
##ine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
##tra I-Disease
##ns I-Disease
##fer I-Disease
##ase I-Disease
( O
hp O
##rt O
) O
causes O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

previous O
characterization O
of O
a O
mutant O
form O
of O
hp O
##rt O
, O
hp O
##rt O
##yal O
##e O
, O
from O
a O
subject O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
revealed O
normal O
m O
##rna O
and O
protein O
concentrations O
, O
no O
residual O
cat O
##alytic O
activity O
, O
and O
cat O
##ho O
##dal O
migration O
upon O
page O
. O

we O
have O
clone O
##d O
and O
sequence O
##d O
hp O
##rt O
##yal O
##e O
c O
##dn O
##a O
. O

the O
n O
##uc O
##leo O
##tide O
sequence O
of O
full O
- O
length O
hp O
##rt O
##yal O
##e O
c O
##dn O
##a O
revealed O
a O
single O
n O
##uc O
##leo O
##tide O
substitution O
compared O
with O
normal O
hp O
##rt O
c O
##dn O
##a O
g O
- O
- O
- O
- O
c O
at O
n O
##uc O
##leo O
##tide O
position O
211 O
. O

this O
trans O
##version O
predict O
##s O
substitution O
of O
a O
##rg O
##ini O
##ne O
for O
g O
##ly O
##cine O
at O
amino O
acid O
position O
71 O
, O
explaining O
the O
cat O
##ho O
##dal O
migration O
of O
hp O
##rt O
##yal O
##e O
. O

ch O
##ou O
- O
f O
##as O
##man O
secondary O
structure O
analysis O
predict O
##s O
a O
change O
in O
the O
probability O
of O
beta O
- O
turn O
formation O
in O
the O
region O
containing O
the O
mutation O
. O

inclusion O
of O
the O
bulk O
##y O
a O
##rg O
##ini O
##ne O
side O
chain O
in O
place O
of O
g O
##ly O
##cine O
probably O
disrupt O
##s O
protein O
folding O
as O
well O
. O

c O
##lon O
##ing O
mutant O
forms O
of O
c O
##dn O
##a O
allows O
identification O
of O
specific O
mutations O
, O
provides O
insight O
into O
mutation O
##al O
mechanisms O
, O
and O
facilitate O
##s O
structure O
- O
function O
analysis O
of O
mutant O
proteins O
. O
. O

two O
point O
mutations O
are O
responsible O
for O
g O
##6 O
##p O
##d O
p O
##oly O
##mor O
##phism O
in O
sa O
##rdi O
##nia O
. O

the O
human O
x O
- O
linked O
gene O
encoding O
glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
is O
highly O
p O
##oly O
##morphic O
; O
more O
than O
300 O
g O
##6 O
##p O
##d O
variants O
have O
been O
identified O
. O

g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
different O
geographical O
areas O
appears O
to O
have O
arise O
##n O
through O
independent O
mutation O
##al O
events O
, O
but O
within O
the O
same O
population O
it O
may O
also O
be O
he O
##tero O
##gene O
##ous O
. O

one O
example O
is O
the O
island O
of O
sa O
##rdi O
##nia O
, O
where O
careful O
clinical O
and O
bio O
##chemical O
studies O
have O
identified O
four O
different O
g O
##6 O
##p O
##d O
variants O
. O

we O
clone O
##d O
and O
sequence O
##d O
the O
four O
g O
##6 O
##p O
##d O
variants O
from O
sa O
##rdi O
##nia O
and O
found O
that O
only O
two O
mutations O
are O
responsible O
for O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
this O
area O
one O
mutation O
is O
the O
cause O
of O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
seat I-Disease
##tle I-Disease
- I-Disease
like I-Disease
p I-Disease
##hen I-Disease
##otype I-Disease
, O
a O
mild O
##er O
form O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
; O
the O
other O
mutation O
is O
responsible O
for O
all O
forms O
of O
very O
severe O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
sa O
##rdi O
##nia O
and O
, O
possibly O
, O
in O
the O
me O
##dit O
##er O
##rane O
##an O
. O
. O

chronic B-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
( O
c B-Disease
##ns I-Disease
##ha I-Disease
) O
and O
glucose B-Disease
6 I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
a O
patient O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##otic I-Disease
p I-Disease
##oly I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

molecular O
study O
of O
a O
new O
variant O
( O
g O
##6 O
##p O
##d O
clinic O
) O
with O
marked O
##ly O
acidic O
p O
##h O
op O
##ti O
##mum O
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
variant O
with O
severe O
er B-Disease
##yt I-Disease
##hr I-Disease
##oc I-Disease
##ytic I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
and O
a O
unique O
p O
##h O
op O
##ti O
##mum O
is O
described O
in O
a O
young O
patient O
with O
chronic B-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
( O
c B-Disease
##ns I-Disease
##ha I-Disease
) O
and O
f B-Disease
##ami I-Disease
##lial I-Disease
am I-Disease
##yl I-Disease
##oid I-Disease
##otic I-Disease
p I-Disease
##oly I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
f B-Disease
##ap I-Disease
) O
. O

chronic B-Disease
hem I-Disease
##oly I-Disease
##sis I-Disease
was O
present O
in O
the O
absence O
of O
infections O
, O
o O
##xi O
##dant O
drugs O
or O
ing O
##est O
##ion O
of O
f O
##aba O
beans O
. O

residual O
enzyme O
activity O
was O
about O
2 O
. O

6 O
% O
and O
63 O
% O
of O
normal O
activity O
in O
er O
##yt O
##hr O
##ocytes O
and O
le O
##uc O
##ocytes O
, O
respectively O
. O

a O
molecular O
study O
using O
standard O
methods O
showed O
g O
##6 O
##p O
##d O
in O
the O
patient O
to O
have O
normal O
electro O
##ph O
##ore O
##tic O
mobility O
( O
at O
p O
##h O
7 O
. O
0 O
, O
8 O
. O
0 O
and O
8 O
. O
8 O
) O
, O
normal O
apparent O
affinity O
for O
substrates O
( O
km O
, O
g O
##6 O
##p O
and O
na O
##d O
##p O
) O
and O
a O
slightly O
abnormal O
u O
##til O
##ization O
of O
substrate O
analogue O
##s O
( O
decreased O
de O
##ami O
##no O
- O
na O
##d O
##p O
and O
increased O
2 O
- O
de O
##ox O
##y O
##g O
##lu O
##cos O
##e O
- O
6 O
- O
phosphate O
u O
##til O
##ization O
) O
. O

heat O
stability O
was O
found O
to O
be O
marked O
##ly O
decreased O
( O
8 O
% O
of O
residual O
activity O
after O
20 O
min O
of O
in O
##cu O
##bation O
at O
46 O
degrees O
c O
) O
and O
a O
particular O
characteristic O
of O
this O
enzyme O
was O
a O
bi O
##pha O
##si O
##c O
p O
##h O
curve O
with O
a O
greatly O
increased O
activity O
at O
low O
p O
##h O
. O

although O
molecular O
characteristics O
of O
this O
variant O
closely O
resemble O
those O
of O
g O
##6 O
##p O
##d O
bang O
##ko O
##k O
and O
g O
##6 O
##p O
##d O
du O
##arte O
, O
it O
can O
be O
distinguished O
from O
these O
and O
all O
other O
previously O
reported O
variants O
by O
virtue O
of O
its O
unusual O
p O
##h O
curve O
. O

therefore O
the O
present O
variant O
has O
been O
designated O
g O
##6 O
##p O
##d O
clinic O
to O
distinguish O
it O
from O
other O
g O
##6 O
##p O
##d O
variants O
previously O
described O

molecular O
detection O
of O
ch O
##rom O
##oso O
##mal O
trans O
##location O
##s O
that O
disrupt O
the O
put O
##ative O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
su O
##s O
##ce O
##pt O
##ibility O
lo O
##cus O
. O

a O
candidate O
d O
##na O
sequence O
with O
many O
of O
the O
properties O
predicted O
for O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
su O
##s O
##ce O
##pt O
##ibility O
( O
r O
##b O
##1 O
) O
lo O
##cus O
has O
been O
clone O
##d O
( O
s O
. O
h O
. O
friend O
, O
r O
. O
be O
##rna O
##rds O
, O
s O
. O
r O
##ogel O
##j O
, O
r O
. O
a O
. O
we O
##in O
##berg O
, O
j O
. O
m O
. O
rap O
##ap O
##ort O
, O
d O
. O
m O
. O
al O
##bert O
, O
and O
t O
. O
p O
. O
dry O
##ja O
, O
nature O
[ O
lo O
##ndon O
] O
32 O
##3 O
64 O
##3 O
- O
64 O
##5 O
, O
1986 O
) O
. O

the O
large O
size O
of O
this O
gene O
( O
ca O
. O
200 O
k O
##ilo O
##base O
##s O
[ O
k O
##b O
] O
) O
and O
its O
multiple O
dispersed O
ex O
##ons O
( O
w O
##iggs O
et O
al O
. O
, O
n O
. O
en O
##g O
##l O
. O
j O
. O
me O
##d O
. O
31 O
##8 O
151 O
- O
157 O
, O
1988 O
) O
com O
##plicate O
molecular O
screening O
strategies O
important O
in O
pre O
##nat O
##al O
and O
pre O
##sy O
##mpt O
##oma O
##tic O
diagnosis O
and O
in O
carrier O
detection O
. O

here O
we O
used O
field O
in O
##version O
gel O
electro O
##ph O
##ores O
##is O
( O
fi O
##ge O
) O
to O
construct O
a O
restriction O
map O
of O
approximately O
1 O
, O
000 O
k O
##b O
of O
d O
##na O
surrounding O
the O
r O
##b O
##1 O
lo O
##cus O
and O
to O
detect O
the O
trans O
##location O
break O
##points O
in O
three O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
patients O
. O

d O
##na O
probe O
##s O
from O
either O
the O
5 O
or O
3 O
end O
of O
the O
gene O
were O
used O
to O
detect O
a O
250 O
- O
k O
##b O
e O
##agi O
restriction O
fragment O
in O
d O
##na O
from O
un O
##af O
##fected O
individuals O
. O

both O
probe O
##s O
identified O
an O
additional O
hybrid O
##izing O
fragment O
in O
the O
d O
##na O
from O
each O
patient O
, O
permitting O
the O
break O
##points O
in O
all O
three O
to O
be O
mapped O
within O
the O
clone O
##d O
r O
##b O
##1 O
gene O
. O

analysis O
of O
the O
break O
##point O
in O
one O
trans O
##location O
cell O
line O
allowed O
the O
r O
##b O
##1 O
gene O
to O
be O
oriented O
with O
its O
5 O
end O
toward O
the O
cent O
##rome O
##re O
. O

the O
5 O
end O
of O
the O
gene O
also O
appeared O
to O
be O
associated O
with O
a O
cluster O
##ing O
of O
sites O
for O
several O
in O
##f O
##re O
##quent O
##ly O
c O
##lea O
##ving O
restriction O
enzymes O
, O
indicating O
the O
presence O
of O
an O
hp O
##ai O
##i O
tiny O
fragment O
island O
. O

the O
detection O
and O
mapping O
of O
the O
trans O
##location O
break O
##points O
of O
all O
three O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
patients O
to O
within O
the O
put O
##ative O
r O
##b O
##1 O
gene O
sub O
##stant O
##iated O
the O
authenticity O
of O
this O
candidate O
sequence O
and O
demonstrated O
the O
utility O
of O
fi O
##ge O
in O
detect O
##ing O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
##s O
affecting O
this O
lo O
##cus O
. O

inherited O
c B-Disease
##3 I-Disease
deficiency I-Disease
with O
re O
##current O
infections O
and O
g B-Disease
##lo I-Disease
##mer I-Disease
##ulon I-Disease
##ep I-Disease
##hr I-Disease
##itis I-Disease
. O

a O
10 O
- O
year O
- O
old O
la O
##ot O
##ian O
boy O
had O
ho O
##mo O
##zy O
##go O
##us O
deficiency B-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
and O
re O
##current O
bacterial B-Disease
infections I-Disease
beginning O
at O
age O
5 O
months O
. O

cellular O
and O
humor O
##al O
immunity O
were O
normal O
, O
as O
were O
p O
##oly O
##mor O
##phon O
##uc O
##lea O
##r O
le O
##uk O
##oc O
##yte O
ch O
##em O
##ota O
##xi O
##s O
and O
b O
##act O
##eric O
##idal O
activities O
. O

serum O
complement O
- O
mediated O
hem O
##oly O
##tic O
, O
ch O
##em O
##ota O
##ctic O
, O
and O
op O
##sonic O
activities O
were O
def O
##icient O
. O

in O
v O
##it O
##ro O
addition O
of O
pu O
##rified O
c O
##3 O
to O
patient O
serum O
restored O
hem O
##oly O
##tic O
complement O
to O
normal O
levels O
, O
and O
plasma O
in O
##fusion O
during O
each O
of O
four O
episodes O
of O
pneumonia B-Disease
significantly O
enhanced O
serum O
op O
##sonic O
activity O
for O
as O
long O
as O
36 O
hours O
. O

a O
re O
##nal O
bio O
##psy O
specimen O
revealed O
me B-Disease
##sang I-Disease
##io I-Disease
##pathic I-Disease
g I-Disease
##lo I-Disease
##mer I-Disease
##ulon I-Disease
##ep I-Disease
##hr I-Disease
##itis I-Disease
, O
although O
significant O
levels O
of O
circulating O
i O
##gg O
immune O
complexes O
were O
not O
detected O
. O

these O
findings O
further O
support O
the O
association O
of O
c B-Disease
##3 I-Disease
deficiency I-Disease
with O
immune B-Disease
- I-Disease
complex I-Disease
disease I-Disease
and O
suggest O
that O
plasma O
in O
##fusion O
may O
be O
an O
ad O
##junct O
to O
anti O
##biotic O
therapy O
in O
the O
management O
of O
severe O
p B-Disease
##yo I-Disease
##genic I-Disease
infections I-Disease
in O
patients O
with O
c B-Disease
##3 I-Disease
deficiency I-Disease
. O
. O

d O
##na O
restriction O
fragments O
associated O
with O
alpha O
1 O
- O
anti O
##try O
##ps O
##in O
indicate O
a O
single O
origin O
for O
deficiency O
all O
##ele O
p O
##i O
z O
. O

the O
alpha O
1 O
- O
pro O
##te O
##ase O
inhibitor O
, O
or O
alpha O
- O
anti O
##try O
##ps O
##in O
( O
a O
##at O
) O
, O
a O
major O
plasma O
inhibitor O
of O
le O
##uk O
##oc O
##yte O
el O
##ast O
##ase O
and O
bacterial O
pro O
##te O
##ases O
, O
is O
encoded O
at O
the O
p O
##i O
lo O
##cus O
on O
chromosome O
14 O
( O
14 O
##q O
##24 O
. O
3 O
- O
q O
##32 O
. O
1 O
) O
. O

a O
deficiency B-Disease
of I-Disease
a I-Disease
##at I-Disease
in O
individuals O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
p O
##i O
z O
all O
##ele O
occurs O
in O
about O
1 O
in O
2 O
, O
000 O
- O
8 O
, O
000 O
ca O
##uca O
##sian O
##s O
and O
is O
associated O
with O
an O
increased O
risk O
of O
early O
adult O
onset O
em B-Disease
##phy I-Disease
##se I-Disease
##ma I-Disease
and O
liver B-Disease
disease I-Disease
in O
childhood O
. O

we O
have O
now O
used O
d O
##na O
p O
##oly O
##mor O
##phism O
##s O
associated O
with O
the O
a O
##at O
gene O
to O
investigate O
the O
origin O
of O
the O
p O
##i O
z O
all O
##ele O
. O

using O
two O
g O
##eno O
##mic O
probe O
##s O
extending O
into O
the O
5 O
and O
3 O
flank O
##ing O
regions O
, O
respectively O
, O
we O
have O
identified O
eight O
p O
##oly O
##morphic O
restriction O
sites O
. O

extensive O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
occurs O
throughout O
the O
probe O
##d O
region O
with O
the O
p O
##i O
z O
all O
##ele O
, O
but O
not O
with O
normal O
p O
##i O
m O
all O
##ele O
##s O
. O

the O
z O
all O
##ele O
occurs O
mainly O
with O
one O
ha O
##p O
##lot O
##ype O
, O
indicating O
a O
single O
, O
relatively O
recent O
, O
origin O
in O
ca O
##uca O
##sian O
##s O

segregation O
analysis O
of O
a O
marker O
local O
##ised O
x O
##p O
##21 O
. O
2 O
- O
x O
##p O
##21 O
. O
3 O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
families O
. O

a O
d O
##na O
marker O
c O
##7 O
, O
local O
##ised O
x O
##p O
##21 O
. O

1 O
- O
x O
##p O
##21 O
. O

3 O
, O
has O
been O
studied O
in O
kind O
##red O
##s O
se O
##g O
##re O
##gating O
for O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
and O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
b B-Disease
##m I-Disease
##d I-Disease
) O
. O

in O
d B-Disease
##m I-Disease
##d I-Disease
families O
four O
crossover O
##s O
were O
observed O
in O
38 O
inform O
##ative O
me O
##ios O
##es O
between O
c O
##7 O
and O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
( O
the O
##ta O
= O
0 O
. O
12 O
, O
z O
ma O
##x O
= O
+ O
2 O
. O
72 O
) O
. O

in O
b B-Disease
##m I-Disease
##d I-Disease
families O
no O
re O
##comb O
##ina O
##nts O
were O
observed O
in O
the O
16 O
inform O
##ative O
me O
##ios O
##es O
studied O
. O

these O
data O
are O
consistent O
with O
the O
local O
##isation O
of O
the O
mutations O
in O
these O
disorders O
being O
in O
the O
same O
region O
of O
x O
##p O
##21 O
. O

studies O
in O
families O
also O
se O
##g O
##re O
##gating O
for O
the O
d O
##na O
marker O
75 O
##4 O
support O
the O
previously O
reported O
physical O
order O
of O
these O
lo O
##ci O
as O
x O
cent O
##rome O
##re O
- O
75 O
##4 O
- O
d O
##m O
##d O
- O
b O
##m O
##d O
- O
c O
##7 O
- O
x O
te O
##lo O
##mere O
. O

a O
re O
##comb O
##ination O
fraction O
of O
0 O
. O

11 O
( O
z O
ma O
##x O
= O
+ O
5 O
. O
58 O
) O
was O
found O
between O
d O
##m O
##d O
- O
75 O
##4 O
by O
combining O
our O
previously O
published O
data O
with O
the O
data O
presented O
here O
. O

c O
##7 O
and O
75 O
##4 O
thus O
provide O
good O
br O
##id O
##ging O
markers O
for O
the O
diagnosis O
of O
d B-Disease
##m I-Disease
##d I-Disease
and O
b B-Disease
##m I-Disease
##d I-Disease

isolation O
of O
molecular O
probe O
##s O
associated O
with O
the O
chromosome O
15 O
instability O
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

flow O
c O
##yt O
##ome O
##try O
and O
re O
##comb O
##ina O
##nt O
d O
##na O
techniques O
have O
been O
used O
to O
obtain O
re O
##age O
##nts O
for O
a O
molecular O
analysis O
of O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

hind O
##ii O
##i O
total O
- O
dig O
##est O
libraries O
were O
prepared O
in O
la O
##mb O
##da O
p O
##hage O
ch O
##aro O
##n O
21 O
##a O
from O
flow O
- O
sorted O
inverted O
du O
##plicate O
##d O
no O
. O
15 O
human O
chromosome O
##s O
and O
prop O
##aga O
##ted O
on O
re O
##comb O
##ination O
- O
pro O
##ficient O
( O
le O
##39 O
##2 O
) O
and O
re O
##c O
##b O
##c O
- O
, O
s O
##b O
##c O
##b O
- O
( O
d O
##b O
##12 O
##5 O
##7 O
) O
bacteria O
. O

twelve O
distinct O
chromosome O
15 O
- O
specific O
probe O
##s O
have O
been O
isolated O
. O

eight O
localized O
to O
the O
region O
15 O
##q O
##11 O
- O
- O
- O
- O
13 O
. O

four O
of O
these O
eight O
sub O
##loc O
##ali O
##zed O
to O
band O
15 O
##q O
##11 O
. O

2 O
and O
are O
shown O
to O
be O
deleted O
in O
d O
##na O
of O
one O
of O
two O
patients O
examined O
with O
the O
p B-Disease
##ws I-Disease
. O

he O
##tero O
##du O
##plex O
analysis O
of O
two O
of O
these O
clone O
##s O
, O
which O
grew O
on O
d O
##b O
##12 O
##5 O
##7 O
but O
not O
on O
le O
##39 O
##2 O
, O
revealed O
stem O
- O
loop O
structures O
in O
the O
insert O
##s O
, O
in O
##dicative O
of O
inverted O
, O
repeated O
d O
##na O
elements O
. O

such O
d O
##na O
repeats O
might O
account O
for O
some O
of O
the O
c O
##lon O
##ing O
instability O
of O
d O
##na O
segments O
from O
pro O
##ximal O
15 O
##q O
. O

analysis O
of O
the O
genetic O
and O
physical O
instability O
associated O
with O
the O
repeated O
sequences O
we O
have O
isolated O
from O
band O
15 O
##q O
##11 O
. O

2 O
may O
el O
##uc O
##ida O
##te O
the O
molecular O
basis O
for O
the O
instability O
of O
this O
ch O
##rom O
##oso O
##mal O
region O
in O
patients O
with O
the O
p B-Disease
##ws I-Disease
or O
other O
diseases O
associated O
with O
ch B-Disease
##rom I-Disease
##oso I-Disease
##mal I-Disease
abnormal I-Disease
##ities I-Disease
in O
the O
pro O
##ximal O
long O
arm O
of O
human O
chromosome O
15 O

analysis O
of O
del O
##eti O
##ons O
in O
d O
##na O
from O
patients O
with O
be B-Disease
##cker I-Disease
and I-Disease
du I-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
genetic I-Disease
disorder I-Disease
for O
which O
the O
bio O
##chemical O
defect O
is O
as O
yet O
unknown O
. O

recently O
, O
two O
clone O
##d O
segments O
of O
human O
x O
- O
chromosome O
d O
##na O
have O
been O
described O
which O
detect O
structural O
alterations O
within O
or O
near O
the O
genetic O
lo O
##cus O
responsible O
for O
the O
disorder O
. O

both O
of O
these O
clone O
##d O
segments O
were O
described O
as O
tightly O
linked O
to O
the O
lo O
##cus O
and O
were O
capable O
of O
detect O
##ing O
del O
##eti O
##ons O
in O
the O
d O
##na O
of O
boys O
affected O
with O
d B-Disease
##m I-Disease
##d I-Disease
. O

in O
an O
attempt O
to O
determine O
more O
precisely O
the O
occurrence O
of O
these O
del O
##eti O
##ons O
within O
a O
large O
population O
of O
d B-Disease
##m I-Disease
##d I-Disease
patients O
and O
the O
accuracy O
of O
one O
of O
the O
segments O
, O
d O
##x O
##s O
##16 O
##4 O
( O
per O
##t O
##8 O
##7 O
) O
, O
in O
determining O
the O
inheritance O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
x O
chromosome O
, O
the O
sub O
##c O
##lone O
##s O
1 O
, O
8 O
and O
15 O
were O
made O
available O
to O
many O
investigators O
throughout O
the O
world O
. O

here O
we O
describe O
the O
combined O
results O
of O
more O
than O
20 O
research O
laboratories O
with O
respect O
to O
the O
occurrence O
of O
del O
##eti O
##ons O
at O
the O
d O
##x O
##s O
##16 O
##4 O
lo O
##cus O
in O
d O
##na O
samples O
isolated O
from O
patients O
with O
d B-Disease
##m I-Disease
##d I-Disease
and O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
b B-Disease
##m I-Disease
##d I-Disease
) O
. O

the O
results O
indicate O
that O
the O
d O
##x O
##s O
##16 O
##4 O
lo O
##cus O
apparently O
re O
##comb O
##ines O
with O
d B-Disease
##m I-Disease
##d I-Disease
5 O
% O
of O
the O
time O
, O
but O
is O
probably O
located O
between O
independent O
sites O
of O
mutation O
which O
yield O
d B-Disease
##m I-Disease
##d I-Disease
. O

the O
break O
##points O
of O
some O
del O
##eti O
##ons O
are O
del O
##ine O
##ated O
within O
the O
d O
##x O
##s O
##16 O
##4 O
lo O
##cus O
, O
and O
it O
is O
evident O
that O
the O
del O
##eti O
##ons O
at O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
are O
frequent O
and O
extremely O
large O
. O
. O

a O
potential O
animal O
model O
for O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
through O
introduction O
of O
hp O
##rt O
mutations O
into O
mice O
. O

the O
human O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
is O
a O
rare O
ne B-Disease
##uro I-Disease
##logical I-Disease
and I-Disease
behaviour I-Disease
##al I-Disease
disorder I-Disease
, O
affecting O
only O
males O
, O
which O
is O
caused O
by O
an O
inherited B-Disease
deficiency I-Disease
in O
the O
level O
of O
activity O
of O
the O
pu O
##rine O
salvage O
enzyme O
h O
##y O
##pox O
##ant O
##hine O
- O
g O
##uan O
##os O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
transfer O
##ase O
( O
hp O
##rt O
) O
. O

how O
the O
resulting O
alterations O
in O
pu O
##rine O
metabolism O
lead O
to O
the O
severe O
symptoms O
characteristic O
of O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patients O
is O
still O
not O
understood O
. O

no O
mutations O
at O
the O
hp O
##rt O
lo O
##cus O
leading O
to O
loss O
of O
activity O
have O
been O
described O
in O
laboratory O
animals O
. O

to O
derive O
an O
animal O
model O
for O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
, O
we O
have O
used O
culture O
##d O
mouse O
em O
##b O
##ryo O
##nic O
stem O
cells O
, O
m O
##uta O
##gen O
##ized O
by O
re O
##tro O
##vir O
##al O
insertion O
and O
selected O
for O
loss O
of O
hp O
##rt O
activity O
, O
to O
construct O
ch O
##ima O
##eric O
mice O
. O

two O
c O
##lon O
##al O
lines O
carrying O
different O
mutant O
hp O
##rt O
all O
##ele O
##s O
have O
given O
rise O
to O
g O
##er O
##m O
cells O
in O
ch O
##ima O
##era O
##s O
, O
allowing O
the O
der O
##ivation O
of O
strains O
of O
mutant O
mice O
having O
the O
same O
bio O
##chemical O
defect O
as O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patients O
. O

male O
mice O
carrying O
the O
mutant O
all O
##ele O
##s O
are O
viable O
and O
analysis O
of O
their O
cells O
shows O
a O
total O
lack O
of O
hp O
##rt O
activity O
. O
. O

re O
- O
evaluation O
of O
the O
sub O
##loc O
##ali O
##zation O
of O
est O
##era O
##se O
d O
and O
its O
relation O
to O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
lo O
##cus O
by O
in O
sit O
##u O
hybrid O
##ization O
. O

in O
sit O
##u O
hybrid O
##ization O
of O
a O
c O
##dn O
##a O
probe O
for O
the O
est O
##era O
##se O
d O
gene O
( O
es O
##d O
) O
was O
carried O
out O
on O
human O
chromosome O
##s O
. O

the O
probe O
hybrid O
##ized O
most O
strongly O
to O
13 O
##q O
##14 O
. O

2 O
and O
13 O
##q O
##14 O
. O

3 O
. O

this O
observation O
raises O
doubts O
concerning O
the O
most O
recently O
published O
assignment O
of O
es O
##d O
to O
13 O
##q O
##14 O
. O

1 O
. O

a O
del O
##eti O
##on O
in O
an O
individual O
with O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
was O
reported O
to O
separate O
the O
closely O
linked O
es O
##d O
and O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
( O
r O
##b O
##1 O
) O
lo O
##ci O
, O
placing O
es O
##d O
pro O
##ximal O
to O
r O
##b O
##1 O
. O

quantitative O
in O
sit O
##u O
hybrid O
##ization O
studies O
of O
this O
del O
##eti O
##on O
do O
not O
confirm O
this O
interpretation O
. O

rather O
, O
they O
suggest O
that O
es O
##d O
is O
missing O
from O
the O
deleted O
chromosome O
13 O
and O
du O
##plicate O
##d O
on O
the O
normal O
ho O
##mo O
##log O
. O

from O
these O
findings O
, O
we O
conclude O
that O
the O
del O
##eti O
##on O
in O
this O
individual O
cannot O
be O
used O
to O
determine O
the O
orientation O
nor O
the O
sub O
##loc O
##ali O
##zation O
of O
es O
##d O
and O
r O
##b O
##1 O
within O
the O
13 O
##q O
##14 O
region O
. O

hereditary B-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
associated O
with O
common O
variable O
im B-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
. O

ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
in O
a O
19 O
- O
year O
- O
old O
boy O
was O
associated O
with O
variable O
im B-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
manifest O
##ed O
by O
marked O
h B-Disease
##y I-Disease
##po I-Disease
##im I-Disease
##mu I-Disease
##no I-Disease
##g I-Disease
##lo I-Disease
##bul I-Disease
##ine I-Disease
##mia I-Disease
and O
impaired O
anti O
##body O
responses O
, O
normal O
circulating O
b O
l O
##ymph O
##ocytes O
, O
and O
sub O
##nor O
##mal O
t O
- O
cell O
functions O
. O

neither O
anti O
##ly O
##mp O
##ho O
##cy O
##tic O
auto O
##anti O
##bo O
##dies O
nor O
ch B-Disease
##rom I-Disease
##oso I-Disease
##mal I-Disease
abnormal I-Disease
##ities I-Disease
were O
found O
. O

serum O
im O
##mu O
##no O
##g O
##lo O
##bul O
##in O
levels O
were O
within O
normal O
limits O
in O
his O
parents O
and O
brother O
who O
were O
he O
##tero O
##zy O
##go O
##us O
for O
c B-Disease
##2 I-Disease
deficiency I-Disease
. O

the O
patients O
l O
##ymph O
##ocytes O
were O
ho O
##mo O
##zy O
##go O
##us O
at O
the O
h O
##la O
- O
d O
lo O
##cus O
but O
expressed O
an O
anti O
##gen O
different O
from O
d O
##w O
##2 O
. O
. O

mild O
and O
severe O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
associated O
with O
del O
##eti O
##ons O
in O
x O
##p O
##21 O
of O
the O
human O
x O
chromosome O
. O

we O
have O
anal O
##ys O
##ed O
over O
300 O
patients O
suffering O
from O
du B-Disease
##chen I-Disease
##ne I-Disease
or I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
or O
b B-Disease
##m I-Disease
##d I-Disease
) O
. O

del O
##eti O
##ons O
have O
been O
characterised O
which O
en O
##com O
##pass O
either O
the O
per O
##t O
##8 O
##7 O
( O
d O
##x O
##s O
##16 O
##4 O
) O
lo O
##cus O
only O
, O
the O
x O
##j O
##1 O
. O

1 O
( O
d O
##x O
##s O
##20 O
##6 O
) O
and O
hip O
##25 O
lo O
##ci O
only O
, O
or O
all O
three O
lo O
##ci O
. O

these O
lo O
##ci O
have O
been O
shown O
to O
lie O
within O
the O
d B-Disease
##m I-Disease
##d I-Disease
region O
covering O
several O
hundred O
k O
##ilo O
##base O
##s O
( O
k O
##b O
) O
of O
d O
##na O
. O

one O
mildly O
affected O
b B-Disease
##m I-Disease
##d I-Disease
patient O
possesses O
a O
del O
##eti O
##on O
of O
at O
least O
110 O
k O
##b O
including O
ex O
##ons O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

other O
patients O
with O
similar O
ex O
##on O
del O
##eti O
##ons O
, O
or O
smaller O
del O
##eti O
##ons O
, O
show O
the O
more O
severe O
p O
##hen O
##otype O
typical O
of O
d B-Disease
##m I-Disease
##d I-Disease
. O

we O
conclude O
from O
these O
studies O
that O
the O
severity O
of O
the O
clinical O
p O
##hen O
##otype O
cannot O
be O
explained O
on O
the O
basis O
of O
the O
size O
of O
the O
del O
##eti O
##on O
. O

we O
discuss O
this O
in O
the O
context O
of O
candidate O
gene O
sequences O
. O

patterns O
of O
ex O
##on O
del O
##eti O
##ons O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

a O
panel O
of O
patients O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
and O
b B-Disease
##m I-Disease
##d I-Disease
) O
has O
been O
screened O
with O
the O
c O
##dn O
##a O
probe O
##s O
c O
##f O
##5 O
##6 O
##a O
and O
c O
##f O
##23 O
##a O
, O
which O
detect O
ex O
##ons O
in O
the O
central O
part O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

one O
or O
more O
ex O
##ons O
were O
deleted O
in O
60 O
% O
of O
patients O
. O

the O
del O
##eti O
##ons O
were O
mapped O
and O
prove O
to O
be O
he O
##tero O
##gene O
##ous O
in O
size O
and O
extent O
, O
particularly O
in O
d B-Disease
##m I-Disease
##d I-Disease
. O

del O
##eti O
##ons O
specific O
to O
d B-Disease
##m I-Disease
##d I-Disease
and O
to O
b B-Disease
##m I-Disease
##d I-Disease
are O
described O
. O

half O
of O
all O
b B-Disease
##m I-Disease
##d I-Disease
patients O
have O
a O
del O
##eti O
##on O
of O
one O
particular O
small O
group O
of O
ex O
##ons O
; O
smaller O
del O
##eti O
##ons O
within O
this O
same O
group O
produce O
the O
more O
severe O
d B-Disease
##m I-Disease
##d I-Disease
. O
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
child O
with O
fever B-Disease
, O
skin B-Disease
r I-Disease
##ash I-Disease
, O
and O
art B-Disease
##hra I-Disease
##l I-Disease
##gia I-Disease
##s I-Disease
: O
response O
to O
trans O
##fusion O
of O
whole O
blood O
. O

a O
previously O
well O
34 O
- O
month O
- O
old O
male O
presenting O
with O
fever B-Disease
, O
skin B-Disease
r I-Disease
##ash I-Disease
, O
and O
art B-Disease
##hra I-Disease
##l I-Disease
##gia I-Disease
##s I-Disease
was O
found O
to O
lack O
c O
##3 O
by O
im O
##mu O
##no O
##chemical O
( O
und O
##ete O
##ct O
##able O
) O
and O
hem O
##oly O
##tic O
( O
1 O
% O
normal O
) O
ass O
##ays O
. O

no O
infectious O
agent O
could O
be O
demonstrated O
. O

protein O
levels O
of O
c O
##l O
##q O
. O

c O
##4 O
, O
c O
##5 O
, O
proper O
##din O
, O
and O
c O
##3 O
##b O
- O
in O
##a O
and O
hem O
##oly O
##tic O
activities O
of O
complement O
components O
c O
##1 O
to O
c O
##9 O
except O
c O
##3 O
were O
normal O
or O
elevated O
; O
total O
hem O
##oly O
##tic O
complement O
activity O
was O
13 O
% O
of O
normal O
and O
was O
re O
##con O
##stituted O
by O
pu O
##rified O
c O
##3 O
. O

proper O
##din O
factor O
b O
was O
70 O
##2 O
( O
normal O
175 O
to O
275 O
) O
mug O
/ O
m O
##l O
, O
and O
was O
not O
c O
##lea O
##ver O
upon O
addition O
of O
z O
##ym O
##osa O
##n O
or O
co O
##bra O
venom O
factor O
. O

the O
serum O
had O
normal O
immune O
ad O
##herence O
activity O
, O
but O
was O
def O
##icient O
in O
ability O
to O
op O
##son O
##ize O
can O
##di O
##da O
al O
##bic O
##ans O
for O
up O
##take O
and O
es O
##cher O
##ichi O
##a O
co O
##li O
for O
killing O
by O
ne O
##uro O
##phi O
##ls O
, O
generate O
ne O
##ut O
##rop O
##hil O
ch O
##em O
##ota O
##ctic O
factors O
and O
in O
##hibit O
the O
growth O
of O
e O
. O
co O
##li O
; O
these O
activities O
were O
restored O
by O
pu O
##rified O
c O
##3 O
. O

a O
trans O
##fusion O
of O
320 O
m O
##l O
1 O
- O
hour O
- O
old O
normal O
whole O
blood O
on O
the O
fifty O
- O
second O
day O
resulted O
in O
transit O
##ory O
elevation O
of O
the O
c O
##3 O
level O
to O
25 O
mg O
/ O
d O
##l O
with O
a O
fall O
- O
off O
( O
approximately O
2 O
1 O
/ O
2 O
% O
per O
hour O
) O
to O
und O
##ete O
##ct O
##able O
levels O
by O
69 O
hours O
; O
it O
was O
followed O
by O
disappearance O
of O
the O
skin B-Disease
r I-Disease
##ash I-Disease
and O
art B-Disease
##hra I-Disease
##l I-Disease
##gia I-Disease
##s I-Disease
and O
return O
to O
normal O
of O
the O
previously O
elevated O
temperature O
and O
c O
##rp O
levels O
. O

c O
##3 O
levels O
in O
family O
members O
( O
seven O
of O
24 O
half O
- O
normal O
) O
, O
lack O
of O
anti O
- O
c O
##3 O
activity O
, O
normal O
c O
##3 O
##b O
- O
in O
##a O
levels O
and O
a O
normal O
rate O
of O
cat O
##ab O
##olis O
##m O
of O
trans O
##fused O
c O
##3 O
indicated O
that O
the O
deficiency O
was O
inherited O
with O
auto O
##so O
##mal O
co O
##dom O
##ina O
##nce O
and O
involved O
decreased B-Disease
synthesis I-Disease
of I-Disease
c I-Disease
##3 I-Disease
. O

thus O
, O
this O
child O
is O
a O
unique O
individual O
with O
inherited B-Disease
c I-Disease
##3 I-Disease
deficiency I-Disease
presenting O
with O
absence O
of O
repeated O
infections O
, O
whose O
symptoms O
of O
fever B-Disease
, O
skin B-Disease
r I-Disease
##ash I-Disease
, O
and O
art B-Disease
##hra I-Disease
##l I-Disease
##gia I-Disease
were O
a O
##bate O
##d O
by O
whole O
blood O
trans O
##fusion O
. O
. O

glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variants O
and O
their O
frequency O
in O
g O
##uang O
##dong O
, O
chin O
##a O
. O

er O
##yt O
##hr O
##oc O
##yte O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
was O
characterized O
in O
blood O
samples O
obtained O
from O
97 O
randomly O
selected O
males O
with O
enzyme B-Disease
deficiency I-Disease
from O
various O
regions O
of O
g O
##uang O
##dong O
province O
, O
chin O
##a O
. O

nine O
new O
variants O
( O
g O
##d O
ka O
##ip O
##ing O
, O
g O
##d O
b O
##ol O
##uo O
, O
g O
##d O
h O
##ui O
##yang O
, O
g O
##d O
g O
##ao O
##min O
, O
g O
##d O
q O
##ing O
- O
b O
##ai O
##jiang O
, O
g O
##d O
g O
##ao O
##zhou O
, O
g O
##d O
h O
##ua O
##zhou O
, O
g O
##d O
na O
##nh O
##ai O
, O
and O
g O
##d O
g O
##uang O
##zhou O
) O
were O
identified O
. O

of O
the O
31 O
variants O
found O
in O
this O
province O
, O
g O
##d O
ka O
##ip O
##ing O
, O
g O
##d O
ta O
##i O
##wan O
- O
ha O
##kka O
, O
g O
##d O
ha O
##ad O
ya O
##i O
, O
g O
##d O
ha O
##ad O
ya O
##i O
- O
like O
and O
g O
##d O
h O
##ui O
##yang O
occurred O
most O
frequently O
. O

the O
frequency O
of O
each O
variant O
was O
calculated O
. O

the O
results O
demonstrated O
that O
the O
genetic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
was O
high O
in O
this O
area O
. O
. O

ho O
##mo O
##zy O
##go O
##us O
and O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##ons O
of O
the O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
gene O
in O
patients O
and O
carriers O
of O
severe B-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
. O

severe B-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
is O
characterized O
by O
und O
##ete O
##ct O
##able O
or O
trace O
quantities O
of O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
in O
plasma O
and O
tissue O
stores O
. O

we O
have O
studied O
the O
g O
##eno O
##mic O
d O
##na O
of O
10 O
affected O
individuals O
from O
six O
families O
with O
this O
disorder O
using O
probe O
##s O
from O
the O
5 O
and O
3 O
ends O
of O
the O
v O
##w O
##f O
c O
##dn O
##a O
and O
with O
a O
probe O
extending O
from O
the O
5 O
end O
into O
the O
central O
region O
. O

southern O
b O
##lot O
##s O
of O
restriction O
end O
##on O
##uc O
##lea O
##se O
dig O
##ests O
and O
gene O
dos O
##age O
analysis O
measurements O
carried O
out O
with O
quantitative O
slot O
b O
##lot O
##s O
of O
und O
##ige O
##sted O
g O
##eno O
##mic O
d O
##na O
separated O
these O
patients O
into O
three O
groups O
. O

the O
first O
group O
consisted O
of O
a O
family O
with O
complete O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
of O
the O
v O
##w O
##f O
gene O
in O
the O
four O
pro O
##band O
##s O
. O

gene O
dos O
##age O
analysis O
was O
consistent O
with O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##ons O
in O
both O
of O
the O
as O
##ym O
##pt O
##oma O
##tic O
parents O
and O
four O
as O
##ym O
##pt O
##oma O
##tic O
siblings O
of O
this O
kind O
##red O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

the O
second O
group O
was O
comprised O
of O
a O
family O
in O
which O
there O
was O
a O
complete O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##on O
of O
the O
v O
##w O
##f O
gene O
in O
the O
pro O
##band O
and O
one O
as O
##ym O
##pt O
##oma O
##tic O
parent O
, O
suggesting O
that O
a O
different O
type O
of O
genetic B-Disease
abnormal I-Disease
##ity I-Disease
was O
inherited O
from O
the O
other O
parent O
. O

thus O
, O
the O
patient O
appeared O
to O
be O
do O
##ub O
##ly O
he O
##tero O
##zy O
##go O
##us O
for O
interacting O
genetic B-Disease
abnormal I-Disease
##ities I-Disease
affecting O
v O
##w O
##f O
expression O
. O

in O
the O
third O
group O
, O
no O
gene O
del O
##eti O
##ons O
could O
be O
detected O
. O

all O
##oan O
##ti O
##bo O
##dies O
developed O
only O
in O
the O
kind O
##red O
with O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
. O

these O
techniques O
should O
prove O
useful O
in O
identifying O
carriers O
of O
severe B-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
and O
also O
in O
defining O
patients O
predict O
##ably O
at O
risk O
of O
developing O
all O
##oan O
##ti O
##bo O
##dies O
to O
v O
##w O
##f O
. O

s B-Disease
##jo I-Disease
##gren I-Disease
- I-Disease
la I-Disease
##rs I-Disease
##son I-Disease
syndrome I-Disease
. O

impaired O
fatty O
alcohol O
oxidation O
in O
culture O
##d O
fi O
##bro O
##blast O
##s O
due O
to O
def O
##icient O
fatty O
alcohol O
: O
ni O
##cot O
##ina O
##mi O
##de O
ad O
##eni O
##ne O
din O
##uc O
##leo O
##tide O
o O
##xi O
##dor O
##ed O
##uc O
##tase O
activity O
. O

lip O
##id O
metabolism O
was O
studied O
in O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
from O
patients O
with O
the O
inherited B-Disease
disorder I-Disease
, O
s B-Disease
##jo I-Disease
##gren I-Disease
- I-Disease
la I-Disease
##rs I-Disease
##son I-Disease
syndrome I-Disease
( O
s B-Disease
##ls I-Disease
) O
. O

intact O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
in O
##cu O
##bate O
##d O
in O
the O
presence O
of O
[ O
1 O
- O
14 O
##c O
] O
palm O
##itate O
accumulated O
more O
radioactive O
he O
##xa O
##de O
##cano O
##l O
than O
did O
normal O
cells O
, O
whereas O
incorporation O
of O
radio O
##act O
##ivity O
into O
other O
cellular O
lip O
##ids O
was O
un O
##altered O
. O

the O
he O
##xa O
##de O
##cano O
##l O
content O
of O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
was O
abnormal O
##ly O
elevated O
. O

he O
##xa O
##de O
##cano O
##l O
accumulation O
was O
not O
due O
to O
increased O
fatty O
alcohol O
synthesis O
nor O
its O
def O
##icient O
u O
##til O
##ization O
for O
g O
##ly O
##cer O
##ol O
et O
##her O
synthesis O
. O

the O
half O
- O
life O
of O
in O
##tra O
##cellular O
he O
##xa O
##de O
##cano O
##l O
loaded O
into O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
was O
increased O
( O
70 O
min O
) O
compared O
with O
normal O
( O
15 O
min O
) O
, O
and O
intact O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
showed O
impaired O
oxidation O
of O
[ O
14 O
##c O
] O
- O
he O
##xa O
##de O
##cano O
##l O
to O
fatty O
acid O
. O

fatty O
alcohol O
na O
##d O
+ O
o O
##xi O
##dor O
##ed O
##uc O
##tase O
, O
the O
enzyme O
cat O
##aly O
##zing O
this O
reaction O
, O
was O
def O
##icient O
in O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
. O

mean O
total O
activity O
in O
s B-Disease
##ls I-Disease
fi O
##bro O
##blast O
##s O
( O
n O
= O
5 O
) O
was O
13 O
% O
of O
that O
in O
normal O
fi O
##bro O
##blast O
##s O
, O
and O
palm O
##ito O
##yl O
co O
##a O
- O
in O
##hibit O
##able O
activity O
was O
1 O
% O
of O
normal O
. O

fi O
##bro O
##blast O
##s O
from O
two O
o O
##b O
##liga O
##te O
s B-Disease
##ls I-Disease
he O
##tero O
##zy O
##got O
##es O
had O
enzyme O
activities O
intermediate O
between O
that O
in O
normal O
fi O
##bro O
##blast O
##s O
and O
individuals O
with O
s B-Disease
##ls I-Disease
. O

these O
results O
suggest O
that O
the O
primary O
defect O
in O
s B-Disease
##ls I-Disease
is O
deficiency B-Disease
of I-Disease
fatty I-Disease
alcohol I-Disease
na I-Disease
##d I-Disease
+ I-Disease
o I-Disease
##xi I-Disease
##dor I-Disease
##ed I-Disease
##uc I-Disease
##tase I-Disease
. O

s B-Disease
##ls I-Disease
represents O
the O
first O
inherited B-Disease
disorder I-Disease
in O
man O
associated O
with O
an O
isolated O
abnormal B-Disease
##ity I-Disease
in I-Disease
fatty I-Disease
alcohol I-Disease
metabolism I-Disease
. O
. O

g O
##er O
##mina O
##l O
mosaic O
##ism O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

we O
have O
identified O
a O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
p O
##ed O
##ig O
##ree O
where O
the O
disease O
is O
associated O
with O
a O
molecular O
del O
##eti O
##on O
within O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
. O

we O
have O
examined O
the O
me O
##iot O
##ic O
segregation O
products O
of O
the O
common O
female O
ancestor O
using O
marker O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
( O
r O
##f O
##l O
##ps O
) O
detected O
by O
probe O
##s O
that O
lie O
within O
this O
del O
##eti O
##on O
. O

these O
studies O
show O
that O
this O
female O
has O
transmitted O
three O
distinct O
types O
of O
x O
chromosome O
to O
her O
offspring O
. O

this O
observation O
may O
be O
explained O
by O
post O
##ulating O
that O
the O
mutation O
arose O
as O
a O
post O
##zy O
##got O
##ic O
del O
##eti O
##on O
within O
this O
common O
ancestor O
, O
who O
was O
consequently O
g O
##er O
##mina O
##lly O
mosaic O
. O
. O

ne O
##bul O
##in O
seen O
in O
d B-Disease
##m I-Disease
##d I-Disease
males O
including O
one O
patient O
with O
a O
large O
d O
##na O
del O
##eti O
##on O
encompassing O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

the O
presence O
of O
ne O
##bul O
##in O
in O
a O
muscle O
specimen O
from O
a O
patient O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
due O
to O
a O
large O
del O
##eti O
##on O
pre O
##c O
##lude O
##s O
the O
possibility O
that O
this O
protein O
is O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
product O
. O
. O

expression O
of O
the O
m O
##uri O
##ne O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
in O
muscle O
and O
brain O
. O

complementary O
d O
##na O
clone O
##s O
were O
isolated O
that O
represent O
the O
5 O
terminal O
2 O
. O

5 O
k O
##ilo O
##base O
##s O
of O
the O
m O
##uri O
##ne O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d O
##m O
##d O
) O
messenger O
r O
##na O
( O
m O
##rna O
) O
. O

mouse O
d O
##m O
##d O
m O
##rna O
was O
detect O
##able O
in O
skeletal O
and O
cardiac O
muscle O
and O
at O
a O
level O
approximately O
90 O
percent O
lower O
in O
brain O
. O

d O
##m O
##d O
m O
##rna O
is O
also O
present O
, O
but O
at O
much O
lower O
than O
normal O
levels O
, O
in O
both O
the O
muscle O
and O
brain O
of O
three O
different O
strains O
of O
d B-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
m O
##d O
##x O
mice O
. O

the O
identification O
of O
d O
##m O
##d O
m O
##rna O
in O
brain O
raises O
the O
possibility O
of O
a O
relation O
between O
human O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
expression O
and O
the O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
found O
in O
some O
d B-Disease
##m I-Disease
##d I-Disease
males O
. O

these O
results O
also O
provide O
evidence O
that O
the O
m O
##d O
##x O
mutations O
are O
all O
##eli O
##c O
variants O
of O
mouse O
d O
##m O
##d O
gene O
mutations O
. O

glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
and O
incidence O
of O
hem B-Disease
##ato I-Disease
##log I-Disease
##ic I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncy I-Disease
. O

we O
have O
evaluated O
the O
hypothesis O
of O
a O
negative O
association O
between O
glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
and O
cancer B-Disease
in O
a O
co O
##hor O
##t O
of O
48 O
##1 O
sa O
##rdi O
##nian O
males O
with O
hem B-Disease
##ato I-Disease
##logical I-Disease
ma I-Disease
##li I-Disease
##gna I-Disease
##ncies I-Disease
. O

the O
frequency O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
the O
patients O
was O
not O
different O
from O
the O
incidence O
in O
a O
group O
of O
16 O
, O
219 O
controls O
. O

the O
same O
conclusion O
resulted O
from O
the O
comparison O
of O
the O
frequency O
of O
expression O
of O
the O
g O
##d O
##b O
gene O
in O
23 O
he O
##tero O
##zy O
##go O
##us O
women O
having O
a O
c O
##lon O
##al O
hem B-Disease
##ato I-Disease
##log I-Disease
##ic I-Disease
disease I-Disease
and O
a O
control O
group O
of O
37 O
healthy O
he O
##tero O
##zy O
##got O
##es O
. O

therefore O
at O
present O
there O
is O
no O
evidence O
that O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
has O
a O
protective O
effect O
against O
development O
of O
hem B-Disease
##ato I-Disease
##log I-Disease
##ic I-Disease
neo I-Disease
##p I-Disease
##las I-Disease
##ms I-Disease
. O
. O

he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
, O
pig B-Disease
##mented I-Disease
o I-Disease
##cular I-Disease
fund I-Disease
##us I-Disease
lesions I-Disease
and O
jaw B-Disease
lesions I-Disease
in O
g B-Disease
##ard I-Disease
##ner I-Disease
syndrome I-Disease
. O

he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
is O
a O
rare O
neo B-Disease
##p I-Disease
##las I-Disease
##m I-Disease
of O
infants O
and O
children O
only O
recently O
documented O
in O
association O
with O
hereditary B-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
of I-Disease
the I-Disease
co I-Disease
##lon I-Disease
[ O
kings O
##ton O
et O
al O
. O
, O
1983 O
] O
. O

we O
report O
four O
children O
with O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
from O
four O
unrelated O
families O
with O
g B-Disease
##ard I-Disease
##ner I-Disease
syndrome I-Disease
( O
g B-Disease
##s I-Disease
) O
. O

one O
child O
, O
now O
19 O
years O
old O
, O
survived O
after O
a O
re O
##section O
of O
a O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
in O
infancy O
and O
recently O
was O
found O
to O
have O
g B-Disease
##s I-Disease
. O

he O
has O
an O
associated O
o B-Disease
##don I-Disease
##tom I-Disease
##a I-Disease
and O
pig B-Disease
##mented I-Disease
o I-Disease
##cular I-Disease
fund I-Disease
##us I-Disease
lesions I-Disease
, O
both O
of O
which O
have O
been O
shown O
to O
be O
clinical O
markers O
of O
g B-Disease
##s I-Disease
. O

many O
individuals O
in O
these O
four O
g B-Disease
##s I-Disease
families O
, O
both O
affected O
and O
at O
risk O
, O
have O
o B-Disease
##ste I-Disease
##oma I-Disease
##to I-Disease
##us I-Disease
jaw I-Disease
lesions I-Disease
and O
pig B-Disease
##mented I-Disease
o I-Disease
##cular I-Disease
fund I-Disease
##us I-Disease
lesions I-Disease
. O

a O
search O
for O
co B-Disease
##lon I-Disease
##ic I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
should O
be O
made O
in O
families O
of O
infants O
and O
children O
with O
he B-Disease
##pa I-Disease
##to I-Disease
##blast I-Disease
##oma I-Disease
. O

if O
the O
child O
survives O
, O
he O
or O
she O
should O
be O
monitored O
for O
the O
later O
appearance O
of O
co B-Disease
##lon I-Disease
##ic I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
. O

the O
finding O
of O
jaw B-Disease
lesions I-Disease
and O
/ O
or O
pig B-Disease
##mented I-Disease
o I-Disease
##cular I-Disease
fund I-Disease
##us I-Disease
lesions I-Disease
in O
relatives O
at O
risk O
are O
indication O
##s O
of O
the O
possible O
presence O
of O
the O
g B-Disease
##s I-Disease
gene O
. O

identification O
of O
an O
altered O
s O
##p O
##lice O
site O
in O
ash O
##ken O
##azi O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
. O

ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
genetic I-Disease
disorder I-Disease
resulting O
from O
mutation O
of O
the O
he O
##xa O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
l O
##ys O
##oso O
##mal O
enzyme O
, O
beta O
- O
n O
- O
ace O
##ty O
##l O
##he O
##x O
##osa O
##mini O
##das O
##e O
a O
( O
re O
##f O
. O
1 O
) O
. O

a O
relatively O
high O
frequency O
of O
carriers O
( O
1 O
/ O
27 O
) O
of O
a O
lethal O
, O
infant O
##ile O
form O
of O
the O
disease O
is O
found O
in O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
, O
but O
it O
is O
not O
yet O
evident O
whether O
this O
has O
resulted O
from O
a O
founder O
effect O
and O
random O
genetic O
drift O
or O
from O
a O
selective O
advantage O
of O
he O
##tero O
##zy O
##got O
##es O
. O

we O
have O
identified O
a O
single O
- O
base O
mutation O
in O
a O
clone O
##d O
fragment O
of O
the O
he O
##xa O
gene O
from O
an O
ash O
##ken O
##azi O
j O
##ew O
##ish O
patient O
. O

this O
change O
, O
the O
substitution O
of O
a O
c O
for O
g O
in O
the O
first O
n O
##uc O
##leo O
##tide O
of O
intro O
##n O
12 O
is O
expected O
to O
result O
in O
defect O
##ive O
s O
##p O
##licing O
of O
the O
messenger O
r O
##na O
. O

a O
test O
for O
the O
mutant O
all O
##ele O
based O
on O
am O
##p O
##lification O
of O
d O
##na O
by O
the O
polymer O
##ase O
chain O
re O
##ction O
and O
c O
##lea O
##vage O
of O
a O
d O
##de O
##i O
restriction O
site O
generated O
by O
the O
mutation O
revealed O
that O
this O
case O
and O
two O
other O
cases O
of O
the O
ash O
##ken O
##azi O
, O
infant O
##ile O
form O
of O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
are O
he O
##tero O
##zy O
##go O
##us O
for O
two O
different O
mutations O
. O

the O
occurrence O
of O
multiple O
mutant O
all O
##ele O
##s O
warrant O
##s O
further O
examination O
of O
the O
selective O
advantage O
hypothesis O
. O
. O

x B-Disease
- I-Disease
linked I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
m O
##us O
m O
##us O
##culus O
. O

a O
mouse O
with O
x B-Disease
- I-Disease
linked I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
has O
been O
recovered O
in O
offspring O
of O
1 O
- O
et O
##hyl O
- O
1 O
- O
ni O
##tro O
##so O
##ure O
##a O
- O
treated O
male O
mice O
. O

the O
activity O
alter O
##ation O
was O
detected O
in O
blood O
but O
can O
also O
be O
observed O
in O
other O
tissue O
extract O
##s O
. O

hem O
##iz O
##y O
##go O
##us O
, O
he O
##tero O
##zy O
##go O
##us O
, O
and O
ho O
##mo O
##zy O
##go O
##us O
mutant O
##s O
have O
, O
respectively O
, O
about O
15 O
, O
60 O
, O
and O
15 O
% O
g O
##6 O
##p O
##d O
remaining O
activity O
in O
the O
blood O
as O
compared O
to O
the O
wild O
type O
. O

er O
##yt O
##hr O
##oc O
##yte O
in O
##dices O
did O
not O
show O
differences O
between O
mutant O
##s O
and O
wild O
types O
. O

the O
mutation O
does O
not O
affect O
the O
electro O
##ph O
##ore O
##tic O
migration O
, O
the O
is O
##oe O
##lect O
##ric O
point O
, O
or O
the O
thermal O
stability O
. O

kinetic O
properties O
, O
such O
as O
the O
km O
for O
glucose O
- O
6 O
- O
phosphate O
or O
for O
na O
##d O
##p O
and O
the O
relative O
u O
##til O
##ization O
of O
substrate O
analogue O
##s O
, O
showed O
no O
differences O
between O
wild O
types O
and O
mutant O
##s O
with O
the O
exception O
of O
the O
relative O
u O
##til O
##ization O
of O
de O
##ami O
##no O
- O
na O
##d O
##p O
which O
was O
significantly O
lower O
in O
mutant O
##s O
. O

this O
is O
presently O
the O
only O
animal O
model O
for O
x B-Disease
- I-Disease
linked I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
humans O
. O
. O

diverse O
point O
mutations O
in O
the O
human O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
gene O
cause O
enzyme B-Disease
deficiency I-Disease
and O
mild O
or O
severe O
hem B-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
; I-Disease
e I-Disease
##c I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
a O
common O
genetic B-Disease
abnormal I-Disease
##ity I-Disease
affecting O
an O
estimated O
400 O
million O
people O
worldwide O
. O

clinical O
and O
bio O
##chemical O
analyses O
have O
identified O
many O
variants O
exhibiting O
a O
range O
of O
p O
##hen O
##otype O
##s O
, O
which O
have O
been O
well O
characterized O
from O
the O
hem O
##ato O
##logical O
point O
of O
view O
. O

however O
, O
until O
now O
, O
their O
precise O
molecular O
basis O
has O
remained O
unknown O
. O

we O
have O
clone O
##d O
and O
sequence O
##d O
seven O
mutant O
g O
##6 O
##p O
##d O
all O
##ele O
##s O
. O

in O
the O
non O
##de O
##ficient O
p O
##oly O
##morphic O
a O
##f O
##rica O
##n O
variant O
g O
##6 O
##p O
##d O
a O
we O
have O
found O
a O
single O
point O
mutation O
. O

the O
other O
six O
mutant O
##s O
investigated O
were O
all O
associated O
with O
enzyme B-Disease
deficiency I-Disease
. O

in O
one O
of O
the O
common O
##est O
, O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
, O
which O
is O
associated O
with O
f B-Disease
##avi I-Disease
##sm I-Disease
among O
other O
clinical O
manifest O
##ations O
, O
a O
single O
amino O
acid O
replacement O
was O
found O
( O
se O
##rine O
- O
- O
- O
- O
p O
##hen O
##yla O
##lani O
##ne O
) O
it O
must O
be O
responsible O
for O
the O
decreased O
stability O
and O
the O
reduced O
cat O
##alytic O
efficiency O
of O
this O
enzyme O
. O

single O
point O
mutations O
were O
also O
found O
in O
g O
##6 O
##p O
##d O
meta O
##pont O
##o O
( O
southern O
it O
##aly O
) O
and O
in O
g O
##6 O
##p O
##d O
il O
##esh O
##a O
( O
ni O
##ger O
##ia O
) O
, O
which O
are O
as O
##ym O
##pt O
##oma O
##tic O
, O
and O
in O
g O
##6 O
##p O
##d O
chat O
##ham O
, O
which O
was O
observed O
in O
an O
in O
##dian O
boy O
with O
neon B-Disease
##ata I-Disease
##l I-Disease
j I-Disease
##au I-Disease
##ndi I-Disease
##ce I-Disease
. O

in O
g O
##6 O
##p O
##d O
" O
mater O
##a O
, O
" O
which O
is O
now O
known O
to O
be O
the O
same O
as O
g O
##6 O
##p O
##d O
a O
- O
, O
two O
separate O
point O
mutations O
were O
found O
, O
one O
of O
which O
is O
the O
same O
as O
in O
g O
##6 O
##p O
##d O
a O
. O

in O
g O
##6 O
##p O
##d O
sa O
##nti O
##ago O
, O
a O
de O
no O
##vo O
mutation O
( O
g O
##ly O
##cine O
- O
- O
- O
- O
a O
##rg O
##ini O
##ne O
) O
is O
associated O
with O
severe O
chronic O
hem B-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
. O

the O
mutations O
observed O
show O
a O
striking O
pre O
##dom O
##ina O
##nce O
of O
c O
- O
- O
- O
- O
t O
transitions O
, O
with O
c O
##g O
double O
##ts O
involved O
in O
four O
of O
seven O
cases O
. O

thus O
, O
diverse O
point O
mutations O
may O
account O
largely O
for O
the O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

tight O
link O
##age O
between O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
a O
##poli O
##pop O
##rote O
##in O
e O
genes O
revealed O
with O
all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
. O

in O
16 O
families O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
a O
novel O
approach O
based O
on O
use O
of O
all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
has O
been O
employed O
to O
study O
the O
link O
##age O
relationship O
between O
the O
a O
##poli O
##pop O
##rote O
##in O
e O
( O
a O
##po O
##e O
) O
gene O
and O
d B-Disease
##m I-Disease
. O

synthetic O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
, O
designed O
to O
disc O
##rim O
##inate O
between O
a O
##po O
##e O
all O
##ele O
##s O
e O
##ps O
##ilon O
3 O
and O
e O
##ps O
##ilon O
4 O
, O
enabled O
us O
to O
distinguish O
he O
##tero O
##zy O
##go O
##us O
carriers O
in O
a O
hybrid O
##ization O
ass O
##ay O
. O

in O
a O
subset O
of O
families O
, O
the O
relevant O
segment O
of O
the O
a O
##po O
##e O
gene O
was O
en O
##zy O
##matical O
##ly O
am O
##plified O
to O
increase O
the O
sensitivity O
of O
the O
method O
. O

for O
d O
##m O
and O
a O
##po O
##e O
, O
a O
maximum O
lo O
##d O
score O
( O
z O
##max O
of O
7 O
. O

47 O
was O
obtained O
at O
a O
re O
##comb O
##ination O
frequency O
( O
the O
##ta O
) O
of O
0 O
. O

04 O
##7 O
( O
male O
the O
##ta O
= O
female O
the O
##ta O
) O
. O

no O
re O
##comb O
##ination O
( O
maximum O
lo O
##d O
score O
of O
5 O
. O
61 O
at O
the O
##ta O
= O
0 O
. O
0 O
) O
was O
found O
between O
a O
##po O
##e O
and O
the O
a O
##poli O
##pop O
##rote O
##in O
c O
##ii O
( O
a O
##po O
##c O
##2 O
) O
gene O
. O

these O
results O
suggest O
that O
, O
in O
addition O
to O
a O
##po O
##c O
##2 O
, O
a O
##po O
##e O
is O
a O
useful O
marker O
for O
pre O
##sy O
##mpt O
##oma O
##tic O
d B-Disease
##m I-Disease
diagnosis O
. O

regional O
local O
##ization O
of O
p O
##oly O
##morphic O
d O
##na O
lo O
##ci O
on O
the O
pro O
##ximal O
long O
arm O
of O
the O
x O
chromosome O
using O
del O
##eti O
##ons O
associated O
with O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
. O

in O
two O
unrelated O
families O
, O
males O
have O
been O
identified O
who O
suffer O
from O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
and O
at O
the O
same O
time O
have O
an O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
on O
the O
pro O
##ximal O
long O
arm O
of O
the O
x O
chromosome O
. O

by O
high O
- O
resolution O
band O
##ing O
we O
have O
characterized O
the O
del O
##eti O
##on O
chromosome O
##s O
as O
del O
( O
x O
) O
( O
q O
##21 O
. O
1 O
- O
q O
##21 O
1 O
- O
q O
##21 O
. O
33 O
) O
and O
del O
( O
x O
) O
( O
q O
##21 O
. O
2 O
- O
q O
##21 O
2 O
- O
q O
##21 O
. O
31 O
) O
respectively O
. O

by O
southern O
b O
##lot O
analysis O
we O
have O
mapped O
ten O
different O
p O
##oly O
##morphic O
d O
##na O
lo O
##ci O
relative O
to O
the O
position O
of O
the O
del O
##eti O
##on O
and O
the O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
lo O
##cus O
t O
##c O
##d O
. O

one O
probe O
, O
p O
##31 O
, O
was O
shown O
to O
cover O
one O
of O
the O
break O
##points O
of O
the O
smallest O
del O
##eti O
##on O
. O

the O
following O
order O
of O
the O
lo O
##ci O
was O
suggested O
by O
del O
##eti O
##on O
mapping O
c O
##en O
- O
d O
##x O
##s O
##10 O
##6 O
- O
d O
##x O
##s O
##7 O
##2 O
- O
t O
##c O
##d O
- O
( O
d O
##xy O
##s O
##1 O
/ O
d O
##xy O
##s O
##23 O
/ O
d O
##xy O
##s O
##5 O
) O
- O
d O
##xy O
##s O
##2 O
- O
( O
d O
##xy O
##s O
##12 O
/ O
d O
##x O
##s O
##3 O
) O
- O
( O
d O
##x O
##s O
##17 O
/ O
d O
##x O
##s O
##10 O
##1 O
) O
- O
x O
##q O
##ter O
. O

re O
##tro O
##vir O
##al O
- O
mediated O
gene O
transfer O
of O
human O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
into O
ni O
##h O
3 O
##t O
##3 O
and O
he B-Disease
##pa I-Disease
##tom I-Disease
##a I-Disease
cells O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
caused O
by O
deficiency B-Disease
of I-Disease
the I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
enzyme I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

a O
full O
- O
length O
human O
p O
##ah O
c O
##dn O
##a O
sequence O
has O
been O
inserted O
into O
p O
##zi O
##p O
- O
neo O
##s O
##v O
( O
x O
) O
, O
which O
is O
a O
re O
##tro O
##vir O
##al O
vector O
containing O
the O
bacterial O
neo O
gene O
. O

the O
re O
##comb O
##ina O
##nt O
has O
been O
trans O
##fected O
into O
ps O
##i O
2 O
cells O
, O
which O
provide O
synthesis O
of O
the O
re O
##tro O
##vir O
##al O
caps O
##id O
. O

re O
##comb O
##ina O
##nt O
virus O
was O
detected O
in O
the O
culture O
medium O
of O
the O
trans O
##fected O
ps O
##i O
2 O
cells O
, O
which O
is O
capable O
of O
transmitting O
the O
human O
p O
##ah O
gene O
into O
mouse O
ni O
##h O
3 O
##t O
##3 O
cells O
by O
infection O
leading O
to O
stable O
incorporation O
of O
the O
re O
##comb O
##ina O
##nt O
pro O
##virus O
. O

infected O
cells O
express O
p O
##ah O
m O
##rna O
, O
im O
##mu O
##nor O
##ea O
##ctive O
p O
##ah O
protein O
, O
and O
exhibit O
p O
##ter O
##in O
- O
dependent O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
activity O
. O

the O
re O
##comb O
##ina O
##nt O
virus O
is O
also O
capable O
of O
in O
##fect O
##ing O
a O
mouse O
he B-Disease
##pa I-Disease
##tom I-Disease
##a I-Disease
cell O
line O
that O
does O
not O
normally O
s O
##ynth O
##esi O
##ze O
p O
##ah O
. O

p O
##ah O
activity O
is O
present O
in O
the O
cellular O
extract O
##s O
and O
the O
entire O
h O
##ydro O
##xy O
##lation O
system O
is O
re O
##con O
##stituted O
in O
the O
he B-Disease
##pa I-Disease
##tom I-Disease
##a I-Disease
cells O
infected O
with O
the O
re O
##comb O
##ina O
##nt O
viruses O
. O

thus O
, O
re O
##comb O
##ina O
##nt O
viruses O
containing O
human O
p O
##ah O
c O
##dn O
##a O
provide O
a O
means O
for O
introducing O
functional O
p O
##ah O
into O
ma O
##mmal O
##ian O
cells O
of O
he O
##pa O
##tic O
origin O
and O
can O
potentially O
be O
introduced O
into O
whole O
animals O
as O
a O
model O
for O
so O
##matic O
gene O
therapy O
for O
p B-Disease
##ku I-Disease
. O
. O

est O
##imation O
of O
the O
male O
to O
female O
ratio O
of O
mutation O
rates O
from O
the O
segregation O
of O
x O
- O
ch O
##rom O
##oso O
##mal O
d O
##na O
ha O
##p O
##lot O
##ype O
##s O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
families O
. O

a O
novel O
procedure O
is O
presented O
to O
estimate O
the O
ratio O
of O
male O
to O
female O
mutation O
rates O
for O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

x O
- O
specific O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
are O
used O
to O
establish O
d O
##na O
ha O
##p O
##lot O
##ype O
##s O
in O
three O
- O
generation O
d B-Disease
##m I-Disease
##d I-Disease
families O
. O

from O
the O
proportion O
of O
d B-Disease
##m I-Disease
##d I-Disease
patients O
who O
have O
inherited O
their O
maternal O
grandfather O
##s O
x O
chromosome O
, O
the O
ratio O
of O
mutation O
rates O
can O
be O
calculated O
. O

in O
contrast O
to O
classical O
methods O
, O
the O
proposed O
procedure O
is O
not O
restricted O
to O
s O
##poradic O
or O
familiar O
cases O
nor O
is O
any O
information O
on O
the O
carrier O
status O
of O
female O
relatives O
required O
. O
. O

del O
##eti O
##ons O
of O
a O
d O
##na O
sequence O
in O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
and O
me B-Disease
##sen I-Disease
##chy I-Disease
##mal I-Disease
tumors I-Disease
: O
organization O
of O
the O
sequence O
and O
its O
encoded O
protein O
. O

re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
is O
a O
childhood B-Disease
tumor I-Disease
that O
can O
arise O
because O
of O
mutant O
all O
##ele O
##s O
acquired O
as O
so O
##matic O
or O
g O
##er O
##mina O
##l O
mutations O
. O

the O
mutant O
all O
##ele O
can O
be O
carried O
in O
the O
g O
##er O
##m O
line O
. O

the O
mutations O
creating O
these O
all O
##ele O
##s O
act O
by O
in O
##act O
##ivating O
copies O
of O
a O
re O
##cess O
##ive O
on O
##co O
##gene O
located O
within O
band O
q O
##14 O
of O
chromosome O
13 O
and O
termed O
the O
r O
##b O
##1 O
lo O
##cus O
. O

we O
have O
reported O
isolation O
of O
a O
c O
##dn O
##a O
fragment O
that O
recognizes O
ch O
##rom O
##oso O
##mal O
sequences O
possessing O
many O
of O
the O
attributes O
of O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
gene O
associated O
with O
the O
r O
##b O
##1 O
lo O
##cus O
. O

we O
now O
report O
that O
this O
segment O
is O
additionally O
the O
target O
of O
so O
##matic O
mutations O
in O
me B-Disease
##sen I-Disease
##chy I-Disease
##mal I-Disease
tumors I-Disease
among O
patients O
having O
no O
apparent O
pre O
##dis O
##position O
to O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
and O
no O
previous O
evidence O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

these O
tumors B-Disease
provide O
additional O
evidence O
that O
the O
clone O
##d O
sequences O
are O
representative O
of O
a O
gene O
that O
is O
a O
frequent O
target O
of O
in O
##act O
##ivation O
during O
tumor O
##ige O
##nes O
##is O
. O

sequence O
analysis O
of O
this O
c O
##dn O
##a O
provides O
little O
insight O
into O
its O
normal O
functional O
role O
. O
. O

treatment O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
with O
growth O
hormone O
inhibitor O
##s O
. O

a O
controlled O
, O
double O
- O
blind O
therapeutic O
trial O
with O
the O
drug O
ma O
##zin O
##do O
##l O
, O
a O
growth O
hormone O
inhibitor O
, O
was O
performed O
in O
a O
pair O
of O
7 O
1 O
/ O
2 O
year O
- O
old O
mon O
##oz O
##y O
##got O
##ic O
twins O
, O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

the O
rational O
##e O
for O
this O
trial O
was O
based O
on O
a O
patient O
( O
reported O
previously O
) O
affected O
simultaneously O
with O
d B-Disease
##m I-Disease
##d I-Disease
and O
growth B-Disease
hormone I-Disease
( I-Disease
g I-Disease
##h I-Disease
) I-Disease
deficiency I-Disease
, O
who O
is O
showing O
a O
ben O
##ign O
course O
of O
the O
d B-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
process I-Disease
and O
is O
still O
walking O
at O
18 O
years O
. O

one O
of O
the O
twins O
received O
2 O
mg O
of O
ma O
##zin O
##do O
##l O
daily O
, O
while O
the O
other O
received O
a O
place O
##bo O
. O

the O
assessment O
, O
repeated O
every O
2 O
months O
, O
included O
weight O
and O
height O
measurements O
, O
functional O
and O
motor O
ability O
tests O
, O
er O
##go O
##metry O
and O
determination O
##s O
of O
serum O
enzymes O
and O
g O
##h O
levels O
. O

after O
one O
year O
of O
trial O
the O
code O
was O
broken O
and O
it O
was O
seen O
that O
the O
twin O
under O
place O
##bo O
treatment O
was O
striking O
##ly O
worse O
than O
his O
brother O
, O
the O
progression O
of O
whose O
condition O
was O
practically O
arrested O
. O

these O
results O
strongly O
suggest O
that O
treatment O
with O
a O
g O
##h O
inhibitor O
is O
beneficial O
for O
d B-Disease
##m I-Disease
##d I-Disease
patients O
. O
. O

identification O
and O
local O
##ization O
of O
mutations O
at O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
lo O
##cus O
by O
rib O
##on O
##uc O
##lea O
##se O
a O
c O
##lea O
##vage O
. O

many O
mutations O
leading O
to O
human O
disease O
are O
the O
result O
of O
single O
d O
##na O
base O
pair O
changes O
that O
cannot O
be O
identified O
by O
southern O
analysis O
. O

this O
has O
prompted O
the O
development O
of O
alternative O
ass O
##ays O
for O
point O
mutation O
detection O
. O

the O
recently O
described O
rib O
##on O
##uc O
##lea O
##se O
a O
c O
##lea O
##vage O
procedure O
, O
with O
a O
p O
##oly O
##uri O
##dy O
##lic O
acid O
- O
paper O
affinity O
ch O
##roma O
##tography O
step O
, O
has O
been O
used O
to O
identify O
the O
mutation O
##al O
lesions O
in O
the O
h O
##y O
##pox O
##ant O
##hine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
hp O
##rt O
) O
messenger O
r O
##nas O
of O
patients O
with O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

distinctive O
rib O
##on O
##uc O
##lea O
##se O
a O
c O
##lea O
##vage O
patterns O
were O
identified O
in O
messenger O
r O
##na O
from O
5 O
of O
14 O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patients O
who O
were O
chosen O
because O
no O
hp O
##rt O
southern O
or O
northern O
b O
##lot O
##ting O
pattern O
changes O
had O
been O
found O
. O

this O
approach O
now O
allows O
hp O
##rt O
mutation O
detection O
in O
50 O
percent O
of O
the O
cases O
of O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

the O
p O
##oly O
##uri O
##dy O
##lic O
acid O
- O
paper O
affinity O
procedure O
provides O
a O
general O
method O
for O
analysis O
of O
low O
abundance O
messenger O
r O
##nas O
. O
. O

two O
new O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
associated O
with O
hereditary B-Disease
non I-Disease
- I-Disease
s I-Disease
##pher I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
: O
g O
##6 O
##p O
##d O
way O
##ne O
and O
g O
##6 O
##p O
##d O
h O
##uron O
. O

two O
new O
def O
##icient O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
causing O
hereditary B-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
( O
h B-Disease
##ns I-Disease
##ha I-Disease
) O
are O
described O
. O

both O
of O
these O
are O
unique O
and O
they O
have O
been O
named O
g O
##6 O
##p O
##d O
way O
##ne O
and O
g O
##6 O
##p O
##d O
h O
##uron O
. O

patients O
with O
g O
##6 O
##p O
##d O
way O
##ne O
underwent O
s O
##ple O
##nect O
##omy O
and O
no O
objective O
improvement O
was O
noted O
. O

the O
patients O
with O
g O
##6 O
##p O
##d O
h O
##uron O
were O
under O
medical O
observation O
for O
a O
considerable O
period O
of O
time O
without O
the O
diagnosis O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
being O
entertained O
because O
the O
family O
was O
of O
northern O
euro O
##pe O
##an O
origin O
. O

since O
s O
##poradic O
variants O
of O
g O
##6 O
##p O
##d O
causing O
h B-Disease
##ns I-Disease
##ha I-Disease
show O
no O
special O
racial O
pre O
##di O
##lect O
##ion O
, O
the O
diagnosis O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
should O
always O
be O
considered O
in O
patients O
with O
this O
syndrome O
. O
. O

si O
##alo O
##ph O
##ori O
##n O
, O
a O
surface O
si O
##alog O
##ly O
##co O
##p O
##rote O
##in O
defect O
##ive O
in O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
, O
is O
involved O
in O
human O
t O
l O
##ymph O
##oc O
##yte O
proliferation O
. O

the O
ma O
##b O
l O
##10 O
was O
used O
to O
determine O
the O
distribution O
and O
the O
function O
of O
si O
##alo O
##ph O
##ori O
##n O
, O
the O
heavily O
g O
##ly O
##cos O
##yla O
##ted O
surface O
molecule O
that O
is O
def O
##icient O
/ O
defect O
##ive O
in O
l O
##ymph O
##ocytes O
of O
patients O
with O
the O
x B-Disease
- I-Disease
linked I-Disease
im I-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
w I-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O

dual O
- O
parameter O
f O
##ac O
##s O
analysis O
indicated O
that O
si O
##alo O
##ph O
##ori O
##n O
is O
expressed O
on O
c O
##d O
##4 O
+ O
and O
c O
##d O
##8 O
+ O
l O
##ymph O
##ocytes O
, O
on O
a O
sub O
##pop O
##ulation O
of O
peripheral O
blood O
b O
l O
##ymph O
##ocytes O
, O
on O
all O
thy O
##mo O
##cy O
##tes O
, O
and O
on O
a O
sub O
##pop O
##ulation O
of O
bone O
ma O
##rrow O
cells O
. O

functional O
studies O
demonstrated O
that O
l O
##10 O
ma O
##b O
stimulate O
##s O
the O
proliferation O
of O
peripheral O
blood O
t O
l O
##ymph O
##ocytes O
as O
measured O
by O
stimulation O
of O
[ O
3 O
##h O
] O
thy O
##mi O
##dine O
incorporation O
. O

the O
time O
course O
and O
magnitude O
of O
increased O
[ O
3 O
##h O
] O
thy O
##mi O
##dine O
incorporation O
by O
t O
l O
##ymph O
##ocytes O
in O
response O
to O
l O
##10 O
ma O
##b O
parallel O
##ed O
that O
induced O
by O
anti O
- O
c O
##d O
##3 O
ma O
##b O
. O

effective O
stimulation O
was O
dependent O
on O
the O
presence O
of O
mon O
##ocytes O
and O
the O
f O
##c O
portion O
of O
l O
##10 O
ma O
##b O
. O

stimulation O
of O
l O
##ymph O
##ocytes O
by O
l O
##10 O
, O
like O
stimulation O
by O
anti O
- O
c O
##d O
##3 O
ma O
##b O
, O
involves O
increased O
expression O
of O
4 O
##f O
##2 O
, O
h O
##la O
- O
d O
##r O
, O
and O
il O
- O
2 O
- O
r O
. O

these O
observations O
suggest O
that O
si O
##alo O
##ph O
##ori O
##n O
functions O
in O
t O
cell O
activation O
. O
. O

h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
in O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

cut B-Disease
##aneous I-Disease
and I-Disease
o I-Disease
##cular I-Disease
pig I-Disease
##mentation I-Disease
were O
evaluated O
in O
29 O
individuals O
with O
the O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

criteria O
for O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
included O
the O
presence O
of O
type O
i O
or O
ii O
skin O
, O
the O
light O
##est O
skin O
type O
in O
the O
family O
by O
history O
, O
and O
i O
##ris O
trans O
##lu O
##ce O
##ncy O
on O
globe O
trans O
##ill O
##umi O
##nation O
. O

on O
the O
basis O
of O
these O
criteria O
, O
48 O
% O
of O
the O
p B-Disease
##ws I-Disease
individuals O
were O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mented I-Disease
. O

the O
presence O
of O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
correlated O
with O
a O
small O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
on O
the O
pro O
##ximal O
long O
arm O
of O
chromosome O
15 O
; O
however O
, O
this O
del O
##eti O
##on O
was O
also O
found O
in O
individuals O
who O
did O
not O
meet O
the O
full O
criteria O
for O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
. O

hair O
##bul O
##b O
t O
##yr O
##os O
##inas O
##e O
activity O
and O
g O
##lut O
##ath O
##ione O
content O
, O
as O
well O
as O
urine O
c O
##ys O
##tein O
##yl O
##do O
##pa O
ex O
##cre O
##tion O
, O
were O
low O
in O
p B-Disease
##ws I-Disease
individuals O
with O
and O
without O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
and O
did O
not O
separate O
these O
two O
groups O
. O

we O
conclude O
that O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
is O
found O
in O
a O
significant O
proportion O
of O
individuals O
with O
p B-Disease
##ws I-Disease
and O
that O
the O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
may O
be O
associated O
with O
a O
del O
##eti O
##on O
of O
the O
long O
arm O
of O
chromosome O
15 O
. O

the O
mechanism O
for O
the O
h B-Disease
##y I-Disease
##pop I-Disease
##ig I-Disease
##mentation I-Disease
is O
unknown O
. O
. O

p O
##hen O
##otype O
he O
##tero O
##gene O
##ity O
among O
hem O
##iz O
##y O
##got O
##es O
in O
a O
family O
bio O
##chemical O
##ly O
screened O
for O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

we O
report O
on O
two O
clinical O
##ly O
, O
ne O
##uro O
##logical O
##ly O
normal O
relatives O
of O
a O
boy O
affected O
by O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
; O
they O
were O
found O
repeatedly O
to O
have O
the O
bio O
##chemical O
defect O
of O
an O
al B-Disease
##d I-Disease
hem O
##iz O
##y O
##got O
##e O
. O

the O
ass O
##ay O
consisted O
in O
the O
determination O
of O
very O
- O
long O
- O
chain O
fatty O
acids O
in O
l O
##yo O
##phi O
##li O
##zed O
and O
re O
##con O
##stituted O
plasma O
. O

while O
no O
evidence O
of O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
disease I-Disease
( O
le B-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
or O
my B-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
) O
was O
present O
in O
these O
hem O
##iz O
##y O
##got O
##es O
, O
ad B-Disease
##ren I-Disease
##oc I-Disease
##ort I-Disease
##ical I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
pro O
##voking O
com O
##pen O
##sat O
##ory O
high O
act O
##h O
release O
was O
found O
in O
both O
. O

these O
findings O
should O
be O
taken O
into O
consideration O
when O
counseling O
families O
in O
which O
cases O
with O
clinical O
##ly O
expressed O
al B-Disease
##d I-Disease
are O
represented O
in O
several O
generations O
. O
. O

the O
mapping O
of O
a O
c O
##dn O
##a O
from O
the O
human O
x B-Disease
- I-Disease
linked I-Disease
du I-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
to O
the O
mouse O
x O
chromosome O
. O

the O
recent O
discovery O
of O
sequences O
at O
the O
site O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
in O
humans O
has O
opened O
up O
the O
possibility O
of O
a O
detailed O
molecular O
analysis O
of O
the O
genes O
in O
humans O
and O
in O
related O
ma O
##mmal O
##ian O
species O
. O

until O
relatively O
recently O
, O
there O
was O
no O
obvious O
mouse O
model O
of O
this O
genetic B-Disease
disease I-Disease
for O
the O
development O
of O
therapeutic O
strategies O
. O

the O
identification O
of O
a O
mouse O
x O
- O
linked O
mutant O
showing O
muscular B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
m O
##d O
##x O
, O
has O
provided O
a O
candidate O
mouse O
genetic O
ho O
##mo O
##logue O
to O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
; O
the O
relatively O
mild O
path O
##ological O
features O
of O
m O
##d O
##x O
suggest O
it O
may O
have O
more O
in O
common O
with O
mutations O
of O
the O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
type O
at O
the O
same O
human O
lo O
##cus O
, O
however O
. O

but O
the O
close O
genetic O
link O
##age O
of O
m O
##d O
##x O
to O
g O
##6 O
##p O
##d O
and O
hp O
##rt O
on O
the O
mouse O
x O
chromosome O
, O
coupled O
with O
its O
comparatively O
mild O
path O
##ology O
, O
have O
suggested O
that O
the O
m O
##d O
##x O
mutation O
may O
instead O
correspond O
to O
em B-Disease
##ery I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
which O
itself O
is O
closely O
linked O
to O
d O
##na O
markers O
at O
x O
##q O
##28 O
- O
q O
##ter O
in O
the O
region O
of O
g O
##6 O
##p O
##d O
on O
the O
human O
x O
chromosome O
. O

using O
an O
inter O
##sp O
##ec O
##ific O
mouse O
domestic O
##us O
/ O
s O
##p O
##ret O
##us O
cross O
, O
se O
##g O
##re O
##gating O
for O
a O
variety O
of O
markers O
on O
the O
mouse O
x O
chromosome O
, O
we O
have O
positioned O
on O
the O
mouse O
x O
chromosome O
sequences O
ho O
##mo O
##log O
##ous O
to O
a O
d B-Disease
##m I-Disease
##d I-Disease
c O
##dn O
##a O
clone O
. O

these O
sequences O
map O
pro O
##vocative O
##ly O
close O
to O
the O
m O
##d O
##x O
mutation O
and O
unexpectedly O
distant O
from O
sparse O
fur O
, O
s O
##pf O
, O
the O
mouse O
ho O
##mo O
##logue O
of O
o O
##t O
##c O
( O
or O
##ni O
##thin O
##e O
trans O
##car O
##ba O
##my O
##lase O
) O
which O
is O
closely O
linked O
to O
d B-Disease
##m I-Disease
##d I-Disease
on O
the O
human O
x O
chromosome O
. O
. O

local O
##ization O
of O
the O
region O
ho O
##mo O
##log O
##ous O
to O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
on O
the O
mouse O
x O
chromosome O
. O

recent O
progress O
has O
resulted O
in O
part O
of O
the O
gene O
m O
##uta O
##ted O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
and I-Disease
the I-Disease
mild I-Disease
##er I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##es I-Disease
being O
clone O
##d O
and O
has O
suggested O
that O
the O
gene O
itself O
extends O
over O
1 O
, O
000 O
to O
2 O
, O
000 O
k O
##ilo O
##base O
##s O
( O
k O
##b O
) O
. O

to O
study O
how O
mutations O
in O
this O
gene O
affect O
muscle O
development O
and O
integrity O
, O
it O
would O
be O
of O
interest O
to O
have O
available O
a O
mouse O
model O
of O
the O
human O
disease O
. O

the O
mouse O
m O
##d O
##x O
mutation O
affects O
muscle O
and O
con O
##fers O
a O
mild O
d B-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
syndrome I-Disease
, O
but O
it O
is O
not O
clear O
whether O
this O
mutation O
is O
equivalent O
to O
du B-Disease
##chen I-Disease
##ne I-Disease
/ I-Disease
be I-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
in O
man O
. O

here O
we O
describe O
the O
use O
of O
two O
sequences O
from O
the O
human O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
that O
cross O
- O
hybrid O
##ize O
to O
mouse O
x O
- O
linked O
sequences O
to O
local O
##ize O
the O
gene O
ho O
##mo O
##log O
##ous O
to O
d B-Disease
##m I-Disease
##d I-Disease
in O
the O
mouse O
. O

both O
sequences O
map O
to O
the O
region O
of O
10 O
cent O
##imo O
##rgan O
lying O
between O
the O
ta O
##bby O
( O
ta O
) O
and O
s O
##t O
##14 O
- O
1 O
( O
d O
##x O
##pas O
##8 O
) O
lo O
##ci O
, O
close O
to O
the O
p O
##hos O
##ph O
##ory O
##lase O
b O
kinase O
lo O
##cus O
( O
p O
##h O
##k O
) O
. O

by O
analogy O
with O
the O
human O
x O
- O
chromosome O
, O
we O
conclude O
that O
the O
region O
in O
the O
mouse O
around O
the O
g O
##6 O
##p O
##d O
and O
s O
##t O
##14 O
- O
1 O
lo O
##ci O
may O
contain O
two O
genes O
corresponding O
to O
distinct O
human O
my B-Disease
##op I-Disease
##ath I-Disease
##ies I-Disease
em B-Disease
##ery I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
which O
is O
known O
to O
be O
closely O
linked O
to O
s O
##t O
##14 O
- O
1 O
in O
man O
and O
the O
d B-Disease
##m I-Disease
##d I-Disease
ho O
##mo O
##logue O
described O
here O
. O
. O

g O
##t O
to O
at O
transition O
at O
a O
s O
##p O
##lice O
donor O
site O
causes O
skip O
##ping O
of O
the O
preceding O
ex O
##on O
in O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

classical B-Disease
p I-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
human I-Disease
genetic I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

we O
isolated O
several O
mutant O
p O
##ah O
c O
##dn O
##a O
clone O
##s O
from O
a O
p B-Disease
##ku I-Disease
carrier O
individual O
and O
showed O
that O
they O
contained O
an O
internal O
116 O
base O
pair O
del O
##eti O
##on O
, O
corresponding O
precisely O
to O
ex O
##on O
12 O
of O
the O
human O
ch O
##rom O
##oso O
##mal O
p O
##ah O
gene O
. O

the O
del O
##eti O
##on O
causes O
the O
synthesis O
of O
a O
t O
##runcated O
protein O
lacking O
the O
c O
- O
terminal O
52 O
amino O
acids O
. O

gene O
transfer O
and O
expression O
studies O
using O
the O
mutant O
p O
##ah O
c O
##dn O
##a O
indicated O
that O
the O
del O
##eti O
##on O
a O
##bol O
##ishes O
p O
##ah O
activity O
in O
the O
cell O
as O
a O
result O
of O
protein O
instability O
. O

to O
determine O
the O
molecular O
basis O
of O
the O
del O
##eti O
##on O
, O
the O
mutant O
ch O
##rom O
##oso O
##mal O
p O
##ah O
gene O
was O
isolated O
from O
this O
individual O
and O
shown O
to O
contain O
a O
g O
##t O
- O
- O
greater O
than O
at O
substitution O
at O
the O
5 O
s O
##p O
##lice O
donor O
site O
of O
intro O
##n O
12 O
. O

thus O
, O
the O
consequence O
of O
the O
s O
##p O
##lice O
donor O
site O
mutation O
in O
the O
human O
liver O
is O
the O
skip O
##ping O
of O
the O
preceding O
ex O
##on O
during O
r O
##na O
s O
##p O
##licing O
. O
. O

conservation O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
in O
mice O
and O
humans O
. O

a O
portion O
of O
the O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
gene O
trans O
##cript O
from O
human O
f O
##etal O
skeletal O
muscle O
and O
mouse O
adult O
heart O
was O
sequence O
##d O
, O
representing O
approximately O
25 O
percent O
of O
the O
total O
, O
14 O
- O
k O
##b O
d B-Disease
##m I-Disease
##d I-Disease
trans O
##cript O
. O

the O
nuclei O
##c O
acid O
and O
predicted O
amino O
acid O
sequences O
from O
the O
two O
species O
are O
nearly O
90 O
percent O
ho O
##mo O
##log O
##ous O
. O

the O
amino O
acid O
sequence O
that O
is O
predicted O
from O
this O
portion O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
indicates O
that O
the O
protein O
product O
might O
serve O
a O
structural O
role O
in O
muscle O
, O
but O
the O
abundance O
and O
tissue O
distribution O
of O
the O
messenger O
r O
##na O
suggests O
that O
the O
d B-Disease
##m I-Disease
##d I-Disease
protein O
is O
not O
ne O
##bul O
##in O
. O
. O

f O
##ami O
##lial O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
with O
apparently O
normal O
chromosome O
##s O
. O

we O
report O
on O
4 O
si O
##bs O
( O
2 O
##f O
, O
2 O
##m O
) O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

diagnosis O
was O
made O
clinical O
##ly O
on O
the O
basis O
of O
history O
, O
behavior O
, O
and O
physical O
findings O
in O
3 O
of O
the O
si O
##bs O
. O

the O
other O
child O
had O
died O
at O
age O
10 O
months O
with O
a O
history O
and O
clinical O
findings O
typical O
of O
first O
phase O
of O
p B-Disease
##ws I-Disease
. O

results O
of O
chromosome O
studies O
on O
the O
parents O
and O
surviving O
si O
##bs O
were O
normal O
. O

the O
implications O
of O
this O
unusual O
f O
##ami O
##lial O
occurrence O
for O
our O
understanding O
of O
p B-Disease
##ws I-Disease
are O
discussed O
. O
. O

ne O
##bul O
##in O
and O
t O
##iti O
##n O
expression O
in O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
appears O
normal O
. O

mon O
##oc O
##lon O
##al O
antibodies O
which O
recognize O
different O
e O
##pit O
##ope O
##s O
on O
either O
t O
##iti O
##n O
or O
ne O
##bul O
##in O
show O
normal O
stain O
##ing O
patterns O
on O
frozen O
sections O
of O
three O
muscle O
bio O
##ps O
##ies O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

gel O
electro O
##ph O
##ores O
##is O
and O
im O
##mu O
##nob O
##lot O
##ting O
performed O
on O
two O
of O
these O
muscle O
bio O
##ps O
##ies O
show O
the O
normal O
pattern O
of O
t O
##iti O
##n O
and O
ne O
##bul O
##in O
p O
##oly O
##pe O
##pt O
##ides O
. O

since O
the O
donor O
of O
one O
of O
these O
bio O
##ps O
##ies O
has O
a O
large O
del O
##eti O
##on O
of O
the O
5 O
- O
region O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
, O
our O
results O
argue O
against O
the O
recent O
proposal O
that O
ne O
##bul O
##in O
is O
the O
gene O
m O
##uta O
##ted O
in O
d B-Disease
##m I-Disease
##d I-Disease
. O
. O

he B-Disease
##tero I-Disease
##zy I-Disease
##go I-Disease
##us I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
associated O
with O
an B-Disease
##gio I-Disease
##ede I-Disease
##ma I-Disease
, O
my B-Disease
##ast I-Disease
##hen I-Disease
##ia I-Disease
g I-Disease
##ra I-Disease
##vis I-Disease
, O
and O
systemic B-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
. O

we O
describe O
a O
patient O
with O
my B-Disease
##ast I-Disease
##hen I-Disease
##ia I-Disease
g I-Disease
##ra I-Disease
##vis I-Disease
, O
systemic B-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
, O
and O
an B-Disease
##gio I-Disease
##ede I-Disease
##ma I-Disease
associated O
with O
he O
##tero O
##zy O
##go O
##us O
complement B-Disease
factor I-Disease
2 I-Disease
( I-Disease
c I-Disease
##2 I-Disease
) I-Disease
deficiency I-Disease
. O

the O
significance O
of O
this O
association O
is O
controversial O
, O
though O
the O
association O
of O
c B-Disease
##2 I-Disease
deficiency I-Disease
with O
certain O
his O
##to O
##com O
##pa O
##ti O
##bility O
anti O
##gens O
suggests O
possible O
link O
##age O
to O
immune O
response O
genes O
. O

to O
our O
knowledge O
this O
is O
the O
first O
report O
of O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
in O
association O
with O
this O
combination O
of O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
disorders I-Disease
, O
and O
we O
discuss O
the O
a O
##eti O
##ological O
implications O
. O
. O

genetic O
analysis O
of O
an O
inherited O
deficiency B-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
br O
##itt O
##any O
span O
##iel O
dogs O
. O

genetically O
determined O
c B-Disease
##3 I-Disease
deficiency I-Disease
in O
br O
##itt O
##any O
span O
##iel O
dogs O
shares O
a O
number O
of O
bio O
##chemical O
and O
clinical O
characteristics O
with O
the O
human O
disorder O
. O

in O
humans O
, O
the O
gene O
for O
c B-Disease
##3 I-Disease
deficiency I-Disease
is O
a O
null O
gene O
that O
is O
all O
##eli O
##c O
to O
the O
structural O
gene O
for O
c O
##3 O
and O
is O
not O
linked O
to O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
lo O
##cus O
. O

the O
current O
study O
used O
all O
##otype O
analysis O
of O
can O
##ine O
c O
##3 O
in O
order O
to O
demonstrate O
that O
the O
gene O
for O
c B-Disease
##3 I-Disease
deficiency I-Disease
in O
these O
dogs O
is O
also O
a O
null O
gene O
all O
##eli O
##c O
to O
the O
structural O
gene O
for O
c O
##3 O
. O

in O
addition O
, O
preliminary O
p O
##ed O
##ig O
##ree O
analysis O
suggests O
that O
the O
gene O
for O
can O
##ine O
c B-Disease
##3 I-Disease
deficiency I-Disease
is O
apparently O
not O
closely O
linked O
to O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
complex O
of O
the O
dog O
. O

thus O
, O
it O
appears O
that O
c B-Disease
##3 I-Disease
deficiency I-Disease
in O
br O
##itt O
##any O
span O
##iel O
dogs O
not O
only O
shares O
bio O
##chemical O
and O
clinical O
features O
with O
c B-Disease
##3 I-Disease
deficiency I-Disease
in O
humans O
, O
but O
also O
shares O
some O
genetic O
characteristics O
with O
the O
human O
disorder O
. O
. O

gene O
transfer O
and O
expression O
of O
human O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
caused O
by O
a O
genetic O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

a O
full O
- O
length O
complementary O
d O
##na O
clone O
of O
human O
p O
##ah O
was O
inserted O
into O
a O
e O
##uka O
##ryo O
##tic O
expression O
vector O
and O
transferred O
into O
mouse O
ni O
##h O
##3 O
##t O
##3 O
cells O
which O
do O
not O
normally O
express O
p O
##ah O
. O

the O
transformed O
mouse O
cells O
expressed O
p O
##ah O
messenger O
r O
##na O
, O
im O
##mu O
##nor O
##ea O
##ctive O
protein O
, O
and O
en O
##zy O
##matic O
activity O
that O
are O
characteristic O
of O
the O
normal O
human O
liver O
products O
, O
demonstrating O
that O
a O
single O
gene O
contains O
all O
of O
the O
necessary O
genetic O
information O
to O
code O
for O
functional O
p O
##ah O
. O

these O
results O
support O
the O
use O
of O
the O
human O
p O
##ah O
probe O
in O
pre O
##nat O
##al O
diagnosis O
and O
detection O
of O
carriers O
, O
to O
provide O
new O
opportunities O
for O
the O
bio O
##chemical O
characterization O
of O
normal O
and O
mutant O
enzymes O
, O
and O
in O
the O
investigation O
of O
alternative O
genetic O
the O
##rap O
##ies O
for O
p B-Disease
##ku I-Disease
. O
. O

regional O
mapping O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
and O
the O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
lo O
##cus O
in O
the O
human O
genome O
. O

p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
of O
amino O
acid O
metabolism O
caused O
by O
a O
deficiency B-Disease
of I-Disease
the I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
enzyme I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
; O
p O
##hen O
##yla O
##lani O
##ne O
4 O
- O
mon O
##oo O
##xy O
##gen O
##ase O
, O
e O
##c O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

a O
c O
##dn O
##a O
clone O
for O
human O
p O
##ah O
has O
previously O
been O
used O
to O
assign O
the O
corresponding O
gene O
to O
human O
chromosome O
12 O
. O

to O
define O
the O
regional O
map O
position O
of O
the O
disease O
lo O
##cus O
and O
the O
p O
##ah O
gene O
on O
human O
chromosome O
12 O
, O
d O
##na O
was O
isolated O
from O
human O
- O
ha O
##ms O
##ter O
so O
##matic O
cell O
hybrid O
##s O
with O
various O
del O
##eti O
##ons O
of O
human O
chromosome O
12 O
and O
was O
analyzed O
by O
southern O
b O
##lot O
analysis O
using O
the O
human O
c O
##dn O
##a O
p O
##ah O
clone O
as O
a O
hybrid O
##ization O
probe O
. O

from O
these O
results O
, O
together O
with O
detailed O
bio O
##chemical O
and O
c O
##yt O
##ogen O
##etic O
characterization O
of O
the O
hybrid O
cells O
, O
the O
region O
on O
chromosome O
12 O
containing O
the O
human O
p O
##ah O
gene O
has O
been O
defined O
as O
12 O
##q O
##14 O
. O

3 O
- O
- O
- O
- O
q O
##ter O
3 O
- O
- O
- O
- O
q O
##ter O
. O

the O
p O
##ah O
map O
position O
on O
chromosome O
12 O
was O
further O
localized O
by O
in O
sit O
##u O
hybrid O
##ization O
of O
125 O
##i O
- O
labeled O
human O
p O
##ah O
c O
##dn O
##a O
to O
chromosome O
##s O
prepared O
from O
a O
human O
l O
##ymph O
##ob O
##last O
##oid O
cell O
line O
. O

results O
of O
these O
experiments O
demonstrated O
that O
the O
region O
on O
chromosome O
12 O
containing O
the O
p O
##ah O
gene O
and O
the O
p B-Disease
##ku I-Disease
lo O
##cus O
in O
man O
is O
12 O
##q O
##22 O
- O
- O
- O
- O
12 O
##q O
##24 O
. O

1 O
. O

these O
results O
not O
only O
provide O
a O
regional O
##ized O
map O
position O
for O
a O
major O
human O
disease O
lo O
##cus O
but O
also O
can O
serve O
as O
a O
reference O
point O
for O
link O
##age O
analysis O
with O
other O
d O
##na O
markers O
on O
human O
chromosome O
12 O

he O
##tero O
##gene O
##ity O
of O
type B-Disease
i I-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
: O
evidence O
for O
a O
subgroup O
with O
an O
abnormal O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
. O

type B-Disease
i I-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
( O
v B-Disease
##w I-Disease
##d I-Disease
) O
is O
characterized O
by O
equally O
low O
plasma O
concentrations O
of O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
anti O
##gen O
( O
v O
##w O
##f O
a O
##g O
) O
and O
r O
##ist O
##oc O
##eti O
##n O
co O
##fa O
##ctor O
( O
r O
##ico O
##f O
) O
and O
by O
the O
presence O
of O
all O
v O
##w O
##f O
multi O
##mers O
in O
sodium O
do O
##de O
##cy O
##l O
su O
##lf O
##ate O
( O
s O
##ds O
) O
- O
a O
##gar O
##ose O
gel O
electro O
##ph O
##ores O
##is O
. O

for O
17 O
patients O
( O
13 O
kind O
##red O
##s O
) O
diagnosed O
with O
these O
criteria O
, O
we O
have O
studied O
the O
plate O
##let O
contents O
of O
v O
##w O
##f O
a O
##g O
and O
r O
##ico O
##f O
and O
the O
changes O
of O
these O
in O
plasma O
after O
d O
##da O
##v O
##p O
in O
##fusion O
. O

plate O
##let O
v O
##w O
##f O
a O
##g O
and O
r O
##ico O
##f O
were O
normal O
in O
four O
kind O
##red O
##s O
( O
called O
" O
plate O
##let O
normal O
" O
subgroup O
) O
; O
following O
1 O
- O
de O
##ami O
##no O
- O
8 O
- O
d O
- O
a O
##rg O
##ini O
##ne O
v O
##as O
##op O
##ress O
##in O
; O
plasma O
v O
##w O
##f O
a O
##g O
, O
r O
##ico O
##f O
and O
the O
bleeding O
time O
( O
b O
##t O
) O
became O
normal O
. O

in O
six O
kind O
##red O
##s O
, O
plate O
##let O
v O
##w O
##f O
a O
##g O
and O
r O
##ico O
##f O
were O
equally O
low O
( O
plate O
##let O
low O
) O
; O
after O
d O
##da O
##v O
##p O
, O
plasma O
v O
##w O
##f O
a O
##g O
and O
r O
##ico O
##f O
remained O
low O
, O
and O
the O
b O
##t O
was O
prolonged O
. O

in O
three O
additional O
kind O
##red O
##s O
, O
plate O
##lets O
contained O
normal O
concentrations O
of O
v O
##w O
##f O
a O
##g O
, O
but O
r O
##ico O
##f O
was O
very O
low O
( O
plate O
##let O
disco O
##rda O
##nt O
) O
; O
even O
though O
a O
complete O
set O
of O
multi O
##mers O
was O
found O
in O
plasma O
and O
plate O
##lets O
, O
there O
was O
a O
relatively O
small O
amount O
of O
large O
multi O
##mers O
. O

after O
d O
##da O
##v O
##p O
, O
plasma O
v O
##w O
##f O
a O
##g O
became O
normal O
, O
but O
r O
##ico O
##f O
remained O
low O
and O
the O
b O
##t O
was O
very O
prolonged O
. O

these O
findings O
demonstrated O
that O
there O
can O
be O
an O
abnormal O
v O
##w O
##f O
( O
r O
##ico O
##f O
less O
than O
v O
##w O
##f O
a O
##g O
) O
even O
in O
type B-Disease
i I-Disease
v I-Disease
##w I-Disease
##d I-Disease
, O
co O
##ex O
##ist O
##ing O
with O
a O
complete O
set O
of O
v O
##w O
##f O
multi O
##mers O
( O
plate O
##let O
disco O
##rda O
##nt O
) O
; O
that O
the O
abnormal O
v O
##w O
##f O
can O
be O
shown O
more O
clearly O
in O
plate O
##lets O
than O
in O
plasma O
or O
else O
in O
plasma O
after O
d O
##da O
##v O
##p O
in O
##fusion O
; O
and O
that O
d O
##da O
##v O
##p O
normal O
##izes O
the O
b O
##t O
only O
in O
those O
patients O
with O
normal O
plate O
##let O
levels O
of O
both O
v O
##w O
##f O
a O
##g O
and O
r O
##ico O
##f O
( O
plate O
##let O
normal O
) O
. O
. O

genetic O
analysis O
in O
families O
with O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
. O

we O
have O
brought O
together O
information O
on O
86 O
##4 O
affected O
individuals O
in O
164 O
families O
( O
including O
three O
new O
p O
##ed O
##ig O
##ree O
##s O
) O
reported O
in O
the O
137 O
year O
period O
since O
1845 O
when O
dem O
##ar O
##qua O
##y O
first O
described O
a O
family O
with O
what O
was O
later O
called O
van B-Disease
der I-Disease
w I-Disease
##oud I-Disease
##e I-Disease
syndrome I-Disease
( O
v B-Disease
##ws I-Disease
) O
. O

both O
types O
of O
oral B-Disease
c I-Disease
##le I-Disease
##ft I-Disease
, O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
( O
c B-Disease
##p I-Disease
) O
and O
c B-Disease
##le I-Disease
##ft I-Disease
lip I-Disease
with O
or O
without O
c B-Disease
##p I-Disease
( O
c B-Disease
##l I-Disease
##p I-Disease
) O
, O
se O
##g O
##re O
##gate O
in O
these O
families O
together O
with O
lower O
lip B-Disease
pits I-Disease
or O
fist B-Disease
##ula I-Disease
##e I-Disease
in O
an O
auto O
##so O
##mal O
dominant O
mode O
with O
high O
pen O
##et O
##rance O
estimated O
to O
be O
k O
= O
. O

89 O
and O
. O

99 O
by O
different O
methods O
. O

c O
##le O
##ft O
types O
( O
c B-Disease
##l I-Disease
##p I-Disease
and O
c B-Disease
##p I-Disease
) O
occur O
in O
v B-Disease
##ws I-Disease
in O
the O
same O
proportions O
as O
in O
the O
general O
non O
- O
v O
##ws O
population O
, O
i O
##e O
, O
about O
twice O
as O
many O
c O
##le O
##ft O
- O
bearing O
individuals O
have O
c B-Disease
##l I-Disease
##p I-Disease
as O
have O
c B-Disease
##p I-Disease
. O

on O
the O
other O
hand O
, O
we O
do O
not O
find O
the O
usually O
observed O
excess O
of O
females O
with O
c B-Disease
##p I-Disease
and O
excess O
of O
males O
with O
c B-Disease
##l I-Disease
##p I-Disease
; O
in O
v B-Disease
##ws I-Disease
the O
sex O
ratios O
are O
more O
nearly O
equal O
. O

lip B-Disease
pits I-Disease
also O
are O
equally O
distributed O
between O
the O
sexes O
. O

affected O
males O
and O
females O
are O
equally O
likely O
to O
transmit O
v B-Disease
##ws I-Disease
. O

however O
, O
there O
is O
an O
excess O
of O
less O
severely O
affected O
individuals O
among O
transmitter O
##s O
and O
a O
deficiency O
of O
more O
severely O
affected O
, O
brought O
about O
by O
a O
pro O
##band O
bias O
and O
differential O
f O
##ec O
##und O
##ity O
. O

the O
expression O
of O
v B-Disease
##ws I-Disease
is O
significantly O
modified O
by O
the O
genetic O
background O
more O
extreme O
p O
##hen O
##otype O
##s O
in O
parents O
tend O
to O
produce O
more O
extreme O
expression O
in O
their O
children O
. O

for O
a O
v B-Disease
##ws I-Disease
gene O
carrier O
the O
relative O
risk O
of O
transmitting O
a O
c O
##le O
##ft O
is O
26 O
. O

45 O
% O
; O
that O
of O
transmitting O
lower O
lip B-Disease
pits I-Disease
is O
23 O
. O

55 O
% O
. O

three O
p O
##ed O
##ig O
##ree O
##s O
of O
lip B-Disease
pits I-Disease
in O
the O
literature O
show O
no O
c O
##le O
##fts O
among O
a O
significant O
number O
of O
affected O
individuals O
. O

control O
of O
gene O
expression O
in O
v B-Disease
##ws I-Disease
in O
the O
three O
target O
tissues O
appears O
to O
be O
independent O
and O
separately O
designated O
. O

mutation O
rate O
of O
the O
v B-Disease
##ws I-Disease
gene O
is O
calculated O
to O
be O
1 O
. O

8 O
x O
10 O
( O
- O
5 O
) O

hereditary B-Disease
c I-Disease
##7 I-Disease
deficiency I-Disease
. O

diagnosis O
and O
h O
##la O
studies O
in O
a O
f O
##rench O
- O
can O
##adia O
##n O
family O
. O

the O
serum O
of O
a O
44 O
- O
y O
##r O
- O
old O
woman O
of O
f O
##rench O
- O
can O
##adia O
##n O
descent O
having O
a O
b O
- O
27 O
positive O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
was O
def B-Disease
##icient I-Disease
in I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##7 O
) O
as O
determined O
by O
hem O
##oly O
##tic O
and O
im O
##mu O
##no O
##chemical O
methods O
. O

no O
inhibitor O
against O
c O
##7 O
was O
detected O
, O
and O
the O
levels O
of O
all O
other O
complement O
components O
were O
normal O
. O

no O
deficiency O
in O
the O
op O
##sonic O
activity O
of O
the O
serum O
was O
found O
, O
and O
the O
results O
of O
basic O
co O
##agu O
##lation O
studies O
of O
the O
plasma O
were O
normal O
. O

on O
investigation O
of O
the O
patients O
family O
, O
two O
sisters O
were O
found O
to O
have O
the O
same O
deficiency O
but O
were O
otherwise O
in O
good O
health O
. O

the O
seven O
other O
siblings O
were O
he O
##tero O
##zy O
##go O
##us O
for O
c B-Disease
##7 I-Disease
deficiency I-Disease
, O
while O
the O
paternal O
aunt O
had O
a O
normal O
c O
##7 O
level O
. O

in O
the O
third O
generation O
, O
six O
children O
of O
the O
three O
ho O
##mo O
##zy O
##go O
##us O
sisters O
and O
five O
children O
of O
he O
##tero O
##zy O
##got O
##es O
were O
available O
for O
testing O
. O

studies O
of O
the O
h O
##la O
anti O
##gens O
in O
all O
the O
22 O
subjects O
and O
in O
three O
spouse O
##s O
indicated O
no O
close O
link O
##age O
between O
the O
cm B-Disease
def I-Disease
##icient I-Disease
##y I-Disease
and O
the O
h O
##la O
system O
. O

in O
addition O
, O
the O
simultaneous O
occurrence O
of O
two O
hereditary O
complement B-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
( I-Disease
c I-Disease
##2 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
) I-Disease
was O
discovered O
in O
one O
family O
of O
this O
remarkable O
kind O
##red O
. O
. O

genetic O
defect B-Disease
in I-Disease
secret I-Disease
##ion I-Disease
of I-Disease
complement I-Disease
c I-Disease
##5 I-Disease
in O
mice O
. O

a O
genetic O
deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
( I-Disease
c I-Disease
##5 I-Disease
) I-Disease
component I-Disease
of I-Disease
complement I-Disease
##1 I-Disease
- I-Disease
3 I-Disease
, O
a O
serum O
g O
##ly O
##co O
##p O
##rote O
##in O
of O
molecular O
weight O
( O
m O
##w O
) O
220 O
, O
000 O
( O
re O
##f O
. O
4 O
) O
, O
has O
been O
found O
in O
39 O
% O
of O
in O
##bred O
strains O
of O
mice O
##3 O
. O

se O
##ra O
of O
def O
##icient O
mice O
lack O
detect O
##able O
c O
##5 O
activity O
and O
protein O
##2 O
, O
3 O
. O

in O
addition O
def O
##icient O
mice O
produce O
anti O
##body O
to O
mouse O
c O
##5 O
when O
injected O
with O
se O
##ra O
from O
c O
##5 O
sufficient O
( O
normal O
) O
strains O
. O

le O
##vy O
et O
al O
. O

5 O
showed O
that O
so O
##matic O
cell O
hybrid O
##s O
between O
c O
##5 O
def O
##icient O
( O
b O
##10 O
. O
d O
##2 O
/ O
old O
line O
) O
mac O
##rop O
##hage O
##s O
and O
either O
c O
##5 O
sufficient O
( O
b O
##10 O
. O
d O
##2 O
/ O
new O
line O
) O
mouse O
kidney O
or O
chicken O
er O
##yt O
##hr O
##ob O
##last O
##s O
secret O
##ed O
ha O
##em O
##oly O
##tically O
active O
mouse O
c O
##5 O
in O
v O
##it O
##ro O
. O

several O
possible O
molecular O
mechanisms O
to O
account O
for O
the O
findings O
were O
considered O
, O
but O
insufficient O
direct O
data O
were O
available O
to O
choose O
among O
them O
. O

we O
recently O
reported O
that O
mouse O
( O
c O
##d O
. O
1 O
strain O
) O
per O
##ito O
##nea O
##l O
cells O
in O
culture O
synthesis O
##e O
and O
secret O
##e O
a O
single O
chain O
precursor O
, O
pro O
- O
c O
##5 O
( O
m O
##w O
approximately O
210 O
, O
000 O
) O
, O
of O
the O
two O
- O
chain O
( O
alpha O
chain O
, O
125 O
, O
000 O
and O
beta O
chain O
83 O
, O
000 O
m O
##w O
) O
c O
##5 O
protein O
##6 O
. O

radio O
##la O
##bell O
##ed O
precursor O
c O
##5 O
was O
contained O
within O
the O
cells O
and O
was O
secret O
##ed O
into O
the O
tissue O
culture O
media O
. O

using O
similar O
methods O
, O
we O
now O
find O
that O
c B-Disease
##5 I-Disease
deficiency I-Disease
in O
each O
of O
five O
different O
mouse O
strains O
( O
a O
##k O
##r O
, O
s O
##w O
##r O
, O
d O
##ba O
/ O
2 O
##j O
##8 O
a O
/ O
he O
##j O
and O
b O
##10 O
. O
d O
##2 O
/ O
old O
line O
) O
is O
due O
to O
a O
failure O
in O
secret O
##ion O
of O
c O
##5 O
protein O
and O
not O
to O
a O
failure O
in O
bio O
##sy O
##nt O
##hesis O
of O
pro O
- O
c O
##5 O

re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
with O
absence B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
: O
an O
evaluation O
of O
underlying O
im O
##mu O
##no O
##log O
##ic O
mechanisms O
. O

a O
51 O
/ O
2 O
- O
year O
- O
old O
black O
girl O
with O
re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
and O
absence B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##6 O
) O
is O
reported O
. O

to O
explore O
the O
path O
##ogen O
##esis O
of O
re O
##current O
ne B-Disease
##isse I-Disease
##rial I-Disease
infections I-Disease
in O
c B-Disease
##6 I-Disease
deficiency I-Disease
, O
a O
detailed O
analysis O
of O
her O
immune O
competence O
was O
conducted O
. O

her O
serum O
had O
normal O
ch O
##em O
##ota O
##ctic O
, O
op O
##sonic O
, O
alternative O
complement O
pathway O
, O
and O
specific O
anti O
##body O
activity O
, O
but O
lacked O
complement O
- O
mediated O
b O
##act O
##eri O
##oly O
##tic O
activity O
. O

in O
addition O
, O
her O
c B-Disease
##6 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
serum O
was O
in O
##dis O
##ting O
##ui O
##sha O
##ble O
from O
normal O
serum O
in O
a O
complement O
- O
dependent O
ass O
##ay O
of O
p O
##ha O
##go O
##cy O
##te O
b O
##act O
##eric O
##idal O
activity O
. O

absent O
b O
##act O
##eri O
##oly O
##sis O
remains O
the O
only O
consistent O
defect O
associated O
with O
re O
##current O
ne B-Disease
##isse I-Disease
##rial I-Disease
infections I-Disease
and O
absence O
of O
one O
of O
the O
late O
- O
acting O
complement O
components O
. O
. O

deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
human O
subjects O
. O

clinical O
, O
genetic O
and O
im O
##mu O
##no O
##log O
##ic O
studies O
in O
a O
large O
kind O
##red O
. O

the O
discovery O
of O
a O
large O
kind O
##red O
with O
a O
her O
##ita O
##ble O
deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##5 O
) O
has O
permitted O
the O
accumulation O
of O
new O
clinical O
, O
genetic O
and O
im O
##mu O
##no O
##log O
##ic O
data O
concerning O
the O
role O
of O
c O
##5 O
in O
human O
subjects O
. O

the O
pro O
##band O
, O
who O
has O
had O
nine O
episodes O
of O
di O
##sse O
##minated O
go B-Disease
##no I-Disease
##co I-Disease
##cca I-Disease
##l I-Disease
infection I-Disease
, O
has O
a O
hem O
##oly O
##tic O
c O
##5 O
level O
of O
approximately O
0 O
. O

5 O
per O
cent O
of O
normal O
. O

no O
c O
##5 O
protein O
was O
detect O
##able O
, O
but O
low O
levels O
of O
functional O
c O
##5 O
activity O
could O
be O
found O
using O
a O
sensitive O
b O
##act O
##eric O
##idal O
ass O
##ay O
. O

the O
pro O
##band O
##s O
twin O
as O
well O
as O
another O
sister O
also O
had O
extremely O
low O
levels O
of O
hem O
##oly O
##tic O
c O
##5 O
( O
approximately O
0 O
. O
5 O
per O
cent O
normal O
) O
, O
but O
both O
these O
subjects O
have O
been O
healthy O
. O

hem O
##oly O
##tic O
complement O
and O
b O
##act O
##eri O
##oly O
##tic O
activity O
could O
be O
restored O
by O
the O
addition O
of O
pu O
##rified O
c O
##5 O
. O

no O
ch O
##em O
##ota O
##ctic O
activity O
for O
p O
##oly O
##mor O
##phon O
##uc O
##lea O
##r O
le O
##uk O
##ocytes O
could O
be O
generated O
in O
the O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
serum O
##s O
upon O
activation O
of O
either O
the O
classic O
or O
alternative O
pathways O
, O
again O
demonstrating O
the O
importance O
of O
c O
##5 O
in O
human O
subjects O
for O
the O
production O
of O
ch O
##em O
##ota O
##ctic O
factors O
. O

the O
ch O
##em O
##ota O
##ctic O
re O
##sp O
##ons O
##ive O
##ness O
of O
the O
patients O
p O
##oly O
##mor O
##phon O
##uc O
##lea O
##r O
le O
##uk O
##ocytes O
and O
mon O
##ocytes O
to O
pre O
##formed O
ch O
##em O
##ota O
##ctic O
factors O
was O
not O
depressed O
. O

twenty O
- O
two O
of O
32 O
other O
family O
members O
from O
three O
generations O
had O
depressed O
whole O
hem O
##oly O
##tic O
complement O
levels O
. O

in O
19 O
of O
30 O
family O
members O
, O
levels O
of O
hem O
##oly O
##tic O
c O
##5 O
ranged O
from O
13 O
to O
64 O
per O
cent O
of O
normal O
. O

no O
link O
##age O
for O
c B-Disease
##5 I-Disease
deficiency I-Disease
and O
the O
a O
or O
b O
lo O
##ci O
of O
the O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
complex O
could O
be O
found O
. O

these O
data O
suggest O
an O
auto O
##so O
##mal O
co O
##dom O
##ina O
##nt O
mode O
of O
inheritance O
of O
c B-Disease
##5 I-Disease
deficiency I-Disease
. O

deficiency B-Disease
of I-Disease
c I-Disease
##5 I-Disease
is O
compatible O
with O
good O
health O
, O
but O
it O
can O
be O
associated O
with O
repeated O
di O
##sse O
##minated O
go B-Disease
##no I-Disease
##co I-Disease
##cca I-Disease
##l I-Disease
infection I-Disease

incidence O
and O
characteristics O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variants O
in O
j O
##apa O
##n O
. O

a O
total O
of O
3000 O
men O
living O
in O
ya O
##ma O
##guchi O
were O
screened O
for O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
using O
be O
##ut O
##lers O
spot O
test O
and O
three O
types O
of O
star O
##ch O
gel O
electro O
##ph O
##ores O
##is O
. O

these O
electro O
##ph O
##ores O
##is O
used O
a O
phosphate O
buffer O
system O
at O
p O
##h O
7 O
. O

0 O
, O
a O
t O
##ris O
- O
ed O
##ta O
- O
b O
##ora O
##te O
buffer O
system O
at O
p O
##h O
8 O
. O

6 O
, O
and O
a O
t O
##ris O
- O
h O
##ydro O
##ch O
##lor O
##ide O
buffer O
system O
at O
p O
##h O
8 O
. O
. O

fifteen O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
variants O
were O
found O
at O
the O
rate O
of O
0 O
. O

5 O
% O
and O
classified O
into O
four O
groups O
. O

as O
new O
variants O
, O
g O
##6 O
##p O
##d O
k O
##ona O
##n O
, O
ka O
##mi O
##ube O
, O
and O
k O
##i O
##wa O
were O
identified O
. O

these O
three O
variants O
had O
a O
mild O
to O
moderate O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
and O
were O
not O
associated O
with O
any O
clinical O
signs O
. O

g O
##6 O
##p O
##d O
k O
##ona O
##n O
had O
fast O
electro O
##ph O
##ore O
##tic O
mobility O
as O
compared O
with O
normal O
levels O
, O
g O
##6 O
##p O
##d O
k O
##i O
##wa O
had O
slightly O
elevated O
electro O
##ph O
##ore O
##tic O
mobility O
, O
and O
g O
##6 O
##p O
##d O
ka O
##mi O
##ube O
had O
normal O
electro O
##ph O
##ore O
##tic O
mobility O
. O

these O
three O
variants O
had O
normal O
levels O
of O
km O
g O
##6 O
##p O
, O
km O
na O
##d O
##p O
, O
and O
k O
##i O
na O
##d O
##ph O
, O
normal O
u O
##til O
##izations O
of O
both O
2 O
- O
de O
##ox O
##y O
- O
g O
##6 O
##p O
and O
de O
##ami O
##no O
- O
nap O
##d O
, O
normal O
heat O
stability O
, O
and O
a O
normal O
p O
##h O
curve O
. O

the O
other O
variant O
was O
g O
##6 O
##p O
##d O
u O
##be O
, O
which O
we O
had O
previously O
found O
in O
ya O
##ma O
##guchi O
( O
nak O
##ashi O
##ma O
et O
al O
. O
, O
1977 O
) O
. O

one O
boy O
with O
g O
##6 O
##p O
##d O
u O
##be O
was O
k O
##ore O
##an O

u O
##til O
##ization O
of O
pu O
##rine O
##s O
by O
an O
hp O
##rt O
variant O
in O
an O
intelligent O
, O
non O
##mu O
##til O
##ative O
patient O
with O
features O
of O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

the O
patient O
, O
h O
. O

ch O
##r O
. O

b O
. O
, O
was O
among O
the O
first O
reported O
with O
h B-Disease
##yper I-Disease
##uri I-Disease
##ce I-Disease
##mia I-Disease
and O
central B-Disease
nervous I-Disease
system I-Disease
symptoms I-Disease
. O

he O
has O
been O
found O
to O
have O
a O
variant O
of O
h O
##y O
##pox O
##ant O
##hine O
g O
##uan O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
transfer O
##ase O
( O
hp O
##rt O
; O
e O
. O
c O
. O
2 O
. O
4 O
. O
2 O
. O
8 O
) O
distinct O
from O
the O
enzyme O
present O
in O
patients O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

the O
patient O
had O
ch B-Disease
##ro I-Disease
##eo I-Disease
##ath I-Disease
##eto I-Disease
##sis I-Disease
, O
spa B-Disease
##stic I-Disease
##ity I-Disease
, O
d B-Disease
##ys I-Disease
##art I-Disease
##hr I-Disease
##ic I-Disease
speech I-Disease
, O
and O
h B-Disease
##yper I-Disease
##uri I-Disease
##ce I-Disease
##mia I-Disease
. O

however O
, O
his O
intelligence O
was O
normal O
and O
he O
had O
no O
evidence O
of O
self O
- O
m O
##uti O
##lation O
. O

there O
was O
no O
activity O
of O
hp O
##rt O
in O
the O
l O
##ys O
##ates O
of O
er O
##yt O
##hr O
##ocytes O
and O
culture O
##d O
fi O
##bro O
##blast O
##s O
when O
analyzed O
in O
the O
usual O
manner O
. O

using O
a O
newly O
developed O
method O
for O
the O
study O
of O
pu O
##rine O
metabolism O
in O
intact O
culture O
##d O
cells O
, O
this O
patient O
was O
found O
to O
meta O
##bol O
##ize O
some O
9 O
% O
of O
8 O
- O
14 O
##c O
- O
h O
##y O
##pox O
##ant O
##hine O
, O
and O
90 O
% O
of O
the O
is O
##oto O
##pe O
utilized O
was O
converted O
to O
ad O
##eni O
##ne O
and O
g O
##uan O
##ine O
n O
##uc O
##leo O
##tide O
##s O
. O

in O
contrast O
, O
cells O
from O
patients O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
were O
virtually O
completely O
unable O
to O
convert O
h O
##y O
##pox O
##ant O
##hine O
to O
n O
##uc O
##leo O
##tide O
##s O
. O

the O
patients O
fi O
##bro O
##blast O
##s O
were O
even O
more O
efficient O
in O
the O
metabolism O
of O
8 O
- O
14 O
##c O
- O
g O
##uan O
##ine O
, O
which O
was O
utilized O
to O
the O
extent O
of O
27 O
% O
, O
over O
80 O
% O
of O
which O
was O
converted O
to O
g O
##uan O
##ine O
and O
ad O
##eni O
##ne O
n O
##uc O
##leo O
##tide O
##s O
. O

the O
growth O
of O
the O
culture O
##d O
fi O
##bro O
##blast O
##s O
of O
this O
patient O
was O
intermediate O
in O
media O
containing O
h O
##y O
##pox O
##ant O
##hine O
amino O
##pt O
##eri O
##n O
thy O
##mi O
##dine O
( O
hat O
) O
, O
whereas O
the O
growth O
of O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
cells O
was O
in O
##hibit O
##ed O
and O
normal O
cells O
grew O
normally O
. O

similarly O
in O
8 O
- O
a O
##za O
##gua O
##nine O
, O
6 O
- O
th O
##io O
##gua O
##nine O
, O
and O
8 O
- O
a O
##za O
##hy O
##pox O
##ant O
##hine O
, O
the O
growth O
of O
the O
patients O
cells O
was O
intermediate O
between O
normal O
and O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
cells O
. O

these O
observations O
provide O
further O
evidence O
for O
genetic O
he O
##tero O
##gene O
##ity O
among O
patients O
with O
disorders O
in O
pu O
##rine O
metabolism O
involving O
the O
hp O
##rt O
gene O
. O

they O
document O
that O
this O
famous O
patient O
did O
not O
have O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease

local O
##isation O
of O
the O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
by O
link O
##age O
to O
clone O
##d O
d O
##na O
sequences O
. O

a O
link O
##age O
study O
in O
30 O
be B-Disease
##cker I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
b B-Disease
##m I-Disease
##d I-Disease
) O
kind O
##red O
##s O
using O
three O
clone O
##d O
d O
##na O
sequences O
from O
the O
x O
chromosome O
which O
demonstrate O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
##s O
( O
r O
##f O
##l O
##ps O
) O
, O
suggests O
that O
the O
b B-Disease
##m I-Disease
##d I-Disease
gene O
is O
located O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
, O
in O
the O
p O
##21 O
region O
. O

the O
genes O
for O
be B-Disease
##cker I-Disease
and I-Disease
du I-Disease
##chen I-Disease
##ne I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##es I-Disease
must O
therefore O
be O
closely O
linked O
, O
if O
not O
all O
##eli O
##c O
, O
and O
any O
future O
d O
##na O
probe O
##s O
found O
to O
be O
of O
practical O
use O
in O
one O
disorder O
should O
be O
equally O
applicable O
to O
the O
other O
. O

the O
link O
##age O
analysis O
also O
provides O
data O
on O
the O
frequency O
of O
re O
##comb O
##ination O
along O
the O
short O
arm O
of O
the O
x O
chromosome O
, O
and O
across O
the O
cent O
##rome O
##ric O
region O
. O
. O

molecular O
evidence O
for O
new O
mutation O
at O
the O
hp O
##rt O
lo O
##cus O
in O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
patients O
. O

h O
##y O
##pox O
##ant O
##hine O
- O
g O
##uan O
##ine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
hp O
##rt O
; O
e O
##c O
##2 O
. O
4 O
. O
2 O
. O
8 O
) O
, O
which O
functions O
in O
the O
metabolic O
salvage O
of O
pu O
##rine O
##s O
, O
is O
encoded O
by O
an O
x O
- O
linked O
gene O
in O
man O
. O

partial O
hp B-Disease
##rt I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
are O
associated O
with O
go B-Disease
##ut I-Disease
##y I-Disease
art I-Disease
##hr I-Disease
##itis I-Disease
, O
while O
absence O
of O
activity O
results O
in O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
( O
l B-Disease
- I-Disease
n I-Disease
) O
. O

l B-Disease
- I-Disease
n I-Disease
patients O
fail O
to O
reproduce O
and O
the O
he O
##tero O
##zy O
##go O
##us O
state O
appears O
to O
con O
##fer O
no O
selective O
advantage O
. O

thus O
, O
ha O
##lda O
##nes O
principle O
predict O
##s O
that O
new O
mutations O
at O
the O
hp O
##rt O
lo O
##cus O
must O
occur O
frequently O
in O
order O
for O
l B-Disease
- I-Disease
n I-Disease
syndrome I-Disease
to O
be O
maintained O
in O
the O
population O
. O

this O
constant O
introduction O
of O
new O
mutations O
would O
be O
expected O
to O
result O
in O
a O
he O
##tero O
##gene O
##ous O
collection O
of O
genetic B-Disease
lesions I-Disease
, O
some O
of O
which O
may O
be O
novel O
. O

as O
we O
report O
here O
, O
the O
mutations O
in O
the O
hp O
##rt O
gene O
of O
seven O
l B-Disease
- I-Disease
n I-Disease
patients O
, O
selected O
from O
an O
initial O
survey O
of O
28 O
patients O
, O
have O
been O
characterized O
and O
all O
were O
found O
to O
be O
distinctly O
different O
, O
as O
predicted O
. O

the O
origin O
of O
one O
unusual O
mutation O
has O
been O
identified O
by O
analysis O
of O
d O
##na O
from O
four O
generations O
of O
family O
members O
. O

further O
molecular O
analysis O
of O
the O
origin O
of O
new O
mutations O
at O
the O
hp O
##rt O
lo O
##cus O
should O
aid O
in O
re O
##sol O
##ving O
the O
issue O
of O
an O
apparent O
difference O
in O
the O
frequency O
of O
hp O
##rt O
mutations O
in O
males O
and O
females O

all O
##eli O
##c O
exclusion O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
in O
plate O
##lets O
and O
t O
l O
##ymph O
##ocytes O
from O
a O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
carrier O
. O

an O
o O
##b O
##liga O
##te O
carrier O
of O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
who O
was O
also O
he O
##tero O
##zy O
##go O
##us O
for O
the O
a O
and O
b O
types O
of O
x O
- O
linked O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
was O
found O
. O

with O
her O
it O
became O
possible O
to O
determine O
whether O
all O
##eli O
##c O
exclusion O
occurs O
in O
particular O
cell O
- O
types O
of O
the O
was B-Disease
carrier O
. O

if O
so O
, O
the O
remaining O
cells O
of O
a O
particular O
cell O
- O
type O
would O
express O
only O
the O
normal O
x O
chromosome O
and O
only O
one O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
is O
##oe O
##nz O
##yme O
would O
be O
demons O
##tra O
##ble O
. O

this O
carrier O
had O
only O
the O
b O
is O
##oe O
##nz O
##yme O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
in O
plate O
##lets O
and O
thy O
##mus O
- O
derived O
t O
l O
##ymph O
##ocytes O
, O
although O
both O
is O
##oe O
##nz O
##yme O
##s O
a O
and O
b O
were O
present O
in O
er O
##yt O
##hr O
##ocytes O
and O
ne O
##ut O
##rop O
##hil O
##s O
. O

these O
findings O
suggest O
that O
selection O
against O
the O
was B-Disease
gene O
occurs O
in O
plate O
##lets O
and O
thy O
##mus O
- O
derived O
t O
l O
##ymph O
##ocytes O
and O
that O
the O
defects O
associated O
with O
was B-Disease
expressed O
in O
these O
cell O
- O
types O
may O
be O
implicated O
in O
the O
genes O
##is O
of O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O
. O

complement B-Disease
deficiency I-Disease
and O
ne B-Disease
##ph I-Disease
##rit I-Disease
##is I-Disease
. O

a O
report O
of O
a O
family O
. O

a O
family O
is O
described O
in O
which O
three O
children O
had O
ho O
##mo O
##zy O
##go O
##us O
deficiency B-Disease
of I-Disease
c I-Disease
##3 I-Disease
and O
in O
which O
both O
parents O
and O
two O
other O
children O
were O
he O
##tero O
##zy O
##go O
##us O
for O
the O
c O
##3 O
null O
gene O
. O

one O
child O
with O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##3 I-Disease
deficiency I-Disease
was O
found O
to O
have O
me O
##mb O
##rano O
##p O
##rol O
##ifer O
##ative O
g B-Disease
##lo I-Disease
##mer I-Disease
##ulon I-Disease
##ep I-Disease
##hr I-Disease
##itis I-Disease
; O
protein B-Disease
##uria I-Disease
and O
/ O
or O
micro O
##scopic O
##al O
ha B-Disease
##ema I-Disease
##tur I-Disease
##ia I-Disease
was O
present O
in O
all O
three O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##3 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
children O
. O

all O
children O
with O
ho O
##mo O
##zy O
##go O
##us O
or O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##3 I-Disease
deficiency I-Disease
were O
, O
to O
a O
varying O
degree O
, O
susceptible O
to O
infection O
. O

the O
only O
child O
of O
the O
family O
with O
normal O
complement O
had O
no O
increased O
risk O
of O
infection O
and O
no O
re B-Disease
##nal I-Disease
disease I-Disease
. O

this O
family O
study O
provides O
further O
support O
for O
the O
proposal O
that O
c B-Disease
##3 I-Disease
deficiency I-Disease
pre O
##dis O
##pose O
##s O
to O
ne B-Disease
##ph I-Disease
##rit I-Disease
##is I-Disease
. O
. O

he O
##tero O
##gene O
##ity O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
al O
##ger O
##ia O
. O

study O
in O
northern O
al O
##ger O
##ia O
with O
description O
of O
five O
new O
variants O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
was O
found O
in O
3 O
. O

2 O
% O
of O
the O
male O
population O
living O
in O
the O
urban O
area O
of O
al O
##gie O
##rs O
. O

the O
def O
##icient O
subjects O
originated O
from O
multiple O
geographic O
regions O
of O
northern O
al O
##ger O
##ia O
, O
with O
prevalence O
of O
individuals O
of O
be O
##rber O
- O
ka O
##by O
##le O
origin O
. O

red O
blood O
cell O
g O
##6 O
##p O
##d O
was O
partially O
pu O
##rified O
and O
characterized O
in O
def O
##icient O
males O
from O
17 O
families O
, O
and O
six O
different O
variants O
were O
found O
. O

among O
them O
, O
only O
one O
, O
the O
g O
##d O
( O
- O
) O
ka O
##by O
##le O
variant O
, O
had O
been O
previously O
described O
. O

it O
was O
detected O
in O
nine O
families O
. O

the O
other O
five O
variants O
were O
new O
g O
##d O
( O
- O
) O
la O
##gh O
##ou O
##at O
( O
four O
cases O
) O
, O
g O
##d O
( O
- O
) O
b O
##lid O
##a O
( O
one O
case O
) O
, O
g O
##d O
( O
- O
) O
then O
##ia O
( O
one O
case O
) O
, O
g O
##d O
( O
- O
) O
t O
##itte O
##ri O
( O
one O
case O
) O
, O
and O
g O
##d O
( O
- O
) O
al O
##ger O
( O
two O
brothers O
) O
. O

striking O
##ly O
, O
the O
common O
me O
##dit O
##er O
##rane O
##an O
variant O
was O
not O
found O
. O

g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
he O
##tero O
##gene O
##ous O
in O
northern O
al O
##ger O
##ia O
where O
auto O
##cht O
##ono O
##us O
variants O
seem O
to O
pre O
##va O
##il O
. O

the O
ka O
##by O
##le O
variant O
may O
be O
common O
in O
this O
country O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
##hibit O
##s O
in O
v O
##it O
##ro O
growth O
of O
p O
##las O
##mo O
##dium O
f O
##al O
##ci O
##par O
##um O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
; I-Disease
e I-Disease
##c I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
- I-Disease
def I-Disease
##icient I-Disease
red O
blood O
cells O
from O
male O
hem O
##iz O
##y O
##got O
##es O
and O
female O
he O
##tero O
##zy O
##got O
##es O
from O
the O
island O
of O
sa O
##rdi O
##nia O
were O
studied O
for O
their O
ability O
to O
support O
growth O
in O
v O
##it O
##ro O
of O
the O
malaria B-Disease
- O
causing O
organism O
p O
##las O
##mo O
##dium O
f O
##al O
##ci O
##par O
##um O
. O

parasite O
growth O
was O
approximately O
one O
- O
third O
of O
normal O
in O
both O
hem O
##i O
- O
and O
he O
##tero O
##zy O
##got O
##es O
for O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

in O
sa O
##rdi O
##nian O
##s O
with O
the O
beta O
0 O
- O
th O
##ala O
##sse O
##mia O
trait O
, O
parasite O
growth O
was O
normal O
except O
when O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
occurred O
together O
with O
the O
th B-Disease
##ala I-Disease
##sse I-Disease
##mia I-Disease
trait O
. O

the O
data O
support O
the O
hypothesis O
that O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
may O
con O
##fer O
a O
selective O
advantage O
in O
a O
ma B-Disease
##lar I-Disease
##ious I-Disease
area O
; O
the O
female O
he O
##tero O
##zy O
##got O
##e O
may O
be O
at O
a O
particular O
advantage O
because O
resistance O
to O
malaria B-Disease
equals O
that O
of O
male O
hem O
##iz O
##y O
##got O
##es O
, O
but O
the O
risk O
of O
fatal B-Disease
hem I-Disease
##oly I-Disease
##sis I-Disease
may O
be O
less O
. O

however O
, O
more O
female O
he O
##tero O
##zy O
##got O
##es O
must O
be O
studied O
to O
confirm O
this O
hypothesis O
. O

no O
protective O
effect O
of O
beta O
0 O
- O
th O
##ala O
##sse O
##mia O
trait O
could O
be O
demonstrated O
in O
v O
##it O
##ro O
. O

bone O
ma O
##rrow O
transplant O
in O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

an O
all O
##ogen O
##ei O
##c O
bone O
ma O
##rrow O
transplant O
( O
b O
##m O
##t O
) O
from O
a O
normal O
h O
##la O
identical O
sibling O
donor O
was O
performed O
in O
a O
13 O
- O
year O
- O
old O
boy O
with O
rapidly O
progressive O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
. O

en O
##gra O
##ft O
##ment O
and O
complete O
hem O
##ato O
##log O
##ic O
recovery O
occurred O
within O
4 O
weeks O
, O
but O
ne B-Disease
##uro I-Disease
##log I-Disease
##ic I-Disease
de I-Disease
##ter I-Disease
##ior I-Disease
##ation I-Disease
continued O
. O

the O
patient O
died O
of O
an O
ad B-Disease
##eno I-Disease
##virus I-Disease
infection I-Disease
141 O
days O
after O
b O
##m O
##t O
. O

al B-Disease
##d I-Disease
is O
characterized O
by O
abnormal O
##ly O
high O
plasma O
levels O
of O
very O
long O
chain O
fatty O
acids O
( O
v O
##l O
##c O
##fa O
) O
as O
a O
result O
of O
impaired O
capacity O
to O
de O
##grade O
them O
. O

ten O
days O
after O
b O
##m O
##t O
, O
the O
white O
blood O
cell O
v O
##l O
##c O
##fa O
levels O
and O
enzyme O
activity O
became O
normal O
; O
after O
3 O
months O
, O
there O
was O
progressive O
reduction O
of O
plasma O
v O
##l O
##c O
##fa O
to O
levels O
only O
slightly O
above O
normal O
. O
. O

[ O
g O
##d O
- O
all O
##ele O
distribution O
patterns O
in O
a O
##zer O
##ba O
##ija O
##n O
. O
ii O
##i O
. O
the O
identification O
of O
mutant O
forms O
of O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
] O

in O
28 O
families O
with O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
living O
in O
3 O
settlements O
of O
she O
##ki O
##i O
district O
of O
a O
##zer O
##ba O
##ija O
##n O
11 O
g O
##6 O
##p O
##d O
variants O
of O
ii O
and O
ii O
##i O
classes O
differing O
by O
kinetic O
properties O
were O
identified O
according O
who O
program O
. O

9 O
of O
them O
are O
characterized O
with O
the O
same O
electro O
##ph O
##ore O
##tic O
mobility O
. O

comparison O
of O
g O
##6 O
##p O
##d O
s O
##pect O
##ra O
in O
two O
sub O
##pop O
##ulation O
##s O
and O
in O
a O
mixed O
group O
permits O
to O
make O
a O
conclusion O
about O
existence O
of O
common O
and O
rare O
g O
##6 O
##p O
##d O
all O
##ele O
##s O
in O
examined O
population O
. O

they O
distribute O
by O
gene O
drift O
supported O
by O
natural O
selection O
. O

among O
7 O
samples O
of O
g O
##6 O
##p O
##d O
with O
normal O
and O
increased O
activity O
two O
new O
variants O
of O
i O
##v O
class O
- O
- O
n O
##uk O
##ha O
and O
b O
##ash O
- O
k O
##ung O
##ut O
- O
- O
were O
found O
. O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
: O
survey O
of O
303 O
cases O
: O
bio O
##chemistry O
, O
diagnosis O
, O
and O
therapy O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
is O
a O
genetically O
determined O
disorder O
associated O
with O
progressive B-Disease
central I-Disease
dem I-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
and O
ad B-Disease
##rena I-Disease
##l I-Disease
co I-Disease
##rt I-Disease
##ical I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
. O

all O
affected O
persons O
show O
increased O
levels O
of O
saturated O
un O
##bra O
##nched O
very O
- O
long O
- O
chain O
fatty O
acids O
, O
particularly O
he O
##xa O
##cos O
##ano O
##ate O
( O
c O
##26 O
0 O
) O
, O
because O
of O
impaired O
capacity O
to O
de O
##grade O
these O
acids O
. O

this O
degradation O
normally O
takes O
place O
in O
a O
sub O
##cellular O
organ O
##elle O
called O
the O
per O
##ox O
##is O
##ome O
, O
and O
al B-Disease
##d I-Disease
, O
together O
with O
z B-Disease
##ell I-Disease
##we I-Disease
##gers I-Disease
c I-Disease
##ere I-Disease
##bro I-Disease
##he I-Disease
##pa I-Disease
##tore I-Disease
##nal I-Disease
syndrome I-Disease
, O
is O
now O
considered O
to O
belong O
to O
the O
newly O
formed O
category O
of O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorders I-Disease
. O

bio O
##chemical O
ass O
##ays O
permit O
pre O
##nat O
##al O
diagnosis O
, O
as O
well O
as O
identification O
of O
most O
he O
##tero O
##zy O
##got O
##es O
. O

we O
have O
identified O
303 O
patients O
with O
al B-Disease
##d I-Disease
in O
217 O
kind O
##red O
##s O
. O

these O
patients O
show O
a O
wide O
p O
##hen O
##otypic O
variation O
. O

sixty O
percent O
of O
patients O
had O
childhood O
al B-Disease
##d I-Disease
and O
17 O
% O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
, O
both O
of O
which O
are O
x O
- O
linked O
, O
with O
the O
gene O
mapped O
to O
x O
##q O
##28 O
. O

neon B-Disease
##ata I-Disease
##l I-Disease
al I-Disease
##d I-Disease
, O
a O
distinct O
entity O
with O
auto O
##so O
##mal O
re O
##cess O
##ive O
inheritance O
and O
points O
of O
resemblance O
to O
z B-Disease
##ell I-Disease
##we I-Disease
##gers I-Disease
syndrome I-Disease
, O
accounted O
for O
7 O
% O
of O
the O
cases O
. O

although O
excess O
c O
##26 O
0 O
in O
the O
brain O
of O
patients O
with O
al B-Disease
##d I-Disease
is O
partially O
of O
diet O
##ary O
origin O
, O
diet O
##ary O
c O
##26 O
0 O
restriction O
did O
not O
produce O
clear O
benefit O
. O

bone O
ma O
##rrow O
transplant O
lowered O
the O
plasma O
c O
##26 O
0 O
level O
but O
failed O
to O
arrest O
ne O
##uro O
##logical O
progression O
. O
. O

genetic O
p O
##oly O
##mor O
##phism O
of O
g O
##6 O
##p O
##d O
in O
a O
b O
##ul O
##gar O
##ian O
population O
. O

considerable O
genetic O
he O
##tero O
##gene O
##ity O
in O
g O
##6 O
##p O
##d O
was O
found O
in O
the O
b O
##ul O
##gar O
##ian O
population O
- O
14 O
g O
##6 O
##p O
##d O
variants O
isolated O
from O
117 O
hem O
##iz O
##y O
##go O
##us O
carriers O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

of O
these O
, O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
type O
was O
a O
p O
##oly O
##morphic O
variant O
and O
g O
##6 O
##p O
##d O
co O
##rin O
##th O
occurred O
with O
high O
frequency O
. O

two O
new O
variants O
were O
identified O
- O
g O
##6 O
##p O
##d O
r O
##udo O
##se O
##m O
and O
g O
##6 O
##p O
##d O
ne O
##del O
##ino O
. O

in O
a O
selected O
group O
of O
78 O
subjects O
with O
clinical O
manifest O
##ations O
, O
four O
variants O
were O
established O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rani O
##an O
, O
g O
##6 O
##p O
##d O
co O
##rin O
##th O
, O
g O
##6 O
##p O
##d O
seat O
##tle O
and O
g O
##6 O
##p O
##d O
oh O
##ut O
ii O
. O
. O

clinical O
use O
of O
d O
##na O
markers O
linked O
to O
the O
gene O
for O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

seventy O
families O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
known O
to O
the O
institute O
of O
child O
health O
fall O
into O
three O
categories O
with O
respect O
to O
potential O
link O
##age O
analysis O
with O
the O
x O
chromosome O
d O
##na O
markers O
r O
##c O
##8 O
and O
l O
##1 O
. O

28 O
that O
bridge O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

families O
in O
which O
there O
is O
at O
least O
one O
o O
##b O
##liga O
##tory O
female O
he O
##tero O
##zy O
##got O
##e O
( O
n O
= O
13 O
) O
. O

here O
prediction O
and O
exclusion O
of O
d B-Disease
##m I-Disease
##d I-Disease
gene O
transmission O
may O
be O
possible O
, O
the O
accuracy O
being O
dependent O
on O
the O
close O
##ness O
of O
the O
link O
##age O
of O
the O
d O
##na O
marker O
( O
s O
) O
to O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
; O
an O
ill O
##ust O
##rative O
case O
is O
reported O
. O

families O
in O
which O
there O
is O
a O
single O
affected O
boy O
, O
who O
also O
has O
one O
or O
more O
healthy O
brothers O
( O
n O
= O
26 O
) O
. O

given O
an O
inform O
##ative O
restriction O
fragment O
length O
p O
##oly O
##mor O
##phism O
( O
r O
##f O
##l O
##p O
) O
, O
the O
probability O
that O
the O
boy O
represents O
a O
new O
mutation O
can O
be O
re O
##ass O
##essed O
; O
it O
is O
also O
possible O
to O
exclude O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
in O
a O
sister O
. O

families O
with O
a O
single O
affected O
boy O
with O
no O
brother O
( O
n O
= O
30 O
) O
. O

here O
exclusion O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
in O
a O
sister O
may O
be O
possible O
. O

only O
in O
one O
family O
was O
there O
no O
possibility O
of O
useful O
link O
##age O
analysis O
. O

the O
link O
##age O
analysis O
required O
is O
described O
, O
and O
the O
need O
to O
check O
d B-Disease
##m I-Disease
##d I-Disease
families O
for O
inform O
##ative O
r O
##f O
##l O
##ps O
is O
stressed O
. O

family O
studies O
in O
be B-Disease
##cht I-Disease
##ere I-Disease
##w I-Disease
' I-Disease
s I-Disease
syndrome I-Disease
( O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
) O
ii O
##i O
. O

genetics O
. O

the O
results O
of O
segregation O
analyses O
in O
75 O
families O
where O
the O
pro O
##band O
had O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
, O
are O
presented O
. O

of O
the O
278 O
adult O
, O
living O
first O
degree O
relatives O
, O
approximately O
85 O
% O
cooperate O
##d O
in O
the O
study O
. O

clinical O
and O
radio O
##graphical O
examinations O
were O
performed O
and O
h O
##la O
typing O
was O
conducted O
. O

the O
results O
were O
in O
agreement O
with O
our O
hypothesis O
that O
an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
is O
part O
of O
a O
syndrome O
where O
different O
genetic O
factors O
interact O
. O

such O
known O
factors O
are O
h O
##la O
b O
##27 O
associated O
disease O
su O
##s O
##ce O
##pt O
##ibility O
, O
su O
##s O
##ce O
##pt O
##ibility O
to O
ps B-Disease
##oria I-Disease
##tic I-Disease
art I-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
and O
su O
##s O
##ce O
##pt O
##ibility O
to O
enter B-Disease
##o I-Disease
- I-Disease
art I-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
. O

radio O
##graphical O
sa B-Disease
##c I-Disease
##ro I-Disease
- I-Disease
il I-Disease
##ii I-Disease
##tis I-Disease
was O
restricted O
to O
h O
##la O
b O
##27 O
positive O
relatives O
, O
and O
was O
more O
frequently O
found O
in O
relatives O
to O
pro O
##band O
##s O
with O
ps B-Disease
##oria I-Disease
##sis I-Disease
than O
in O
relatives O
to O
pro O
##band O
##s O
without O
ps B-Disease
##oria I-Disease
##sis I-Disease
. O

environmental O
factors O
( O
in O
##test O
##inal O
bacteria O
) O
are O
known O
to O
trigger O
the O
disease O
at O
least O
in O
some O
persons O
, O
and O
we O
have O
post O
##ulated O
that O
all O
or O
most O
of O
them O
have O
the O
pre O
##dis O
##position O
to O
develop O
disease O
. O

thus O
, O
the O
syndrome O
has O
a O
multi O
##fa O
##ctor O
##ial O
et O
##iology O
. O

the O
p O
##hen O
##otypic O
expressions O
of O
the O
different O
genetic O
pre O
##dis O
##position O
##s O
involved O
, O
include O
sa B-Disease
##c I-Disease
##ro I-Disease
- I-Disease
il I-Disease
##ii I-Disease
##tis I-Disease
, O
ps B-Disease
##oria I-Disease
##sis I-Disease
, O
acute B-Disease
anterior I-Disease
u I-Disease
##ve I-Disease
##itis I-Disease
, O
peripheral O
art B-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
and O
inflammatory B-Disease
bow I-Disease
##el I-Disease
disease I-Disease
. O

we O
suggest O
the O
descriptive O
name O
hereditary B-Disease
multi I-Disease
##fo I-Disease
##cal I-Disease
re I-Disease
##lap I-Disease
##sing I-Disease
inflammation I-Disease
( O
hem B-Disease
##ri I-Disease
) O
for O
this O
syndrome O
. O

an B-Disease
##ky I-Disease
##los I-Disease
##ing I-Disease
s I-Disease
##po I-Disease
##ndy I-Disease
##lit I-Disease
##is I-Disease
, O
ps B-Disease
##oria I-Disease
##tic I-Disease
art I-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
and O
enter B-Disease
##o I-Disease
- I-Disease
art I-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
may O
be O
regarded O
as O
clinical O
sub O
- O
types O
of O
the O
syndrome O
. O
. O

p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
and O
chromosome O
15 O
. O

a O
clinical O
discussion O
of O
20 O
cases O
. O

a O
chromosome B-Disease
15 I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
was O
observed O
in O
12 O
of O
20 O
patients O
, O
17 O
of O
whom O
were O
clinical O
##ly O
suspected O
of O
having O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

the O
clinical O
features O
of O
eight O
cases O
with O
15 O
##q O
##11 O
- O
12 O
del O
##eti O
##on O
were O
very O
similar O
to O
those O
originally O
described O
in O
p B-Disease
##ws I-Disease
. O

on O
the O
other O
hand O
, O
the O
group O
of O
normal O
ka O
##ryo O
##type O
patients O
is O
he O
##tero O
##gene O
##ous O
, O
and O
their O
features O
do O
not O
strictly O
correspond O
to O
the O
clinical O
definition O
of O
p B-Disease
##ws I-Disease
. O

however O
, O
the O
hypothesis O
that O
p B-Disease
##ws I-Disease
is O
associated O
with O
del O
##eti O
##on O
of O
15 O
##q O
##11 O
- O
12 O
can O
neither O
explain O
the O
apparently O
balanced O
trans O
##location O
##s O
of O
chromosome O
15 O
nor O
account O
for O
the O
small O
super O
##num O
##era O
##ry O
meta O
##centric O
chromosome O
##s O
corresponding O
to O
an O
is O
##och O
##rom O
##oso O
##me O
15 O
for O
band O
15 O
##q O
##11 O
observed O
in O
some O
cases O
. O
. O

the O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
gene O
in O
north O
am O
##eric O
##an O
j O
##ew O
##ish O
populations O
: O
geographic O
variations O
and O
origin O
. O

from O
data O
collected O
in O
a O
north O
am O
##eric O
##an O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
he O
##tero O
##zy O
##got O
##e O
screening O
program O
, O
the O
t B-Disease
##s I-Disease
##d I-Disease
carrier O
frequency O
among O
46 O
, O
304 O
j O
##ew O
##ish O
individuals O
was O
found O
to O
be O
. O

03 O
##24 O
( O
1 O
in O
31 O
individuals O
) O
. O

this O
frequency O
is O
consistent O
with O
earlier O
estimates O
based O
on O
t B-Disease
##s I-Disease
##d I-Disease
incidence O
data O
. O

t B-Disease
##s I-Disease
##d I-Disease
carrier O
frequencies O
were O
then O
examined O
by O
single O
country O
and O
single O
region O
of O
origin O
in O
28 O
, O
02 O
##9 O
j O
##ews O
within O
this O
sample O
for O
whom O
such O
data O
were O
available O
for O
analysis O
. O

j O
##ews O
with O
p O
##olis O
##h O
and O
/ O
or O
r O
##uss O
##ian O
ancestry O
constituted O
88 O
% O
of O
this O
sample O
and O
had O
a O
t B-Disease
##s I-Disease
##d I-Disease
carrier O
frequency O
of O
. O

03 O
##27 O
. O

no O
t B-Disease
##s I-Disease
##d I-Disease
carriers O
were O
observed O
among O
the O
166 O
j O
##ews O
of O
near O
eastern O
origins O
. O

relative O
to O
j O
##ews O
of O
p O
##olis O
##h O
and O
r O
##uss O
##ian O
origins O
, O
there O
was O
at O
least O
a O
two O
##fold O
increase O
in O
the O
t B-Disease
##s I-Disease
##d I-Disease
carrier O
frequency O
in O
j O
##ews O
of O
au O
##st O
##rian O
, O
hung O
##arian O
, O
and O
c O
##ze O
##cho O
##s O
##lov O
##aki O
##an O
origins O
( O
p O
less O
than O
. O
00 O
##5 O
) O
. O

these O
findings O
suggest O
that O
the O
t B-Disease
##s I-Disease
##d I-Disease
gene O
pro O
##life O
##rated O
among O
the O
ant O
##ec O
##ede O
##nts O
of O
modern O
ash O
##ken O
##azi O
j O
##ew O
##ry O
after O
the O
second O
diaspora O
( O
70 O
a O
. O
d O
. O
) O
and O
before O
their O
major O
migration O
##s O
to O
regions O
of O
p O
##ola O
##nd O
and O
r O
##uss O
##ia O
( O
before O
1100 O
a O
. O
d O
. O
) O
. O

human O
deficiency B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
patient O
with O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
and O
no O
ha B-Disease
##em I-Disease
##ost I-Disease
##asis I-Disease
abnormal I-Disease
##ity I-Disease
. O

a O
case O
of O
human O
complete O
c B-Disease
##6 I-Disease
deficiency I-Disease
is O
reported O
. O

the O
patient O
, O
a O
31 O
year O
old O
white O
male O
, O
was O
seen O
on O
the O
occasion O
of O
an O
isolated O
episode O
of O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
men I-Disease
##ing I-Disease
##itis I-Disease
. O

serum O
complement O
hem O
##oly O
##tic O
and O
b O
##act O
##eric O
##idal O
activities O
were O
lacking O
and O
could O
be O
restored O
to O
normal O
by O
addition O
of O
appropriate O
amounts O
of O
pu O
##rified O
c O
##6 O
. O

no O
hem B-Disease
##ost I-Disease
##atic I-Disease
abnormal I-Disease
##ities I-Disease
were O
observed O
. O
. O

absence B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
patient O
with O
chronic B-Disease
men I-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##ce I-Disease
##mia I-Disease
presenting O
as O
v B-Disease
##as I-Disease
##cu I-Disease
##lit I-Disease
##is I-Disease
. O

a O
previously O
healthy O
40 O
- O
year O
- O
old O
man O
presenting O
with O
fever B-Disease
, O
art B-Disease
##hr I-Disease
##itis I-Disease
, O
and O
cut B-Disease
##aneous I-Disease
v I-Disease
##as I-Disease
##cu I-Disease
##lit I-Disease
##is I-Disease
was O
found O
to O
have O
chronic B-Disease
men I-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##ce I-Disease
##mia I-Disease
. O

evaluation O
of O
his O
complement O
system O
showed O
an O
absence O
of O
functional O
and O
anti O
##genic O
c O
##7 O
, O
compatible O
with O
a O
complete O
deficiency B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

study O
of O
the O
patients O
family O
spanning O
four O
generations O
showed O
he O
##tero O
##zy O
##go O
##us O
deficiency B-Disease
of I-Disease
c I-Disease
##7 I-Disease
in O
five O
members O
. O

chronic B-Disease
ne I-Disease
##isse I-Disease
##rial I-Disease
infection I-Disease
can O
be O
associated O
with O
c B-Disease
##7 I-Disease
deficiency I-Disease
and O
must O
be O
distinguished O
from O
other O
causes O
of O
cut B-Disease
##aneous I-Disease
v I-Disease
##as I-Disease
##cu I-Disease
##lit I-Disease
##is I-Disease
. O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
disco I-Disease
##id I-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
associated O
with O
he O
##tero O
##zy O
##got O
##e O
c B-Disease
##2 I-Disease
deficiency I-Disease
. O

two O
siblings O
with O
chronic B-Disease
disco I-Disease
##id I-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
and O
several O
family O
members O
were O
found O
with O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
. O

an O
association O
with O
his O
##to O
##com O
##pa O
##ti O
##bility O
markers O
h O
##la O
- O
b O
##18 O
and O
h O
##la O
- O
d O
##w O
##2 O
was O
demonstrated O
, O
and O
the O
slow O
all O
##otype O
of O
factor O
b O
was O
present O
. O

link O
##age O
studies O
in O
this O
family O
suggested O
a O
close O
link O
##age O
between O
the O
c B-Disease
##2 I-Disease
deficiency I-Disease
gene O
and O
genes O
coding O
for O
b O
##18 O
, O
d O
##w O
##2 O
, O
and O
b O
##fs O
anti O
##gens O
. O

one O
h O
##la O
- O
a O
##c O
##b O
/ O
d O
##b O
##f O
re O
##comb O
##ina O
##nt O
was O
observed O
showing O
closer O
link O
##age O
between O
h O
##la O
- O
d O
and O
b O
##f O
than O
between O
h O
##la O
- O
b O
and O
b O
##f O
. O
. O

severe B-Disease
- I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
associated O
with O
chronic O
hem B-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
, O
g B-Disease
##ran I-Disease
##ulo I-Disease
##cy I-Disease
##te I-Disease
d I-Disease
##ys I-Disease
##function I-Disease
, O
and O
increased O
su O
##s O
##ce O
##pt O
##ibility O
to O
infections O
: O
description O
of O
a O
new O
molecular O
variant O
( O
g O
##6 O
##p O
##d O
bar O
##cel O
##ona O
) O
. O

molecular O
, O
kinetic O
, O
and O
functional O
studies O
were O
carried O
out O
on O
er O
##yt O
##hr O
##ocytes O
and O
le O
##uk O
##ocytes O
in O
a O
span O
##ish O
male O
with O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
con B-Disease
##gen I-Disease
##ital I-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
( O
c B-Disease
##ns I-Disease
##ha I-Disease
) O
, O
and O
increased O
su O
##s O
##ce O
##pt O
##ibility O
to O
infections O
. O

g O
##6 O
##p O
##d O
activity O
was O
absent O
in O
patients O
red O
cells O
and O
was O
about O
2 O
% O
of O
normal O
in O
le O
##uk O
##ocytes O
. O

molecular O
studies O
using O
standard O
methods O
( O
who O
, O
1967 O
) O
showed O
g O
##6 O
##p O
##d O
in O
the O
patient O
to O
have O
a O
slightly O
fast O
electro O
##ph O
##ore O
##tic O
mobility O
at O
p O
##h O
8 O
. O

0 O
with O
otherwise O
normal O
properties O
( O
heat O
stability O
at O
46 O
degrees O
c O
, O
apparent O
affinity O
for O
substrates O
, O
op O
##ti O
##mum O
p O
##h O
, O
and O
u O
##til O
##ization O
of O
substrate O
analogue O
##s O
) O
. O

other O
tests O
showed O
the O
patients O
g O
##ran O
##ulo O
##cy O
##tes O
to O
en O
##gu O
##lf O
late O
##x O
particles O
normally O
, O
but O
to O
have O
impaired O
reduction O
of O
ni O
##tro O
##b O
##lue O
te O
##tra O
##zo O
##lium O
and O
f O
##er O
##ric O
##yt O
##och O
##rome O
- O
c O
as O
well O
as O
reduced O
i O
##od O
##ination O
. O

ch O
##em O
##ota O
##xi O
##s O
and O
random O
migration O
of O
the O
patients O
g O
##ran O
##ulo O
##cy O
##tes O
were O
normal O
as O
were O
my O
##elo O
##per O
##ox O
##idas O
##e O
, O
le O
##uk O
##oc O
##yte O
al O
##kal O
##ine O
p O
##hos O
##pha O
##tase O
( O
lap O
) O
, O
and O
ultra O
##st O
##ructural O
features O
. O

the O
molecular O
characteristics O
of O
g O
##6 O
##p O
##d O
in O
the O
patient O
differed O
from O
those O
of O
all O
previously O
reported O
variants O
associated O
with O
c B-Disease
##ns I-Disease
##ha I-Disease
, O
so O
the O
present O
variant O
was O
provisional O
##ly O
called O
g O
##6 O
##p O
##d O
bar O
##cel O
##ona O
to O
distinguish O
it O
from O
other O
g O
##6 O
##p O
##d O
variants O
previously O
described O
. O

possible O
mechanisms O
for O
the O
severe O
deficiency B-Disease
of I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
in O
er O
##yt O
##hr O
##ocytes O
and O
g O
##ran O
##ulo O
##cy O
##tes O
was O
investigated O
by O
studies O
on O
the O
im O
##mu O
##no O
##log O
##ic O
specific O
activity O
of O
the O
mutant O
enzyme O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
. O

the O
description O
of O
13 O
new O
variants O
. O

a O
total O
of O
36 O
##2 O
males O
from O
various O
regions O
of O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
were O
screened O
for O
red O
cell O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
activity O
. O

twenty O
- O
six O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
def I-Disease
##icient I-Disease
individuals O
were O
identified O
. O

bio O
##chemical O
characterization O
of O
g O
##6 O
##p O
##d O
pu O
##rified O
from O
these O
subjects O
has O
revealed O
13 O
new O
variants O
and O
several O
copies O
of O
previously O
described O
forms O
of O
g O
##6 O
##p O
##d O
. O

this O
study O
illustrate O
##s O
the O
extreme O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
among O
the O
people O
of O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
. O
. O

he O
##tero O
##gene O
##ity O
of O
" O
me O
##dit O
##er O
##rane O
##an O
type O
" O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
spa O
##in O
and O
description O
of O
two O
new O
variants O
associated O
with O
f B-Disease
##avi I-Disease
##sm I-Disease
. O

glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
; O
e O
##c O
1 O
. O

1 O
. O

1 O
. O

49 O
from O
thirty O
- O
six O
unrelated O
span O
##ish O
males O
was O
partially O
pu O
##rified O
from O
blood O
, O
and O
the O
variants O
were O
characterized O
bio O
##chemical O
##ly O
and O
electro O
##ph O
##ore O
##tically O
according O
to O
the O
methods O
recommended O
by O
the O
world O
health O
organization O
. O

subjects O
were O
from O
multiple O
geographic O
regions O
within O
spa O
##in O
, O
and O
all O
suffered O
from O
hem B-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
, O
either O
acute O
( O
34 O
cases O
) O
or O
chronic O
non O
##sp O
##her O
##oc O
##ytic O
( O
2 O
cases O
) O
. O

almost O
all O
the O
variants O
studied O
presented O
residual O
er O
##yt O
##hr O
##oc O
##yte O
g O
##6 O
##p O
##d O
activity O
ranging O
from O
0 O
to O
10 O
% O
of O
normal O
, O
and O
five O
different O
mutant O
##s O
were O
responsible O
for O
the O
def O
##icient O
p O
##hen O
##otype O
. O

three O
variants O
were O
similar O
to O
others O
previously O
described O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
( O
11 O
cases O
) O
, O
g O
##6 O
##p O
##d O
at O
##hen O
##s O
- O
like O
( O
3 O
cases O
) O
, O
and O
g O
##6 O
##p O
##d O
union O
( O
2 O
cases O
) O
. O

the O
remaining O
variants O
were O
different O
from O
the O
numerous O
variants O
already O
reported O
and O
have O
been O
considered O
as O
new O
mutant O
##s O
. O

provisional O
##ly O
they O
are O
called O
g O
##6 O
##p O
##d O
bet O
##ica O
( O
19 O
cases O
) O
and O
g O
##6 O
##p O
##d O
men O
##or O
##ca O
( O
1 O
case O
) O
. O

the O
present O
study O
constitutes O
the O
first O
attempt O
to O
character O
##ize O
the O
def B-Disease
##icient I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
variants O
found O
in O
spa O
##in O
and O
supplies O
new O
data O
on O
the O
relationship O
between O
molecular O
characteristics O
of O
def O
##icient O
variants O
and O
their O
clinical O
manifest O
##ations O
. O

the O
most O
important O
findings O
can O
be O
summarized O
as O
follows O
( O
1 O
) O
the O
span O
##ish O
population O
is O
characterized O
by O
an O
important O
he O
##tero O
##gene O
##ity O
in O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O

( O
2 O
) O
although O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
is O
very O
frequent O
, O
it O
presents O
a O
relatively O
high O
degree O
of O
p O
##oly O
##mor O
##phism O
. O

( O
3 O
) O
f B-Disease
##avi I-Disease
##sm I-Disease
has O
been O
observed O
associated O
with O
all O
kinds O
of O
variants O
described O
here O
. O

( O
4 O
) O
g O
##6 O
##p O
##d O
bet O
##ica O
, O
which O
is O
the O
most O
frequent O
variant O
found O
in O
subjects O
of O
southern O
span O
##ish O
origin O
, O
has O
been O
observed O
associated O
with O
f B-Disease
##avi I-Disease
##sm I-Disease
in O
all O
cases O
except O
one O
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variant O
( O
g O
##6 O
##p O
##d O
na O
##gano O
) O
associated O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
variant O
associated O
with O
chronic B-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
was O
reported O
. O

the O
patient O
, O
a O
6 O
- O
year O
- O
old O
j O
##apa O
##nese O
male O
, O
was O
noticed O
to O
have O
hem B-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
soon O
after O
birth O
, O
and O
a O
diagnosis O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
was O
made O
at O
the O
age O
of O
2 O
. O

he O
had O
episodes O
of O
hem B-Disease
##oly I-Disease
##tic I-Disease
crisis I-Disease
several O
times O
after O
upper B-Disease
respiratory I-Disease
infection I-Disease
. O

g O
##6 O
##p O
##d O
activity O
of O
the O
patient O
was O
5 O
. O

5 O
% O
of O
normal O
. O

the O
en O
##zy O
##matic O
characteristics O
were O
examined O
when O
he O
was O
5 O
years O
old O
, O
and O
his O
g O
##6 O
##p O
##d O
showed O
faster O
- O
than O
- O
normal O
electro O
##ph O
##ore O
##tic O
mobility O
, O
low O
km O
g O
##6 O
##p O
, O
high O
km O
na O
##d O
##p O
, O
low O
k O
##i O
na O
##d O
##ph O
, O
normal O
u O
##til O
##ization O
of O
substrate O
analogue O
##s O
, O
heat O
instability O
, O
and O
a O
normal O
p O
##h O
op O
##ti O
##mum O
curve O
. O

from O
these O
results O
, O
this O
was O
considered O
to O
be O
a O
new O
variant O
and O
was O
designated O
g O
##6 O
##p O
##d O
na O
##gano O
. O

infection O
- O
induced O
hem B-Disease
##oly I-Disease
##sis I-Disease
and O
chronic B-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
seem O
to O
be O
due O
to O
marked O
##ly O
impaired O
enzyme O
activity O
and O
thermal O
instability O
. O

he O
##tero O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
- I-Disease
deficiency I-Disease
and O
my B-Disease
##ast I-Disease
##hen I-Disease
##ia I-Disease
g I-Disease
##ra I-Disease
##vis I-Disease
. O

complement B-Disease
deficiency I-Disease
states O
in O
my B-Disease
##ast I-Disease
##hen I-Disease
##ia I-Disease
g I-Disease
##ra I-Disease
##vis I-Disease
( O
mg B-Disease
) O
have O
not O
been O
reported O
previously O
. O

we O
describe O
a O
19 O
- O
year O
- O
old O
woman O
with O
typical O
mg B-Disease
and O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##2 I-Disease
deficiency I-Disease
, O
along O
with O
h O
##la O
typing O
of O
the O
patient O
and O
her O
immediate O
family O
. O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
: O
increased O
plasma O
content O
of O
saturated O
very O
long O
chain O
fatty O
acids O
. O

with O
a O
new O
method O
we O
measured O
the O
saturated O
very O
long O
chain O
fatty O
acids O
in O
the O
plasma O
of O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
hem O
##iz O
##y O
##got O
##es O
, O
al B-Disease
##d I-Disease
he O
##tero O
##zy O
##got O
##es O
, O
and O
controls O
. O

al B-Disease
##d I-Disease
hem O
##iz O
##y O
##got O
##es O
showed O
increased O
levels O
of O
he O
##xa O
##cos O
##ano O
##ate O
( O
c O
##26 O
fatty O
acid O
) O
which O
represented O
0 O
. O

08 O
##1 O
+ O
/ O
- O
0 O
. O

00 O
##6 O
##6 O
% O
( O
se O
##m O
) O
of O
total O
fatty O
acids O
, O
compared O
to O
0 O
. O

01 O
##5 O
+ O
/ O
- O
0 O
. O

00 O
##32 O
% O
in O
the O
controls O
. O

c O
##25 O
, O
c O
##24 O
, O
and O
c O
##23 O
fatty O
acids O
were O
also O
increased O
, O
but O
the O
c O
##22 O
and O
c O
##20 O
fatty O
acids O
were O
normal O
. O

c O
##26 O
levels O
were O
also O
increased O
in O
most O
al B-Disease
##d I-Disease
he O
##tero O
##zy O
##got O
##es O
, O
with O
a O
mean O
level O
0 O
. O

05 O
##7 O
+ O
/ O
- O
0 O
. O

00 O
##6 O
##3 O
% O
of O
total O
fatty O
acids O
. O

the O
technique O
can O
be O
used O
for O
diagnosis O
and O
carrier O
identification O
, O
and O
in O
the O
evaluation O
of O
therapy O
. O

abnormal O
high O
density O
lip O
##op O
##rote O
##ins O
in O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
. O

the O
plasma O
lip O
##op O
##rote O
##in O
profiles O
and O
high O
density O
lip O
##op O
##rote O
##ins O
( O
h O
##dl O
) O
were O
characterized O
in O
patients O
with O
the O
genetic B-Disease
disease I-Disease
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
. O

abnormal B-Disease
##ities I-Disease
in I-Disease
the I-Disease
h I-Disease
##dl I-Disease
may O
contribute O
to O
their O
increased O
at O
##her O
##ogen O
##esis O
and O
excessive O
deposits O
of O
tissue O
s O
##tero O
##ls O
in O
the O
presence O
of O
low O
or O
low O
- O
normal O
concentrations O
of O
plasma O
ch O
##ole O
##ster O
##ol O
( O
165 O
+ O
/ O
- O
25 O
mg O
/ O
d O
##l O
) O
and O
low O
density O
lip O
##op O
##rote O
##ins O
( O
l O
##dl O
) O
. O

the O
mean O
h O
##dl O
- O
ch O
##ole O
##ster O
##ol O
concentration O
in O
the O
c B-Disease
##t I-Disease
##x I-Disease
plasma O
##s O
was O
14 O
. O

5 O
+ O
/ O
- O
3 O
. O

2 O
mg O
/ O
d O
##l O
, O
about O
one O
- O
third O
the O
normal O
value O
. O

the O
low O
h O
##dl O
- O
ch O
##ole O
##ster O
##ol O
reflects O
a O
low O
concentration O
and O
an O
abnormal O
lip O
##id O
composition O
of O
the O
plasma O
h O
##dl O
. O

relative O
to O
normal O
h O
##dl O
, O
the O
ch O
##ole O
##ster O
##yl O
est O
##ers O
are O
low O
, O
free O
ch O
##ole O
##ster O
##ol O
and O
p O
##hos O
##ph O
##oli O
##pid O
##s O
essentially O
normal O
, O
and O
t O
##rig O
##ly O
##cer O
##ides O
increased O
. O

the O
ratio O
of O
a O
##pop O
##rote O
##in O
( O
a O
##po O
) O
to O
total O
ch O
##ole O
##ster O
##ol O
in O
the O
h O
##dl O
of O
c B-Disease
##t I-Disease
##x I-Disease
was O
two O
to O
three O
times O
greater O
than O
normal O
. O

in O
the O
c B-Disease
##t I-Disease
##x I-Disease
h O
##dl O
, O
the O
ratio O
of O
a O
##po O
##ai O
to O
a O
##po O
##ai O
##i O
was O
high O
, O
the O
proportion O
of O
a O
##po O
##c O
low O
, O
and O
a O
normally O
minor O
form O
of O
a O
##po O
##ai O
increased O
relative O
to O
other O
forms O
. O

the O
h O
##dl O
in O
electron O
micro O
##graphs O
appeared O
normal O
m O
##or O
##phological O
##ly O
and O
in O
particle O
size O
. O

the O
abnormal O
##ities O
in O
lip O
##op O
##rote O
##in O
distribution O
profile O
and O
composition O
of O
the O
plasma O
h O
##dl O
result O
from O
metabolic O
defects O
that O
are O
not O
understood O
but O
may O
be O
linked O
to O
the O
genetic B-Disease
defect I-Disease
in O
bi O
##le O
acid O
synthesis O
in O
c B-Disease
##t I-Disease
##x I-Disease
. O

as O
a O
consequence O
, O
it O
is O
probable O
that O
the O
normal O
functions O
of O
the O
h O
##dl O
, O
possibly O
including O
m O
##od O
##ulation O
of O
l O
##dl O
- O
ch O
##ole O
##ster O
##ol O
up O
##take O
and O
the O
removal O
of O
excess O
ch O
##ole O
##ster O
##ol O
from O
peripheral O
tissues O
, O
are O
per O
##tur O
##bed O
significantly O
in O
this O
disease O
. O

genetics O
of O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
: O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
with O
high O
gene O
frequency O
in O
se O
##pha O
##rdi O
##m O
of O
m O
##oro O
##cca O
##n O
origin O
. O

we O
described O
6 O
patients O
( O
from O
3 O
families O
) O
affected O
with O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
. O

all O
are O
se O
##pha O
##rdi O
##c O
j O
##ews O
of O
m O
##oro O
##cca O
##n O
extraction O
. O

in O
view O
of O
the O
small O
number O
of O
c B-Disease
##t I-Disease
##x I-Disease
patients O
diagnosed O
in O
the O
world O
( O
a O
total O
of O
50 O
including O
our O
6 O
patients O
) O
, O
we O
are O
probably O
dealing O
with O
an O
ethnic O
subgroup O
with O
a O
high O
c O
##t O
##x O
gene O
frequency O
, O
which O
we O
have O
estimated O
to O
be O
1 O
/ O
108 O
. O

since O
there O
are O
differences O
in O
expression O
in O
this O
disease O
, O
we O
recommend O
ch O
##ole O
##stan O
##ol O
study O
in O
cases O
of O
und O
##ia O
##gno O
##sed O
cat B-Disease
##ara I-Disease
##ct I-Disease
or O
tend B-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##as I-Disease
in O
childhood O
or O
early O
ad O
##ole O
##scence O
. O

the O
diagnosis O
in O
c B-Disease
##t I-Disease
##x I-Disease
is O
important O
not O
only O
for O
genetic O
counseling O
, O
but O
also O
in O
ve O
##i O
##w O
of O
possible O
treatment O
. O
. O

new O
genetic O
variants O
of O
glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
in O
it O
##aly O
. O

six O
new O
variants O
of O
human O
er O
##yt O
##hr O
##oc O
##yte O
g O
##6 O
##p O
##d O
have O
been O
characterized O
. O

all O
of O
them O
were O
found O
in O
it O
##alia O
##n O
males O
and O
all O
were O
associated O
with O
enzyme B-Disease
deficiency I-Disease
, O
but O
only O
two O
with O
signs O
of O
ha B-Disease
##em I-Disease
##oly I-Disease
##sis I-Disease
. O

these O
and O
other O
variants O
reported O
in O
the O
literature O
, O
which O
must O
thus O
far O
be O
regarded O
as O
s O
##poradic O
, O
are O
found O
to O
map O
in O
parts O
of O
it O
##aly O
where O
common O
types O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
are O
also O
prevalent O
. O
. O

variants O
of O
er O
##yt O
##hr O
##oc O
##yte O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
( O
g O
##6 O
##p O
##d O
) O
in O
b O
##ul O
##gar O
##ian O
populations O
. O

ten O
variants O
of O
er O
##yt O
##hr O
##oc O
##yte O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
were O
identified O
in O
22 O
patients O
with O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
from O
three O
districts O
of O
b O
##ul O
##gar O
##ia O
. O

co O
##rin O
##th O
- O
like O
and O
f O
##ay O
##ou O
##m O
- O
like O
variants O
were O
the O
most O
frequent O
; O
me O
##dit O
##er O
##rane O
##an O
, O
oh O
##ut O
ii O
, O
k O
##il O
##gor O
##e O
, O
b O
##ost O
##on O
, O
p O
##oz O
##nan O
, O
and O
pan O
##ay O
variants O
and O
two O
new O
variants O
, O
pet O
##rich O
and O
got O
##ze O
del O
##chev O
, O
were O
each O
found O
in O
one O
or O
two O
carriers O
. O

no O
correlation O
was O
revealed O
between O
clinical O
and O
bio O
##chemical O
p O
##oly O
##mor O
##phism O
. O
. O

ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
in O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O

ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
was O
detected O
in O
five O
of O
32 O
patients O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
who O
were O
participating O
in O
a O
study O
of O
transfer O
factor O
( O
t O
##f O
) O
therapy O
. O

in O
two O
patients O
, O
ne B-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
was O
present O
before O
t O
##f O
and O
did O
not O
appear O
changed O
by O
t O
##f O
therapy O
. O

one O
of O
these O
patients O
subsequently O
developed O
progressive O
re B-Disease
##nal I-Disease
failure I-Disease
requiring O
dial O
##ys O
##is O
beginning O
5 O
1 O
/ O
2 O
years O
after O
t O
##f O
therapy O
. O

in O
two O
patients O
, O
decreased O
re O
##nal O
function O
appeared O
very O
soon O
after O
the O
administration O
of O
t O
##f O
. O

one O
patient O
showed O
gradually O
decreasing O
re O
##nal O
function O
beginning O
after O
two O
years O
of O
t O
##f O
therapy O
. O

an O
additional O
patient O
was O
identified O
who O
died O
with O
re B-Disease
##nal I-Disease
failure I-Disease
without O
having O
received O
t O
##f O
. O

the O
results O
suggest O
that O
re B-Disease
##nal I-Disease
failure I-Disease
occurs O
in O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
more O
frequently O
than O
generally O
recognized O
and O
that O
administration O
of O
t O
##f O
may O
pre O
##ci O
##pit O
##ate O
or O
accelerate O
the O
re B-Disease
##nal I-Disease
disease I-Disease
in O
patients O
with O
this O
syndrome O
. O
. O

w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
: O
cellular O
imp O
##air O
##ments O
and O
their O
imp O
##lication O
for O
carrier O
detection O
. O

a O
family O
in O
which O
two O
male O
siblings O
were O
affected O
with O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
was O
studied O
using O
g O
- O
6 O
- O
p O
##d O
is O
##oe O
##nz O
##yme O
##s O
as O
an O
x O
- O
linked O
marker O
in O
order O
to O
investigate O
the O
nature O
of O
cellular O
abnormal O
##ities O
. O

isolated O
peripheral O
blood O
cell O
types O
from O
the O
do O
##ub O
##ly O
he O
##tero O
##zy O
##go O
##us O
mother O
of O
the O
affected O
males O
seemingly O
failed O
to O
express O
the O
g O
- O
6 O
- O
p O
##d O
all O
##ele O
in O
c O
##is O
position O
with O
the O
was B-Disease
all O
##ele O
while O
her O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
expressed O
both O
g O
- O
6 O
- O
p O
##d O
all O
##ele O
##s O
. O

additionally O
, O
a O
his O
##to O
##gram O
analysis O
of O
plate O
##let O
size O
revealed O
a O
single O
population O
of O
abnormal O
##ly O
small O
plate O
##lets O
in O
the O
affected O
prop O
##os O
##it O
##us O
, O
whereas O
the O
he O
##tero O
##zy O
##go O
##us O
mother O
had O
no O
app O
##re O
##cia O
##ble O
small O
plate O
##let O
sub O
##pop O
##ulation O
. O

in O
v O
##it O
##ro O
culture O
of O
hem O
##op O
##oi O
##etic O
pro O
##gen O
##itor O
cells O
of O
the O
he O
##tero O
##zy O
##go O
##us O
mother O
showed O
that O
the O
majority O
of O
pro O
##gen O
##itor O
cells O
did O
not O
express O
the O
was B-Disease
all O
##ele O
. O

however O
, O
a O
small O
number O
of O
cells O
expressing O
the O
g O
- O
6 O
- O
p O
##d O
type O
linked O
with O
the O
was B-Disease
all O
##ele O
were O
detected O
. O

the O
proportion O
of O
the O
latter O
pro O
##gen O
##itors O
was O
significantly O
higher O
among O
more O
primitive O
pro O
##gen O
##itors O
( O
those O
giving O
rise O
to O
later O
appearing O
colonies O
) O
. O

this O
observation O
suggests O
that O
selection O
against O
cells O
expressing O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
defect I-Disease
takes O
place O
in O
the O
hem O
##op O
##oi O
##etic O
system O
of O
the O
he O
##tero O
##zy O
##go O
##us O
female O
and O
offers O
a O
possible O
means O
of O
carrier O
detection O
in O
some O
women O
. O

link O
##age O
studies O
in O
this O
family O
revealed O
one O
example O
of O
probable O
re O
##comb O
##ination O
between O
the O
lo O
##ci O
for O
was B-Disease
and O
g O
- O
6 O
- O
p O
##d O
among O
three O
inform O
##ative O
subjects O
, O
suggesting O
that O
these O
two O
lo O
##ci O
may O
not O
be O
closely O
linked O
on O
the O
x O
- O
chromosome O
. O
. O

a O
new O
c O
##t O
pattern O
in O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

a O
new O
c O
##t O
pattern O
was O
observed O
in O
2 O
patients O
with O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
. O

this O
pattern O
, O
which O
the O
authors O
call O
type O
ii O
, O
is O
characterized O
by O
the O
absence O
of O
posterior O
per O
##ive O
##nt O
##ric O
##ular O
areas O
of O
decreased O
at O
##ten O
##uation O
around O
the O
t O
##rig O
##one O
on O
non O
- O
contrast O
scan O
##s O
after O
contrast O
in O
##fusion O
, O
however O
, O
there O
is O
striking O
enhance O
##ment O
of O
various O
white O
- O
matter O
structures O
( O
tracts O
or O
fiber O
systems O
) O
such O
as O
the O
internal O
capsule O
##s O
, O
corpus O
call O
##os O
##um O
, O
co O
##rona O
r O
##adia O
##ta O
, O
force O
##ps O
major O
, O
and O
cerebral O
p O
##ed O
##un O
##cles O
. O

this O
is O
different O
from O
numerous O
previous O
descriptions O
of O
the O
c O
##t O
pattern O
in O
al B-Disease
##d I-Disease
. O

type B-Disease
ii I-Disease
al I-Disease
##d I-Disease
does O
not O
appear O
to O
have O
been O
seen O
in O
any O
other O
le B-Disease
##uk I-Disease
##oe I-Disease
##nce I-Disease
##pha I-Disease
##lop I-Disease
##athy I-Disease
and O
is O
probably O
specific O
for O
a O
p O
##hen O
##otypic O
variant O
or O
an O
evolving O
stage O
of O
al B-Disease
##d I-Disease
. O
. O

further O
evidence O
for O
he O
##tero O
##gene O
##ity O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
. O

four O
new O
g O
##6 O
##p O
##d O
variants O
have O
been O
characterized O
in O
individuals O
from O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
. O

this O
study O
demonstrates O
that O
the O
previously O
reported O
mark O
##ham O
variant O
and O
the O
newly O
characterized O
sa O
##lat O
##a O
variant O
may O
be O
widely O
distributed O
in O
p O
##ap O
##ua O
new O
g O
##uin O
##ea O
. O

th O
data O
presented O
here O
together O
with O
those O
of O
previously O
published O
studies O
demonstrate O
a O
degree O
of O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
that O
is O
much O
higher O
than O
that O
in O
other O
regions O
of O
the O
world O
where O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
common O
. O
. O

increased O
incidence O
of O
cat B-Disease
##ara I-Disease
##cts I-Disease
in O
male O
subjects O
def B-Disease
##icient I-Disease
in I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
r O
##b O
##cs O
was O
found O
significantly O
more O
frequently O
in O
210 O
male O
cat B-Disease
##ara I-Disease
##ct I-Disease
##ous I-Disease
patients O
than O
in O
67 O
##2 O
control O
subjects O
of O
sa O
##rdi O
##nian O
origin O
. O

the O
frequency O
of O
the O
deficiency O
was O
increasingly O
higher O
in O
pre O
##sen O
##ile O
cat B-Disease
##ara I-Disease
##cts I-Disease
. O

in O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
group O
, O
the O
incidence O
of O
co B-Disease
##rt I-Disease
##ical I-Disease
and I-Disease
total I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
was O
also O
increased O
. O

it O
is O
suggested O
that O
decrease O
of O
the O
g O
##6 O
##p O
##d O
activity O
in O
the O
lens O
, O
which O
a O
##cco O
##mp O
##ani O
##es O
its O
deficiency O
in O
the O
er O
##yt O
##hr O
##oc O
##yte O
, O
might O
play O
a O
role O
in O
the O
cat O
##ara O
##ct O
##o O
- O
genes O
##is O
of O
these O
patients O
. O

more O
##over O
, O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
should O
be O
added O
to O
other O
conditions O
, O
such O
as O
the O
gal B-Disease
##act I-Disease
##ose I-Disease
##mic I-Disease
states O
and O
rib B-Disease
##of I-Disease
##lav I-Disease
##in I-Disease
deficiency I-Disease
, O
where O
cat B-Disease
##ara I-Disease
##cts I-Disease
represent O
a O
sensitive O
indicator O
of O
metabolic B-Disease
abnormal I-Disease
##ities I-Disease
of O
the O
r O
##b O
##c O
. O
. O

molecular O
basis O
of O
human O
mitochondrial O
very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
causing O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
and O
sudden B-Disease
death I-Disease
in O
childhood O
. O

beta O
- O
oxidation O
of O
long O
- O
chain O
fatty O
acids O
provides O
the O
major O
source O
of O
energy O
in O
the O
heart O
. O

defects O
in O
enzymes O
of O
the O
beta O
- O
oxidation O
pathway O
cause O
sudden B-Disease
, I-Disease
une I-Disease
##x I-Disease
##plain I-Disease
##ed I-Disease
death I-Disease
in O
childhood O
, O
acute O
he B-Disease
##pa I-Disease
##tic I-Disease
en I-Disease
##ce I-Disease
##pha I-Disease
##lop I-Disease
##athy I-Disease
or O
liver B-Disease
failure I-Disease
, O
skeletal B-Disease
my I-Disease
##op I-Disease
##athy I-Disease
, O
and O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
. O

very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
[ O
v O
##l O
##ca O
##d O
; O
very O
- O
long O
- O
chain O
- O
a O
##cy O
##l O
- O
co O
##a O
( O
accept O
##or O
) O
2 O
, O
3 O
- O
o O
##xi O
##dor O
##ed O
##uc O
##tase O
, O
e O
##c O
1 O
. O
3 O
3 O
. O
99 O
99 O
. O
13 O
] O
cat O
##aly O
##zes O
the O
first O
step O
in O
beta O
- O
oxidation O
. O

we O
have O
isolated O
the O
human O
v O
##l O
##ca O
##d O
c O
##dn O
##a O
and O
gene O
and O
determined O
the O
complete O
n O
##uc O
##leo O
##tide O
sequences O
. O

polymer O
##ase O
chain O
reaction O
am O
##p O
##lification O
of O
v O
##l O
##ca O
##d O
m O
##rna O
and O
g O
##eno O
##mic O
ex O
##ons O
defined O
the O
molecular O
defects O
in O
two O
patients O
with O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
who O
presented O
with O
une O
##x O
##plain O
##ed O
cardiac B-Disease
arrest I-Disease
and O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
. O

in O
one O
, O
a O
ho O
##mo O
##zy O
##go O
##us O
mutation O
in O
the O
consensus O
din O
##uc O
##leo O
##tide O
of O
the O
donor O
s O
##p O
##lice O
site O
( O
g O
+ O
1 O
- O
- O
[UNK] O
a O
) O
was O
associated O
with O
universal O
skip O
##ping O
of O
the O
prior O
ex O
##on O
( O
ex O
##on O
11 O
) O
. O

the O
second O
patient O
was O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
, O
with O
a O
miss O
##ense O
mutation O
, O
c O
##18 O
##37 O
- O
- O
[UNK] O
t O
, O
changing O
the O
a O
##rg O
##ini O
##ne O
at O
residue O
61 O
##3 O
to O
try O
##pt O
##op O
##han O
on O
one O
all O
##ele O
and O
a O
single O
base O
del O
##eti O
##on O
at O
the O
intro O
##n O
- O
ex O
##on O
6 O
boundary O
as O
the O
second O
mutation O
. O

this O
initial O
del O
##ine O
##ation O
of O
human O
mutations O
in O
v O
##l O
##ca O
##d O
suggests O
that O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
reduces O
my O
##oc O
##ard O
##ial O
fatty O
acid O
beta O
- O
oxidation O
and O
energy O
production O
and O
is O
associated O
with O
card B-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
and O
sudden B-Disease
death I-Disease
in O
childhood O
. O

a O
##ber O
##rant O
sub O
##cellular O
local O
##ization O
of O
br O
##ca O
##1 O
in O
breast B-Disease
cancer I-Disease
. O

the O
br O
##ca O
##1 O
gene O
product O
was O
identified O
as O
a O
220 O
- O
k O
##ilo O
##dal O
##ton O
nuclear O
p O
##hos O
##ph O
##op O
##rote O
##in O
in O
normal O
cells O
, O
including O
breast O
duct O
##al O
e O
##pit O
##hel O
##ial O
cells O
, O
and O
in O
18 O
of O
20 O
tumor B-Disease
cell O
lines O
derived O
from O
tissues O
other O
than O
breast O
and O
o O
##vary O
. O

in O
16 O
of O
17 O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
lines O
and O
17 O
of O
17 O
samples O
of O
cells O
obtained O
from O
ma O
##li O
##gnant O
e O
##ff O
##usions O
, O
however O
, O
br O
##ca O
##1 O
localized O
mainly O
in O
c O
##yt O
##op O
##las O
##m O
. O

absence O
of O
br O
##ca O
##1 O
or O
a O
##ber O
##rant O
sub O
##cellular O
location O
was O
also O
observed O
to O
a O
variable O
extent O
in O
his O
##to O
##logical O
sections O
of O
many O
breast B-Disease
cancer I-Disease
bio O
##ps O
##ies O
. O

these O
findings O
suggest O
that O
br B-Disease
##ca I-Disease
##1 I-Disease
abnormal I-Disease
##ities I-Disease
may O
be O
involved O
in O
the O
path O
##ogen O
##esis O
of O
many O
breast B-Disease
cancer I-Disease
##s I-Disease
, O
s O
##poradic O
as O
well O
as O
f O
##ami O
##lial O
. O
. O

mapping O
of O
the O
mouse O
ho O
##mo O
##logue O
of O
the O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
gene O
to O
mouse O
chromosome O
8 O
. O

at O
##p O
##7 O
##b O
, O
the O
gene O
altered O
in O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
( O
w B-Disease
##d I-Disease
) O
patients O
, O
lies O
in O
a O
block O
of O
ho O
##mology O
shared O
between O
human O
chromosome O
13 O
##q O
##14 O
and O
the O
central O
region O
of O
mouse O
chromosome O
14 O
. O

however O
, O
we O
have O
mapped O
the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
of O
at O
##p O
##7 O
##b O
( O
at O
##p O
##7 O
##b O
) O
to O
mouse O
chromosome O
8 O
by O
so O
##matic O
cell O
hybrid O
analysis O
. O

analysis O
of O
80 O
inter O
##sp O
##ec O
##ific O
back O
##cross O
offspring O
was O
used O
to O
position O
at O
##p O
##7 O
##b O
close O
to O
d O
##8 O
##mit O
##3 O
and O
another O
at O
##pas O
##e O
lo O
##cus O
, O
at O
##p O
##4 O
##b O
, O
on O
mouse O
chromosome O
8 O
. O

at O
##p O
##4 O
##b O
lies O
in O
13 O
##q O
##34 O
and O
is O
separated O
from O
at O
##p O
##7 O
##b O
by O
several O
lo O
##ci O
whose O
mouse O
ho O
##mo O
##logue O
##s O
map O
to O
mouse O
chromosome O
14 O
. O

the O
assignment O
of O
at O
##p O
##7 O
##b O
to O
mouse O
chromosome O
8 O
identifies O
a O
previously O
un O
##re O
##co O
##gni O
##zed O
region O
of O
ho O
##mology O
between O
this O
chromosome O
and O
human O
chromosome O
13 O
. O

this O
assignment O
suggests O
a O
possible O
location O
for O
the O
toxic O
milk O
mutation O
in O
the O
mouse O
, O
which O
has O
been O
proposed O
as O
a O
ho O
##mo O
##logue O
of O
w B-Disease
##d I-Disease
. O
. O

g O
##er O
##m O
##line O
mutations O
of O
the O
br O
##ca O
##1 O
gene O
in O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
provide O
evidence O
for O
a O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
. O

mutations O
in O
the O
br O
##ca O
##1 O
gene O
, O
discovered O
in O
1994 O
, O
are O
associated O
with O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
. O

we O
have O
anal O
##ys O
##ed O
60 O
families O
with O
a O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
for O
g O
##er O
##m O
##line O
mutations O
in O
br O
##ca O
##1 O
. O

twenty O
- O
two O
different O
mutations O
were O
detected O
in O
32 O
families O
( O
53 O
% O
) O
, O
of O
which O
14 O
are O
previously O
un O
##re O
##port O
##ed O
. O

we O
observed O
a O
significant O
correlation O
between O
the O
location O
of O
the O
mutation O
in O
the O
gene O
and O
the O
ratio O
of O
breast B-Disease
to I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
incidence O
within O
each O
family O
. O

our O
data O
suggest O
a O
transition O
in O
risk O
such O
that O
mutations O
in O
the O
3 O
third O
of O
the O
gene O
are O
associated O
with O
a O
lower O
proportion O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

ha O
##p O
##lot O
##ype O
analysis O
supports O
previous O
data O
which O
suggest O
some O
br O
##ca O
##1 O
mutation O
carriers O
have O
common O
ancestors O
; O
however O
, O
we O
have O
found O
at O
least O
two O
examples O
where O
re O
##current O
mutations O
appear O
to O
have O
arise O
##n O
independently O
. O
. O

hereditary O
deficiency B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
and O
re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
infection I-Disease
: O
investigations O
of O
an O
i O
##ris O
##h O
family O
using O
a O
novel O
ha O
##em O
##oly O
##tic O
screening O
ass O
##ay O
for O
complement O
activity O
and O
c O
##7 O
m O
/ O
n O
all O
##ot O
##y O
##ping O
. O

terminal B-Disease
complement I-Disease
component I-Disease
deficiency I-Disease
pre O
##dis O
##pose O
##s O
to O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
infection I-Disease
and O
is O
inherited O
in O
an O
auto O
##so O
##mal O
co O
- O
dominant O
manner O
. O

an O
i O
##ris O
##h O
family O
is O
described O
, O
in O
which O
2 O
of O
3 O
brothers O
had O
re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
infection I-Disease
. O

a O
novel O
screening O
ass O
##ay O
was O
used O
to O
investigate O
for O
terminal B-Disease
complement I-Disease
deficiency I-Disease
and O
the O
2 O
affected O
brothers O
were O
found O
to O
be O
completely B-Disease
def I-Disease
##icient I-Disease
in I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##7 O
) O
. O

enzyme O
- O
linked O
im O
##mu O
##nos O
##or O
##bent O
ass O
##ay O
for O
c O
##7 O
revealed O
lower O
than O
normal O
levels O
in O
the O
remaining O
brother O
and O
parents O
. O

c O
##7 O
m O
/ O
n O
protein O
p O
##oly O
##mor O
##phism O
all O
##ot O
##y O
##ping O
, O
used O
to O
investigate O
the O
segregation O
of O
the O
c B-Disease
##7 I-Disease
deficiency I-Disease
genes O
, O
showed O
that O
the O
apparently O
complement O
sufficient O
brother O
was O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##7 I-Disease
def I-Disease
##icient I-Disease
and O
a O
carrier O
of O
one O
of O
the O
deficiency O
genes O
. O

complement O
screening O
should O
be O
carried O
out O
in O
any O
individual O
suffering O
re O
##current O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
infection I-Disease
or O
infection O
with O
an O
uncommon O
men B-Disease
##ing I-Disease
##oc I-Disease
##oc I-Disease
##cal I-Disease
se O
##rog O
##roup O
. O

identification O
of O
complement B-Disease
def I-Disease
##icient I-Disease
patients O
allows O
the O
implementation O
of O
strategies O
to O
prevent O
re O
##current O
infection O
. O
. O

molecular O
basis O
of O
sub B-Disease
##to I-Disease
##tal I-Disease
complement I-Disease
c I-Disease
##6 I-Disease
deficiency I-Disease
. O

a O
car O
##box O
##y O
- O
terminal O
##ly O
t O
##runcated O
but O
functional O
##ly O
active O
c O
##6 O
. O

individuals O
with O
sub B-Disease
##to I-Disease
##tal I-Disease
complement I-Disease
c I-Disease
##6 I-Disease
deficiency I-Disease
possess O
a O
c O
##6 O
molecule O
that O
is O
14 O
% O
shorter O
than O
normal O
c O
##6 O
and O
present O
in O
low O
but O
detect O
##able O
concentrations O
( O
1 O
- O
2 O
% O
of O
the O
normal O
mean O
) O
. O

we O
now O
show O
that O
this O
d O
##ys O
##morphic O
c O
##6 O
is O
b O
##act O
##eric O
##idal O
##ly O
active O
and O
lacks O
an O
e O
##pit O
##ope O
that O
was O
mapped O
to O
the O
most O
car O
##box O
##y O
- O
terminal O
part O
of O
c O
##6 O
using O
c O
##6 O
c O
##dn O
##a O
fragments O
expressed O
as O
fusion O
proteins O
in O
the O
pu O
##ex O
expression O
system O
. O

we O
thus O
predicted O
that O
the O
abnormal O
c O
##6 O
molecule O
might O
be O
car O
##box O
##y O
- O
terminal O
##ly O
t O
##runcated O
and O
sought O
a O
mutation O
in O
an O
area O
approximately O
14 O
% O
from O
the O
car O
##box O
##y O
- O
terminal O
end O
of O
the O
coding O
sequence O
. O

by O
se O
##quencing O
p O
##c O
##r O
- O
am O
##plified O
products O
from O
this O
region O
, O
we O
found O
, O
in O
three O
individuals O
from O
two O
families O
, O
a O
mutation O
that O
might O
p O
##laus O
##ibly O
be O
responsible O
for O
the O
defect O
. O

all O
three O
have O
an O
abnormal O
5 O
s O
##p O
##lice O
donor O
site O
of O
intro O
##n O
15 O
, O
which O
would O
probably O
prevent O
s O
##p O
##licing O
. O

an O
in O
- O
frame O
stop O
co O
##don O
is O
found O
17 O
co O
##don O
##s O
downstream O
from O
the O
intro O
##n O
boundary O
, O
which O
would O
lead O
to O
a O
t O
##runcated O
p O
##oly O
##pe O
##pt O
##ide O
13 O
. O

5 O
% O
smaller O
than O
normal O
c O
##6 O
. O

this O
result O
was O
unexpected O
, O
as O
earlier O
studies O
mapped O
the O
c O
##5 O
##b O
binding O
site O
, O
or O
a O
put O
##ative O
en O
##zy O
##matic O
region O
, O
to O
this O
part O
of O
c O
##6 O
. O

interesting O
##ly O
, O
all O
three O
subjects O
were O
probably O
he O
##tero O
##zy O
##go O
##us O
for O
both O
sub B-Disease
##to I-Disease
##tal I-Disease
c I-Disease
##6 I-Disease
and I-Disease
complete I-Disease
c I-Disease
##6 I-Disease
deficiency I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
: O
evidence O
for O
a O
possible O
dominant O
- O
negative O
r O
##na O
mutation O
. O

the O
t O
##rin O
##uc O
##leo O
##tide O
expansion O
mutation O
causing O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
is O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
a O
protein O
kinase O
gene O
. O

the O
molecular O
mechanisms O
by O
which O
the O
expanded O
repeat O
causes O
the O
clinical O
##ly O
variable O
and O
multi B-Disease
##sy I-Disease
##ste I-Disease
##mic I-Disease
disease I-Disease
, O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
are O
not O
understood O
. O

it O
has O
been O
particularly O
difficult O
to O
rational O
##ize O
the O
dominant O
inheritance O
with O
the O
fact O
that O
the O
expansion O
mutation O
lies O
outside O
of O
the O
protein O
- O
encoding O
gene O
elements O
, O
and O
should O
not O
be O
translated O
into O
protein O
. O

here O
we O
use O
muscle O
bio O
##ps O
##ies O
from O
classical O
adult O
- O
onset O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
patients O
to O
study O
the O
accumulation O
of O
trans O
##cripts O
from O
both O
the O
normal O
and O
expanded O
d B-Disease
##m I-Disease
kinase O
genes O
in O
patient O
muscle O
, O
and O
compare O
the O
results O
to O
normal O
and O
my B-Disease
##op I-Disease
##ath I-Disease
##ic I-Disease
controls O
. O

we O
found O
relatively O
small O
decreases O
of O
d B-Disease
##m I-Disease
kinase O
r O
##na O
in O
the O
total O
r O
##na O
pool O
from O
muscle O
; O
however O
, O
these O
reduction O
##s O
were O
not O
disease O
specific O
. O

analysis O
of O
p O
##oly O
( O
a O
) O
+ O
r O
##na O
showed O
dramatic O
decreases O
of O
both O
the O
mutant O
and O
normal O
d B-Disease
##m I-Disease
kinase O
r O
##nas O
, O
and O
these O
changes O
were O
disease O
- O
specific O
. O

our O
findings O
are O
consistent O
with O
a O
novel O
molecular O
path O
##ogen O
##etic O
mechanism O
for O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
both O
the O
normal O
and O
expanded O
d B-Disease
##m I-Disease
kinase O
genes O
are O
trans O
##cribed O
in O
patient O
muscle O
, O
but O
the O
abnormal O
expansion O
- O
containing O
r O
##na O
has O
a O
dominant O
effect O
on O
r O
##na O
metabolism O
by O
preventing O
the O
accumulation O
of O
p O
##oly O
( O
a O
) O
+ O
r O
##na O
. O

the O
ability O
of O
the O
expansion O
mutation O
to O
alter O
accumulation O
of O
p O
##oly O
( O
a O
) O
+ O
r O
##na O
in O
trans O
suggests O
that O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
may O
be O
the O
first O
example O
of O
a O
dominant O
- O
negative O
mutation O
manifest O
##ed O
at O
the O
r O
##na O
level O
. O
. O

a O
strong O
candidate O
for O
the O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
br O
##ca O
##1 O
. O

a O
strong O
candidate O
for O
the O
17 O
##q O
- O
linked O
br O
##ca O
##1 O
gene O
, O
which O
influences O
su O
##s O
##ce O
##pt O
##ibility O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
has O
been O
identified O
by O
position O
##al O
c O
##lon O
##ing O
methods O
. O

probable O
pre O
##dis O
##po O
##sing O
mutations O
have O
been O
detected O
in O
five O
of O
eight O
kind O
##red O
##s O
presumed O
to O
se O
##g O
##re O
##gate O
br O
##ca O
##1 O
su O
##s O
##ce O
##pt O
##ibility O
all O
##ele O
##s O
. O

the O
mutations O
include O
an O
11 O
- O
base O
pair O
del O
##eti O
##on O
, O
a O
1 O
- O
base O
pair O
insertion O
, O
a O
stop O
co O
##don O
, O
a O
miss O
##ense O
substitution O
, O
and O
an O
in O
##ferred O
regulatory O
mutation O
. O

the O
br O
##ca O
##1 O
gene O
is O
expressed O
in O
numerous O
tissues O
, O
including O
breast O
and O
o O
##vary O
, O
and O
en O
##codes O
a O
predicted O
protein O
of O
1863 O
amino O
acids O
. O

this O
protein O
contains O
a O
zinc O
finger O
domain O
in O
its O
amino O
- O
terminal O
region O
, O
but O
is O
otherwise O
unrelated O
to O
previously O
described O
proteins O
. O

identification O
of O
br O
##ca O
##1 O
should O
facilitate O
early O
diagnosis O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
in O
some O
individuals O
as O
well O
as O
a O
better O
understanding O
of O
breast B-Disease
cancer I-Disease
biology O
. O
. O

molecular O
characterization O
of O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
( O
type O
1 O
) O
mutations O
in O
j O
##apa O
##nese O
. O

we O
characterized O
two O
novel O
mutations O
of O
the O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
gal O
##t O
) O
gene O
in O
two O
j O
##apa O
##nese O
patients O
with O
gal B-Disease
##t I-Disease
deficiency I-Disease
and O
identified O
n O
##31 O
##4 O
##d O
and O
r O
##33 O
##3 O
##w O
mutations O
, O
previously O
found O
in O
ca O
##uca O
##sian O
##s O
. O

one O
novel O
miss O
##ense O
mutation O
was O
an O
g O
- O
to O
- O
a O
transition O
in O
ex O
##on O
8 O
, O
resulting O
in O
the O
substitution O
of O
a O
##rg O
##ini O
##ne O
by O
his O
##ti O
##dine O
at O
the O
co O
##don O
231 O
( O
r O
##23 O
##1 O
##h O
) O
. O

gal O
##t O
activity O
of O
the O
r O
##23 O
##1 O
##h O
mutant O
construct O
was O
reduced O
to O
15 O
% O
of O
normal O
controls O
in O
a O
co O
##s O
cell O
expression O
system O
. O

the O
other O
was O
a O
s O
##p O
##licing O
mutation O
, O
an O
a O
- O
to O
- O
g O
transition O
at O
the O
38th O
n O
##uc O
##leo O
##tide O
in O
ex O
##on O
3 O
( O
31 O
##8 O
##a O
- O
- O
[UNK] O
g O
) O
, O
resulting O
in O
a O
38 O
- O
b O
##p O
del O
##eti O
##on O
in O
the O
gal O
##t O
c O
##dn O
##a O
by O
act O
##ivating O
a O
cry O
##ptic O
s O
##p O
##lice O
accept O
##or O
site O
. O

in O
seven O
j O
##apa O
##nese O
families O
( O
14 O
all O
##ele O
##s O
for O
classic O
form O
and O
one O
all O
##ele O
for O
du O
##arte O
variant O
) O
with O
gal B-Disease
##t I-Disease
deficiency I-Disease
, O
the O
r O
##23 O
##1 O
##h O
and O
31 O
##8 O
##a O
- O
- O
[UNK] O
g O
mutations O
were O
found O
only O
on O
both O
all O
##ele O
##s O
of O
the O
pro O
##band O
. O

the O
n O
##31 O
##4 O
##d O
and O
r O
##33 O
##3 O
##w O
mutations O
were O
found O
on O
one O
all O
##ele O
each O
. O

the O
q O
##18 O
##8 O
##r O
was O
prevalent O
in O
the O
united O
states O
but O
not O
in O
j O
##apa O
##nese O
patients O
. O

the O
n O
##31 O
##4 O
##d O
mutation O
was O
associated O
with O
the O
du O
##arte O
variant O
in O
j O
##apa O
##nese O
persons O
, O
as O
well O
as O
in O
the O
united O
states O
. O

we O
s O
##pec O
##ulate O
that O
classic B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
appear O
to O
differ O
between O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
patients O
. O

our O
limited O
data O
set O
on O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
in O
j O
##apa O
##nese O
suggests O
that O
the O
n O
##31 O
##4 O
##d O
gal O
##t O
mutation O
encoding O
the O
du O
##arte O
variant O
arose O
before O
as O
##ian O
and O
ca O
##uca O
##sian O
people O
diver O
##ged O
and O
that O
classic B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
arose O
and O
/ O
or O
accumulated O
after O
the O
diver O
##gence O
of O
as O
##ian O
and O
ca O
##uca O
##sian O
populations O
. O
. O

three O
novel O
an B-Disease
##iri I-Disease
##dia I-Disease
mutations O
in O
the O
human O
p O
##ax O
##6 O
gene O
. O

an B-Disease
##iri I-Disease
##dia I-Disease
( O
i B-Disease
##ris I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
con I-Disease
##gen I-Disease
##ital I-Disease
disorder I-Disease
of I-Disease
the I-Disease
eye I-Disease
. O

mutations O
in O
the O
human O
an B-Disease
##iri I-Disease
##dia I-Disease
( O
p O
##ax O
##6 O
) O
gene O
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

in O
the O
study O
reported O
here O
we O
describe O
p O
##ax O
##6 O
mutations O
in O
one O
s O
##poradic O
and O
five O
f O
##ami O
##lial O
cases O
with O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

of O
the O
four O
different O
mutations O
identified O
, O
one O
was O
identical O
to O
a O
previously O
reported O
mutation O
( O
c O
- O
- O
[UNK] O
t O
transition O
at O
co O
##don O
240 O
) O
, O
and O
three O
were O
novel O
two O
in O
the O
g O
##ly O
##cine O
- O
rich O
region O
and O
one O
in O
the O
pro O
##line O
/ O
se O
##rine O
/ O
th O
##re O
##oni O
##ne O
- O
rich O
( O
ps O
##t O
) O
region O
. O

one O
p O
##ax O
##6 O
mutation O
found O
in O
the O
ps O
##t O
region O
was O
associated O
with O
cat B-Disease
##ara I-Disease
##cts I-Disease
in O
an O
an B-Disease
##iri I-Disease
##dia I-Disease
family O
. O

another O
s O
##p O
##lice O
mutation O
in O
the O
ps O
##t O
domain O
occurred O
in O
an O
an B-Disease
##iri I-Disease
##dia I-Disease
patient O
with O
an B-Disease
##os I-Disease
##mia I-Disease
( O
inability O
to O
smell O
) O
. O

the O
six O
new O
an B-Disease
##iri I-Disease
##dia I-Disease
cases O
reported O
here O
have O
mutations O
predicted O
to O
generate O
incomplete O
p O
##ax O
##6 O
proteins O
. O

these O
results O
support O
the O
theory O
that O
human O
an B-Disease
##iri I-Disease
##dia I-Disease
is O
caused O
by O
ha B-Disease
##p I-Disease
##lo I-Disease
##ins I-Disease
##uff I-Disease
##iciency I-Disease
of I-Disease
p I-Disease
##ax I-Disease
##6 I-Disease
. O
. O

the O
carrier O
frequency O
of O
the O
br O
##ca O
##1 O
185 O
##dela O
##g O
mutation O
is O
approximately O
1 O
percent O
in O
ash O
##ken O
##azi O
j O
##ew O
##ish O
individuals O
. O

since O
br O
##ca O
##1 O
, O
the O
first O
major O
gene O
responsible O
for O
inherited B-Disease
breast I-Disease
cancer I-Disease
, O
was O
clone O
##d O
, O
more O
than O
50 O
unique O
mutations O
have O
been O
detected O
in O
the O
g O
##er O
##m O
##line O
of O
individuals O
with O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

in O
high O
- O
risk O
p O
##ed O
##ig O
##ree O
##s O
, O
female O
carriers O
of O
br O
##ca O
##1 O
mutations O
have O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
, O
and O
a O
40 O
- O
50 O
% O
risk O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

however O
, O
the O
mutation O
s O
##tat O
##s O
of O
individuals O
un O
##sel O
##ec O
##ted O
for O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
has O
not O
been O
determined O
, O
and O
it O
is O
not O
known O
whether O
mutations O
in O
such O
individuals O
con O
##fer O
the O
same O
risk O
of O
cancer B-Disease
as O
in O
individuals O
from O
the O
high O
- O
risk O
families O
studied O
so O
far O
. O

following O
the O
finding O
of O
a O
185 O
##dela O
##g O
frames O
##hi O
##ft O
mutation O
in O
several O
ash O
##ken O
##azi O
j O
##ew O
##ish O
breast O
/ O
o O
##var O
##ian O
families O
, O
we O
have O
determined O
the O
frequency O
of O
this O
mutation O
in O
85 O
##8 O
ash O
##ken O
##azi O
##m O
seeking O
genetic O
testing O
for O
conditions O
unrelated O
to O
cancer B-Disease
, O
and O
in O
81 O
##5 O
reference O
individuals O
not O
selected O
for O
ethnic O
origin O
. O

we O
observed O
the O
185 O
##dela O
##g O
mutation O
in O
0 O
. O

9 O
% O
of O
ash O
##ken O
##azi O
##m O
( O
95 O
% O
confidence O
limit O
, O
0 O
. O
4 O
- O
1 O
. O
8 O
% O
) O
and O
in O
none O
of O
the O
reference O
samples O
. O

our O
results O
suggest O
that O
one O
in O
a O
hundred O
women O
of O
ash O
##ken O
##azi O
descent O
may O
be O
at O
especially O
high O
risk O
of O
developing O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

identification O
and O
local O
##ization O
of O
hunting O
##tin O
in O
brain O
and O
human O
l O
##ymph O
##ob O
##last O
##oid O
cell O
lines O
with O
anti O
- O
fusion O
protein O
antibodies O
. O

the O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
p O
##hen O
##otype O
is O
associated O
with O
expansion O
of O
a O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
the O
it O
##15 O
gene O
, O
which O
is O
predicted O
to O
en O
##code O
a O
34 O
##8 O
- O
k O
##da O
protein O
named O
hunting O
##ton O
. O

we O
used O
p O
##oly O
##c O
##lon O
##al O
and O
mon O
##oc O
##lon O
##al O
anti O
- O
fusion O
protein O
antibodies O
to O
identify O
native O
hunting O
##tin O
in O
rat O
, O
monkey O
, O
and O
human O
. O

western O
b O
##lot O
##s O
revealed O
a O
protein O
with O
the O
expected O
molecular O
weight O
which O
is O
present O
in O
the O
soluble O
fraction O
of O
rat O
and O
monkey O
brain O
tissues O
and O
l O
##ymph O
##ob O
##last O
##oid O
cells O
from O
control O
cases O
. O

in O
l O
##ymph O
##ob O
##last O
##oid O
cell O
lines O
from O
juvenile O
- O
onset O
he O
##tero O
##zy O
##got O
##e O
h B-Disease
##d I-Disease
cases O
, O
both O
normal O
and O
mutant O
hunting O
##tin O
are O
expressed O
, O
and O
increasing O
repeat O
expansion O
leads O
to O
lower O
levels O
of O
the O
mutant O
protein O
. O

im O
##mu O
##no O
##cy O
##to O
##chemistry O
indicates O
that O
hunting O
##tin O
is O
located O
in O
neurons O
throughout O
the O
brain O
, O
with O
the O
highest O
levels O
evident O
in O
larger O
neurons O
. O

in O
the O
human O
s O
##tri O
##at O
##um O
, O
hunting O
##tin O
is O
en O
##rich O
##ed O
in O
a O
patch O
- O
like O
distribution O
, O
potentially O
corresponding O
to O
the O
first O
areas O
affected O
in O
h B-Disease
##d I-Disease
. O

sub O
##cellular O
local O
##ization O
of O
hunting O
##tin O
is O
consistent O
with O
a O
c O
##yt O
##oso O
##lic O
protein O
primarily O
found O
in O
so O
##mat O
##ode O
##nd O
##ritic O
regions O
. O

hunting O
##tin O
appears O
to O
particularly O
associate O
with O
micro O
##tub O
##ules O
, O
although O
some O
is O
also O
associated O
with O
s O
##yna O
##ptic O
ve O
##si O
##cles O
. O

on O
the O
basis O
of O
the O
local O
##ization O
of O
hunting O
##tin O
in O
association O
with O
micro O
##tub O
##ules O
, O
we O
s O
##pec O
##ulate O
that O
the O
mutation O
imp O
##air O
##s O
the O
c O
##yt O
##os O
##kel O
##etal O
anchor O
##ing O
or O
transport O
of O
mit O
##och O
##ond O
##ria O
, O
ve O
##si O
##cles O
, O
or O
other O
organ O
##elles O
or O
molecules O
. O
. O

marked O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
associated O
with O
expansion O
of O
a O
ca O
##g O
repeat O
sequence O
at O
the O
spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
3 I-Disease
/ I-Disease
mac I-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
lo O
##cus O
. O

the O
spin B-Disease
##oc I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
3 I-Disease
lo O
##cus O
( O
s B-Disease
##ca I-Disease
##3 I-Disease
) O
for O
type B-Disease
i I-Disease
auto I-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
ad B-Disease
##ca I-Disease
type I-Disease
i I-Disease
) O
, O
a O
clinical O
##ly O
and O
genetically O
he O
##tero O
##gene O
##ous O
group O
of O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disorders I-Disease
, O
has O
been O
mapped O
to O
chromosome O
14 O
##q O
##32 O
. O

1 O
1 O
. O

ad B-Disease
##ca I-Disease
type I-Disease
i I-Disease
patients O
from O
families O
se O
##g O
##re O
##gating O
s B-Disease
##ca I-Disease
##3 I-Disease
share O
clinical O
features O
in O
common O
with O
those O
with O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
, O
the O
gene O
of O
which O
maps O
to O
the O
same O
region O
. O

we O
show O
here O
that O
the O
disease O
gene O
se O
##g O
##re O
##gating O
in O
each O
of O
three O
f O
##rench O
ad B-Disease
##ca I-Disease
type I-Disease
i I-Disease
kind O
##red O
##s O
and O
in O
a O
f O
##rench O
family O
with O
ne O
##uro O
##path O
##ological O
findings O
suggesting O
the O
at O
##ax O
##och O
##ore O
##ic O
form O
of O
den B-Disease
##tat I-Disease
##or I-Disease
##ub I-Disease
##rop I-Disease
##all I-Disease
##ido I-Disease
##lu I-Disease
##ys I-Disease
##ian I-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
carries O
an O
expanded O
ca O
##g O
repeat O
sequence O
located O
at O
the O
same O
lo O
##cus O
as O
that O
for O
m B-Disease
##j I-Disease
##d I-Disease
. O

analysis O
of O
the O
mutation O
in O
these O
families O
shows O
a O
strong O
negative O
correlation O
between O
size O
of O
the O
expanded O
ca O
##g O
repeat O
and O
age O
at O
onset O
of O
clinical O
disease O
. O

instability O
of O
the O
expanded O
triple O
##t O
repeat O
was O
not O
found O
to O
be O
affected O
by O
sex O
of O
the O
parent O
transmitting O
the O
mutation O
. O

evidence O
was O
found O
for O
so O
##matic O
and O
go O
##na O
##dal O
mosaic O
##ism O
for O
all O
##ele O
##s O
carrying O
expanded O
t O
##rin O
##uc O
##leo O
##tide O
repeats O
. O

over O
##ex O
##press O
##ion O
of O
d O
##m O
##20 O
messenger O
r O
##na O
in O
two O
brothers O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
is O
a O
rare B-Disease
, I-Disease
sex I-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
, I-Disease
d I-Disease
##ys I-Disease
##my I-Disease
##elin I-Disease
##ating I-Disease
disease I-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
that O
has O
been O
associated O
with O
mutations O
in O
the O
my O
##elin O
pro O
##te O
##oli O
##pid O
protein O
( O
p O
##l O
##p O
) O
gene O
. O

only O
25 O
% O
of O
patients O
studied O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
have O
ex O
##onic O
mutations O
in O
this O
gene O
, O
the O
underlying O
cause O
of O
the O
disease O
in O
the O
remaining O
patients O
is O
unknown O
. O

the O
p O
##l O
##p O
gene O
en O
##codes O
two O
major O
alternatively O
s O
##p O
##lice O
##d O
trans O
##cripts O
called O
p O
##l O
##p O
and O
d O
##m O
##20 O
. O

p O
##l O
##p O
messenger O
r O
##na O
is O
specifically O
expressed O
in O
central O
nervous O
system O
tissue O
, O
whereas O
d O
##m O
##20 O
messenger O
r O
##na O
is O
found O
in O
central O
nervous O
system O
, O
cardiac O
, O
and O
other O
tissues O
. O

we O
studied O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
from O
2 O
brothers O
with O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
who O
exhibited O
no O
detect O
##able O
ex O
##onic O
mutation O
of O
the O
p O
##l O
##p O
gene O
. O

examination O
of O
r O
##na O
from O
these O
cells O
showed O
that O
the O
level O
of O
d O
##m O
##20 O
messenger O
r O
##na O
is O
elevated O
six O
##fold O
relative O
to O
male O
control O
skin O
fi O
##bro O
##blast O
##s O
. O

an O
unrelated O
female O
carrier O
, O
also O
with O
no O
detect O
##able O
ex O
##onic O
mutation O
, O
showed O
a O
three O
##fold O
increase O
in O
d O
##m O
##20 O
messenger O
r O
##na O
in O
culture O
##d O
skin O
fi O
##bro O
##blast O
##s O
. O

our O
findings O
suggest O
that O
in O
some O
patients O
, O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
is O
caused O
by O
over O
##ex O
##press O
##ion O
of O
p O
##l O
##p O
gene O
trans O
##cripts O
, O
and O
that O
in O
these O
families O
a O
50 O
% O
increase O
of O
d O
##m O
##20 O
messenger O
r O
##na O
in O
females O
, O
relative O
to O
the O
increase O
in O
affected O
males O
, O
can O
identify O
a O
female O
carrier O
. O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
and O
x B-Disease
- I-Disease
linked I-Disease
con I-Disease
##gen I-Disease
##ital I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
are O
caused O
by O
mutations O
of O
the O
same O
gene O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
, O
small O
plate O
##lets O
, O
e B-Disease
##cz I-Disease
##ema I-Disease
, O
re O
##current O
infections O
, O
and O
im B-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
. O

besides O
the O
classic O
was B-Disease
p O
##hen O
##otype O
, O
there O
is O
a O
group O
of O
patients O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
x I-Disease
- I-Disease
linked I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
( O
x B-Disease
##lt I-Disease
) O
who O
have O
small O
plate O
##lets O
but O
only O
trans O
##ient O
e B-Disease
##cz I-Disease
##ema I-Disease
, O
if O
any O
, O
and O
minimal O
immune B-Disease
deficiency I-Disease
. O

because O
the O
gene O
responsible O
for O
was B-Disease
has O
been O
sequence O
##d O
, O
it O
was O
possible O
to O
co O
##rrel O
##ate O
the O
was B-Disease
p O
##hen O
##otype O
##s O
with O
was B-Disease
gene O
mutations O
. O

using O
a O
finger O
##print O
##ing O
screening O
technique O
, O
we O
determined O
the O
approximate O
location O
of O
the O
mutation O
in O
13 O
unrelated O
was B-Disease
patients O
with O
mild O
to O
severe O
clinical O
symptoms O
. O

direct O
sequence O
analysis O
of O
c O
##dn O
##a O
and O
g O
##eno O
##mic O
d O
##na O
obtained O
from O
patient O
- O
derived O
cell O
lines O
showed O
12 O
unique O
mutations O
distributed O
throughout O
the O
was B-Disease
gene O
, O
including O
insertion O
##s O
, O
del O
##eti O
##ons O
, O
and O
point O
mutations O
resulting O
in O
amino O
acid O
substitution O
##s O
, O
termination O
, O
ex O
##on O
skip O
##ping O
, O
or O
s O
##p O
##licing O
defects O
. O

of O
4 O
unrelated O
patients O
with O
the O
x B-Disease
##lt I-Disease
p O
##hen O
##otype O
, O
3 O
had O
miss O
##ense O
mutations O
affecting O
ex O
##on O
2 O
and O
1 O
had O
a O
s O
##p O
##lice O
- O
site O
mutation O
affecting O
ex O
##on O
9 O
. O

patients O
with O
classic O
was B-Disease
had O
more O
complex O
mutations O
, O
resulting O
in O
termination O
co O
##don O
##s O
, O
frames O
##hi O
##ft O
, O
and O
early O
termination O
. O

these O
findings O
provide O
direct O
evidence O
that O
x B-Disease
##lt I-Disease
and O
was B-Disease
are O
caused O
by O
mutations O
of O
the O
same O
gene O
and O
suggest O
that O
severe O
clinical O
p O
##hen O
##otype O
##s O
are O
associated O
with O
complex O
mutations O
. O
. O

my B-Disease
##oto I-Disease
##nia I-Disease
le I-Disease
##vior I-Disease
is O
a O
chloride B-Disease
channel I-Disease
disorder I-Disease
. O

the O
group O
of O
dominant B-Disease
non I-Disease
- I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
##s I-Disease
, O
comprising O
disorders O
characterized O
by O
clinical O
##ly O
similar O
forms O
of O
my O
##ogenic O
muscle O
stiff O
##ness O
, O
is O
genetically O
in O
##hom O
##ogen O
##eous O
. O

dominant B-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
con I-Disease
##gen I-Disease
##ita I-Disease
( O
th B-Disease
##oms I-Disease
##ens I-Disease
disease I-Disease
) O
is O
linked O
to O
c O
##l O
##c O
##n O
##1 O
, O
the O
gene O
encoding O
the O
major O
muscle O
chloride O
channel O
, O
localized O
on O
chromosome O
7 O
##q O
##35 O
. O

in O
contrast O
, O
dominant B-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
##s I-Disease
sensitive O
to O
potassium O
are O
caused O
by O
point O
mutations O
in O
s O
##c O
##n O
##4 O
##a O
on O
chromosome O
17 O
##q O
, O
the O
gene O
for O
the O
alpha O
subunit O
of O
the O
adult O
skeletal O
muscle O
sodium O
channel O
. O

no O
link O
##age O
or O
molecular O
genetic O
data O
are O
as O
yet O
available O
on O
my B-Disease
##oto I-Disease
##nia I-Disease
le I-Disease
##vior I-Disease
characterized O
by O
mild O
##er O
symptoms O
and O
later O
onset O
of O
my B-Disease
##oto I-Disease
##nia I-Disease
than O
in O
th B-Disease
##oms I-Disease
##ens I-Disease
disease I-Disease
, O
and O
absence O
of O
muscle B-Disease
h I-Disease
##yper I-Disease
##tro I-Disease
##phy I-Disease
. O

we O
report O
a O
c O
##l O
##c O
##n O
##1 O
g O
##ln O
- O
55 O
##2 O
- O
a O
##rg O
substitution O
for O
a O
family O
with O
dominant O
inheritance O
previously O
diagnosed O
to O
have O
my B-Disease
##oto I-Disease
##nia I-Disease
le I-Disease
##vior I-Disease
. O

thus O
, O
this O
disorder O
appears O
as O
a O
variant O
of O
th B-Disease
##oms I-Disease
##ens I-Disease
disease I-Disease
due O
to O
mutations O
leading O
to O
low O
clinical O
express O
##ivity O
. O

in O
addition O
, O
we O
report O
a O
novel O
il O
##e O
- O
290 O
- O
met O
c O
##l O
##c O
##n O
##1 O
mutation O
for O
a O
typical O
th O
##oms O
##en O
p O
##ed O
##ig O
##ree O
. O

in O
another O
family O
previously O
diagnosed O
as O
having O
th B-Disease
##oms I-Disease
##ens I-Disease
disease I-Disease
, O
we O
unexpectedly O
found O
a O
c O
##l O
##c O
##n O
##1 O
14 O
b O
##p O
del O
##eti O
##on O
known O
to O
cause O
re B-Disease
##cess I-Disease
##ive I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
, O
and O
a O
rare O
t O
##rp O
- O
118 O
- O
g O
##ly O
p O
##oly O
##mor O
##phism O
. O
. O

southern O
analysis O
reveals O
a O
large O
del O
##eti O
##on O
at O
the O
h O
##y O
##pox O
##ant O
##hine O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
lo O
##cus O
in O
a O
patient O
with O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

whole O
g O
##eno O
##mic O
hp O
##rt O
clone O
##s O
were O
used O
in O
southern O
analysis O
to O
screen O
the O
integrity O
of O
the O
hp O
##rt O
gene O
in O
a O
family O
that O
includes O
a O
patient O
with O
hp B-Disease
##rt I-Disease
enzyme I-Disease
deficiency I-Disease
ca O
##usal O
to O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

a O
5 O
k O
##b O
d O
##na O
sequence O
del O
##eti O
##on O
was O
found O
to O
have O
its O
end O
##points O
in O
the O
first O
and O
third O
intro O
##ns O
. O

the O
probe O
##s O
identified O
the O
carrier O
status O
of O
female O
family O
members O
, O
aided O
by O
an O
r O
##f O
##l O
##p O
carried O
by O
the O
mothers O
normal O
x O
- O
chromosome O
. O
. O

character O
##isation O
of O
molecular O
defects O
in O
x B-Disease
- I-Disease
linked I-Disease
am I-Disease
##elo I-Disease
##genesis I-Disease
imp I-Disease
##er I-Disease
##fect I-Disease
##a I-Disease
( O
a O
##ih O
##1 O
) O
. O

am O
##elo O
##gen O
##ins O
are O
an O
he O
##tero O
##gen O
##ous O
family O
of O
proteins O
produced O
by O
am O
##elo O
##blast O
##s O
of O
the O
en O
##amel O
organ O
during O
tooth O
development O
. O

disturbance O
##s O
of O
en O
##amel O
formation O
occur O
in O
am B-Disease
##elo I-Disease
##genesis I-Disease
imp I-Disease
##er I-Disease
##fect I-Disease
##a I-Disease
, O
a O
clinical O
##ly O
he O
##tero O
##gen O
##ous O
group O
of O
inherited B-Disease
disorders I-Disease
characterised O
by O
defect O
##ive O
en O
##amel O
bio O
##mine O
##ral O
##isation O
. O

an O
am O
##elo O
##gen O
##in O
gene O
, O
am O
##g O
##x O
, O
has O
been O
mapped O
to O
the O
short O
of O
the O
x O
chromosome O
( O
x O
##p O
##22 O
. O
1 O
- O
p O
##22 O
. O
3 O
) O
and O
has O
been O
implicated O
in O
the O
molecular O
path O
##ology O
of O
x B-Disease
- I-Disease
linked I-Disease
am I-Disease
##elo I-Disease
##genesis I-Disease
imp I-Disease
##er I-Disease
##fect I-Disease
##a I-Disease
( O
a B-Disease
##ih I-Disease
##1 I-Disease
) O
. O

we O
have O
identified O
three O
families O
exhibiting O
a B-Disease
##ih I-Disease
##1 I-Disease
and O
screened O
the O
am O
##g O
##x O
gene O
for O
mutations O
using O
single O
- O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
analysis O
and O
d O
##na O
se O
##quencing O
. O

three O
novel O
mutations O
were O
identified O
a O
c O
- O
t O
substitution O
in O
ex O
##on O
5 O
, O
and O
a O
g O
- O
t O
substitution O
and O
single O
c O
##yt O
##os O
##ine O
del O
##eti O
##on O
in O
ex O
##on O
6 O
, O
confirming O
the O
existence O
of O
extensive O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
in O
this O
condition O
. O

the O
identification O
of O
family O
- O
specific O
mutations O
will O
enable O
early O
identification O
of O
affected O
individuals O
and O
correlation O
of O
clinical O
p O
##hen O
##otype O
with O
g O
##eno O
##type O
will O
facilitate O
an O
objective O
system O
of O
disease O
classification O
. O

frequency O
of O
ex O
##on O
15 O
miss O
##ense O
mutation O
( O
44 O
##2 O
##d O
: O
g O
) O
in O
ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
gene O
in O
h B-Disease
##yper I-Disease
##al I-Disease
##pha I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mic I-Disease
j O
##apa O
##nese O
subjects O
. O

ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
( O
c O
##et O
##p O
) O
transfers O
ch O
##ole O
##ster O
##yl O
est O
##er O
from O
high O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
to O
a O
##po O
b O
- O
containing O
lip O
##op O
##rote O
##ins O
. O

the O
h B-Disease
##yper I-Disease
##al I-Disease
##pha I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
caused O
by O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
is O
fairly O
common O
in O
j O
##apa O
##n O
and O
one O
of O
the O
most O
common O
mutations O
in O
the O
c O
##et O
##p O
gene O
is O
the O
s O
##p O
##licing O
defect O
of O
the O
intro O
##n O
14 O
, O
the O
all O
##eli O
##c O
frequency O
of O
which O
has O
been O
shown O
to O
be O
0 O
. O

00 O
##4 O
##9 O
in O
the O
j O
##apa O
##nese O
general O
population O
. O

recently O
, O
we O
have O
reported O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
15 O
of O
the O
c O
##et O
##p O
gene O
( O
44 O
##2 O
##d O
g O
) O
, O
showing O
a O
dominant O
effect O
on O
the O
c O
##et O
##p O
activity O
and O
h O
##dl O
- O
ch O
##ole O
##ster O
##ol O
level O
. O

in O
the O
current O
study O
, O
we O
determined O
the O
frequency O
of O
this O
new O
mutation O
in O
j O
##apa O
##nese O
h B-Disease
##yper I-Disease
##al I-Disease
##pha I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mic I-Disease
( O
h O
##dl O
- O
ch O
##ole O
##ster O
##ol O
[UNK] O
or O
= O
100 O
mg O
/ O
d O
##l O
) O
subjects O
. O

a O
rapid O
and O
easy O
screening O
method O
for O
this O
new O
mutation O
was O
developed O
using O
a O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
- O
mediated O
site O
- O
directed O
m O
##uta O
##genesis O
. O

among O
117 O
j O
##apa O
##nese O
h B-Disease
##yper I-Disease
##al I-Disease
##pha I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mic I-Disease
subjects O
( O
h O
##dl O
- O
ch O
##ole O
##ster O
##ol O
; O
116 O
. O
7 O
+ O
/ O
- O
16 O
. O
5 O
mg O
/ O
d O
##l O
, O
mean O
+ O
/ O
- O
s O
. O
d O
. O
) O
without O
the O
intro O
##n O
14 O
s O
##p O
##lice O
defect O
, O
three O
ho O
##mo O
##zy O
##got O
##es O
( O
2 O
. O
5 O
% O
) O
and O
34 O
he O
##tero O
##zy O
##got O
##es O
( O
29 O
. O
1 O
% O
) O
were O
found O
to O
have O
the O
44 O
##2 O
##d O
g O
mutation O
. O

the O
relative O
all O
##eli O
##c O
frequency O
of O
this O
mutation O
was O
calculated O
to O
be O
0 O
. O

17 O
. O

one O
of O
the O
ho O
##mo O
##zy O
##got O
##es O
for O
the O
44 O
##2 O
##d O
g O
mutation O
was O
the O
patient O
previously O
described O
by O
us O
as O
having O
h B-Disease
##yper I-Disease
##al I-Disease
##pha I-Disease
##lip I-Disease
##op I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
with O
corn B-Disease
##eal I-Disease
op I-Disease
##acity I-Disease
and O
co B-Disease
##rona I-Disease
##ry I-Disease
heart I-Disease
disease I-Disease
. O

this O
was O
the O
first O
reported O
subject O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
who O
also O
demonstrated O
at B-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rot I-Disease
##ic I-Disease
symptoms I-Disease
. O

in O
ho O
##mo O
##zy O
##go O
##us O
subjects O
, O
c O
##et O
##p O
activity O
ranged O
from O
37 O
% O
to O
62 O
% O
of O
the O
normal O
value O
, O
which O
was O
consistent O
with O
the O
results O
obtained O
from O
the O
trans O
##ient O
expression O
experiment O
previously O
reported O
; O
however O
, O
the O
specific O
activity O
of O
c O
##et O
##p O
was O
not O
as O
low O
as O
expected O
. O

( O
abstract O
t O
##runcated O
at O
250 O
words O
) O

m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
type I-Disease
i I-Disease
##va I-Disease
: O
common O
double O
del O
##eti O
##on O
in O
the O
n O
- O
ace O
##ty O
##l O
##gal O
##act O
##osa O
##mine O
- O
6 O
- O
su O
##lf O
##ata O
##se O
gene O
( O
gal O
##ns O
) O
. O

m B-Disease
##uc I-Disease
##op I-Disease
##oly I-Disease
##sa I-Disease
##cc I-Disease
##hari I-Disease
##dos I-Disease
##is I-Disease
i I-Disease
##va I-Disease
( O
m B-Disease
##ps I-Disease
i I-Disease
##va I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
in I-Disease
n I-Disease
- I-Disease
ace I-Disease
##ty I-Disease
##l I-Disease
##gal I-Disease
##act I-Disease
##osa I-Disease
##mine I-Disease
- I-Disease
6 I-Disease
- I-Disease
su I-Disease
##lf I-Disease
##ata I-Disease
##se I-Disease
( O
gal O
##ns O
) O
. O

we O
found O
two O
separate O
del O
##eti O
##ons O
of O
nearly O
8 O
. O

0 O
and O
6 O
. O

0 O
k O
##b O
in O
the O
gal O
##ns O
gene O
, O
including O
some O
ex O
##ons O
. O

there O
are O
al O
##u O
repetitive O
elements O
near O
the O
break O
##points O
of O
the O
8 O
. O

0 O
- O
k O
##b O
del O
##eti O
##on O
, O
and O
this O
del O
##eti O
##on O
resulted O
from O
an O
al O
##u O
- O
al O
##u O
re O
##comb O
##ination O
. O

the O
other O
6 O
. O

0 O
- O
k O
##b O
del O
##eti O
##on O
involved O
illegitimate O
re O
##comb O
##ination O
##al O
events O
between O
incomplete O
short O
direct O
repeats O
of O
8 O
b O
##p O
at O
del O
##eti O
##on O
break O
##points O
. O

the O
same O
rear O
##rang O
##ement O
has O
been O
observed O
in O
a O
he O
##tero O
##alle O
##lic O
state O
in O
four O
unrelated O
patients O
. O

this O
is O
the O
first O
documentation O
of O
a O
common O
double O
del O
##eti O
##on O
a O
gene O
that O
is O
not O
a O
member O
of O
a O
gene O
cluster O
. O

detection O
of O
eight O
br O
##ca O
##1 O
mutations O
in O
10 O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
, O
including O
1 O
family O
with O
male B-Disease
breast I-Disease
cancer I-Disease
. O

genetic O
e O
##pid O
##em O
##iol O
##ogical O
evidence O
suggests O
that O
mutations O
in O
br O
##ca O
##1 O
may O
be O
responsible O
for O
approximately O
one O
half O
of O
early O
onset O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
cancer I-Disease
and O
the O
majority O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

the O
recent O
c O
##lon O
##ing O
of O
br O
##ca O
##1 O
allows O
for O
the O
direct O
detection O
of O
mutations O
, O
but O
the O
f O
##eas O
##ibility O
of O
pre O
##sy O
##mpt O
##oma O
##tic O
screening O
for O
cancer B-Disease
su O
##s O
##ce O
##pt O
##ibility O
is O
unknown O
. O

we O
analyzed O
g O
##eno O
##mic O
d O
##na O
from O
one O
affected O
individual O
from O
each O
of O
24 O
families O
with O
at O
least O
three O
cases O
of O
o B-Disease
##var I-Disease
##ian I-Disease
or I-Disease
breast I-Disease
cancer I-Disease
, O
using O
s O
##s O
##c O
##p O
ass O
##ays O
. O

variant O
s O
##s O
##c O
##p O
bands O
were O
sub O
##c O
##lone O
##d O
and O
sequence O
##d O
. O

all O
##ele O
- O
specific O
o O
##li O
##gon O
##uc O
##leo O
##tide O
hybrid O
##ization O
was O
used O
to O
verify O
sequence O
changes O
and O
to O
screen O
d O
##na O
from O
control O
individuals O
. O

six O
frames O
##hi O
##ft O
and O
two O
miss O
##ense O
mutations O
were O
detected O
in O
10 O
different O
families O
. O

a O
frames O
##hi O
##ft O
mutation O
was O
detected O
in O
a O
male O
pro O
##band O
affected O
with O
both O
breast B-Disease
and I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O

a O
40 O
- O
b O
##p O
del O
##eti O
##on O
was O
detected O
in O
a O
patient O
who O
developed O
in B-Disease
##tra I-Disease
- I-Disease
abdominal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##tosis I-Disease
1 O
year O
after O
prop O
##hyl O
##actic O
o O
##op O
##hore O
##ct O
##omy O
. O

mutations O
were O
detected O
throughout O
the O
gene O
, O
and O
only O
one O
was O
detected O
in O
more O
than O
a O
single O
family O
. O

these O
results O
provide O
further O
evidence O
that O
inherited B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
can O
occur O
as O
a O
consequence O
of O
a O
wide O
array O
of O
br O
##ca O
##1 O
mutations O
. O

these O
results O
suggests O
that O
development O
of O
a O
screening O
test O
for O
br O
##ca O
##1 O
mutations O
will O
be O
technically O
challenging O
. O

the O
finding O
of O
a O
mutation O
in O
a O
family O
with O
male B-Disease
breast I-Disease
cancer I-Disease
, O
not O
previously O
thought O
to O
be O
related O
to O
br O
##ca O
##1 O
, O
also O
illustrate O
##s O
the O
potential O
difficulties O
of O
genetic O
counseling O
for O
individuals O
known O
to O
carry O
mutations O
. O
. O

natural O
selection O
of O
hem O
##i O
- O
and O
he O
##tero O
##zy O
##got O
##es O
for O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
a O
##f O
##rica O
by O
resistance O
to O
severe O
malaria B-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
, O
the O
most O
common O
en B-Disease
##zy I-Disease
##mo I-Disease
##pathy I-Disease
of O
humans O
, O
affects O
over O
400 O
million O
people O
. O

the O
geographical O
correlation O
of O
its O
distribution O
with O
the O
historical O
endemic O
##ity O
of O
malaria B-Disease
suggests O
that O
this O
disorder O
has O
risen O
in O
frequency O
through O
natural O
selection O
by O
malaria B-Disease
. O

however O
, O
attempts O
to O
confirm O
that O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
protective O
in O
case O
- O
control O
studies O
of O
malaria B-Disease
have O
yielded O
conflicting O
results O
. O

hence O
, O
for O
this O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
, O
it O
is O
unclear O
whether O
both O
male O
hem O
##iz O
##y O
##got O
##es O
and O
female O
he O
##tero O
##zy O
##got O
##es O
are O
protected O
or O
, O
as O
frequently O
suggested O
, O
only O
females O
. O

further O
##more O
, O
how O
much O
protection O
may O
be O
afforded O
is O
unknown O
. O

here O
we O
report O
that O
, O
in O
two O
large O
case O
- O
control O
studies O
of O
over O
2 O
, O
000 O
a O
##f O
##rica O
##n O
children O
, O
the O
common O
a O
##f O
##rica O
##n O
form O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
( O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
a I-Disease
- I-Disease
) O
is O
associated O
with O
a O
46 O
- O
58 O
% O
reduction O
in O
risk O
of O
severe O
malaria B-Disease
for O
both O
female O
he O
##tero O
##zy O
##got O
##es O
and O
male O
hem O
##iz O
##y O
##got O
##es O
. O

a O
mathematical O
model O
incorporating O
the O
measured O
selective O
advantage O
against O
malaria B-Disease
suggests O
that O
a O
counter O
##bal O
##an O
##cing O
selective O
disadvantage O
, O
associated O
with O
this O
enzyme B-Disease
deficiency I-Disease
, O
has O
re O
##tar O
##ded O
its O
rise O
in O
frequency O
in O
malaria B-Disease
- O
endemic O
regions O
. O

although O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
now O
regarded O
as O
a O
generally O
ben O
##ign O
disorder O
, O
in O
earlier O
environmental O
conditions O
it O
could O
have O
been O
significantly O
disadvantage O
##ous O
. O
. O

the O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
p O
##ax O
##3 O
/ O
f O
##kh O
##r O
fusion O
protein O
is O
a O
transcription O
##al O
act O
##iva O
##tor O
. O

ch O
##ime O
##ric O
transcription O
factors O
, O
created O
by O
gene O
fusion O
##s O
as O
the O
result O
of O
ch O
##rom O
##oso O
##mal O
trans O
##location O
##s O
, O
have O
been O
implicated O
in O
the O
path O
##ogen O
##esis O
of O
several O
path O
##ological O
##ly O
di O
##sp O
##arate O
solid B-Disease
tumors I-Disease
. O

the O
p O
##ax O
##3 O
/ O
f O
##kh O
##r O
fusion O
gene O
, O
formed O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q O
##35 O
; O
q O
##14 O
) O
in O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
, O
en O
##codes O
a O
hybrid O
protein O
that O
contains O
both O
p O
##ax O
##3 O
d O
##na O
binding O
domains O
, O
the O
paired O
box O
and O
home O
##od O
##oma O
##in O
, O
linked O
to O
the O
bi O
##sect O
##ed O
d O
##na O
binding O
domain O
of O
f O
##kh O
##r O
, O
a O
member O
of O
the O
fork O
##head O
family O
of O
transcription O
factors O
. O

here O
we O
report O
that O
p O
##ax O
##3 O
and O
p O
##ax O
##3 O
/ O
f O
##kh O
##r O
display O
similar O
, O
but O
not O
identical O
trans O
##act O
##ivation O
activities O
when O
tested O
with O
model O
p O
##ax O
recognition O
sequences O
. O

no O
functional O
role O
could O
be O
as O
##cribed O
solely O
to O
the O
residual O
f O
##kh O
##r O
binding O
domain O
present O
in O
the O
fusion O
protein O
, O
but O
f O
##kh O
##r O
was O
found O
to O
contribute O
a O
strong O
car O
##box O
##yl O
terminal O
activation O
domain O
replacing O
the O
one O
located O
in O
the O
un O
##rea O
##rra O
##nged O
p O
##ax O
##3 O
gene O
. O

we O
show O
that O
the O
native O
p O
##ax O
##3 O
/ O
f O
##kh O
##r O
protein O
present O
in O
tumor B-Disease
cells O
with O
this O
trans O
##location O
has O
transcription O
##al O
characteristics O
similar O
to O
the O
in O
v O
##it O
##ro O
expressed O
protein O
. O

the O
ability O
of O
the O
p O
##ax O
##3 O
/ O
f O
##kh O
##r O
hybrid O
protein O
to O
bind O
d O
##na O
in O
a O
sequence O
specific O
manner O
and O
to O
trans O
##act O
##ivate O
the O
expression O
of O
artificial O
reporter O
genes O
suggests O
that O
its O
a O
##ber O
##rant O
expression O
could O
sub O
##vert O
the O
transcription O
##al O
programs O
that O
normally O
control O
the O
growth O
, O
differentiation O
, O
and O
survival O
of O
primitive O
my O
##ogenic O
precursor O
##s O
in O
v O
##ivo O
. O
. O

a O
p O
##16 O
##ink O
##4 O
##a O
- O
ins O
##ens O
##itive O
c O
##d O
##k O
##4 O
mutant O
targeted O
by O
c O
##yt O
##oly O
##tic O
t O
l O
##ymph O
##ocytes O
in O
a O
human O
me B-Disease
##lan I-Disease
##oma I-Disease
. O

a O
m O
##uta O
##ted O
c O
##y O
##c O
##lin O
- O
dependent O
kinase O
4 O
( O
c O
##d O
##k O
##4 O
) O
was O
identified O
as O
a O
tumor B-Disease
- O
specific O
anti O
##gen O
recognized O
by O
h O
##la O
- O
a O
##2 O
. O

1 O
- O
restricted O
auto O
##log O
##ous O
c O
##yt O
##oly O
##tic O
t O
l O
##ymph O
##ocytes O
( O
c O
##tl O
##s O
) O
in O
a O
human O
me B-Disease
##lan I-Disease
##oma I-Disease
. O

the O
m O
##uta O
##ted O
c O
##d O
##k O
##4 O
all O
##ele O
was O
present O
in O
auto O
##log O
##ous O
culture O
##d O
me B-Disease
##lan I-Disease
##oma I-Disease
cells O
and O
meta O
##sta O
##sis O
tissue O
, O
but O
not O
in O
the O
patients O
l O
##ymph O
##ocytes O
. O

the O
mutation O
, O
an O
a O
##rg O
##ini O
##ne O
- O
to O
- O
c O
##ys O
##tein O
##e O
exchange O
at O
residue O
24 O
, O
was O
part O
of O
the O
c O
##d O
##k O
##4 O
p O
##eptide O
recognized O
by O
c O
##tl O
##s O
and O
prevented O
binding O
of O
the O
c O
##d O
##k O
##4 O
inhibitor O
p O
##16 O
##ink O
##4 O
##a O
, O
but O
not O
of O
p O
##21 O
or O
of O
p O
##27 O
##ki O
##p O
##1 O
. O

the O
same O
mutation O
was O
found O
in O
one O
additional O
me B-Disease
##lan I-Disease
##oma I-Disease
among O
28 O
me B-Disease
##lan I-Disease
##oma I-Disease
##s I-Disease
analyzed O
. O

these O
results O
suggest O
that O
mutation O
of O
c O
##d O
##k O
##4 O
can O
create O
a O
tumor B-Disease
- O
specific O
anti O
##gen O
and O
can O
disrupt O
the O
cell O
- O
cycle O
regulation O
ex O
##ert O
##ed O
by O
the O
tumor B-Disease
suppress O
##or O
p O
##16 O
##ink O
##4 O
##a O
. O
. O

rapid O
detection O
of O
br O
##ca O
##1 O
mutations O
by O
the O
protein O
t O
##run O
##cation O
test O
. O

more O
than O
75 O
% O
of O
the O
reported O
mutations O
in O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
gene O
, O
br O
##ca O
##1 O
, O
result O
in O
t O
##runcated O
proteins O
. O

we O
have O
used O
the O
protein O
t O
##run O
##cation O
test O
( O
p O
##tt O
) O
to O
screen O
for O
mutations O
in O
ex O
##on O
11 O
, O
which O
en O
##codes O
61 O
% O
of O
br O
##ca O
##1 O
. O

in O
45 O
patients O
from O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
we O
found O
six O
novel O
mutations O
two O
single O
n O
##uc O
##leo O
##tide O
insertion O
##s O
, O
three O
small O
del O
##eti O
##ons O
( O
1 O
- O
5 O
b O
##p O
) O
and O
a O
nonsense O
mutation O
identified O
two O
unrelated O
families O
. O

further O
##more O
, O
we O
were O
able O
to O
am O
##p O
##lify O
the O
remaining O
coding O
region O
by O
r O
##t O
- O
p O
##c O
##r O
using O
l O
##ymph O
##oc O
##yte O
r O
##na O
. O

combined O
with O
p O
##tt O
, O
we O
detected O
a O
##ber O
##rant O
##ly O
s O
##p O
##lice O
##d O
products O
affecting O
ex O
##ons O
5 O
and O
6 O
in O
one O
of O
two O
br O
##ca O
##1 O
- O
linked O
families O
examined O
. O

the O
protein O
t O
##run O
##cation O
test O
promises O
to O
become O
a O
valuable O
technique O
in O
detect O
##ing O
br O
##ca O
##1 O
mutations O
. O
. O

c O
##lon O
##ing O
of O
human O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##en O
##zy O
##me O
a O
de O
##hy O
##dr O
##ogen O
##ase O
and O
molecular O
characterization O
of O
its O
deficiency O
in O
two O
patients O
. O

two O
overlapping O
c O
##dn O
##a O
clone O
##s O
( O
1 O
, O
99 O
##1 O
b O
##p O
and O
73 O
##6 O
b O
##p O
, O
respectively O
) O
encoding O
the O
precursor O
of O
human O
mitochondrial O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##en O
##zy O
##me O
a O
de O
##hy O
##dr O
##ogen O
##ase O
( O
v O
##l O
##ca O
##d O
) O
were O
clone O
##d O
and O
sequence O
##d O
. O

the O
c O
##dn O
##a O
insert O
##s O
of O
these O
clone O
##s O
together O
en O
##com O
##pass O
a O
region O
of O
2 O
, O
177 O
bases O
, O
encoding O
the O
entire O
protein O
of O
65 O
##5 O
amino O
acids O
, O
including O
a O
40 O
- O
amino O
acid O
leader O
p O
##eptide O
and O
a O
61 O
##5 O
- O
amino O
acid O
mature O
p O
##oly O
##pe O
##pt O
##ide O
. O

p O
##c O
##r O
- O
am O
##plified O
v O
##l O
##ca O
##d O
c O
##dn O
##as O
were O
sequence O
##d O
in O
culture O
##d O
fi O
##bro O
##blast O
##s O
from O
two O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
patients O
. O

in O
both O
patients O
, O
a O
105 O
- O
b O
##p O
del O
##eti O
##on O
encompassing O
bases O
107 O
##8 O
- O
118 O
##2 O
in O
v O
##l O
##ca O
##d O
c O
##dn O
##a O
was O
identified O
. O

the O
del O
##eti O
##on O
seems O
to O
occur O
due O
to O
ex O
##on O
skip O
##ping O
during O
processing O
of O
v O
##l O
##ca O
##d O
pre O
- O
m O
##rna O
. O

this O
is O
the O
first O
demonstration O
of O
a O
mutation O
causing O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
. O

quantitative O
c O
##dn O
##a O
expression O
of O
normal O
human O
v O
##l O
##ca O
##d O
was O
performed O
in O
the O
patients O
fi O
##bro O
##blast O
##s O
, O
using O
v O
##ac O
##cini O
##a O
viral O
system O
, O
which O
demonstrated O
that O
the O
deficiency B-Disease
of I-Disease
the I-Disease
normal I-Disease
v I-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
protein I-Disease
causes O
impaired O
long O
- O
chain O
fatty O
acid O
beta O
- O
oxidation O
activity O
in O
the O
patients O
fi O
##bro O
##blast O
##s O
. O

in O
patient O
fi O
##bro O
##blast O
##s O
, O
raising O
v O
##l O
##ca O
##d O
activity O
to O
approximately O
20 O
% O
of O
normal O
control O
fi O
##bro O
##blast O
activity O
raised O
palm O
##itic O
acid O
beta O
- O
oxidation O
flux O
to O
the O
level O
found O
in O
control O
fi O
##bro O
##blast O
##s O
, O
which O
may O
offer O
important O
information O
for O
the O
rational O
design O
of O
future O
so O
##matic O
gene O
therapy O
for O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
. O
. O

brain B-Disease
disease I-Disease
and O
molecular O
analysis O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

abnormal O
am O
##p O
##lification O
of O
a O
c O
##t O
##g O
repeat O
on O
chromosome O
19 O
is O
the O
molecular O
basis O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
. O

expansion O
of O
the O
repeat O
has O
been O
correlated O
with O
severity O
of O
several O
clinical O
features O
of O
the O
disease O
. O

we O
performed O
extensive O
cognitive O
testing O
, O
cerebral O
magnetic O
resonance O
imaging O
( O
m O
##ri O
) O
and O
a O
molecular O
analysis O
in O
28 O
cases O
of O
d B-Disease
##m I-Disease
to O
determine O
the O
relationship O
between O
the O
molecular O
defect O
and O
brain B-Disease
disease I-Disease
. O

performance O
in O
two O
or O
more O
cognitive O
tests O
was O
path O
##ological O
in O
10 O
cases O
. O

fourteen O
patients O
had O
sub O
##cor O
##tical O
white B-Disease
matter I-Disease
lesions I-Disease
on O
m O
##ri O
, O
14 O
had O
cerebral B-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
. O

am O
##p O
##lification O
of O
the O
c O
##t O
##g O
repeat O
showed O
a O
strong O
correlation O
with O
cognitive O
test O
deficit O
##s O
when O
exceeding O
a O
length O
of O
over O
1000 O
t O
##rin O
##uc O
##leo O
##tide O
##s O
. O

m O
##ri O
lesions O
were O
associated O
with O
impaired O
ps O
##ych O
##ometric O
performance O
, O
but O
m O
##ri O
and O
molecular O
findings O
were O
only O
weakly O
related O
. O

disease O
duration O
influenced O
the O
appearance O
and O
amount O
of O
white B-Disease
matter I-Disease
lesions I-Disease
on O
m O
##ri O
. O

q O
##uant O
##ification O
of O
c O
##t O
##g O
repeat O
size O
may O
allow O
an O
early O
estimate O
on O
the O
probability O
of O
brain O
involvement O
in O
d B-Disease
##m I-Disease
; O
cognitive B-Disease
d I-Disease
##ys I-Disease
##function I-Disease
is O
associated O
with O
white B-Disease
matter I-Disease
lesions I-Disease
and O
cerebral B-Disease
at I-Disease
##rop I-Disease
##hy I-Disease
later O
on O
in O
the O
course O
. O
. O

mutations O
in O
the O
gene O
for O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
in O
patients O
with O
different O
clinical O
p O
##hen O
##otype O
##s O
. O

recently O
, O
the O
gene O
for O
the O
most O
common O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorder I-Disease
, O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
) O
, O
has O
been O
described O
encoding O
a O
per O
##ox O
##is O
##oma O
##l O
membrane O
transport O
##er O
protein O
. O

we O
analyzed O
the O
entire O
protein O
- O
coding O
sequence O
of O
this O
gene O
by O
reverse O
- O
transcription O
p O
##c O
##r O
, O
s O
##s O
##c O
##p O
, O
and O
d O
##na O
se O
##quencing O
in O
five O
patients O
with O
different O
clinical O
expression O
of O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
and O
in O
their O
female O
relatives O
; O
these O
clinical O
expressions O
were O
cerebral O
childhood O
al B-Disease
##d I-Disease
, O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
, O
and O
" O
add B-Disease
##ison I-Disease
disease I-Disease
only I-Disease
" O
( O
ad B-Disease
##o I-Disease
) O
p O
##hen O
##otype O
. O

in O
the O
three O
patients O
exhibiting O
the O
classical O
picture O
of O
severe O
childhood O
al B-Disease
##d I-Disease
we O
identified O
in O
the O
5 O
portion O
of O
the O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
gene O
a O
38 O
- O
b O
##p O
del O
##eti O
##on O
that O
causes O
a O
frames O
##hi O
##ft O
mutation O
, O
a O
3 O
- O
b O
##p O
del O
##eti O
##on O
leading O
to O
a O
del O
##eti O
##on O
of O
an O
amino O
acid O
in O
the O
at O
##p O
- O
binding O
domain O
of O
the O
al B-Disease
##d I-Disease
protein O
, O
and O
a O
miss O
##ense O
mutation O
. O

in O
the O
patient O
with O
the O
clinical O
p O
##hen O
##otype O
of O
am B-Disease
##n I-Disease
, O
a O
nonsense O
mutation O
in O
co O
##don O
212 O
, O
along O
with O
a O
second O
site O
mutation O
at O
co O
##don O
178 O
, O
was O
observed O
. O

analysis O
of O
the O
patient O
with O
the O
ad B-Disease
##o I-Disease
p O
##hen O
##otype O
revealed O
a O
further O
miss O
##ense O
mutation O
at O
a O
highly O
conserved O
position O
in O
the O
al O
##d O
##p O
/ O
pm O
##p O
##70 O
comparison O
. O

the O
disrupt O
##ive O
nature O
of O
two O
mutations O
( O
i O
. O
e O
. O
, O
the O
frames O
##hi O
##ft O
and O
the O
nonsense O
mutation O
) O
in O
patients O
with O
bio O
##chemical O
##ly O
proved O
childhood O
al B-Disease
##d I-Disease
and O
am B-Disease
##n I-Disease
further O
strongly O
supports O
the O
hypothesis O
that O
alterations O
in O
this O
gene O
play O
a O
crucial O
role O
in O
the O
path O
##ogen O
##esis O
of O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
. O

since O
the O
current O
bio O
##chemical O
techniques O
for O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
carrier O
detection O
in O
affected O
families O
lack O
sufficient O
reliability O
, O
our O
procedure O
described O
for O
systematic O
mutation O
scanning O
is O
also O
capable O
of O
improving O
genetic O
counseling O
and O
pre O
##nat O
##al O
diagnosis O

du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
in O
the O
same O
patient O
. O

we O
report O
on O
the O
first O
patient O
identified O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

the O
family O
of O
the O
prop O
##os O
##it O
##us O
had O
a O
strong O
history O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
and O
there O
was O
an O
in O
##tra O
##fa O
##mi O
##lial O
path O
##ological O
expansion O
of O
the O
responsible O
c O
##t O
##g O
repeat O
between O
the O
mildly O
affected O
mother O
( O
160 O
repeats O
; O
normal O
27 O
repeats O
) O
and O
her O
more O
severely O
affected O
son O
( O
650 O
repeats O
) O
, O
and O
his O
sister O
( O
650 O
repeats O
) O
. O

the O
prop O
##os O
##it O
##us O
was O
an O
isolated O
case O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
with O
marked O
d B-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##n I-Disease
deficiency I-Disease
in O
muscle O
bio O
##psy O
. O

the O
patient O
was O
still O
am O
##bula O
##tory O
post O
age O
16 O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
could O
interfere O
to O
some O
extent O
with O
the O
progression O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

however O
, O
other O
interpretations O
are O
possible O
. O

twelve O
percent O
of O
d O
##ys O
##tro O
##phi O
##n O
re O
##vert O
##ant O
fibers O
as O
observed O
by O
im O
##mu O
##no O
##his O
##to O
##chemistry O
could O
be O
sufficient O
to O
am O
##eli O
##ora O
##te O
typical O
d B-Disease
##m I-Disease
##d I-Disease
clinical O
severity O
, O
or O
the O
patient O
may O
present O
a O
so O
##matic O
mosaic O
. O

the O
path O
##op O
##hy O
##sio O
##logical O
interactions O
of O
these O
two O
un O
##link O
##ed O
disorders O
are O
discussed O
at O
the O
clinical O
and O
his O
##top O
##ath O
##ological O
levels O
. O
. O

age O
at O
diagnosis O
as O
an O
indicator O
of O
eligibility O
for O
br O
##ca O
##1 O
d O
##na O
testing O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
cancer I-Disease
. O

we O
searched O
for O
criteria O
that O
could O
indicate O
breast B-Disease
cancer I-Disease
families O
with O
a O
high O
prior O
probability O
of O
being O
caused O
by O
the O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
lo O
##cus O
br O
##ca O
##1 O
on O
chromosome O
17 O
. O

to O
this O
end O
, O
we O
performed O
a O
link O
##age O
study O
with O
59 O
consecutive O
##ly O
collected O
du O
##tch O
breast B-Disease
cancer I-Disease
families O
, O
including O
16 O
with O
at O
least O
one O
case O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

we O
used O
an O
intake O
cut O
- O
off O
of O
at O
least O
three O
first O
- O
degree O
relatives O
with O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
at O
any O
age O
. O

significant O
evidence O
for O
link O
##age O
was O
found O
only O
among O
the O
13 O
breast B-Disease
cancer I-Disease
families O
with O
a O
mean O
age O
at O
diagnosis O
of O
less O
than O
45 O
years O
. O

an O
unexpectedly O
low O
proportion O
of O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
were O
estimated O
to O
be O
linked O
to O
br O
##ca O
##1 O
, O
which O
could O
be O
due O
to O
a O
founder O
effect O
in O
the O
du O
##tch O
population O
. O

given O
the O
expected O
log O
##istic O
##al O
problems O
in O
clinical O
management O
now O
that O
br O
##ca O
##1 O
has O
been O
identified O
, O
we O
propose O
an O
interim O
period O
in O
which O
only O
families O
with O
a O
strong O
positive O
family O
history O
for O
early O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
will O
be O
offered O
br O
##ca O
##1 O
mutation O
testing O
. O
. O

link O
##age O
analysis O
of O
26 O
can O
##adia O
##n O
breast B-Disease
and I-Disease
breast I-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

we O
have O
examined O
26 O
can O
##adia O
##n O
families O
with O
hereditary B-Disease
breast I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
for O
link O
##age O
to O
markers O
flank O
##ing O
the O
br O
##ca O
##1 O
gene O
on O
chromosome O
17 O
##q O
##12 O
- O
q O
##21 O
. O

of O
the O
15 O
families O
that O
contain O
cases O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
94 O
% O
were O
estimated O
to O
be O
linked O
to O
br O
##ca O
##1 O
. O

in O
contrast O
, O
there O
was O
no O
overall O
evidence O
of O
link O
##age O
in O
the O
group O
of O
10 O
families O
with O
breast B-Disease
cancer I-Disease
without O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

a O
genetic O
re O
##comb O
##ina O
##nt O
in O
a O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
family O
indicates O
a O
placement O
of O
br O
##ca O
##1 O
te O
##lo O
##mer O
##ic O
to O
d O
##17 O
##s O
##7 O
##7 O
##6 O
, O
and O
helps O
to O
define O
the O
region O
of O
assignment O
of O
the O
cancer B-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
. O

other O
cancer B-Disease
##s I-Disease
of O
interest O
that O
appeared O
in O
the O
br O
##ca O
##1 O
- O
linked O
families O
included O
primary B-Disease
per I-Disease
##ito I-Disease
##nea I-Disease
##l I-Disease
cancer I-Disease
, O
cancer B-Disease
of I-Disease
the I-Disease
fall I-Disease
##op I-Disease
##ian I-Disease
tube I-Disease
, O
and O
ma B-Disease
##li I-Disease
##gnant I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
. O
. O

structural O
analysis O
of O
the O
5 O
' O
region O
of O
mouse O
and O
human O
hunting B-Disease
##ton I-Disease
disease I-Disease
genes O
reveals O
conservation O
of O
put O
##ative O
promoter O
region O
and O
di O
- O
and O
t O
##rin O
##uc O
##leo O
##tide O
p O
##oly O
##mor O
##phism O
##s O
. O

we O
have O
previously O
clone O
##d O
and O
characterized O
the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
of O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
gene O
and O
shown O
that O
it O
maps O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
s O
##yn O
##ten O
##y O
with O
human O
chromosome O
4 O
##p O
##16 O
. O

3 O
3 O
. O

here O
we O
present O
a O
detailed O
comparison O
of O
the O
sequence O
of O
the O
put O
##ative O
promoter O
and O
the O
organization O
of O
the O
5 O
g O
##eno O
##mic O
region O
of O
the O
m O
##uri O
##ne O
( O
h O
##dh O
) O
and O
human O
h B-Disease
##d I-Disease
genes O
encompassing O
the O
first O
five O
ex O
##ons O
. O

we O
show O
that O
in O
this O
region O
these O
two O
genes O
share O
identical O
ex O
##on O
boundaries O
, O
but O
have O
different O
- O
size O
intro O
##ns O
. O

two O
din O
##uc O
##leo O
##tide O
( O
c O
##t O
) O
and O
one O
t O
##rin O
##uc O
##leo O
##tide O
intro O
##nic O
p O
##oly O
##mor O
##phism O
in O
h O
##dh O
and O
an O
intro O
##nic O
ca O
p O
##oly O
##mor O
##phism O
in O
the O
h B-Disease
##d I-Disease
gene O
were O
identified O
. O

comparison O
of O
94 O
##0 O
- O
b O
##p O
sequence O
5 O
to O
the O
put O
##ative O
translation O
start O
site O
reveals O
a O
highly O
conserved O
region O
( O
78 O
. O
8 O
% O
n O
##uc O
##leo O
##tide O
identity O
) O
between O
h O
##dh O
and O
the O
h B-Disease
##d I-Disease
gene O
from O
n O
##uc O
##leo O
##tide O
- O
56 O
to O
- O
206 O
( O
of O
h O
##dh O
) O
. O

neither O
h O
##dh O
nor O
the O
h B-Disease
##d I-Disease
gene O
have O
typical O
ta O
##ta O
or O
cc O
##aa O
##t O
elements O
, O
but O
both O
show O
one O
put O
##ative O
a O
##p O
##2 O
binding O
site O
and O
numerous O
potential O
s O
##p O
##1 O
binding O
sites O
. O

the O
high O
sequence O
identity O
between O
h O
##dh O
and O
the O
h B-Disease
##d I-Disease
gene O
for O
approximately O
200 O
b O
##p O
5 O
to O
the O
put O
##ative O
translation O
start O
site O
indicates O
that O
these O
sequences O
may O
play O
a O
role O
in O
regulating O
expression O
of O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
gene O

the O
protein O
def O
##icient O
in O
low B-Disease
##e I-Disease
syndrome I-Disease
is O
a O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
- O
4 O
, O
5 O
- O
bi O
##sp O
##hos O
##phate O
5 O
- O
p O
##hos O
##pha O
##tase O
. O

low B-Disease
##e I-Disease
syndrome I-Disease
, O
also O
known O
as O
o B-Disease
##cu I-Disease
##loc I-Disease
##ere I-Disease
##bro I-Disease
##rena I-Disease
##l I-Disease
syndrome I-Disease
, O
is O
caused O
by O
mutations O
in O
the O
x O
chromosome O
- O
encoded O
o O
##c O
##rl O
gene O
. O

the O
o O
##c O
##rl O
protein O
is O
51 O
% O
identical O
to O
in O
##os O
##ito O
##l O
p O
##oly O
##ph O
##os O
##phate O
5 O
- O
p O
##hos O
##pha O
##tase O
ii O
( O
5 O
- O
p O
##hos O
##pha O
##tase O
ii O
) O
from O
human O
plate O
##lets O
over O
a O
span O
of O
74 O
##4 O
a O
##a O
, O
suggesting O
that O
o O
##c O
##rl O
may O
be O
a O
similar O
enzyme O
. O

we O
engineered O
a O
construct O
of O
the O
o O
##c O
##rl O
c O
##dn O
##a O
that O
en O
##codes O
amino O
acids O
ho O
##mo O
##log O
##ous O
to O
the O
plate O
##let O
5 O
- O
p O
##hos O
##pha O
##tase O
for O
expression O
in O
b O
##ac O
##ulo O
##virus O
- O
infected O
s O
##f O
##9 O
insect O
cells O
. O

this O
c O
##dn O
##a O
en O
##codes O
a O
##a O
264 O
- O
96 O
##8 O
of O
the O
o O
##c O
##rl O
protein O
. O

the O
re O
##comb O
##ina O
##nt O
protein O
was O
found O
to O
cat O
##aly O
##ze O
the O
reactions O
also O
carried O
out O
by O
plate O
##let O
5 O
- O
p O
##hos O
##pha O
##tase O
ii O
. O

thus O
o O
##c O
##rl O
converts O
in O
##os O
##ito O
##l O
1 O
, O
4 O
, O
5 O
- O
t O
##ris O
##ph O
##os O
##phate O
to O
in O
##os O
##ito O
##l O
1 O
, O
4 O
- O
bi O
##sp O
##hos O
##phate O
, O
and O
it O
converts O
in O
##os O
##ito O
##l O
1 O
, O
3 O
, O
4 O
, O
5 O
- O
te O
##tra O
##kis O
##ph O
##os O
##phate O
to O
in O
##os O
##ito O
##l O
1 O
, O
3 O
, O
4 O
- O
t O
##ris O
##ph O
##os O
##phate O
. O

most O
important O
, O
the O
enzyme O
converts O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
4 O
, O
5 O
- O
bi O
##sp O
##hos O
##phate O
to O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
4 O
- O
phosphate O
. O

the O
relative O
ability O
of O
o O
##c O
##rl O
to O
cat O
##aly O
##ze O
the O
three O
reactions O
is O
different O
from O
that O
of O
5 O
- O
p O
##hos O
##pha O
##tase O
ii O
and O
from O
that O
of O
another O
5 O
- O
p O
##hos O
##pha O
##tase O
is O
##oe O
##nz O
##yme O
from O
plate O
##lets O
, O
5 O
- O
p O
##hos O
##pha O
##tase O
i O
. O

the O
re O
##comb O
##ina O
##nt O
o O
##c O
##rl O
protein O
h O
##ydro O
##ly O
##zes O
the O
p O
##hos O
##ph O
##oli O
##pid O
substrate O
10 O
- O
to O
30 O
- O
fold O
better O
than O
5 O
- O
p O
##hos O
##pha O
##tase O
ii O
, O
and O
5 O
- O
p O
##hos O
##pha O
##tase O
i O
does O
not O
c O
##lea O
##ve O
the O
lip O
##id O
at O
all O
. O

we O
also O
show O
that O
o O
##c O
##rl O
functions O
as O
a O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
4 O
, O
5 O
- O
bi O
##sp O
##hos O
##phate O
5 O
- O
p O
##hos O
##pha O
##tase O
in O
o O
##c O
##rl O
- O
expressing O
s O
##f O
##9 O
cells O
. O

these O
results O
suggest O
that O
o O
##c O
##rl O
is O
mainly O
a O
lip O
##id O
p O
##hos O
##pha O
##tase O
that O
may O
control O
cellular O
levels O
of O
a O
critical O
meta O
##bol O
##ite O
, O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
4 O
, O
5 O
- O
bi O
##sp O
##hos O
##phate O
. O

deficiency O
of O
this O
enzyme O
apparently O
causes O
the O
pro O
##te O
##an O
manifest O
##ations O
of O
low B-Disease
##e I-Disease
syndrome I-Disease
. O
. O

new O
founder O
ha O
##p O
##lot O
##ype O
##s O
at O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
in O
southern O
a O
##f O
##rica O
. O

the O
association O
between O
normal O
all O
##ele O
##s O
at O
the O
c O
##t O
##g O
repeat O
and O
two O
nearby O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
my O
##oto O
##nin O
protein O
kinase O
gene O
, O
the O
al O
##u O
insertion O
/ O
del O
##eti O
##on O
p O
##oly O
##mor O
##phism O
and O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
kinase O
( O
d O
##m O
##k O
) O
( O
g O
/ O
t O
) O
intro O
##n O
9 O
/ O
hi O
##n O
##fi O
p O
##oly O
##mor O
##phism O
, O
has O
been O
analyzed O
in O
south O
a O
##f O
##rica O
##n O
ne O
##gro O
##ids O
, O
a O
population O
in O
which O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
has O
not O
been O
described O
. O

south O
a O
##f O
##rica O
##n O
ne O
##gro O
##ids O
have O
a O
c O
##t O
##g O
all O
##eli O
##c O
distribution O
that O
is O
significantly O
different O
from O
that O
in O
ca O
##uca O
##so O
##ids O
and O
j O
##apa O
##nese O
the O
c O
##t O
##g O
repeat O
lengths O
of O
[UNK] O
or O
= O
19 O
are O
very O
rare O
. O

the O
striking O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
between O
specific O
all O
##ele O
##s O
at O
the O
al O
##u O
p O
##oly O
##mor O
##phism O
( O
al O
##u O
( O
ins O
) O
and O
al O
##u O
( O
del O
) O
) O
, O
the O
hi O
##n O
##fi O
p O
##oly O
##mor O
##phism O
( O
hi O
##n O
##fi O
- O
1 O
and O
hi O
##n O
##fi O
- O
2 O
) O
, O
and O
the O
c O
##t O
##g O
repeat O
p O
##oly O
##mor O
##phism O
seen O
in O
ca O
##uca O
##so O
##id O
( O
euro O
##pe O
##ans O
and O
can O
##adia O
##ns O
) O
populations O
was O
also O
found O
in O
the O
south O
a O
##f O
##rica O
##n O
ne O
##gro O
##id O
population O
. O

numerous O
ha O
##p O
##lot O
##ype O
##s O
, O
not O
previously O
described O
in O
euro O
##pe O
##ans O
, O
were O
, O
however O
, O
found O
. O

it O
thus O
seems O
likely O
that O
only O
a O
small O
number O
of O
these O
" O
a O
##f O
##rica O
##n O
" O
chromosome O
##s O
were O
present O
in O
the O
pro O
##gen O
##itors O
of O
all O
non O
- O
a O
##f O
##rica O
##n O
peoples O
. O

these O
data O
provide O
support O
for O
the O
" O
out O
of O
a O
##f O
##rica O
" O
model O
for O
the O
origin O
of O
modern O
humans O
and O
suggest O
that O
the O
rare O
ancestral O
d B-Disease
##m I-Disease
mutation O
event O
may O
have O
occurred O
after O
the O
migration O
from O
a O
##f O
##rica O
, O
hence O
the O
absence O
of O
d B-Disease
##m I-Disease
in O
sub O
- O
sa O
##hara O
##n O
ne O
##gro O
##id O
peoples O
. O
. O

disco O
##rda O
##nt O
clinical O
outcome O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
relatives O
showing O
( O
c O
##t O
##g O
) O
n O
[UNK] O
700 O
repeats O
. O

a O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
family O
is O
described O
in O
which O
disco O
##rda O
##nt O
d B-Disease
##m I-Disease
p O
##hen O
##otype O
##s O
were O
found O
in O
the O
children O
of O
two O
affected O
sisters O
with O
similar O
c O
##t O
##g O
expansion O
and O
clinical O
manifest O
##ations O
. O

in O
this O
family O
, O
con O
##gen O
##ital O
as O
well O
as O
early O
severe O
childhood O
and O
later O
childhood O
onset O
d B-Disease
##m I-Disease
co O
##ex O
##ist O
. O

this O
observation O
strengthen O
##s O
the O
limited O
ability O
of O
l O
##ymph O
##ocytes O
c O
##t O
##g O
repeat O
number O
analysis O
in O
predict O
##ing O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
in O
d B-Disease
##m I-Disease
patients O
. O
. O

pu O
##rification O
of O
human O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##en O
##zy O
##me O
a O
de O
##hy O
##dr O
##ogen O
##ase O
and O
characterization O
of O
its O
deficiency O
in O
seven O
patients O
. O

mitochondrial O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##en O
##zy O
##me O
a O
de O
##hy O
##dr O
##ogen O
##ase O
( O
v O
##l O
##ca O
##d O
) O
was O
pu O
##rified O
from O
human O
liver O
. O

the O
molecular O
masses O
of O
the O
native O
enzyme O
and O
the O
subunit O
were O
estimated O
to O
be O
154 O
and O
70 O
k O
##d O
, O
respectively O
. O

the O
enzyme O
was O
found O
to O
cat O
##aly O
##ze O
the O
major O
part O
of O
mitochondrial O
palm O
##ito O
##yl O
##coe O
##nz O
##yme O
a O
de O
##hy O
##dr O
##ogen O
##ation O
in O
liver O
, O
heart O
, O
skeletal O
muscle O
, O
and O
skin O
fi O
##bro O
##blast O
##s O
( O
89 O
- O
97 O
, O
86 O
- O
99 O
, O
96 O
- O
99 O
, O
and O
78 O
- O
87 O
% O
, O
respectively O
) O
. O

skin O
fi O
##bro O
##blast O
##s O
from O
26 O
patients O
suspected O
of O
having O
a O
disorder O
of O
mitochondrial O
beta O
- O
oxidation O
were O
analyzed O
for O
v O
##l O
##ca O
##d O
protein O
using O
im O
##mu O
##nob O
##lot O
##ting O
, O
and O
7 O
of O
them O
contained O
und O
##ete O
##ct O
##able O
or O
trace O
levels O
of O
the O
enzyme O
. O

the O
seven O
def O
##icient O
fi O
##bro O
##blast O
lines O
were O
characterized O
by O
measuring O
a O
##cy O
##l O
- O
co O
##en O
##zy O
##me O
a O
de O
##hy O
##dr O
##ogen O
##ation O
activities O
, O
overall O
palm O
##itic O
acid O
oxidation O
, O
and O
v O
##l O
##ca O
##d O
protein O
synthesis O
using O
pulse O
- O
chase O
, O
further O
confirming O
the O
diagnosis O
of O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
. O

these O
results O
suggested O
the O
he O
##tero O
##gen O
##ous O
nature O
of O
the O
mutations O
causing O
the O
deficiency O
in O
the O
seven O
patients O
. O

clinical O
##ly O
, O
all O
patients O
with O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
exhibited O
cardiac B-Disease
disease I-Disease
. O

at O
least O
four O
of O
them O
presented O
with O
h B-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
. O

this O
frequency O
( O
[UNK] O
57 O
% O
) O
was O
much O
higher O
than O
that O
observed O
in O
patients O
with O
other O
disorders O
of O
mitochondrial O
long O
- O
chain O
fatty O
acid O
oxidation O
that O
may O
be O
accompanied O
by O
cardiac B-Disease
disease I-Disease
in O
infants O
. O
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
man O
. O

ii O
. O

biological O
properties O
of O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
human O
serum O
. O

the O
first O
known O
human O
kind O
##red O
with O
hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c O
##5 O
) O
was O
documented O
in O
the O
accompanying O
report O
. O

this O
study O
examines O
several O
biological O
properties O
of O
c B-Disease
##5 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
( O
c B-Disease
##5 I-Disease
##d I-Disease
) O
human O
serum O
, O
particularly O
se O
##ra O
obtained O
from O
two O
c B-Disease
##5 I-Disease
##d I-Disease
ho O
##mo O
##zy O
##got O
##es O
. O

the O
pro O
##band O
, O
who O
has O
inactive O
systemic B-Disease
l I-Disease
##up I-Disease
##us I-Disease
er I-Disease
##yt I-Disease
##hem I-Disease
##ato I-Disease
##sus I-Disease
is O
completely O
lacking O
c O
##5 O
, O
while O
her O
healthy O
half O
- O
sister O
has O
1 O
- O
2 O
% O
of O
normal O
levels O
. O

both O
se O
##ra O
were O
severely O
impaired O
in O
their O
ability O
to O
generate O
ch O
##em O
##ota O
##ctic O
activity O
for O
normal O
human O
ne O
##ut O
##rop O
##hil O
##s O
upon O
in O
##cu O
##bation O
with O
aggregate O
##d O
human O
gamma O
- O
g O
##lo O
##bul O
##in O
or O
es O
##cher O
##ichi O
##a O
co O
##li O
end O
##oto O
##xin O
. O

this O
function O
was O
fully O
restored O
in O
the O
siblings O
serum O
, O
and O
substantially O
improved O
in O
the O
pro O
##band O
##s O
serum O
, O
by O
addition O
of O
highly O
pu O
##rified O
human O
c O
##5 O
to O
normal O
serum O
concentrations O
. O

se O
##ra O
from O
eight O
family O
members O
who O
were O
apparently O
he O
##tero O
##zy O
##go O
##us O
for O
c B-Disease
##5 I-Disease
deficiency I-Disease
gave O
normal O
ch O
##em O
##ota O
##ctic O
scores O
. O

the O
ability O
of O
c B-Disease
##5 I-Disease
##d I-Disease
serum O
to O
op O
##son O
##ize O
sa O
##cc O
##har O
##omy O
##ces O
c O
##ere O
##vis O
##iae O
( O
b O
##aker O
##s O
yeast O
) O
or O
can O
##di O
##da O
al O
##bic O
##ans O
for O
ing O
##est O
##ion O
by O
normal O
ne O
##ut O
##rop O
##hil O
##s O
was O
completely O
normal O
. O

in O
addition O
, O
c B-Disease
##5 I-Disease
##d I-Disease
serum O
was O
capable O
of O
promoting O
normal O
p O
##ha O
##go O
##cy O
##tosis O
and O
in O
##tra O
##cellular O
killing O
of O
s O
##ta O
##phy O
##loc O
##oc O
##cus O
au O
##reus O
. O

the O
pro O
##band O
##s O
serum O
was O
incapable O
of O
media O
##ting O
l O
##ys O
##is O
of O
er O
##yt O
##hr O
##ocytes O
from O
a O
patient O
with O
par B-Disease
##ox I-Disease
##ys I-Disease
##mal I-Disease
no I-Disease
##cturnal I-Disease
hem I-Disease
##og I-Disease
##lo I-Disease
##bin I-Disease
##uria I-Disease
in O
both O
the O
su O
##c O
##rose O
hem O
##oly O
##sia O
and O
acid O
hem O
##oly O
##sis O
tests O
, O
and O
also O
lacked O
b O
##act O
##eric O
##idal O
activity O
against O
se O
##ns O
##iti O
##zed O
or O
un O
##sen O
##si O
##tized O
salmon O
##ella O
t O
##y O
##phi O
. O

the O
siblings O
serum O
, O
containing O
only O
1 O
- O
2 O
% O
of O
normal O
c O
##5 O
, O
effectively O
l O
##ys O
##ed O
s O
. O
t O
##y O
##phi O
, O
but O
only O
at O
eight O
##fold O
lower O
serum O
di O
##lution O
##s O
as O
compared O
to O
normal O
##s O
. O

these O
findings O
under O
##sco O
##re O
the O
critical O
role O
of O
c O
##5 O
in O
the O
generation O
of O
ch O
##em O
##ota O
##ctic O
activity O
and O
in O
c O
##yt O
##oly O
##tic O
reactions O
, O
as O
opposed O
to O
a O
non O
##ob O
##liga O
##tory O
or O
minimal O
role O
in O
op O
##son O
##ization O
, O
at O
least O
for O
the O
organisms O
under O
study O
. O
. O

human O
per O
##ox O
##is O
##oma O
##l O
targeting O
signal O
- O
1 O
receptor O
restore O
##s O
per O
##ox O
##is O
##oma O
##l O
protein O
import O
in O
cells O
from O
patients O
with O
fatal O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorders I-Disease
. O

two O
per O
##ox O
##is O
##oma O
##l O
targeting O
signals O
, O
p O
##ts O
##1 O
and O
p O
##ts O
##2 O
, O
are O
involved O
in O
the O
import O
of O
proteins O
into O
the O
per O
##ox O
##is O
##ome O
matrix O
. O

human O
patients O
with O
fatal O
generalized O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
deficiency I-Disease
disorders I-Disease
fall O
into O
at O
least O
nine O
genetic O
complement O
##ation O
groups O
. O

cells O
from O
many O
of O
these O
patients O
are O
def O
##icient O
in O
the O
import O
of O
p O
##ts O
##1 O
- O
containing O
proteins O
, O
but O
the O
causes O
of O
the O
protein O
- O
import O
defect O
in O
these O
patients O
are O
unknown O
. O

we O
have O
clone O
##d O
and O
sequence O
##d O
the O
human O
c O
##dn O
##a O
ho O
##mo O
##logue O
( O
p O
##ts O
##1 O
##r O
) O
of O
the O
p O
##ichi O
##a O
pastor O
##is O
p O
##as O
##8 O
gene O
, O
the O
p O
##ts O
##1 O
receptor O
( O
m O
##cco O
##llum O
, O
d O
. O
, O
e O
. O
mon O
##oso O
##v O
, O
and O
s O
. O
sub O
##rama O
##ni O
. O
1993 O
. O
j O
. O
cell O
bio O
##l O
. O
121 O
76 O
##1 O
- O
77 O
##4 O
) O
. O

the O
p O
##ts O
##1 O
##r O
m O
##rna O
is O
expressed O
in O
all O
human O
tissues O
examined O
. O

antibodies O
to O
the O
human O
p O
##ts O
##1 O
##r O
recognize O
this O
protein O
in O
human O
, O
monkey O
, O
rat O
, O
and O
ha O
##ms O
##ter O
cells O
. O

the O
protein O
is O
localized O
mainly O
in O
the O
c O
##yt O
##oso O
##l O
but O
is O
also O
found O
to O
be O
associated O
with O
per O
##ox O
##is O
##ome O
##s O
. O

part O
of O
the O
per O
##ox O
##is O
##oma O
##l O
p O
##ts O
##1 O
##r O
protein O
is O
tightly O
bound O
to O
the O
per O
##ox O
##is O
##oma O
##l O
membrane O
. O

antibodies O
to O
p O
##ts O
##1 O
##r O
in O
##hibit O
per O
##ox O
##is O
##oma O
##l O
protein O
- O
import O
of O
p O
##ts O
##1 O
- O
containing O
proteins O
in O
a O
per O
##me O
##abi O
##li O
##zed O
ch O
##o O
cell O
system O
. O

in O
v O
##it O
##ro O
- O
translated O
p O
##ts O
##1 O
##r O
protein O
specifically O
binds O
a O
se O
##rine O
- O
l O
##ys O
##ine O
- O
le O
##uc O
##ine O
- O
p O
##eptide O
. O

a O
p O
##as O
##8 O
- O
p O
##ts O
##1 O
##r O
fusion O
protein O
complement O
##s O
the O
p O
. O
pastor O
##is O
p O
##as O
##8 O
mutant O
. O

the O
p O
##ts O
##1 O
##r O
c O
##dn O
##a O
also O
complement O
##s O
the O
p B-Disease
##ts I-Disease
##1 I-Disease
protein I-Disease
- I-Disease
import I-Disease
defect I-Disease
in O
skin O
fi O
##bro O
##blast O
##s O
from O
patients O
- O
- O
belonging O
to O
complement O
##ation O
group O
two O
- O
- O
diagnosed O
as O
having O
neon B-Disease
##ata I-Disease
##l I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
or O
z B-Disease
##ell I-Disease
##we I-Disease
##ger I-Disease
syndrome I-Disease
. O

the O
p O
##ts O
##1 O
##r O
gene O
has O
been O
localized O
to O
a O
ch O
##rom O
##oso O
##mal O
location O
where O
no O
other O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorder I-Disease
genes O
are O
known O
to O
map O
. O

our O
findings O
represent O
the O
only O
case O
in O
which O
the O
molecular O
basis O
of O
the O
protein B-Disease
- I-Disease
import I-Disease
deficiency I-Disease
in O
human O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorders I-Disease
is O
understood O
. O

spectrum O
of O
g O
##er O
##m O
##line O
mutations O
in O
the O
r O
##b O
##1 O
gene O
: O
a O
study O
of O
232 O
patients O
with O
hereditary B-Disease
and I-Disease
non I-Disease
hereditary I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
r O
##b O
##1 O
gene O
con O
##fer O
hereditary O
pre O
##dis O
##position O
to O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

we O
have O
performed O
a O
mutation O
survey O
of O
the O
r O
##b O
##1 O
gene O
in O
232 O
patients O
with O
hereditary B-Disease
or I-Disease
non I-Disease
hereditary I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

we O
systematically O
explored O
all O
27 O
ex O
##ons O
and O
flank O
##ing O
sequences O
as O
well O
as O
the O
pro O
##moto O
##r O
. O

all O
types O
of O
point O
mutations O
are O
represented O
and O
are O
found O
une O
##qua O
##lly O
distributed O
along O
the O
r O
##b O
##1 O
gene O
sequence O
. O

in O
the O
population O
we O
studied O
, O
ex O
##ons O
3 O
, O
8 O
, O
18 O
and O
19 O
are O
prefer O
##ential O
##ly O
altered O
. O

the O
range O
of O
frequency O
of O
detection O
of O
g O
##er O
##m O
##line O
mutations O
is O
about O
20 O
% O
, O
indicating O
that O
other O
mechanisms O
of O
in O
##act O
##ivation O
of O
r O
##b O
##1 O
should O
be O
involved O
. O

the O
spectrum O
of O
mutations O
presented O
here O
should O
help O
to O
improve O
the O
clinical O
management O
of O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
and O
to O
understand O
the O
molecular O
mechanisms O
leading O
to O
tumor O
##ige O
##nes O
##is O
. O
. O

an B-Disease
##iri I-Disease
##dia I-Disease
- O
associated O
c O
##yt O
##ogen O
##etic O
rear O
##rang O
##ement O
##s O
suggest O
that O
a O
position O
effect O
may O
cause O
the O
mutant O
p O
##hen O
##otype O
. O

current O
evidence O
suggests O
that O
an B-Disease
##iri I-Disease
##dia I-Disease
( O
absence B-Disease
of I-Disease
i I-Disease
##ris I-Disease
) O
is O
caused O
by O
loss O
of O
function O
of O
one O
copy O
of O
the O
p O
##ax O
##6 O
gene O
, O
which O
maps O
to O
11 O
##p O
##13 O
. O

we O
present O
the O
further O
character O
##isation O
of O
two O
an B-Disease
##iri I-Disease
##dia I-Disease
p O
##ed O
##ig O
##ree O
##s O
in O
which O
the O
disease O
se O
##g O
##re O
##gate O
##s O
with O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
##s O
which O
involve O
11 O
##p O
##13 O
but O
do O
not O
disrupt O
the O
p O
##ax O
##6 O
gene O
. O

we O
have O
isolated O
three O
human O
ya O
##c O
clone O
##s O
which O
en O
##com O
##pass O
the O
p O
##ax O
##6 O
lo O
##cus O
and O
we O
have O
used O
these O
to O
show O
that O
in O
both O
cases O
the O
ch O
##rom O
##oso O
##mal O
break O
##point O
is O
at O
least O
85 O
k O
##b O
di O
##stal O
of O
the O
3 O
end O
of O
p O
##ax O
##6 O
. O

in O
addition O
, O
the O
open O
reading O
frame O
of O
p O
##ax O
##6 O
is O
apparently O
free O
of O
mutations O
. O

we O
propose O
that O
the O
p O
##ax O
##6 O
gene O
on O
the O
rear O
##ranged O
chromosome O
11 O
is O
in O
an O
inappropriate O
ch O
##roma O
##tin O
environment O
for O
normal O
expression O
and O
therefore O
that O
a O
position O
effect O
is O
the O
underlying O
mechanism O
of O
disease O
in O
these O
families O
. O
. O

so O
##matic O
mutations O
in O
the O
br O
##ca O
##1 O
gene O
in O
s B-Disease
##poradic I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
. O

the O
br O
##ca O
##1 O
gene O
on O
chromosome O
17 O
##q O
##21 O
is O
responsible O
for O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
syndrome I-Disease
of O
increased O
su O
##s O
##ce O
##pt O
##ibility O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
but O
no O
so O
##matic O
mutations O
in O
t B-Disease
##umour I-Disease
##s I-Disease
have O
yet O
been O
described O
. O

to O
study O
the O
potential O
role O
of O
br O
##ca O
##1 O
in O
s O
##poradic O
car O
##cin O
##ogen O
##esis O
, O
we O
anal O
##ys O
##ed O
the O
g O
##eno O
##mic O
d O
##na O
of O
t B-Disease
##umour I-Disease
and O
normal O
fraction O
##s O
of O
47 O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
for O
mutations O
in O
br O
##ca O
##1 O
using O
the O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
technique O
. O

we O
now O
describe O
so O
##matic O
mutations O
in O
the O
d O
##na O
of O
four O
t B-Disease
##umour I-Disease
##s I-Disease
which O
also O
had O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
( O
lo O
##h O
) O
at O
a O
br O
##ca O
##1 O
in O
##tra O
##genic O
marker O
. O

our O
data O
support O
a O
t B-Disease
##umour I-Disease
suppress O
##or O
mechanism O
for O
br O
##ca O
##1 O
; O
so O
##matic O
mutations O
and O
lo O
##h O
may O
result O
in O
in O
##act O
##ivation O
of O
br O
##ca O
##1 O
in O
at O
least O
a O
small O
number O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O
. O

decreased O
expression O
of O
br O
##ca O
##1 O
accelerate O
##s O
growth O
and O
is O
often O
present O
during O
s B-Disease
##poradic I-Disease
breast I-Disease
cancer I-Disease
progression O
. O

we O
have O
characterized O
expression O
of O
the O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
gene O
, O
br O
##ca O
##1 O
, O
in O
cases O
of O
non B-Disease
- I-Disease
hereditary I-Disease
( I-Disease
s I-Disease
##poradic I-Disease
) I-Disease
breast I-Disease
cancer I-Disease
and O
analyzed O
the O
effect O
of O
anti O
##sen O
##se O
in O
##hibition O
of O
br O
##ca O
##1 O
on O
the O
pro O
##life O
##rative O
rate O
of O
ma O
##mma O
##ry O
e O
##pit O
##hel O
##ial O
cells O
. O

br O
##ca O
##1 O
m O
##rna O
levels O
are O
marked O
##ly O
decreased O
during O
the O
transition O
from O
car B-Disease
##cin I-Disease
##oma I-Disease
in I-Disease
sit I-Disease
##u I-Disease
to O
invasive B-Disease
cancer I-Disease
. O

experimental O
in O
##hibition O
of O
br O
##ca O
##1 O
expression O
with O
anti O
##sen O
##se O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
produced O
accelerated O
growth O
of O
normal O
and O
ma O
##li O
##gnant O
ma O
##mma O
##ry O
cells O
, O
but O
had O
no O
effect O
on O
non O
- O
ma O
##mma O
##ry O
e O
##pit O
##hel O
##ial O
cells O
. O

these O
studies O
suggest O
that O
br O
##ca O
##1 O
may O
normally O
serve O
as O
a O
negative O
regulator O
of O
ma O
##mma O
##ry O
e O
##pit O
##hel O
##ial O
cell O
growth O
whose O
function O
is O
compromised O
in O
breast B-Disease
cancer I-Disease
either O
by O
direct O
mutation O
or O
alterations O
in O
gene O
expression O
. O
. O

additional O
case O
of O
female O
mon O
##oz O
##y O
##got O
##ic O
twins O
disco O
##rda O
##nt O
for O
the O
clinical O
manifest O
##ations O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
due O
to O
opposite O
x O
- O
chromosome O
in O
##act O
##ivation O
. O

a O
pair O
of O
female O
mon O
##oz O
##y O
##got O
##ic O
( O
m O
##z O
) O
twins O
, O
he O
##tero O
##zy O
##go O
##us O
carriers O
for O
a O
del O
##eti O
##on O
in O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
and O
disco O
##rda O
##nt O
for O
the O
clinical O
manifest O
##ations O
of O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
were O
analyzed O
by O
molecular O
studies O
, O
in O
sit O
##u O
hybrid O
##ization O
, O
and O
met O
##hyl O
##ation O
pattern O
of O
x O
chromosome O
##s O
to O
search O
for O
opposite O
x O
in O
##act O
##ivation O
as O
an O
explanation O
of O
their O
clinical O
disco O
##rda O
##nce O
. O

results O
in O
l O
##ymph O
##ocytes O
and O
skin O
fi O
##bro O
##blast O
cell O
lines O
suggest O
a O
partial O
mirror O
in O
##act O
##ivation O
with O
the O
normal O
x O
chromosome O
prefer O
##ential O
##ly O
active O
in O
the O
un O
##af O
##fected O
twin O
, O
and O
the O
maternal O
deleted O
x O
chromosome O
prefer O
##ential O
##ly O
active O
in O
the O
affected O
twin O
. O

a O
review O
shows O
that O
m O
##z O
female O
twins O
disco O
##rda O
##nt O
for O
x B-Disease
- I-Disease
linked I-Disease
diseases I-Disease
are O
not O
uncommon O
. O

twin O
##ning O
and O
x O
in O
##act O
##ivation O
may O
be O
inter O
##rel O
##ated O
and O
could O
explain O
the O
female O
twins O
disco O
##rda O
##nt O
for O
x O
- O
linked O
traits O
. O
. O

x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
: O
a O
novel O
mutation O
of O
the O
al B-Disease
##d I-Disease
gene O
in O
6 O
members O
of O
a O
family O
presenting O
with O
5 O
different O
p O
##hen O
##otype O
##s O
. O

fragments O
of O
the O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
c O
##dn O
##a O
from O
a O
patient O
with O
adolescent B-Disease
al I-Disease
##d I-Disease
were O
am O
##plified O
by O
polymer O
##ase O
chain O
reaction O
and O
sub O
##c O
##lone O
##d O
. O

bid O
##ire O
##ctional O
se O
##quencing O
of O
the O
entire O
coding O
al B-Disease
##d I-Disease
gene O
disclosed O
a O
c O
##yt O
##os O
##ine O
to O
g O
##uan O
##ine O
trans O
##version O
at O
n O
##uc O
##leo O
##tide O
145 O
##1 O
in O
ex O
##on O
five O
, O
resulting O
in O
substitution O
of O
pro O
##line O
48 O
##4 O
by O
a O
##rg O
##ini O
##ne O
. O

five O
of O
nine O
siblings O
of O
the O
patient O
, O
comprising O
two O
cerebral B-Disease
al I-Disease
##d I-Disease
, O
one O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
, O
one O
add B-Disease
##ison I-Disease
only I-Disease
as O
well O
as O
the O
s O
##ym O
##pt O
##oma O
##tic O
mother O
( O
all O
a O
##cc O
##um O
##ulating O
very O
long O
chain O
fatty O
acids O
) O
carried O
this O
mutation O
, O
which O
was O
not O
found O
in O
the O
un O
##af O
##fected O
persons O
, O
in O
five O
unrelated O
al B-Disease
##d I-Disease
patients O
, O
and O
in O
twenty O
controls O
. O

we O
propose O
that O
this O
miss O
##ense O
mutation O
generated O
the O
disease O
per O
se O
as O
well O
as O
the O
metabolic O
defect O
; O
the O
different O
p O
##hen O
##otype O
##s O
, O
however O
, O
must O
have O
originated O
by O
means O
of O
additional O
path O
##ogen O
##etic O
factors O
. O
. O

novel O
mutation O
at O
the O
initiation O
co O
##don O
in O
the O
nor B-Disease
##rie I-Disease
disease I-Disease
gene O
in O
two O
j O
##apa O
##nese O
families O
. O

we O
have O
identified O
a O
new O
mutation O
of O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
) O
gene O
in O
two O
j O
##apa O
##nese O
males O
from O
unrelated O
families O
; O
they O
showed O
typical O
o O
##cular O
features O
of O
n B-Disease
##d I-Disease
but O
no O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
or O
hearing B-Disease
imp I-Disease
##air I-Disease
##ment I-Disease
. O

a O
mutation O
was O
found O
in O
both O
patients O
at O
the O
initiation O
co O
##don O
of O
ex O
##on O
2 O
of O
the O
n B-Disease
##d I-Disease
gene O
( O
at O
##g O
to O
g O
##t O
##g O
) O
, O
with O
otherwise O
normal O
n O
##uc O
##leo O
##tide O
sequences O
. O

their O
mothers O
had O
the O
normal O
and O
mutant O
types O
of O
the O
gene O
, O
which O
was O
expected O
for O
he O
##tero O
##zy O
##got O
##es O
of O
the O
disease O
. O

the O
mutation O
of O
the O
initiation O
co O
##don O
would O
cause O
the O
failure O
of O
n B-Disease
##d I-Disease
gene O
expression O
or O
a O
defect O
in O
translation O
thereby O
t O
##run O
##cating O
the O
amino O
terminus O
of O
n B-Disease
##d I-Disease
protein O
. O

in O
view O
of O
the O
r O
##arity O
and O
marked O
he O
##tero O
##gene O
##ity O
of O
mutations O
in O
the O
n B-Disease
##d I-Disease
gene O
, O
the O
present O
apparently O
unrelated O
j O
##apa O
##nese O
families O
who O
have O
lived O
in O
the O
same O
area O
for O
over O
two O
centuries O
presumably O
share O
the O
origin O
of O
the O
mutation O
. O
. O

anticipation O
resulting O
in O
elimination O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
gene O
: O
a O
follow O
up O
study O
of O
one O
extended O
family O
. O

we O
have O
re O
- O
examined O
an O
extended O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
family O
, O
previously O
described O
in O
1955 O
, O
in O
order O
to O
study O
the O
long O
term O
effects O
of O
anticipation O
in O
d B-Disease
##m I-Disease
and O
in O
particular O
the O
implications O
for O
families O
affected O
by O
this O
disease O
. O

this O
follow O
up O
study O
provides O
data O
on O
35 O
gene O
carriers O
and O
46 O
as O
##ym O
##pt O
##oma O
##tic O
at O
risk O
family O
members O
in O
five O
generations O
. O

clinical O
anticipation O
, O
defined O
as O
the O
ca O
##sca O
##de O
of O
mild O
, O
adult O
, O
childhood O
, O
or O
con B-Disease
##gen I-Disease
##ital I-Disease
disease I-Disease
in O
subsequent O
generations O
, O
appeared O
to O
be O
a O
relentless O
process O
, O
occurring O
in O
all O
affected O
branches O
of O
the O
family O
. O

the O
ca O
##sca O
##de O
was O
found O
to O
proceed O
as O
##ync O
##hr O
##ono O
##us O
##ly O
in O
the O
different O
branches O
, O
mainly O
because O
of O
an O
une O
##qua O
##l O
number O
of O
generations O
with O
mild O
disease O
. O

the O
transition O
from O
the O
mild O
to O
the O
adult O
type O
was O
associated O
with O
transmission O
through O
a O
male O
parent O
. O

stable O
transmission O
of O
the O
as O
##ym O
##pt O
##oma O
##tic O
/ O
mild O
p O
##hen O
##otype O
showed O
a O
female O
transmission O
bias O
. O

we O
further O
examined O
the O
extent O
and O
causes O
of O
gene O
loss O
in O
this O
p O
##ed O
##ig O
##ree O
. O

gene O
loss O
in O
the O
patient O
group O
was O
complete O
, O
owing O
to O
in B-Disease
##fer I-Disease
##tility I-Disease
of O
the O
male O
patients O
with O
adult O
onset O
disease O
and O
the O
fact O
that O
mentally B-Disease
re I-Disease
##tar I-Disease
##ded I-Disease
patients O
did O
not O
pro O
##cre O
##ate O
. O

out O
of O
the O
46 O
at O
risk O
subjects O
in O
the O
two O
youngest O
generations O
, O
only O
one O
was O
found O
to O
have O
a O
full O
mutation O
. O

this O
is O
the O
only O
subject O
who O
may O
transmit O
the O
gene O
to O
the O
sixth O
generation O
. O

no O
pro O
##tom O
##uta O
##tion O
carriers O
were O
found O
in O
the O
fourth O
and O
fifth O
generations O
. O

therefore O
it O
is O
highly O
probable O
that O
the O
d B-Disease
##m I-Disease
gene O
will O
be O
eliminated O
from O
this O
p O
##ed O
##ig O
##ree O
within O
one O
generation O
. O

the O
high O
population O
frequency O
of O
d B-Disease
##m I-Disease
can O
at O
present O
not O
be O
explained O
by O
the O
contribution O
of O
as O
##ym O
##pt O
##oma O
##tic O
cases O
in O
the O
younger O
generations O
of O
known O
families O
, O
but O
is O
probably O
caused O
by O
the O
events O
in O
the O
ancestral O
generations O
. O
. O

the O
gene O
for O
spinal B-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
3 O
( O
s O
##ca O
##3 O
) O
is O
located O
in O
a O
region O
of O
approximately O
3 O
cm O
on O
chromosome O
14 O
##q O
##24 O
. O
3 O
- O
q O
##32 O
. O
2 O
. O

s O
##ca O
##3 O
, O
the O
gene O
for O
spinal B-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
3 O
, O
was O
recently O
mapped O
to O
a O
15 O
- O
cm O
interval O
between O
d O
##14 O
##s O
##6 O
##7 O
and O
d O
##14 O
##s O
##8 O
##1 O
on O
chromosome O
14 O
##q O
, O
by O
link O
##age O
analysis O
in O
two O
families O
of O
f O
##rench O
ancestry O
. O

the O
s O
##ca O
##3 O
candidate O
region O
has O
now O
been O
refined O
by O
link O
##age O
analysis O
with O
four O
new O
micro O
##sat O
##elli O
##te O
markers O
( O
d O
##14 O
##s O
##25 O
##6 O
, O
d O
##14 O
##s O
##29 O
##1 O
, O
d O
##14 O
##s O
##28 O
##0 O
, O
and O
a O
##f O
##m O
##34 O
##3 O
##v O
##f O
##1 O
) O
in O
the O
same O
two O
families O
, O
in O
which O
19 O
additional O
individuals O
were O
g O
##eno O
##type O
##d O
, O
and O
in O
a O
third O
f O
##rench O
family O
. O

combined O
two O
- O
point O
link O
##age O
analyses O
show O
that O
the O
new O
markers O
, O
d O
##14 O
##s O
##28 O
##0 O
and O
a O
##f O
##m O
##34 O
##3 O
##v O
##f O
##1 O
, O
are O
tightly O
linked O
to O
the O
s O
##ca O
##3 O
lo O
##cus O
, O
with O
ma O
##ximal O
lo O
##d O
scores O
, O
at O
re O
##comb O
##ination O
fraction O
, O
( O
the O
##ta O
) O
= O
. O

00 O
, O
of O
7 O
. O

05 O
and O
13 O
. O

70 O
, O
respectively O
. O

combined O
multi O
##point O
and O
re O
##comb O
##ina O
##nt O
ha O
##p O
##lot O
##ype O
analyses O
local O
##ize O
the O
s O
##ca O
##3 O
lo O
##cus O
to O
a O
3 O
- O
cm O
interval O
flanked O
by O
d O
##14 O
##s O
##29 O
##1 O
and O
d O
##14 O
##s O
##8 O
##1 O
. O

the O
same O
all O
##ele O
for O
d O
##14 O
##s O
##28 O
##0 O
se O
##g O
##re O
##gate O
##s O
with O
the O
disease O
lo O
##cus O
in O
the O
three O
kind O
##red O
##s O
. O

this O
all O
##ele O
is O
frequent O
in O
the O
f O
##rench O
population O
, O
however O
, O
and O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
is O
not O
clearly O
established O
. O

the O
s O
##ca O
##3 O
lo O
##cus O
remains O
within O
the O
29 O
- O
cm O
region O
on O
14 O
##q O
##24 O
. O

3 O
- O
q O
##32 O
. O

2 O
containing O
the O
gene O
for O
the O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
, O
which O
is O
clinical O
##ly O
related O
to O
the O
p O
##hen O
##otype O
determined O
by O
s O
##ca O
##3 O
, O
but O
it O
cannot O
yet O
be O
concluded O
that O
both O
diseases O
result O
from O
alterations O
of O
the O
same O
gene O

an O
evaluation O
of O
genetic O
he O
##tero O
##gene O
##ity O
in O
145 O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

breast B-Disease
cancer I-Disease
link O
##age O
consortium O
. O

the O
breast B-Disease
- I-Disease
o I-Disease
##vary I-Disease
cancer I-Disease
- I-Disease
family I-Disease
syndrome I-Disease
is O
a O
dominant O
pre O
##dis O
##position O
to O
cancer B-Disease
of I-Disease
the I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ies I-Disease
which O
has O
been O
mapped O
to O
chromosome O
region O
17 O
##q O
##12 O
- O
q O
##21 O
. O

the O
majority O
, O
but O
not O
all O
, O
of O
breast B-Disease
- I-Disease
o I-Disease
##vary I-Disease
cancer I-Disease
families O
show O
link O
##age O
to O
this O
su O
##s O
##ce O
##pt O
##ibility O
lo O
##cus O
, O
designated O
br O
##ca O
##1 O
. O

we O
report O
here O
the O
results O
of O
a O
link O
##age O
analysis O
of O
145 O
families O
with O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

these O
families O
contain O
either O
a O
total O
of O
three O
or O
more O
cases O
of O
early O
- O
onset O
( O
before O
age O
60 O
years O
) O
breast B-Disease
cancer I-Disease
or O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

all O
families O
contained O
at O
least O
one O
case O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

overall O
, O
an O
estimated O
76 O
% O
of O
the O
145 O
families O
are O
linked O
to O
the O
br O
##ca O
##1 O
lo O
##cus O
. O

none O
of O
the O
13 O
families O
with O
cases O
of O
male B-Disease
breast I-Disease
cancer I-Disease
appear O
to O
be O
linked O
, O
but O
it O
is O
estimated O
that O
92 O
% O
( O
95 O
% O
confidence O
interval O
76 O
% O
- O
100 O
% O
) O
of O
families O
with O
no O
male B-Disease
breast I-Disease
cancer I-Disease
and O
with O
two O
or O
more O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
are O
linked O
to O
br O
##ca O
##1 O
. O

these O
data O
suggest O
that O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
- I-Disease
family I-Disease
syndrome I-Disease
is O
genetically O
he O
##tero O
##gene O
##ous O
. O

however O
, O
the O
large O
majority O
of O
families O
with O
early O
- O
onset O
breast B-Disease
cancer I-Disease
and O
with O
two O
or O
more O
cases O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
are O
likely O
to O
be O
due O
to O
br O
##ca O
##1 O
mutations O
. O
. O

molecular O
basis O
of O
essential B-Disease
f I-Disease
##ru I-Disease
##ct I-Disease
##os I-Disease
##uria I-Disease
: O
molecular O
c O
##lon O
##ing O
and O
mutation O
##al O
analysis O
of O
human O
k O
##eto O
##he O
##x O
##oki O
##nas O
##e O
( O
f O
##ru O
##ct O
##oki O
##nas O
##e O
) O
. O

essential B-Disease
f I-Disease
##ru I-Disease
##ct I-Disease
##os I-Disease
##uria I-Disease
is O
one O
of O
the O
oldest O
known O
in B-Disease
##born I-Disease
errors I-Disease
of I-Disease
metabolism I-Disease
. O

it O
is O
a O
ben O
##ign O
condition O
which O
is O
believed O
to O
result O
from O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
f I-Disease
##ru I-Disease
##ct I-Disease
##oki I-Disease
##nas I-Disease
##e I-Disease
( O
k O
##eto O
##he O
##x O
##oki O
##nas O
##e O
, O
k O
##h O
##k O
, O
e O
. O
c O
. O
2 O
. O
7 O
. O
1 O
. O
3 O
) O
. O

this O
enzyme O
cat O
##aly O
##ses O
the O
first O
step O
of O
metabolism O
of O
diet O
##ary O
f O
##ru O
##ct O
##ose O
, O
conversion O
of O
f O
##ru O
##ct O
##ose O
to O
f O
##ru O
##ct O
##ose O
- O
1 O
- O
phosphate O
. O

despite O
the O
early O
recognition O
of O
this O
disorder O
, O
the O
primary O
structure O
of O
human O
k O
##h O
##k O
and O
the O
molecular O
basis O
of O
essential B-Disease
f I-Disease
##ru I-Disease
##ct I-Disease
##os I-Disease
##uria I-Disease
have O
not O
been O
previously O
defined O
. O

in O
this O
report O
, O
the O
isolation O
and O
se O
##quencing O
of O
full O
- O
length O
c O
##dn O
##a O
clone O
##s O
encoding O
human O
k O
##eto O
##he O
##x O
##oki O
##nas O
##e O
are O
described O
. O

alternative O
m O
##rna O
species O
and O
alternative O
k O
##h O
##k O
is O
##oz O
##yme O
##s O
are O
produced O
by O
alternative O
p O
##oly O
##ade O
##ny O
##lation O
and O
s O
##p O
##licing O
of O
the O
k O
##h O
##k O
gene O
. O

the O
k O
##h O
##k O
proteins O
show O
a O
high O
level O
of O
sequence O
conservation O
relative O
to O
rat O
k O
##h O
##k O
. O

direct O
evidence O
that O
mutation O
of O
the O
k O
##h O
##k O
structural O
gene O
is O
the O
cause O
of O
essential B-Disease
f I-Disease
##ru I-Disease
##ct I-Disease
##os I-Disease
##uria I-Disease
was O
also O
obtained O
. O

in O
a O
well O
- O
characterized O
family O
, O
in O
which O
three O
of O
eight O
siblings O
have O
f B-Disease
##ru I-Disease
##ct I-Disease
##os I-Disease
##uria I-Disease
, O
all O
affected O
individuals O
are O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
two O
mutations O
g O
##ly O
##40 O
##ar O
##g O
and O
al O
##a O
##43 O
##th O
##r O
. O

both O
mutations O
result O
from O
g O
- O
- O
[UNK] O
a O
transitions O
, O
and O
each O
alter O
##s O
the O
same O
conserved O
region O
of O
the O
k O
##h O
##k O
protein O
. O

neither O
mutation O
was O
seen O
in O
a O
sample O
of O
52 O
unrelated O
control O
individuals O
. O

an O
additional O
conservative O
amino O
acid O
change O
( O
v O
##al O
##4 O
##9 O
##ii O
##e O
) O
was O
present O
on O
the O
k O
##h O
##k O
all O
##ele O
bearing O
al O
##a O
##43 O
##th O
##r O

ho O
##mo O
##zy O
##go O
##us O
presence O
of O
the O
crossover O
( O
fusion O
gene O
) O
mutation O
identified O
in O
a O
type B-Disease
ii I-Disease
g I-Disease
##au I-Disease
##cher I-Disease
disease I-Disease
f O
##etus O
: O
is O
this O
analogous O
to O
the O
g O
##au O
##cher O
knock O
- O
out O
mouse O
model O
? O

g B-Disease
##au I-Disease
##cher I-Disease
disease I-Disease
( O
g B-Disease
##d I-Disease
) O
is O
an O
inherited O
deficiency B-Disease
of I-Disease
beta I-Disease
- I-Disease
g I-Disease
##lu I-Disease
##co I-Disease
##cer I-Disease
##eb I-Disease
##ros I-Disease
##idas I-Disease
##e I-Disease
( O
e O
##c O
3 O
. O
1 O
. O
2 O
. O
45 O
, O
gene O
symbol O
g O
##ba O
) O
. O

in O
type B-Disease
i I-Disease
g I-Disease
##d I-Disease
, O
the O
c O
##ns O
is O
not O
involved O
( O
non O
##ne O
##uron O
##op O
##ath O
##ic O
) O
, O
whereas O
in O
type B-Disease
ii I-Disease
g I-Disease
##d I-Disease
( O
acute O
ne O
##uron O
##op O
##ath O
##ic O
) O
c O
##ns O
involvement O
is O
early O
and O
rapidly O
progressive O
, O
while O
in O
type B-Disease
ii I-Disease
##i I-Disease
g I-Disease
##d I-Disease
( O
sub O
##ac O
##ute O
ne O
##uron O
##op O
##ath O
##ic O
) O
c O
##ns O
involvement O
occurs O
later O
and O
is O
slowly O
progressive O
. O

the O
t O
##64 O
##33 O
##c O
( O
l O
##44 O
##4 O
##p O
) O
substitution O
is O
prevalent O
in O
type B-Disease
g I-Disease
##d I-Disease
ii I-Disease
. O

it O
may O
occur O
alone O
as O
a O
single O
base O
- O
pair O
mutation O
but O
often O
is O
found O
as O
part O
of O
a O
complex O
all O
##ele O
containing O
additional O
g O
##ba O
n O
##uc O
##leo O
##tide O
substitution O
##s O
, O
g O
##64 O
##6 O
##8 O
##c O
( O
a O
##45 O
##6 O
##p O
) O
and O
g O
##64 O
##8 O
##2 O
##c O
( O
v O
##46 O
##0 O
##v O
) O
, O
without O
( O
re O
##c O
##nc O
##ii O
) O
or O
with O
( O
re O
##ct O
##l O
) O
g O
##5 O
##9 O
##5 O
##7 O
##c O
( O
d O
##40 O
##9 O
##h O
) O
. O

this O
complex O
all O
##ele O
is O
presumed O
to O
have O
formed O
by O
re O
##comb O
##ination O
( O
crossover O
, O
fusion O
) O
of O
the O
structural O
gene O
with O
the O
pseudo O
##gene O
, O
which O
contains O
the O
m O
##uta O
##ted O
sequences O
. O

two O
complex O
all O
##ele O
##s O
have O
never O
been O
demonstrated O
to O
co O
##ex O
##ist O
in O
any O
individual O
. O

we O
devised O
a O
selective O
p O
##c O
##r O
method O
for O
the O
specific O
am O
##p O
##lification O
of O
the O
normal O
and O
/ O
or O
fusion O
gene O
. O

using O
this O
procedure O
we O
demonstrated O
the O
fusion O
gene O
in O
ho O
##mo O
##zy O
##go O
##us O
form O
for O
the O
first O
time O
, O
in O
a O
mac O
##ed O
##onia O
##n O
/ O
ash O
##ken O
##azi O
j O
##ew O
##ish O
g B-Disease
##d I-Disease
type I-Disease
ii I-Disease
f O
##etus O
. O

both O
parents O
were O
carriers O
of O
the O
re O
##comb O
##ination O
. O

this O
was O
confirmed O
by O
direct O
sequence O
analysis O
. O

a O
previous O
concept O
##us O
in O
this O
family O
was O
still B-Disease
##born I-Disease
at O
36 O
weeks O
, O
with O
features O
of O
severe O
type B-Disease
ii I-Disease
g I-Disease
##d I-Disease
. O

neon O
##ates O
showing O
a O
severe O
clinical O
p O
##hen O
##otype O
, O
analogous O
to O
the O
early O
neon O
##ata O
##l O
lethal O
disease O
occurring O
in O
mice O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
null O
all O
##ele O
produced O
by O
targeted O
disruption O
of O
g O
##ba O
, O
have O
been O
described O
elsewhere O
, O
but O
the O
specific O
mutations O
in O
these O
cases O
have O
not O
yet O
been O
characterized O
. O

( O
abstract O
t O
##runcated O
at O
250 O
words O
) O

late O
infant O
##ile O
meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
in O
is O
##rae O
##l O
. O

meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
is O
a O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disease I-Disease
in O
which O
the O
l O
##ys O
##oso O
##mal O
enzyme O
, O
a O
##ryl O
su O
##lf O
##ata O
##se O
a O
( O
a O
##rsa O
) O
is O
def O
##icient O
. O

the O
disease O
is O
inherited O
as O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
and O
its O
frequency O
is O
estimated O
to O
be O
1 O
/ O
40 O
, O
000 O
live O
births O
. O

the O
gene O
of O
a O
##rsa O
has O
been O
clone O
##d O
and O
up O
to O
now O
eight O
mutations O
causing O
m B-Disease
##ld I-Disease
have O
been O
reported O
. O

another O
mutation O
, O
p O
##d O
, O
leads O
to O
the O
deficiency O
of O
the O
enzyme O
in O
v O
##it O
##ro O
( O
pseudo O
##de O
##ficiency O
) O
without O
any O
known O
clinical O
effect O
. O

the O
p O
##d O
mutation O
is O
frequent O
in O
all O
populations O
. O

in O
is O
##rae O
##l O
, O
late O
infant O
##ile O
m B-Disease
##ld I-Disease
was O
found O
to O
be O
very O
frequent O
in O
a O
small O
j O
##ew O
##ish O
is O
##olate O
, O
the O
ha O
##bba O
##ni O
##te O
j O
##ews O
( O
1 O
/ O
75 O
live O
births O
) O
. O

the O
molecular O
analysis O
demonstrated O
that O
in O
the O
ha O
##bba O
##ni O
##te O
population O
, O
the O
mutation O
occurred O
on O
an O
all O
##ele O
with O
the O
p O
##d O
mutation O
. O

the O
loss O
of O
a O
##rsa O
activity O
is O
due O
to O
a O
point O
mutation O
c O
[UNK] O
t O
leading O
to O
a O
change O
of O
pro O
##line O
to O
le O
##uc O
##ine O
. O

m B-Disease
##ld I-Disease
is O
also O
frequent O
among O
m O
##os O
##lem O
a O
##rab O
##s O
in O
j O
##erus O
##ale O
##m O
. O

the O
mutation O
is O
a O
transition O
g O
[UNK] O
a O
destroying O
the O
s O
##p O
##lice O
donor O
site O
of O
ex O
##on O
2 O
. O

this O
mutation O
has O
been O
reported O
in O
patients O
with O
the O
late O
infant O
##ile O
m B-Disease
##ld I-Disease
from O
different O
ethnic O
groups O
. O

the O
ch O
##rist O
##ian O
a O
##rab O
##s O
in O
is O
##rae O
##l O
also O
have O
a O
high O
incidence O
of O
the O
disease O
( O
1 O
/ O
10 O
, O
000 O
live O
births O
) O
; O
the O
mutation O
in O
this O
population O
is O
still O
unknown O
. O

knowledge O
of O
the O
different O
mutations O
causing O
m B-Disease
##ld I-Disease
in O
these O
defined O
populations O
will O
allow O
a O
carrier O
screening O
program O
to O
be O
carried O
out O
and O
prevent O
the O
birth O
of O
additional O
affected O
children O
. O
. O

a O
single O
amino O
acid O
substitution O
( O
g O
##10 O
##3 O
##d O
) O
in O
the O
type O
ii O
co O
##lla O
##gen O
triple O
he O
##lix O
produces O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
is O
a O
moderately O
severe O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
p O
##hen O
##otype O
that O
results O
from O
mutations O
in O
the O
gene O
for O
type O
ii O
co O
##lla O
##gen O
, O
co O
##l O
##2 O
##a O
##1 O
. O

characteristics O
of O
the O
disorder O
include O
a O
short B-Disease
trunk I-Disease
and I-Disease
ex I-Disease
##tre I-Disease
##mit I-Disease
##ies I-Disease
, O
mid B-Disease
- I-Disease
face I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
c B-Disease
##le I-Disease
##ft I-Disease
p I-Disease
##ala I-Disease
##te I-Disease
, O
my B-Disease
##op I-Disease
##ia I-Disease
, O
re B-Disease
##tina I-Disease
##l I-Disease
detachment I-Disease
, O
and O
hearing B-Disease
loss I-Disease
. O

recently O
, O
del O
##eti O
##ons O
of O
all O
or O
part O
of O
ex O
##on O
12 O
have O
been O
identified O
in O
individuals O
with O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
suggesting O
that O
mutations O
within O
this O
region O
of O
the O
protein O
may O
primarily O
result O
in O
the O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
p O
##hen O
##otype O
. O

we O
used O
s O
##s O
##c O
##p O
to O
analyze O
an O
am O
##plified O
g O
##eno O
##mic O
d O
##na O
fragment O
containing O
ex O
##on O
12 O
from O
seven O
individuals O
with O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

an O
abnormal O
##ity O
was O
identified O
in O
one O
patient O
. O

d O
##na O
sequence O
analysis O
demonstrated O
that O
the O
patient O
was O
he O
##tero O
##zy O
##go O
##us O
for O
a O
g O
to O
a O
transition O
that O
implied O
substitution O
of O
g O
##ly O
##cine O
##10 O
##3 O
of O
the O
triple O
he O
##lica O
##l O
domain O
by O
as O
##par O
##tate O
. O

the O
mutation O
was O
not O
observed O
in O
d O
##na O
from O
either O
of O
the O
clinical O
##ly O
un O
##af O
##fected O
parents O
of O
the O
pro O
##band O
. O

protein O
micro O
##se O
##quencing O
demonstrated O
expression O
of O
the O
abnormal O
all O
##ele O
in O
cart O
##ila O
##ge O
. O

these O
data O
demonstrate O
that O
point O
mutations O
which O
result O
in O
single O
amino O
acid O
substitution O
##s O
can O
produce O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
and O
further O
support O
the O
hypothesis O
that O
alter O
##ation O
of O
a O
domain O
, O
which O
includes O
the O
region O
encoded O
by O
ex O
##on O
12 O
, O
in O
the O
type O
ii O
co O
##lla O
##gen O
protein O
leads O
to O
this O
disorder O
. O
. O

ca O
##g O
expansion O
##s O
in O
a O
novel O
gene O
for O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
at O
chromosome O
14 O
##q O
##32 O
. O
1 O
. O

we O
have O
identified O
a O
novel O
gene O
containing O
ca O
##g O
repeats O
and O
mapped O
it O
to O
chromosome O
14 O
##q O
##32 O
. O

1 O
, O
the O
genetic O
lo O
##cus O
for O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
. O

in O
normal O
individuals O
the O
gene O
contains O
between O
13 O
and O
36 O
ca O
##g O
repeats O
, O
whereas O
most O
of O
the O
clinical O
##ly O
diagnosed O
patients O
and O
all O
of O
the O
affected O
members O
of O
a O
family O
with O
the O
clinical O
and O
path O
##ological O
diagnosis O
of O
m B-Disease
##j I-Disease
##d I-Disease
show O
expansion O
of O
the O
repeat O
- O
number O
( O
from O
68 O
- O
79 O
) O
. O

southern O
b O
##lot O
analyses O
and O
g O
##eno O
##mic O
c O
##lon O
##ing O
demonstrates O
the O
existence O
of O
related O
genes O
. O

these O
results O
raise O
the O
possibility O
that O
similar O
abnormal O
##ities O
in O
related O
genes O
may O
give O
rise O
to O
diseases O
similar O
to O
m B-Disease
##j I-Disease
##d I-Disease
. O

mutations O
in O
the O
br O
##ca O
##1 O
gene O
in O
families O
with O
early O
- O
onset O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

we O
anal O
##ys O
##ed O
50 O
pro O
##band O
##s O
with O
a O
family O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
for O
g O
##er O
##m O
##line O
mutations O
in O
the O
coding O
region O
of O
the O
br O
##ca O
##1 O
candidate O
gene O
, O
using O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
analysis O
on O
p O
##c O
##r O
- O
am O
##plified O
g O
##eno O
##mic O
d O
##na O
. O

a O
total O
of O
eight O
put O
##ative O
disease O
- O
causing O
alterations O
were O
identified O
four O
of O
these O
are O
frames O
##hi O
##fts O
and O
two O
are O
nonsense O
mutations O
. O

in O
addition O
, O
we O
found O
two O
miss O
##ense O
mutations O
, O
one O
of O
which O
changes O
the O
final O
c O
##ys O
##tein O
##e O
of O
the O
br O
##ca O
##1 O
zinc O
finger O
motif O
to O
g O
##ly O
##cine O
. O

these O
data O
are O
consistent O
with O
a O
t B-Disease
##umour I-Disease
suppress O
##or O
model O
, O
and O
support O
the O
notion O
that O
this O
candidate O
gene O
is O
in O
fact O
br O
##ca O
##1 O
. O

the O
he O
##tero O
##gene O
##ity O
of O
mutations O
, O
coupled O
with O
the O
large O
size O
of O
the O
gene O
, O
indicates O
that O
clinical O
application O
of O
br O
##ca O
##1 O
mutation O
testing O
will O
be O
technically O
challenging O
. O
. O

confirmation O
of O
br O
##ca O
##1 O
by O
analysis O
of O
g O
##er O
##m O
##line O
mutations O
linked O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
ten O
families O
. O

we O
provide O
genetic O
evidence O
supporting O
the O
identity O
of O
the O
candidate O
gene O
for O
br O
##ca O
##1 O
through O
the O
characterization O
of O
g O
##er O
##m O
##line O
mutations O
in O
63 O
breast B-Disease
cancer I-Disease
patients O
and O
10 O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
patients O
in O
ten O
families O
with O
cancer B-Disease
linked O
to O
chromosome O
17 O
##q O
##21 O
. O

nine O
different O
mutations O
were O
detected O
by O
screening O
br O
##ca O
##1 O
d O
##na O
and O
r O
##na O
by O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
and O
direct O
se O
##quencing O
. O

seven O
mutations O
lead O
to O
protein O
t O
##run O
##cation O
##s O
at O
sites O
throughout O
the O
gene O
. O

one O
miss O
##ense O
mutation O
( O
which O
occurred O
independently O
in O
two O
families O
) O
leads O
to O
loss O
of O
a O
c O
##ys O
##tein O
##e O
in O
the O
zinc O
binding O
domain O
. O

an O
intro O
##nic O
single O
base O
##pair O
substitution O
destroys O
an O
accept O
##or O
site O
and O
activate O
##s O
a O
cry O
##ptic O
s O
##p O
##lice O
site O
, O
leading O
to O
a O
59 O
base O
##pair O
insertion O
and O
chain O
termination O
. O

the O
four O
families O
with O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
had O
chain O
termination O
mutations O
in O
the O
n O
- O
terminal O
half O
of O
the O
protein O
. O
. O

high O
resolution O
genetic O
analysis O
suggests O
one O
ancestral O
pre O
##dis O
##po O
##sing O
ha O
##p O
##lot O
##ype O
for O
the O
origin O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
mutation O
. O

the O
mutation O
causing O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
has O
been O
identified O
as O
an O
am O
##p O
##lification O
of O
an O
unstable O
t O
##rin O
##uc O
##leo O
##tide O
( O
c O
##t O
##g O
) O
n O
repeat O
in O
over O
99 O
% O
of O
the O
global O
d B-Disease
##m I-Disease
population O
. O

it O
is O
in O
complete O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
with O
an O
al O
##u O
element O
p O
##oly O
##mor O
##phism O
within O
the O
d B-Disease
##m I-Disease
kinase O
gene O
, O
suggesting O
that O
d B-Disease
##m I-Disease
is O
a O
consequence O
of O
one O
or O
few O
ancestral O
mutations O
. O

a O
recent O
analysis O
utilizing O
this O
p O
##oly O
##mor O
##phism O
as O
well O
as O
a O
flank O
##ing O
din O
##uc O
##leo O
##tide O
marker O
, O
suggested O
that O
similar O
to O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
d B-Disease
##m I-Disease
exhibited O
a O
founder O
effect O
( O
im O
##bert O
et O
al O
. O
, O
1993 O
nature O
gene O
##t O
. O
4 O
, O
72 O
- O
76 O
) O
. O

in O
contrast O
, O
the O
low O
reproductive O
fitness O
of O
individuals O
with O
con O
##gen O
##ital O
d B-Disease
##m I-Disease
( O
the O
end O
##point O
of O
genetic O
anticipation O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
) O
suggests O
a O
higher O
rate O
of O
new O
mutations O
. O

we O
present O
a O
high O
resolution O
genetic O
analysis O
of O
the O
d B-Disease
##m I-Disease
lo O
##cus O
using O
p O
##c O
##r O
based O
ass O
##ays O
of O
nine O
p O
##oly O
##mor O
##phism O
##s O
, O
spanning O
a O
physical O
distance O
of O
30 O
k O
##b O
, O
within O
and O
immediately O
flank O
##ing O
the O
d B-Disease
##m I-Disease
kinase O
gene O
. O

the O
persistent O
complete O
all O
##eli O
##c O
association O
of O
the O
d B-Disease
##m I-Disease
mutation O
with O
all O
these O
p O
##oly O
##mor O
##phism O
##s O
provides O
further O
support O
to O
previous O
observations O
and O
suggests O
more O
strongly O
that O
the O
d B-Disease
##m I-Disease
mutation O
occurred O
on O
the O
background O
of O
a O
particular O
ha O
##p O
##lot O
##ype O
in O
which O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
became O
inherent O
##ly O
unstable O
and O
therefore O
pre O
##dis O
##posed O
to O
am O
##p O
##lification O
. O

genetic O
instability O
in O
human O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cell O
lines O
. O

we O
have O
analyzed O
the O
stability O
of O
micro O
##sat O
##elli O
##tes O
in O
cell O
lines O
derived O
from O
human O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
and O
found O
that O
5 O
out O
of O
10 O
of O
the O
o B-Disease
##var I-Disease
##ian I-Disease
tumor I-Disease
cell O
lines O
are O
genetically O
unstable O
at O
the O
majority O
of O
the O
lo O
##ci O
analyzed O
. O

in O
clone O
##s O
and O
sub O
##c O
##lone O
##s O
derived O
serial O
##ly O
from O
one O
of O
these O
cell O
lines O
( O
27 O
##7 O
##4 O
; O
se B-Disease
##rous I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##car I-Disease
##cin I-Disease
##oma I-Disease
) O
, O
a O
very O
high O
proportion O
of O
micro O
##sat O
##elli O
##tes O
distributed O
in O
many O
different O
regions O
of O
the O
genome O
change O
their O
size O
in O
a O
me O
##rc O
##uria O
##l O
fashion O
. O

we O
conclude O
that O
g O
##eno O
##mic O
instability O
in O
o B-Disease
##var I-Disease
##ian I-Disease
tumors I-Disease
is O
a O
dynamic O
and O
ongoing O
process O
whose O
high O
frequency O
may O
have O
been O
previously O
under O
##est O
##imated O
by O
p O
##c O
##r O
- O
based O
all O
##elo O
##ty O
##ping O
of O
bulk O
tumor B-Disease
tissue O
. O

we O
have O
identified O
the O
source O
of O
the O
genetic O
instability O
in O
one O
o B-Disease
##var I-Disease
##ian I-Disease
tumor I-Disease
as O
a O
point O
mutation O
( O
r O
##5 O
##24 O
##p O
) O
in O
the O
human O
mi O
##sma O
##tch O
- O
repair O
gene O
m O
##sh O
##2 O
( O
salmon O
##ella O
m O
##uts O
ho O
##mo O
##logue O
) O
, O
which O
has O
recently O
been O
shown O
to O
be O
involved O
in O
hereditary B-Disease
non I-Disease
##pol I-Disease
##y I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

patient O
27 O
##7 O
##4 O
was O
a O
38 O
- O
year O
- O
old O
he O
##tero O
##zy O
##got O
##e O
, O
and O
her O
normal O
tissue O
carried O
both O
mutant O
and O
wild O
- O
type O
all O
##ele O
##s O
of O
the O
human O
m O
##sh O
##2 O
gene O
. O

however O
the O
wild O
- O
type O
all O
##ele O
was O
lost O
at O
some O
point O
early O
during O
tumor O
##ige O
##nes O
##is O
so O
that O
d O
##na O
isolated O
either O
from O
the O
patients O
o B-Disease
##var I-Disease
##ian I-Disease
tumor I-Disease
or O
from O
the O
27 O
##7 O
##4 O
cell O
line O
carries O
only O
the O
mutant O
all O
##ele O
of O
the O
human O
m O
##sh O
##2 O
gene O
. O

the O
genetic O
instability O
observed O
in O
the O
tumor B-Disease
and O
cell O
line O
d O
##na O
, O
together O
with O
the O
g O
##er O
##m O
- O
line O
mutation O
in O
a O
mi O
##sma O
##tch O
- O
repair O
gene O
, O
suggest O
that O
the O
m O
##sh O
##2 O
gene O
is O
involved O
in O
the O
onset O
and O
/ O
or O
progression O
in O
a O
subset O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O
. O

br O
##ca O
##1 O
mutations O
in O
primary O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
data O
from O
f B-Disease
##ami I-Disease
##lial I-Disease
tumors I-Disease
suggest O
that O
br O
##ca O
##1 O
, O
a O
gene O
that O
con O
##fers O
su O
##s O
##ce O
##pt O
##ibility O
to O
o B-Disease
##var I-Disease
##ian I-Disease
and I-Disease
early I-Disease
- I-Disease
onset I-Disease
breast B-Disease
cancer I-Disease
, O
en O
##codes O
a O
tumor B-Disease
suppress O
##or O
. O

the O
br O
##ca O
##1 O
region O
is O
also O
subject O
to O
all O
##eli O
##c O
loss O
in O
s B-Disease
##poradic I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
, O
an O
indication O
that O
br O
##ca O
##1 O
mutations O
may O
occur O
so O
##matical O
##ly O
in O
these O
tumors B-Disease
. O

the O
br O
##ca O
##1 O
coding O
region O
was O
examined O
for O
mutations O
in O
primary O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
tumors I-Disease
that O
show O
all O
##ele O
loss O
at O
the O
br O
##ca O
##1 O
lo O
##cus O
. O

mutations O
were O
detected O
in O
3 O
of O
32 O
breast O
and O
1 O
of O
12 O
o B-Disease
##var I-Disease
##ian I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
; O
all O
four O
mutations O
were O
g O
##er O
##m O
##line O
alterations O
and O
occurred O
in O
early O
- O
onset O
cancer B-Disease
##s I-Disease
. O

these O
results O
suggest O
that O
mutation O
of O
br O
##ca O
##1 O
may O
not O
be O
critical O
in O
the O
development O
of O
the O
majority O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
that O
arise O
in O
the O
absence O
of O
a O
mutant O
g O
##er O
##m O
##line O
all O
##ele O
. O
. O

p O
##ax O
##6 O
gene O
dos O
##age O
effect O
in O
a O
family O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
, O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
an B-Disease
##op I-Disease
##ht I-Disease
##hal I-Disease
##mia I-Disease
and O
central B-Disease
nervous I-Disease
system I-Disease
defects I-Disease
. O

the O
human O
eye O
ma O
##lf O
##orm O
##ation O
an B-Disease
##iri I-Disease
##dia I-Disease
results O
from O
ha B-Disease
##p I-Disease
##lo I-Disease
##ins I-Disease
##uff I-Disease
##iciency I-Disease
of I-Disease
p I-Disease
##ax I-Disease
##6 I-Disease
, O
a O
paired O
box O
d O
##na O
- O
binding O
protein O
. O

to O
study O
this O
dos O
##age O
effect O
, O
we O
characterized O
two O
p O
##ax O
##6 O
mutations O
in O
a O
family O
se O
##g O
##re O
##gating O
an B-Disease
##iri I-Disease
##dia I-Disease
and O
a O
mild O
##er O
syndrome O
consisting O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
cat I-Disease
##ara I-Disease
##cts I-Disease
and O
late O
onset O
corn B-Disease
##eal I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

the O
nonsense O
mutations O
, O
at O
co O
##don O
##s O
103 O
and O
35 O
##3 O
, O
t O
##run O
##cate O
p O
##ax O
##6 O
within O
the O
n O
- O
terminal O
paired O
and O
c O
- O
terminal O
ps O
##t O
domains O
, O
respectively O
. O

the O
wild O
- O
type O
ps O
##t O
domain O
activate O
##s O
transcription O
autonomous O
##ly O
and O
the O
mutant O
form O
has O
partial O
activity O
. O

a O
compound O
he O
##tero O
##zy O
##got O
##e O
had O
severe O
c B-Disease
##rani I-Disease
##of I-Disease
##ac I-Disease
##ial I-Disease
and I-Disease
central I-Disease
nervous I-Disease
system I-Disease
defects I-Disease
and O
no B-Disease
eyes I-Disease
. O

the O
pattern O
of O
ma O
##lf O
##orm O
##ations O
is O
similar O
to O
that O
in O
ho O
##mo O
##zy O
##go O
##us O
se O
##y O
mice O
and O
suggests O
a O
critical O
role O
for O
p O
##ax O
##6 O
in O
controlling O
the O
migration O
and O
differentiation O
of O
specific O
ne O
##uron O
##al O
pro O
##gen O
##itor O
cells O
in O
the O
brain O
. O
. O

a O
physical O
map O
and O
candidate O
genes O
in O
the O
br O
##ca O
##1 O
region O
on O
chromosome O
17 O
##q O
##12 O
- O
21 O
. O

we O
have O
constructed O
a O
physical O
map O
of O
a O
4 O
cm O
region O
on O
chromosome O
17 O
##q O
##12 O
- O
21 O
that O
contains O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
gene O
br O
##ca O
##1 O
. O

the O
map O
comprises O
a O
con O
##ti O
##g O
of O
137 O
overlapping O
yeast O
artificial O
chromosome O
##s O
and O
p O
##1 O
clone O
##s O
, O
onto O
which O
we O
have O
placed O
112 O
p O
##c O
##r O
markers O
. O

we O
have O
localized O
more O
than O
20 O
genes O
on O
this O
map O
, O
ten O
of O
which O
had O
not O
been O
mapped O
to O
the O
region O
previously O
, O
and O
have O
isolated O
30 O
c O
##dn O
##a O
clone O
##s O
representing O
partial O
sequences O
of O
as O
yet O
unidentified O
genes O
. O

two O
genes O
that O
lie O
within O
a O
narrow O
region O
defined O
by O
me O
##iot O
##ic O
break O
##points O
in O
br O
##ca O
##1 O
patients O
have O
been O
sequence O
##d O
in O
breast B-Disease
cancer I-Disease
patients O
without O
revealing O
any O
del O
##eter O
##ious O
mutations O
. O

these O
new O
re O
##age O
##nts O
should O
facilitate O
the O
identification O
of O
br O
##ca O
##1 O
. O
. O

the O
le O
##c O
rat O
has O
a O
del O
##eti O
##on O
in O
the O
copper O
transporting O
at O
##pas O
##e O
gene O
ho O
##mo O
##log O
##ous O
to O
the O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
gene O
. O

the O
long O
- O
e O
##van O
##s O
c O
##innamon O
( O
le O
##c O
) O
rat O
shows O
similarity O
to O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
in O
many O
clinical O
and O
bio O
##chemical O
features O
. O

we O
have O
clone O
##d O
c O
##dn O
##as O
for O
the O
rat O
gene O
( O
at O
##p O
##7 O
##b O
) O
ho O
##mo O
##log O
##ous O
to O
the O
human O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
gene O
( O
at O
##p O
##7 O
##b O
) O
and O
have O
used O
them O
to O
identify O
a O
partial O
del O
##eti O
##on O
in O
the O
at O
##p O
##7 O
##b O
gene O
in O
the O
le O
##c O
rat O
. O

the O
del O
##eti O
##on O
removes O
at O
least O
900 O
b O
##p O
of O
the O
coding O
region O
at O
the O
3 O
end O
, O
includes O
the O
crucial O
at O
##p O
binding O
domain O
and O
extends O
downstream O
of O
the O
gene O
. O

our O
results O
provide O
convincing O
evidence O
for O
defining O
the O
le O
##c O
rat O
as O
an O
animal O
model O
for O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

this O
model O
will O
be O
important O
for O
studying O
liver O
path O
##op O
##hy O
##sio O
##logy O
, O
for O
developing O
therapy O
for O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
and O
for O
studying O
the O
pathway O
of O
copper O
transport O
and O
its O
possible O
interaction O
with O
other O
heavy O
metals O
. O
. O

g O
##eno O
##mic O
organization O
of O
the O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
gene O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
, O
the O
most O
frequent O
per B-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disorder I-Disease
, O
is O
a O
severe O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disease I-Disease
associated O
with O
an O
imp B-Disease
##air I-Disease
##ment I-Disease
of I-Disease
very I-Disease
long I-Disease
chain I-Disease
fatty I-Disease
acids I-Disease
beta I-Disease
- I-Disease
oxidation I-Disease
. O

we O
have O
recently O
identified O
by O
position O
##al O
c O
##lon O
##ing O
the O
gene O
responsible O
for O
al B-Disease
##d I-Disease
, O
located O
in O
x O
##q O
##28 O
. O

it O
en O
##codes O
a O
new O
member O
of O
the O
" O
a O
##b O
##c O
" O
super O
##family O
of O
membrane O
- O
associated O
transport O
##ers O
that O
shows O
, O
in O
particular O
, O
significant O
ho O
##mology O
to O
the O
70 O
- O
k O
##da O
per O
##ox O
##is O
##oma O
##l O
membrane O
protein O
( O
pm O
##p O
##70 O
) O
. O

we O
report O
here O
a O
detailed O
characterization O
of O
the O
al B-Disease
##d I-Disease
gene O
structure O
. O

it O
extends O
over O
21 O
k O
##b O
and O
consists O
of O
10 O
ex O
##ons O
. O

to O
facilitate O
the O
detection O
of O
mutations O
in O
al B-Disease
##d I-Disease
patients O
, O
we O
have O
determined O
the O
intro O
##nic O
sequences O
flank O
##ing O
the O
ex O
##ons O
as O
well O
as O
the O
sequence O
of O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
and O
of O
the O
immediate O
5 O
promoter O
region O
. O

sequences O
present O
in O
di O
##stal O
ex O
##ons O
cross O
- O
hybrid O
##ize O
strongly O
to O
additional O
sequences O
in O
the O
human O
genome O
. O

the O
al B-Disease
##d I-Disease
gene O
has O
been O
positioned O
on O
a O
pulsed O
- O
field O
map O
between O
d O
##x O
##s O
##15 O
and O
the O
l O
##1 O
##cam O
gene O
, O
about O
650 O
k O
##b O
upstream O
from O
the O
color O
pig O
##ment O
genes O
. O

the O
frequent O
occurrence O
of O
color O
vision O
an O
##oma O
##lies O
observed O
in O
patients O
with O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
the O
adult O
onset O
form O
of O
al B-Disease
##d I-Disease
) O
thus O
does O
not O
represent O
a O
con B-Disease
##ti I-Disease
##guous I-Disease
gene I-Disease
syndrome I-Disease
but O
a O
secondary O
manifest O
##ation O
of O
al B-Disease
##d I-Disease
. O
. O

the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
##s O
of O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
gene O
( O
h O
##dh O
) O
and O
the O
alpha O
- O
add O
##uc O
##in O
gene O
( O
add O
##1 O
) O
map O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
s O
##yn O
##ten O
##y O
with O
human O
chromosome O
4 O
##p O
##16 O
. O
3 O
. O

hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
is O
a O
severe O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disorder I-Disease
associated O
with O
a O
novel O
gene O
( O
it O
##15 O
) O
. O

recently O
, O
we O
reported O
the O
c O
##lon O
##ing O
of O
h O
##dh O
, O
the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
of O
it O
##15 O
. O

here O
, O
using O
an O
inter O
##sp O
##ec O
##ific O
back O
##cross O
, O
we O
have O
mapped O
both O
h O
##dh O
and O
the O
mouse O
ho O
##mo O
##logue O
of O
human O
alpha O
- O
add O
##uc O
##in O
( O
add O
##1 O
) O
, O
a O
membrane O
- O
associated O
c O
##yt O
##os O
##kel O
##etal O
protein O
gene O
. O

both O
of O
these O
genes O
map O
in O
the O
same O
position O
on O
mouse O
chromosome O
5 O
in O
a O
region O
associated O
with O
ancestral O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
##s O
and O
show O
no O
re O
##comb O
##ination O
with O
d O
##5 O
##h O
##4 O
##s O
##43 O
, O
d O
##5 O
##h O
##4 O
##s O
##11 O
##5 O
, O
and O
d O
##5 O
##h O
##4 O
##s O
##6 O
##2 O
, O
the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
##s O
of O
d O
##4 O
##s O
##43 O
, O
d O
##4 O
##s O
##11 O
##5 O
, O
and O
d O
##4 O
##s O
##6 O
##2 O
, O
respectively O
. O

further O
mapping O
studies O
of O
humans O
, O
mice O
, O
and O
other O
ma O
##mmal O
##ian O
species O
should O
reveal O
the O
nature O
of O
the O
rear O
##rang O
##ement O
##s O
affecting O
this O
ch O
##rom O
##oso O
##mal O
segment O
during O
ma O
##mmal O
##ian O
evolution O
. O
. O

genetic O
ch B-Disease
##ole I-Disease
##ster I-Disease
##yl I-Disease
est I-Disease
##er I-Disease
transfer I-Disease
protein I-Disease
deficiency I-Disease
caused O
by O
two O
prevalent O
mutations O
as O
a O
major O
de O
##ter O
##mina O
##nt O
of O
increased O
levels O
of O
high O
density O
lip O
##op O
##rote O
##in O
ch O
##ole O
##ster O
##ol O
. O

genetic O
de O
##ter O
##mina O
##nts O
of O
h O
##dl O
ch O
##ole O
##ster O
##ol O
( O
h O
##dl O
- O
c O
) O
levels O
in O
the O
general O
population O
are O
poorly O
understood O
. O

we O
previously O
described O
plasma O
ch B-Disease
##ole I-Disease
##ster I-Disease
##yl I-Disease
est I-Disease
##er I-Disease
transfer I-Disease
protein I-Disease
( I-Disease
c I-Disease
##et I-Disease
##p I-Disease
) I-Disease
deficiency I-Disease
due O
to O
an O
intro O
##n O
14 O
g O
( O
+ O
1 O
) O
- O
to O
- O
a O
mutation O
( O
in O
##t O
##14 O
a O
) O
in O
several O
families O
with O
very O
high O
h O
##dl O
- O
c O
levels O
in O
j O
##apa O
##n O
. O

subjects O
with O
h O
##dl O
- O
c O
[UNK] O
or O
= O
100 O
mg O
/ O
d O
##l O
( O
n O
= O
130 O
) O
were O
screened O
by O
p O
##c O
##r O
single O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
analysis O
of O
the O
c O
##et O
##p O
gene O
. O

two O
other O
mutations O
were O
identified O
by O
d O
##na O
se O
##quencing O
or O
prime O
##r O
- O
mediated O
restriction O
map O
modification O
of O
p O
##c O
##r O
products O
a O
novel O
intro O
##n O
14 O
s O
##p O
##lice O
donor O
site O
mutation O
caused O
by O
a O
t O
insertion O
at O
position O
+ O
3 O
from O
the O
ex O
##on O
##14 O
/ O
intro O
##n O
##14 O
boundary O
( O
in O
##t O
##14 O
t O
) O
and O
a O
miss O
##ense O
mutation O
( O
as O
##p O
##44 O
##2 O
to O
g O
##ly O
) O
within O
ex O
##on O
15 O
( O
d O
##44 O
##2 O
##g O
) O
. O

the O
in O
##t O
##14 O
t O
mutation O
was O
only O
found O
in O
one O
family O
. O

however O
, O
the O
d O
##44 O
##2 O
##g O
and O
in O
##t O
##14 O
a O
mutations O
were O
highly O
prevalent O
in O
subjects O
with O
h O
##dl O
- O
c O
[UNK] O
or O
= O
60 O
mg O
/ O
d O
##l O
, O
with O
combined O
all O
##ele O
frequencies O
of O
9 O
% O
, O
12 O
% O
, O
21 O
% O
and O
43 O
% O
for O
h O
##dl O
- O
c O
60 O
- O
79 O
, O
80 O
- O
99 O
, O
100 O
- O
119 O
, O
and O
[UNK] O
or O
= O
120 O
mg O
/ O
d O
##l O
, O
respectively O
. O

further O
##more O
, O
prevalence O
##s O
of O
the O
d O
##44 O
##2 O
##g O
and O
in O
##t O
##14 O
a O
mutations O
were O
extremely O
high O
in O
a O
general O
sample O
of O
j O
##apa O
##nese O
men O
( O
n O
= O
236 O
) O
, O
with O
he O
##tero O
##zy O
##got O
##e O
frequencies O
of O
7 O
% O
and O
2 O
% O
, O
respectively O
. O

these O
two O
mutations O
accounted O
for O
about O
10 O
% O
of O
the O
total O
variance O
of O
h O
##dl O
- O
c O
in O
this O
population O
. O

the O
p O
##hen O
##otype O
in O
a O
genetic O
compound O
he O
##tero O
##zy O
##got O
##e O
( O
in O
##t O
##14 O
t O
and O
in O
##t O
##14 O
a O
) O
was O
similar O
to O
that O
of O
in O
##t O
##14 O
a O
ho O
##mo O
##zy O
##got O
##es O
( O
no O
detect O
##able O
c O
##et O
##p O
and O
marked O
##ly O
increased O
h O
##dl O
- O
c O
) O
, O
indicating O
that O
the O
in O
##t O
##14 O
t O
produces O
a O
null O
all O
##ele O
. O

in O
four O
d O
##44 O
##2 O
##g O
ho O
##mo O
##zy O
##got O
##es O
, O
mean O
h O
##dl O
- O
c O
levels O
( O
86 O
+ O
/ O
- O
26 O
mg O
/ O
d O
##l O
) O
were O
lower O
than O
in O
in O
##t O
##14 O
a O
ho O
##mo O
##zy O
##got O
##es O
( O
158 O
+ O
/ O
- O
35 O
mg O
/ O
d O
##l O
) O
, O
reflecting O
residual O
c O
##et O
##p O
activity O
in O
plasma O
. O

in O
47 O
d O
##44 O
##2 O
##g O
he O
##tero O
##zy O
##got O
##es O
, O
mean O
h O
##dl O
- O
c O
levels O
were O
91 O
+ O
/ O
- O
23 O
mg O
/ O
d O
##l O
, O
similar O
to O
the O
level O
in O
d O
##44 O
##2 O
##g O
ho O
##mo O
##zy O
##got O
##es O
, O
and O
significantly O
greater O
than O
mean O
h O
##dl O
- O
c O
levels O
in O
in O
##t O
##14 O
a O
he O
##tero O
##zy O
##got O
##es O
( O
69 O
+ O
/ O
- O
15 O
mg O
/ O
d O
##l O
) O
. O

thus O
, O
the O
d O
##44 O
##2 O
##g O
mutation O
acts O
differently O
to O
the O
null O
mutations O
with O
weaker O
effects O
on O
h O
##dl O
in O
the O
ho O
##mo O
##zy O
##go O
##us O
state O
and O
stronger O
effects O
in O
the O
he O
##tero O
##zy O
##got O
##es O
, O
suggesting O
dominant O
expression O
of O
a O
partially O
defect O
##ive O
all O
##ele O
. O

c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
, O
reflecting O
two O
prevalent O
mutations O
( O
d O
##44 O
##2 O
##g O
and O
in O
##t O
##14 O
a O
) O
, O
is O
the O
first O
example O
of O
a O
genetic B-Disease
deficiency I-Disease
state O
which O
is O
sufficiently O
common O
to O
explain O
a O
significant O
fraction O
of O
the O
variation O
in O
h O
##dl O
- O
c O
in O
the O
general O
population O
. O
. O

treatment O
of O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
: O
effects O
of O
ch O
##eno O
##de O
##ox O
##ych O
##olic O
acid O
, O
p O
##ra O
##vas O
##tat O
##in O
, O
and O
combined O
use O
. O

treatments O
by O
oral O
administration O
of O
ch O
##eno O
##de O
##ox O
##ych O
##olic O
acid O
( O
c O
##d O
##ca O
) O
alone O
, O
3 O
- O
h O
##ydro O
##xy O
- O
3 O
- O
met O
##hyl O
##g O
##lut O
##ary O
##l O
( O
h O
##m O
##g O
) O
co O
##a O
red O
##uc O
##tase O
inhibitor O
( O
p O
##ra O
##vas O
##tat O
##in O
) O
alone O
, O
and O
combination O
of O
the O
two O
drugs O
were O
attempted O
for O
7 O
patients O
with O
c B-Disease
##ere I-Disease
##bro I-Disease
##tend I-Disease
##ino I-Disease
##us I-Disease
x I-Disease
##ant I-Disease
##hom I-Disease
##ato I-Disease
##sis I-Disease
( O
c B-Disease
##t I-Disease
##x I-Disease
) O
. O

c O
##d O
##ca O
treatment O
at O
a O
dose O
of O
300 O
mg O
/ O
day O
reduced O
serum O
ch O
##ole O
##stan O
##ol O
( O
67 O
. O
3 O
% O
reduction O
) O
, O
la O
##th O
##ost O
##ero O
##l O
( O
50 O
. O
8 O
% O
) O
, O
camp O
##ester O
##ol O
( O
61 O
. O
7 O
% O
) O
and O
sit O
##ost O
##ero O
##l O
( O
12 O
. O
7 O
% O
) O
. O

however O
, O
the O
se O
##ra O
of O
the O
patients O
changed O
to O
be O
" O
at O
##her O
##ogenic O
" O
; O
total O
ch O
##ole O
##ster O
##ol O
, O
t O
##rig O
##ly O
##cer O
##ide O
and O
low O
- O
density O
lip O
##op O
##rote O
##in O
( O
l O
##dl O
) O
- O
ch O
##ole O
##ster O
##ol O
were O
increased O
, O
while O
high O
- O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
- O
ch O
##ole O
##ster O
##ol O
was O
decreased O
. O

con O
##trar O
##ily O
, O
p O
##ra O
##vas O
##tat O
##in O
at O
a O
dose O
of O
10 O
mg O
/ O
day O
improved O
the O
se O
##ra O
of O
the O
patients O
to O
be O
marked O
##ly O
" O
anti O
- O
at O
##her O
##ogenic O
" O
, O
but O
the O
reduction O
##s O
of O
ch O
##ole O
##stan O
##ol O
( O
30 O
. O
4 O
% O
) O
, O
la O
##th O
##ost O
##ero O
##l O
( O
44 O
. O
0 O
% O
) O
, O
camp O
##ester O
##ol O
( O
22 O
. O
9 O
% O
) O
and O
sit O
##ost O
##ero O
##l O
( O
9 O
. O
6 O
% O
) O
were O
inadequate O
. O

combined O
treatment O
with O
c O
##d O
##ca O
and O
p O
##ra O
##vas O
##tat O
##in O
showed O
good O
overlapping O
of O
the O
effects O
of O
each O
drug O
alone O
. O

the O
se O
##ra O
of O
the O
patients O
were O
apparently O
more O
" O
anti O
- O
at O
##her O
##ogenic O
" O
than O
those O
after O
c O
##d O
##ca O
treatment O
. O

serum O
ch O
##ole O
##stan O
##ol O
concentration O
was O
still O
2 O
. O

7 O
times O
higher O
than O
in O
controls O
, O
but O
the O
serum O
la O
##th O
##ost O
##ero O
##l O
level O
was O
within O
the O
normal O
range O
, O
indicating O
that O
the O
enhance O
##ment O
of O
overall O
ch O
##ole O
##ster O
##ol O
synthesis O
in O
the O
patients O
was O
sufficiently O
suppressed O
. O

plant O
s O
##tero O
##l O
levels O
were O
also O
within O
the O
normal O
range O
. O

the O
combination O
of O
c O
##d O
##ca O
and O
p O
##ra O
##vas O
##tat O
##in O
was O
a O
good O
treatment O
for O
c B-Disease
##t I-Disease
##x I-Disease
, O
based O
on O
the O
improvement O
of O
serum O
lip O
##op O
##rote O
##in O
metabolism O
, O
the O
suppression O
of O
ch O
##ole O
##ster O
##ol O
synthesis O
, O
and O
reduction O
##s O
of O
ch O
##ole O
##stan O
##ol O
and O
plant O
s O
##tero O
##l O
levels O
. O

in O
all O
of O
7 O
patients O
, O
the O
progression O
of O
disease O
was O
arrested O
, O
but O
dramatic O
effects O
on O
clinical O
manifest O
##ations O
, O
x B-Disease
##ant I-Disease
##hom I-Disease
##a I-Disease
, O
and O
electro O
##phy O
##sio O
##logical O
findings O
could O
not O
be O
found O
after O
the O
treatment O
of O
these O
drugs O

mutation O
spectrum O
in O
the O
ch B-Disease
##m I-Disease
gene O
of O
da O
##nish O
and O
s O
##wed O
##ish O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
patients O
. O

the O
recent O
isolation O
of O
the O
complete O
open O
reading O
frame O
of O
the O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
( O
ch B-Disease
##m I-Disease
) O
gene O
and O
the O
characterization O
of O
the O
ex O
##on O
- O
intro O
##n O
boundaries O
has O
paved O
the O
way O
to O
mutation O
detection O
in O
patients O
with O
classical O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
. O

we O
have O
performed O
mutation O
screening O
in O
patients O
from O
15 O
da O
##nish O
and O
s O
##wed O
##ish O
families O
by O
using O
southern O
b O
##lot O
hybrid O
##ization O
and O
the O
polymer O
##ase O
chain O
reaction O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
) O
technique O
. O

ca O
##usa O
##tive O
mutations O
in O
the O
ch B-Disease
##m I-Disease
gene O
were O
detected O
in O
at O
least O
12 O
families O
, O
indicating O
that O
a O
substantial O
part O
of O
the O
mutations O
can O
be O
identified O
by O
this O
approach O
. O

in O
four O
of O
these O
families O
del O
##eti O
##ons O
of O
different O
sizes O
were O
found O
. O

thus O
, O
in O
one O
patient O
, O
the O
del O
##eti O
##on O
resulted O
in O
the O
absence O
of O
only O
one O
ex O
##on O
, O
while O
in O
another O
the O
del O
##eti O
##on O
comprised O
the O
entire O
ch B-Disease
##m I-Disease
gene O
. O

mapping O
of O
the O
del O
##eti O
##on O
end O
##points O
in O
these O
four O
patients O
and O
in O
another O
11 O
male O
patients O
with O
size O
##able O
del O
##eti O
##ons O
enabled O
us O
to O
construct O
a O
very O
detailed O
map O
of O
intervals O
2 O
and O
3 O
of O
x O
##q O
##21 O
. O

in O
the O
remaining O
11 O
da O
##nish O
and O
s O
##wed O
##ish O
families O
at O
least O
8 O
ca O
##usa O
##tive O
mutations O
were O
found O
by O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
analysis O
and O
direct O
se O
##quencing O
. O

interesting O
##ly O
, O
all O
ch B-Disease
##m I-Disease
gene O
mutations O
detected O
thus O
far O
in O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
patients O
give O
rise O
to O
the O
introduction O
of O
a O
premature O
stop O
co O
##don O
. O
. O

pre O
##dom O
##ina O
##nce O
of O
the O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
p O
##hen O
##otype O
of O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
in O
the O
net O
##her O
##lands O
: O
a O
survey O
of O
30 O
kind O
##red O
##s O
. O

x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
) O
is O
an O
inherited B-Disease
disorder I-Disease
of O
per O
##ox O
##is O
##oma O
##l O
beta O
- O
oxidation O
associated O
with O
accumulation O
of O
saturated O
very O
long O
- O
chain O
fatty O
acids O
, O
which O
results O
in O
central O
and O
peripheral O
dem B-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
and O
in O
impaired B-Disease
function I-Disease
of I-Disease
ad I-Disease
##rena I-Disease
##l I-Disease
cortex I-Disease
and I-Disease
test I-Disease
##es I-Disease
. O

the O
p O
##hen O
##otypic O
expression O
is O
highly O
variable O
, O
childhood B-Disease
cerebral I-Disease
al I-Disease
##d I-Disease
( O
cc B-Disease
##ald I-Disease
) O
and O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
being O
the O
main O
variants O
. O

we O
explored O
the O
30 O
du O
##tch O
kind O
##red O
##s O
well O
known O
to O
the O
du O
##tch O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
study O
group O
and O
p O
##hen O
##otype O
##d O
77 O
male O
patients O
35 O
( O
46 O
% O
) O
had O
am B-Disease
##n I-Disease
and O
24 O
( O
31 O
% O
) O
cc B-Disease
##ald I-Disease
or O
adolescent B-Disease
cerebral I-Disease
al I-Disease
##d I-Disease
( O
ad B-Disease
##ol I-Disease
##cal I-Disease
##d I-Disease
) O
. O

these O
percentage O
##s O
differ O
significantly O
from O
previous O
reports O
, O
in O
which O
25 O
to O
28 O
% O
of O
the O
patients O
developed O
am B-Disease
##n I-Disease
and O
53 O
to O
57 O
% O
cc B-Disease
##ald I-Disease
or O
ad B-Disease
##ol I-Disease
##cal I-Disease
##d I-Disease
. O

our O
findings O
indicate O
that O
- O
- O
at O
least O
in O
the O
net O
##her O
##lands O
- O
- O
am B-Disease
##n I-Disease
may O
be O
the O
most O
frequent O
p O
##hen O
##otype O
of O
x B-Disease
- I-Disease
al I-Disease
##d I-Disease
. O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
gene O
en O
##codes O
an O
80 O
k O
##da O
membrane O
protein O
. O

an O
anti O
##body O
against O
the O
synthetic O
c O
- O
terminal O
p O
##eptide O
##s O
de O
##duced O
from O
the O
c O
##dn O
##a O
of O
the O
gene O
responsible O
for O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
was O
produced O
to O
character O
##ize O
the O
product O
of O
the O
al B-Disease
##d I-Disease
gene O
. O

the O
anti O
##body O
reacted O
with O
the O
80 O
k O
##da O
band O
protein O
in O
control O
fi O
##bro O
##blast O
##s O
, O
while O
no O
bands O
were O
detected O
in O
the O
fi O
##bro O
##blast O
##s O
from O
a O
patient O
with O
al B-Disease
##d I-Disease
( O
# O
163 O
) O
, O
in O
which O
m O
##rna O
of O
the O
al B-Disease
##d I-Disease
gene O
was O
und O
##ete O
##ct O
##able O
based O
on O
northern O
b O
##lot O
analysis O
. O

the O
29 O
##3 O
##t O
cells O
trans O
##fected O
with O
the O
full O
- O
coding O
c O
##dn O
##a O
inserted O
in O
the O
expression O
vector O
produced O
a O
new O
80 O
k O
##da O
protein O
, O
as O
detected O
by O
western O
b O
##lot O
. O

in O
an O
im O
##mu O
##no O
##cy O
##to O
##logical O
study O
, O
the O
stain O
##ing O
was O
in O
a O
pu O
##nc O
##tate O
pattern O
, O
in O
the O
normal O
fi O
##bro O
##blast O
##s O
. O

however O
, O
there O
was O
no O
pu O
##nc O
##tate O
stain O
##ing O
in O
the O
# O
163 O
cells O
. O

these O
data O
thus O
indicate O
that O
the O
al B-Disease
##d I-Disease
gene O
en O
##codes O
an O
80 O
k O
##da O
membrane O
protein O
. O
. O

isolation O
of O
the O
gene O
for O
m B-Disease
##cle I-Disease
##od I-Disease
syndrome I-Disease
that O
en O
##codes O
a O
novel O
membrane O
transport O
protein O
. O

m B-Disease
##cle I-Disease
##od I-Disease
syndrome I-Disease
is O
an O
x B-Disease
- I-Disease
linked I-Disease
multi I-Disease
##sy I-Disease
##ste I-Disease
##m I-Disease
disorder I-Disease
characterized O
by O
abnormal O
##ities O
in O
the O
ne O
##uro O
##mus O
##cular O
and O
hem O
##ato O
##po O
##iet O
##ic O
systems O
. O

we O
have O
assembled O
a O
co O
##sm O
##id O
con O
##ti O
##g O
of O
360 O
k O
##b O
that O
encompasses O
the O
m B-Disease
##cle I-Disease
##od I-Disease
gene O
lo O
##cus O
. O

a O
50 O
k O
##b O
del O
##eti O
##on O
was O
detected O
by O
screening O
d O
##na O
from O
patients O
with O
radio O
##la O
##bel O
##ed O
whole O
co O
##sm O
##ids O
, O
and O
two O
transcription O
units O
were O
identified O
within O
this O
del O
##eti O
##on O
. O

the O
m O
##rna O
expression O
pattern O
of O
one O
of O
them O
, O
designated O
as O
x O
##k O
, O
co O
##rrel O
##ates O
closely O
to O
the O
m B-Disease
##cle I-Disease
##od I-Disease
p O
##hen O
##otype O
. O

x O
##k O
en O
##codes O
a O
novel O
protein O
with O
structural O
characteristics O
of O
pro O
##kar O
##yo O
##tic O
and O
e O
##uka O
##ryo O
##tic O
membrane O
transport O
proteins O
. O

n O
##uc O
##leo O
##tide O
sequence O
analysis O
of O
x O
##k O
from O
two O
unrelated O
m B-Disease
##cle I-Disease
##od I-Disease
patients O
has O
identified O
point O
mutations O
at O
conserved O
s O
##p O
##lice O
donor O
and O
accept O
##or O
sites O
. O

these O
findings O
provide O
direct O
evidence O
that O
x O
##k O
is O
responsible O
for O
m B-Disease
##cle I-Disease
##od I-Disease
syndrome I-Disease
. O
. O

x B-Disease
- I-Disease
linked I-Disease
spa I-Disease
##stic I-Disease
para I-Disease
##ple I-Disease
##gia I-Disease
and O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
are O
all B-Disease
##eli I-Disease
##c I-Disease
disorders I-Disease
at O
the O
pro O
##te O
##oli O
##pid O
protein O
lo O
##cus O
. O

three O
forms O
of O
x B-Disease
- I-Disease
linked I-Disease
spa I-Disease
##stic I-Disease
para I-Disease
##ple I-Disease
##gia I-Disease
( O
s B-Disease
##p I-Disease
##g I-Disease
) O
have O
been O
defined O
. O

one O
lo O
##cus O
( O
s O
##p O
##g O
1 O
) O
maps O
to O
x O
##q O
##28 O
while O
two O
clinical O
##ly O
distinct O
forms O
map O
to O
x O
##q O
##22 O
( O
s O
##p O
##g O
##2 O
) O
. O

a O
rare O
x B-Disease
- I-Disease
linked I-Disease
d I-Disease
##ys I-Disease
##my I-Disease
##elin I-Disease
##ating I-Disease
disorder I-Disease
of O
the O
central O
nervous O
system O
, O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
, O
has O
also O
been O
mapped O
to O
x O
##q O
##21 O
- O
q O
##22 O
, O
and O
is O
caused O
by O
mutations O
in O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
( O
p O
##l O
##p O
) O
which O
en O
##codes O
two O
my O
##elin O
proteins O
, O
p O
##l O
##p O
and O
d O
##m O
##20 O
. O

while O
narrowing O
the O
genetic O
interval O
containing O
s O
##p O
##g O
##2 O
in O
a O
large O
p O
##ed O
##ig O
##ree O
, O
we O
found O
that O
p O
##l O
##p O
was O
the O
closest O
marker O
to O
the O
disease O
lo O
##cus O
, O
imp O
##lica O
##ting O
p O
##l O
##p O
as O
a O
possible O
candidate O
gene O
. O

we O
have O
found O
that O
a O
point O
mutation O
( O
his O
##13 O
##9 O
##ty O
##r O
) O
in O
ex O
##on O
3 O
##b O
of O
an O
affected O
male O
produces O
a O
mutant O
p O
##l O
##p O
but O
a O
normal O
d O
##m O
##20 O
, O
and O
se O
##g O
##re O
##gate O
##s O
with O
the O
disease O
( O
z O
##max O
= O
6 O
. O
63 O
, O
the O
##ta O
= O
0 O
. O
00 O
) O
. O

it O
appears O
, O
therefore O
, O
that O
s O
##p O
##g O
##2 O
and O
pm B-Disease
##d I-Disease
are O
all B-Disease
##eli I-Disease
##c I-Disease
disorders I-Disease

can B-Disease
##avan I-Disease
disease I-Disease
: O
mutations O
among O
j O
##ew O
##ish O
and O
non O
- O
j O
##ew O
##ish O
patients O
. O

can B-Disease
##avan I-Disease
disease I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
as I-Disease
##par I-Disease
##to I-Disease
##acy I-Disease
##lase I-Disease
( O
as O
##pa O
) O
. O

sixty O
- O
four O
pro O
##band O
##s O
were O
analyzed O
for O
mutations O
in O
the O
as O
##pa O
gene O
. O

three O
point O
mutations O
- O
- O
69 O
##3 O
##c O
- O
- O
[UNK] O
a O
, O
85 O
##4 O
##a O
- O
- O
[UNK] O
c O
, O
and O
91 O
##4 O
##c O
- O
- O
[UNK] O
a O
- O
- O
were O
identified O
in O
the O
coding O
sequence O
. O

the O
69 O
##3 O
##c O
- O
- O
[UNK] O
a O
and O
91 O
##4 O
##c O
- O
- O
[UNK] O
a O
base O
changes O
, O
resulting O
in O
nonsense O
t O
##yr O
##23 O
##1 O
- O
- O
[UNK] O
te O
##r O
and O
miss O
##ense O
al O
##a O
##30 O
##5 O
- O
- O
[UNK] O
g O
##lu O
mutations O
, O
respectively O
, O
lead O
to O
complete O
loss O
of O
as O
##pa O
activity O
in O
in O
v O
##it O
##ro O
expression O
studies O
. O

the O
85 O
##4 O
##a O
- O
- O
[UNK] O
c O
trans O
##version O
converted O
g O
##lu O
to O
al O
##a O
in O
co O
##don O
285 O
. O

the O
g O
##lu O
##28 O
##5 O
- O
- O
[UNK] O
al O
##a O
mutant O
as O
##pa O
has O
2 O
. O

5 O
% O
of O
the O
activity O
expressed O
by O
the O
wild O
- O
type O
enzyme O
. O

a O
fourth O
mutation O
, O
43 O
##3 O
- O
- O
2 O
( O
a O
- O
- O
[UNK] O
g O
) O
transition O
, O
was O
identified O
at O
the O
s O
##p O
##lice O
- O
accept O
##or O
site O
in O
intro O
##n O
2 O
. O

the O
s O
##p O
##lice O
- O
site O
mutation O
would O
lead O
to O
skip O
##ping O
of O
ex O
##on O
3 O
, O
accompanied O
by O
a O
frames O
##hi O
##ft O
, O
and O
thus O
would O
produce O
a O
##ber O
##rant O
as O
##pa O
. O

of O
the O
128 O
unrelated O
can B-Disease
##avan I-Disease
chromosome O
##s O
analyzed O
, O
88 O
were O
from O
pro O
##band O
##s O
of O
ash O
##ken O
##azi O
j O
##ew O
##ish O
descent O
. O

the O
g O
##lu O
##28 O
##5 O
- O
- O
[UNK] O
al O
##a O
mutation O
was O
predominant O
( O
82 O
. O
9 O
% O
) O
in O
this O
population O
, O
followed O
by O
the O
t O
##yr O
##23 O
##1 O
- O
- O
[UNK] O
te O
##r O
( O
14 O
. O
8 O
% O
) O
and O
43 O
##3 O
- O
- O
2 O
( O
a O
- O
- O
[UNK] O
g O
) O
( O
1 O
. O
1 O
% O
) O
mutations O
. O

the O
three O
mutations O
account O
for O
98 O
. O

8 O
% O
of O
the O
can B-Disease
##avan I-Disease
chromosome O
##s O
of O
ash O
##ken O
##azi O
j O
##ew O
##ish O
origin O
. O

the O
al O
##a O
##30 O
##5 O
- O
- O
[UNK] O
g O
##lu O
mutation O
was O
found O
exclusively O
in O
non O
- O
j O
##ew O
##ish O
pro O
##band O
##s O
of O
euro O
##pe O
##an O
descent O
and O
constituted O
60 O
% O
of O
the O
40 O
mutant O
chromosome O
##s O
. O

predominant O
occurrence O
of O
certain O
mutations O
among O
ash O
##ken O
##azi O
j O
##ew O
##ish O
and O
non O
- O
j O
##ew O
##ish O
patients O
with O
can B-Disease
##avan I-Disease
disease I-Disease
would O
suggest O
a O
founding O
- O
father O
effect O
in O
propagation O
of O
these O
mutant O
chromosome O
##s O

intelligence O
q O
##uo O
##tien O
##t O
profile O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
inter O
##gene O
##ration O
##al O
deficit O
, O
and O
correlation O
with O
c O
##t O
##g O
am O
##p O
##lification O
. O

an O
abbreviated O
we O
##chs O
##ler O
adult O
intelligence O
scale O
revised O
( O
wa O
##is O
- O
r O
) O
was O
used O
to O
assess O
verbal O
and O
arithmetic O
##al O
cognitive O
performance O
in O
55 O
subjects O
with O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
, O
covering O
all O
grades O
of O
disease O
severity O
, O
and O
31 O
controls O
at O
50 O
% O
risk O
of O
inherit O
##ing O
d B-Disease
##m I-Disease
. O

scaled O
scores O
from O
the O
assessment O
were O
converted O
into O
an O
intelligence O
q O
##uo O
##tien O
##t O
( O
i O
##q O
) O
est O
##imation O
on O
each O
person O
. O

significant O
i O
##q O
differences O
were O
found O
between O
( O
1 O
) O
all O
55 O
d B-Disease
##m I-Disease
subjects O
( O
mean O
90 O
. O
2 O
, O
s O
##d O
16 O
. O
1 O
) O
and O
31 O
controls O
( O
102 O
. O
6 O
, O
s O
##d O
9 O
. O
4 O
) O
, O
with O
no O
sex O
differences O
in O
either O
group O
; O
( O
2 O
) O
15 O
affected O
parents O
( O
99 O
. O
3 O
, O
s O
##d O
12 O
. O
2 O
) O
and O
their O
affected O
children O
( O
88 O
. O
1 O
, O
s O
##d O
17 O
. O
2 O
) O
, O
where O
significance O
was O
dependent O
on O
parental O
sex O
being O
female O
; O
and O
( O
3 O
) O
15 O
pairs O
of O
affected O
si O
##bs O
( O
89 O
. O
6 O
, O
s O
##d O
13 O
. O
2 O
) O
and O
their O
normal O
si O
##bs O
( O
100 O
. O
2 O
, O
s O
##d O
7 O
. O
6 O
) O
. O

i O
##q O
steadily O
declined O
as O
( O
1 O
) O
the O
age O
of O
onset O
of O
signs O
and O
symptoms O
decreased O
, O
and O
( O
2 O
) O
the O
c O
##t O
##g O
expansion O
size O
increased O
. O

the O
correlation O
appeared O
to O
be O
more O
linear O
with O
age O
of O
onset O
. O

the O
correlation O
of O
i O
##q O
difference O
and O
c O
##t O
##g O
expansion O
difference O
in O
both O
the O
d B-Disease
##m I-Disease
parent O
- O
child O
pairs O
and O
normal O
si O
##b O
- O
affected O
si O
##b O
pairs O
was O
poor O
, O
indicating O
that O
c O
##t O
##g O
expansion O
is O
not O
a O
reliable O
predict O
##or O
of O
i O
##q O
either O
in O
individual O
persons O
or O
families O
. O

further O
analysis O
of O
cognitive O
function O
in O
d B-Disease
##m I-Disease
is O
required O
to O
c O
##lar O
##ify O
specific O
deficit O
##s O
characteristic O
of O
this O
patient O
group O

ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
and O
a O
c O
##yt O
##ogen O
##etic O
del O
##eti O
##on O
of O
chromosome O
5 O
resulting O
from O
a O
maternal O
in O
##tra O
##ch O
##rom O
##oso O
##mal O
insertion O
. O

we O
present O
the O
clinical O
and O
laboratory O
findings O
in O
an O
institutional O
##ised O
adult O
patient O
originally O
referred O
for O
autism B-Disease
. O

a O
high O
risk O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
was O
predicted O
when O
an O
inter O
##st O
##iti O
##al O
del O
##eti O
##on O
of O
the O
long O
arm O
of O
chromosome O
5 O
, O
del O
( O
5 O
) O
( O
q O
##15 O
##q O
##22 O
. O
3 O
) O
, O
was O
detected O
in O
her O
l O
##ymph O
##ocytes O
and O
del O
##eti O
##on O
of O
the O
m O
##cc O
and O
a B-Disease
##p I-Disease
##c I-Disease
genes O
confirmed O
by O
molecular O
analysis O
. O

ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
and O
car B-Disease
##cin I-Disease
##oma I-Disease
of I-Disease
the I-Disease
re I-Disease
##ct I-Disease
##um I-Disease
were O
subsequently O
diagnosed O
in O
the O
patient O
. O

she O
was O
profound O
##ly O
mentally B-Disease
re I-Disease
##tar I-Disease
##ded I-Disease
, O
au B-Disease
##tist I-Disease
##ic I-Disease
, O
and O
had O
minor O
d B-Disease
##ys I-Disease
##morphic I-Disease
features I-Disease
consistent O
with O
those O
of O
previous O
patients O
with O
similar O
del O
##eti O
##ons O
. O

the O
del O
##eti O
##on O
arose O
as O
a O
result O
of O
re O
##comb O
##ination O
within O
the O
small O
insertion O
loop O
formed O
at O
me O
##ios O
##is O
by O
the O
direct O
insertion O
( O
dir O
ins O
( O
5 O
) O
( O
q O
##22 O
. O
3 O
##q O
##14 O
. O
2 O
##q O
##15 O
) O
) O
found O
in O
the O
patients O
mother O
. O

this O
family O
further O
confirms O
the O
c O
##yt O
##ogen O
##etic O
mapping O
of O
both O
m O
##cc O
and O
a B-Disease
##p I-Disease
##c I-Disease
genes O
to O
5 O
##q O
##22 O
and O
comparison O
with O
other O
recent O
cases O
suggests O
that O
both O
genes O
and O
their O
closely O
linked O
markers O
lie O
within O
the O
5 O
##q O
##22 O
. O

1 O
sub O
##band O

f B-Disease
##ami I-Disease
##lial I-Disease
male I-Disease
breast I-Disease
cancer I-Disease
is O
not O
linked O
to O
the O
br O
##ca O
##1 O
lo O
##cus O
on O
chromosome O
17 O
##q O
. O

breast B-Disease
cancer I-Disease
in O
men O
is O
about O
a O
hundred O
##fold O
less O
common O
than O
in O
women O
and O
this O
has O
hind O
##ered O
research O
into O
its O
genetic O
basis O
. O

we O
have O
examined O
22 O
families O
with O
at O
least O
one O
case O
of O
male B-Disease
breast I-Disease
cancer I-Disease
for O
link O
##age O
to O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
lo O
##cus O
, O
br O
##ca O
##1 O
, O
on O
chromosome O
17 O
##q O
. O

we O
found O
strong O
evidence O
against O
link O
##age O
to O
br O
##ca O
##1 O
( O
lo O
##d O
score O
- O
16 O
. O
63 O
) O
and O
the O
best O
estimate O
of O
the O
proportion O
of O
linked O
families O
was O
0 O
% O
( O
95 O
% O
c O
##i O
0 O
- O
18 O
% O
) O
. O

our O
results O
indicate O
that O
there O
is O
a O
gene O
( O
s O
) O
other O
than O
br O
##ca O
##1 O
which O
pre O
##dis O
##pose O
##s O
to O
early O
- O
onset O
breast B-Disease
cancer I-Disease
in O
women O
and O
which O
con O
##fers O
a O
higher O
risk O
of O
male B-Disease
breast I-Disease
cancer I-Disease
. O

identification O
of O
additional O
p O
##ed O
##ig O
##ree O
##s O
that O
include O
cases O
of O
male B-Disease
breast I-Disease
cancer I-Disease
may O
therefore O
facilitate O
the O
mapping O
and O
isolation O
of O
this O
gene O
. O

the O
e O
##ws O
gene O
, O
involved O
in O
e B-Disease
##wing I-Disease
family I-Disease
of I-Disease
tumors I-Disease
, O
ma B-Disease
##li I-Disease
##gnant I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
of I-Disease
soft I-Disease
parts I-Disease
and O
des B-Disease
##mo I-Disease
##p I-Disease
##lastic I-Disease
small I-Disease
round I-Disease
cell I-Disease
tumors I-Disease
, O
codes O
for O
an O
r O
##na O
binding O
protein O
with O
novel O
regulatory O
domains O
. O

the O
e O
##ws O
gene O
, O
which O
maps O
to O
band O
q O
##12 O
of O
human O
chromosome O
22 O
, O
is O
involved O
in O
a O
wide O
variety O
of O
human O
solid B-Disease
tumors I-Disease
including O
e B-Disease
##wing I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
, O
related O
primitive O
ne B-Disease
##uro I-Disease
##ec I-Disease
##to I-Disease
##der I-Disease
##mal I-Disease
tumors I-Disease
, O
ma B-Disease
##li I-Disease
##gnant I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
of I-Disease
soft I-Disease
parts I-Disease
and O
des B-Disease
##mo I-Disease
##p I-Disease
##lastic I-Disease
small I-Disease
round I-Disease
cell I-Disease
tumors I-Disease
. O

in O
these O
tumors B-Disease
, O
the O
e O
##ws O
is O
fused O
to O
genes O
encoding O
transcription O
##al O
act O
##iva O
##tors O
/ O
re O
##press O
##ors O
, O
like O
fl O
##i O
- O
1 O
or O
er O
##g O
or O
at O
##f O
1 O
or O
w O
##t O
##1 O
. O

to O
better O
understand O
the O
function O
of O
the O
e O
##ws O
protein O
, O
we O
clone O
##d O
the O
e O
##ws O
c O
##dn O
##a O
. O

sequence O
analysis O
of O
this O
c O
##dn O
##a O
revealed O
differential O
s O
##p O
##licing O
involving O
two O
ex O
##ons O
encoding O
72 O
amino O
acids O
. O

both O
alternatively O
s O
##p O
##lice O
##d O
trans O
##cripts O
, O
e O
##ws O
and O
e O
##ws O
- O
b O
, O
are O
expressed O
in O
a O
variety O
of O
cells O
. O

because O
e O
##ws O
proteins O
contain O
put O
##ative O
conserved O
r O
##na O
binding O
motifs O
, O
we O
studied O
the O
r O
##na O
binding O
properties O
of O
the O
e O
##ws O
protein O
. O

the O
e O
##ws O
- O
b O
protein O
binds O
to O
r O
##na O
in O
v O
##it O
##ro O
and O
, O
specifically O
, O
to O
p O
##oly O
g O
and O
p O
##oly O
u O
. O

the O
r O
##na O
binding O
activity O
was O
localized O
to O
the O
car O
##box O
##y O
terminal O
86 O
amino O
acids O
, O
which O
constitute O
r O
##gg O
box O
. O

thus O
the O
amino O
terminal O
domain O
of O
e O
##ws O
( O
n O
##t O
##d O
- O
e O
##ws O
) O
, O
which O
is O
involved O
in O
chromosome O
trans O
##location O
may O
regulate O
the O
specific O
##ity O
of O
r O
##na O
binding O
activity O
of O
e O
##ws O
. O

an O
e O
##ws O
- O
er O
##g O
ch O
##ime O
##ric O
protein O
, O
which O
is O
found O
in O
e B-Disease
##wing I-Disease
##s I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
cells O
, O
functions O
as O
a O
transcription O
##al O
act O
##iva O
##tor O
. O

mutation O
##al O
analysis O
of O
e O
##ws O
- O
er O
##g O
ch O
##ime O
##ric O
protein O
revealed O
that O
n O
##t O
##d O
- O
e O
##ws O
functions O
as O
a O
regulatory O
domain O
for O
the O
transcription O
##al O
activation O
properties O
of O
e O
##ws O
- O
er O
##g O
ch O
##ime O
##ric O
protein O
. O
. O

can B-Disease
##avan I-Disease
disease I-Disease
: O
g O
##eno O
##mic O
organization O
and O
local O
##ization O
of O
human O
as O
##pa O
to O
17 O
##p O
##13 O
- O
te O
##r O
and O
conservation O
of O
the O
as O
##pa O
gene O
during O
evolution O
. O

can B-Disease
##avan I-Disease
disease I-Disease
, O
or O
s B-Disease
##po I-Disease
##ng I-Disease
##y I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
of I-Disease
the I-Disease
brain I-Disease
, O
is O
a O
severe O
le B-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
as I-Disease
##par I-Disease
##to I-Disease
##acy I-Disease
##lase I-Disease
( O
as O
##pa O
) O
. O

recently O
, O
a O
miss O
##ense O
mutation O
was O
identified O
in O
human O
as O
##pa O
coding O
sequence O
from O
patients O
with O
can B-Disease
##avan I-Disease
disease I-Disease
. O

the O
human O
as O
##pa O
gene O
has O
been O
clone O
##d O
and O
found O
to O
span O
29 O
k O
##b O
of O
the O
genome O
. O

human O
as O
##par O
##to O
##acy O
##lase O
is O
coded O
by O
six O
ex O
##ons O
intervened O
by O
five O
intro O
##ns O
. O

the O
ex O
##ons O
vary O
from O
94 O
( O
ex O
##on O
ii O
##i O
) O
to O
51 O
##4 O
( O
ex O
##on O
v O
##i O
) O
bases O
. O

the O
ex O
##on O
/ O
intro O
##n O
s O
##p O
##lice O
junction O
sites O
follow O
the O
g O
##t O
/ O
a O
##g O
consensus O
sequence O
rule O
. O

southern O
b O
##lot O
analysis O
of O
g O
##eno O
##mic O
d O
##na O
from O
human O
/ O
mouse O
so O
##matic O
cell O
hybrid O
cell O
lines O
localized O
as O
##pa O
to O
human O
chromosome O
17 O
. O

the O
human O
as O
##pa O
lo O
##cus O
was O
further O
mapped O
in O
the O
17 O
##p O
##13 O
- O
te O
##r O
region O
by O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
. O

the O
b O
##ov O
##ine O
as O
##pa O
gene O
has O
also O
been O
clone O
##d O
, O
and O
its O
ex O
##on O
/ O
intro O
##n O
organization O
is O
identical O
to O
that O
of O
the O
human O
gene O
. O

the O
500 O
- O
base O
sequence O
upstream O
of O
the O
in O
##iti O
##ator O
at O
##g O
co O
##don O
in O
the O
human O
gene O
and O
that O
in O
the O
b O
##ov O
##ine O
gene O
are O
77 O
% O
identical O
. O

human O
as O
##pa O
coding O
sequences O
cross O
- O
hybrid O
##ize O
with O
g O
##eno O
##mic O
d O
##na O
from O
yeast O
, O
chicken O
, O
rabbit O
, O
cow O
, O
dog O
, O
mouse O
, O
rat O
, O
and O
monkey O
. O

the O
specific O
##ity O
of O
cross O
- O
species O
hybrid O
##ization O
of O
coding O
sequences O
suggests O
that O
as O
##par O
##to O
##acy O
##lase O
has O
been O
conserved O
during O
evolution O
. O

it O
should O
now O
be O
possible O
to O
identify O
mutations O
in O
the O
non O
##co O
##ding O
g O
##eno O
##mic O
sequences O
that O
lead O
to O
can B-Disease
##avan I-Disease
disease I-Disease
and O
to O
study O
the O
regulation O
of O
as O
##pa O
. O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
: O
size O
- O
and O
sex O
- O
dependent O
dynamics O
of O
c O
##t O
##g O
me O
##iot O
##ic O
instability O
, O
and O
so O
##matic O
mosaic O
##ism O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
a O
progressive O
ne B-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
disorder I-Disease
which O
results O
from O
el O
##ong O
##ations O
of O
an O
unstable O
( O
c O
##t O
##g O
) O
n O
repeat O
, O
located O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
the O
d B-Disease
##m I-Disease
gene O
. O

a O
correlation O
has O
been O
demonstrated O
between O
the O
increase O
in O
the O
repeat O
number O
of O
this O
sequence O
and O
the O
severity O
of O
the O
disease O
. O

however O
, O
the O
clinical O
status O
of O
patients O
cannot O
be O
un O
##am O
##bi O
##guous O
##ly O
as O
##cer O
##tain O
##ed O
solely O
on O
the O
basis O
of O
the O
number O
of O
c O
##t O
##g O
repeats O
. O

more O
##over O
, O
the O
exclusive O
maternal O
inheritance O
of O
the O
con O
##gen O
##ital O
form O
remains O
une O
##x O
##plain O
##ed O
. O

our O
observation O
of O
differently O
sized O
repeats O
in O
various O
d B-Disease
##m I-Disease
tissues O
from O
the O
same O
individual O
may O
explain O
why O
the O
size O
of O
the O
mutation O
observed O
in O
l O
##ymph O
##ocytes O
does O
not O
necessarily O
co O
##rrel O
##ate O
with O
the O
severity O
and O
nature O
of O
symptoms O
. O

through O
a O
molecular O
and O
genetic O
study O
of O
142 O
families O
including O
41 O
##8 O
d B-Disease
##m I-Disease
patients O
, O
we O
have O
investigated O
the O
dynamics O
of O
the O
c O
##t O
##g O
repeat O
me O
##iot O
##ic O
instability O
. O

a O
positive O
correlation O
between O
the O
size O
of O
the O
repeat O
and O
the O
inter O
##gene O
##ration O
##al O
en O
##lar O
##gement O
was O
observed O
similarly O
through O
male O
and O
female O
me O
##ios O
##es O
for O
[UNK] O
or O
= O
0 O
. O

5 O
- O
k O
##b O
c O
##t O
##g O
sequences O
. O

beyond O
0 O
. O

5 O
k O
##b O
, O
the O
inter O
##gene O
##ration O
##al O
variation O
was O
more O
important O
through O
female O
me O
##ios O
##es O
, O
whereas O
a O
tendency O
to O
compression O
was O
observed O
almost O
exclusively O
in O
male O
me O
##ios O
##es O
, O
for O
[UNK] O
or O
= O
1 O
. O

5 O
- O
k O
##b O
fragments O
. O

this O
implies O
a O
size O
- O
and O
sex O
- O
dependent O
me O
##iot O
##ic O
instability O
. O

more O
##over O
, O
segregation O
analysis O
supports O
the O
hypothesis O
of O
a O
maternal O
as O
well O
as O
a O
f O
##ami O
##lial O
pre O
##dis O
##position O
for O
the O
occurrence O
of O
the O
con O
##gen O
##ital O
form O
. O

finally O
, O
this O
analysis O
reveals O
a O
significant O
excess O
of O
transmitting O
grandfather O
##s O
partially O
accounted O
for O
by O
increased O
fertility O
in O
affected O
males O

illegitimate O
transcription O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
gene O
in O
l O
##ymph O
##ocytes O
for O
identification O
of O
mutations O
in O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

taking O
advantage O
of O
the O
illegitimate O
transcription O
of O
the O
p O
##hen O
##yla O
##lani O
##ne O
h O
##ydro O
##xy O
##lase O
( O
p O
##ah O
) O
gene O
, O
we O
have O
been O
able O
to O
anal O
##ys O
##e O
the O
p O
##ah O
c O
##dn O
##a O
sequence O
of O
h B-Disease
##yper I-Disease
##phe I-Disease
##ny I-Disease
##lal I-Disease
##ani I-Disease
##ne I-Disease
##mic I-Disease
children O
in O
circulating O
l O
##ymph O
##ocytes O
. O

using O
this O
approach O
, O
we O
have O
also O
identified O
3 O
novel O
mutations O
in O
c O
##dn O
##a O
from O
liver O
and O
l O
##ymph O
##ocytes O
of O
two O
patients O
. O

one O
mutation O
, O
detected O
by O
the O
abnormal O
pattern O
of O
migration O
of O
an O
am O
##plified O
fragment O
, O
is O
a O
c O
to O
t O
transition O
in O
the O
s O
##p O
##lice O
accept O
##or O
site O
of O
intro O
##n O
10 O
, O
which O
resulted O
in O
the O
skip O
##ping O
of O
ex O
##on O
11 O
with O
the O
premature O
termination O
of O
r O
##na O
translation O
downstream O
from O
ex O
##on O
12 O
( O
- O
3 O
i O
##v O
##s O
##10 O
) O
. O

the O
other O
two O
mutations O
are O
miss O
##ense O
mutations O
in O
ex O
##ons O
10 O
and O
11 O
( O
respectively O
, O
l O
##33 O
##3 O
##f O
and O
e O
##39 O
##0 O
##g O
) O
. O

the O
present O
study O
supports O
the O
view O
that O
circulating O
l O
##ymph O
##ocytes O
give O
easy O
access O
to O
p O
##ah O
gene O
trans O
##cripts O
whose O
n O
##uc O
##leo O
##tide O
sequence O
is O
identical O
to O
that O
reported O
in O
liver O
and O
therefore O
represent O
a O
useful O
tool O
for O
molecular O
genetic O
studies O
in O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O
. O

high O
residual O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
activity O
in O
a O
patient O
with O
late B-Disease
- I-Disease
infant I-Disease
##ile I-Disease
meta I-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

we O
identified O
a O
patient O
suffering O
from O
late B-Disease
- I-Disease
infant I-Disease
##ile I-Disease
meta I-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
who O
has O
a O
residual O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
activity O
of O
about O
10 O
% O
. O

fi O
##bro O
##blast O
##s O
of O
the O
patient O
show O
significant O
su O
##lf O
##ati O
##de O
degradation O
activity O
exceeding O
that O
of O
adult B-Disease
m I-Disease
##ld I-Disease
patients O
. O

analysis O
of O
the O
a O
##rsa O
gene O
in O
this O
patient O
revealed O
he O
##tero O
##zy O
##gos O
##ity O
for O
two O
new O
mutant O
all O
##ele O
##s O
in O
one O
all O
##ele O
, O
del O
##eti O
##on O
of O
c O
44 O
##7 O
in O
ex O
##on O
2 O
leads O
to O
a O
frames O
##hi O
##ft O
and O
to O
a O
premature O
stop O
co O
##don O
at O
amino O
acid O
position O
105 O
; O
in O
the O
second O
all O
##ele O
, O
a O
g O
- O
- O
[UNK] O
a O
transition O
in O
ex O
##on O
5 O
causes O
a O
g O
##ly O
##30 O
##9 O
- O
- O
[UNK] O
se O
##r O
substitution O
. O

trans O
##ient O
expression O
of O
the O
mutant O
se O
##r O
##30 O
##9 O
- O
a O
##rsa O
resulted O
in O
only O
13 O
% O
enzyme O
activity O
of O
that O
observed O
in O
cells O
expressing O
normal O
a O
##rsa O
. O

the O
mutant O
a O
##rsa O
is O
correctly O
targeted O
to O
the O
l O
##ys O
##oso O
##mes O
but O
is O
unstable O
. O

these O
findings O
are O
in O
contrast O
to O
previous O
results O
showing O
that O
the O
late B-Disease
- I-Disease
infant I-Disease
##ile I-Disease
type I-Disease
of I-Disease
m I-Disease
##ld I-Disease
is O
always O
associated O
with O
the O
complete O
absence O
of O
a O
##rsa O
activity O
. O

the O
expression O
of O
the O
mutant O
a O
##rsa O
protein O
may O
be O
influenced O
by O
particular O
features O
of O
o O
##li O
##go O
##den O
##dr O
##ocytes O
, O
such O
that O
the O
level O
of O
mutant O
enzyme O
is O
lower O
in O
these O
cells O
than O
in O
others O
. O
. O

an O
a O
##ryl O
##sul O
##fa O
##tase O
a O
( O
a O
##rsa O
) O
miss O
##ense O
mutation O
( O
t O
##27 O
##4 O
##m O
) O
causing O
late B-Disease
- I-Disease
infant I-Disease
##ile I-Disease
meta I-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
. O

meta B-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
m B-Disease
##ld I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
l I-Disease
##ys I-Disease
##oso I-Disease
##mal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
a I-Disease
##ryl I-Disease
##sul I-Disease
##fa I-Disease
##tase I-Disease
a I-Disease
( O
a O
##rsa O
; O
e O
##c O
3 O
. O
1 O
. O
6 O
. O
8 O
) O
. O

the O
8 O
a O
##rsa O
ex O
##ons O
and O
adjacent O
intro O
##n O
boundaries O
from O
a O
patient O
with O
late B-Disease
- I-Disease
infant I-Disease
##ile I-Disease
meta I-Disease
##ch I-Disease
##romatic I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
were O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
am O
##plified O
in O
seven O
discrete O
reactions O
. O

am O
##plified O
a O
##rsa O
ex O
##ons O
were O
anal O
##ys O
##ed O
for O
the O
presence O
of O
sequence O
alterations O
by O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
, O
followed O
by O
direct O
se O
##quencing O
of O
p O
##c O
##r O
products O
. O

the O
patient O
was O
found O
to O
be O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
c O
- O
- O
[UNK] O
t O
transition O
in O
ex O
##on O
i O
##v O
that O
results O
in O
the O
substitution O
of O
a O
highly O
conserved O
th O
##re O
##oni O
##ne O
residue O
at O
amino O
acid O
27 O
##4 O
with O
a O
met O
##hi O
##oni O
##ne O
( O
t O
##27 O
##4 O
##m O
) O
. O

analysis O
of O
a O
further O
29 O
m B-Disease
##ld I-Disease
patients O
revealed O
the O
presence O
of O
five O
additional O
ho O
##mo O
##zy O
##got O
##es O
for O
t O
##27 O
##4 O
##m O
. O

all O
6 O
t O
##27 O
##4 O
##m O
ho O
##mo O
##zy O
##got O
##es O
( O
representing O
four O
families O
) O
were O
of O
le O
##ban O
##ese O
descent O
, O
and O
all O
were O
known O
to O
be O
the O
result O
of O
con O
##sang O
##uin O
##eous O
marriages O
. O

the O
altered O
amino O
acid O
is O
rigid O
##ly O
conserved O
among O
10 O
su O
##lf O
##ata O
##ses O
from O
es O
##cher O
##ichi O
##a O
co O
##li O
to O
humans O
; O
therefore O
, O
it O
is O
most O
likely O
that O
the O
result O
##ant O
mutant O
protein O
will O
have O
little O
or O
no O
enzyme O
activity O
. O

this O
is O
consistent O
with O
the O
very O
low O
a O
##rsa O
activity O
measured O
in O
these O
patients O
and O
their O
uniform O
##ly O
severe O
clinical O
presentation O

mutations O
in O
the O
p O
##ax O
##6 O
gene O
in O
patients O
with O
hereditary O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

the O
14 O
ex O
##ons O
of O
the O
p O
##ax O
##6 O
gene O
have O
been O
anal O
##ys O
##ed O
ex O
##on O
- O
by O
- O
ex O
##on O
using O
s O
##s O
##c O
##p O
in O
6 O
an B-Disease
##iri I-Disease
##dia I-Disease
families O
. O

in O
each O
family O
band O
shifts O
were O
observed O
on O
the O
s O
##s O
##c O
##p O
gel O
##s O
for O
only O
one O
ex O
##on O
and O
direct O
p O
##c O
##r O
- O
se O
##quencing O
revealed O
mutations O
in O
each O
case O
. O

two O
mutations O
involved O
c O
- O
- O
[UNK] O
t O
transitions O
in O
c O
##ga O
##ar O
##g O
co O
##don O
##s O
in O
ex O
##ons O
9 O
and O
11 O
. O

another O
c O
- O
- O
[UNK] O
t O
transition O
converted O
a O
ca O
##g O
- O
g O
##lut O
##amine O
to O
a O
tag O
- O
stop O
in O
ex O
##on O
7 O
. O

small O
insertion O
##s O
created O
frames O
##hi O
##fts O
which O
produced O
downstream O
stop O
co O
##don O
##s O
in O
another O
two O
patients O
and O
an O
a O
- O
- O
[UNK] O
t O
mutation O
disrupted O
the O
s O
##p O
##lice O
donor O
site O
of O
ex O
##on O
5 O
in O
the O
remaining O
family O
. O

thus O
, O
complete O
in O
##act O
##ivation O
of O
the O
p O
##ax O
##6 O
gene O
is O
predicted O
in O
all O
cases O
. O

analysis O
of O
other O
affected O
members O
of O
the O
families O
showed O
that O
, O
in O
each O
case O
, O
all O
affected O
individuals O
carried O
the O
same O
family O
- O
specific O
mutation O
. O

one O
p O
##oly O
##mor O
##phism O
was O
found O
in O
ex O
##on O
7 O
. O

this O
data O
strongly O
supports O
the O
can O
##di O
##da O
##ture O
of O
p O
##ax O
##6 O
as O
the O
gene O
responsible O
for O
hereditary O
an B-Disease
##iri I-Disease
##dia I-Disease
. O
. O

three O
novel O
mutations O
in O
five O
unrelated O
subjects O
with O
hereditary O
protein B-Disease
s I-Disease
deficiency I-Disease
type I-Disease
i I-Disease
. O

a O
panel O
of O
eight O
unrelated O
subjects O
with O
inherited O
type B-Disease
i I-Disease
protein I-Disease
s I-Disease
deficiency I-Disease
was O
screened O
for O
mutations O
in O
the O
pro O
##s O
##1 O
gene O
. O

in O
five O
subjects O
an O
abnormal O
##ity O
was O
found O
but O
mutations O
were O
not O
detected O
in O
the O
remaining O
three O
subjects O
. O

two O
subjects O
shared O
a O
g O
- O
- O
[UNK] O
a O
transition O
at O
position O
+ O
5 O
of O
the O
donor O
s O
##p O
##lice O
site O
consensus O
sequence O
of O
intro O
##n O
10 O
. O

also O
in O
two O
subjects O
an O
a O
- O
- O
[UNK] O
t O
trans O
##version O
was O
detected O
in O
the O
stop O
##co O
##don O
of O
the O
pro O
##s O
##1 O
gene O
; O
this O
trans O
##version O
predict O
##s O
a O
protein O
s O
molecule O
that O
is O
extended O
by O
14 O
amino O
acids O
. O

the O
fifth O
subject O
was O
found O
to O
possess O
two O
sequence O
abnormal O
##ities O
. O

one O
all O
##ele O
carried O
a O
g O
- O
- O
[UNK] O
a O
transition O
near O
the O
donor O
s O
##p O
##lice O
junction O
of O
intro O
##n O
2 O
, O
but O
this O
abnormal O
##ity O
is O
probably O
neutral O
, O
since O
it O
was O
inherited O
from O
the O
parent O
with O
normal O
protein O
s O
anti O
##gen O
levels O
. O

in O
the O
other O
all O
##ele O
a O
single O
t O
insertion O
in O
co O
##don O
- O
25 O
was O
found O
. O

analysis O
of O
plate O
##let O
r O
##na O
showed O
that O
only O
the O
m O
##rna O
with O
the O
a O
- O
- O
[UNK] O
t O
mutation O
in O
the O
stop O
##co O
##don O
is O
present O
in O
amounts O
comparable O
to O
wild O
##type O
r O
##na O
. O

m O
##rna O
from O
the O
all O
##ele O
##s O
with O
the O
other O
two O
mutations O
was O
either O
und O
##ete O
##ct O
##able O
or O
present O
in O
greatly O
reduced O
amounts O
. O

the O
latter O
indicates O
that O
a O
m O
##rna O
based O
approach O
is O
not O
feasible O
for O
the O
genetic O
analysis O
of O
protein B-Disease
s I-Disease
deficiency I-Disease
type I-Disease
i I-Disease
. O
. O

characteristics O
of O
inter O
##gene O
##ration O
##al O
contraction O
##s O
of O
the O
c O
##t O
##g O
repeat O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
, O
the O
size O
of O
a O
c O
##t O
##g O
repeat O
in O
the O
d B-Disease
##m I-Disease
kinase O
gene O
generally O
increases O
in O
successive O
generations O
with O
clinical O
evidence O
of O
anticipation O
. O

however O
, O
there O
have O
also O
been O
cases O
with O
an O
inter O
##gene O
##ration O
##al O
contraction O
of O
the O
repeat O
. O

we O
examined O
1 O
, O
48 O
##9 O
d B-Disease
##m I-Disease
parent O
- O
offspring O
pairs O
, O
of O
which O
95 O
( O
6 O
. O
4 O
% O
) O
showed O
such O
contraction O
##s O
in O
peripheral O
blood O
le O
##uk O
##ocytes O
( O
p O
##b O
##l O
) O
. O

in O
56 O
of O
the O
95 O
pairs O
, O
clinical O
data O
allowed O
an O
analysis O
of O
their O
anticipation O
status O
. O

it O
is O
surprising O
that O
anticipation O
occurred O
in O
27 O
( O
48 O
% O
) O
of O
these O
56 O
pairs O
, O
while O
none O
clearly O
showed O
a O
later O
onset O
of O
d B-Disease
##m I-Disease
in O
the O
s O
##ym O
##pt O
##oma O
##tic O
offspring O
. O

the O
contraction O
occurred O
in O
76 O
( O
10 O
% O
) O
of O
75 O
##3 O
paternal O
transmissions O
and O
in O
19 O
( O
3 O
% O
) O
of O
73 O
##6 O
maternal O
transmissions O
. O

anticipation O
was O
observed O
more O
frequently O
in O
maternal O
( O
85 O
% O
) O
than O
in O
paternal O
( O
37 O
% O
) O
transmissions O
( O
p O
[UNK] O
. O
00 O
##1 O
) O
. O

the O
parental O
repeat O
size O
correlated O
with O
the O
size O
of O
inter O
##gene O
##ration O
##al O
contraction O
( O
r O
##2 O
= O
. O
50 O
, O
p O
[UNK] O
[UNK] O
. O
00 O
##1 O
) O
, O
and O
the O
slope O
of O
linear O
re O
##gression O
was O
steep O
##er O
in O
paternal O
( O
- O
. O
62 O
) O
than O
in O
maternal O
( O
- O
. O
30 O
) O
transmissions O
( O
p O
[UNK] O
[UNK] O
. O
00 O
##1 O
) O
. O

sixteen O
d B-Disease
##m I-Disease
parents O
had O
multiple O
d B-Disease
##m I-Disease
offspring O
with O
the O
c O
##t O
##g O
repeat O
contraction O
##s O
. O

this O
frequency O
was O
higher O
than O
the O
frequency O
expected O
from O
the O
probability O
of O
the O
repeat O
contraction O
##s O
( O
6 O
. O
4 O
% O
) O
and O
the O
size O
of O
d B-Disease
##m I-Disease
si O
##b O
population O
( O
1 O
. O
54 O
d B-Disease
##m I-Disease
offspring O
per O
d B-Disease
##m I-Disease
parent O
, O
in O
96 O
##8 O
d B-Disease
##m I-Disease
parents O
) O
. O

we O
conclude O
that O
( O
1 O
) O
inter O
##gene O
##ration O
##al O
contraction O
##s O
of O
the O
c O
##t O
##g O
repeat O
in O
le O
##uk O
##oc O
##yte O
d O
##na O
frequently O
a O
##cco O
##mp O
##ani O
##es O
apparent O
anticipation O
, O
especially O
when O
d B-Disease
##m I-Disease
is O
maternal O
##ly O
transmitted O
, O
and O
( O
2 O
) O
the O
paternal O
origin O
of O
the O
repeat O
and O
the O
presence O
of O
the O
repeat O
contraction O
in O
a O
sibling O
increase O
the O
probability O
of O
the O
c O
##t O
##g O
repeat O
contraction O

go O
##nos O
##oma O
##l O
mosaic O
##ism O
in O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
patients O
: O
involvement O
of O
mit O
##otic O
events O
in O
( O
c O
##t O
##g O
) O
n O
repeat O
variation O
and O
selection O
against O
extreme O
expansion O
in O
sperm O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
caused O
by O
abnormal O
expansion O
of O
a O
p O
##oly O
##morphic O
( O
c O
##t O
##g O
) O
n O
repeat O
, O
located O
in O
the O
d B-Disease
##m I-Disease
protein O
kinase O
gene O
. O

we O
determined O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
lengths O
in O
a O
broad O
range O
of O
tissue O
d O
##nas O
from O
patients O
with O
mild O
, O
classical O
, O
or O
con O
##gen O
##ital O
manifest O
##ation O
of O
d B-Disease
##m I-Disease
. O

differences O
in O
the O
repeat O
length O
were O
seen O
in O
so O
##matic O
tissues O
from O
single O
d B-Disease
##m I-Disease
individuals O
and O
twins O
. O

repeats O
appeared O
to O
expand O
to O
a O
similar O
extent O
in O
tissues O
originating O
from O
the O
same O
em O
##b O
##ryo O
##nal O
origin O
. O

in O
most O
male O
patients O
carrying O
intermediate O
- O
or O
small O
- O
sized O
expansion O
##s O
in O
blood O
, O
the O
repeat O
lengths O
covered O
a O
marked O
##ly O
wider O
range O
in O
sperm O
. O

in O
contrast O
, O
male O
patients O
with O
large O
all O
##ele O
expansion O
##s O
in O
blood O
( O
[UNK] O
700 O
c O
##t O
##gs O
) O
had O
similar O
or O
smaller O
repeats O
in O
sperm O
, O
when O
detect O
##able O
. O

sperm O
all O
##ele O
##s O
with O
[UNK] O
1 O
, O
000 O
c O
##t O
##gs O
were O
not O
seen O
. O

we O
conclude O
that O
d B-Disease
##m I-Disease
patients O
can O
be O
considered O
go O
##nos O
##oma O
##l O
mosaic O
##s O
, O
i O
. O

e O
e O
. O
, O
combined O
so O
##matic O
and O
g O
##er O
##m O
- O
line O
tissue O
mosaic O
##s O
. O

most O
remarkably O
, O
we O
observed O
multiple O
cases O
where O
the O
length O
distributions O
of O
intermediate O
- O
or O
small O
- O
sized O
all O
##ele O
##s O
in O
fathers O
sperm O
were O
significantly O
different O
from O
that O
in O
their O
offspring O
##s O
blood O
. O

our O
combined O
findings O
indicate O
that O
inter O
##gene O
##ration O
##al O
length O
changes O
in O
the O
unstable O
c O
##t O
##g O
repeat O
are O
most O
likely O
to O
occur O
during O
early O
em O
##b O
##ryo O
##nic O
mit O
##otic O
divisions O
in O
both O
so O
##matic O
and O
g O
##er O
##m O
- O
line O
tissue O
formation O
. O

both O
the O
initial O
c O
##t O
##g O
length O
, O
the O
overall O
number O
of O
cell O
divisions O
involved O
in O
tissue O
formation O
, O
and O
perhaps O
a O
specific O
selection O
process O
in O
sperm O
##ato O
##genesis O
may O
influence O
the O
dynamics O
of O
this O
process O
. O

a O
model O
explaining O
mit O
##otic O
instability O
and O
sex O
- O
dependent O
segregation O
phenomena O
in O
d B-Disease
##m I-Disease
manifest O
##ation O
is O
discussed O

regional O
##ly O
cluster O
##ed O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
are O
associated O
with O
a O
severe O
p O
##hen O
##otype O
and O
occur O
at O
a O
high O
frequency O
in O
new O
mutation O
cases O
of O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
. O

g O
##er O
##m O
##line O
mutation O
in O
a O
##p O
##c O
at O
5 O
##q O
##21 O
- O
22 O
results O
in O
the O
dominant O
##ly O
inherited O
syndrome O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
. O

so O
##matic O
mutation O
in O
this O
gene O
is O
an O
early O
event O
in O
color O
##ec O
##tal O
t O
##umour O
##ige O
##nes O
##is O
. O

both O
types O
of O
mutation O
are O
concentrated O
in O
the O
5 O
half O
of O
ex O
##on O
15 O
. O

we O
have O
used O
single O
strand O
conform O
##ational O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
and O
he O
##tero O
##du O
##plex O
analysis O
to O
screen O
for O
variants O
in O
this O
region O
of O
the O
gene O
in O
a O
total O
of O
45 O
affected O
but O
unrelated O
individuals O
. O

eighteen O
patients O
had O
no O
family O
history O
of O
the O
disease O
; O
of O
these O
11 O
were O
classified O
as O
having O
a O
severe O
p O
##hen O
##otype O
, O
based O
on O
an O
early O
age O
at O
presentation O
or O
cancer B-Disease
development O
. O

this O
compared O
with O
6 O
of O
27 O
f O
##ami O
##lial O
cases O
. O

a O
5 O
b O
##p O
del O
##eti O
##on O
at O
co O
##don O
130 O
##9 O
reported O
to O
occur O
in O
10 O
- O
15 O
% O
of O
un O
##sel O
##ec O
##ted O
a B-Disease
##p I-Disease
##c I-Disease
patients O
worldwide O
, O
was O
found O
in O
5 O
of O
the O
18 O
new O
mutation O
cases O
and O
4 O
of O
the O
27 O
f O
##ami O
##lial O
cases O
all O
nine O
were O
class O
##ed O
as O
severe O
. O

a O
further O
3 O
new O
mutations O
and O
1 O
f O
##ami O
##lial O
mutation O
were O
located O
downstream O
from O
co O
##don O
130 O
##9 O
, O
these O
individuals O
similarly O
being O
class O
##ed O
as O
p O
##hen O
##otypic O
##ally O
severe O
. O

in O
contrast O
all O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
detected O
in O
affected O
individuals O
with O
an O
average O
p O
##hen O
##otype O
were O
located O
prior O
to O
co O
##don O
130 O
##9 O
. O

the O
frequent O
association O
of O
a O
severe O
p O
##hen O
##otype O
with O
fresh O
mutation O
may O
explain O
the O
apparent O
conflict O
of O
a O
high O
mutation O
rate O
( O
20 O
- O
30 O
% O
) O
in O
a O
condition O
, O
which O
on O
average O
, O
is O
lethal O
at O
a O
post O
- O
reproductive O
age O
. O
. O

mutations O
at O
the O
p O
##ax O
##6 O
lo O
##cus O
are O
found O
in O
he O
##tero O
##gene O
##ous O
anterior B-Disease
segment I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ations I-Disease
including O
pet B-Disease
##ers I-Disease
' I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
. O

mutation O
or O
del O
##eti O
##on O
of O
the O
p O
##ax O
##6 O
gene O
under O
##lies O
many O
cases O
of O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

three O
lines O
of O
evidence O
now O
con O
##ver O
##ge O
to O
imp O
##lica O
##te O
p O
##ax O
##6 O
more O
widely O
in O
anterior B-Disease
segment I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ations I-Disease
including O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
. O

first O
, O
a O
child O
with O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
is O
deleted O
for O
one O
copy O
of O
p O
##ax O
##6 O
. O

second O
, O
affected O
members O
of O
a O
family O
with O
dominant O
##ly O
inherited O
anterior B-Disease
segment I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ations I-Disease
, O
including O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
are O
he O
##tero O
##zy O
##go O
##us O
for O
an O
r O
##26 O
##g O
mutation O
in O
the O
p O
##ax O
##6 O
paired O
box O
. O

third O
, O
a O
proportion O
of O
se O
##y O
/ O
+ O
small O
##eye O
mice O
, O
he O
##tero O
##zy O
##go O
##us O
for O
a O
nonsense O
mutation O
in O
m O
##uri O
##ne O
p O
##ax O
- O
6 O
, O
have O
an O
o O
##cular O
p O
##hen O
##otype O
resembling O
pet B-Disease
##ers I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
. O

we O
therefore O
propose O
that O
a O
variety O
of O
anterior B-Disease
segment I-Disease
an I-Disease
##oma I-Disease
##lies I-Disease
may O
be O
associated O
with O
p O
##ax O
##6 O
mutations O
. O
. O

hunting B-Disease
##ton I-Disease
disease I-Disease
without O
ca O
##g O
expansion O
: O
p O
##hen O
##oc O
##op O
##ies O
or O
errors O
in O
assignment O
? O

hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
has O
been O
shown O
to O
be O
associated O
with O
an O
expanded O
ca O
##g O
repeat O
within O
a O
novel O
gene O
on O
4 O
##p O
##16 O
. O

3 O
( O
it O
##15 O
) O
. O

a O
total O
of O
30 O
of O
1 O
, O
02 O
##2 O
affected O
persons O
( O
2 O
. O
9 O
% O
of O
our O
co O
##hor O
##t O
) O
did O
not O
have O
an O
expanded O
ca O
##g O
in O
the O
disease O
range O
. O

the O
reasons O
for O
not O
observing O
expansion O
in O
affected O
individuals O
are O
important O
for O
determining O
the O
sensitivity O
of O
using O
repeat O
length O
both O
for O
diagnosis O
of O
affected O
patients O
and O
for O
predict O
##ive O
testing O
programs O
and O
may O
have O
biological O
relevance O
for O
the O
understanding O
of O
the O
molecular O
mechanism O
underlying O
h B-Disease
##d I-Disease
. O

here O
we O
show O
that O
the O
majority O
( O
18 O
) O
of O
the O
individuals O
with O
normal O
sized O
all O
##ele O
##s O
represent O
mi O
##s O
##dia O
##gno O
##sis O
, O
sample O
mix O
- O
up O
, O
or O
c O
##lerical O
error O
. O

the O
remaining O
12 O
patients O
represent O
possible O
p O
##hen O
##oc O
##op O
##ies O
for O
h B-Disease
##d I-Disease
. O

in O
at O
least O
four O
cases O
, O
family O
studies O
of O
these O
p O
##hen O
##oc O
##op O
##ies O
excluded O
4 O
##p O
##16 O
. O

3 O
as O
the O
region O
responsible O
for O
the O
p O
##hen O
##otype O
. O

mutations O
in O
the O
h B-Disease
##d I-Disease
gene O
that O
are O
other O
than O
ca O
##g O
expansion O
have O
not O
been O
excluded O
for O
the O
remaining O
eight O
cases O
; O
however O
, O
in O
as O
many O
as O
seven O
of O
these O
persons O
, O
retrospective O
review O
of O
these O
patients O
clinical O
features O
identified O
characteristics O
not O
typical O
for O
h B-Disease
##d I-Disease
. O

this O
study O
shows O
that O
on O
rare O
occasions O
mutations O
in O
other O
, O
as O
- O
yet O
- O
und O
##ef O
##ined O
genes O
can O
present O
with O
a O
clinical O
p O
##hen O
##otype O
very O
similar O
to O
that O
of O
h B-Disease
##d I-Disease

frequent O
detection O
of O
co O
##don O
87 O
##7 O
mutation O
in O
the O
and O
##rogen O
receptor O
gene O
in O
advanced B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
##s I-Disease
. O

pro O
##static O
tissue O
specimens O
derived O
from O
trans O
##ure O
##th O
##ral O
re O
##section O
##s O
of O
patients O
with O
meta B-Disease
##static I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
were O
analyzed O
for O
genetic O
alterations O
in O
the O
hormone O
- O
binding O
domain O
of O
the O
and O
##rogen O
receptor O
( O
a O
##r O
) O
gene O
. O

direct O
se O
##quencing O
of O
the O
polymer O
##ase O
chain O
reaction O
- O
derived O
d O
##nas O
of O
6 O
of O
24 O
specimens O
revealed O
a O
co O
##don O
87 O
##7 O
mutation O
( O
act O
- O
- O
[UNK] O
g O
##ct O
, O
th O
##r O
- O
- O
[UNK] O
al O
##a O
) O
in O
the O
hormone O
- O
binding O
domain O
of O
the O
a O
##r O
gene O
. O

this O
same O
a O
##r O
mutation O
has O
been O
reported O
previously O
in O
a O
meta B-Disease
##static I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
cell O
line O
, O
l O
##nc O
##ap O
, O
where O
this O
mutation O
con O
##fers O
upon O
the O
a O
##r O
an O
altered O
l O
##igan O
##d O
- O
binding O
specific O
##ity O
which O
is O
stimulate O
##d O
by O
est O
##rogen O
##s O
, O
pro O
##ges O
##tage O
##ns O
, O
and O
anti O
##and O
##rogen O
##s O
. O

it O
is O
possible O
that O
analogous O
to O
an O
activated O
/ O
altered O
growth O
factor O
receptor O
on O
##co O
##gene O
, O
co O
##don O
87 O
##7 O
mutant O
a O
##r O
with O
altered O
l O
##igan O
##d O
binding O
may O
provide O
a O
selective O
growth O
advantage O
in O
the O
genes O
##is O
of O
a O
subset O
of O
advanced B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O

although O
est O
##rogen O
##s O
are O
used O
in O
##f O
##re O
##quent O
##ly O
, O
anti O
##and O
##rogen O
##s O
are O
used O
increasingly O
in O
ho O
##rmon O
##al O
therapy O
for O
patients O
with O
advanced B-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O

the O
s O
##ti O
##mu O
##lator O
##y O
effect O
of O
these O
therapeutic O
agents O
on O
the O
co O
##don O
87 O
##7 O
mutant O
a O
##r O
further O
suggests O
that O
this O
frequently O
observed O
a O
##r O
mutation O
may O
contribute O
to O
the O
treatment O
re O
##fra O
##ctor O
##y O
disease O
. O
. O

the O
human O
gene O
for O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
) O
maps O
to O
chromosome O
3 O
##q O
. O

al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
( O
a B-Disease
##ku I-Disease
; O
m O
##ck O
##us O
##ick O
no O
. O
203 O
##500 O
) O
is O
a O
rare O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
caused O
by O
the O
lack O
of O
ho O
##mo O
##gent O
##isi O
##c O
acid O
o O
##xi O
##das O
##e O
activity O
. O

patients O
ex O
##cre O
##te O
large O
amounts O
of O
ho O
##mo O
##gent O
##isi O
##c O
acid O
in O
their O
urine O
and O
a O
black O
o O
##ch O
##ron O
##otic O
pig O
##ment O
is O
deposited O
in O
their O
cart O
##ila O
##ge O
and O
co O
##lla O
##gen O
##ous O
tissues O
. O

o B-Disease
##ch I-Disease
##ron I-Disease
##osis I-Disease
is O
the O
predominant O
clinical O
com O
##plication O
of O
the O
disease O
leading O
to O
o B-Disease
##ch I-Disease
##ron I-Disease
##otic I-Disease
art I-Disease
##hr I-Disease
##op I-Disease
##athy I-Disease
, O
dark O
urine O
, O
pig O
##ment O
changes O
of O
the O
skin O
, O
and O
other O
clinical O
features O
. O

a O
mutation O
causing O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
in O
the O
mouse O
has O
mapped O
to O
chromosome O
16 O
. O

considering O
conserved O
s O
##yn O
##ten O
##y O
, O
we O
were O
able O
to O
map O
the O
human O
gene O
to O
chromosome O
3 O
##q O
in O
six O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
p O
##ed O
##ig O
##ree O
##s O
of O
s O
##lov O
##ak O
origin O
. O
. O

structure O
of O
the O
human O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
gene O
s O
##g O
##lt O
##1 O
. O

in O
##test O
##inal O
up O
##take O
of O
diet O
##ary O
glucose O
and O
gal O
##act O
##ose O
is O
mediated O
by O
the O
s O
##g O
##lt O
##1 O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
of O
the O
brush O
border O
. O

an O
s O
##g O
##lt O
##1 O
miss O
##ense O
mutation O
under O
##lies O
hereditary B-Disease
glucose I-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
, O
characterized O
by O
potentially O
fatal O
di B-Disease
##ar I-Disease
##r I-Disease
##hea I-Disease
; O
con O
##verse O
##ly O
, O
oral O
re O
##hy O
##dra O
##tion O
therapy O
exploits O
normal O
transport O
to O
alleviate O
life O
- O
threatening O
di B-Disease
##ar I-Disease
##r I-Disease
##hea I-Disease
of O
infectious O
origin O
. O

we O
have O
mapped O
the O
entire O
human O
s O
##g O
##lt O
##1 O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
gene O
from O
co O
##sm O
##id O
and O
la O
##mb O
##da O
p O
##hage O
clone O
##s O
representing O
a O
g O
##eno O
##mic O
region O
of O
112 O
k O
##ilo O
##base O
##s O
. O

transcription O
initiation O
occurred O
from O
a O
site O
27 O
base O
pairs O
3 O
of O
a O
ta O
##ta O
##a O
sequence O
. O

all O
ex O
##on O
- O
flank O
##ing O
regions O
were O
sequence O
##d O
, O
and O
the O
entire O
112 O
- O
k O
##ilo O
##base O
region O
mapped O
with O
four O
restriction O
enzymes O
. O

s O
##g O
##lt O
##1 O
is O
comprised O
of O
15 O
ex O
##ons O
( O
spanning O
72 O
k O
##ilo O
##base O
##s O
) O
; O
a O
possible O
evolutionary O
origin O
from O
a O
six O
- O
membrane O
- O
span O
ancestral O
precursor O
via O
a O
gene O
du O
##plication O
event O
is O
suggested O
from O
comparison O
of O
ex O
##ons O
against O
protein O
secondary O
structure O
and O
from O
sequence O
considerations O
. O

a O
new O
miss O
##ense O
mutation O
in O
ex O
##on O
1 O
causing O
glucose B-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
is O
also O
described O
. O

this O
is O
the O
first O
na O
( O
+ O
) O
- O
dependent O
co O
##tra O
##ns O
##port O
##er O
gene O
structure O
reported O
. O

these O
data O
facilitate O
the O
search O
for O
new O
glucose B-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
- O
related O
mutations O
in O
this O
important O
gene O
and O
provide O
a O
basis O
for O
future O
evolutionary O
comparisons O
with O
other O
na O
( O
+ O
) O
- O
dependent O
co O
##tra O
##ns O
##port O
##ers O
. O
. O

four O
novel O
p O
##ep O
##d O
all O
##ele O
##s O
causing O
pro B-Disease
##lid I-Disease
##ase I-Disease
deficiency I-Disease
. O

mutations O
at O
the O
p O
##ep O
##d O
lo O
##cus O
cause O
pro B-Disease
##lid I-Disease
##ase I-Disease
deficiency I-Disease
( O
m O
##ck O
##us O
##ick O
170 O
##100 O
) O
, O
a O
rare O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
characterized O
by O
im B-Disease
##ino I-Disease
##di I-Disease
##pe I-Disease
##pt I-Disease
##id I-Disease
##uria I-Disease
, O
skin B-Disease
ul I-Disease
##cer I-Disease
##s I-Disease
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
and O
re O
##current O
infections O
. O

four O
p O
##ep O
##d O
mutations O
from O
five O
severely O
affected O
individuals O
were O
characterized O
by O
analysis O
of O
reverse O
- O
trans O
##cribed O
, O
p O
##c O
##r O
- O
am O
##plified O
( O
r O
##t O
- O
p O
##c O
##r O
) O
c O
##dn O
##a O
. O

we O
used O
s O
##s O
##c O
##p O
analysis O
on O
four O
overlapping O
c O
##dn O
##a O
fragments O
covering O
the O
entire O
coding O
region O
of O
the O
p O
##ep O
##d O
gene O
and O
detected O
abnormal O
s O
##s O
##c O
##p O
bands O
for O
the O
fragment O
spanning O
all O
or O
part O
of O
ex O
##ons O
13 O
- O
15 O
in O
three O
of O
the O
pro O
##band O
##s O
. O

direct O
se O
##quencing O
of O
the O
mutant O
c O
##dn O
##as O
showed O
a O
g O
- O
- O
[UNK] O
a O
, O
134 O
##2 O
substitution O
( O
g O
##44 O
##8 O
##r O
) O
in O
two O
patients O
and O
a O
3 O
- O
b O
##p O
del O
##eti O
##on O
( O
delta O
e O
##45 O
##2 O
or O
delta O
e O
##45 O
##3 O
) O
in O
another O
. O

in O
the O
other O
two O
pro O
##band O
##s O
the O
am O
##plified O
products O
were O
of O
reduced O
size O
. O

direct O
se O
##quencing O
of O
these O
mutant O
c O
##dn O
##as O
revealed O
a O
del O
##eti O
##on O
of O
ex O
##on O
5 O
in O
one O
patient O
and O
of O
ex O
##on O
7 O
in O
the O
other O
. O

intro O
##nic O
sequences O
flank O
##ing O
ex O
##ons O
5 O
and O
7 O
were O
identified O
using O
inverse O
p O
##c O
##r O
followed O
by O
direct O
se O
##quencing O
. O

conventional O
p O
##c O
##r O
and O
direct O
se O
##quencing O
then O
established O
the O
intro O
##n O
- O
ex O
##on O
borders O
of O
the O
mutant O
g O
##eno O
##mic O
d O
##na O
revealing O
two O
s O
##p O
##lice O
accept O
##or O
mutations O
a O
g O
- O
- O
[UNK] O
c O
substitution O
at O
position O
- O
1 O
of O
intro O
##n O
4 O
and O
an O
a O
- O
- O
[UNK] O
g O
substitution O
at O
position O
- O
2 O
of O
intro O
##n O
6 O
. O

our O
results O
indicate O
that O
the O
severe O
form O
of O
pro B-Disease
##lid I-Disease
##ase I-Disease
deficiency I-Disease
is O
caused O
by O
multiple O
p O
##ep O
##d O
all O
##ele O
##s O
. O

in O
this O
report O
we O
attempt O
to O
begin O
the O
process O
of O
describing O
these O
all O
##ele O
##s O
and O
catalog O
##ing O
their O
p O
##hen O
##otypic O
expression O
. O
. O

re O
##comb O
##ination O
##s O
in O
individuals O
ho O
##mo O
##zy O
##go O
##us O
by O
descent O
local O
##ize O
the O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
lo O
##cus O
in O
a O
clone O
##d O
450 O
- O
k O
##b O
interval O
. O

the O
lo O
##cus O
for O
fried B-Disease
##re I-Disease
##ich I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
( O
f B-Disease
##rda I-Disease
) O
, O
a O
severe O
ne B-Disease
##uro I-Disease
##de I-Disease
##gene I-Disease
##rative I-Disease
disease I-Disease
, O
is O
tightly O
linked O
to O
markers O
d O
##9 O
##s O
##5 O
and O
d O
##9 O
##s O
##15 O
, O
and O
analysis O
of O
rare O
re O
##comb O
##ination O
events O
has O
suggested O
the O
order O
c O
##en O
- O
f O
##rda O
- O
d O
##9 O
##s O
##5 O
- O
d O
##9 O
##s O
##15 O
- O
q O
##ter O
. O

we O
report O
here O
the O
construction O
of O
a O
ya O
##c O
con O
##ti O
##g O
extending O
800 O
k O
##b O
cent O
##rome O
##ric O
to O
d O
##9 O
##s O
##5 O
and O
the O
isolation O
of O
five O
new O
micro O
##sat O
##elli O
##te O
markers O
from O
this O
region O
. O

in O
order O
to O
map O
these O
markers O
with O
respect O
to O
the O
f B-Disease
##rda I-Disease
lo O
##cus O
, O
all O
within O
a O
1 O
- O
cm O
confidence O
interval O
, O
we O
sought O
to O
increase O
the O
genetic O
information O
of O
available O
f B-Disease
##rda I-Disease
families O
by O
considering O
ho O
##mo O
##zy O
##gos O
##ity O
by O
descent O
and O
association O
with O
founder O
ha O
##p O
##lot O
##ype O
##s O
in O
isolated O
populations O
. O

this O
approach O
allowed O
us O
to O
identify O
one O
phase O
- O
known O
re O
##comb O
##ination O
and O
one O
probable O
historic O
re O
##comb O
##ination O
on O
ha O
##p O
##lot O
##ype O
##s O
from O
reunion O
island O
patients O
, O
both O
of O
which O
place O
three O
of O
the O
five O
markers O
pro O
##ximal O
to O
f B-Disease
##rda I-Disease
. O

this O
represents O
the O
first O
identification O
of O
close O
f B-Disease
##rda I-Disease
flank O
##ing O
markers O
on O
the O
cent O
##rome O
##ric O
side O
. O

the O
two O
other O
markers O
allowed O
us O
to O
narrow O
the O
break O
##point O
of O
a O
previously O
identified O
di O
##stal O
re O
##comb O
##ination O
that O
is O
[UNK] O
180 O
k O
##b O
from O
d O
##9 O
##s O
##5 O
( O
26 O
##p O
) O
. O

taken O
together O
, O
the O
results O
place O
the O
f B-Disease
##rda I-Disease
lo O
##cus O
in O
a O
450 O
- O
k O
##b O
interval O
, O
which O
is O
small O
enough O
for O
direct O
search O
of O
candidate O
genes O
. O

a O
detailed O
rare O
cutter O
restriction O
map O
and O
a O
co O
##sm O
##id O
con O
##ti O
##g O
covering O
this O
interval O
were O
constructed O
and O
should O
facilitate O
the O
search O
of O
genes O
in O
this O
region O
. O
. O

investigation O
of O
the O
##rm O
##ore O
##gu O
##lator O
##y O
characteristics O
in O
patients O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

a O
survey O
instrument O
is O
used O
to O
assess O
temperature O
regulation O
characteristics O
in O
children O
with O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
compared O
to O
3 O
control O
groups O
si O
##bs O
of O
p B-Disease
##ws I-Disease
patients O
( O
si O
##b O
) O
, O
ne B-Disease
##uro I-Disease
##de I-Disease
##vel I-Disease
##op I-Disease
##mental I-Disease
##ly I-Disease
hand I-Disease
##ica I-Disease
##pped I-Disease
children O
( O
n O
##d O
) O
, O
and O
age O
and O
gender O
matched O
well O
children O
( O
w O
##c O
) O
. O

significant O
differences O
were O
found O
between O
p B-Disease
##ws I-Disease
patients O
, O
si O
##b O
controls O
, O
and O
w O
##c O
controls O
in O
the O
prevalence O
of O
f O
##eb O
##ril O
##e O
con O
##vu O
##ls O
##ions O
, O
fever O
- O
associated O
symptoms O
, O
and O
temperature O
less O
than O
94 O
degrees O
f O
. O

no O
differences O
were O
noted O
in O
any O
variable O
between O
the O
p B-Disease
##ws I-Disease
patients O
and O
the O
n O
##d O
controls O
, O
suggesting O
that O
these O
abnormal O
##ities O
are O
not O
unique O
to O
p B-Disease
##ws I-Disease
, O
but O
can O
occur O
in O
any O
ne B-Disease
##uro I-Disease
##de I-Disease
##vel I-Disease
##op I-Disease
##mental I-Disease
##ly I-Disease
hand I-Disease
##ica I-Disease
##pped I-Disease
individual O
, O
further O
suggesting O
these O
do O
not O
necessarily O
reflect O
syndrome O
- O
specific O
h B-Disease
##y I-Disease
##pot I-Disease
##hala I-Disease
##mic I-Disease
abnormal I-Disease
##ities I-Disease
. O
. O

p O
##hen O
##otypic O
variation O
including O
re B-Disease
##tin I-Disease
##itis I-Disease
pig I-Disease
##mento I-Disease
##sa I-Disease
, O
pattern B-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
and O
fund B-Disease
##us I-Disease
fl I-Disease
##avi I-Disease
##ma I-Disease
##cula I-Disease
##tus I-Disease
in O
a O
single O
family O
with O
a O
del O
##eti O
##on O
of O
co O
##don O
153 O
or O
154 O
of O
the O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
gene O
. O

background O
and O
objectives O
mutations O
of O
the O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
gene O
have O
been O
reported O
in O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
re I-Disease
##tin I-Disease
##itis I-Disease
pig I-Disease
##mento I-Disease
##sa I-Disease
, O
pattern O
mac B-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
and O
re B-Disease
##tin I-Disease
##itis I-Disease
pu I-Disease
##nc I-Disease
##tata I-Disease
al I-Disease
##bes I-Disease
##cens I-Disease
. O

we O
report O
here O
##in O
the O
occurrence O
of O
three O
separate O
p O
##hen O
##otype O
##s O
within O
a O
single O
family O
with O
a O
novel O
3 O
- O
base O
pair O
del O
##eti O
##on O
of O
co O
##don O
153 O
or O
154 O
of O
the O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
gene O
. O

design O
case O
reports O
with O
clinical O
features O
, O
flu O
##ores O
##ce O
##in O
an O
##gio O
##graphy O
, O
kinetic O
per O
##ime O
##try O
, O
electro O
##phy O
##sio O
##logical O
studies O
, O
and O
molecular O
genetics O
. O

setting O
university O
medical O
centers O
. O

patients O
a O
75 O
- O
year O
- O
old O
woman O
, O
her O
two O
daughters O
( O
aged O
44 O
and O
50 O
years O
) O
, O
and O
her O
49 O
- O
year O
- O
old O
son O
were O
screened O
for O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
mutations O
because O
of O
the O
presence O
of O
multiple O
p O
##hen O
##otype O
##s O
within O
the O
same O
family O
. O

results O
the O
mother O
presented O
at O
age O
63 O
years O
with O
a O
profound O
##ly O
abnormal O
electro O
##ret O
##ino O
##gram O
( O
er O
##g O
) O
and O
adult O
- O
onset O
re B-Disease
##tin I-Disease
##itis I-Disease
pig I-Disease
##mento I-Disease
##sa I-Disease
that O
progressed O
dramatically O
over O
12 O
years O
, O
with O
marked O
loss O
of O
peripheral O
visual O
field O
. O

one O
daughter O
developed O
pattern B-Disease
mac I-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
at O
age O
31 O
years O
. O

at O
age O
44 O
years O
, O
her O
er O
##g O
was O
moderately O
abnormal O
but O
her O
clinical O
disease O
was O
limited O
to O
the O
mac O
##ula O
. O

another O
daughter O
presented O
at O
age O
42 O
years O
with O
mac B-Disease
##ular I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
and O
over O
10 O
years O
developed O
the O
clinical O
picture O
of O
fund B-Disease
##us I-Disease
fl I-Disease
##avi I-Disease
##ma I-Disease
##cula I-Disease
##tus I-Disease
. O

her O
peripheral O
visual O
field O
was O
preserved O
but O
her O
er O
##g O
was O
moderately O
abnormal O
. O

the O
son O
had O
onset O
of O
mac B-Disease
##ular I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
at O
age O
44 O
years O
. O

per B-Disease
##ice I-Disease
##nt I-Disease
##ral I-Disease
s I-Disease
##cot I-Disease
##oma I-Disease
##s I-Disease
were O
present O
and O
the O
er O
##g O
was O
marked O
##ly O
abnormal O
. O

flu O
##ores O
##ce O
##in O
an O
##gio O
##graphy O
revealed O
pu O
##nc O
##tate O
pig O
##ment O
e O
##pit O
##hel O
##ial O
transmission O
defects O
. O

conclusions O
a O
3 O
- O
base O
pair O
del O
##eti O
##on O
of O
co O
##don O
153 O
or O
154 O
of O
the O
per O
##ip O
##her O
##in O
/ O
r O
##ds O
gene O
can O
produce O
clinical O
##ly O
di O
##sp O
##arate O
p O
##hen O
##otype O
##s O
even O
within O
the O
same O
family O
. O
. O

assignment O
of O
the O
human O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
gene O
s O
##g O
##lt O
##1 O
to O
chromosome O
22 O
##q O
##13 O
. O
1 O
. O

the O
na O
+ O
/ O
glucose O
co O
##tra O
##ns O
##port O
##er O
gene O
s O
##g O
##lt O
##1 O
en O
##codes O
the O
primary O
carrier O
protein O
responsible O
for O
the O
up O
##take O
of O
the O
diet O
##ary O
sugar O
##s O
glucose O
and O
gal O
##act O
##ose O
from O
the O
in O
##test O
##inal O
l O
##ume O
##n O
. O

s O
##g O
##lt O
##1 O
transport O
activity O
is O
currently O
exploited O
in O
oral O
re O
##hy O
##dra O
##tion O
therapy O
. O

the O
75 O
- O
k O
##da O
g O
##ly O
##co O
##p O
##rote O
##in O
is O
localized O
in O
the O
brush O
border O
of O
the O
in O
##test O
##inal O
e O
##pit O
##hel O
##ium O
and O
is O
predicted O
to O
comprise O
12 O
membrane O
spans O
. O

in O
two O
patients O
with O
the O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disease I-Disease
glucose I-Disease
/ I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
ma I-Disease
##la I-Disease
##bs I-Disease
##or I-Disease
##ption I-Disease
, O
the O
underlying O
cause O
was O
found O
to O
be O
a O
miss O
##ense O
mutation O
in O
s O
##g O
##lt O
##1 O
, O
and O
the O
as O
##p O
##28 O
- O
- O
[UNK] O
as O
##n O
change O
was O
demonstrated O
in O
v O
##it O
##ro O
to O
eliminate O
s O
##g O
##lt O
##1 O
transport O
activity O
. O

the O
s O
##g O
##lt O
##1 O
gene O
was O
previously O
shown O
to O
reside O
on O
the O
di O
##stal O
q O
arm O
of O
chromosome O
22 O
( O
11 O
. O
2 O
- O
- O
[UNK] O
q O
##ter O
) O
. O

we O
have O
used O
a O
co O
##sm O
##id O
probe O
for O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
, O
which O
re O
##fines O
the O
local O
##ization O
to O
22 O
##q O
##13 O
. O

1 O
, O
and O
provide O
an O
example O
of O
the O
utility O
of O
the O
s O
##g O
##lt O
##1 O
probe O
as O
a O
diagnostic O
for O
genetic B-Disease
diseases I-Disease
associated O
with O
trans O
##location O
##s O
of O
chromosome O
22 O
. O

restriction O
of O
o O
##cular O
fund O
##us O
lesions O
to O
a O
specific O
subgroup O
of O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
in O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
patients O
. O

in O
humans O
, O
alter O
##ation O
of O
the O
tumor B-Disease
suppress O
##or O
gene O
, O
a B-Disease
##p I-Disease
##c I-Disease
, O
causes O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
, O
a O
condition O
causing O
pre O
##dis O
##position O
to O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

the O
syndrome O
inconsistent O
##ly O
associates O
characteristic O
patches O
of O
con B-Disease
##gen I-Disease
##ital I-Disease
h I-Disease
##yper I-Disease
##tro I-Disease
##phy I-Disease
of I-Disease
the I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
pig I-Disease
##ment I-Disease
e I-Disease
##pit I-Disease
##hel I-Disease
##ium I-Disease
( O
ch B-Disease
##rp I-Disease
##e I-Disease
) O
. O

o O
##cular O
examination O
revealed O
that O
patients O
expressing O
ch B-Disease
##rp I-Disease
##e I-Disease
tend O
to O
cluster O
within O
specific O
families O
. O

the O
exact O
a B-Disease
##p I-Disease
##c I-Disease
mutation O
was O
identified O
in O
42 O
unrelated O
patients O
. O

in O
all O
cases O
these O
mutations O
were O
predicted O
to O
lead O
to O
the O
synthesis O
of O
a O
t O
##runcated O
protein O
. O

the O
extent O
of O
ch B-Disease
##rp I-Disease
##e I-Disease
was O
found O
to O
be O
dependent O
on O
the O
position O
of O
the O
mutation O
along O
the O
coding O
sequence O
. O

ch B-Disease
##rp I-Disease
##e I-Disease
lesions O
are O
almost O
always O
absent O
if O
the O
mutation O
occurs O
before O
ex O
##on O
9 O
, O
but O
are O
systematically O
present O
if O
it O
occurs O
after O
this O
ex O
##on O
. O

thus O
, O
the O
range O
of O
p O
##hen O
##otypic O
expression O
observed O
among O
affected O
patients O
may O
result O
in O
part O
from O
different O
all O
##eli O
##c O
manifest O
##ations O
of O
a B-Disease
##p I-Disease
##c I-Disease
mutations O
. O
. O

the O
effects O
of O
d O
##ys O
##tro O
##phi O
##n O
gene O
mutations O
on O
the O
er O
##g O
in O
mice O
and O
humans O
. O

purpose O
. O

the O
authors O
earlier O
findings O
of O
a O
negative O
electro O
##ret O
##ino O
##gram O
( O
er O
##g O
) O
in O
a O
boy O
with O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
led O
them O
to O
investigate O
d O
##ys O
##tro O
##phi O
##n O
gene O
del O
##eti O
##ons O
and O
er O
##gs O
in O
five O
boys O
with O
d B-Disease
##m I-Disease
##d I-Disease
. O

the O
authors O
wanted O
to O
determined O
whether O
there O
were O
similar O
er O
##g O
findings O
in O
an O
animal O
model O
for O
d B-Disease
##m I-Disease
##d I-Disease
, O
the O
m O
##d O
##x O
mouse O
. O

methods O
. O

g O
##an O
##z O
##feld O
er O
##gs O
were O
recorded O
in O
five O
boys O
with O
d B-Disease
##m I-Disease
##d I-Disease
after O
a O
complete O
op O
##ht O
##hal O
##mic O
examination O
. O

the O
d O
##ys O
##tro O
##phi O
##n O
gene O
was O
analyzed O
by O
southern O
b O
##lot O
hybrid O
##ization O
. O

er O
##gs O
were O
recorded O
in O
an O
##est O
##he O
##tized O
m O
##d O
##x O
and O
control O
mice O
with O
a O
modified O
grass O
photos O
##ti O
##mu O
##lator O
( O
grass O
instrument O
company O
, O
q O
##uin O
##cy O
, O
ma O
) O
. O

results O
. O

op O
##ht O
##hal O
##mic O
examinations O
in O
all O
five O
boys O
had O
normal O
findings O
, O
yet O
an O
abnormal O
negative O
er O
##g O
was O
recorded O
for O
each O
subject O
. O

the O
subjects O
gene O
del O
##eti O
##ons O
were O
variable O
, O
ranging O
from O
large O
del O
##eti O
##ons O
to O
no O
detect O
##able O
del O
##eti O
##ons O
. O

the O
er O
##gs O
of O
the O
m O
##d O
##x O
mice O
were O
normal O
and O
did O
not O
differ O
significantly O
from O
those O
of O
the O
control O
mice O
. O

conclusions O
. O

the O
authors O
believe O
the O
unique O
er O
##g O
recorded O
for O
the O
human O
subjects O
is O
a O
manifest O
##ation O
of O
d B-Disease
##m I-Disease
##d I-Disease
associated O
with O
defects O
at O
the O
d O
##ys O
##tro O
##phi O
##n O
gene O
lo O
##cus O
and O
represents O
a O
new O
clinical O
entity O
. O

the O
er O
##g O
of O
the O
m O
##d O
##x O
mouse O
may O
be O
spared O
for O
several O
reasons O
, O
including O
mild O
##er O
effects O
of O
the O
mouse O
gene O
defect O
, O
differences O
in O
muscle O
and O
re O
##tina O
##l O
gene O
product O
, O
or O
species O
differences O
in O
the O
bio O
##chemical O
role O
of O
d O
##ys O
##tro O
##phi O
##n O
. O

the O
er O
##g O
shows O
promise O
of O
becoming O
a O
non O
##in O
##vasive O
diagnostic O
tool O
for O
d B-Disease
##m I-Disease
##d I-Disease
and O
its O
mild O
##er O
all O
##eli O
##c O
forms O
. O
. O

association O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
tumor I-Disease
suppress O
##or O
protein O
with O
cat O
##eni O
##ns O
. O

mutations O
of O
a O
##p O
##c O
appear O
to O
initiate O
s O
##poradic O
and O
inherited O
forms O
of O
human O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

although O
these O
mutations O
have O
been O
well O
characterized O
, O
little O
is O
known O
about O
the O
function O
of O
the O
a B-Disease
##p I-Disease
##c I-Disease
gene O
product O
. O

two O
cellular O
proteins O
that O
associate O
with O
a B-Disease
##p I-Disease
##c I-Disease
were O
identified O
by O
n O
##uc O
##leo O
##tide O
sequence O
analysis O
and O
p O
##eptide O
mapping O
as O
the O
e O
- O
ca O
##dh O
##eri O
##n O
- O
associated O
proteins O
alpha O
- O
and O
beta O
- O
cat O
##eni O
##n O
. O

a O
27 O
- O
residue O
fragment O
of O
a O
##p O
##c O
containing O
a O
15 O
- O
amino O
acid O
repeat O
was O
sufficient O
for O
the O
interaction O
with O
the O
cat O
##eni O
##ns O
. O

these O
results O
suggest O
an O
important O
link O
between O
tumor B-Disease
initiation O
and O
cell O
ad O
##hesion O
. O
. O

difference O
in O
met O
##hyl O
##ation O
patterns O
within O
the O
d O
##15 O
##s O
##9 O
region O
of O
chromosome O
15 O
##q O
##11 O
- O
13 O
in O
first O
cousins O
with O
angel B-Disease
##man I-Disease
syndrome I-Disease
and O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
. O

abnormal O
##ities O
of O
chromosome O
region O
15 O
##q O
##11 O
- O
13 O
are O
associated O
with O
angel B-Disease
##man I-Disease
syndrome I-Disease
( O
as B-Disease
) O
and O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

differences O
between O
the O
met O
##hyl O
##ation O
patterns O
of O
the O
region O
of O
chromosome O
15 O
##q O
##11 O
- O
13 O
which O
hybrid O
##izes O
to O
the O
highly O
conserved O
d O
##na O
, O
d O
##n O
##34 O
, O
in O
normal O
individuals O
and O
in O
patients O
with O
as B-Disease
and O
p B-Disease
##ws I-Disease
have O
been O
described O
. O

we O
report O
on O
a O
family O
in O
which O
first O
cousins O
are O
affected O
by O
as B-Disease
and O
p B-Disease
##ws I-Disease
as O
a O
result O
of O
a O
f O
##ami O
##lial O
para O
##centric O
in O
##version O
of O
15 O
##q O
##11 O
- O
q O
##13 O
. O

the O
results O
of O
the O
studies O
on O
this O
family O
demonstrate O
the O
differences O
in O
the O
met O
##hyl O
##ation O
patterns O
in O
the O
2 O
conditions O
and O
the O
phenomenon O
of O
g O
##eno O
##mic O
imprint O
##ing O
, O
whereby O
genetic O
information O
is O
expressed O
differently O
dependent O
on O
the O
parent O
of O
origin O
. O
. O

ha O
##p O
##lot O
##ype O
studies O
in O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

in O
51 O
families O
with O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
, O
we O
have O
studied O
d O
##na O
ha O
##p O
##lot O
##ype O
##s O
of O
din O
##uc O
##leo O
##tide O
repeat O
p O
##oly O
##mor O
##phism O
##s O
( O
ca O
repeats O
) O
in O
the O
13 O
##q O
##14 O
. O

3 O
region O
, O
to O
examine O
these O
markers O
for O
association O
with O
the O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
gene O
( O
w B-Disease
##nd I-Disease
) O
. O

in O
addition O
to O
a O
marker O
( O
d O
##13 O
##s O
##13 O
##3 O
) O
described O
elsewhere O
, O
we O
have O
developed O
three O
new O
highly O
p O
##oly O
##morphic O
markers O
( O
d O
##13 O
##s O
##31 O
##4 O
, O
d O
##13 O
##s O
##31 O
##5 O
, O
and O
d O
##13 O
##s O
##31 O
##6 O
) O
close O
to O
the O
w B-Disease
##nd I-Disease
lo O
##cus O
. O

we O
have O
examined O
the O
distribution O
of O
marker O
all O
##ele O
##s O
at O
the O
lo O
##ci O
studied O
and O
have O
found O
that O
d O
##13 O
##s O
##31 O
##4 O
, O
d O
##13 O
##s O
##13 O
##3 O
, O
and O
d O
##13 O
##s O
##31 O
##6 O
each O
show O
non O
##rand O
##om O
distribution O
on O
chromosome O
##s O
carrying O
the O
w B-Disease
##nd I-Disease
mutation O
. O

we O
have O
studied O
ha O
##p O
##lot O
##ype O
##s O
of O
these O
three O
markers O
and O
have O
found O
that O
there O
are O
highly O
significant O
differences O
between O
w B-Disease
##nd I-Disease
and O
normal O
ha O
##p O
##lot O
##ype O
##s O
in O
northern O
euro O
##pe O
##an O
families O
. O

these O
findings O
have O
important O
implications O
for O
mutation O
detection O
and O
molecular O
diagnosis O
in O
families O
with O
w B-Disease
##ils I-Disease
##on I-Disease
disease I-Disease
. O

genetic O
analysis O
of O
the O
br O
##ca O
##1 O
region O
in O
a O
large O
breast O
/ O
o O
##var O
##ian O
family O
: O
re O
##fine O
##ment O
of O
the O
minimal O
region O
containing O
br O
##ca O
##1 O
. O

we O
have O
analyzed O
a O
single O
multi O
- O
affected O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
p O
##ed O
##ig O
##ree O
( O
b O
##ov O
##3 O
) O
and O
have O
shown O
consistent O
inheritance O
of O
markers O
on O
chromosome O
17 O
##q O
with O
the O
disease O
confirming O
that O
this O
family O
is O
due O
to O
the O
br O
##ca O
##1 O
gene O
. O

analysis O
of O
17 O
##q O
ha O
##p O
##lot O
##ype O
##s O
shows O
a O
re O
##comb O
##ination O
event O
in O
a O
bilateral O
breast B-Disease
cancer I-Disease
case O
which O
suggests O
that O
the O
br O
##ca O
##1 O
gene O
lies O
di O
##stal O
to O
d O
##17 O
##s O
##8 O
##5 O
##7 O
; O
d O
##17 O
##s O
##8 O
##5 O
##7 O
is O
thus O
the O
new O
pro O
##ximal O
boundary O
for O
the O
region O
containing O
br O
##ca O
##1 O
. O

combining O
this O
information O
with O
previously O
published O
mapping O
information O
suggests O
that O
br O
##ca O
##1 O
is O
contained O
in O
a O
region O
estimated O
at O
1 O
- O
1 O
. O

5 O
m O
##b O
in O
length O
. O

all O
seven O
breast B-Disease
t I-Disease
##umour I-Disease
/ O
blood O
pairs O
examined O
from O
this O
family O
show O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
in O
the O
t B-Disease
##umour I-Disease
##s I-Disease
. O

the O
all O
##el O
retained O
in O
each O
t B-Disease
##umour I-Disease
was O
from O
the O
disease O
- O
bearing O
chromosome O
imp O
##lica O
##ting O
br O
##ca O
##1 O
as O
a O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
. O

we O
have O
sequence O
##d O
the O
17 O
beta O
- O
o O
##est O
##rad O
##iol O
de O
##hy O
##dr O
##ogen O
##ase O
genes O
( O
ed O
##h O
##17 O
##b O
##1 O
and O
ed O
##h O
##17 O
##b O
##2 O
) O
which O
have O
been O
suggested O
as O
candidate O
genes O
for O
br O
##ca O
##1 O
in O
four O
members O
of O
this O
family O
. O

no O
g O
##er O
##m O
##line O
mutations O
were O
detected O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
kinase O
is O
a O
component O
of O
ne O
##uro O
##mus O
##cular O
junction O
##s O
. O

the O
clinical O
manifest O
##ation O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
correlated O
to O
the O
extent O
of O
expansion O
of O
an O
unstable O
[ O
c O
##t O
##g O
] O
n O
d O
##na O
motif O
. O

recent O
studies O
have O
demonstrated O
that O
this O
t O
##rin O
##uc O
##leo O
##tide O
motif O
forms O
part O
of O
the O
last O
, O
3 O
un O
##tra O
##ns O
##lated O
ex O
##on O
of O
a O
gene O
which O
potentially O
en O
##codes O
multiple O
protein O
is O
##of O
##orms O
of O
a O
se O
##rine O
/ O
th O
##re O
##oni O
##ne O
protein O
kinase O
( O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
, O
d O
##m O
- O
p O
##k O
) O
. O

we O
report O
here O
on O
the O
development O
of O
anti O
##ser O
##a O
against O
synthetic O
d O
##m O
- O
p O
##k O
p O
##eptide O
anti O
##gens O
and O
their O
use O
in O
bio O
##chemical O
and O
his O
##to O
##chemical O
studies O
. O

im O
##mu O
##nor O
##ea O
##ctive O
d O
##m O
- O
kinase O
protein O
of O
53 O
k O
##d O
is O
present O
at O
low O
levels O
in O
skeletal O
and O
cardiac O
muscle O
extract O
##s O
of O
d B-Disease
##m I-Disease
patients O
and O
normal O
controls O
. O

im O
##mu O
##no O
##his O
##to O
##chemical O
stain O
##ing O
revealed O
that O
d O
##m O
- O
p O
##k O
is O
local O
##ised O
prominently O
at O
sites O
of O
ne O
##uro O
##mus O
##cular O
and O
my O
##ote O
##ndi O
##nous O
junction O
##s O
( O
nm O
##j O
##s O
and O
m O
##t O
##j O
##s O
) O
of O
human O
and O
rode O
##nt O
skeletal O
muscles O
. O

further O
##more O
, O
very O
low O
levels O
of O
im O
##mu O
##nor O
##ea O
##ctive O
d O
##m O
- O
p O
##k O
protein O
are O
present O
in O
the O
sa O
##rc O
##op O
##las O
##m O
of O
predominantly O
type O
i O
fibre O
##s O
in O
various O
muscles O
. O

striking O
##ly O
, O
presence O
of O
the O
protein O
can O
also O
be O
demonstrated O
for O
nm O
##j O
##s O
of O
muscular O
tissues O
of O
adult O
and O
con O
##gen O
##ital O
cases O
of O
d B-Disease
##m I-Disease
, O
with O
no O
gross O
changes O
in O
structural O
organisation O
. O

our O
findings O
provide O
a O
basis O
for O
further O
character O
##isation O
of O
the O
role O
of O
the O
kinase O
in O
protein O
assembly O
processes O
or O
signal O
media O
##tion O
at O
s O
##yna O
##ptic O
sites O
and O
ultimately O
for O
the O
understanding O
of O
the O
complex O
path O
##op O
##hy O
##sio O
##logy O
of O
d B-Disease
##m I-Disease
. O
. O

marked O
##ly O
accelerated O
cat O
##ab O
##olis O
##m O
of O
a O
##poli O
##pop O
##rote O
##in O
a O
- O
ii O
( O
a O
##po O
##a O
- O
ii O
) O
and O
high O
density O
lip O
##op O
##rote O
##ins O
containing O
a O
##po O
##a O
- O
ii O
in O
classic O
le O
##ci O
##thin O
: O
ch B-Disease
##ole I-Disease
##ster I-Disease
##ol I-Disease
a I-Disease
##cy I-Disease
##lt I-Disease
##ran I-Disease
##s I-Disease
##fer I-Disease
##ase I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
. O

classic B-Disease
( I-Disease
complete I-Disease
) I-Disease
le I-Disease
##ci I-Disease
##thin I-Disease
ch I-Disease
##ole I-Disease
##ster I-Disease
##ol I-Disease
a I-Disease
##cy I-Disease
##lt I-Disease
##ran I-Disease
##s I-Disease
##fer I-Disease
##ase I-Disease
( I-Disease
l I-Disease
##cat I-Disease
) I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
( O
partial B-Disease
l I-Disease
##cat I-Disease
deficiency I-Disease
) O
are O
genetic O
syndrome O
##s O
associated O
with O
marked O
##ly O
decreased O
plasma O
levels O
of O
high O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
ch O
##ole O
##ster O
##ol O
but O
not O
with O
an O
increased O
risk O
of O
at B-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rot I-Disease
##ic I-Disease
card I-Disease
##iovascular I-Disease
disease I-Disease
. O

we O
investigated O
the O
metabolism O
of O
the O
h O
##dl O
a O
##poli O
##pop O
##rote O
##ins O
( O
a O
##po O
) O
a O
##po O
##a O
- O
i O
and O
a O
##po O
##a O
- O
ii O
in O
a O
total O
of O
five O
patients O
with O
l B-Disease
##cat I-Disease
deficiency I-Disease
, O
one O
with O
classic B-Disease
l I-Disease
##cat I-Disease
deficiency I-Disease
and O
four O
with O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
. O

plasma O
levels O
of O
a O
##po O
##a O
- O
ii O
were O
decreased O
to O
a O
proportion O
##ately O
greater O
extent O
( O
23 O
% O
of O
normal O
) O
than O
a O
##po O
##a O
- O
i O
( O
30 O
% O
of O
normal O
) O
. O

in O
addition O
, O
plasma O
concentrations O
of O
h O
##dl O
particles O
containing O
both O
a O
##po O
##a O
- O
i O
and O
a O
##po O
##a O
- O
ii O
( O
l O
##pa O
- O
i O
a O
- O
ii O
) O
were O
much O
lower O
( O
18 O
% O
of O
normal O
) O
than O
those O
of O
particles O
containing O
only O
a O
##po O
##a O
- O
i O
( O
l O
##pa O
- O
i O
) O
( O
51 O
% O
of O
normal O
) O
. O

the O
metabolic O
basis O
for O
the O
low O
levels O
of O
a O
##po O
##a O
- O
ii O
and O
l O
##pa O
- O
i O
a O
- O
ii O
was O
investigated O
in O
all O
five O
patients O
using O
both O
ex O
##ogen O
##ous O
radio O
##tra O
##cer O
and O
end O
##ogen O
##ous O
stable O
is O
##oto O
##pe O
label O
##ing O
techniques O
. O

the O
mean O
plasma O
residence O
time O
of O
a O
##po O
##a O
- O
i O
was O
decreased O
at O
2 O
. O

08 O
+ O
/ O
- O
0 O
. O

27 O
d O
( O
controls O
4 O
. O
74 O
+ O
/ O
- O
0 O
. O
65 O
days O
) O
; O
however O
, O
the O
residence O
time O
of O
a O
##po O
##a O
- O
ii O
was O
even O
shorter O
at O
1 O
. O

66 O
+ O
/ O
- O
0 O
. O

24 O
d O
( O
controls O
5 O
. O
25 O
+ O
/ O
- O
0 O
. O
61 O
d O
) O
. O

in O
addition O
, O
the O
cat O
##ab O
##olis O
##m O
of O
a O
##po O
##a O
- O
i O
in O
l O
##pa O
- O
i O
a O
- O
ii O
was O
substantially O
faster O
than O
that O
of O
a O
##po O
##a O
- O
i O
in O
l O
##pa O
- O
i O
. O

in O
summary O
, O
genetic O
syndrome O
##s O
of O
either O
complete B-Disease
or I-Disease
partial I-Disease
l I-Disease
##cat I-Disease
deficiency I-Disease
result O
in O
low O
levels O
of O
h O
##dl O
through O
prefer O
##ential O
h O
##yper O
##cat O
##ab O
##olis O
##m O
of O
a O
##po O
##a O
- O
ii O
and O
h O
##dl O
particles O
containing O
a O
##po O
##a O
- O
ii O
. O

because O
l O
##pa O
- O
i O
has O
been O
proposed O
to O
be O
more O
protective O
than O
l O
##pa O
- O
i O
a O
- O
ii O
against O
at B-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rosis I-Disease
, O
this O
selective O
effect O
on O
the O
metabolism O
of O
l O
##pa O
- O
i O
a O
- O
ii O
may O
provide O
a O
potential O
explanation O
why O
patients O
with O
classic B-Disease
l I-Disease
##cat I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
are O
not O
at O
increased O
risk O
for O
premature O
at B-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rosis I-Disease
despite O
marked O
##ly O
decreased O
levels O
of O
h O
##dl O
ch O
##ole O
##ster O
##ol O
and O
a O
##po O
##a O
- O
i O

x B-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

a O
sa O
##udi O
a O
##rab O
boy O
presented O
in O
early O
childhood O
with O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
, O
m O
##or O
##phological O
##ly O
large O
and O
normal O
sized O
plate O
##lets O
, O
increased O
mean O
plate O
##let O
volume O
, O
and O
a O
h O
##yper O
##me O
##ga O
##kar O
##yo O
##cy O
##tic O
bone O
ma O
##rrow O
. O

there O
was O
no O
clinical O
and O
laboratory O
evidence O
of O
any O
significant O
im B-Disease
##mu I-Disease
##nological I-Disease
abnormal I-Disease
##ities I-Disease
. O

similar O
findings O
in O
two O
other O
brothers O
suggested O
strongly O
that O
they O
were O
all O
suffering O
from O
an O
x B-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##eni I-Disease
##c I-Disease
disorder I-Disease
. O

results O
of O
d O
##na O
analysis O
with O
the O
probe O
m O
##27 O
beta O
are O
consistent O
with O
x O
link O
##age O
and O
indicate O
also O
that O
the O
lo O
##cus O
of O
the O
relevant O
gene O
lies O
close O
to O
or O
is O
identical O
to O
the O
lo O
##cus O
of O
the O
gene O
for O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

because O
of O
various O
features O
which O
include O
the O
presence O
of O
large O
and O
normal O
sized O
plate O
##lets O
( O
rather O
than O
small O
plate O
##lets O
) O
and O
freedom O
from O
significant O
immune B-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
, O
it O
is O
likely O
that O
the O
x B-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
in O
this O
family O
is O
an O
isolated O
entity O
quite O
distinct O
from O
the O
classical O
was B-Disease
p O
##hen O
##otype O
. O

however O
, O
a O
modified O
expression O
of O
the O
was B-Disease
gene O
producing O
a O
mild O
p O
##hen O
##otypic O
variant O
cannot O
be O
excluded O
entirely O
. O
. O

mac B-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
associated O
with O
mutations O
at O
co O
##don O
172 O
in O
the O
human O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
slow O
gene O
. O

background O
recently O
, O
mutations O
in O
the O
re B-Disease
##tina I-Disease
##l I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
slow O
( O
r O
##ds O
) O
gene O
which O
codes O
for O
per O
##ip O
##her O
##in O
- O
r O
##ds O
have O
been O
implicated O
as O
a O
cause O
of O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
re I-Disease
##tin I-Disease
##itis I-Disease
pig I-Disease
##mento I-Disease
##sa I-Disease
. O

because O
this O
gene O
is O
expressed O
in O
both O
rods O
and O
cones O
, O
mutations O
in O
the O
r O
##ds O
gene O
might O
be O
expected O
to O
cause O
de O
##gene O
##ration O
affecting O
either O
the O
s O
##cot O
##op O
##ic O
or O
photo O
##pic O
systems O
. O

mutations O
at O
co O
##don O
172 O
of O
the O
r O
##ds O
gene O
have O
been O
identified O
in O
three O
families O
with O
auto O
##so O
##mal O
dominant O
##ly O
inherited O
, O
progressive O
mac B-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

methods O
affected O
individuals O
underwent O
op O
##ht O
##hal O
##mic O
examination O
, O
s O
##cot O
##op O
##ic O
per O
##ime O
##try O
, O
dark O
adapt O
##ome O
##try O
, O
measurement O
of O
color O
- O
contrast O
sensitivity O
, O
and O
electro O
##ret O
##ino O
##graphy O
to O
character O
##ize O
the O
photo O
##re O
##ceptor O
d O
##ys O
##function O
. O

results O
in O
all O
but O
one O
affected O
member O
, O
symptoms O
of O
progressive O
central O
visual B-Disease
loss I-Disease
developed O
in O
the O
third O
or O
fourth O
decade O
of O
life O
accompanied O
by O
central B-Disease
s I-Disease
##cot I-Disease
##oma I-Disease
and O
well O
- O
dem O
##ar O
##cated O
at B-Disease
##rop I-Disease
##hy I-Disease
of I-Disease
the I-Disease
re I-Disease
##tina I-Disease
##l I-Disease
pig I-Disease
##ment I-Disease
e I-Disease
##pit I-Disease
##hel I-Disease
##ium I-Disease
and O
ch B-Disease
##orio I-Disease
##cap I-Disease
##illa I-Disease
##ris I-Disease
of I-Disease
the I-Disease
mac I-Disease
##ula I-Disease
. O

in O
general O
, O
cone O
and O
rod O
threshold O
##s O
were O
elevated O
, O
and O
color O
- O
contrast O
sensitivity O
was O
absent O
in O
the O
central O
visual O
field O
. O

peripheral O
##ly O
, O
the O
s O
##cot O
##op O
##ic O
se O
##ns O
##iti O
##vi O
##ties O
were O
normal O
, O
as O
was O
the O
recovery O
from O
b O
##lea O
##ch O
. O

cone O
electro O
##ret O
##ino O
##gram O
##s O
were O
diminished O
in O
amplitude O
, O
and O
delayed O
in O
all O
affected O
adults O
except O
one O
. O

rod O
electro O
##ret O
##ino O
##gram O
##s O
were O
normal O
or O
near O
normal O
in O
amplitude O
, O
and O
had O
normal O
imp O
##licit O
times O
. O

affected O
as O
##ym O
##pt O
##oma O
##tic O
children O
had O
mac O
##ular O
changes O
, O
abnormal O
color O
- O
contrast O
sensitivity O
, O
and O
reduced O
pattern O
and O
cone O
electro O
##ret O
##ino O
##gram O
##s O
. O

conclusion O
these O
results O
indicate O
that O
mutations O
in O
the O
r O
##ds O
gene O
can O
be O
expressed O
as O
a O
mac B-Disease
##ular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
with O
evidence O
of O
primary O
cone B-Disease
d I-Disease
##ys I-Disease
##function I-Disease
and O
preservation O
of O
peripheral O
rod O
function O
. O
. O

anonymous O
marker O
lo O
##ci O
within O
400 O
k O
##b O
of O
h O
##la O
- O
a O
generate O
ha O
##p O
##lot O
##ype O
##s O
in O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
with O
the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
( O
h O
##fe O
) O

the O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
gene O
( O
h O
##fe O
) O
maps O
to O
6 O
##p O
##21 O
. O

3 O
and O
is O
less O
than O
1 O
cm O
from O
the O
h O
##la O
class O
i O
genes O
; O
however O
, O
the O
precise O
physical O
location O
of O
the O
gene O
has O
remained O
el O
##usive O
and O
controversial O
. O

the O
un O
##am O
##bi O
##guous O
identification O
of O
a O
crossover O
event O
within O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
families O
is O
very O
difficult O
; O
it O
is O
particularly O
hampered O
by O
the O
var O
##iability O
of O
the O
p O
##hen O
##otypic O
expression O
as O
well O
as O
by O
the O
sex O
- O
and O
age O
- O
related O
pen O
##et O
##rance O
of O
the O
disease O
. O

for O
these O
practical O
considerations O
, O
traditional O
link O
##age O
analysis O
could O
prove O
of O
limited O
value O
in O
further O
re O
##fining O
the O
extra O
##pol O
##ated O
physical O
position O
of O
h O
##fe O
. O

we O
therefore O
embarked O
upon O
a O
link O
##age O
- O
di O
##se O
##qui O
##li O
##bri O
##um O
analysis O
of O
h O
##fe O
and O
normal O
chromosome O
##s O
from O
the O
br O
##itt O
##any O
population O
. O

in O
the O
present O
report O
, O
66 O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
families O
yielding O
151 O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
chromosome O
##s O
and O
182 O
normal O
chromosome O
##s O
were O
r O
##f O
##l O
##p O
- O
typed O
with O
a O
battery O
of O
probe O
##s O
, O
including O
two O
newly O
derived O
p O
##oly O
##morphic O
markers O
from O
the O
6 O
. O

7 O
and O
h O
##la O
- O
f O
lo O
##ci O
located O
150 O
and O
250 O
k O
##b O
te O
##lo O
##mer O
##ic O
to O
h O
##la O
- O
a O
, O
respectively O
. O

the O
results O
suggest O
a O
strong O
peak O
of O
existing O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
focused O
within O
the O
i O
##8 O
##2 O
- O
to O
- O
6 O
. O

7 O
interval O
( O
approximately O
250 O
k O
##b O
) O
. O

the O
zone O
of O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
is O
flanked O
by O
the O
i O
##9 O
##7 O
lo O
##cus O
, O
positioned O
30 O
k O
##b O
pro O
##ximal O
to O
i O
##8 O
##2 O
, O
and O
the O
h O
##la O
- O
f O
gene O
, O
found O
250 O
k O
##b O
di O
##stal O
to O
h O
##la O
- O
a O
, O
markers O
of O
which O
display O
no O
significant O
association O
with O
h O
##fe O
. O

these O
data O
support O
the O
possibility O
that O
h O
##fe O
resides O
within O
the O
400 O
- O
k O
##b O
expanse O
of O
d O
##na O
between O
i O
##9 O
##7 O
and O
h O
##la O
- O
f O
. O

alternatively O
, O
the O
very O
tight O
association O
of O
h O
##la O
- O
a O
##3 O
and O
all O
##ele O
1 O
of O
the O
6 O
. O

7 O
lo O
##cus O
, O
both O
of O
which O
are O
comprised O
by O
the O
major O
ancestral O
or O
founder O
h O
##fe O
ha O
##p O
##lot O
##ype O
in O
br O
##itt O
##any O
, O
supports O
the O
possibility O
that O
the O
disease O
gene O
may O
reside O
immediately O
te O
##lo O
##mer O
##ic O
to O
the O
6 O
. O

7 O
lo O
##cus O
within O
the O
link O
##age O
- O
di O
##se O
##qui O
##li O
##bri O
##um O
zone O
. O

additionally O
, O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
ha O
##p O
##lot O
##ype O
##s O
possessing O
h O
##la O
- O
a O
##11 O
and O
the O
low O
- O
frequency O
h O
##la O
- O
f O
p O
##oly O
##mor O
##phism O
( O
all O
##ele O
2 O
) O
are O
supportive O
of O
a O
separate O
founder O
chromosome O
containing O
a O
second O
, O
independently O
arising O
mutant O
all O
##ele O
. O

overall O
, O
the O
establishment O
of O
a O
likely O
" O
hem B-Disease
##och I-Disease
##roma I-Disease
##tosis I-Disease
critical O
region O
" O
cent O
##rome O
##ric O
boundary O
and O
the O
identification O
of O
a O
link O
##age O
- O
di O
##se O
##qui O
##li O
##bri O
##um O
zone O
both O
significantly O
contribute O
to O
a O
reduction O
in O
the O
amount O
of O
d O
##na O
required O
to O
be O
searched O
for O
novel O
coding O
sequences O
con O
##stituting O
the O
h B-Disease
##fe I-Disease
defect I-Disease

g O
##eno O
##mic O
structure O
of O
the O
e O
##ws O
gene O
and O
its O
relationship O
to O
e O
##ws O
##r O
##1 O
, O
a O
site O
of O
tumor B-Disease
- O
associated O
chromosome O
trans O
##location O
. O

the O
e O
##ws O
gene O
has O
been O
identified O
based O
on O
its O
location O
at O
the O
chromosome O
22 O
break O
##point O
of O
the O
t O
( O
11 O
; O
22 O
) O
( O
q O
##24 O
; O
q O
##12 O
) O
trans O
##location O
that O
character O
##izes O
e B-Disease
##wing I-Disease
sa I-Disease
##rc I-Disease
##oma I-Disease
and O
related O
ne B-Disease
##uro I-Disease
##ec I-Disease
##to I-Disease
##der I-Disease
##mal I-Disease
tumors I-Disease
. O

the O
e O
##ws O
gene O
spans O
about O
40 O
k O
##b O
of O
d O
##na O
and O
is O
encoded O
by O
17 O
ex O
##ons O
. O

the O
n O
##uc O
##leo O
##tide O
sequence O
of O
the O
ex O
##ons O
is O
identical O
to O
that O
of O
the O
previously O
described O
c O
##dn O
##a O
. O

the O
first O
7 O
ex O
##ons O
en O
##code O
the O
n O
- O
terminal O
domain O
of O
e O
##ws O
, O
which O
consists O
of O
a O
repeated O
de O
##generate O
##d O
p O
##oly O
##pe O
##pt O
##ide O
of O
7 O
to O
12 O
residues O
rich O
in O
t O
##yr O
##os O
##ine O
, O
se O
##rine O
, O
th O
##re O
##oni O
##ne O
, O
g O
##ly O
##cine O
, O
and O
g O
##lut O
##amine O
. O

ex O
##ons O
11 O
, O
12 O
, O
and O
13 O
en O
##code O
the O
put O
##ative O
r O
##na O
binding O
domain O
. O

the O
three O
g O
##ly O
##cine O
- O
and O
a O
##rg O
##ini O
##ne O
- O
rich O
motifs O
of O
the O
gene O
are O
mainly O
encoded O
by O
ex O
##ons O
8 O
- O
9 O
, O
14 O
, O
and O
16 O
. O

the O
d O
##na O
sequence O
in O
the O
5 O
region O
of O
the O
gene O
has O
features O
of O
a O
c O
##p O
##g O
- O
rich O
island O
and O
lacks O
canonical O
promoter O
elements O
, O
such O
as O
ta O
##ta O
and O
cc O
##aa O
##t O
consensus O
sequences O
. O

positions O
of O
the O
chromosome O
22 O
break O
##points O
were O
determined O
for O
19 O
e B-Disease
##wing I-Disease
tumors I-Disease
. O

they O
were O
localized O
in O
intro O
##ns O
7 O
or O
8 O
in O
18 O
cases O
and O
in O
intro O
##n O
10 O
in O
1 O
case O
. O
. O

nor B-Disease
##rie I-Disease
disease I-Disease
gene O
: O
characterization O
of O
del O
##eti O
##ons O
and O
possible O
function O
. O

position O
##al O
c O
##lon O
##ing O
experiments O
have O
resulted O
recently O
in O
the O
isolation O
of O
a O
candidate O
gene O
for O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
pseudo B-Disease
##gli I-Disease
##oma I-Disease
; O
n B-Disease
##d I-Disease
##p I-Disease
) O
, O
a O
severe O
x B-Disease
- I-Disease
linked I-Disease
ne I-Disease
##uro I-Disease
##de I-Disease
##vel I-Disease
##op I-Disease
##mental I-Disease
disorder I-Disease
. O

here O
we O
report O
the O
isolation O
and O
analysis O
of O
human O
g O
##eno O
##mic O
d O
##na O
clone O
##s O
encompassing O
the O
n B-Disease
##d I-Disease
##p I-Disease
gene O
. O

the O
gene O
spans O
28 O
k O
##b O
and O
consists O
of O
3 O
ex O
##ons O
, O
the O
first O
of O
which O
is O
entirely O
contained O
within O
the O
5 O
un O
##tra O
##ns O
##lated O
region O
. O

detailed O
analysis O
of O
g O
##eno O
##mic O
del O
##eti O
##ons O
in O
nor B-Disease
##rie I-Disease
patients O
shows O
that O
they O
are O
he O
##tero O
##gene O
##ous O
, O
both O
in O
size O
and O
in O
position O
. O

by O
p O
##c O
##r O
analysis O
, O
we O
found O
that O
expression O
of O
the O
n B-Disease
##d I-Disease
##p I-Disease
gene O
was O
not O
confined O
to O
the O
eye O
or O
to O
the O
brain O
. O

an O
extensive O
d O
##na O
and O
protein O
sequence O
comparison O
between O
the O
human O
n B-Disease
##d I-Disease
##p I-Disease
gene O
and O
related O
genes O
from O
the O
database O
revealed O
ho O
##mology O
with O
c O
##ys O
##tein O
##e O
- O
rich O
protein O
- O
binding O
domains O
of O
immediate O
- O
- O
early O
genes O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
. O

we O
propose O
that O
n O
##d O
##p O
is O
a O
molecule O
related O
in O
function O
to O
these O
genes O
and O
may O
be O
involved O
in O
a O
pathway O
that O
regulate O
##s O
neural O
cell O
differentiation O
and O
proliferation O
. O
. O

the O
normal O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
all O
##ele O
, O
or O
a O
closely O
linked O
gene O
, O
influences O
age O
at O
onset O
of O
h B-Disease
##d I-Disease
. O

we O
evaluated O
the O
hypothesis O
that O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
is O
influenced O
by O
the O
normal O
h B-Disease
##d I-Disease
all O
##ele O
by O
comparing O
transmission O
patterns O
of O
genetically O
linked O
markers O
at O
the O
d O
##4 O
##s O
##10 O
lo O
##cus O
in O
the O
normal O
parent O
against O
age O
at O
onset O
in O
the O
affected O
offspring O
. O

analysis O
of O
information O
from O
21 O
si O
##bs O
##hips O
in O
14 O
kind O
##red O
##s O
showed O
a O
significant O
tendency O
for O
si O
##bs O
who O
have O
similar O
onset O
ages O
to O
share O
the O
same O
d O
##4 O
##s O
##10 O
all O
##ele O
from O
the O
normal O
parent O
. O

affected O
si O
##bs O
who O
inherited O
different O
d O
##4 O
##s O
##10 O
all O
##ele O
##s O
from O
the O
normal O
parent O
tended O
to O
have O
more O
variable O
ages O
at O
onset O
. O

these O
findings O
suggest O
that O
the O
expression O
of O
h B-Disease
##d I-Disease
is O
m O
##od O
##ulated O
by O
the O
normal O
h B-Disease
##d I-Disease
all O
##ele O
or O
by O
a O
closely O
linked O
lo O
##cus O
. O
. O

further O
investigation O
of O
the O
he O
##xa O
gene O
intro O
##n O
9 O
donor O
s O
##p O
##lice O
site O
mutation O
frequently O
found O
in O
non O
- O
j O
##ew O
##ish O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
patients O
from O
the O
br O
##itis O
##h O
is O
##les O
. O

in O
a O
previous O
study O
we O
found O
that O
a O
ta B-Disease
##y I-Disease
- I-Disease
sa I-Disease
##chs I-Disease
disease I-Disease
( O
t B-Disease
##s I-Disease
##d I-Disease
) O
causing O
mutation O
in O
the O
intro O
##n O
9 O
donor O
s O
##p O
##lice O
site O
of O
the O
he O
##xa O
gene O
occurs O
at O
high O
frequency O
in O
non O
- O
j O
##ew O
##ish O
patients O
and O
carriers O
from O
the O
br O
##itis O
##h O
is O
##les O
. O

it O
was O
found O
more O
frequently O
in O
subjects O
of O
i O
##ris O
##h O
, O
s O
##cott O
##ish O
, O
and O
we O
##ls O
##h O
origin O
compared O
with O
en O
##gli O
##sh O
origin O
( O
63 O
% O
and O
31 O
% O
respectively O
) O
. O

we O
have O
now O
tested O
, O
in O
a O
blind O
study O
, O
26 O
am O
##eric O
##an O
t B-Disease
##s I-Disease
##d I-Disease
carriers O
and O
28 O
non O
- O
carriers O
who O
have O
br O
##itis O
##h O
ancestry O
for O
the O
intro O
##n O
9 O
s O
##p O
##lice O
site O
mutation O
. O

six O
of O
the O
carriers O
and O
none O
of O
the O
controls O
were O
positive O
for O
the O
mutation O
. O

all O
six O
had O
i O
##ris O
##h O
ancestry O
, O
compared O
with O
nine O
of O
the O
20 O
other O
( O
intro O
##n O
9 O
mutation O
negative O
) O
t B-Disease
##s I-Disease
##d I-Disease
carriers O
( O
p O
[UNK] O
0 O
. O
05 O
) O
. O

these O
results O
confirm O
the O
previously O
found O
high O
frequency O
of O
the O
intro O
##n O
9 O
mutation O
in O
non O
- O
j O
##ew O
##ish O
t B-Disease
##s I-Disease
##d I-Disease
families O
of O
br O
##itis O
##h O
is O
##les O
, O
particularly O
i O
##ris O
##h O
, O
origin O
, O
and O
reinforce O
the O
need O
to O
screen O
such O
families O
for O
this O
mutation O
. O

molecular O
mechanisms O
of O
on O
##co O
##genic O
mutations O
in O
tumors B-Disease
from O
patients O
with O
bilateral B-Disease
and I-Disease
un I-Disease
##ila I-Disease
##teral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

the O
r O
##b O
##1 O
gene O
from O
12 O
human O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
tumors I-Disease
has O
been O
analyzed O
ex O
##on O
- O
by O
- O
ex O
##on O
with O
the O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
technique O
. O

mutations O
were O
found O
in O
all O
tumors B-Disease
, O
and O
one O
- O
third O
of O
the O
tumors B-Disease
had O
independent O
mutations O
in O
both O
all O
##ele O
##s O
neither O
of O
which O
were O
found O
in O
the O
g O
##er O
##m O
line O
, O
confirming O
their O
true O
s O
##poradic O
nature O
. O

in O
the O
remaining O
two O
- O
thirds O
of O
the O
tumors B-Disease
only O
one O
mutation O
was O
found O
, O
consistent O
with O
the O
loss O
- O
of O
- O
he O
##tero O
##zy O
##gos O
##ity O
theory O
of O
tumor O
##ige O
##nes O
##is O
. O

point O
mutations O
, O
the O
majority O
of O
which O
were O
c O
- O
- O
[UNK] O
t O
transitions O
, O
were O
the O
most O
common O
abnormal O
##ity O
and O
usually O
resulted O
in O
the O
conversion O
of O
an O
a O
##rg O
##ini O
##ne O
co O
##don O
to O
a O
stop O
co O
##don O
. O

small O
del O
##eti O
##ons O
were O
the O
second O
most O
common O
abnormal O
##ity O
and O
most O
often O
created O
a O
downstream O
stop O
co O
##don O
as O
the O
result O
of O
a O
reading O
frames O
##hi O
##ft O
. O

del O
##eti O
##ons O
and O
point O
mutations O
also O
affected O
s O
##p O
##lice O
junction O
##s O
. O

direct O
repeats O
were O
present O
at O
the O
break O
##point O
junction O
##s O
in O
the O
majority O
of O
del O
##eti O
##ons O
, O
supporting O
a O
slipped O
- O
mi O
##sp O
##air O
##ing O
mechanism O
. O

point O
mutations O
generally O
produced O
d O
##na O
sequences O
which O
resulted O
in O
perfect O
ho O
##mology O
with O
end O
##ogen O
##ous O
sequences O
which O
lay O
within O
14 O
b O
##p O
. O
. O

p O
##ax O
##6 O
mutations O
in O
an B-Disease
##iri I-Disease
##dia I-Disease
. O

an B-Disease
##iri I-Disease
##dia I-Disease
is O
a O
con B-Disease
##gen I-Disease
##ital I-Disease
ma I-Disease
##lf I-Disease
##orm I-Disease
##ation I-Disease
of I-Disease
the I-Disease
eye I-Disease
, O
chiefly O
characterised O
by O
i B-Disease
##ris I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
which O
can O
cause O
blind B-Disease
##ness I-Disease
. O

the O
p O
##ax O
##6 O
gene O
was O
isolated O
as O
a O
candidate O
an B-Disease
##iri I-Disease
##dia I-Disease
gene O
by O
position O
##al O
c O
##lon O
##ing O
from O
the O
smallest O
region O
of O
overlap O
of O
an B-Disease
##iri I-Disease
##dia I-Disease
- O
associated O
del O
##eti O
##ons O
. O

subsequently O
p O
##ax O
##6 O
in O
##tra O
##genic O
mutations O
were O
demonstrated O
in O
small O
##eye O
, O
a O
mouse O
mutant O
which O
is O
an O
animal O
model O
for O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
and O
six O
human O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
. O

in O
this O
paper O
we O
describe O
four O
additional O
p O
##ax O
##6 O
point O
mutations O
in O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
, O
both O
s O
##poradic O
and O
f O
##ami O
##lial O
. O

these O
mutations O
highlight O
regions O
of O
the O
gene O
which O
are O
essential O
for O
normal O
p O
##ax O
##6 O
function O
. O

in O
addition O
, O
the O
frequency O
at O
which O
we O
have O
found O
p O
##ax O
##6 O
mutations O
suggests O
that O
lesions O
in O
p O
##ax O
##6 O
will O
account O
for O
most O
cases O
of O
an B-Disease
##iri I-Disease
##dia I-Disease
. O
. O

detection O
of O
a O
novel O
a O
##rg O
##ini O
##ne O
v O
##as O
##op O
##ress O
##in O
defect O
by O
did O
##eo O
##xy O
finger O
##print O
##ing O
. O

auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
is O
a O
f O
##ami O
##lial O
form O
of O
diabetes B-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
. O

this O
disorder O
is O
associated O
with O
variable O
levels O
of O
a O
##rg O
##ini O
##ne O
v O
##as O
##op O
##ress O
##in O
( O
a O
##v O
##p O
) O
and O
diabetes B-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
of O
varying O
severity O
, O
which O
responds O
to O
ex O
##ogen O
##ous O
a O
##v O
##p O
. O

to O
determine O
the O
molecular O
basis O
of O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
ne I-Disease
##uro I-Disease
##hy I-Disease
##pop I-Disease
##hy I-Disease
##sea I-Disease
##l I-Disease
diabetes I-Disease
ins I-Disease
##ip I-Disease
##id I-Disease
##us I-Disease
, O
the O
a O
##v O
##p O
genes O
of O
members O
of O
a O
large O
kind O
##red O
were O
analyzed O
. O

a O
new O
method O
, O
called O
did O
##eo O
##xy O
finger O
##print O
##ing O
, O
was O
used O
to O
detect O
an O
a O
##v O
##p O
mutation O
that O
was O
characterized O
by O
d O
##na O
se O
##quencing O
. O

the O
novel O
defect O
found O
changes O
the O
last O
co O
##don O
of O
the O
a O
##v O
##p O
signal O
p O
##eptide O
from O
al O
##ani O
##ne O
to O
th O
##re O
##oni O
##ne O
, O
which O
should O
per O
##tur O
##b O
c O
##lea O
##vage O
of O
mature O
a O
##v O
##p O
from O
its O
precursor O
protein O
and O
in O
##hibit O
its O
secret O
##ion O
or O
action O
. O
. O

g O
##er O
##mina O
##l O
mosaic O
##ism O
in O
a O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
family O
: O
implications O
for O
genetic O
counsel O
##ling O
. O

in O
this O
study O
we O
describe O
a O
three O
- O
generation O
family O
in O
which O
two O
siblings O
were O
affected O
by O
du B-Disease
##chen I-Disease
##ne I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
##d I-Disease
) O
. O

im O
##mu O
##no O
##his O
##to O
##chemical O
analysis O
of O
muscle O
d O
##ys O
##tro O
##phi O
##n O
and O
ha O
##p O
##lot O
##ype O
analysis O
of O
the O
d B-Disease
##m I-Disease
##d I-Disease
lo O
##cus O
revealed O
that O
the O
x O
chromosome O
carrying O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
was O
transmitted O
from O
the O
healthy O
maternal O
grandfather O
to O
his O
three O
daughters O
, O
including O
the O
pro O
##band O
##s O
mother O
. O

these O
findings O
indicate O
that O
the O
grandfather O
was O
a O
g O
##er O
##mina O
##l O
mosaic O
for O
the O
d B-Disease
##m I-Disease
##d I-Disease
gene O
. O

the O
definition O
of O
the O
carrier O
status O
in O
two O
possible O
carriers O
led O
us O
to O
give O
accurate O
genetic O
counsel O
##ling O
and O
to O
prevent O
the O
birth O
of O
an O
affected O
boy O
. O

the O
results O
of O
this O
study O
demonstrate O
the O
useful O
##ness O
of O
ha O
##p O
##lot O
##ype O
analysis O
and O
im O
##mu O
##no O
##his O
##to O
##chemical O
muscle O
d O
##ys O
##tro O
##phi O
##n O
studies O
to O
detect O
hidden O
g O
##er O
##mina O
##l O
mosaic O
##ism O
and O
to O
improve O
genetic O
counsel O
##ling O
. O
. O

genetic O
mapping O
of O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
syndrome I-Disease
to O
a O
small O
interval O
on O
chromosome O
17 O
##q O
##12 O
- O
21 O
: O
exclusion O
of O
candidate O
genes O
ed O
##h O
##17 O
##b O
##2 O
and O
r O
##ara O
. O

a O
su O
##s O
##ce O
##pt O
##ibility O
gene O
for O
hereditary B-Disease
breast I-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
br O
##ca O
##1 O
, O
has O
been O
assigned O
by O
link O
##age O
analysis O
to O
chromosome O
17 O
##q O
##21 O
. O

candidate O
genes O
in O
this O
region O
include O
ed O
##h O
##17 O
##b O
##2 O
, O
which O
en O
##codes O
est O
##rad O
##iol O
17 O
beta O
- O
h O
##ydro O
##xy O
##ster O
##oid O
de O
##hy O
##dr O
##ogen O
##ase O
ii O
( O
17 O
beta O
- O
h O
##s O
##d O
ii O
) O
, O
and O
r O
##ara O
, O
the O
gene O
for O
re O
##tino O
##ic O
acid O
receptor O
alpha O
. O

we O
have O
typed O
22 O
breast B-Disease
and I-Disease
breast I-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
with O
eight O
p O
##oly O
##mor O
##phism O
##s O
from O
the O
chromosome O
17 O
##q O
##12 O
- O
21 O
region O
, O
including O
two O
in O
the O
ed O
##h O
##17 O
##b O
##2 O
gene O
. O

genetic O
re O
##comb O
##ination O
with O
the O
breast B-Disease
cancer I-Disease
trait O
exclude O
##s O
r O
##ara O
from O
further O
consideration O
as O
a O
candidate O
gene O
for O
br O
##ca O
##1 O
. O

both O
br O
##ca O
##1 O
and O
ed O
##h O
##17 O
##b O
##2 O
map O
to O
a O
6 O
cm O
interval O
( O
between O
th O
##ra O
##1 O
and O
d O
##17 O
##s O
##5 O
##7 O
##9 O
) O
and O
no O
re O
##comb O
##ination O
was O
observed O
between O
the O
two O
genes O
. O

however O
, O
direct O
se O
##quencing O
of O
overlapping O
p O
##c O
##r O
products O
containing O
the O
entire O
ed O
##h O
##17 O
##b O
##2 O
gene O
in O
four O
unrelated O
affected O
women O
did O
not O
un O
##cover O
any O
sequence O
variation O
, O
other O
than O
previously O
described O
p O
##oly O
##mor O
##phism O
##s O
. O

mutations O
in O
the O
ed O
##h O
##17 O
##b O
##2 O
gene O
, O
therefore O
do O
not O
appear O
to O
be O
responsible O
for O
the O
hereditary B-Disease
breast I-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
syndrome I-Disease
. O

single O
me O
##iot O
##ic O
crossover O
##s O
in O
affected O
women O
suggest O
that O
br O
##ca O
##1 O
is O
flanked O
by O
the O
lo O
##ci O
r O
##ara O
and O
d O
##17 O
##s O
##7 O
##8 O
. O
. O

a O
miss O
##ense O
mutation O
in O
the O
ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
gene O
with O
possible O
dominant O
effects O
on O
plasma O
high O
density O
lip O
##op O
##rote O
##ins O
. O

plasma O
h O
##dl O
are O
a O
negative O
risk O
factor O
for O
at B-Disease
##her I-Disease
##os I-Disease
##cle I-Disease
##rosis I-Disease
. O

ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
( O
c O
##et O
##p O
; O
47 O
##6 O
amino O
acids O
) O
transfers O
ch O
##ole O
##ster O
##yl O
est O
##er O
from O
h O
##dl O
to O
other O
lip O
##op O
##rote O
##ins O
. O

subjects O
with O
ho O
##mo O
##zy O
##go O
##us O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
caused O
by O
a O
gene O
s O
##p O
##licing O
defect O
have O
marked O
##ly O
elevated O
h O
##dl O
; O
however O
, O
he O
##tero O
##zy O
##got O
##es O
have O
only O
mild O
increases O
in O
h O
##dl O
. O

we O
describe O
two O
pro O
##band O
##s O
with O
a O
c O
##et O
##p O
miss O
##ense O
mutation O
( O
44 O
##2 O
d O
g O
) O
. O

although O
he O
##tero O
##zy O
##go O
##us O
, O
they O
have O
three O
##fold O
increases O
in O
h O
##dl O
concentration O
and O
marked O
##ly O
decreased O
plasma O
c O
##et O
##p O
mass O
and O
activity O
, O
suggesting O
that O
the O
mutation O
has O
dominant O
effects O
on O
c O
##et O
##p O
and O
h O
##dl O
in O
v O
##ivo O
. O

cellular O
expression O
of O
mutant O
c O
##dn O
##a O
results O
in O
secret O
##ion O
of O
only O
30 O
% O
of O
wild O
type O
c O
##et O
##p O
activity O
. O

more O
##over O
, O
co O
##ex O
##press O
##ion O
of O
wild O
type O
and O
mutant O
c O
##dn O
##as O
leads O
to O
in O
##hibition O
of O
wild O
type O
secret O
##ion O
and O
activity O
. O

the O
dominant O
effects O
of O
the O
c O
##et O
##p O
miss O
##ense O
mutation O
during O
cellular O
expression O
probably O
explains O
why O
the O
pro O
##band O
##s O
have O
marked O
##ly O
increased O
h O
##dl O
in O
the O
he O
##tero O
##zy O
##go O
##us O
state O
, O
and O
suggests O
that O
the O
active O
molecular O
species O
of O
c O
##et O
##p O
may O
be O
multi O
##mer O
##ic O
. O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
in O
the O
co O
##l O
##chi O
##cine O
era O
: O
the O
fate O
of O
one O
family O
. O

in O
order O
to O
demonstrate O
the O
effect O
of O
prop O
##hyl O
##actic O
co O
##l O
##chi O
##cine O
treatment O
on O
the O
natural O
history O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
, O
a O
family O
is O
presented O
with O
6 O
out O
of O
9 O
siblings O
affected O
by O
f B-Disease
##m I-Disease
##f I-Disease
. O

each O
patient O
represents O
a O
different O
stage O
of O
the O
am B-Disease
##yl I-Disease
##oid I-Disease
##otic I-Disease
kidney I-Disease
disease I-Disease
of O
f B-Disease
##m I-Disease
##f I-Disease
and O
the O
effect O
of O
continuous O
co O
##l O
##chi O
##cine O
treatment O
on O
its O
course O
. O

considered O
together O
, O
the O
members O
of O
this O
family O
present O
an O
almost O
complete O
clinical O
, O
genetic O
, O
and O
behavioral O
picture O
of O
the O
disease O
. O
. O

detection O
of O
a O
new O
sub O
##mic O
##ros O
##copic O
nor B-Disease
##rie I-Disease
disease I-Disease
del O
##eti O
##on O
interval O
with O
a O
novel O
d O
##na O
probe O
isolated O
by O
differential O
al O
##u O
p O
##c O
##r O
finger O
##print O
c O
##lon O
##ing O
. O

differential O
al O
##u O
p O
##c O
##r O
finger O
##print O
c O
##lon O
##ing O
was O
used O
to O
is O
##olate O
a O
d O
##na O
probe O
from O
the O
x O
##p O
##11 O
. O

4 O
- O
- O
[UNK] O
p O
##11 O
. O

21 O
region O
of O
the O
human O
x O
chromosome O
. O

this O
novel O
sequence O
, O
c O
##p O
##x O
##r O
##31 O
##8 O
( O
d O
##x O
##s O
##7 O
##42 O
) O
, O
detect O
##s O
a O
new O
sub O
##mic O
##ros O
##copic O
del O
##eti O
##on O
interval O
at O
the O
nor B-Disease
##rie I-Disease
disease I-Disease
lo O
##cus O
( O
n O
##d O
##p O
) O
. O

combining O
our O
data O
with O
the O
consensus O
genetic O
map O
of O
the O
pro O
##ximal O
short O
arm O
of O
the O
x O
chromosome O
, O
we O
propose O
the O
physical O
order O
x O
##ce O
##n O
- O
d O
##x O
##s O
##14 O
- O
d O
##x O
##s O
##25 O
##5 O
- O
( O
d O
##x O
##s O
##42 O
##6 O
, O
t O
##im O
##p O
) O
- O
( O
d O
##x O
##s O
##7 O
##42 O
- O
( O
[ O
ma O
##ob O
- O
ma O
##oa O
- O
d O
##x O
##s O
##7 O
] O
, O
n O
##d O
##p O
) O
- O
d O
##x O
##s O
##7 O
##7 O
- O
d O
##x O
##s O
##22 O
##8 O
) O
- O
d O
##x O
##s O
##20 O
##9 O
- O
d O
##x O
##s O
##14 O
##8 O
- O
d O
##x O
##s O
##19 O
##6 O
- O
+ O
+ O
+ O
x O
##pt O
##er O
. O

the O
c O
##p O
##x O
##r O
##31 O
##8 O
probe O
and O
a O
sub O
##c O
##lone O
from O
a O
co O
##sm O
##id O
corresponding O
to O
the O
d O
##x O
##s O
##7 O
lo O
##cus O
were O
converted O
into O
sequence O
- O
tag O
##ged O
sites O
. O

finally O
, O
d O
##x O
##s O
##7 O
##42 O
, O
d O
##s O
##x O
##7 O
, O
d O
##x O
##s O
##7 O
##7 O
, O
and O
ma O
##oa O
were O
integrated O
into O
a O
physical O
map O
spanning O
the O
nor B-Disease
##rie I-Disease
disease I-Disease
lo O
##cus O

put O
##ative O
x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
gene O
shares O
unexpected O
ho O
##mology O
with O
a O
##b O
##c O
transport O
##ers O
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disease I-Disease
affecting O
1 O
/ O
20 O
, O
000 O
males O
either O
as O
cerebral B-Disease
al I-Disease
##d I-Disease
in O
childhood O
or O
as O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
in O
adults O
. O

childhood O
al B-Disease
##d I-Disease
is O
the O
more O
severe O
form O
, O
with O
onset O
of O
ne O
##uro O
##logical O
symptoms O
between O
5 O
- O
12 O
years O
of O
age O
. O

central B-Disease
nervous I-Disease
system I-Disease
dem I-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
progresses O
rapidly O
and O
death O
occurs O
within O
a O
few O
years O
. O

am B-Disease
##n I-Disease
is O
a O
mild O
##er O
form O
of O
the O
disease O
with O
onset O
at O
15 O
- O
30 O
years O
of O
age O
and O
a O
more O
progressive O
course O
. O

ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
( O
add B-Disease
##ison I-Disease
##s I-Disease
disease I-Disease
) O
may O
remain O
the O
only O
clinical O
manifest O
##ation O
of O
al B-Disease
##d I-Disease
. O

the O
principal O
bio O
##chemical O
abnormal O
##ity O
of O
al B-Disease
##d I-Disease
is O
the O
accumulation O
of O
very O
- O
long O
- O
chain O
fatty O
acids O
( O
v O
##l O
##c O
##fa O
) O
because O
of O
impaired O
beta O
- O
oxidation O
in O
per O
##ox O
##is O
##ome O
##s O
. O

the O
normal O
oxidation O
of O
v O
##l O
##c O
##fa O
- O
co O
##a O
in O
patients O
fi O
##bro O
##blast O
##s O
suggested O
that O
the O
gene O
coding O
for O
the O
v O
##l O
##c O
##fa O
- O
co O
##a O
s O
##ynth O
##eta O
##se O
could O
be O
a O
candidate O
gene O
for O
al B-Disease
##d I-Disease
. O

here O
we O
use O
position O
##al O
c O
##lon O
##ing O
to O
identify O
a O
gene O
partially O
deleted O
in O
6 O
of O
85 O
independent O
patients O
with O
al B-Disease
##d I-Disease
. O

in O
f O
##ami O
##lial O
cases O
, O
the O
del O
##eti O
##ons O
segregated O
with O
the O
disease O
. O

an O
identical O
del O
##eti O
##on O
was O
detected O
in O
two O
brothers O
presenting O
with O
different O
clinical O
al B-Disease
##d I-Disease
p O
##hen O
##otype O
##s O
. O

candidate O
ex O
##ons O
were O
identified O
by O
computer O
analysis O
of O
g O
##eno O
##mic O
sequences O
and O
used O
to O
is O
##olate O
complementary O
d O
##nas O
by O
ex O
##on O
connection O
and O
screening O
of O
c O
##dn O
##a O
libraries O
. O

the O
de O
##duced O
protein O
sequence O
shows O
significant O
sequence O
identity O
to O
a O
per O
##ox O
##is O
##oma O
##l O
membrane O
protein O
of O
m O
( O
r O
) O
70 O
##k O
that O
is O
involved O
in O
per O
##ox O
##is O
##ome O
bio O
##genesis O
and O
belongs O
to O
the O
at O
##p O
- O
binding O
cassette O
super O
##family O
of O
transport O
##ers O
. O
. O

targeted O
modification O
of O
the O
a O
##poli O
##pop O
##rote O
##in O
b O
gene O
results O
in O
h B-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
and O
developmental B-Disease
abnormal I-Disease
##ities I-Disease
in O
mice O
. O

f B-Disease
##ami I-Disease
##lial I-Disease
h I-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
co I-Disease
##dom I-Disease
##ina I-Disease
##nt I-Disease
disorder I-Disease
resulting O
in O
a O
dramatic O
reduction O
in O
plasma O
concentrations O
of O
a O
##poli O
##pop O
##rote O
##in O
( O
a O
##po O
) O
b O
, O
ch O
##ole O
##ster O
##ol O
, O
and O
beta O
- O
mi O
##grating O
lip O
##op O
##rote O
##ins O
. O

a O
benefit O
of O
h B-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
is O
that O
mildly O
affected O
individuals O
may O
be O
protected O
from O
co B-Disease
##rona I-Disease
##ry I-Disease
vascular I-Disease
disease I-Disease
. O

we O
have O
used O
gene O
targeting O
to O
generate O
mice O
with O
a O
modified O
a O
##po O
##b O
all O
##ele O
. O

mice O
containing O
this O
all O
##ele O
display O
all O
of O
the O
hall O
##marks O
of O
human O
h B-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
they O
produce O
a O
t O
##runcated O
a O
##po O
##b O
protein O
, O
a O
##po O
##b O
##70 O
, O
and O
have O
marked O
##ly O
decreased O
plasma O
concentrations O
of O
a O
##po O
##b O
, O
beta O
- O
lip O
##op O
##rote O
##ins O
, O
and O
total O
ch O
##ole O
##ster O
##ol O
. O

in O
addition O
, O
the O
mice O
manifest O
several O
characteristics O
that O
are O
occasionally O
observed O
in O
human O
h B-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
, O
including O
reduced O
plasma O
t O
##rig O
##ly O
##cer O
##ide O
concentrations O
, O
fast O
##ing O
ch B-Disease
##yl I-Disease
##omi I-Disease
##c I-Disease
##rone I-Disease
##mia I-Disease
, O
and O
reduced O
high O
density O
lip O
##op O
##rote O
##in O
ch O
##ole O
##ster O
##ol O
. O

an O
unexpected O
finding O
is O
that O
the O
modified O
a O
##po O
##b O
all O
##ele O
is O
strongly O
associated O
with O
ex B-Disease
##ence I-Disease
##pha I-Disease
##lus I-Disease
and O
h B-Disease
##ydro I-Disease
##ce I-Disease
##pha I-Disease
##lus I-Disease
. O

these O
mice O
should O
help O
increase O
our O
understanding O
of O
h B-Disease
##y I-Disease
##po I-Disease
##bet I-Disease
##ali I-Disease
##pop I-Disease
##rote I-Disease
##ine I-Disease
##mia I-Disease
, O
at B-Disease
##her I-Disease
##ogen I-Disease
##esis I-Disease
, O
and O
the O
et O
##iology O
of O
ex B-Disease
##ence I-Disease
##pha I-Disease
##lus I-Disease
and O
h B-Disease
##ydro I-Disease
##ce I-Disease
##pha I-Disease
##lus I-Disease
. O
. O

a O
novel O
disease O
with O
deficiency B-Disease
of I-Disease
mitochondrial I-Disease
very I-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
a I-Disease
##cy I-Disease
##l I-Disease
- I-Disease
co I-Disease
##a I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
. O

palm O
##ito O
##yl O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
activity O
in O
skin O
fi O
##bro O
##blast O
##s O
from O
seven O
patients O
with O
unidentified O
defects O
of O
fatty O
acid O
oxidation O
was O
measured O
in O
the O
presence O
and O
absence O
of O
antibodies O
against O
medium O
- O
chain O
, O
long O
- O
chain O
, O
and O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ases O
( O
v O
##l O
##ca O
##d O
) O
. O

two O
of O
the O
patients O
, O
4 O
- O
5 O
month O
old O
boys O
, O
were O
found O
to O
have O
a O
novel O
disease O
, O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
, O
as O
judged O
from O
the O
results O
of O
very O
low O
palm O
##ito O
##yl O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
activity O
and O
the O
lack O
of O
im O
##mu O
##nor O
##ea O
##ct O
##ivity O
toward O
anti O
##body O
raised O
to O
pu O
##rified O
v O
##l O
##ca O
##d O
. O
. O

molecular O
characterization O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
in O
patients O
of O
chin O
##ese O
descent O
and O
identification O
of O
new O
base O
substitution O
##s O
in O
the O
human O
g O
##6 O
##p O
##d O
gene O
. O

the O
underlying O
d O
##na O
changes O
associated O
with O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
- I-Disease
def I-Disease
##icient I-Disease
as O
##ians O
have O
not O
been O
extensively O
investigated O
. O

to O
fill O
this O
gap O
, O
we O
sequence O
##d O
the O
g O
##6 O
##p O
##d O
gene O
of O
43 O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
chin O
##ese O
whose O
g O
##6 O
##p O
##d O
was O
well O
characterized O
bio O
##chemical O
##ly O
. O

d O
##na O
samples O
were O
obtained O
from O
peripheral O
blood O
of O
these O
individuals O
for O
se O
##quencing O
using O
a O
direct O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
se O
##quencing O
procedure O
. O

from O
these O
43 O
samples O
, O
we O
have O
identified O
five O
different O
types O
of O
n O
##uc O
##leo O
##tide O
substitution O
##s O
in O
the O
g O
##6 O
##p O
##d O
gene O
at O
c O
##dn O
##a O
138 O
##8 O
from O
g O
to O
a O
( O
a O
##rg O
to O
his O
) O
; O
at O
c O
##dn O
##a O
137 O
##6 O
from O
g O
to O
t O
( O
a O
##rg O
to O
le O
##u O
) O
; O
at O
c O
##dn O
##a O
102 O
##4 O
from O
c O
to O
t O
( O
le O
##u O
to O
p O
##he O
) O
; O
at O
c O
##dn O
##a O
39 O
##2 O
from O
g O
to O
t O
( O
g O
##ly O
to O
v O
##al O
) O
; O
at O
c O
##dn O
##a O
95 O
from O
a O
to O
g O
( O
his O
to O
a O
##rg O
) O
. O

these O
five O
n O
##uc O
##leo O
##tide O
substitution O
##s O
account O
for O
over O
83 O
% O
of O
our O
43 O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
samples O
and O
these O
substitution O
##s O
have O
not O
been O
reported O
in O
non O
- O
as O
##ians O
. O

the O
substitution O
##s O
found O
at O
c O
##dn O
##a O
39 O
##2 O
and O
c O
##dn O
##a O
102 O
##4 O
are O
new O
findings O
. O

the O
substitution O
##s O
at O
c O
##dn O
##a O
137 O
##6 O
and O
138 O
##8 O
account O
for O
over O
50 O
% O
of O
the O
43 O
samples O
examined O
indicating O
a O
high O
prevalence O
of O
these O
two O
all O
##ele O
##s O
among O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
- I-Disease
def I-Disease
##icient I-Disease
chin O
##ese O
. O

our O
findings O
add O
support O
to O
the O
notion O
that O
diverse O
point O
mutations O
may O
account O
largely O
for O
much O
of O
the O
p O
##hen O
##otypic O
he O
##tero O
##gene O
##ity O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
. O
. O

identification O
of O
mutations O
in O
da O
##nish O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
families O
. O

we O
have O
searched O
for O
mutations O
in O
the O
ch B-Disease
##oro I-Disease
##ider I-Disease
##emia I-Disease
gene O
( O
ch B-Disease
##m I-Disease
) O
in O
patients O
from O
12 O
da O
##nish O
families O
in O
which O
ch B-Disease
##m I-Disease
is O
se O
##g O
##re O
##gating O
. O

employing O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
, O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
analysis O
, O
and O
direct O
d O
##na O
se O
##quencing O
, O
different O
mutations O
have O
been O
identified O
in O
6 O
patients O
. O

all O
the O
mutations O
will O
interfere O
with O
the O
correct O
translation O
of O
the O
m O
##rna O
predict O
##ing O
a O
t O
##runcated O
protein O
or O
no O
gene O
product O
at O
all O
. O
. O

structure O
and O
g O
##eno O
##mic O
sequence O
of O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
kinase O
) O
gene O
. O

the O
mutation O
causing O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
has O
recently O
been O
identified O
as O
an O
unstable O
c O
##t O
##g O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
located O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
a O
gene O
encoding O
for O
a O
protein O
with O
put O
##ative O
se O
##rine O
- O
th O
##re O
##oni O
##ne O
protein O
kinase O
activity O
. O

in O
this O
report O
we O
present O
the O
g O
##eno O
##mic O
sequences O
of O
the O
human O
and O
m O
##uri O
##ne O
d B-Disease
##m I-Disease
kinase O
gene O
. O

a O
comparison O
of O
these O
sequences O
with O
each O
other O
and O
with O
known O
c O
##dn O
##a O
sequences O
from O
both O
species O
, O
led O
us O
to O
predict O
a O
translation O
initiation O
co O
##don O
, O
as O
well O
as O
determine O
the O
organization O
of O
the O
d B-Disease
##m I-Disease
kinase O
gene O
. O

several O
p O
##oly O
##mor O
##phism O
##s O
within O
the O
human O
d B-Disease
##m I-Disease
kinase O
gene O
have O
been O
identified O
, O
and O
p O
##c O
##r O
ass O
##ays O
to O
detect O
two O
of O
these O
are O
described O
. O

the O
complete O
sequence O
and O
characterization O
of O
the O
structure O
of O
the O
d B-Disease
##m I-Disease
kinase O
gene O
, O
as O
well O
as O
the O
identification O
of O
novel O
p O
##oly O
##mor O
##phism O
##s O
within O
the O
gene O
, O
represent O
an O
important O
step O
in O
a O
further O
understanding O
of O
the O
genetics O
of O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
and O
the O
molecular O
biology O
of O
the O
gene O
. O
. O

auto O
##so O
##mal O
re O
##cess O
##ive O
transmission O
of O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
a I-Disease
due O
to O
a O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
mutation O
. O

the O
differential O
diagnosis O
of O
the O
genetic B-Disease
bleeding I-Disease
disorders I-Disease
, O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
a I-Disease
and O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
, O
is O
occasionally O
con O
##founded O
by O
the O
close O
molecular O
relationship O
of O
co O
##agu O
##lation O
factor O
v O
##ii O
##i O
and O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
( O
v O
##w O
##f O
) O
. O

this O
report O
describes O
the O
auto O
##so O
##mal O
inheritance O
of O
a O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
a I-Disease
p O
##hen O
##otype O
due O
to O
a O
mutation O
of O
v O
##w O
##f O
that O
results O
in O
defect O
##ive O
factor O
v O
##ii O
##i O
binding O
. O

the O
pro O
##band O
was O
a O
female O
patient O
with O
low O
levels O
of O
factor O
v O
##ii O
##i O
activity O
. O

polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
am O
##p O
##lification O
and O
d O
##na O
se O
##quencing O
were O
employed O
to O
examine O
ex O
##ons O
encoding O
the O
put O
##ative O
factor O
v O
##ii O
##i O
binding O
domain O
of O
v O
##w O
##f O
. O

the O
patient O
was O
found O
to O
be O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
single O
point O
mutation O
causing O
a O
th O
##r O
- O
- O
[UNK] O
met O
substitution O
at O
amino O
acid O
position O
28 O
in O
the O
mature O
v O
##w O
##f O
subunit O
. O

the O
p O
##hen O
##otypic O
expression O
of O
the O
mutation O
was O
determined O
to O
be O
re O
##cess O
##ive O
because O
he O
##tero O
##zy O
##go O
##us O
family O
members O
were O
clinical O
##ly O
un O
##af O
##fected O
. O

re O
##comb O
##ina O
##nt O
v O
##w O
##f O
containing O
the O
observed O
amino O
acid O
substitution O
was O
expressed O
in O
co O
##s O
- O
1 O
cells O
. O

the O
mutant O
v O
##w O
##f O
was O
processed O
and O
secret O
##ed O
normally O
, O
and O
was O
functional O
##ly O
equivalent O
to O
wild O
- O
type O
v O
##w O
##f O
in O
its O
ability O
to O
bind O
to O
plate O
##lets O
. O

however O
, O
the O
mutant O
failed O
to O
bind O
factor O
v O
##ii O
##i O
, O
demonstrating O
that O
the O
mutation O
was O
functional O
##ly O
related O
to O
the O
observed O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
p O
##hen O
##otype O
. O

the O
family O
we O
describe O
demonstrates O
the O
re O
##cess O
##ive O
inheritance O
of O
a O
recently O
recognized O
class O
of O
genetic O
bleeding O
disorders O
, O
we O
call O
" O
auto O
##so O
##mal O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
. O

" O
we O
conclude O
that O
v O
##w O
##f O
mutation O
may O
be O
an O
under O
recognized O
cause O
of O
hem B-Disease
##op I-Disease
##hil I-Disease
##ia I-Disease
, O
especially O
in O
cases O
where O
the O
inheritance O
pattern O
is O
not O
consistent O
with O
x O
- O
linked O
transmission O
. O

so O
##matic O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
mutation O
in O
clear O
cell O
p B-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##ma I-Disease
of I-Disease
the I-Disease
e I-Disease
##pid I-Disease
##idy I-Disease
##mis I-Disease
. O

p B-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##ma I-Disease
of I-Disease
the I-Disease
e I-Disease
##pid I-Disease
##idy I-Disease
##mis I-Disease
is O
an O
uncommon O
ben O
##ign O
les O
##ion O
that O
may O
occur O
s O
##poradic O
##ally O
or O
as O
a O
manifest O
##ation O
of O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
disease I-Disease
. O

neither O
im O
##mu O
##no O
##his O
##to O
##chemical O
studies O
nor O
molecular O
genetic O
analyses O
of O
the O
v B-Disease
##hl I-Disease
gene O
have O
been O
reported O
previously O
for O
this O
les O
##ion O
. O

the O
authors O
describe O
two O
cases O
of O
clear O
cell O
p B-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##ma I-Disease
of I-Disease
the I-Disease
e I-Disease
##pid I-Disease
##idy I-Disease
##mis I-Disease
, O
both O
of O
which O
were O
initially O
confused O
with O
meta B-Disease
##static I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

both O
lesions O
showed O
positive O
im O
##mu O
##no O
##his O
##to O
##chemical O
stain O
##ing O
for O
low O
and O
intermediate O
molecular O
weight O
k O
##era O
##tin O
##s O
( O
ca O
##m O
5 O
. O
2 O
and O
a O
##e O
##1 O
/ O
a O
##e O
##3 O
) O
, O
em O
##a O
, O
v O
##iment O
##in O
, O
alpha O
1 O
- O
anti O
##try O
##ps O
##in O
, O
and O
alpha O
1 O
- O
anti O
##chy O
##mot O
##ry O
##ps O
##in O
. O

each O
was O
negative O
for O
c O
##ea O
. O

because O
clear O
cell O
p B-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
c I-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##ma I-Disease
is O
similar O
to O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
his O
##to O
##logical O
##ly O
, O
and O
because O
both O
occur O
as O
components O
of O
the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
complex O
, O
the O
authors O
analyzed O
both O
cases O
for O
the O
presence O
of O
mutations O
in O
the O
v B-Disease
##hl I-Disease
gene O
. O

a O
so O
##matic O
v B-Disease
##hl I-Disease
gene O
mutation O
was O
detected O
in O
one O
of O
the O
two O
tumors B-Disease
by O
polymer O
##ase O
chain O
reaction O
followed O
by O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
. O

direct O
se O
##quencing O
revealed O
a O
c O
##yt O
##os O
##ine O
to O
thy O
##mine O
transition O
at O
n O
##uc O
##leo O
##tide O
69 O
##4 O
, O
resulting O
in O
the O
replacement O
of O
an O
a O
##rg O
##ini O
##ne O
with O
a O
stop O
co O
##don O
after O
the O
sixth O
amino O
acid O
of O
ex O
##on O
3 O
. O

as O
the O
v B-Disease
##hl I-Disease
gene O
is O
believed O
to O
function O
as O
a O
tumor B-Disease
suppress O
##or O
gene O
, O
v B-Disease
##hl I-Disease
gene O
mutations O
may O
play O
a O
role O
in O
the O
initiation O
of O
tumor O
##ige O
##nes O
##is O
in O
s O
##poradic O
c B-Disease
##ys I-Disease
##tad I-Disease
##eno I-Disease
##mas I-Disease
of I-Disease
the I-Disease
e I-Disease
##pid I-Disease
##idy I-Disease
##mis I-Disease
. O

identification O
of O
was O
##p O
mutations O
in O
patients O
with O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
and O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
reveals O
all O
##eli O
##c O
he O
##tero O
##gene O
##ity O
at O
the O
was B-Disease
lo O
##cus O
. O

mutation O
in O
the O
gene O
encoding O
the O
recently O
isolated O
was O
##p O
protein O
has O
now O
been O
identified O
as O
the O
genetic B-Disease
defect I-Disease
responsible O
for O
the O
x B-Disease
- I-Disease
linked I-Disease
w I-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
a O
primary O
im B-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
disease I-Disease
associated O
with O
extensive O
p O
##hen O
##otypic O
var O
##iability O
. O

to O
el O
##uc O
##ida O
##te O
the O
range O
of O
was O
##p O
mutations O
responsible O
for O
was B-Disease
, O
we O
used O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
analysis O
to O
screen O
for O
was O
##p O
gene O
mutation O
in O
19 O
unrelated O
boys O
with O
the O
diagnosis O
of O
classical O
or O
at O
##ten O
##uated O
was B-Disease
or O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

all O
19 O
patients O
had O
was O
##p O
mutations O
, O
each O
of O
which O
localized O
to O
the O
initial O
three O
or O
terminal O
three O
ex O
##ons O
of O
the O
gene O
, O
and O
the O
majority O
of O
which O
were O
unique O
in O
each O
case O
. O

however O
, O
a O
miss O
##ense O
mutation O
which O
results O
in O
substitution O
of O
the O
a O
##rg O
##ini O
##ne O
at O
was B-Disease
co O
##don O
86 O
was O
identified O
in O
three O
boys O
with O
severe O
was B-Disease
as O
well O
as O
in O
one O
boy O
presenting O
with O
th B-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
alone O
. O

while O
the O
three O
mutations O
found O
in O
the O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
patients O
leave O
the O
reading O
frame O
intact O
, O
about O
one O
- O
half O
of O
the O
gene O
alterations O
detected O
in O
both O
severe O
and O
at O
##ten O
##uated O
was B-Disease
patients O
result O
in O
frames O
##hi O
##fted O
trans O
##cript O
and O
premature O
translation O
termination O
. O

these O
findings O
therefore O
confirm O
the O
association O
of O
was B-Disease
with O
was O
##p O
mutation O
and O
identify O
was O
##p O
mutation O
as O
a O
cause O
for O
isolated O
con B-Disease
##gen I-Disease
##ital I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
in O
males O
. O

while O
the O
was O
##p O
gene O
defects O
responsible O
for O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
and O
other O
mild O
presentations O
of O
was B-Disease
do O
not O
appear O
distinct O
from O
those O
resulting O
in O
severe O
was B-Disease
, O
these O
data O
indicate O
that O
analysis O
of O
was O
##p O
gene O
mutation O
provides O
a O
valuable O
tool O
for O
distinguishing O
the O
spectrum O
of O
was B-Disease
patients O
and O
the O
subset O
of O
males O
with O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
who O
represent O
mild O
cases O
of O
was B-Disease
. O
. O

was O
##p O
gene O
mutations O
in O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
and O
x B-Disease
- I-Disease
linked I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

the O
was O
##p O
gene O
has O
been O
recently O
clone O
##d O
from O
x O
##p O
##11 O
. O

23 O
and O
shown O
to O
be O
m O
##uta O
##ted O
in O
three O
patients O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

we O
have O
developed O
a O
screening O
protocol O
for O
identifying O
was O
##p O
gene O
alterations O
in O
g O
##eno O
##mic O
d O
##na O
and O
have O
identified O
a O
spectrum O
of O
novel O
mutations O
in O
12 O
additional O
unrelated O
families O
. O

these O
miss O
##ense O
, O
nonsense O
and O
frames O
##hi O
##ft O
mutations O
involve O
eight O
of O
the O
12 O
ex O
##ons O
of O
the O
gene O
. O

two O
mutations O
creating O
premature O
termination O
co O
##don O
##s O
were O
associated O
with O
lack O
of O
detect O
##able O
m O
##rna O
on O
northern O
b O
##lot O
##s O
. O

four O
amino O
acid O
substitution O
##s O
, O
le O
##u O
##27 O
##phe O
, O
th O
##r O
##48 O
##ile O
, O
v O
##al O
##75 O
##met O
and O
a O
##rg O
##47 O
##7 O
##ly O
##s O
, O
were O
found O
in O
patients O
with O
con B-Disease
##gen I-Disease
##ital I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
and O
no O
clinical O
##ly O
evident O
immune O
defect O
indicating O
that O
the O
was O
##p O
gene O
is O
the O
site O
for O
mutations O
in O
x B-Disease
- I-Disease
linked I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
as O
well O
as O
in O
was B-Disease
. O

a O
t O
- O
cell O
line O
from O
a O
was B-Disease
patient O
contained O
two O
independent O
d O
##na O
alterations O
, O
a O
constitutional O
frames O
##hi O
##ft O
mutation O
, O
also O
present O
in O
peripheral O
blood O
le O
##uk O
##ocytes O
from O
the O
patient O
, O
and O
com O
##pen O
##sat O
##ory O
s O
##p O
##lice O
site O
mutation O
unique O
to O
the O
cell O
line O
. O

the O
distribution O
of O
eight O
miss O
##ense O
mutations O
provides O
valuable O
information O
on O
amino O
acids O
which O
are O
essential O
for O
normal O
protein O
function O
, O
and O
suggests O
that O
sites O
in O
the O
first O
two O
ex O
##ons O
are O
hot O
- O
spots O
for O
mutation O
. O

evidence O
for O
inter O
- O
generation O
##al O
instability O
in O
the O
ca O
##g O
repeat O
in O
the O
m O
##j O
##d O
##1 O
gene O
and O
for O
conserved O
ha O
##p O
##lot O
##ype O
##s O
at O
flank O
##ing O
markers O
amongst O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
subjects O
with O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
. O

the O
size O
of O
the O
( O
ca O
##g O
) O
n O
repeat O
array O
in O
the O
3 O
' O
end O
of O
the O
m O
##j O
##d O
##1 O
gene O
and O
the O
ha O
##p O
##lot O
##ype O
at O
a O
series O
of O
micro O
##sat O
##elli O
##te O
markers O
surrounding O
the O
m O
##j O
##d O
##1 O
gene O
were O
examined O
in O
a O
large O
co O
##hor O
##t O
of O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
subjects O
affected O
with O
mac B-Disease
##had I-Disease
##o I-Disease
- I-Disease
j I-Disease
##ose I-Disease
##ph I-Disease
disease I-Disease
( O
m B-Disease
##j I-Disease
##d I-Disease
) O
. O

our O
data O
provide O
five O
novel O
observations O
. O

first O
, O
m B-Disease
##j I-Disease
##d I-Disease
is O
associated O
with O
expansion O
f O
##o O
the O
array O
from O
the O
normal O
range O
of O
14 O
- O
37 O
repeats O
to O
68 O
- O
84 O
repeats O
in O
most O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
subjects O
, O
but O
no O
subjects O
were O
observed O
with O
expansion O
##s O
intermediate O
in O
size O
between O
those O
of O
the O
normal O
and O
m B-Disease
##j I-Disease
##d I-Disease
affected O
groups O
. O

second O
, O
the O
expanded O
all O
##ele O
associated O
with O
m B-Disease
##j I-Disease
##d I-Disease
displays O
inter O
- O
generation O
##al O
instability O
, O
particularly O
in O
male O
me O
##ios O
##es O
, O
and O
this O
instability O
was O
associated O
with O
the O
clinical O
phenomenon O
of O
anticipation O
. O

third O
, O
the O
size O
of O
the O
expanded O
all O
##ele O
is O
not O
only O
inverse O
##ly O
correlated O
with O
the O
age O
- O
of O
- O
onset O
of O
m B-Disease
##j I-Disease
##d I-Disease
( O
r O
= O
- O
0 O
. O
73 O
##8 O
, O
p O
[UNK] O
0 O
. O
00 O
##1 O
) O
, O
but O
is O
also O
correlated O
with O
the O
frequency O
of O
other O
clinical O
features O
[ O
e O
. O
g O
. O
pseudo O
##ex O
##op O
##ht O
##hal O
##mos O
and O
pyramid O
##al O
signs O
were O
more O
frequent O
in O
subjects O
with O
large O
repeats O
( O
p O
[UNK] O
0 O
. O
00 O
##1 O
and O
p O
[UNK] O
0 O
. O
05 O
respectively O
) O
] O
. O

fourth O
, O
the O
disease O
p O
##hen O
##otype O
is O
significantly O
more O
severe O
and O
had O
an O
early O
age O
of O
onset O
( O
16 O
years O
) O
in O
a O
subject O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
expanded O
all O
##ele O
, O
which O
contrasts O
with O
hunting B-Disease
##ton I-Disease
disease I-Disease
and O
suggests O
that O
the O
expanded O
all O
##ele O
in O
the O
m O
##j O
##d O
##1 O
gene O
could O
ex O
##ert O
its O
effect O
either O
by O
a O
dominant O
negative O
effect O
( O
put O
##ative O
##ly O
excluded O
in O
h B-Disease
##d I-Disease
) O
or O
by O
a O
gain O
of O
function O
effect O
as O
proposed O
for O
h B-Disease
##d I-Disease
. O

finally O
, O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
subjects O
affected O
with O
m B-Disease
##j I-Disease
##d I-Disease
share O
ha O
##p O
##lot O
##ype O
##s O
at O
several O
markers O
surrounding O
the O
m O
##j O
##d O
##1 O
gene O
, O
which O
are O
uncommon O
in O
the O
normal O
j O
##apa O
##nese O
and O
ca O
##uca O
##sian O
population O
, O
and O
which O
suggests O
the O
existence O
either O
of O
common O
founders O
in O
these O
populations O
or O
of O
chromosome O
##s O
susceptible O
to O
path O
##olo O
##gic O
expansion O
of O
the O
ca O
##g O
repeat O
in O
the O
m O
##j O
##d O
##1 O
gene O
. O

a O
4 O
- O
me O
##ga O
##base O
ya O
##c O
con O
##ti O
##g O
that O
spans O
the O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
region O
on O
human O
chromosome O
8 O
##q O
##24 O
. O
1 O
: O
use O
in O
re O
##fining O
the O
location O
of O
the O
t B-Disease
##rich I-Disease
##or I-Disease
##hino I-Disease
##pha I-Disease
##lang I-Disease
##eal I-Disease
syndrome I-Disease
and O
multiple O
ex O
##ost O
##ose O
##s O
genes O
( O
t O
##rp O
##s O
##1 O
and O
ex O
##t O
##1 O
) O
. O

we O
have O
constructed O
a O
physical O
map O
covering O
over O
4 O
m O
##b O
of O
human O
chromosome O
8 O
##q O
##24 O
. O

1 O
and O
used O
this O
map O
to O
re O
##fine O
the O
locations O
of O
the O
genes O
responsible O
for O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
. O

the O
map O
is O
composed O
of O
overlapping O
ya O
##c O
clone O
##s O
that O
were O
identified O
and O
ordered O
in O
relation O
to O
sequence O
tag O
##ged O
sites O
mapped O
to O
the O
la O
##nger O
- O
g O
##ied O
##ion O
ch O
##rom O
##oso O
##mal O
region O
on O
so O
##matic O
cell O
hybrid O
##s O
. O

the O
minimal O
region O
of O
overlap O
of O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
del O
##eti O
##ons O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
del O
##eti O
##ons O
define O
the O
end O
##points O
. O

the O
chromosome O
8 O
break O
##point O
of O
a O
balanced O
t O
( O
8 O
; O
9 O
) O
( O
q O
##24 O
. O
11 O
; O
q O
##33 O
. O
3 O
) O
trans O
##location O
from O
a O
patient O
with O
t B-Disease
##rich I-Disease
##or I-Disease
##hino I-Disease
##pha I-Disease
##lang I-Disease
##eal I-Disease
syndrome I-Disease
( O
t B-Disease
##rp I-Disease
##s I-Disease
i O
) O
was O
found O
to O
be O
located O
just O
within O
the O
pro O
##ximal O
end O
of O
the O
minimal O
del O
##eti O
##on O
region O
. O

a O
del O
##eti O
##on O
of O
8 O
##q O
##24 O
. O

11 O
- O
q O
##24 O
. O

3 O
in O
a O
patient O
with O
multiple O
ex O
##ost O
##ose O
##s O
was O
found O
to O
overlap O
the O
di O
##stal O
end O
of O
the O
l B-Disease
##gs I-Disease
del O
##eti O
##on O
region O
, O
indicating O
that O
the O
ex O
##t O
##1 O
gene O
is O
di O
##stal O
to O
the O
t O
##rp O
##s O
##1 O
gene O
and O
supporting O
the O
hypothesis O
that O
la B-Disease
##nger I-Disease
- I-Disease
g I-Disease
##ied I-Disease
##ion I-Disease
syndrome I-Disease
is O
due O
to O
loss O
of O
functional O
copies O
of O
both O
the O
t O
##rp O
##s O
##1 O
and O
the O
ex O
##t O
##1 O
genes O

br O
##ca O
##1 O
mutations O
in O
a O
population O
- O
based O
sample O
of O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

background O
. O

inherited O
mutations O
in O
the O
br O
##ca O
##1 O
gene O
are O
associated O
with O
a O
high O
risk O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
some O
families O
. O

however O
, O
little O
is O
known O
about O
the O
contribution O
of O
br O
##ca O
##1 O
mutations O
to O
breast B-Disease
cancer I-Disease
in O
the O
general O
population O
. O

we O
analyzed O
d O
##na O
samples O
from O
women O
enrolled O
in O
a O
population O
- O
based O
study O
of O
early O
- O
onset O
breast B-Disease
cancer I-Disease
to O
assess O
the O
spectrum O
and O
frequency O
of O
g O
##er O
##m O
- O
line O
br O
##ca O
##1 O
mutations O
in O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

methods O
. O

we O
studied O
80 O
women O
in O
whom O
breast B-Disease
cancer I-Disease
was O
diagnosed O
before O
the O
age O
of O
35 O
, O
and O
who O
were O
not O
selected O
on O
the O
basis O
of O
family O
history O
. O

g O
##eno O
##mic O
d O
##na O
was O
studied O
for O
br O
##ca O
##1 O
mutations O
by O
analysis O
involving O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
##s O
and O
with O
all O
##ele O
- O
specific O
ass O
##ays O
. O

alterations O
were O
defined O
by O
d O
##na O
se O
##quencing O
. O

results O
. O

g O
##er O
##m O
- O
line O
br O
##ca O
##1 O
mutations O
were O
identified O
in O
6 O
of O
the O
80 O
women O
. O

four O
additional O
rare O
sequence O
variants O
of O
unknown O
functional O
importance O
were O
also O
identified O
. O

two O
of O
the O
mutations O
and O
three O
of O
the O
rare O
sequence O
variants O
were O
found O
among O
the O
39 O
women O
who O
reported O
no O
family O
history O
of O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

none O
of O
the O
mutations O
and O
only O
one O
of O
the O
rare O
variants O
was O
identified O
in O
a O
reference O
population O
of O
73 O
unrelated O
subjects O
. O

conclusions O
. O

alterations O
in O
br O
##ca O
##1 O
were O
identified O
in O
approximately O
10 O
percent O
of O
this O
co O
##hor O
##t O
of O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

the O
risk O
of O
harbor O
##ing O
a O
mutation O
was O
not O
limited O
to O
women O
with O
family O
histories O
of O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

these O
results O
represent O
a O
minimal O
estimate O
of O
the O
frequency O
of O
br O
##ca O
##1 O
mutations O
in O
this O
population O
. O

comprehensive O
methods O
of O
identifying O
br O
##ca O
##1 O
mutations O
and O
understanding O
their O
importance O
will O
be O
needed O
before O
testing O
of O
women O
in O
the O
general O
population O
can O
be O
undertaken O
. O
. O

novel O
inherited O
mutations O
and O
variable O
express O
##ivity O
of O
br O
##ca O
##1 O
all O
##ele O
##s O
, O
including O
the O
founder O
mutation O
185 O
##dela O
##g O
in O
ash O
##ken O
##azi O
j O
##ew O
##ish O
families O
. O

thirty O
- O
seven O
families O
with O
four O
or O
more O
cases O
of O
breast B-Disease
cancer I-Disease
or O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
were O
analyzed O
for O
mutations O
in O
br O
##ca O
##1 O
. O

twelve O
different O
g O
##er O
##m O
- O
line O
mutations O
, O
four O
novel O
and O
eight O
previously O
observed O
, O
were O
detected O
in O
16 O
families O
. O

five O
families O
of O
ash O
##ken O
##azi O
j O
##ew O
##ish O
descent O
carried O
the O
185 O
##dela O
##g O
mutation O
and O
shared O
the O
same O
ha O
##p O
##lot O
##ype O
at O
eight O
p O
##oly O
##morphic O
markers O
spanning O
approximately O
850 O
k O
##b O
at O
br O
##ca O
##1 O
. O

express O
##ivity O
of O
185 O
##dela O
##g O
in O
these O
families O
varied O
, O
from O
early O
- O
onset O
breast B-Disease
cancer I-Disease
without O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

mutation O
41 O
##8 O
##4 O
##del O
##t O
##ca O
##a O
occurred O
independently O
in O
two O
families O
. O

in O
one O
family O
, O
pen O
##et O
##rance O
was O
complete O
, O
with O
females O
developing O
early O
- O
onset O
breast B-Disease
cancer I-Disease
or O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
the O
male O
carrier O
developing O
pro B-Disease
##static I-Disease
cancer I-Disease
, O
whereas O
, O
in O
the O
other O
family O
, O
pen O
##et O
##rance O
was O
incomplete O
and O
only O
breast B-Disease
cancer I-Disease
occurred O
, O
diagnosed O
at O
ages O
38 O
- O
81 O
years O
. O

two O
novel O
nonsense O
mutations O
led O
to O
the O
loss O
of O
mutant O
br O
##ca O
##1 O
trans O
##cript O
in O
families O
with O
10 O
and O
6 O
cases O
of O
early O
- O
onset O
breast B-Disease
cancer I-Disease
and O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

a O
66 O
##5 O
- O
n O
##t O
segment O
of O
the O
br O
##ca O
##1 O
3 O
- O
u O
##tr O
and O
1 O
. O

3 O
k O
##b O
of O
g O
##eno O
##mic O
sequence O
including O
the O
put O
##ative O
promoter O
region O
were O
invariant O
by O
single O
- O
strand O
conform O
##ation O
analysis O
in O
13 O
families O
without O
coding O
- O
sequence O
mutations O
. O

overall O
in O
our O
series O
, O
br O
##ca O
##1 O
mutations O
have O
been O
detected O
in O
26 O
families O
16 O
with O
positive O
br O
##ca O
##1 O
lo O
##d O
scores O
, O
7 O
with O
negative O
lo O
##d O
scores O
( O
reflecting O
multiple O
s O
##poradic O
breast B-Disease
cancer I-Disease
##s I-Disease
) O
, O
and O
3 O
not O
tested O
for O
link O
##age O
. O

three O
other O
families O
have O
positive O
lo O
##d O
scores O
for O
link O
##age O
to O
br O
##ca O
##2 O
, O
but O
13 O
families O
without O
detected O
br O
##ca O
##1 O
mutations O
have O
negative O
lo O
##d O
scores O
for O
both O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
variant O
, O
g O
##6 O
##p O
##d O
or O
##issa O
( O
44 O
al O
##a O
- O
- O
[UNK] O
g O
##ly O
) O
, O
is O
the O
major O
p O
##oly O
##morphic O
variant O
in O
tribal O
populations O
in O
in O
##dia O
. O

deficiency B-Disease
of I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( O
g O
##6 O
##p O
##d O
) O
is O
usually O
found O
at O
high O
frequencies O
in O
areas O
of O
the O
world O
where O
malaria B-Disease
has O
been O
endemic O
. O

the O
frequency O
and O
genetic O
basis O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
have O
been O
studied O
in O
a O
##f O
##rica O
, O
around O
the O
me O
##dit O
##er O
##rane O
##an O
, O
and O
in O
the O
far O
east O
, O
but O
little O
such O
information O
is O
available O
about O
the O
situation O
in O
in O
##dia O
. O

to O
determine O
the O
extent O
of O
he O
##tero O
##gene O
##ity O
of O
g O
##6 O
##p O
##d O
, O
we O
have O
studied O
several O
different O
in O
##dian O
populations O
by O
screening O
for O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
followed O
by O
molecular O
analysis O
of O
def O
##icient O
all O
##ele O
##s O
. O

the O
frequency O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
varies O
between O
3 O
% O
and O
15 O
% O
in O
different O
tribal O
and O
urban O
groups O
. O

remarkably O
, O
a O
previously O
un O
##re O
##port O
##ed O
def O
##icient O
variant O
, O
g O
##6 O
##p O
##d O
or O
##issa O
( O
44 O
al O
##a O
- O
- O
[UNK] O
g O
##ly O
) O
, O
is O
responsible O
for O
most O
of O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
in O
tribal O
in O
##dian O
populations O
but O
is O
not O
found O
in O
urban O
populations O
, O
where O
most O
of O
the O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
is O
due O
to O
the O
g O
##6 O
##p O
##d O
me O
##dit O
##er O
##rane O
##an O
( O
188 O
se O
##r O
- O
- O
[UNK] O
p O
##he O
) O
variant O
. O

the O
km O
##na O
##d O
##p O
of O
g O
##6 O
##p O
##d O
or O
##issa O
is O
five O
##fold O
higher O
than O
that O
of O
the O
normal O
enzyme O
. O

this O
may O
be O
due O
to O
the O
fact O
that O
the O
al O
##ani O
##ne O
residue O
that O
is O
replaced O
by O
g O
##ly O
##cine O
is O
part O
of O
a O
put O
##ative O
co O
##en O
##zy O
##me O
- O
binding O
site O
. O
. O

evidence O
for O
link O
##age O
of O
bi B-Disease
##pol I-Disease
##ar I-Disease
disorder I-Disease
to O
chromosome O
18 O
with O
a O
parent O
- O
of O
- O
origin O
effect O
. O

a O
su O
##s O
##ce O
##pt O
##ibility O
gene O
on O
chromosome O
18 O
and O
a O
parent O
- O
of O
- O
origin O
effect O
have O
been O
suggested O
for O
bi B-Disease
##pol I-Disease
##ar I-Disease
affect I-Disease
##ive I-Disease
disorder I-Disease
( O
b B-Disease
##pad I-Disease
) O
. O

we O
have O
studied O
28 O
nuclear O
families O
selected O
for O
apparent O
un O
##ili O
##nea O
##l O
transmission O
of O
the O
b B-Disease
##pad I-Disease
p O
##hen O
##otype O
, O
by O
using O
31 O
p O
##oly O
##morphic O
markers O
spanning O
chromosome O
18 O
. O

evidence O
for O
link O
##age O
was O
tested O
with O
affected O
- O
si O
##b O
- O
pair O
and O
lo O
##d O
score O
methods O
under O
two O
definitions O
of O
the O
affected O
p O
##hen O
##otype O
. O

the O
affected O
- O
si O
##b O
##pair O
analyses O
indicated O
excess O
all O
##ele O
sharing O
for O
markers O
on O
18 O
##p O
within O
the O
region O
reported O
previously O
. O

the O
greatest O
sharing O
was O
at O
d O
##18 O
##s O
##37 O
64 O
% O
in O
bi O
##pol O
##ar O
and O
re O
##current O
un O
##ip O
##olar O
( O
r O
##up O
) O
si O
##b O
pairs O
( O
p O
= O
. O
000 O
##6 O
) O
. O

in O
addition O
, O
excess O
sharing O
of O
the O
paternal O
##ly O
, O
but O
not O
maternal O
##ly O
, O
transmitted O
all O
##ele O
##s O
was O
observed O
at O
three O
markers O
on O
18 O
##q O
at O
d O
##18 O
##s O
##41 O
, O
51 O
bi O
##pol O
##ar O
and O
r O
##up O
si O
##b O
pairs O
were O
con O
##cor O
##dant O
for O
paternal O
##ly O
transmitted O
all O
##ele O
##s O
, O
and O
21 O
pairs O
were O
disco O
##rda O
##nt O
( O
p O
= O
000 O
##4 O
) O
. O

the O
evidence O
for O
link O
##age O
to O
lo O
##ci O
on O
both O
18 O
##p O
and O
18 O
##q O
was O
strongest O
in O
the O
11 O
paternal O
p O
##ed O
##ig O
##ree O
##s O
, O
i O
. O

e O
e O
. O
, O
those O
in O
which O
the O
father O
or O
one O
of O
the O
fathers O
si O
##bs O
is O
affected O
. O

in O
these O
p O
##ed O
##ig O
##ree O
##s O
, O
the O
greatest O
all O
##ele O
sharing O
( O
81 O
% O
; O
p O
= O
. O
000 O
##0 O
##2 O
) O
and O
the O
highest O
lo O
##d O
score O
( O
3 O
. O
51 O
; O
p O
##hi O
= O
0 O
. O
0 O
) O
were O
observed O
at O
d O
##18 O
##s O
##41 O
. O

our O
results O
provide O
further O
support O
for O
link O
##age O
of O
b B-Disease
##pad I-Disease
to O
chromosome O
18 O
and O
the O
first O
molecular O
evidence O
for O
a O
parent O
- O
of O
- O
origin O
effect O
operating O
in O
this O
disorder O
. O

the O
number O
of O
lo O
##ci O
involved O
, O
and O
their O
precise O
location O
, O
require O
further O
study O

a O
prevalent O
mutation O
for O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
among O
black O
am O
##eric O
##ans O
. O

objective O
to O
define O
the O
mutation O
causing O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
in O
patients O
of O
black O
am O
##eric O
##an O
origin O
who O
have O
no O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
gal O
##t O
) O
activity O
in O
er O
##yt O
##hr O
##ocytes O
but O
good O
clinical O
outcome O
. O

methods O
we O
discovered O
a O
mutation O
caused O
by O
a O
c O
- O
- O
[UNK] O
t O
transition O
at O
base O
- O
pair O
115 O
##8 O
of O
the O
gal O
##t O
gene O
that O
results O
in O
a O
se O
##rine O
- O
to O
- O
le O
##uc O
##ine O
substitution O
at O
co O
##don O
135 O
( O
s O
##13 O
##5 O
##l O
) O
. O

we O
developed O
a O
method O
with O
which O
to O
screen O
populations O
for O
its O
prevalence O
. O

we O
compared O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
among O
er O
##yt O
##hr O
##ocytes O
, O
le O
##uk O
##ocytes O
, O
and O
transformed O
l O
##ymph O
##ob O
##last O
##s O
, O
as O
well O
as O
total O
body O
oxidation O
of O
d O
- O
( O
13 O
##c O
) O
- O
gal O
##act O
##ose O
to O
13 O
##co O
##2 O
among O
three O
g O
##eno O
##type O
##s O
for O
gal O
##t O
( O
s O
##13 O
##5 O
##l O
/ O
s O
##13 O
##5 O
##l O
, O
q O
##18 O
##8 O
##r O
/ O
q O
##18 O
##8 O
##r O
, O
and O
normal O
/ O
normal O
) O
. O

results O
we O
found O
a O
48 O
% O
prevalence O
of O
the O
s O
##13 O
##5 O
##l O
mutation O
among O
17 O
black O
am O
##eric O
##an O
patients O
with O
classic B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
and O
a O
1 O
% O
prevalence O
in O
a O
population O
of O
50 O
black O
am O
##eric O
##ans O
without O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
. O

the O
s O
##13 O
##5 O
##l O
mutation O
was O
not O
found O
in O
84 O
white O
patients O
with O
g O
/ O
g O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
nor O
in O
87 O
white O
control O
subjects O
without O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
. O

we O
found O
normal O
whole O
body O
oxidation O
of O
d O
- O
( O
13 O
##c O
) O
- O
gal O
##act O
##ose O
by O
the O
patient O
ho O
##mo O
##zy O
##go O
##us O
for O
s O
##13 O
##5 O
##l O
and O
various O
degrees O
of O
enzyme O
imp O
##air O
##ment O
among O
different O
tissues O
. O

conclusions O
the O
s O
##13 O
##5 O
##l O
mutation O
in O
the O
gal O
##t O
gene O
is O
a O
prevalent O
cause O
of O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
among O
black O
patients O
. O

because O
gal O
##t O
activity O
varies O
in O
different O
tissues O
of O
patients O
ho O
##mo O
##zy O
##go O
##us O
for O
s O
##13 O
##5 O
##l O
, O
they O
may O
have O
a O
better O
clinical O
outcome O
than O
patients O
who O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
q O
##18 O
##8 O
##r O
when O
both O
are O
treated O
from O
infancy O
. O
. O

a O
high O
incidence O
of O
br O
##ca O
##1 O
mutations O
in O
20 O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

we O
have O
analyzed O
20 O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
, O
the O
majority O
of O
which O
show O
positive O
evidence O
of O
link O
##age O
to O
chromosome O
17 O
##q O
##12 O
for O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
br O
##ca O
##1 O
gene O
. O

br O
##ca O
##1 O
mutations O
co O
##se O
##g O
##re O
##gating O
with O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
were O
identified O
in O
16 O
families O
, O
including O
1 O
family O
with O
a O
case O
of O
male B-Disease
breast I-Disease
cancer I-Disease
. O

nine O
of O
these O
mutations O
have O
not O
been O
reported O
previously O
. O

the O
majority O
of O
mutations O
were O
found O
to O
generate O
a O
premature O
stop O
co O
##don O
leading O
to O
the O
formation O
of O
a O
t O
##runcated O
br O
##ca O
##1 O
protein O
of O
2 O
% O
- O
88 O
% O
of O
the O
expected O
normal O
length O
. O

two O
mutations O
altered O
the O
ring O
finger O
domain O
. O

se O
##quencing O
of O
g O
##eno O
##mic O
d O
##na O
led O
to O
the O
identification O
of O
a O
mutation O
in O
the O
coding O
region O
of O
br O
##ca O
##1 O
in O
12 O
families O
, O
and O
c O
##dn O
##a O
analysis O
revealed O
an O
abnormal O
or O
missing O
br O
##ca O
##1 O
trans O
##cript O
in O
4 O
of O
the O
8 O
remaining O
families O
. O

a O
total O
of O
eight O
mutations O
were O
associated O
with O
a O
reduced O
quantity O
of O
br O
##ca O
##1 O
trans O
##cript O
. O

we O
were O
unable O
to O
detect O
br O
##ca O
##1 O
mutations O
in O
4 O
of O
the O
20 O
families O
, O
but O
only O
1 O
of O
these O
was O
clearly O
linked O
to O
br O
##ca O
##1 O
. O

it O
is O
expected O
that O
the O
majority O
of O
clear O
examples O
of O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
syndrome I-Disease
will O
be O
associated O
with O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
coding O
region O
of O
br O
##ca O
##1 O
. O
. O

br B-Disease
##ca I-Disease
##1 I-Disease
deficiency I-Disease
results O
in O
early O
em B-Disease
##b I-Disease
##ryo I-Disease
##nic I-Disease
lethal I-Disease
##ity I-Disease
characterized O
by O
ne B-Disease
##uro I-Disease
##ep I-Disease
##ith I-Disease
##eli I-Disease
##al I-Disease
abnormal I-Disease
##ities I-Disease
. O

the O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
, O
br O
##ca O
##1 O
, O
has O
been O
clone O
##d O
and O
shown O
to O
en O
##code O
a O
zinc O
- O
finger O
protein O
of O
unknown O
function O
. O

mutations O
in O
br O
##ca O
##1 O
account O
for O
at O
least O
80 O
% O
of O
families O
with O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
as O
well O
as O
some O
non O
- O
f O
##ami O
##lial O
s O
##poradic O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

the O
loss O
of O
wild O
- O
type O
br O
##ca O
##1 O
in O
t B-Disease
##umour I-Disease
##s I-Disease
of O
individuals O
carrying O
one O
non O
##function O
##al O
br O
##ca O
##1 O
all O
##ele O
suggests O
that O
br O
##ca O
##1 O
en O
##codes O
a O
t B-Disease
##umour I-Disease
suppress O
##or O
that O
may O
in O
##hibit O
the O
proliferation O
of O
ma O
##mma O
##ry O
e O
##pit O
##hel O
##ial O
cells O
. O

to O
examine O
the O
role O
of O
br O
##ca O
##1 O
in O
normal O
tissue O
growth O
and O
differentiation O
, O
and O
to O
generate O
a O
potential O
model O
for O
the O
cancer B-Disease
su O
##s O
##ce O
##pt O
##ibility O
associated O
with O
loss O
of O
br O
##ca O
##1 O
function O
, O
we O
have O
created O
a O
mouse O
line O
carrying O
a O
mutation O
in O
one O
br O
##ca O
##1 O
all O
##ele O
. O

analysis O
of O
mice O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
mutant O
all O
##ele O
indicate O
that O
br O
##ca O
##1 O
is O
critical O
for O
normal O
development O
, O
as O
these O
mice O
died O
in O
u O
##tero O
between O
10 O
and O
13 O
days O
of O
g O
##esta O
##tion O
( O
e O
##10 O
- O
e O
##13 O
) O
. O

abnormal O
##ities O
in O
br B-Disease
##ca I-Disease
##1 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
em O
##b O
##ryo O
##s O
were O
most O
evident O
in O
the O
neural O
tube O
, O
with O
40 O
% O
of O
the O
em O
##b O
##ryo O
##s O
presenting O
with O
varying O
degrees O
of O
spin B-Disease
##a I-Disease
bi I-Disease
##fi I-Disease
##da I-Disease
and O
an B-Disease
##ence I-Disease
##pha I-Disease
##ly I-Disease
. O

in O
addition O
, O
the O
ne O
##uro O
##ep O
##ith O
##eli O
##um O
in O
br B-Disease
##ca I-Disease
##1 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
em O
##b O
##ryo O
##s O
appeared O
di O
##sor O
##ganized O
, O
with O
signs O
of O
both O
rapid O
proliferation O
and O
excessive O
cell O
death O
. O
. O

identification O
of O
mutations O
in O
the O
al O
##d O
- O
gene O
of O
20 O
families O
with O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
/ O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
. O

ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
, O
an O
x B-Disease
- I-Disease
linked I-Disease
inherited I-Disease
metabolic I-Disease
disorder I-Disease
, O
is O
the O
most O
frequent O
in B-Disease
##born I-Disease
per I-Disease
##ox I-Disease
##is I-Disease
##oma I-Disease
##l I-Disease
disease I-Disease
. O

it O
leads O
to O
dem B-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
in I-Disease
the I-Disease
central I-Disease
and I-Disease
peripheral I-Disease
nervous I-Disease
system I-Disease
. O

defect O
##ive O
beta O
- O
oxidation O
of O
saturated O
very O
long O
chain O
fatty O
acids O
( O
v O
##l O
##c O
##fa O
##s O
; O
c O
##22 O
0 O
- O
c O
##26 O
0 O
) O
in O
per O
##ox O
##is O
##ome O
##s O
has O
been O
shown O
to O
lead O
to O
an O
accumulation O
of O
v O
##l O
##c O
##fa O
##s O
in O
le O
##uk O
##oid O
areas O
of O
the O
central O
nervous O
system O
, O
peripheral O
nerves O
, O
ad O
##rena O
##l O
g O
##land O
, O
and O
blood O
. O

the O
al B-Disease
##d I-Disease
gene O
has O
been O
recently O
identified O
and O
en O
##codes O
a O
74 O
##5 O
- O
amino O
- O
acid O
protein O
. O

we O
screened O
patients O
with O
ad B-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
/ O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
al B-Disease
##d I-Disease
/ O
am B-Disease
##n I-Disease
) O
from O
20 O
kind O
##red O
##s O
for O
mutations O
in O
the O
al B-Disease
##d I-Disease
gene O
. O

eleven O
miss O
##ense O
and O
two O
nonsense O
mutations O
, O
five O
del O
##eti O
##ons O
, O
and O
one O
insertion O
were O
detected O
by O
direct O
se O
##quencing O
of O
eight O
reverse O
trans O
##cribed O
fragments O
of O
the O
al B-Disease
##d I-Disease
- O
gene O
m O
##rna O
. O

four O
mutations O
could O
be O
shown O
to O
be O
de O
no O
##vo O
. O

all O
mutations O
could O
be O
confirmed O
in O
carriers O
by O
se O
##quencing O
g O
##eno O
##mic O
d O
##na O
. O

no O
correlation O
between O
the O
type O
of O
mutation O
and O
the O
severity O
of O
the O
p O
##hen O
##otype O
could O
be O
observed O
. O

the O
mutations O
were O
not O
detected O
in O
the O
al B-Disease
##d I-Disease
gene O
of O
30 O
healthy O
persons O
. O
. O

the O
m O
##uri O
##ne O
ho O
##mo O
##log O
of O
the O
human O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
br O
##ca O
##1 O
maps O
to O
mouse O
chromosome O
11 O
##d O
. O

the O
recently O
clone O
##d O
human O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
, O
br O
##ca O
##1 O
, O
is O
located O
on O
human O
chromosome O
17 O
##q O
##21 O
. O

we O
have O
isolated O
m O
##uri O
##ne O
g O
##eno O
##mic O
clone O
##s O
containing O
br O
##ca O
##1 O
as O
a O
first O
step O
in O
generating O
a O
mouse O
model O
for O
the O
loss O
of O
br O
##ca O
##1 O
function O
. O

a O
mouse O
g O
##eno O
##mic O
library O
was O
screened O
using O
probe O
##s O
corresponding O
to O
ex O
##on O
11 O
of O
the O
human O
br O
##ca O
##1 O
gene O
. O

two O
overlapping O
mouse O
clone O
##s O
were O
identified O
that O
hybrid O
##ized O
to O
human O
br O
##ca O
##1 O
ex O
##ons O
9 O
- O
12 O
. O

sequence O
analysis O
of O
1 O
. O

4 O
k O
##b O
of O
the O
region O
of O
these O
clone O
##s O
corresponding O
to O
part O
of O
human O
ex O
##on O
11 O
revealed O
72 O
% O
nuclei O
##c O
acid O
identity O
but O
only O
50 O
% O
amino O
acid O
identity O
with O
the O
human O
gene O
. O

the O
longest O
of O
the O
mouse O
br O
##ca O
##1 O
g O
##eno O
##mic O
clone O
##s O
maps O
to O
chromosome O
11 O
##d O
, O
as O
determined O
by O
two O
- O
color O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
. O

the O
s O
##yn O
##ten O
##y O
to O
human O
chromosome O
17 O
was O
confirmed O
by O
co O
##hy O
##bri O
##di O
##zation O
with O
the O
mouse O
probe O
for O
the O
n O
##f O
##1 O
- O
gene O
. O

this O
comparative O
study O
confirms O
that O
the O
relative O
location O
of O
the O
br O
##ca O
##1 O
gene O
has O
been O
conserved O
between O
mice O
and O
humans O
. O

ate B-Disease
##los I-Disease
##te I-Disease
##ogen I-Disease
##esis I-Disease
type I-Disease
ii I-Disease
is O
caused O
by O
mutations O
in O
the O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
su O
##lf O
##ate O
- O
transport O
##er O
gene O
( O
d O
##t O
##ds O
##t O
) O
: O
evidence O
for O
a O
p O
##hen O
##otypic O
series O
involving O
three O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
. O

ate B-Disease
##los I-Disease
##te I-Disease
##ogen I-Disease
##esis I-Disease
type I-Disease
ii I-Disease
( O
a B-Disease
##o I-Disease
ii I-Disease
) O
is O
a O
neon O
##ata O
##lly O
lethal O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
whose O
clinical O
and O
his O
##to O
##logical O
characteristics O
resemble O
those O
of O
another O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
the O
much O
less O
severe O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
( O
d B-Disease
##t I-Disease
##d I-Disease
) O
. O

the O
similarity O
suggests O
a O
shared O
path O
##ogen O
##esis O
involving O
lesions O
in O
the O
same O
bio O
##chemical O
pathway O
and O
perhaps O
the O
same O
gene O
. O

d B-Disease
##t I-Disease
##d I-Disease
is O
caused O
by O
mutations O
in O
the O
recently O
identified O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
su O
##lf O
##ate O
- O
transport O
##er O
gene O
( O
d O
##t O
##ds O
##t O
) O
. O

here O
, O
we O
report O
that O
a B-Disease
##oi I-Disease
##i I-Disease
patients O
also O
have O
d O
##t O
##ds O
##t O
mutations O
, O
which O
lead O
to O
defect O
##ive O
up O
##take O
of O
in O
##or O
##gan O
##ic O
su O
##lf O
##ate O
and O
insufficient O
su O
##lf O
##ation O
of O
mac O
##rom O
##ole O
##cule O
##s O
by O
patient O
me O
##sen O
##chy O
##mal O
cells O
in O
v O
##it O
##ro O
. O

together O
with O
our O
recent O
observation O
that O
a O
third O
even O
more O
severe O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
a O
##cho O
##nd O
##rogen O
##esis O
type O
i O
##b O
, O
is O
also O
caused O
by O
mutations O
in O
d O
##t O
##ds O
##t O
, O
these O
results O
demonstrate O
a O
p O
##hen O
##otypic O
series O
of O
three O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
of O
increasing O
severity O
caused O
by O
lesions O
in O
a O
single O
su O
##lf O
##ate O
- O
transport O
##er O
gene O
. O

the O
severity O
of O
the O
p O
##hen O
##otype O
appears O
to O
be O
correlated O
with O
the O
predicted O
effect O
of O
the O
mutations O
on O
the O
residual O
activity O
of O
the O
d O
##t O
##ds O
##t O
protein O
. O
. O

ha O
##p O
##lot O
##ype O
and O
p O
##hen O
##otype O
analysis O
of O
six O
re O
##current O
br O
##ca O
##1 O
mutations O
in O
61 O
families O
: O
results O
of O
an O
international O
study O
. O

several O
br O
##ca O
##1 O
mutations O
have O
now O
been O
found O
to O
occur O
in O
geographically O
diverse O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

to O
investigate O
mutation O
origin O
and O
mutation O
- O
specific O
p O
##hen O
##otype O
##s O
due O
to O
br O
##ca O
##1 O
, O
we O
constructed O
a O
ha O
##p O
##lot O
##ype O
of O
nine O
p O
##oly O
##morphic O
markers O
within O
or O
immediately O
flank O
##ing O
the O
br O
##ca O
##1 O
lo O
##cus O
in O
a O
set O
of O
61 O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
selected O
for O
having O
one O
of O
six O
re O
##current O
br O
##ca O
##1 O
mutations O
. O

tests O
of O
both O
mutations O
and O
family O
- O
specific O
differences O
in O
age O
at O
diagnosis O
were O
not O
significant O
. O

a O
comparison O
of O
the O
six O
mutations O
in O
the O
relative O
proportions O
of O
cases O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
was O
suggest O
##ive O
of O
an O
effect O
( O
p O
= O
. O
06 O
##9 O
) O
, O
with O
57 O
% O
of O
women O
presumed O
affected O
because O
of O
the O
129 O
##4 O
del O
40 O
br O
##ca O
##1 O
mutation O
having O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
compared O
with O
14 O
% O
of O
affected O
women O
with O
the O
s O
##p O
##lice O
- O
site O
mutation O
in O
intro O
##n O
5 O
of O
br O
##ca O
##1 O
. O

for O
the O
br O
##ca O
##1 O
mutations O
studied O
here O
, O
the O
individual O
mutations O
are O
estimated O
to O
have O
arise O
##n O
9 O
- O
170 O
generations O
ago O
. O

in O
general O
, O
a O
high O
degree O
of O
ha O
##p O
##lot O
##ype O
conservation O
across O
the O
region O
was O
observed O
, O
with O
ha O
##p O
##lot O
##ype O
differences O
most O
often O
due O
to O
mutations O
in O
the O
short O
- O
tandem O
- O
repeat O
markers O
, O
although O
some O
likely O
instances O
of O
re O
##comb O
##ination O
also O
were O
observed O
. O

for O
several O
of O
the O
instances O
, O
there O
was O
evidence O
for O
multiple O
, O
independent O
, O
br O
##ca O
##1 O
mutation O
##al O
events O
. O

isolation O
of O
the O
mouse O
ho O
##mo O
##logue O
of O
br O
##ca O
##1 O
and O
genetic O
mapping O
to O
mouse O
chromosome O
11 O
. O

the O
br O
##ca O
##1 O
gene O
is O
in O
large O
part O
responsible O
for O
hereditary B-Disease
human I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

here O
we O
report O
the O
isolation O
of O
the O
m O
##uri O
##ne O
br O
##ca O
##1 O
ho O
##mo O
##logue O
c O
##dn O
##a O
clone O
##s O
. O

in O
addition O
, O
we O
identified O
g O
##eno O
##mic O
p O
##1 O
clone O
##s O
that O
contain O
most O
, O
if O
not O
all O
, O
of O
the O
mouse O
br O
##ca O
##1 O
lo O
##cus O
. O

d O
##na O
sequence O
analysis O
revealed O
that O
the O
mouse O
and O
human O
coding O
regions O
are O
75 O
% O
identical O
at O
the O
n O
##uc O
##leo O
##tide O
level O
while O
the O
predicted O
amino O
acid O
identity O
is O
only O
58 O
% O
. O

a O
d O
##na O
sequence O
variant O
in O
the O
br O
##ca O
##1 O
lo O
##cus O
was O
identified O
and O
used O
to O
map O
this O
gene O
on O
a O
( O
m O
##us O
m O
. O
m O
##us O
##culus O
c O
##ze O
##ch O
ii O
x O
c O
##5 O
##7 O
##b O
##l O
/ O
k O
##s O
##j O
) O
f O
##1 O
x O
c O
##5 O
##7 O
##b O
##l O
/ O
k O
##s O
##j O
inter O
##su O
##bs O
##pecific O
back O
##cross O
to O
di O
##stal O
mouse O
chromosome O
11 O
. O

the O
mapping O
of O
this O
gene O
to O
a O
region O
highly O
s O
##yn O
##ten O
##ic O
with O
human O
chromosome O
17 O
, O
coupled O
with O
southern O
and O
northern O
analyses O
, O
confirms O
that O
we O
isolated O
the O
m O
##uri O
##ne O
br O
##ca O
##1 O
ho O
##mo O
##logue O
rather O
than O
a O
related O
ring O
finger O
gene O
. O

the O
isolation O
of O
the O
mouse O
br O
##ca O
##1 O
ho O
##mo O
##logue O
will O
facilitate O
the O
creation O
of O
mouse O
models O
for O
g O
##er O
##m O
##line O
br B-Disease
##ca I-Disease
##1 I-Disease
defects I-Disease
. O
. O

em B-Disease
##eri I-Disease
##n I-Disease
deficiency I-Disease
at O
the O
nuclear O
membrane O
in O
patients O
with O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
. O

mutations O
in O
the O
s O
##ta O
gene O
at O
the O
x O
##q O
##28 O
lo O
##cus O
have O
been O
found O
in O
patients O
with O
x B-Disease
- I-Disease
linked I-Disease
em I-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
ed B-Disease
##m I-Disease
##d I-Disease
) O
. O

this O
gene O
en O
##codes O
a O
hit O
##her O
##to O
unknown O
protein O
named O
em O
##eri O
##n O
. O

to O
el O
##uc O
##ida O
##te O
the O
sub O
##cellular O
local O
##ization O
of O
em O
##eri O
##n O
, O
we O
raised O
two O
anti O
##ser O
##a O
against O
synthetic O
p O
##eptide O
fragments O
predicted O
from O
em O
##eri O
##n O
c O
##dn O
##a O
. O

using O
both O
anti O
##ser O
##a O
, O
we O
found O
positive O
nuclear O
membrane O
stain O
##ing O
in O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
in O
the O
normal O
controls O
and O
in O
patients O
with O
ne B-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
diseases I-Disease
other O
than O
ed B-Disease
##m I-Disease
##d I-Disease
. O

in O
contrast O
, O
a O
deficiency O
in O
im O
##mu O
##no O
##f O
##lu O
##ores O
##cent O
stain O
##ing O
of O
skeletal O
and O
cardiac O
muscle O
from O
ed B-Disease
##m I-Disease
##d I-Disease
patients O
was O
observed O
. O

a O
34 O
k O
##d O
protein O
is O
im O
##mu O
##nor O
##ea O
##ctive O
with O
the O
anti O
##ser O
##a O
- O
- O
the O
protein O
is O
equivalent O
to O
that O
predicted O
for O
em O
##eri O
##n O
. O

together O
, O
our O
findings O
suggest O
the O
specific O
deficiency B-Disease
of I-Disease
em I-Disease
##eri I-Disease
##n I-Disease
in O
the O
nuclear O
membrane O
of O
muscle O
cells O
in O
patients O
with O
ed B-Disease
##m I-Disease
##d I-Disease
. O
. O

growth B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
and O
t B-Disease
##umour I-Disease
in O
##hibition O
by O
br O
##ca O
##1 O
. O

inherited O
mutations O
in O
br O
##ca O
##1 O
pre O
##dis O
##pose O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
but O
the O
role O
of O
br O
##ca O
##1 O
in O
s O
##poradic O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
has O
previously O
been O
el O
##usive O
. O

here O
, O
we O
show O
that O
re O
##tro O
##vir O
##al O
transfer O
of O
the O
wild O
- O
type O
br O
##ca O
##1 O
gene O
in O
##hibit O
##s O
growth O
in O
v O
##it O
##ro O
of O
all O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cell O
lines O
tested O
, O
but O
not O
co B-Disease
##lon I-Disease
or I-Disease
lung I-Disease
cancer I-Disease
cells O
or O
fi O
##bro O
##blast O
##s O
. O

mutant O
br O
##ca O
##1 O
has O
no O
effect O
on O
growth O
of O
breast B-Disease
cancer I-Disease
cells O
; O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cell O
growth O
is O
not O
affected O
by O
br O
##ca O
##1 O
mutations O
in O
the O
5 O
portion O
of O
the O
gene O
, O
but O
is O
in O
##hibit O
##ed O
by O
3 O
br O
##ca O
##1 O
mutations O
. O

development O
of O
m B-Disease
##c I-Disease
##f I-Disease
- I-Disease
7 I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
in O
nude O
mice O
is O
in O
##hibit O
##ed O
when O
m O
##c O
##f O
- O
7 O
cells O
are O
trans O
##fected O
with O
wild O
- O
type O
, O
but O
not O
mutant O
, O
br O
##ca O
##1 O
. O

most O
importantly O
, O
among O
mice O
with O
established O
m B-Disease
##c I-Disease
##f I-Disease
- I-Disease
7 I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
, O
per O
##ito O
##nea O
##l O
treatment O
with O
a O
re O
##tro O
##vir O
##al O
vector O
expressing O
wild O
- O
type O
br O
##ca O
##1 O
significantly O
in O
##hibit O
##s O
t B-Disease
##umour I-Disease
growth O
and O
increased O
survival O
. O
. O

